<SEC-DOCUMENT>0001079973-25-001464.txt : 20250916
<SEC-HEADER>0001079973-25-001464.hdr.sgml : 20250916
<ACCEPTANCE-DATETIME>20250916163026
ACCESSION NUMBER:		0001079973-25-001464
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		86
FILED AS OF DATE:		20250916
DATE AS OF CHANGE:		20250916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardio Diagnostics Holdings, Inc.
		CENTRAL INDEX KEY:			0001870144
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				870925574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283419
		FILM NUMBER:		251317683

	BUSINESS ADDRESS:	
		STREET 1:		311 W. SUPERIOR STREET
		STREET 2:		SUITE 444
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60645
		BUSINESS PHONE:		855-226-9991

	MAIL ADDRESS:	
		STREET 1:		311 W. SUPERIOR STREET
		STREET 2:		SUITE 444
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60645

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mana Capital Acquisition Corp.
		DATE OF NAME CHANGE:	20210629
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>cdio_posam.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO. 1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:cdio="http://cdio.ai/20250630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD)_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_037_cdio_cdio.ai_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20250101_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001870144 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_XDX_cdio__s1.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000004" name="dei:EntityCentralIndexKey">0001870144</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0010" name="dei:DocumentType">POS AM</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:ChangeInFairValueOfDerivativeLiability" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WarrantsConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:NotesPayableConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CommonStockAndWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:NoncashInterestExpense" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:ChangeInFairValueOfDerivativeLiabilities" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:PaymentsForRightOfUseAsset" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:DebtDiscountRelatedToDerivativeLiability" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:NotePayableConvertedToCommonStock" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInAcquisition" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RightOfUseAssetAddedToOperatingLease" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:DerivativeLiabilitiesIssued" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:DerivativeLiabilitiesConverted" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:ChangeInFairValueRecognizedInOperations" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0999" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="xdx2ixbrl1067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl1073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="xdx2ixbrl1141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" id="xdx2ixbrl1183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-04-012025-06-30" id="xdx2ixbrl1284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl1285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl1287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:FractionalSharesAdjustment" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:FractionalSharesAdjustment" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:FractionalSharesAdjustment" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:FractionalSharesAdjustment" contextRef="From2025-04-012025-06-30" id="xdx2ixbrl1385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="xdx2ixbrl1639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="xdx2ixbrl1669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WarrantsCancelled" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl1800" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WeightedAverageExercisePriceCancelled" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl1802" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WarrantsCancelled" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="xdx2ixbrl1804" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WeightedAverageExercisePriceCancelled" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="xdx2ixbrl1806" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WarrantsCancelled" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="xdx2ixbrl1808" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:WeightedAverageExercisePriceCancelled" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="xdx2ixbrl1810" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IntangibleAssetsCurrent" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="xdx2ixbrl1859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="xdx2ixbrl2076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember" id="xdx2ixbrl2322" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember" id="xdx2ixbrl2324" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cdio-20250630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-25_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-25_custom_TwoInvestmentBankersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TwoInvestmentBankersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cdio:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-022023-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-02</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ChicagoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">cdio:ChicagoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_IA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LeaseOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LeaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LeaseOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LeaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_StockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LegacyCardioStockholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cdio:LegacyCardioStockholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LegacyCardioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:LegacyCardioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LegacyCardioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:LegacyCardioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ManasFormerOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:ManasFormerOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_Plan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:Plan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-23_custom_Plan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:Plan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:PlacementAgentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:AltitudeCapitalGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-23_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-23_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionsMember51358140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-23_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_N2022PlanMember_custom_StockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockOptionsMember51358187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-11-14_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsMember51358218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-23_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:PlacementAgentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:AltitudeCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:AtTheMarketIssuanceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:AtTheMarketIssuanceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-23_custom_N2022PlanMember_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_StockOptionsMember_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StockOptionsMember_custom_N2022PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_StockOptionsMember51358328">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cdio:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_stpr_IA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_stpr_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TheBenchmarkCompanyLLCRightOfFirstRefusalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TheBenchmarkCompanyLLCRightOfFirstRefusalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdio:NorthlandSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_TheBenchmarkCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TheBenchmarkCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-012025-02-07_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-01</xbrli:startDate>
        <xbrli:endDate>2025-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-20_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_AsRevisedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_ReportableSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001202" toRefs="Footnote001232"/>
  <ix:relationship fromRefs="Fact001203" toRefs="Footnote001232"/>
  <ix:relationship fromRefs="Fact001299" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001301" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001303" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001305" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001307" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001309" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001311" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001313" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001315" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001317" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001319" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001321" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001323" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001325" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001327" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001329" toRefs="Footnote001330"/>
  <ix:relationship fromRefs="Fact001332" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001337" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001339" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001344" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1346" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001351" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1353" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1358" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001363" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001368" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1370" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001375" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1377" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1382" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001387" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1389" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001394" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001399" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001401" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001406" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1408" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001413" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1415" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001420" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1422" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1427" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001432" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001437" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001439" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001444" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1446" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001451" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1453" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="xdx2ixbrl1458" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001463" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001468" toRefs="Footnote001469"/>
  <ix:relationship fromRefs="Fact001912" toRefs="Footnote001929"/>
  <ix:relationship fromRefs="Fact001913" toRefs="Footnote001929"/>
  <ix:relationship fromRefs="Fact001975" toRefs="Footnote001992"/>
  <ix:relationship fromRefs="Fact001976" toRefs="Footnote001992"/>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the U.S. Securities and Exchange
Commission on September <span style="font-family: Times New Roman, Times, Serif">16</span>, 2025.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22pt 0pt 0; text-align: right"><b>Registration No. 333-283419</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22pt 0pt 0; text-align: right"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>____________________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POST-EFFECTIVE AMENDMENT NO.&#160;1<br/>
TO<br/>
FORM <span id="xdx_90D_edei--DocumentType_dxL_c20250101__20250630_zJtUMk3Lb0u3" title="::XDX::POS%20AM"><span style="-sec-ix-hidden: xdx2ixbrl0010">S-1</span></span><br/>
REGISTRATION STATEMENT<br/>
UNDER<br/>
THE SECURITIES ACT OF 1933</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>____________________________</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20250101__20250630_z5sYCqv8IeU4"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000011" name="dei:EntityRegistrantName">CARDIO DIAGNOSTICS HOLDINGS, INC.</ix:nonNumeric></span><br/>
</b></span><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 9pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20250101__20250630_z1i3VuNJubn3"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 9pt"><b><span id="xdx_907_edei--EntityPrimarySicNumber_c20250101__20250630_zEV0om7YY8jb"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000013" name="dei:EntityPrimarySicNumber">6770</ix:nonNumeric></span></b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20250101__20250630_zJ7RCRzBYDqf"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-0925574</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of<br/>
incorporation or organization)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Primary Standard Industrial<br/>
Classification Code Number)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 12pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250101__20250630_zbpfJhpqG4Rg"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000015" name="dei:EntityAddressAddressLine1">311 West Superior Street</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20250101__20250630_z9JpAuMweFJf"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 444</ix:nonNumeric></span><br/>
<span id="xdx_901_edei--EntityAddressCityOrTown_c20250101__20250630_zEGWuPvtHTF9"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000017" name="dei:EntityAddressCityOrTown">Chicago</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20250101__20250630_zzh0WUvRdabi"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000018" name="dei:EntityAddressStateOrProvince">IL</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250101__20250630_zpCDLkNwINic"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000019" name="dei:EntityAddressPostalZipCode">60654</ix:nonNumeric></span><br/>
Telephone: (<span id="xdx_907_edei--CityAreaCode_c20250101__20250630_zuGgESTTxcw7"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000020" name="dei:CityAreaCode">855</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20250101__20250630_zsOhhmQrgkwc"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000021" name="dei:LocalPhoneNumber">226-9991</ix:nonNumeric></span><br/>
</b>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>____________________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--ContactPersonnelName_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z0JDnOnxmuw5"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000022" name="dei:ContactPersonnelName">Meeshanthini V. Dogan, Ph.D.</ix:nonNumeric></span><br/>
Chief Executive Officer<br/>
Cardio Diagnostics Holdings, Inc.<br/>
<span id="xdx_900_edei--EntityAddressAddressLine1_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z3g7ggoKTZd5"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000023" name="dei:EntityAddressAddressLine1">311 West Superior Street</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zqgCJQjRO8u1"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 444</ix:nonNumeric></span><br/>
<span id="xdx_908_edei--EntityAddressCityOrTown_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zJDBigcDGA3f"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressCityOrTown">Chicago</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zqrO7G51aeS5"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000026" name="dei:EntityAddressStateOrProvince">IL</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z8yzwPDdvlM"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressPostalZipCode">60654</ix:nonNumeric></span><br/>
Telephone: (<span id="xdx_907_edei--CityAreaCode_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z9gLMQFZ0Fsj"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000028" name="dei:CityAreaCode">855</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20250101__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zcFHWOC8AAAg"><ix:nonNumeric contextRef="From2025-01-012025-06-30_dei_BusinessContactMember" id="Fact000029" name="dei:LocalPhoneNumber">226-9991</ix:nonNumeric></span><br/>
</b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>____________________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Copies to:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>P. Rupert Russell, Esq.<br/>
Shartsis Friese LLP<br/>
425 Market Street, 11th Floor<br/>
San Francisco, CA 94105<br/>
(415) 421-6500</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Approximate date of commencement of proposed sale
to the public: As soon as practicable after this Registration Statement is declared effective.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If this Form is a post-effective&#160;amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If this Form is a post-effective&#160;amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated&#160;filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2&#160;of the Exchange Act.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; text-align: justify"><span style="font-size: 9pt">Large accelerated filer</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 18%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 27%"><span style="font-size: 9pt">Accelerated&#160;filer</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 29%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90B_edei--EntityFilerCategory_c20250101__20250630_zBnIPZ2guG5k"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000030" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9746;</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 9pt">Smaller&#160;reporting&#160;company</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20250101__20250630_zyv5zw52qbZd"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000031" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 9pt">Emerging&#160;growth&#160;company</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250101__20250630_zRBl5S9Xjqya"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;<span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_906_edei--EntityExTransitionPeriod_c20250101__20250630_zfmgEsiFIf3d"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section
8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<div id="xdx_98C_edei--AmendmentDescription_c20250101__20250630_zmAm5Dv2Fjbe">

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000034" name="dei:AmendmentDescription"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">This Post-Effective
Amendment No. 1 (this &#8220;Post-Effective Amendment&#8221;) to the Registration Statement on Form S-1 (File No. 333-283419) of
Cardio Diagnostics Holdings, Inc. (the &#8220;Company,&#8221; &#8220;Cardio,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;), which
was originally declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on December 3, 2024 (the
&#8220;Original Registration Statement&#8221;) is being filed to update the Original Registration Statement and the Prospectus
contained therein with information from the registrant&#8217;s Annual Report on Form 10-K for the year ended&#160;December 31, 2024,
which was filed with the SEC on March 20, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025, which was
filed on August&#160;14, 2025, and to update certain other information in the Original Registration Statement. Unless otherwise
noted, all of the share and price per share information in this Post- Effective Amendment has been adjusted to reflect the 1-for-30
reverse stock split implemented by the Company on May 12, 2025. The audited financial statements included herein have not been
adjusted for the reverse stock split. Certain pre-reverse stock split information included in the Form 10-Q for the period ended
June 30, 2025 has been omitted in this Post-Effective Amendment.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Post-Effective Amendment contains an updated
prospectus (the &#8220;Prospectus&#8221;) relating to the offer and sale of the securities registered by the Original Registration Statement.
No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time
of the initial filing of the Original Registration Statement on November 22, 2024.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p></ix:nonNumeric>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"><b>The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; color: #D2232A"><b>SUBJECT
TO COMPLETION, DATED SEPTEMBER 16, 2025</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #D2232A">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PRELIMINARY PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; color: red"><img src="image_008.jpg" alt="" style="height: 46.8pt; width: 133.2pt"/></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 41,199 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to the resale from time
to time by the Selling Stockholders (which term, as used in this prospectus, includes pledgees, donees, transferees or other&#160;successors-in-interest)
of up to an aggregate of 41,199 shares of common stock, $0.00001 par value (the &#8220;common stock&#8221; or the &#8220;shares&#8221;),
including (i) 18,727 shares sold in the private placement described below and (ii) 22,472 shares issuable upon exercise of common stock
purchase warrants also issued in the private placement and 3,745 shares of which are issuable upon exercise of warrants issued to the
placement agent (collectively, the &#8220;warrants&#8221;) as partial compensation for services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 2, 2024 (pre-dating the 1-for-30 reverse
stock split effected in May 2025), in accordance with executed subscription agreements with seven accredited investors, we closed on the
sale of 561,793 units (the &#8220;units&#8221;), each unit consisting of one share of Common stock and one warrant, which warrants are
exercisable until February 2, 2030 at an exercise price of $1.78, subject to adjustment for stock splits, reverse stock splits and other
similar events of recapitalization, including the 1-for-30 reverse stock split we effected on May 12, 2025. On a post-reverse stock split
basis, we issued 18,727 shares and warrants that are exercisable for 18,727 shares, plus 3,745 placement agent warrants, all at an exercise
price of $53.40. The units were sold to the investors in a private placement at a sale price of $1.78 ($53.40 on a post-reverse stock
split basis) per unit (the &#8220;private placement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not&#160;selling&#160;any securities under
this prospectus, and we will not receive any proceeds from the sale of the shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to bear all of the expenses incurred
in connection with the registration of these shares. The&#160;Selling Stockholders&#160;will pay or assume discounts, commissions, fees
of underwriters,&#160;selling&#160;brokers or dealer managers and similar expenses, if any, incurred for the sale of the shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The&#160;Selling Stockholders&#160;may offer the
shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices
or at privately negotiated prices. For additional information on the methods of sale that may be used by the&#160;Selling Stockholders,
see the section entitled &#8220;<a href="#PlanOfDistribution">Plan of Distribution</a>&#8221; on page 103.<sup>&#160;</sup>For a list of the&#160;Selling Stockholders,
see the section entitled &#8220;<a href="#SellingStockholders">Selling Stockholders</a>&#8221; on page 97.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may amend or supplement this prospectus from
time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements
carefully before you make your investment decision.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock and our publicly-traded warrants
(the &#8220;public warrants&#8221;) are listed on The Nasdaq Capital Market under the symbols &#8220;CDIO&#8221; and &#8220;CDIOW,&#8221;
respectively. On September 12, 2025, the closing price of our common stock was $3.790 and the closing price of our public warrants was
$0.0191.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should carefully read this prospectus and any
prospectus supplement, together with additional information described under the heading &#8220;<a href="#WhereYouCanFind">Where You Can Find More Information</a>&#8221; on page 106 before you invest in any of our securities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sale of some or all of the shares being offered
in this prospectus could have adverse effects on the market for our common stock, including increasing volatility, limiting the availability
of an active market and/or resulting in a significant decline in the public trading price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in">We are an &#8220;emerging
growth company,&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company
reporting requirements for this prospectus and for future filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in"><b>Investing in our securities involves a high
degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in
&#8220;<a href="#RiskFactors">Risk Factors</a>&#8221; beginning of page 7 of this prospectus.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in"><b>You should rely only on the information contained
in this prospectus or any prospectus supplement or amendment hereto. We have not authorized anyone to provide you with different information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.6in">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
date of this Prospectus is [</b></span><b><span style="font-family: Symbol">&#183;</span><span style="font-family: Times New Roman, Times, Serif">],
2025.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom; width: 94%">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top; width: 5%; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#AboutThisProspectus">ABOUT THIS PROSPECTUS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">i</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#MarketRankingData">MARKET, RANKING AND OTHER INDUSTRY DATE</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#Trademarks">TRADEMARKS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#CautionaryNote">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#ProspectusSummary">PROSPECTUS SUMMARY</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#TheOffering">THE OFFERING</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">6</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#RiskFactors">RISK FACTORS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">7</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#UseOfProceeds">USE OF PROCEEDS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#DeterminationoOfferingPrice">DETERMINATION OF OFFERING PRICE</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#MarketpPrice">MARKET, PRICE, TICKER SYMBOLS AND DIVIDEND INFORMATION</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#MDA">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#Business">BUSINESS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#Management">MANAGEMENT</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">79</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#ExecutiveCompensation">EXECUTIVE AND DIRECTOR COMPENSATION</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">88</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#CertainRelationships">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">94</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#PrincipalStockholders">PRINCIPAL STOCKHOLDERS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">95</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#SellingStockholders">SELLING STOCKHOLDERS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#DescriptionOfSecurities">DESCRIPTION OF SECURITIES</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#PlanOfDistribution">PLAN OF DISTRIBUTION</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#LegalMatters">LEGAL MATTERS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">106</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#Experts">EXPERTS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">106</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#WhereYouCanFind">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">106</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><a href="#FinancialStatements">INDEX TO FINANCIAL STATEMENTS</a></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><b>You should rely only on the information provided
in this Prospectus, as well as the information incorporated by reference into this Prospectus and any applicable prospectus supplement.
Neither we nor the Selling Stockholders have authorized anyone to provide you with additional information or information different from
that contained in this Prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. The Selling Stockholders are offering to sell, and
seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. You should not assume that the information
in this Prospectus, any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than
the date of the applicable document. Since the date of this Prospectus and the documents incorporated by reference into this Prospectus,
our business, financial condition, results of operations and prospects may have materially changed.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><b>For investors outside of the United States:
Neither we nor the Selling Stockholders, have done anything that would permit this offering or possession or distribution of this Prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who
come into possession of this Prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities
and the distribution of this Prospectus outside the United States.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="AboutThisProspectus"></span><b>ABOUT THIS PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">This Prospectus is part of a post-effective amendment
to a registration statement on Form&#160;S-1&#160;that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using
the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time,
sell the securities offered by them described in this Prospectus. We will not receive any proceeds from the sale by such Selling Stockholders
of the securities offered by them described in this Prospectus. This Prospectus also relates to the issuance by us of the shares of Common
Stock issuable upon the exercise of any Warrants. We will receive proceeds from any exercise of such Warrants and Options for cash. There
is no assurance that any Warrants and Options covered by this Prospectus will be exercised before their respective expiration dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Neither we nor the Selling Stockholders have
authorized anyone to provide you with any information or to make any representations other than those contained in this Prospectus or
any applicable prospectus supplement. Neither we nor the Selling Stockholders take responsibility for, and can provide no assurance as
to the reliability of, any other information that others may give you. Neither we nor the Selling Stockholders will make an offer to sell
these securities in any jurisdiction where the offer or sale is not permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We may also file a prospectus supplement or additional
post-effective amendments to the Registration Statement of which this Prospectus forms a part that may contain material information relating
to these offerings. Any prospectus supplement or post-effective amendment may also add, update or change information contained in this
Prospectus with respect to that offering. If there is any inconsistency between the information in this Prospectus and any applicable
prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable.
Before purchasing any securities, you should carefully read this Prospectus, any post-effective amendment, and any applicable prospectus
supplement, together with the additional information described under the heading &#8220;Where You Can Find More Information.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="background-color: white">As used in
this Prospectus, unless otherwise indicated or the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
the &#8220;Company,&#8221; and &#8220;Cardio&#8221; refer to the consolidated operations of Cardio Diagnostics Holdings, Inc., a Delaware
corporation, and its consolidated subsidiary following the Business Combination. References to &#8220;Mana&#8221; refer to the Company
prior to the consummation of the Business Combination and references to &#8220;Legacy Cardio&#8221; refer to Cardio Diagnostics, Inc.,
prior to the consummation of the Business Combination, which entity is our wholly-owned subsidiary. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b><span id="MarketRankingData"></span>MARKET, RANKING
AND OTHER INDUSTRY DATA</b></span>&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">This Prospectus contains, and any additional post-effective
amendment or any prospectus supplement may contain, market data and industry statistics and forecasts that are based on independent industry
publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy
or completeness of this information, and we have not independently verified this information. In addition, the market and industry data
and forecasts that may be included in this Prospectus, any post-effective amendment or any prospectus supplement may involve estimates,
assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the
heading &#8220;Risk Factors&#8221; contained in this Prospectus, any post-effective amendment and the applicable prospectus supplement.
Accordingly, investors should not place undue reliance on this information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Certain information contained in this Prospectus
relates to or is based on our own internal estimates and research. While we believe our own internal research is reliable, such research
has not been verified by any independent source. These estimates involve risks and uncertainties and are subject to change based on various
factors, including those discussed under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; in this Prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">i</p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="Trademarks"></span>TRADEMARKS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We own or have rights to trademarks, trade names
and service marks that we use in connection with the operation of our business. In addition, our name, logos and website name and address
are our trademarks or service marks. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to
in this Prospectus are listed without the applicable&#160;<sup>&#174;</sup>, &#8482; and&#160;<sup>SM</sup>&#160;symbols, but we will assert,
to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks. Other trademarks, trade names
and service marks appearing in this Prospectus are the property of their respective owners. We do not intend our use or display of other
companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other
companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="CautionaryNote"></span>CAUTIONARY NOTE
REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">This Prospectus contains
&#8220;forward-looking&#160;statements&#8221; regarding, among other things, our plans, strategies and prospects, both business and financial.
These statements are based on the beliefs and assumptions of our management. Although we believe that our plans, intentions and expectations
reflected in or suggested by these forward-looking&#160;statements are reasonable, we cannot provide assurance that we will achieve or
realize these plans, intentions or expectations. Forward-looking&#160;statements are inherently subject to risks, uncertainties and assumptions.
Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies,
events or results of operations, are forward-looking&#160;statements. The words &#8220;anticipates,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221;
&#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221;
and similar expressions may identify forward-looking&#160;statements, but the absence of these words does not mean that a statement is
not forward-looking. Investors should read statements that contain these words carefully because they:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; width: 97%; vertical-align: bottom"><span style="font-size: 10pt">discuss future expectations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">contain projections of future results of operations or financial condition; or;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">state other &#8220;forward-looking&#8221; information.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">We believe it is important
to communicate our expectations to our securityholders. However, there may be events in the future that management is not able to predict
accurately or over which we have no control. The risk factors and cautionary language contained in this Prospectus provide examples of
risks, uncertainties and events that may cause actual results to differ materially from the expectations described in such forward-looking
statements, including among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; width: 97%; vertical-align: bottom"><span style="font-size: 10pt">the possibility that we may be adversely impacted by economic, business, and/or competitive factors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">our limited operating history makes it difficult to evaluate our business and prospects;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the success, cost and timing of our product development
and commercialization activities, including the degree to which Epi+Gen CHD&#8482;, our initial clinical test, PrecisionCHD&#8482;, our
second clinical test, or HeartRisk&#8482;, our recently introduced software product, are accepted and adopted by patients, healthcare
professionals and other participants in other key channels may not meet our current expectations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">changes in applicable laws or regulations could negatively our current business plans;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to obtain and maintain regulatory clearance or approval for our tests, and any related restrictions and limitations of any cleared or approved product could negatively impact our financial condition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the pricing of our products and services and reimbursement for medical tests conducted using our products and services may not be sufficient to achieve our financial goals;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to successfully compete with other companies currently marketing or engaged in the development of products and services that could serve the same or similar functions as our products and services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others may not meet our current expectations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to maintain our existing or future licenses, or manufacturing, supply and distribution agreements; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to identify, in-license or acquire additional technology needed to develop new products or services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing may not be accurate;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to raise needed financing in the future on acceptable terms, if at all;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">we may be unable to maintain our listing on The Nasdaq Stock Market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">there are other risks and uncertainties indicated in this Prospectus, including those under &#8220;Risk Factors&#8221; herein, and other filings that have been made or will be made with the SEC by us that could materially alter our current expectations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ii</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">These forward-looking statements are based on information
available as of the date of this Prospectus, and our management&#8217;s current expectations, forecasts and assumptions, and involve a
number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views
as of any subsequent date, and you should not place undue reliance on these forward-looking statements. We do not undertake any obligation
to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date
they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise,
except as may be required under applicable securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">All forward-looking statements attributable to
us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation
to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, statements of belief and similar statements
reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to us as
of the date of this Prospectus, and while we believe such information forms a reasonable basis for such statements, such information may
be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of,
all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon
these statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Before you invest in our securities, you should
be aware that the occurrence of one or more of the events described in the &#8220;<a href="#RiskFactors">Risk Factors</a>&#8221; section and elsewhere in this Prospectus
may adversely affect us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;iii</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 8; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="ProspectusSummary"></span><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>The following summary highlights selected information
contained elsewhere in this Prospectus and does not contain all of the information that you should consider in making your investment
decision. Before investing in our securities, you should carefully read this entire Prospectus, including our consolidated financial statements
and the related notes included in this Prospectus and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations.&#8221;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Company </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio was formed to further develop and commercialize
a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (&#8220;CHD&#8221;),
stroke, heart failure and diabetes, by leveraging our Artificial Intelligence (&#8220;AI&#8221;)-driven Integrated Genetic-Epigenetic
Engine&#8482;. As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases.
Cardio aims to become one of the leading medical technology companies for enabling improved prevention, detection, treatment and management
of cardiovascular disease and associated co-morbidities. Cardio is transforming the approach to cardiovascular medicine from reactive
to proactive and hopes to accelerate the adoption of Precision Medicine for all. We believe that incorporating our solutions into routine
clinical practice in and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some
form of cardiovascular disease by 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">According to the CDC, epigenetics is the study
of how a person&#8217;s behaviors and environment can cause changes that affect the way a person&#8217;s genes work. Unlike genetic changes,
epigenetic changes are reversible and do not change one&#8217;s DNA sequence, but they can change how a person&#8217;s body reads a DNA
sequence. We believe that we are the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease
that have clear value propositions for multiple stakeholders including (i) patients, (ii) clinicians, (iii) hospitals/health systems,
(iv) employers and (v) payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">An estimated 80% of cardiovascular disease (&#8220;CVD&#8221;)
is preventable, yet, it is responsible for one in every four deaths and remains the number one killer in the United States for both men
and women. Coronary heart disease is the most common type of CVD and the major cause of heart attacks. The enormous number of unnecessary
heart attacks and deaths associated with CHD is attributable to the failure of current primary prevention approaches in clinical practice
to effectively detect, reduce and monitor risk for CHD prior to life altering and costly health complications. Several reasons for this
failure include (i) the current in-person risk screening approach is incompatible with busy everyday life; (ii) even if the current risk
screening tests are taken, they only identify 44% and 32% of men and women at high risk, respectively; and (iii) the lack of patient care
plan personalization. We believe that a highly accessible, personalized and precise solution for CHD prevention is not currently available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Furthermore, in the aftermath of the COVID-19 pandemic
and the ongoing possibility of a potential re-emergence of COVID variants or other public crises, preventable illnesses such as CHD are
expected to spike. Therefore, now more than ever, there is an urgent need for a highly sensitive, scalable, at-home risk screening tool
that can help physicians better direct care and allow patients to receive the help they need sooner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our first test, Epi+Gen CHD&#8482;, which was introduced
for market testing in 2021, is a three-year symptomatic CHD risk assessment clinical blood test targeting CHD events, including heart
attacks. In June 2023, we announced the nationwide launch of our second product, PrecisionCHD&#8482;, an integrated epigenetic-genetic
clinical blood test for the detection of coronary heart disease. The Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are coupled to Actionable
Clinical Intelligence (&#8220;ACI&#8221;), a platform that offers new epigenetic and genetic insights to clinicians to help improve chronic
care management. In May 2023, we launched CardioInnovate360<sup>TM</sup>, a research-use-only (&#8220;RUO&#8221;) solution to support
the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. In
February 2024, we announced the launch of HeartRisk&#8482;, a cardiovascular risk intelligence platform. The Company earned only $17,065
and $34,890 in revenue for the years ended December 31, 2023 and 2024, respectively, and $23,798 and $8,415 in revenue for the six months
ended June 30, 2024 and 2025, respectively. We are continuing to focus our efforts on establishing relationships with larger organizations
and channel partners to increase adoption of our solutions. However, this process can take many months and up to as much as a year or
more to finalize, depending on the sales channel. For example, hospitals routinely take a year or longer to make purchasing decisions.
While these relationships take considerable time to establish, we believe that our strategy to pursue larger organizations can provide
far greater revenue potential for our existing and future tests and other products. We have begun to see results from this recent shift
in marketing focus: In October 2023, we announced that we have secured an Innovative Technology Contract from Vizient, Inc., the nation&#8217;s
largest provider-driven healthcare performance improvement company, with a customer base encompassing over 60% of hospitals and 97% of
academic medical centers in the United States. In November 2023, we announced that Family Medicine Specialists (&#8220;FMS&#8221;), a
leading Illinois primary care provider with eight locations, is implementing our heart attack risk assessment test, Epi+Gen CHD&#8482;,
covering at least 1,200 BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plan and other health plan patients with CHD risk
factors. In addition to providers and provider organizations, we are also expanding to offer our solutions through employers and benefit
brokers. We have grown our provider and employer pipelines significantly with a major focus on advancing them to close. Beyond the U.S.
market, we also have an arrangement with one of India&#8217;s leading healthcare and medical instrumentation companies to lay the pre-marketing
groundwork via its extensive healthcare network to introduce our solutions in India. In addition to growing the adoption of our solutions,
we have also secured Current Procedural Terminology (&#8220;CPT&#8221;) Proprietary Laboratory Analysis (&#8220;PLA&#8221;) codes from
the American Medical Association for Epi+Gen CHD&#8482; (0439U) and PrecisionCHD&#8482; (0440U), which is a key step in securing payor
coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In the first and second quarters of 2025, our focus
remained in driving adoption of our clinical solutions, predominantly among providers, channel partners and employers. In addition, we
made progress in the Medicare reimbursement process, where we received preliminary gapfill pricing from the Centers for Medicare and Medicaid
for the Epi+Gen CHD and PrecisionCHD tests, onboarding a new employer client and in setting up our laboratory facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that our Epi+Gen CHD&#8482; and PrecisionCHD&#8482;
tests are categorized as laboratory-developed tests, or &#8220;LDTs.&#8221; The FDA has historically taken the position that it has the
authority to regulate LDTs as in-vitro diagnostics (&#8220;IVDs&#8221;) under the Federal Food, Drug, and Cosmetic Act (&#8220;FDC Act&#8221;),
although it has generally exercised enforcement discretion with regard to LDTs. current FDA enforcement discretion policy, an LDT does
not require FDA premarket authorization, or other FDA clearance or approval. As such, we believe that under current FDA policies, the
Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests do not require FDA premarket evaluation of our performance claims or marketing authorization,
and such premarket authorization has not been obtained. However, in May 2024, two lawsuits challenging FDA&#8217;s authority to regulate
LDTs were filed in federal court, and on March 31, 2025, a federal court in Texas vacated the FDA final rule, thereby cancelling the rulemaking&#8217;s
associated requirements. The court held that laboratory developed tests do not meet the definition of a medical device under the Federal
Food, Drug, and Cosmetic (&#8220;FD&amp;C&#8221;) Act, and the FDA therefore lacks jurisdiction to regulate them. Laboratories no longer
need to comply with the regulatory changes that were set to take effect on May 6, 2025, or with the rulemaking&#8217;s other requirements.
The federal government did not seek a stay of the district court&#8217;s opinion and did not file an appeal of the ruling, which means
the district court decision remains in effect. The change in Administration, the current balance of power in Congress, and recent court
rulings make it unlikely that the FDA will be urged to redouble its efforts to regulate LDTs as medical devices for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a company in the early stages of its development,
we continuously reevaluate our business, the market in which we operate and potential new opportunities. We may seek other alternatives
within the healthcare field in order to grow our business and increase revenues. Such alternatives may include, but not be limited to,
combinations or strategic partnerships with other laboratory companies or with medical practices such as hospitalists or behavioral health.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="background-color: white">Mana Capital
Acquisition Corp. was formed on May 19, 2021 under the laws of the State of Delaware as a blank check company for the purpose of engaging
in a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination,
with one or more target businesses or entities. Legacy Cardio</span> was formed in January 2017 as an Iowa limited liability company (Cardio
Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp (Cardio Diagnostics, Inc.) on September 6, 2019. Upon completion
of the Business Combination on October 25, 2022, we changed our name to Cardio Diagnostics Holdings, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our corporate headquarters is located at 311 West
Superior Street, Suite 444, Chicago IL 60654. Our telephone number is (855) 226-9991 and our website address is cardiodiagnosticsinc.com.
The information contained on, or that can be accessed through, our website is not incorporated by reference in this Prospectus and does
not form a part of this Prospectus. The reference to our website address does not constitute incorporation by reference of the information
contained at or available through our website, and you should not consider it to be a part of the Registration Statement or the Prospectus
contained therein.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging Growth Status</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are an &#8220;emerging growth company<i>,</i>&#8221;
as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements
of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Further, Section&#160;102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities
registered under the Securities Exchange Act of 1934, as amended the &#8220;Exchange Act&#8221;), are required to comply with the new
or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period
and comply with the requirements that apply to&#160;non-emerging&#160;growth companies but any such an election to opt out is irrevocable.
We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different
application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company
which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period
difficult or impossible because of the potential differences in accounting standards used.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We will remain an emerging growth company until
the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the completion of the IPO, (b)&#160;in
which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated
filer, which means the market value of our Common Stock held by&#160;non-affiliates&#160;equaled or exceeded $700&#160;million as of June&#160;30th
of that fiscal year, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt securities
during the prior three-year period.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Additionally, we are a &#8220;smaller reporting
company&#8221; as defined in Item 10(f)(1) of Regulation&#160;S-K.&#160;Smaller reporting companies may take advantage of certain reduced
disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (1)&#160;the market value of our Common Stock held by&#160;non-affiliates
equaled or exceeded $250&#160;million as of June 30th of that fiscal year, or (2)&#160;our annual revenues equaled or exceeded $100&#160;million
during such completed fiscal year and the market value of our Common Stock held by&#160;non-affiliates&#160;equaled or exceeded $700&#160;million
as of June&#160;30th of that fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white"><i>Our business is subject
to numerous risks and uncertainties, including those highlighted in the section titled &#8220;Risk Factors,&#8221; that represent challenges
that we face in connection with the successful implementation of our strategy and growth of our business. The occurrence of one or more
of the events or circumstances described in the section titled &#8220;Risk Factors,&#8221; alone or in combination with other events or
circumstances, may adversely affect our ability realize the anticipated benefits of the Business Combination, and may have an adverse
effect on our business, cash flows, financial condition and results of operations. Such risks include, but are not limited to</i>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Business, Industry
and Business Operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We have a limited operating history that makes it impossible to reliably predict future growth and operating results.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We have an unproven business model, have not generated significant revenues and can provide no assurance of generating significant revenues or operating profit.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The market for epigenetic tests is fairly new and unproven, and it may decline or experience limited growth, which would adversely affect our ability to fully realize the potential of our business plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The estimates of market opportunity and forecasts of market growth included in this Prospectus may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">If we are not able to enhance or introduce new products that achieve market acceptance and keep pace with technological developments, our business, results of operations and financial condition could be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The success of our business depends on our ability to expand into new vertical markets and attract new customers in a cost-effective manner.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our growth strategy may not prove viable and expected growth and value may not be realized.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our future growth could be harmed if we lose the services of our key personnel.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We may face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share, our business and operating results will be harmed.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our business depends on customers increasing their use of our existing and future products, and we may experience loss of customers or a decline in their use of our solutions.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We rely on a limited number of suppliers, contract manufacturers, and logistics providers, and our tests are currently performed by a single contract high complexity Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) laboratory.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We may be unable to scale our operations successfully.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">As we grow the size of our organization, we may experience difficulties in managing this growth.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our success depends upon our ability to adapt to a changing market and our continued development of additional tests, other products and services.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our Board of Directors may change our strategies, policies, and procedures without stockholder approval.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We may need to seek alternative business opportunities and change the nature of our business.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We may be subject to general litigation that may materially adversely affect us and our operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our management expects to continue to devote substantial time to maintaining and improving the internal controls over financial reporting and the requirements of being a public company which may, among other things, strain our resources, divert management&#8217;s attention and affect our ability to accurately report our financial results and prevent fraud.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="text-align: left; width: 24px; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Certain of our core technology is licensed, and that license may be terminated if we were to breach our obligations under the license.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our license agreement with University of Iowa Research Foundation (&#8220;UIRF&#8221;) includes a non-exclusive license of &#8220;technical information&#8221; that potentially could grant unaffiliated third parties access to materials and information considered derivative work made by us, which could be used by such licensees to develop competitive products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Government Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We conduct business in a heavily regulated industry, and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">If our products do not receive adequate coverage and reimbursement from third-party payors, our ability to expand access to our tests beyond our initial sales channels will be limited and our overall commercial success will be limited.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to Our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The price of our Common Stock likely will be volatile like the stocks of other early-stage companies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We may not be able to maintain our Nasdaq listing if we are unable to comply with the various listing requirements of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;). In the past, we have received deficiency letters from Nasdaq informing us that because the trading price of our Common Stock failed to meet the minimum bid price required to maintain our listing on the Nasdaq Capital Market, our Common Stock could be delisted unless we were able to satisfy the minimum bid requirement within the cure period or, if granted, the extended cure period. We could face similar threats of delisting from Nasdaq in the future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Because a substantial number of our currently outstanding shares of Common Stock are registered for resale, we may have difficulty raising additional capital when and if needed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">A significant number of shares of our Common Stock are subject to issuance upon exercise of outstanding warrants and options, which upon such exercise or conversion may result in dilution to our security holders.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We have never paid dividends on our Common Stock, and we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Sales of a substantial number of shares of our Common Stock in the public market by our existing stockholders could cause our stock price to decline.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="TheOffering"></span>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 38%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cardio Diagnostics Holdings, Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Offered by the Selling Stockholders&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 41,199 shares of Common Stock</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms of the Offering&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Stockholders will determine when and how each of them will dispose of the shares of Common Stock registered for resale under this prospectus.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Stockholders will receive all of the proceeds from the sale of the Shares offered for sale by them under this prospectus. We will not receive any proceeds from the sale of the securities offered by the Selling Stockholders pursuant to this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Outstanding</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,763,129 as of September 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Stock Market Symbols&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock and public warrants are listed on the Nasdaq Capital Market under the symbols &#8220;CDIO&#8221; and &#8220;CDIOW,&#8221; respectively.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See the section entitled &#8220;<a href="#RiskFactors">Risk Factors</a>&#8221;
    beginning on page 7 and other information included in this prospectus for a discussion of factors you should consider before
    investing in our securities.&#160;</span></td></tr>
  </table>
<p style="margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Unless otherwise noted, the number of our shares
of Common Stock outstanding is based on 1,763,129 shares of Common Stock outstanding as of September 12, 2025 and excludes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: left; vertical-align: top; width: 24px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">128,860 shares of our Common Stock issuable upon the exercise of options, exercisable at prices between $3.60 and $117.00 per share, subject to adjustment for future stock splits, reverse stock splits and other similar events of recapitalization;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">284,292 shares of our Common Stock issuable upon the exercise of outstanding Warrants, exercisable at prices ranging from $53.40 and $345.00 per share, subject to adjustment for stock splits, reverse stock splits and other similar events of recapitalization; and </span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">96,088 shares of our Common Stock reserved for future issuance under our 2022 Equity Incentive Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Unless the context otherwise requires, all numbers
in this Prospectus assume no exercise of any options and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="RiskFactors"></span><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Investing in our securities involves risks.
You should carefully consider the risks and uncertainties described below and the other information in this Prospectus before making an
investment in our Common Stock. Our business, financial condition, results of operations, or prospects could be materially and adversely
affected if any of these risks occurs, and as a result, the market price of our Common Stock could decline and you could lose all or part
of your investment. This Prospectus also contains forward-looking statements that involve risks and uncertainties. See &#8220;<a href="#CautionaryNote">Cautionary Statement Regarding Forward-Looking Statements</a>.&#8221; Our actual results could differ materially and adversely from those anticipated
in these forward-looking statements as a result of certain factors, including those set forth below.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Limited Operating History
and Early Stage of Growth</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We are a medical diagnostic testing company with a limited operating
history and have not yet generated significant revenue from product sales. We have incurred operating losses since our inception and may
never achieve or maintain profitability.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We generated only nominal revenue in 2023 and 2024,
including $17,065 in revenue generated in 2023 and $34,890 in revenue generated in 2024. Our net losses totaled $8,376,834 and $8,383,453
for the years ended December 31, 2023 and 2024, respectively, and we have an accumulated deficit of $22,751,833 at December 31, 2024.
<span style="font-family: Times New Roman PS Std,serif">Revenue, net loss and accumulated deficit as of and at June 30, 2025 totaled $8,415,
$3,318,263 and $26,070,096, respectively. </span>We expect losses to continue as a result of our ongoing activities to increase the adoption
of our products, to gain market recognition and acceptance of our products, to expand our marketing channels and otherwise position ourselves
to grow our revenue opportunities, all of which will require hiring additional employees as well as other significant expenses. We are
unable to predict when we will become profitable, and it is possible that we may never become profitable. We may encounter unforeseen
expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future
net losses will depend, in part, on the rate of future growth of our expenses, which we expect to increase substantially as a public company,
and on our ability to generate revenue, which has been slow to gain traction since our inception. In addition, as of the date of this
Prospectus, the possible future negative impacts of the current administration&#8217;s trade policy, including possible retaliatory tariffs
by countries with whom we do business or may in the future do business, cannot be estimated; however, uncertain trade policies could negatively
impact our future growth and potential profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability
in subsequent periods. If additional capital is not available when required, if at all, or is not available on acceptable terms, we could
be forced to modify or abandon our current business plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We believe our long-term value as a company will be greater if we
focus on growth, which may negatively impact our results of operations in the near term.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe our long-term value as a company will
be greater if we focus on longer-term growth over short-term results. As a result, our results of operations may be negatively impacted
in the near term relative to a strategy focused on maximizing short-term profitability. Significant expenditures on marketing efforts,
potential acquisitions and other expansion efforts may not ultimately grow our business or lead to expected long-term results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our business and the markets in which we operate are new and rapidly
evolving, which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our business and the markets in which we operate
are new and rapidly evolving, which make it difficult to evaluate and assess the success of our business to date, our future prospects
and the risks and challenges that we may encounter. These risks and challenges include our ability to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">attract new customers for our tests through patient awareness, sales and marketing campaigns, as well as through key channel partners;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">gain market acceptance of our current and future tests and services with key constituencies and maintain and expand such relationships;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">comply with existing and new laws and regulations applicable to our business and in our industry;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">anticipate and respond to changes in payor reimbursement rates and the markets in which we operate;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">react to challenges from existing and new competitors;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">maintain and enhance our reputation and brand;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">effectively manage our growth and business operations, including new geographies;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">accurately forecast our revenue and budget for, and manage, our expenses, including capital expenditures; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">hire and retain talented individuals at all levels of our organization;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If we fail to understand fully or adequately address
the challenges that we are currently encountering or that we may encounter in the future, including those challenges described here and
elsewhere in this &#8220;Risk Factors&#8221; section, our business, financial condition and results of operations could be adversely affected.
If the risks and uncertainties that we plan for when operating our business are incorrect or change, or if we fail to manage these risks
successfully, our results of operations could differ materially from our expectations and our business, financial condition and results
of operations could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our limited operating history makes it difficult to evaluate our
future prospects and the risks and challenges we may encounter.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We were established in 2017, and we are continuing
to grow our marketing and management capabilities. Consequently, predictions about our future success or viability may not be as accurate
as they could be if we had a longer operating history. The evolving nature of the medical diagnostics industry increases these uncertainties.
If our growth strategy is not successful, we may not be able to continue to grow our revenue or operations. Our limited operating history,
evolving business and growth make it difficult to evaluate our future prospects and the risks and challenges we may encounter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, as a business with a limited operating
history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We may not
be successful at commercialization, sales and marketing and, as a result, our business may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our quarterly results may fluctuate significantly and may not fully
reflect the underlying performance of our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our results of operations and key metrics discussed
elsewhere in this Prospectus may vary significantly in the future and period-to-period comparisons of our operating results and key metrics
may not provide a full picture of our performance. Accordingly, the results of any one quarter or year should not be relied upon as an
indication of future performance. Our quarterly financial results and metrics may fluctuate as a result of a variety of factors, many
of which are outside of our control, and as a result they may not fully reflect the underlying performance of our business. These quarterly
fluctuations may negatively affect the value of our securities. Factors that may cause these fluctuations include, without limitation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the level of demand for our tests and services, which may vary significantly from period to period;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">our ability to attract new customers, whether patients or strategic channel partners or other customers;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the timing of recognition of revenues;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">the amount and timing of operating expenses;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 23.95pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">general economic, industry and market conditions, both domestically and internationally, including any economic downturns, including from the possible impact of tariffs policies, and adverse impacts resulting from the COVID-19 pandemic, other epidemic outbreak or pandemic and/or the military conflict between Russia and Ukraine;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">the timing of our billing and collections;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">adoption rates by participants in our key channels;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 19pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">increases or decreases in the number of patients, providers and organizations that use our tests or pricing changes upon any signing and renewals of agreements with healthcare sub-vertical channel partners;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">changes in our pricing policies or those of our competitors;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 21.15pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">the timing and success of new offerings by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, practitioners, clinics or outsourcing facilities; extraordinary expenses such as litigation or other dispute-related expenses or settlement payments;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 21.15pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">extraordinary expenses such as litigation or other dispute-related expenses or settlement payments;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">sales tax and other tax determinations by authorities in the jurisdictions in which we conduct business;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">the impact of new accounting pronouncements and the adoption thereof;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">fluctuations in stock-based compensation expenses;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">expenses in connection with mergers, acquisitions or other strategic transactions;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">changes in regulatory and licensing requirements;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">the amount and timing of expenses related to our expansion to markets outside the United States; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; line-height: 96%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 13.55pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">the timing of expenses related to the development or acquisition of technologies or businesses and potential future charges for impairment of goodwill or intangibles from acquired companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Further, in any future period, our revenue growth
could slow, or our revenues could decline for a number of reasons, including slowing demand for our tests and services, increasing competition,
a decrease in the growth of our overall market, or our failure, for any reason, to continue to capitalize on growth opportunities. In
addition, our growth rate may slow in the future as our market penetration rates increase. As a result, our revenues, operating results
and cash flows may fluctuate significantly on a quarterly basis and revenue growth rates may not be sustainable and may decline in the
future, and we may not be able to achieve or sustain profitability in future periods, which could harm our business and cause the market
price of our Common Stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We expect to need to raise additional capital to fund our existing
operations or develop and commercialize new services or expand our operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We expect to spend significant amounts to expand
our existing operations, including expansion into new geographies, to make additional key hires, to expand our sales channels and constituencies
and to develop new tests and services. If we are unable to raise additional capital, we may need to delay the timing of, or scale back,
certain aspects of our business plan and operations. The estimate and our expectation regarding the sufficiency of funds to continue our
business plan and operations are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner
than we currently expect. Until such time, if ever, as we can generate sufficient revenues, we may finance our cash needs through a combination
of equity offerings and debt financings or other sources. In addition, we may seek additional capital due to favorable market conditions
or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our present and future funding requirements will
depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">our ability to achieve revenue growth;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">our ability to effectively manage our expenses and burn rate;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">the cost of expanding our operations, including our geographic scope, and our offerings, including our marketing efforts;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">our rate of progress in launching, commercializing and establishing adoption of our tests and services; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">the effect of competing technological and market developments.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">To the extent that we raise additional capital
through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities
may include liquidation or other preferences that adversely affect your rights as a securityholder. In addition, debt financing and preferred
equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations,
strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable
rights to our technologies, intellectual property, or future revenue streams or grant licenses on terms that may not be favorable to us.
Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability
to advance development activities. If we need additional capital and cannot raise it on acceptable terms, or at all, we may not be able
to, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 4.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 4.2pt; vertical-align: bottom"><span style="font-size: 10pt">invest in our business and continue to grow our brand and expand our customer and patient bases;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">hire and retain employees, including scientists and medical professionals, operations personnel, financial and accounting staff, and sales and marketing staff;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">respond to competitive pressures or unanticipated working capital requirements; <span style="letter-spacing: -0.25pt">or</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">pursue opportunities for acquisitions of, investments in, or strategic alliances and joint ventures with complementary businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may invest in or acquire other businesses, and our business may
suffer if we are unable to successfully integrate an acquired business into our company or otherwise manage the growth associated with
multiple acquisitions.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">From time to time, we may acquire, make investments
in, or enter into strategic alliances and joint ventures with, complementary businesses. These transactions may involve significant risks
and uncertainties, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In the case of an acquisition:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The potential for the acquired business to underperform relative to our expectations and the acquisition price;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The potential for the acquired business to cause our financial results to differ from expectations in any given period, or over the longer-term;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px; padding-top: 0.05pt; line-height: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 96%">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 27.6pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">Unexpected tax consequences from the acquisition, or the tax treatment of the acquired business&#8217;s operations going forward, giving rise to incremental tax liabilities that are difficult to predict;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Difficulty in integrating the acquired business, its operations, and its employees in an efficient and effective manner;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Any unknown liabilities or internal control deficiencies assumed as part of the acquisition; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The potential loss of key employees of the acquired businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In the case of an investment, alliance, joint venture,
or other partnership:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our ability to cooperate with our co-venturer;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Our co-venturer having economic, business, or legal interests or goals that are inconsistent with ours; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">The potential that our co-venturer may be unable to meet is economic or other obligations, which may require us to fulfill those obligations alone or find a suitable replacement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Any such transaction may involve the risk that
our senior management&#8217;s attention will be excessively diverted from our other operations, the risk that our industry does not evolve
as anticipate, and that any intellectual property or personnel skills acquired do not prove to be those needed for our future success,
and the risk that our strategic objectives, cost savings or other anticipate benefits are otherwise not achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may experience difficulties in managing our growth and expanding
our operations.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We expect to experience significant growth in the
scope of our operations. Our ability to manage our operations and future growth will require us to continue to improve our operational,
financial and management controls, compliance programs and reporting systems. We may not be able to implement improvements in an efficient
or timely manner and may discover deficiencies in existing controls, programs, systems and procedures, which could have an adverse effect
on our business, reputation and financial results. Additionally, rapid growth in our business may place a strain on our human and capital
resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Business and Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We have an unproven business model with no assurance of significant
revenues or operating profit.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our current business model is unproven and the
profit potential, if any, is unknown at this time. We are subject to all of the risks inherent in the creation of a new business. Our
ability to achieve profitability is dependent, among other things, on our initial marketing and accompanying product acceptance to generate
sufficient operating cash flow to fund current operations and future expansion. There can be no assurance that our results of operations
or business strategy will achieve significant revenue or profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The market for epigenetic tests is fairly new and unproven, and
it may decline or experience limited growth, which would adversely affect our ability to fully realize the potential of our platform.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Epigenetics is at the heart of our technology,
products and services. According to the CDC, epigenetics is the study of how a person&#8217;s behaviors and environment can cause changes
that affect the way a person&#8217;s genes work. Unlike genetic changes, epigenetic changes are reversible and do not change one&#8217;s
DNA sequence, but they can change how a person&#8217;s body reads a DNA sequence. The market for epigenetic tests is relatively new and
evaluating the size and scope of the market is subject to a number of risks and uncertainties. We believe that our future success will
depend in large part on the growth of this market. The utilization of our solution is still relatively new, and customers may not recognize
the need for, or benefits of, our tests and services, which may prompt them to cease use of our tests and services or decide to adopt
alternative products and services to satisfy their healthcare requirements. In order to expand our business and extend our market position,
we intend to focus our marketing and sales efforts on educating customers about the benefits and technological capabilities of our tests
and services and the application of our tests and services to specific needs of customers in different market verticals. Our ability to
access and expand the market that our tests and services are designed to address depends upon a number of factors, including the cost,
performance and perceived value of the tests and services. Market opportunity estimates are subject to significant uncertainty and are
based on assumptions and estimates. Assessing the market for our solutions in each of the vertical markets we are competing in, or planning
to compete in, is particularly difficult due to a number of factors, including limited available information and rapid evolution of the
market. The market for our tests and services may fail to grow significantly or be unable to meet the level of growth we expect. As a
result, we may experience lower-than-expected demand for our products and services due to lack of customer acceptance, technological challenges,
competing products and services, decreases in expenditures by current and prospective customers, weakening economic conditions and other
causes. If our market share does not experience significant growth, or if demand for our solution does not increase, then our business,
results of operations and financial condition will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The estimates of market opportunity and forecasts of market growth
included in this Prospectus may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our
business could fail to grow at similar rates, if at all.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Market opportunity estimates and growth forecasts
are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The estimates and
forecasts in this Prospectus relating to the size and expected growth of the cardiovascular diagnostics market may prove to be inaccurate.
Even if the market in which we compete meets our size estimates and forecasted growth, our business could fail to grow at similar rates,
if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we are not able to enhance or introduce new products that achieve
market acceptance and keep pace with technological developments, our business, results of operations and financial condition could be
harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our ability to attract new customers and increase
revenue from existing customers depends in part on our ability to enhance and improve our solutions, increase adoption and usage of our
products and introduce new products and features. The success of any enhancements or new products depends on several factors, including
timely completion, adequate quality testing, actual performance quality, market-accepted pricing levels and overall market acceptance
and demand. Enhancements and new products that we develop may not be introduced in a timely or cost-effective manner, may contain defects,
may have interoperability difficulties with our solutions, or may not achieve the market acceptance necessary to generate significant
or any revenue. If we are unable to successfully enhance our existing solutions and capabilities to meet evolving customer requirements,
increase adoption and usage of our solutions, develop new products, or if our efforts to increase the usage of our products are more expensive
than we expect, then our business, results of operations and financial condition could be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The success of our business depends on our ability to expand into
new vertical markets and attract new customers in a cost-effective manner.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In order to grow our business, we plan to drive
greater awareness and adoption of our tests and services from customers across new vertical markets. We intend to increase our investment
in sales and marketing, as well as in technological development, to meet evolving customer needs in these and other markets. There is
no guarantee, however, that we will be successful in gaining new customers from existing and new markets. We have limited experience in
marketing and selling our products and services generally, and in particular in new markets, which may present unique and unexpected challenges
and difficulties. Furthermore, we may incur additional costs to modify our current solutions to conform to the customer&#8217;s requirements,
and we may not be able to generate sufficient revenue to offset these costs. We may also be required to comply with certain regulations
required by government customers, which will require us to incur costs, devote management time and modify our current solutions and operations.
If we are unable to comply with those regulations effectively and in a cost-effective manner, our financial results could be adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If the costs of the new marketing channels we use
or plan to pursue increase dramatically, then we may choose to use alternative and less expensive channels, which may not be as effective
as the channels we currently use or have plans to use. As we add to or change the mix of our marketing strategies, we may need to expand
into more expensive channels than those we are currently in, which could adversely affect our business, results of operations and financial
condition. In addition, we have limited experience marketing our products and services and we may not be successful in selecting the marketing
channels that will provide us with exposure to customers in a cost-effective manner. As part of our strategy to penetrate the new vertical
markets, we expect to incur marketing expenses before we are able to recognize any revenue in such markets, and these expenses may not
result in increased revenue or brand awareness. We expect to make significant expenditures and investments in new marketing activities,
and these investments may not lead to the cost-effective acquisition of additional customers. If we are unable to maintain effective sales
and marketing programs, then our ability to attract new customers or enter into new vertical markets could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Consolidation in the health care industry could have a material
adverse effect on our business, financial condition and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Many health care industry participants and payers
are consolidating to create larger and more integrated health care delivery systems with greater market power. We expect regulatory and
economic conditions to result in additional consolidation in the health care industry in the future. As consolidation accelerates, the
economies of scale of our customers&#8217; organizations may grow. If a customer experiences sizable growth following consolidation, that
customer may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as
health care providers consolidate to create larger and more integrated health care delivery systems with greater market power, these providers
may try to use their market power to negotiate price reductions for our products and services. Finally, consolidation may also result
in the acquisition or future development by our customers of products and services that compete with our products and services. Any of
these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we are not able to compete effectively, our business and operating
results will be harmed.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The market for our tests and services is increasingly
competitive, rapidly evolving and fragmented, and is subject to changing technology and shifting customer needs. Although we believe that
the solutions that we offer are unique, many companies develop and market products and services that compete to varying extents with our
offerings, and we expect competition in our market to continue to intensify. Moreover, industry consolidation may increase competition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">While the clinical epigenetics market is still
fairly new, we face competition from various sources, including large, well-capitalized technology companies such as Cleerly and Prevencio.
These competitors may have better brand name recognition, greater financial and engineering resources and larger sales teams than we have.
As a result, our competitors may be able to develop and introduce competing solutions and technologies that may have greater capabilities
than our solutions or that are able to achieve greater customer acceptance, and they may be able to respond more quickly and effectively
than we can to new or changing opportunities, technologies, standards or customer requirements. In addition, we may also compete with
smaller companies, who may develop their own platforms that perform similar services as our platform. We expect that competition will
increase and intensify as we continue to expand our serviceable markets and improve our tests and services. If we are unable to provide
our tests and services on terms attractive to the customer, the prospective customer may be unwilling to utilize our solutions. If our
competitors&#8217; products, services or technologies become more accepted than our solutions, if they are successful in bringing their
products or services to market earlier than we do, or if their products or services are more technologically capable than ours, then our
revenue could be adversely affected. In addition, increased competition may result in pricing pressures and require us to incur additional
sales and marketing expenses, which could negatively impact our sales, profitability and market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our business depends on customers increasing their use of our solutions,
and we may experience loss of customers or decline in their use of our solutions.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our ability to grow and generate revenue depends,
in part, on our ability to maintain and grow our relationships with existing customers and convince them to increase their usage of our
tests and services. If our customers do not increase their use of our tests and services, then our revenue may not grow, and our results
of operations may be harmed. It is difficult to accurately predict customers&#8217; usage levels and the loss of customers or reductions
in their usage levels may have a negative impact on our business, results of operations and financial condition. If a significant number
of customers cease using, or reduce their usage of our tests and services, then we may be required to expend significantly more on sales
and marketing than we currently plan to expend in order to maintain or increase revenue from customers. These additional expenditures
could adversely affect our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our technologies and products leverage and incorporate</i> AI <i>and
machine learning, and their development, maintenance, and operational success are subject to various risks and uncertainties, some of
which are beyond our control and may adversely affect our business, results of operations and financial condition, and may also result
in reputational harm and liability.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">One of the key components of our technology and
solutions is the use of machine learning/artificial intelligence (&#8220;ML/AI&#8221;). While we have made, and expect to continue to
make, investments in the continued development of AI capabilities, adoption of fast changing AI technology presents risks, challenges
and potential unintended consequences. Also, the markets for our solutions and services are rapidly evolving and are highly competitive,
and many of our competitors are also seeking to incorporate AI into their products. Competing firms may be able to develop and embed AI
in their products more quickly than we can. If our competitors are better able to incorporate AI in their products and we are unable to
compete effectively with them, our business, results of operations and financial condition could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our ML/AI powering our technology and products,
there are known risks of with the use of ML/AI including accuracy, bias, toxicity, privacy, security and data provenance. Developing,
testing and deploying ML/AI systems may also increase the cost of our offerings. Our failure to adequately address potential risks relating
to the use of ML/AI in our technology and solutions could result in litigation regarding, among other things, intellectual property, privacy
and other claims that could result in liability for our company. It may also result in new or increased governmental or regulatory scrutiny,
which could result in regulatory action, legal liabilities, regulatory penalties, and damage to our reputation, potentially harming our
business and financial condition. The use of our AI capabilities could raise ethical or social concerns and our failure to adequately
address these concerns or the failure of our competitors, clients or other end users to do so could negatively impact our brand and reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our success in ML/AI technologies depends significantly
on the continued service of our key technical personnel especially our Chief Technology Officer and our Chief Executive Officer, and our
ability to attract and retain skilled professionals in a competitive market. The loss of key personnel or the inability to hire and retain
the necessary talent could adversely affect our technological competitiveness and operational capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interruptions or performance problems associated with our technology
and infrastructure may adversely affect our business and operating results.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our continued growth depends in part on the ability
of customers to access its tests and services at any time and within an acceptable amount of time. We may in the future experience disruptions,
outages and other performance problems due to a variety of factors, including challenges with suppliers, infrastructure changes, introductions
of new applications and functionality, software errors and defects, capacity constraints due to an increasing number of customers or security
related incidents. In addition, from time-to-time, we or our vendors may experience limited periods of equipment downtime, server downtime
due to server failure or other technical difficulties (as well as maintenance requirements). It may become increasingly difficult to maintain
and improve our performance, especially during high volume times and as our solution becomes more complex and our customer demand and
traffic increases. If our solution is unavailable or if our customers are unable to access our solutions within a reasonable amount of
time or at all, our business would be adversely affected, and its brand could be harmed. In the event of any of the factors described
above, or certain other failures of our infrastructure, customer or patient data may be permanently lost. To the extent that we do not
effectively address capacity constraints, upgrade our systems, as needed, and continually develop our technology and network architecture
to accommodate actual and anticipated changes in technology, customers may cease to use our solutions and our business and operating results
may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We rely on a limited number of suppliers, contract manufacturers,
and logistics providers, and our test is performed by a single contract high complexity Clinical Laboratory Improvement Amendments (CLIA)
laboratory.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">For our Epi+Gen CHD&#8482; and PrecisionCHD&#8482;
tests, we and our vendors rely on a limited number of suppliers for laboratory reagents and sampling kit supplies, contract manufacturers,
and logistics providers. For example, certain proprietary reagents are manufactured under Good Manufacturing Practice (GMP) by a single
contract manufacturer located in Michigan; the blood collection tubes included in the sample collection kits are manufactured by a single
manufacturer; and the tests are performed in one high complexity CLIA laboratory located in Missouri. The reliance on a limited number
of suppliers and a sole contract manufacturer and laboratory present various risks. These include the risk that in the event of an interruption
from any part of our supply chain for any reason, such as a natural catastrophe, labor dispute, or system interruption. We may not be
able to develop an alternate source without incurring material additional costs and substantial delays. For example, during 2021, the
Coronavirus pandemic impacted the ability to conduct in-person training of personnel at the laboratory, which delayed the launch of Epi+Gen
CHD&#8482; by approximately two and a half months. As a public company, the delay of a product launch by a nearly a fiscal quarter could
cause our reported results of operations to fail to meet market expectations, which, in turn, and could negatively impact our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The security of our solutions, networks or computer systems may
be breached, and any unauthorized access to our customer data will have an adverse effect on our business and reputation.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The use of our solutions involves the storage,
transmission and processing of our customers&#8217; private data, and this data may contain confidential and proprietary information of
our customers or their customers, patients, employees, business partners or other persons (&#8220;customer personnel&#8221;) or other
personal or identifying information regarding our customers and customer personnel. Individuals or entities may attempt to penetrate our
network or platform security, or that of our third-party hosting and storage providers, and could gain access to our customer and customer
personnel private data, which could result in the destruction, disclosure or misappropriation of proprietary or confidential information
of our customers and customer personnel. If any of our customers&#8217; or customer personnel&#8217;s private data is leaked, obtained
by others or destroyed without authorization, it could harm our reputation, we could be exposed to civil and criminal liability, and we
may lose our ability to access private data, which will adversely affect the quality and performance of our solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, our platform and services may be subject
to computer malware, viruses and computer hacking, fraudulent use attempts and phishing attacks, all of which have become more prevalent
in our industry. Though it is difficult to determine what, if any, harm may directly result from any specific interruption or attack,
they may include the theft or destruction of data owned by us or our customers or customer personnel, and/or damage to our platform. Any
failure to maintain the performance, reliability, security and availability of our products and technical infrastructure to the satisfaction
of our customers may harm our reputation and our ability to retain existing customers and attract new customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">While we have implemented and is continuing to
implement procedures and safeguards that are designed to prevent security breaches and cyber attacks, they may not be able to protect
against all attempts to breach our systems, and we may not become aware in a timely manner of any such security breach. Unauthorized access
to or security breaches of our platform, network or computer systems, or those of our technology service providers, could result in the
loss of business, reputational damage, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach,
civil and criminal penalties for violation of applicable laws, regulations or contractual obligations and significant costs, fees and
other monetary payments for remediation. If customers believe that our platform does not provide adequate security for the storage of
sensitive information or its transmission over the Internet, our business will be harmed. Customers&#8217; concerns about security or
privacy may deter them from using our solutions for activities that involve personal or other sensitive information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We maintain cybersecurity coverage; however, this
coverage may not continue to be available on acceptable terms, may not be available in sufficient amounts to cover one or more large claims
against us, and may include larger self-insured retentions or certain exclusions. In addition, the insurer might disclaim coverage as
to any future claim. A successful claim not fully covered by our insurance could have a material adverse impact on our liquidity, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Any failure to offer high-quality customer support may adversely
affect our relationships with our customers.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our ability to retain existing customers and attract
new customers depends in part on our ability to maintain a consistently high level of customer service and technical support. Our current
and future customers depend on our customer support team to assist them in utilizing our tests and services effectively and to help them
to resolve issues quickly and to provide ongoing support. If we are unable to hire and train sufficient support resources or are otherwise
unsuccessful in assisting our customers effectively, it could adversely affect our ability to retain existing customers and could prevent
prospective customers from adopting our solutions. We may be unable to respond quickly enough to accommodate short-term increases in demand
for customer support. We also may be unable to modify the nature, scope and delivery of our customer support to compete with changes in
the support services provided by our competitors. Increased demand for customer support, without corresponding revenue, could increase
our costs and adversely affect our business, results of operations and financial condition. Our sales are and will be highly dependent
on our business reputation and on positive recommendations from customers. Any failure to maintain high-quality customer support, or a
market perception that we do not maintain high-quality customer support, could adversely affect our reputation, business, results of operations
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The information that we provide to our customers could be inaccurate
or incomplete, which could harm our business reputation, financial condition, and results of operations.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We aggregate, process, and analyze customers&#8217;/patients&#8217;
healthcare-related data and information for use by our customers. Because data in the healthcare industry is fragmented in origin, inconsistent
in format, and often incomplete, the overall quality of data received or accessed in the healthcare industry is often poor, the degree
or amount of data which is knowingly or unknowingly absent or omitted can be material. If the test results that we provide to our customers
are based on incorrect or incomplete data or if we make mistakes in the capture, input, or analysis of these data, our reputation may
suffer, and our ability to attract and retain customers may be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, in the future, we may assist our customers
with the management and submission of data to governmental entities, including CMS. These processes and submissions are governed by complex
data processing and validation policies and regulations. If we fail to abide by such policies or submits incorrect or incomplete data,
we may be exposed to liability to a client, court, or government agency that concludes that its storage, handling, submission, delivery,
or display of health information or other data was wrongful or erroneous.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our proprietary applications may not operate properly, which could
damage our reputation, give rise to a variety of claims against us, or divert our resources from other purposes, any of which could harm
our business and operating results.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Proprietary software, product and application development
is time-consuming, expensive, and complex, and may involve unforeseen difficulties. We may encounter technical obstacles, and it is possible
that we discover additional problems that prevent our proprietary solutions from operating properly. If our solutions and services do
not function reliably or fail to achieve customer expectations in terms of performance, customers could assert liability claims against
us and attempt to cancel their contracts with us. Moreover, material performance problems, defects, or errors in our existing or new solutions
may arise in the future and may result from, among other things, the lack of interoperability of our applications with systems and data
that we did not develop and the function of which is outside of our control or undetected in our testing. Defects or errors in our solutions
might discourage existing or potential customers from purchasing products and services from us. Correction of defects or errors could
prove to be time consuming, costly, impossible, or impracticable. The existence of errors or defects in our solutions and the correction
of such errors could divert our resources from other matters relating to its business, damage our reputation, increase our costs, and
have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we do not keep pace with technological changes, our solutions
may become less competitive, and our business may suffer.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The clinical epigenetic testing, artificial intelligence/machine
learning-based solutions and the cardiovascular diagnostics markets are undergoing rapid technological change, frequent product and service
innovation and evolving industry standards. If we are unable to provide enhancements and new features for our existing tests and services
or additional tests and services that achieve market acceptance or that keep pace with these technological developments, our business
could be adversely affected. The success of enhancements, new tests and services depends on several factors, including the timely completion,
introduction and market acceptance of the innovations. Failure in this regard may significantly impair our revenue growth. In addition,
because our solutions are designed to operate on existing cloud software and technologies, we will need to continuously modify and enhance
our solutions to keep pace with changes in internet-related hardware, software, communication, browser and database technologies, alongside
changes in laboratory technologies. We may not be successful in either developing these modifications and enhancements or in bringing
them to market in a timely fashion. Furthermore, uncertainties about the timing and nature of new diagnostic tests, network platforms
or technologies, including laboratory technologies, or modifications to existing tests, platforms or technologies, could increase our
research and development expenses. Any failure of our solutions to keep pace with technological changes or operate effectively with future
network platforms and technologies, including laboratory technologies, could reduce the demand for our solutions, result in customer dissatisfaction
and adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our growth strategy may not prove viable and expected growth and
value may not be realized.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">While our overall sales and marketing initiatives
will span the gamut across traditional, print and digital mediums, our primary sales and marketing strategy consists of the branding,
collaboration, co-marketing, and co-sales opportunities involved in strategic channel partnerships. By prioritizing strategic channel
partnerships, we believe we can accelerate our market penetration into the key healthcare sub-verticals we intend to prioritize for our
growth. The key to our efforts is a well-defined and executed channel partnership integration strategy that we believe will serve to accelerate
the sales cycle. Although there is no assurance, we believe such strategic channel partnerships will generate revenue in a myriad of ways,
including larger contracts for our Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests, our HeartRisk platform, and bundling our solutions
alongside other synergistic technologies, services, and products. There can be no assurance that we will be successful in acquiring customers
through these and other strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Market and economic conditions may negatively impact our business,
financial condition and stock price.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Concerns over inflation, tariff policies, energy
costs, geopolitical issues, including the ongoing conflict between Russian and Ukraine, unstable global credit markets and financial conditions,
and volatile oil prices could lead to periods of significant economic instability, diminished liquidity and credit availability, declines
in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic
growth going forward. For example, in March 2022, the U.S. Consumer Price Index (&#8220;CPI&#8221;), which measures a wide-ranging basket
of goods and services, rose 8.5% from the same month a year ago, which represents the largest CPI increase since December of 1981. Our
general business strategy may be adversely affected by any such inflationary fluctuations, economic downturns, volatile business environments
and continued unstable or unpredictable economic and market conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Additionally, rising costs of goods and services
purchased by us, including the cost raw materials used in manufacturing our tests, may have an adverse effect on our gross margins and
profitability in future periods. Potential imposition of new tariff policies by the U.S. and retaliatory tariffs by other countries could
negatively impact our costs, margins and future profitability. If economic and market conditions continue to deteriorate or do not improve,
it may make any necessary debt or equity financing more difficult to complete, more costly and more dilutive to our stockholders. Failure
to secure any necessary financing in a timely manner or on favorable terms could have a material adverse effect on our financial performance
and stock price or could require us to delay or abandon development other business plans. In addition, there is a risk that one or more
of our current and future service providers, manufacturers, suppliers, other partners could be negatively affected by such difficult economic
factors, which could adversely affect our ability to attain our operating goals on schedule and on budget or meet our business and financial
objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our success depends upon our ability to adapt to a changing market
and our continued development of additional tests and services.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Although we believe that we will provide a competitive
range of tests and services, there can be no assurance of acceptance by the marketplace. The procurement of new contracts by us may be
dependent upon the continuing results achieved with current and future customers, upon pricing and operational considerations, as well
as the potential need for continuing improvement to existing products and services. Moreover, the markets for such services may not develop
as expected nor can there be any assurance that we will be successful in our marketing of any such products and services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compliance with changing regulation of corporate governance and
public disclosure will result in significant additional expenses.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Changing laws, regulations, and standards relating
to corporate governance and public disclosure for public companies, including the Sarbanes-Oxley Act of 2002 and various rules and regulations
adopted by the SEC, are creating uncertainty for public companies. Our management will need to invest significant time and financial resources
to comply with both existing and evolving requirements for public companies, which will lead, among other things, to significantly increased
general and administrative expenses and a certain diversion of management time and attention from revenue generating activities to compliance
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Business Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We could experience losses or liability not covered by insurance.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our business exposes us to risks that are inherent
in the provision of testing services that assist clinical decision-making. If customers or customer personnel assert liability claims
against us, any ensuing litigation, regardless of outcome, could result in a substantial cost to the Company, divert management&#8217;s
attention from operations, and decrease market acceptance of our solutions. The limitations of liability set forth in any contracts we
may enter into now or in the future may not be enforceable or may not otherwise protect us from liability for damages. Additionally, we
may be subject to claims that are not explicitly covered by a contract. We also maintain general liability coverage; however, this coverage
may not continue to be available on acceptable terms, may not be available in sufficient amounts to cover one or more large claims against
us, and may include larger self-insured retentions or exclusions for certain products. In addition, the insurer might disclaim coverage
as to any future claim. A successful claim not fully covered by our insurance could have a material adverse impact on our liquidity, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our future growth could be harmed if we lose the services of our
key personnel.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are highly dependent upon the talents and services
of a number of key employees, specifically Meeshanthini Dogan, PhD and Robert Philibert, MD PhD and other senior technical and management
personnel, including our other executive officers, all of whom would be difficult to replace. In 2022, we entered into multi-year employment
agreements with each of our executive officers and a consulting agreement with our non-executive chairman. The loss of the services of
one or more of these key employees would disrupt our business and harm its results of operations. As competition is intense for the type
of highly skilled scientific and medical professionals our business requires, we may not be able to successfully attract and retain senior
leadership necessary to grow our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we are unable to hire, retain and motivate qualified personnel,
our business will suffer.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our future success depends, in part, on our ability
to continue to attract and retain highly skilled personnel. We believe that there is, and will continue to be, intense competition for
highly skilled management, medical, engineering, data science, sales and other personnel with experience in our industry. We must provide
competitive compensation packages and a high-quality work environment to hire, retain and motivate employees. If we are unable to retain
and motivate our existing employees and attract qualified personnel to fill key positions, we may be unable to manage our business effectively,
including the development, marketing and sale of our products, which could adversely affect our business, results of operations and financial
condition. To the extent we hire personnel from competitors, we also may be subject to allegations that they have been improperly solicited
or that they have divulged proprietary or other confidential information. If we are unable to retain our employees, our business, results
of operations and financial condition could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we cannot maintain our corporate culture as it grows, we could
lose the innovation, teamwork, passion and focus on execution that it believes contribute to its success, and its business may be harmed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that our corporate culture is a critical
component to our success. We have and will continue to invest substantial time and resources in building our team. As we grow and develop
the infrastructure of a public company, we may find it difficult to maintain our corporate culture. Any failure to preserve our culture
could negatively affect our future success, including our ability to retain and recruit personnel and effectively focus on and pursue
our corporate objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may be unable to manage our growth.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Currently, we have less than 16 full and part-time
employees. Our ability to manage our growth effectively will require us to continue to improve our operational, financial and management
controls and information systems to accurately forecast sales demand, to manage our operating costs, manage our marketing programs in
conjunction with an emerging market, and attract, train, motivate and manage our employees effectively. Our growth strategy will place
significant demands on our management team and our financial, administrative and other resources. Operating results will depend substantially
on the ability of our officers and key employees to manage changing business conditions and to implement and improve its financial, administrative
and other resources. If management fails to manage the expected growth, our results of operations, financial condition, business and prospects
could be adversely affected. In addition, our growth strategy may depend on effectively integrating future entities, which requires cooperative
efforts from the managers and employees of the respective business entities. If we are unable to respond to and manage changing business
conditions, or the scale of our operations, then the quality of our products and services, our ability to retain key personnel, and our
business could be harmed, which in turn, could adversely affect our results of operations, financial condition, business and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our Board of Directors may change its strategies, policies, and
procedures without stockholder approval, and we may become highly leveraged, which may increase our risk of default under our existing
or future obligations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our investment, financing, leverage, and dividend
policies, and our policies with respect to all other activities, including growth, capitalization, and operations, are determined exclusively
by our board of directors, and may be amended or revised at any time by our board of directors without notice to or a vote of our stockholders.
This could result in the Company conducting operational matters, making investments, or pursuing different business or growth strategies
than those contemplated in this Prospectus. Further, our charter and bylaws do not limit the amount or percentage of indebtedness, funded
or otherwise, that we may incur. High leverage also increases the risk of default on our obligations. In addition, a change in our investment
policies, including the manner in which we allocate our resources across our portfolio or the types of assets in which we seek to invest,
may increase our exposure to interest rate risk and liquidity risk. Changes to our policies with regards to the foregoing could materially
adversely affect our financial condition, results of operations, and cash flow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our business is subject to the risks of earthquakes, fire, floods,
pandemics and other natural catastrophic events, and to interruption by man-made problems, such as power disruptions, computer viruses,
data security breaches or terrorism.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A significant natural disaster, such as a tornado,
hurricane or a flood, occurring at our headquarters or where a business partner is located could adversely affect our business, results
of operations and financial condition. Further, if a natural disaster or man-made problem were to affect our network service providers
or Internet service providers, this could adversely affect the ability of our customers to use our products and platform. In addition,
health epidemics or pandemics, natural disasters and acts of terrorism could cause disruptions in our business, or the businesses of our
customers or service providers. We also rely, and will continue to rely, on our network and third-party infrastructure and enterprise
applications and internal technology systems for our engineering, sales and marketing and operations activities. In the event of a major
disruption caused by a health epidemic or pandemic, natural disaster or man-made problem, we may be unable to continue our operations
and may endure system interruptions, reputational harm, delays in our development activities, lengthy interruptions in service, breaches
of data security and loss of critical data, any of which could adversely affect our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may need to seek alternative business opportunities and change
the nature of our business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a company in the early stages of its development,
we continuously reevaluate our business, the market in which we operate and potential new opportunities. We may seek other alternatives
within the healthcare field in order to grow our business and increase revenues. Such alternatives may include, but not be limited to,
combinations or strategic partnerships with laboratory companies or with medical practices such as hospitalists or behavioral health.
Pursuing alternative business opportunities could increase our expenses, may require us to obtain additional financing, which may not
be available on favorable terms or at all, and result in potentially dilutive issuances of our equity securities or the incurrence of
debt that may be burdensome to service, any of which could have a material adverse effect on our business and operations. In addition,
pursuing alternative business opportunities may never be successful and may divert significant management time and attention. Moreover,
accomplishing and integrating any business opportunity that is pursued by us may disrupt the existing business and may be a complex, risky
and costly endeavor and could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Any legal proceedings or claims against us could be costly and time-consuming
to defend and could harm our reputation regardless of the outcome.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We may in the future become subject to legal proceedings
and claims that arise in the ordinary course of business, including intellectual property, collaboration, licensing agreement, product
liability, employment, class action, whistleblower and other litigation claims, and governmental and other regulatory investigations and
proceedings. Such matters can be time-consuming, divert management&#8217;s attention and resources, cause us to incur significant expenses
or liability, or require us to change our business practices. In addition, the expense of litigation and the timing of this expense from
period to period are difficult to estimate, subject to change, and could adversely affect our financial condition and results of operations.
Because of the potential risks, expenses, and uncertainties of litigation, we may, from time to time, settle disputes, even where we have
meritorious claims or defenses, by agreeing to settlement agreements. Any of the foregoing could adversely affect our business, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our license agreement with the University of Iowa Research Foundation
includes a non-exclusive license of &#8220;technical information&#8221; that potentially could grant unaffiliated third parties access
to materials and information considered derivative work made by us, which could be used by such licensees to develop competitive products.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The University of Iowa Research Foundation, or
UIRF, license agreement grants to us a worldwide, exclusive, non-transferable license under the Patent Rights, as defined in the agreement,
to make, have made, use, sell, offer for sale and import the Licensed Products(s) and/or Licensed Processes, as defined in the agreement,
in the field of research tools and clinical diagnostics for cardiovascular disease, stroke, congestive heart failure and diabetes in humans.
However, the agreement also confers a non-exclusive license as to Technical Information. Technical Information is defined as certain research
and development information, materials, confidential information, technical data, unpatented inventions, know-how and supportive information
owned and controlled by the licensor that was not in the public domain as of May 2, 2017 and that describes the Invention, as defined
in the agreement, its manufacture and/or use and selected by the licensor to provide to us for use in or with the development, manufacture
or use of the Licensed Products and/or Licensed Processes. Technical Information further includes materials, all progeny and derivatives
of the materials made by us or our sublicensees, as well as software or other copyrightable work, all derivatives of such software and
other copyrightable work made by us and our sublicensees. The ability of UIRF to grant non-exclusive licenses to third parties in and
to this broad definition of Technical Information raises the possibility that unaffiliated third parties could use such Technical Information,
including Technical Information used by the Company, to make, use, sell, offer to sell and import products and/or processes that compete
with the Company&#8217;s exclusively-licensed products and/or processes or are positioned in markets that the Company may enter in the
future. Increased competition could result in reduced demand for the Company&#8217;s products and/or processes, slow its growth and materially
adversely affect its business, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We could incur substantial costs in protecting or defending our
intellectual property rights, and any failure to protect or defend our intellectual property could adversely affect our business, results
of operations and financial condition.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our success depends, in part, on our ability to
protect our brand and the proprietary methods and technologies that we develop under patent and other intellectual property laws of the
United States and foreign jurisdictions so that we can prevent others from using our inventions and proprietary information. Any patents
that have been issued or that may be issued in the future may not provide significant protection for our intellectual property. If we
fail to protect our intellectual property rights adequately, our competitors might gain access to our technology and our business, results
of operations and financial condition may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The particular forms of intellectual property protection
that we seek, or our business decisions about when to file patent applications and trademark applications, may not be adequate to protect
our business. We could be required to expend significant resources to monitor and protect our intellectual property rights. Litigation
may be necessary in the future to enforce our intellectual property rights, determine the validity and scope of our proprietary rights
or those of others, or defend against claims of infringement or invalidity. Such litigation could be costly, time-consuming and distracting
to management, result in a diversion of significant resources, lead to the narrowing or invalidation of portions of our intellectual property
and have an adverse effect on our business, results of operations and financial condition. Our efforts to enforce our intellectual property
rights may be met with defenses, counterclaims and countersuits attacking the validity and enforceability of our intellectual property
rights or alleging that we infringe the counterclaimant&#8217;s own intellectual property. Any of our patents, copyrights, trademarks
or other intellectual property rights could be challenged by others or invalidated through administrative process or litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We also rely, in part, on confidentiality agreements
with our business partners, employees, consultants, advisors, customers and others in our efforts to protect our proprietary technology,
processes and methods. These agreements may not effectively prevent disclosure of our confidential information, and it may be possible
for unauthorized parties to copy our software or other proprietary technology or information, or to develop similar technology independently
without our having an adequate remedy for unauthorized use or disclosure of our confidential information. In addition, others may independently
discover our trade secrets and proprietary information, and in these cases, we would not be able to assert any trade secret rights against
those parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and
the failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, the laws of some countries do not
protect intellectual property and other proprietary rights to the same extent as the laws of the United States. To the extent we expand
into international activities, our exposure to unauthorized copying, transfer and use of our proprietary technology or information may
increase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our means of protecting our intellectual property
and proprietary rights may not be adequate or our competitors could independently develop similar technology. If we fail to meaningfully
protect our intellectual property and proprietary rights, our business, results of operations and financial condition could be adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Assertions by third parties of infringement or other violations
by us of its intellectual property rights could result in significant costs and harm our business and operating results.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our success depends upon our ability to refrain
from infringing upon the intellectual property rights of others. Some companies, including some of our competitors, own large numbers
of patents, copyrights and trademarks, which they may use to assert claims against us. As we grow and enter new markets, we will face
a growing number of competitors. As the number of competitors in our industry grows and the functionality of products in different industry
segments overlaps, we expect that software and other solutions in our industry may be subject to such claims by third parties. Third parties
may in the future assert claims of infringement, misappropriation or other violations of intellectual property rights against us. We cannot
assure investors that infringement claims will not be asserted against us in the future, or that, if asserted, any infringement claim
will be successfully defended. A successful claim against us could require that we pay substantial damages or ongoing royalty payments,
prevent us from offering our products and services, or require that we comply with other unfavorable terms. We may also be obligated to
indemnify our customers or business partners or pay substantial settlement costs, including royalty payments, in connection with any such
claim or litigation and to obtain licenses, modify applications or refund fees, which could be costly. Even if we were to prevail in such
a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management
and key personnel from our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Certain of our core technology is licensed, and that license may
be terminated if we were to breach our obligations under the license.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The initial work on our core technology is derived
from work done by our founders while at the University of Iowa, around which there is currently a family of patent applications, the rights
of which are owned by the University of Iowa Research Foundation (UIRF) and exclusively licensed to us. In addition, certain follow-on
work on our core technology also is derived from work done by our founders while at the University of Iowa but was furthered by our founders.
Therefore, certain follow-on work is co-owned by UIRF and us, and exclusively licensed to us under the license agreement with UIRF. That
license agreement and those licenses granted under the license agreement terminate on the expiration of the patent rights licensed under
the license agreement, unless certain proprietary, non-patented technical information is still being used by us, in which case the license
agreement will not terminate until the date of termination of such use. The licenses under the license agreement could terminate prior
to the expiration of the licensed patent rights if we materially breach our obligations under the license agreement, including failing
to pay the applicable license fees and any interest on such fees, and if we fail to fully remedy such breach within the period specified
in the license agreement, or if we enter liquidation, have a receiver or administrator appointed over any assets related to the license
agreement, or cease to carry on business, or file for bankruptcy or if an involuntary bankruptcy petition is filed against us. The license
agreement can also be terminated by either party as a result of any material breach of the license which is not remedied within 30 days
after receiving written notice thereof or by UIRF as a result of any breach of the license which has not been cured within 90 days after
UIRF provides written notice of such breach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Some of our technologies incorporate &#8220;open-source&#8221; software
or other similar licensed technologies, which could become unavailable or subject us to increased costs, delays in production or assessment
or litigation.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In order to provide our products, we currently
use a variety of technologies including, for example, genotyping, digital methylation assessment and data processing technologies owned
by third parties. The terms of these agreements, and any other &#8220;open source&#8221; software agreements we may rely upon in the future,
are subject to change without notice and may increase our costs. Moreover, our failure to comply with the terms of one or more of these
agreements could expose us to business disruption because the license may be terminated automatically due to non- compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The use and distribution of open-source software
may also entail greater risks than the use of third-party commercial software, as open-source licensors generally do not provide warranties
or other contractual protections regarding infringement claims or the quality of the code. Many of the risks associated with use of open-source
software cannot be eliminated and could negatively affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, the wide availability of open-source
code used in our current and future products could expose us to security vulnerabilities. From time to time, we may face claims from third
parties asserting ownership of, or demanding release of, the open-source software or derivative works that we developed using such software
(which could include our proprietary source code), or otherwise seeking to enforce the terms of the applicable open-source license. These
claims could result in litigation that could be costly to defend, have a negative effect on our operating results and financial condition
or require us to devote additional research and development resources to change our existing or future proprietary source code. Responding
to any infringement or noncompliance claim by an open-source vendor, regardless of its validity, discovering certain open-source software
code in our products, or a finding that we have breached the terms of an open- source software license, could harm our business, results
of operations and financial condition. In each case, we would be required to either seek licenses to software or services from other parties
and redesign our products to function with such other parties&#8217; software or services or develop these components internally, which
would result in increased costs and could result in delays to product launches. Furthermore, we might be forced to limit the features
available in our current or future solutions. If these delays and feature limitations occur, our business, results of operations and financial
condition could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Intellectual property that is in-licensed may have been made using
government funding and, thus, may be subject to federal regulations under the Bayh-Dole <span style="letter-spacing: -0.2pt">Act.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="letter-spacing: -0.2pt">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The intellectual property Cardio has licensed from
UIRF is indicated as having been discovered through government funded programs and thus, may be subject to federal regulations under the
Bayh-Dole Act. In general, the Bayh-Dole Act provides the U.S. government certain rights in inventions developed using government funding,
such as a right to a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In
addition, intellectual property generated with government funding is also subject to certain reporting requirements, and the Bayh-Dole
Act requires that any products subject to the Bayh-Dole Act be manufactured substantially in the United States, although this manufacturing
requirement can be waived if the owner of the patents and applications can show that reasonable efforts to manufacture the product substantially
in the United States were unsuccessful, or that under the circumstances, domestic manufacture is not commercially feasible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Under the Bayh-Dole Act, the U.S. government has
the right to take title to inventions developed using a U.S. government funded program, referred to as &#8220;march-in rights,&#8221;
for a number of reasons including, for example, failure to disclose the invention to the government or failure to file an application
within specified time limits. In addition, under the Bayh-Dole Act, the U.S. government has the right to require any invention developed
using U.S. government funding to be granted exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a
third party if it determines that (i) adequate steps have not been taken to commercialize the invention (ii) government action is necessary
to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Compliance with such regulations may limit Cardio&#8217;s
exclusive rights, subject Cardio to expenditure of resources with respect to reporting requirements and limit Cardio&#8217;s ability to
contract with non-U.S. manufacturers. In addition, any exercise by the government of any of the foregoing rights under the Bayh-Dole Act
may affect Cardio&#8217;s competitive position, business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We conduct business in a heavily regulated industry, and if we fail
to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations
or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The healthcare industry is heavily regulated and
closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we provide
and bill for our products services and collect reimbursement from governmental programs and private payors, our contractual relationships
with providers, vendors and customers, our marketing activities and other aspects of our operations. Of particular importance are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the federal physician self-referral law, commonly referred to as the Stark <span style="letter-spacing: -0.2pt">Law;</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the federal Anti-Kickback <span style="letter-spacing: -0.2pt">Act;</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the criminal healthcare fraud provisions of HIPAA;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the federal False Claims <span style="letter-spacing: -0.2pt">Act;</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">reassignment of payment rules that prohibit certain types of billing and collection;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">similar state law provisions pertaining to anti-kickback, self-referral and false claims issues;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">state laws that prohibit general business corporations, such as us, from practicing medicine; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">laws that regulate debt collection practices as applied to our debt collection practices.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Because of the breadth of these laws and the narrowness
of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge
under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws
and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status and
exclusion from the Medicare and Medicaid programs. The risk of us being found in violation of these laws and regulations is increased
by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes
open to a variety of interpretations. Our failure to accurately anticipate the application of these laws and regulations to our business
or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. Any action
against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant
legal expenses, divert management&#8217;s attention from the operation of our business and result in loss of customers and adverse publicity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">To enforce compliance with the federal laws, the
U.S. Department of Justice and the Office of the Inspector General (OIG) have recently increased their scrutiny of healthcare providers,
which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations
can be time- and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement
could increase our costs or otherwise have an adverse effect on our business. In addition, because of the potential for large monetary
exposure under the federal False Claims Act, which provides for treble damages and mandatory minimum penalties of $5,500 to $11,000 per
false claim or statement, healthcare providers often resolve allegations without admissions of liability for significant and material
amounts to avoid the uncertainty of treble damages that may be awarded in litigation proceedings. Such settlements often contain additional
compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement. Given the significant
size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating
healthcare providers&#8217; compliance with the healthcare reimbursement rules and fraud and abuse laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The laws, regulations and standards governing the
provision of healthcare services may change significantly in the future. We cannot assure investors that any new or changed healthcare
laws, regulations or standards will not materially adversely affect our business. We cannot assure investors that a review of our business
by judicial, law enforcement, regulatory or accreditation authorities will not result in a determination that could adversely affect our
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If our products do not receive adequate coverage and reimbursement
from third-party payors, our ability to expand access to our tests beyond the initial sales channels will be limited and our overall commercial
success will be limited.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We currently do not have broad-based coverage and
reimbursement for the Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests. However, our strategy is to expand access to our tests by pursuing
coverage and reimbursement by third-party payors, including government payors. Coverage and reimbursement by third-party payors, including
managed care organizations, private health insurers, and government healthcare programs, such as Medicare and Medicaid in the United States
and similar programs in other countries, for the types of risk assessment and detection tests we perform can be limited and uncertain.
Although the practical impact of recent changes to the Medicaid program are yet to be fully understood, it is possible that Medicaid reimbursement
for our tests could be negatively impacted. Healthcare providers may not order our products unless third-party payors cover and provide
adequate reimbursement for a substantial portion of the price of the products. If we are not able to obtain adequate coverage and an acceptable
level of reimbursement for our products from third-party payors, there could be a greater co-insurance or co- payment obligation for any
individual for whom a test is ordered. The individual may be forced to pay the entire cost of a test out-of-pocket, which could dissuade
physicians from ordering our products and, if ordered, could result in delay in or decreased likelihood of collection of payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Medicare is the single largest U.S. payor and a
particularly important payor for many cardiac-related laboratory services, given the demographics of the Medicare population. Generally,
traditional Medicare fee-for-service will not cover screening tests that are performed in the absence of signs, symptoms, complaints,
personal history of disease, or injury except when there is a statutory provision that explicitly covers the test. Epi+Gen CHD&#8482;
could be considered a screening test under Medicare and, accordingly, may not be eligible for traditional Medicare fee-for- service coverage
and reimbursement unless we pursue substantial additional measures, which would require significant investments, and may ultimately be
unsuccessful or may take several years to achieve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If eligible for reimbursement, laboratory tests
such as ours generally are classified for reimbursement purposes under CMS&#8217;s Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;)
and the American Medical Association&#8217;s (&#8220;AMA&#8221;) Current Procedural Terminology (&#8220;CPT&#8221;) coding systems. We
and payors must use those coding systems to bill and pay for our diagnostic tests, respectively. These HCPCS and CPT codes are associated
with the particular product or service that is provided to the individual. Accordingly, without a HCPCS or CPT code applicable to our
products, the submission of claims could be a significant challenge. Once CMS creates an HCPCS code or the AMA establishes a CPT code,
CMS establishes payment rates and coverage rules under traditional Medicare, and private payors establish rates and coverage rules independently.
Under Medicare, payment for laboratory tests is generally made under the Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;) with payment
amounts assigned to specific HCPCS and CPT codes. In addition, effective January 1, 2018, a new Medicare payment methodology went into
effect for clinical laboratory tests, under which laboratory-reported private payor rates are used to establish Medicare payment rates
for tests reimbursed via the CLFS. The new methodology implements Section 216 of the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;)
and requires laboratories that meet certain requirements related to volume and type of Medicare revenues to report to CMS their private
payor payment rates for each test they perform, the volume of tests paid at each rate, and the HCPCS code associated with the test. CMS
uses the reported information to set the Medicare payment rate for each test at the weighted median private payor rate. The full impact
of the PAMA rate-setting methodology and its applicability to our products remains uncertain at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Coverage and reimbursement by a third-party payor
may depend on a number of factors, including a payor&#8217;s determination that a product is appropriate, medically necessary, and cost-
effective. Each payor will make its own decision as to whether to establish a policy or enter into a contract to cover our products and
the amount it will reimburse for such products. Obtaining approvals from third-party payors to cover our products and establishing adequate
coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may never be
successful. If third-party payors do not provide adequate coverage and reimbursement for our products, our ability to succeed commercially
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Even if we establish relationships with payors
to provide our products at negotiated rates, such agreements would not obligate any healthcare providers to order our products or guarantee
that we would receive reimbursement for our products from these or any other payors at adequate levels. Thus, these payor relationships,
or any similar relationships, may not result in acceptable levels of coverage and reimbursement for our products or meaningful increases
in the number of billable tests we sell to healthcare providers. We believe it may take at least several years to achieve coverage and
adequate reimbursement with a majority of third-party payors, including with those payors offering negotiated rates. In addition, we cannot
predict whether, under what circumstances, or at what payment levels payors will cover and reimburse for our products. We do not expect
Epi+Gen CHD&#8482; or PrecisionCHD&#8482; to have Medicare or other third-party coverage or reimbursement in the near term. However, if
we fail to establish and maintain broad-based coverage and reimbursement for our products, our ability to expand access to our products,
generate increased revenue, and grow our test volume and customer base will be limited, and our overall commercial success will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our products may fail to achieve the degree of market acceptance
necessary for commercial success.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The failure of our products, once introduced, to
be listed in physician guidelines or of our studies to produce favorable results or to be published in peer-reviewed journals could limit
the adoption of our products. In addition, healthcare providers and third-party payors, including Medicare, may rely on physician guidelines
issued by industry groups, medical societies, and other key organizations, before utilizing or reimbursing the cost of any diagnostic
or screening test. Although we have published a study showing the Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are associated with
cost saving, it is not yet, and may never be, listed in any such guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Further, if our products or the technology underlying
them do not receive sufficient favorable exposure in peer-reviewed publications, the rate of physician and market acceptance of our products
and positive reimbursement coverage decisions for our products could be negatively affected. The publication of clinical data in peer-reviewed
journals is an important step in commercializing and obtaining reimbursement for products, such as Epi+Gen CHD&#8482; and PrecisionCHD&#8482;,
and our inability to control when, if ever, results are published may delay or limit our ability to derive sufficient revenues from any
product that is developed using data from a clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Failure to achieve broad market acceptance of our
products, including Epi+Gen CHD&#8482; and PrecisionCHD&#8482;, would materially harm our business, financial condition, and results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Customer Privacy, Cybersecurity
and Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our use and disclosure of personally identifiable information, including
health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations
or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse
effect on our customer base and revenue.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Numerous state and federal laws and regulations
govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of Personally Identifiable Information
(&#8220;PII&#8221;), including protected health information. These laws and regulations include the Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;). HIPAA establishes a set of basic national privacy and security standards for the protection of protected
health information, (&#8220;PHI&#8221;), by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered
entities, and the business associates with whom such covered entities contract for services, which includes Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">HIPAA requires healthcare providers like Cardio
to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative,
physical and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and standard
identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities
associated with the billing and collection of healthcare claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">HIPAA imposes mandatory penalties for certain violations.
Penalties for violations of HIPAA and its implementing regulations start at $100 per violation and are not to exceed $50,000 per violation,
subject to a cap of $1.5 million for violations of the same standard in a single calendar year. However, a single breach incident can
result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts
will be able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create
a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis
for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, HIPAA mandates that the Secretary
of Health and Human Services, or HHS, conduct periodic compliance audits of HIPAA-covered entities or business associates for compliance
with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the
victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">HIPAA further requires that patients be notified
of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information,
with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies
that such notifications must be made &#8220;without unreasonable delay and in no case later than 60 calendar days after discovery of the
breach.&#8221; If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the
name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also
be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS
at least annually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Numerous other federal and state laws protect the
confidentiality, privacy, availability, integrity and security of personally identifiable information, or PII, including PHI. These laws
in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations by
courts and government agencies, creating complex compliance issues for us, and our customers and potentially exposing us to additional
expense, adverse publicity and liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">New health information standards, whether implemented
pursuant to HIPAA, congressional action or otherwise, could have a significant effect on the manner in which we must handle healthcare
related data, and the cost of complying with standards could be significant. If we do not comply with existing or new laws and regulations
related to PHI, it could be subject to criminal or civil sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Because of the extreme sensitivity of the PII that
we store and transmit, the security features of our technology platform are very important. If our security measures, some of which are
managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive customer and patient data,
including HIPAA-regulated PHI. As a result, our reputation could be severely damaged, adversely affecting customer and patient confidence.
Customers may curtail their use of or stop using our services or our customer base could decrease, which would cause our business to suffer.
In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violation of HIPAA and other
applicable laws or regulations and significant costs for remediation, notification to individuals and for measures to prevent future occurrences.
Any potential security breach could also result in increased costs associated with liability for stolen assets or information, repairing
system damage that may have been caused by such breaches, incentives offered to customers or other business partners in an effort to maintain
our business relationships after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying
additional personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain
insurance covering certain security and privacy damages and claims expenses, we may not carry insurance or maintain coverage sufficient
to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from
a security incident.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We outsource important aspects of the storage and
transmission of customer and customer personnel information and thus rely on third parties to manage functions that have material cyber-
security risks. We attempt to address these risks by requiring outsourcing subcontractors who handle customer and customer personnel information
to sign business associate agreements contractually requiring those subcontractors to adequately safeguard personal health data to the
same extent that applies to us and in some cases by requiring such outsourcing subcontractors to undergo third-party security examinations.
In addition, we periodically hire third-party security experts to assess and test our security posture. However, we cannot assure investors
that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission
of client and patient&#8217;s proprietary and protected health information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, U.S. states are adopting new laws
or amending existing laws and regulations, requiring attention to frequently changing regulatory requirements applicable to data related
to individuals. For example, California has enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;). The CCPA gives California
residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive
detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California
consumers (as that term is broadly defined and which can include any of our current or future employees who may be California residents
or any other California residents whose data we collect or process) and provide such residents new ways to opt out of certain sales of
personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that
is expected to increase data breach litigation. As we expand our operations and customer base, the CCPA may increase our compliance costs
and potential liability. Additionally, the California Privacy Rights Act (&#8220;CPRA&#8221;), which was approved by California voters
in the election in November 2020, created obligations relating to consumer data with implementing regulations that, although delayed,
did take effect during 2024. The CPRA modifies the CCPA significantly, potentially resulting in further uncertainty and requiring us to
incur additional costs and expenses in an effort to comply. Additionally, other U.S. states continue to propose, and in certain cases
adopt, privacy-focused legislation such as Colorado, Virginia, Utah and Connecticut. Aspects of these state laws remain unclear, resulting
in further uncertainty and potentially requiring us to modify our data practices and policies and to incur substantial additional costs
and expenses in an effort to comply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Privacy and data security laws and regulations could require us
to make changes to our business, impose additional costs on us and reduce the demand for our tests and services.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our business model contemplates that we will store,
process and transmit both public data and our customers&#8217; and customer personnel&#8217;s private data. Our customers may store and/or
transmit a significant amount of personal or identifying information through our platform. Privacy and data security have become significant
issues in the United States and in other jurisdictions where we may offer our solutions. The regulatory framework relating to privacy
and data security issues worldwide is evolving rapidly and is likely to remain uncertain for the foreseeable future. Federal, state and
foreign government bodies and agencies have in the past adopted, or may in the future adopt, laws and regulations regarding the collection,
use, processing, storage and disclosure of personal or identifying information obtained from customers and other individuals. In addition
to government regulation, privacy advocates and industry groups may propose various self- regulatory standards that may legally or contractually
apply to our business. Because the interpretation and application of many privacy and data security laws, regulations and applicable industry
standards are uncertain, it is possible that these laws, regulations and standards may be interpreted and applied in a manner inconsistent
with our existing privacy and data management practices. As we expand into new jurisdictions or verticals, we will need to understand
and comply with various new requirements applicable in those jurisdictions or verticals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">To the extent applicable to our business or the
businesses of our customers, these laws, regulations and industry standards could have negative effects on our business, including by
increasing our costs and operating expenses, and delaying or impeding our deployment of new core functionality and products. Compliance
with these laws, regulations and industry standards requires significant management time and attention, and failure to comply could result
in negative publicity, subject us to fines or penalties or result in demands that we modify or cease existing business practices. In addition,
the costs of compliance with, and other burdens imposed by, such laws, regulations and industry standards may adversely affect our customers&#8217;
ability or desire to collect, use, process and store personal information using our solutions, which could reduce overall demand for them.
Even the perception of privacy and data security concerns, whether or not valid, may inhibit market acceptance of our solutions in certain
verticals. Furthermore, privacy and data security concerns may cause our customers&#8217; customers, vendors, employees and other industry
participants to resist providing the personal information necessary to allow our customers to use our applications effectively. Any of
these outcomes could adversely affect our business and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risks Affecting Our Company&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>A pandemic, epidemic or outbreak of an infectious disease in the
United States or worldwide, including the re-emergence of the novel strain of coronavirus disease, COVID-19, could adversely affect our
business.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If a pandemic, epidemic or outbreak of an infectious
disease occurs in the United States or worldwide, our business may be adversely affected. If the COVID-19 virus and its potentially more
contagious variants cause an additional resurgence of infection of COVID-19, or if new variants continue to develop resistance to government
approved COVID-19 vaccinations, or if an influenza or other pandemic were to occur, our business, results of operations, financial condition
and liquidity could be negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a result of public health emergencies, we experienced,
and in the future could experience, supply chain disruptions, including shortages, delays and work stoppages among some vendors and suppliers,
travel restrictions and cancellation of events, among other effects, thereby significantly and negatively impacting our operations. In
addition, our results and financial condition may be adversely affected by future federal or state laws, regulations, orders, or other
governmental or regulatory actions addressing public health emergencies such as a COVID-19 or the U.S. health care system, which, if adopted,
could result in direct or indirect restrictions to its business, financial condition, results of operations and cash flow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Changes in accounting standards and subjective
assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results
or financial condition.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Generally accepted accounting principles and related
accounting pronouncements, implementation guidelines and interpretations with regard to a wide range of matters that are relevant to our
business, including but not limited to revenue recognition, allowance for doubtful accounts, content asset amortization policy, valuation
of our Common Stock, stock-based compensation expense and income taxes, are highly complex and involve many subjective assumptions, estimates
and judgments. Changes in these rules or their interpretation or changes in underlying assumptions, estimates or judgments could significantly
change or increase volatility of our reported or expected financial performance or financial condition. Refer to Note 3, &#8220;Summary
of Significant Accounting Policies&#8221; to the Audited Financial Statements included elsewhere in this Prospectus for a description
of recent accounting pronouncements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We are an &#8220;emerging growth company&#8221; and &#8220;smaller
reporting company&#8221; within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements
available to emerging growth companies, it could make our securities less attractive to investors and may make it more difficult to compare
our performance to the performance of other public companies.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are an &#8220;emerging growth company&#8221;
as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible for and intend to take advantage
of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies
for as long as we continue to be an emerging growth company, including, but not limited to, (a) not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (b) reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements and (c) exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not
have access to certain information they may deem important. We will remain an emerging growth company until the earliest of (i) the last
day of the fiscal year in which the market value of shares of Common Stock that are held by non-affiliates exceeds $700 million as of
June 30 of that fiscal year, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more
during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1 billion in non-convertible debt
in the prior three-year period or (iv) December 31, 2026, which is the last day of the fiscal year following the fifth anniversary of
the date of the first sale of Common Stock in Mana&#8217;s initial public offering. We cannot predict whether investors will find our
securities less attractive because it will rely on these exemptions. If some investors find our securities less attractive as a result
of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less
active trading market for our securities and the trading prices of our securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but
any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when
a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company,
can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our
financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted
out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Additionally, we are a &#8220;smaller reporting
company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements. We expect that we will remain a
smaller reporting company until the last day of any fiscal year for so long as either (a) the market value of our Common Stock held by
non-affiliates does not equal or exceed $250 million as of June 30th of that fiscal year, or (b) our annual revenues did not equal or
exceed $100 million during such completed fiscal year and the market value of our Common Stock held by non-affiliates did not equal or
exceed $700 million as of June 30th of that fiscal year. To the extent we take advantage of such reduced disclosure obligations, it may
also make comparison of our financial statements with other public companies difficult or impossible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our stock price may be volatile and may decline regardless of our
operating performance.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The market price of our Common Stock may fluctuate
significantly in response to numerous factors and may continue to fluctuate for these and other reasons, many of which are beyond our
control, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 29px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">actual or anticipated fluctuations in our revenue and results of operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 1pt; line-height: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 96%">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1pt; padding-right: 16.95pt; line-height: 96%; vertical-align: bottom"><span style="font-size: 10pt; line-height: 96%">failure of securities analysts to maintain coverage of the Company, changes in financial estimates or ratings by any securities analysts who follow us or our failure to meet these estimates or the expectations of investors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.35pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.35pt; vertical-align: bottom"><span style="font-size: 10pt">announcements by us or our competitors of significant technical innovations, acquisitions, strategic partnerships, joint ventures, results of operations or capital commitments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">changes in operating performance and stock market valuations of other healthcare-related companies generally, or those in the medical diagnostics industry in particular;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">trading volume of our Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">the inclusion, exclusion or removal of our Common Stock from any indices;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">changes in the Board or management;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">transactions in our Common Stock by directors, officers, affiliates and other major investors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">lawsuits threatened or filed against <span style="letter-spacing: -0.25pt">us;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">changes in laws or regulations applicable to our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">changes in our capital structure, such as future issuances of debt or equity securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">short sales, hedging and other derivative transactions involving our capital stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">general economic conditions in the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">pandemics or other public health crises, including, but not limited to, the COVID-19 pandemic (including additional variants such as the Omicron variant);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">other events or factors, including those resulting from war, incidents of terrorism or responses to these events; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The stock market has recently experienced extreme
price and volume fluctuations. The market prices of securities of companies have experienced fluctuations that often have been unrelated
or disproportionate to their operating results. In the past, stockholders have sometimes instituted securities class action litigation
against companies following periods of volatility in the market price of their securities. Any similar litigation against us could result
in substantial costs, divert management&#8217;s attention and resources, and harm its business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>An active trading market for our Common Stock may not be created
or sustained.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have listed our Common Stock and Public Warrants
on the Nasdaq Capital Market under the symbols &#8220;CDIO&#8221; and &#8220;CDIOW,&#8221; respectively. We cannot assure you that an
active trading market for our securities will be created or sustained. Accordingly, we cannot give you assurance regarding the liquidity
of your investment in our securities, your ability to sell your shares of our Common Stock when desired or the prices that you may obtain
for your shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Future sales of Common Stock in the public market could cause our
share price to decline significantly, even if our business is doing well.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have filed, and the SEC has declared effective,
registration statements covering (i) the resale of Common Stock underlying Public Warrants issued in the Company&#8217;s initial public
offering and a substantial number of shares of Common Stock and shares underlying warrants issued in private placements we completed prior
to our Business Combination; (ii) up to $17 million in securities on a shelf registration statement that was used for an at-the-market
offering of up to $17 million; (iii) up to $9,476,508 in securities on a shelf registration statement that we are currently using for
an at-the-market offering of up to $9,476,508; and (iv) registration statements on Form S-8 covering our 2022 Equity Incentive Plan. Public
sales of securities can continue to be made under these registration statements. In addition, all of the shares we issued in the Business
Combination to holders of Legacy Cardio securities are available for resale under Rule 144 without restriction, subject to certain limitations
that apply to our affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The total number of shares available for resale
under these registration statements and/or under Rule 144 represents a significant percentage of our outstanding shares. The resale, or
expected or potential resale, of a substantial number of our shares of Common Stock in the public market could adversely affect the market
price for our shares of Common Stock and make it more difficult for investors to sell their shares of Common Stock at times and prices
that they feel are appropriate. In particular, we expect that, because there are a substantial number of shares registered pursuant to
various registration statements, the applicable selling stockholders can continue to offer such covered securities for a significant period
of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering
pursuant to a registration statement or Rule 144 may continue for an extended period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Sales of Common Stock pursuant to these registration
statements or pursuant to Rule 144 may make it more difficult for us to sell equity securities in the future at a time and at a price
that we deem appropriate. These sales also could cause the trading price of our Common Stock to fall and make it more difficult for investors
to sell shares of our Common Stock at a time and price that they deem appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If securities or industry analysts either do not publish research
about us or publish inaccurate or unfavorable research about us, our business, or our market, or if they change their recommendations
regarding our Common Stock adversely, the trading price or trading volume of our Common Stock could decline.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The trading market for our Common Stock is influenced
in part by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors.
If one or more of the analysts initiate research with an unfavorable rating or downgrade our Common Stock, provide a more favorable recommendation
about our competitors, or publish inaccurate or unfavorable research about our business, the trading price of our Common Stock would likely
decline. In addition, we currently expect that securities research analysts will establish and publish their own periodic projections
for our business. These projections may vary widely and may not accurately predict the results we actually achieve. Our stock price may
decline if our actual results do not match the projections of these securities research analysts. Furthermore, if no analysts commence
coverage of our Company, the trading price and volume for our Common Stock could be adversely affected. If any analyst who may cover us
were to cease coverage of the Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which
in turn could cause the trading price or trading volume of our Common Stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Delaware law and provisions in our Charter and Bylaws could make
a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of its Common Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Charter and Bylaws contain provisions that
could depress the trading price of our Common Stock by acting to discourage, delay, or prevent a change of control of the Company or changes
in our management that our stockholders may deem advantageous. These provisions include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the right of the board of directors to establish the number of directors and fill any vacancies and newly created directorships;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">director removal solely for cause;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">&#8220;blank check&#8221; preferred stock that the Board could use to implement a stockholder rights plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">the right of the Board to issue our authorized but unissued Common Stock and preferred stock without stockholder approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">no ability of our stockholders to call special meetings of stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">no right of our stockholders to act by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">limitations on the liability of, and the provision of indemnification to, our director and officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.85pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.85pt; vertical-align: bottom"><span style="font-size: 10pt">the right of the board of directors to make, alter, or repeal the Bylaws; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.9pt; vertical-align: bottom"><span style="font-size: 10pt">advance notice requirements for nominations for election to the Board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Any provision of the Charter or Bylaws that has
the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their
shares of our Common Stock, and could also affect the price that some investors are willing to pay for our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our Bylaws provide that the Court of Chancery of the State of Delaware
will be the exclusive forum for substantially all disputes between the Company and our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with the Company or our directors, officers or employees.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Bylaws provide that the Court of Chancery of
the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach
of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, the Charter or Bylaws or any action asserting
a claim against us that is governed by the internal affairs doctrine. These choice of forum provisions may limit a stockholder&#8217;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees
and may discourage these types of lawsuits. This provision would not apply to claims brought to enforce a duty or liability created by
the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. The Bylaws provide further that, to the
fullest extent permitted by law, the federal district courts of the United States will be the exclusive forum for resolving any complaint
asserting a cause of action arising under the Securities Act. However, Section 22 of the Securities Act provides that federal and state
courts have concurrent jurisdiction over lawsuits brought under the Securities Act or the rules and regulations thereunder. To the extent
the exclusive forum provision restricts the courts in which claims arising under the Securities Act may be brought, there is uncertainty
as to whether a court would enforce such a provision. We note that investors cannot waive compliance with the federal securities laws
and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217;
certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions
to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid,
a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there
can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the exclusive-forum
provision contained in the Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We do not intend to pay dividends for the foreseeable future.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We currently intend to retain any future earnings
to finance the operation and expansion of its business and we do not expect to declare or pay any dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Moreover, the terms of any revolving credit facility
into which we or any of our subsidiaries enters may restrict our ability to pay dividends, and any additional debt we or any of our subsidiaries
may incur in the future may include similar restrictions. As a result, stockholders must rely on sales of their Common Stock after price
appreciation as the only way to realize any future gains on their investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may issue additional shares of our Common Stock or other equity
securities without your approval, which would dilute your ownership interests and may depress the market price of our Common Stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On January 26, 2024, the Company entered into
an At-the-Market Issuance Sales Agreement (the &#8220;Sales Agreement&#8221;) with Craig-Hallum Capital Group LLC (&#8220;Craig-Hallum&#8221;).
Sales of our Common Stock pursuant to the Sales Agreement were made under the Company&#8217;s Registration Statement on Form S-3 filed
on January 26, 2024 (File No. 333-276725) declared effective by the SEC on February 1, 2024 and will be made under the Company&#8217;s
Registration Statement on Form S-3 filed on February 7, 2025 (File No. 333-284775) declared effective by the SEC on February 14, 2025.
As of September 12, 2025, we have sold 1,054,841 shares of our Common Stock under the Sales Agreement and may sell up to an additional
approximately $9,372,595 of our Common Stock through Craig-Hallum under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of September 12, 2025, we have Warrants outstanding
to purchase up to 284,292 shares of our Common Stock. We also have the ability to issue an aggregate of 224,948 shares of our Common Stock
under the Cardio Equity Incentive Plan, of which 128,860 options have been granted and are currently exercisable, leaving 96,088 shares
available to award or grant under the Incentive Plan in the form of options, restrictive stock units, restrictive stock and other equity
awards. To the extent Warrants and options are exercised, and RSUs vest, additional shares of Common Stock could be issued, which will
result in dilution to our then existing stockholders and increase the number of shares eligible for resale in the public market. Sales
of substantial numbers of such shares in the public market could depress the market price of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">At the upcoming 2025 annual meeting of stockholders,
our stockholders will be asked to approve the future issuance of shares of Common Stock and/or securities convertible into or exercisable
for Common Stock equal to 20% or more of the Common Stock outstanding in one or more non-public transactions as required by Nasdaq Marketplace
Listing Rule 5635(d) (the "Share Issuance Proposal&#8221;). This proposal is identical to the proposals approved by our stockholders
in 2023 and 2024, neither of which we relied upon for financing options, and the authorizations provided thereby expired. Any non-public
financing transaction undertaken in connection with this approval will be conducted within the parameters set forth in the Share Issuance
Proposal described in the proxy statement for the 2025 annual meeting, if the proposal is approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We may issue additional shares of our Common Stock
or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment
of outstanding indebtedness, without stockholder approval, in a number of circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The issuance of additional shares of Common Stock
or other equity securities of equal or senior rank would have the following effects:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">our existing stockholders&#8217; proportionate ownership interest in the Company will decrease;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the amount of cash available per share, including for payment of dividends (if any) in the future, may decrease;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the relative voting strength of each previously outstanding share of Common Stock may be diminished; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the market price of our shares of Common Stock may decline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may redeem the Public Warrants and the Sponsor Warrants prior
to their exercise at a time that is disadvantageous to you, as a warrant holder, thereby making your Public Warrants or Sponsor Warrants
worthless.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have the ability to redeem outstanding Public
Warrants and Sponsor Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant,
provided that the last reported sales price of our Common Stock equals or exceeds $540 per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading-day period ending on the third
trading day prior to the date on which we give proper notice of such redemption and provided certain other conditions are met. Trading
prices of our Common Stock have not historically exceeded the $540 per share redemption threshold. If and when the Public Warrants and
Sponsor Warrants become redeemable, we may not exercise our redemption right unless there is a current registration statement in effect
with respect to the shares of Common Stock underlying the Warrants. While we have registered the Common Stock issuable upon the exercise
of the Public Warrants and Sponsor Warrants on a separate registration statement, most recently updated by Post-Effective Amendment No.
3, which the SEC declared effective on September 9, 2025, it must remain current and effective by future filings. There can be no assurance
that the registration statement will still be effective at the time that we would like to exercise our redemption rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In the event we have determined to redeem the
Public Warrants and the Sponsor Warrants, holders would be notified of such redemption as described in the Warrant Agreement. Specifically,
we would be required to fix a date for the redemption (the &#8220;Redemption Date&#8221;). Notice of redemption would be mailed by first
class mail, postage prepaid, by the Company not less than 30 days prior to the Redemption Date to the registered holders of the Public
Warrants and the Sponsor Warrants to be redeemed at their last addresses as they appear on the registration books. In addition, beneficial
owners of the redeemable Public Warrants and the Sponsor Warrants will be notified of such redemption via the Company&#8217;s posting
of the redemption notice to DTC. Redemption of the Public Warrants and the Sponsor Warrants could force you (i) to exercise your Public
Warrants and the Sponsor Warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii)
to sell your Public Warrants and the Sponsor Warrants at the then-current market price when you might otherwise wish to hold your Public
Warrants and the Sponsor Warrants or (iii) to accept the nominal redemption price which, at the time the outstanding Public Warrants and
the Sponsor Warrants are called for redemption, is likely to be substantially less than the market value of your Public Warrants and the
Sponsor Warrants. None of the Private Placement Warrants will be redeemable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercise of our Warrants is dependent upon the trading price of
our Common Stock. Because of the disparity between the current stock price and the respective Warrant exercise prices, the Warrants may
never be in the money and may expire worthless.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The exercise prices of our currently outstanding
Warrants range from a high of $345 to a low of $53.40 per share. The likelihood that warrant holders will exercise the Warrants, and therefore,
the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock. The last reported sales price
for which was $3.790 per share on September 12, 2025. If the trading price for our Common Stock is less than the applicable exercise price
of our Warrants, we believe holders of those Warrants will be unlikely to exercise their Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There is no guarantee that the Warrants will be
in the money prior to their expiration, and, as such, the Warrants may expire worthless, and we may receive no proceeds from the exercise
of the Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The Warrant Agreement designates the courts of the State of New
York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions
and proceedings that may be initiated by holders of the Warrants, which could limit the ability of warrant holders to obtain a favorable
judicial forum for disputes with our Company.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Warrant Agreement provides that, subject to
applicable law, (i) any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement, including
under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for
the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive
forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Notwithstanding the foregoing, these provisions of the Warrant Agreement will not apply to suits brought to enforce
any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America
are the sole and exclusive forum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Any person or entity purchasing or otherwise acquiring
any interest in Warrants shall be deemed to have notice of and to have consented to the forum provisions in the Warrant Agreement. If
any action, the subject matter of which is within the scope the forum provisions of the Warrant Agreement, is filed in a court other than
a court of the State of New York or the United States District Court for the Southern District of New York (a &#8220;foreign action&#8221;)
in the name of any holder of Warrants, such holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and
federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions
(an &#8220;enforcement action&#8221;), and (y) having service of process made upon such warrant holder in any such enforcement action
by service upon such warrant holder&#8217;s counsel in the foreign action as agent for such warrant holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">This choice-of-forum provision may limit a warrant
holder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us, which may discourage such lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Alternatively, if a court were to find this provision
of the Warrant Agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we
may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect
our business, financial condition and results of operations and result in a diversion of the time and resources of our management and
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financial reporting obligations of being a public company in the
United States are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a publicly traded company, we incur significant
legal, accounting and other expenses that we did not incur as a privately company. The obligations of being a public company in the United
States require significant expenditures and will continue to place significant demands on our management and other personnel, including
costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance
practices, including those under the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley&#8221;) the Dodd-Frank Wall Street Reform and Consumer
Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment
and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in
corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance
with. Moreover, despite reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities
more time-consuming and costly, particularly after we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these
rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance. Our management
and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep
pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other
potential problems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>If we fail to comply with the rules under Sarbanes-Oxley related
to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control
and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Section 404 of Sarbanes-Oxley requires annual management
assessments of the effectiveness of our internal control over financial reporting. If we fail to comply with the rules under Sarbanes-Oxley
related to disclosure controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal
control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. If material
weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control,
we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting
in accordance with Section 404 of Sarbanes-Oxley. Moreover, effective internal controls are necessary for us to produce reliable financial
reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business
and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of
our Common Stock could drop significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have incurred and will continue to incur additional
costs to remediate material weaknesses in our internal control over financial reporting. The additional reporting and other obligations
imposed by these rules and regulations will continue to increase legal and financial compliance costs and the costs of related legal,
accounting and administrative activities. These increased costs will require us to divert a significant amount of money that could otherwise
be used to expand the business and achieve strategic objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We will need to grow the size of our organization and may experience
difficulties in managing this growth.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As our expansion plans and strategies develop,
and as we continue to operate as a public company, we expect needing additional managerial, operational, sales, marketing, financial and
other personnel. Future growth would impose significant added responsibilities on members of management, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">identifying, recruiting, compensating, integrating, maintaining and motivating additional employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">coping with demands on Management related to the increased size of its business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">assimilating different corporate cultures and business practices;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">converting other entities&#8217; books and records and conforming their practices to ours;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 6.65pt"><span style="font-size: 10pt">integrating operating, accounting and information technology systems of other entities with ours and in maintaining uniform procedures, policies and standards, such as internal accounting controls; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our future financial performance and our ability
to expand our business will depend, in part, on our ability to effectively manage any future growth, and our management may also have
to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to
managing these growth activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If we are not able to effectively expand
our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully
implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research,
development and commercialization goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We are an &#8220;emerging growth company,&#8221; and we cannot be
certain that the reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; will not make our Common Stock
less attractive to investors.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are an &#8220;emerging growth company,&#8221;
as defined under the JOBS Act and will continue to be after the Business Combination is completed. For so long as we are an emerging growth
company, we intend to take advantage of certain exemptions from reporting requirements that are applicable to other public companies that
are not emerging growth companies, including, but not limited to, compliance with the auditor attestation requirements of Section 404
of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="background-color: white">We could
be an emerging growth company through 2026, although we may lose such status earlier, depending on the occurrence of certain events, including
when we have generated total annual gross revenue of at least $1.07 billion or when we are deemed to be a &#8220;large accelerated filer&#8221;
under the Exchange Act, which means that the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of
June 30 of the current year, or when we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We cannot predict if investors will not find our
Common Stock less attractive or our company less comparable to certain other public companies because we rely on these exemptions. If
some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock, and
our stock price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Under the JOBS Act, emerging growth companies can
delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards
and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>As a &#8220;smaller reporting company&#8221; we are permitted to
provide less disclosure than larger public companies which may make our Common Stock less attractive to investors.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are currently a &#8220;smaller reporting company,&#8221;
as defined by Rule 12b-2 of the Exchange Act. As a smaller reporting company, we are eligible to take advantage of certain exemptions
from various reporting requirements applicable to other public companies. Consequently, it may be more challenging for investors to analyze
our results of operations and financial prospects which may result in less investor confidence. Investors may find our Common Stock less
attractive as a result of our smaller reporting company status. If some investors find our Common Stock less attractive, there may be
a less active trading market for our Common Stock and our stock price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>There can be no assurance that we will be able to comply with the
continued listing standards of Nasdaq.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Common Stock is listed on The Nasdaq Capital
Market ("Nasdaq&#8221;). In order to maintain that listing, we must satisfy minimum financial and other requirements including, without
limitation, a requirement that the closing bid price of our Common Stock be at least $1.00 per share. In the last two years, we have received
two deficiency letters from Nasdaq that threatened to delist our securities for failure to maintain the requisite minimum bid price. In
each instance, we have overcome the deficiency within the cure period and therefore, have maintained the Nasdaq listing of our securities.
However, there is no assurance that we will be able to maintain our Nasdaq listing in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If Nasdaq delists our shares of Common Stock and
Public Warrants for failure to meet the listing standards, we and our&#160;securityholders&#160;could face significant material adverse
consequences including:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px; padding-top: 1.2pt">&#160;</td>
    <td style="width: 22px; padding-top: 1.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1.2pt; vertical-align: bottom"><span style="font-size: 10pt">a limited availability of market quotations for our securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.2pt">&#160;</td>
    <td style="padding-top: 1.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1.2pt; vertical-align: bottom"><span style="font-size: 10pt">reduced liquidity for our securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.2pt">&#160;</td>
    <td style="padding-top: 1.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1.2pt; vertical-align: bottom"><span style="font-size: 10pt">a determination that our Common Stock is a "penny stock,&#8221; which will require brokers trading in our Common Stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of our Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.2pt">&#160;</td>
    <td style="padding-top: 1.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1.2pt; vertical-align: bottom"><span style="font-size: 10pt">a limited amount of analyst coverage; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.2pt">&#160;</td>
    <td style="padding-top: 1.2pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1.2pt; vertical-align: bottom"><span style="font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>We may acquire other companies or technologies, which could divert
our management&#8217;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our
operating results.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We may in the future seek to acquire or invest
in businesses, applications and services or technologies that we believe could complement or expand our services, enhance our technical
capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and
cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, we do not have any experience in acquiring
other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies
successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits
from the acquired business due to a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39px">&#160;</td>
    <td style="width: 22px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">unanticipated costs or liabilities associated with the acquisition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">difficulty integrating the accounting systems, operations, and personnel of the acquired</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 10.05pt; vertical-align: bottom"><span style="font-size: 10pt">difficulty converting the customers of the acquired business onto the Platform and contract terms, including disparities in the revenue, licensing, support, or professional services model of the acquired company;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">diversion of management&#8217;s attention from other business concerns;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the potential loss of key employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">use of resources that are needed in other parts of our business; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">use of substantial portions of our available cash to consummate the acquisition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, a significant portion of the purchase
price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment
at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating
results based on this impairment assessment process, which could adversely affect our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Acquisitions could also result in dilutive issuances
of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business
fails to meet our expectations, our operating results, business and financial position may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="UseOfProceeds"></span> USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">All of the shares of Common Stock being offered
hereby are being sold by the Selling Stockholders identified in this prospectus or their permitted transferees. We will not receive any
of the proceeds from these sales. We will bear the out-of-pocket costs, expenses and fees incurred in connection with the registration
of the shares to be sold by the Selling Stockholders, including registration, listing fees, printers and accounting fees and fees and
disbursements of counsel (collectively, the &#8220;Registration Expenses&#8221;). Other than Registration Expenses, the Selling Stockholders
will bear any selling discounts, commissions, placement agent fees, fees or expenses of outside counsel of the Selling Stockholders or
other similar expenses payable with respect to sale of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="DeterminationoOfferingPrice"></span>DETERMINATION OF OFFERING PRICE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The offering price of the shares of Common Stock
issuable upon exercise of the Warrants offered hereby is determined by reference to the exercise price of the Warrants, which varies between
$116.86 and $345.00 per share. The Public Warrants are listed on the Nasdaq under the symbol &#8220;CDIOW.&#8221;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We cannot currently determine the price or prices
at which shares of our Common Stock or Warrants may be resold by the Selling Stockholders under this Prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="MarketpPrice"></span>MARKET PRICE, TICKER SYMBOLS AND DIVIDEND INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Ticker Symbols</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">Our Common Stock and Public
Warrants are currently traded on The Nasdaq Capital Market under the symbols &#8220;CDIO&#8221; and &#8220;CDIOW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Prior to the consummation of the Business Combination
on October 25, 2022, the Mana units, Mana Common Stock, Mana warrants and Mana rights were historically quoted on Nasdaq Global Market
under the symbols &#8220;MANAU,&#8221; &#8220;MANA,&#8221; &#8220;MANAW&#8221; and &#8220;MANAR,&#8221; respectively. The Mana units and
Mana rights were delisted from The Nasdaq Stock Market on October 26, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">On September 12, 2025,
the last reported sales prices of our Common Stock and our Public Warrants were $3.790 per share and $0.0191 per Public Warrant, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Holders of our securities should obtain current
market quotations for their securities. The market price of our securities could vary at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="color: #212529">As of September
12, 2025, </span>there were 59 holders of record of our Common Stock and 6 holders of record of our Public Warrants and Sponsor Warrants.
In addition, we have approximately 72 holders of private placement warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The number of record holders of our Common Stock
and Public Warrants was determined from the records of our transfer agent and does not include beneficial owners of any of our securities
whose securities are held in the names of various security brokers, dealers, and registered clearing agencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company has not paid any cash dividends on
the Common Stock to date and does not intend to pay cash dividends for the foreseeable future. The payment of cash dividends in the future
will be dependent upon the Company&#8217;s revenues and earnings (if any), capital requirements and general financial condition. The payment
of any cash dividends will be within the discretion of our board of directors at such time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="MDA"></span><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS<br/>
AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>As a result of the closing of the Business Combination,
which was accounted for as a reverse recapitalization in accordance with U.S. GAAP as discussed in Note 2 &#8211; Merger Agreement and
Reverse Recapitalization, the consolidated financial statements of Cardio Diagnostics, Inc., a Delaware corporation and our wholly owned
subsidiary, are now the financial statements of the Company. You should read the following discussion and analysis of our financial condition
and results of operations together with our audited consolidated financial statements as of December 31, 2024 and 2023 and for each of
the two years in the period ended December 31, 2024 and the related notes included elsewhere in this Prospectus. You should also review
the unaudited consolidated financial statements as of and for the period ended June 30, 2025 included in this Prospectus for more current
financial information.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Some of the information contained in this discussion
and analysis or set forth elsewhere in this Prospectus, including information with respect to our plans, estimates and strategy for our
business, includes forward-looking statements based upon current expectations that involve risks and uncertainties. You should read the
sections titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward Looking Statements&#8221; for a discussion of
important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis. Our historical results are not necessarily indicative of the results that
may be expected for any period in the future.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="color: #333333"><i>Unless the context
requires otherwise, references to &#8220;Cardio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;
</i></span><i>refer to Cardio Diagnostics Holdings, Inc., a Delaware corporation, together with its consolidated subsidiary.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio was formed to further develop and commercialize
a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (&#8220;CHD&#8221;),
stroke, heart failure and diabetes, by leveraging our Artificial Intelligence (&#8220;AI&#8221;)-driven Integrated Genetic-Epigenetic
Engine&#8482;. As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases.
Cardio aims to become one of the leading medical technology companies for enabling improved prevention, early detection and treatment
of cardiovascular disease. Cardio is transforming the approach to cardiovascular disease from reactive to proactive and hope to accelerate
the adoption of Precision Medicine for all. We believe that incorporating Cardio&#8217;s solutions into routine practice in primary care
and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular
disease by 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio believes that it is the first company to
develop and commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value propositions for multiple
stakeholders including (1) patients, (2) clinicians, (3) hospitals/health systems, (4) employers and (5) payors. According to the CDC,
epigenetics is the study of how a person&#8217;s behaviors and environment can cause changes that affect the way a person&#8217;s genes
work. Unlike genetic changes, epigenetic changes are reversible and do not change one&#8217;s DNA sequence, but they can change how a
person&#8217;s body reads a DNA sequence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio launched its first clinical test, Epi+Gen
CHD&#8482;, a three-year symptomatic CHD risk assessment clinical blood test targeting CHD events, including heart attacks, in 2021 during
the Covid-19 pandemic. As a result, the initial strategy for commercialization involved launching the test via telemedicine and in smaller
provider practices such as concierge medicine practices. The volume of tests through these channels were minimal, and as the circumstances
around Covid-19 pandemic improved, management re-vamped the Company&#8217;s go-to-market strategy to include other healthcare verticals
and stakeholders beyond patients and small providers, including larger provider organizations, group purchasing organizations, employers,
payors and life insurers. This new approach allowed Cardio to expand the reach of our solutions beyond the initial focus areas. Beyond
the launch of Epi+Gen CHD, in March 2023, we announced the launch of our second product, PrecisionCHD&#8482;, an integrated epigenetic-genetic
clinical blood test for the detection of coronary heart disease. The Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are coupled to Actionable
Clinical Intelligence (&#8220;ACI&#8221;), a platform that offers new epigenetic and genetic insights to clinicians prescribing the to
personalize patient management and help improve chronic care management. In May 2023, we launched CardioInnovate360&#8482;, a research-use-only
(&#8220;RUO&#8221;) solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management
of cardiovascular diseases. In February 2024, we announced the launch of HeartRisk&#8482;, a cardiovascular disease risk intelligence
platform. We believe that our Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are categorized as laboratory-developed tests, or &#8220;LDTs.&#8221;
The new go-to-market strategy is also being implemented for these products. Despite long partnership and sales cycles, in some instance
as long as 14 months, Cardio was able to increase the reach of its solutions in 2024, generating revenue from provider organizations and
has continued the development of a more robust sales and partnership pipeline. To further increase reach and potentially accelerate partnerships
and sales cycles, more seasoned sales personnel in the provider and employer verticals were hired in late 2024. In Q1 and Q2 2025, the
focus of the Company remained in driving adoption of our clinical solutions, predominantly among providers, channel partners and employers.
In addition, the Company made progress in the Medicare reimbursement process where the Company received preliminary gapfill pricing from
the Centers for Medicare and Medicaid for the Epi+Gen CHD and PrecisionCHD tests, onboarding a new employer client and in setting up our
laboratory facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio expects that sales and partnership cycles
will continue to be long. Our ongoing strategy for expanding our business operations and increasing revenue generation include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Develop additional products, including clinical tests for stroke, congestive heart failure and diabetes;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Expand clinical and health economics evidence portfolio to continue to demonstrate value of products and increase reach;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Leverage our newly awarded CPT PLA codes and expand reimbursement efforts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Expand the adoption of our products across key channels, including health systems and self-insured employers, including for HeartRisk, Cardio&#8217;s SaaS product;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Explore additional market opportunities in the US and internationally;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Scale our internal operations capabilities with a focus on improving efficiency and reducing our cost of goods sold; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Pursue potential strategic partnership(s) and acquisition(s) of one or more synergistic companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>At the Market Sales Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On January 26, 2024, the Company entered into the
Sales Agreement with Craig-Hallum. Pursuant to the Sales Agreement, the Company may sell, at its option, shares of its Common Stock through
Craig-Hallum, as sales agent. Sales of the Common Stock were made pursuant to the Sales Agreement initially up to an aggregate of $17
million under the Company&#8217;s Registration Statement on Form S-3 filed on January 26, 2024 (File No. 333-276725), and declared effective
by the SEC on February 1, 2024 (the &#8220;Initial Registration Statement&#8221;). Additional sales may be made pursuant to the Sales
Agreement up to an aggregate of $9,476,508 under the Company&#8217;s Registration Statement on Form S-3 filed on February 7, 2025 (File
No. 333-284775), declared effective by the SEC on February 14, 2025 (the &#8220;Additional Registration Statement&#8221;) and its accompanying
Prospectus Supplement dated February 14, 2025. Subject to the terms and conditions of the Sales Agreement, Craig-Hallum may sell the shares,
if any, only by methods deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 promulgated under the Securities Act.
The Company has agreed to pay Craig-Hallum a sales commission of 2.5% of the gross proceeds for sales under the Sales Agreement and to
provide Craig-Hallum with customary indemnification and contribution rights, including for liabilities under the Securities Act. In addition,
the Company is required to reimburse Craig-Hallum for certain specified expenses in connection with entering into the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of August 14, 2025, the Company sold 1,054,841
shares of its Common Stock on a Reverse Stock Split-adjusted basis under the Sales Agreement resulting in proceeds to the Company of $14,782,871,
net of offering costs. The Company has paid Craig-Hallum $379,048 in sales commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Regulatory and Judicial Developments
Regarding LDTs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On May 6, 2024, FDA published a final rule amending
the definition of an in vitro diagnostic (&#8220;IVD&#8221;) device to include tests manufactured by a clinical laboratory. Pursuant to
the rule, laboratory developed tests (&#8220;LDTs&#8221;), i.e., tests designed, manufactured, and used within a single CLIA-certified
high complexity laboratory, are medical devices subject to FDA regulation under the Federal Food, Drug, and Cosmetic Act. The final rule
also announced FDA&#8217;s intention to apply its medical device requirements to LDTs. Under the final rule, all LDTs, unless subject
to a specific exemption, will be subject to premarket authorization requirements (510(k), de novo classification, or PMA) for each LDT
performed by the laboratory, and to postmarket registration and listing, medical device reporting, correction, removal, and recall, complaint
handling, labeling, investigational device, and quality system requirements. FDA intends to phase in these requirements beginning May
6, 2025. The final rule states that certain categories of LDTs will be subject to enforcement discretion with respect to some or all of
these requirements. For example, FDA will apply enforcement discretion to currently marketed LDTs that were first offered prior to May
6, 2024, with respect to most quality system requirements and the requirement for premarket authorization if they are not modified or
modified in only limited ways. Laboratories performing these tests are subject to other requirements, including the requirement to submit
the labeling for the LDT to FDA for review. FDA will similarly exercise enforcement discretion with respect to premarket authorization
for LDTs approved by the New York State Clinical Laboratory Evaluation Program (&#8220;NYS-CLEP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On March 31, 2025, a federal district court vacated
the FDA final rule, thereby cancelling the rulemaking&#8217;s associated requirements. The court held that laboratory developed tests
do not meet the definition of a medical device under the Federal Food, Drug, and Cosmetic (&#8220;FD&amp;C&#8221;) Act and the FDA therefore
lacks jurisdiction to regulate them. Laboratories no longer need to comply with the regulatory changes that were set to take effect on
May 6, 2025, or with the rulemaking&#8217;s other requirements. The federal government did not seek a stay of the district court&#8217;s
opinion and did not file an appeal of the ruling, which means the district court decision remains in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The results of operations presented below should
be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in this Prospectus. The following table
sets forth Cardio&#8217;s results of operations data for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparisons for the years ended December
31, 2024 and 2023:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><b><i></i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Years
    Ended December 31,</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">Revenue</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt">Revenue</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">34,890</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">17,065</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Sales and marketing</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">182,446</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">158,514</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Research and development</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29,125</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">145,182</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,169,458</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,936,646</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Amortization</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,738</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,182</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,400,767</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,259,524</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other (expense) income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,576</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,134,375</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 1.7pt">Net (loss)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,383,453</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,376,834</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#8217;s net loss for the year ended December
31, 2024, was $8,383,453 as compared to $8,376,834 for the year ended December 31, 2023, an increase of $6,619 primarily as a result of
an increase in General and Administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has earned only nominal revenue since inception.
Revenue for the year ended December 31, 2024, was $34,890 compared to $17,065 for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Sales and Marketing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Expenses related to sales and marketing for the
year ended December 31, 2024, were $182,446 as compared to $158,514 for the year ended December 31, 2023, an increase of $23,932. The
overall increase was due to an increase in sales and marketing activity in 2024 due to tradeshow attendance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Research and development expense for the year ended
December 31, 2024, was $29,125 as compared to $145,182 for the year ended December 31, 2023, a decrease of $116,057. The decrease was
attributable to the decrease in laboratory runs performed in 2024 on new product offerings in the pipeline as compared to laboratory runs
performed in 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">General and administrative expenses for the year
ended December 31, 2024, were $8,169,458 as compared to $ $6,936,646 for the year ended December 31, 2023, an increase of $1,232,812.
&#160;The overall increase is primarily due to an increase in stock compensation expenses (mainly as a result of new stock options issued
in the first quarter of 2024), offset by the decrease in D&amp;O insurance expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Amortization</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Amortization expense for the year ended December
31, 2024, was $19,738, as compared to $19,182 for the year ended December 31, 2023. The total amortization expense for the year ended
December 31, 2024 includes the amortization of intangible assets of $16,000 and patent costs of $3,738, respectively, as compared to $16,000
for intangible assets and $3,182 for patent costs for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Other income (expenses)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Total other expenses for the year ended December
31, 2024, was $(17,576) as compared to $(1,134,375) for the year ended December 31, 2023. The total other expenses for the year ended
December 31, 2024 consists of interest expense of $18,640 net of interest income of $1,064. The total other expenses for the year ended
December 31, 2023 consists of interest expense of $6,735,013 offset by gain on extinguishment of debt of $193,350, change in fair value
of derivative liability of $5,406,220 and interest income of $1,068.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comparisons for the Six Months Ended June 30, 2025 and 2024:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following table presents summary of consolidated
operating results for the six-month periods indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; padding-bottom: 1pt">Revenue</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; font-size: 10pt; text-align: right">8,415</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; font-size: 10pt; text-align: right">23,798</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Selling, general and administrative expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,317,674</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,464,306</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,317,674</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,464,306</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other (expense) income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,004</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,071</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&#160;Net (loss)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,318,263</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(5,451,579</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Net Loss</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#8217;s&#160;net&#160;loss for the six months
ended June 30, 2025 was $3,318,263 as compared to $5,451,579 for the six months ended June 30, 2024, a decrease of $2,133,316. The decrease
in net loss was primarily the result of a decrease in General and Administrative <span style="background-color: white">expenses associated
with stock compensation issued in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i></i></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio had $8,415 and $23,798 in revenue for the
six months ended June 30, 2025 and 2024, respectively. The decrease in revenue was <span style="background-color: white">noted in Q1 as
a result of the conclusion of the Family Medicine Specialists&#8217; Heart Attack Prevention testing initiative. Additional providers
have been and are continuing to be onboarded as noted by Q2 revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Selling, General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Selling, General and Administrative Expenses for
the six months ended June 30, 2025, were $3,317,674 as compared to $5,464,306 for the six months ended June 30, 2024, a decrease of $2,146,632.
The overall decrease is primarily due to stock compensation expenses of $2,546,135 in the six months of 2024 as compared to $61,390 in
the same period of 2025, offset by more payroll related expenses due to more personnel in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Selling, General and Administrative Expenses for
the six months ended June 30, 2025 included payroll and related costs of $961,517, research and development expense of $165,296, sales
and marketing expense of $252,863, rent and other facility costs of $155,854, legal and professional fees of $511,264, consulting and
contractor fees of $326,707, insurance expense of $314,830, filing fees of $42,290, transfer agent fees of $11,936, software and web computing
expenses of $180,314, board compensation of $99,390, investor relations expenses of $7,500, general corporate overhead expenses of $233,990
and amortization expense of $53,923. The total amortization expense for the six months ended June 30, 2025 is for intangible assets of
$5,333 and patent costs of $48,590 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Selling, General and Administrative Expenses for
the six months ended June 30, 2024 included payroll and related costs of $3,387,020 (including stock compensation expenses of $2,546,135),
research and development expense of $18,120, sales and marketing expense of $92,181, rent and other facility costs of $101,222, legal
and professional fees of $444,473, consulting and contractor fees of $396,277, insurance expense of $363,558, filing fees of $76,957,
transfer agent fees of $20,153, software and web computing expenses of $137,488, board compensation of $99,958, investor relations expense
of $67,524, general corporate overhead expenses of $249,788 and amortization expense of $9,587. The total amortization expense for the
six months ended June 30, 2024 is for intangible assets of $8,000 and patent costs of $1,587 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 4pt">&#160;</span><span style="font-size: 10pt">We
expect our general corporate overhead to remain relatively flat. However, we expect an increase in payroll and related costs and other
facility costs, including furnishing the laboratory facility, capital expenditure of laboratory equipment, and other laboratory materials,
in order to put our company laboratory into operation in the second half of 2025. Additionally, as a public company, we expect to have
to comply with changing legal and exchange requirements, including as to regulations of the SEC and the continued listing requirements
of the Nasdaq Capital Market. We incur additional annual expenses related to these matters and, among other things, additional directors&#8217;
and officers&#8217; liability insurance, directors&#8217; fees, reporting requirements of the SEC, transfer agent fees, increased auditing
and legal fees and similar expenses.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Other income (expenses)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Total other expense for the six months ended June
30, 2025, was $(9,004) as compared to $(11,071) for the six months ended June 30, 2024. The total other expense for the six months ended
June 30, 2025, consists of interest expense of $9,381, net of interest income of $377. The total other expense for the six months ended
June 30, 2024, consists of interest expense of $11,634, net of interest income of $563.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Liquidity describes the ability of a company to
generate sufficient cash flows in the short- and long-term to meet the cash requirements of its business operations, including working
capital needs, debt service, acquisitions and investments, and other commitments and contractual obligations. We consider liquidity in
terms of cash flows from operations and other sources, and their sufficiency to fund our operations. Historically, our principal sources
of liquidity have been proceeds from the issuance of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On January 26, 2024, we entered into the Sales
Agreement with Craig-Hallum. Pursuant to the Sales Agreement, we may sell, at our option, shares of our Common Stock through Craig-Hallum,
as sales agent. Sales of our Common Stock were made pursuant to the Sales Agreement initially up to an aggregate of $17 million under
a shelf registration statement declared effective in February 2024 (File No. 333-276725) and will continue to be made pursuant to the
Sales Agreement up to an aggregate of $9,476,508 under a second shelf registration statement declared effective in February 2025 (File
No. 333-284775).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of August 14, 2025, we sold 1,054,841 shares
of our Common Stock on a Reverse Stock Split-adjusted basis under the Sales Agreement resulting in proceeds to us of $14,782,871, net
of offering costs. We have paid Craig-Hallum $379,048 in sales commissions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 10pt">On February
2, 2024, we closed a private placement with seven accredited investors, whereby we issued a total of 18,727 (561,793 prior to the
Reverse Stock Split) units (&#8220;Units&#8221;), with each Unit consisting of (i) one share of our Common Stock and (ii) one
six-year Common Stock purchase warrant having an exercise price of $53.40 ($1.78 prior to the Reverse Stock Split) per share,
subject to adjustment (the "Private Placement&#8221;). The Private Placement resulted in the issuance to investors of 18,727
(561,793 prior to the Reverse Stock Split) shares of Common Stock and 18,727 (561,793 prior to the Reverse Stock Split) warrants in
an unregistered offering of securities. The purchase price of the securities was $53.40 ($1.78 prior to the Reverse Stock Split) per
Unit, resulting in gross proceeds to the Company of $1,000,000, before deducting placement agent fees (10% or $100,000) and other
offering expenses. We used the net proceeds from the Private Placement for working capital and general corporate purposes. We have
subsequently registered the Private Placement Common Stock and the Common Stock issuable upon the exercise of the Private Placement
Warrants on a registration statement on Form S-1 that was declared effective by the SEC on December 3, 2024. This Post-Effective Amendment updates that previously filed registration statement to include information from
 our Annual Report on Form 10-K for the year ended&#160;December 31, 2024, which was filed with the SEC on March 20, 2025 and our Quarterly
Report on Form 10-Q for the period ended June 30, 2025, which was filed on August&#160;14, 2025, and to update certain other information
in the registration statement.</span><span style="font-size: 4pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 4pt">&#160;</span><span style="font-size: 10pt">We
have had, and expect that we will continue to have, an ongoing need to raise additional cash from outside sources to fund our operations
and grow our business. We expect that our primary cash needs for the remainder of 2025 and for the foreseeable future will be for funding
day-to-day operations and working capital requirements, funding our growth strategy, paying the setup expenses of our internal laboratory
and paying expenses incurred in connection with our ongoing FDA submission activities.&#160;We explore our financing options on an ongoing
basis. However, given recent stock prices and the extreme volatility of our stock, it continues to be challenging to balance cash that
could be raised and the dilution that might be required to close a particular transaction. We expect that for the remainder of 2025, we
will rely primarily on the ongoing ATM Offering, provided that market conditions are favorable.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">At the upcoming 2025 annual meeting of stockholders,
our stockholders will be asked to approve the future issuance of shares of Common Stock and/or securities convertible into or exercisable
for Common Stock equal to 20% or more of the Common Stock outstanding in one or more non-public transactions as required by Nasdaq Marketplace
Listing Rule 5635(d) (the "Share Issuance Proposal&#8221;). This proposal is identical to the proposals approved by our stockholders
in 2023 and 2024, neither of which we relied upon for financing options, and the authorizations provided thereby expired. Any non-public
financing transaction undertaken in connection with this approval will be conducted within the parameters set forth in the Share Issuance
Proposal described in the proxy statement for the 2025 annual meeting, if the proposal is approved. We currently have no specific plans
for such an offering but believe having that option available provides our Board of Directors with added flexibility in meeting the Company&#8217;s
liquidity needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our long-term future capital requirements will
depend on many factors, including revenue growth rate, the timing and the amount of cash received from customers, the expansion of sales
and marketing activities, the timing and extent of spending to support investments, including research and development efforts, and the
continuing market adoption of our products. In each fiscal year since our inception, we have incurred losses from operations and generated
negative cash flows from operating activities. We expect this trend to continue in future periods for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Unless we are able to generate significant cash
flows from operations, which we do not foresee happening in the near term, we will need to finance our operations through the issuance
of additional equity and/or convertible debt securities. Looking forward, we expect we will need to raise additional capital and generate
revenues to meet long-term operating requirements. If we raise additional funds through the issuance of equity or convertible debt securities,
the percentage ownership of our equity holders could be significantly diluted, particularly at current stock price levels, and these newly-issued
securities may have rights, preferences or privileges senior to those of existing equity holders. If we raise additional funds by obtaining
loans from third parties, the terms of those financing arrangements may include negative covenants or other restrictions on our business
that could impair our operating flexibility and also require us to incur interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Working capital requirements are expected to increase
in line with the growth of the business. We have no lines of credit or other bank financing arrangements. We anticipate that our principal
sources of liquidity, including existing funds and issuances of equity and/or debt, will be sufficient to fund our activities over the
next 12 months. In order to have sufficient cash to fund our operations beyond the next 12 months and grow our business, we will need
to raise additional funds through the issuance of equity and/or debt. We cannot provide any assurance that we will be successful in doing
so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If we are unable to raise additional capital when
desired, our business, financial condition and results of operations would be harmed. Successful transition to attaining profitable operations
depends upon achieving a level of revenue adequate to support our business plan, balanced against ongoing expenses. There is no assurance
that we will be successful in reaching and sustaining profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The exercise prices of our currently outstanding
warrants range from a high of $345 to a low of $53.40 (a high of $11.50 to a low of $1.78 before the Reverse Stock Split) (subject to
adjustment) per share of Common Stock. The likelihood that warrant holders will exercise their warrants, and therefore the amount of cash
proceeds that we might receive, is dependent upon the trading price of our Common Stock, the last reported sales price for which was $3.790
on September 12, 2025. If the trading price of our Common Stock is less than the respective exercise prices of our outstanding warrants,
which has been the case for a substantial period of time, we believe holders of any of our warrants will be unlikely to exercise their
warrants. There is no guarantee that the warrants will be in the money prior to their respective expiration dates, and as such, the warrants
may expire worthless, and we may receive no proceeds from the exercise of warrants. Given the current differential between the trading
price of our Common Stock and the Warrant exercise prices and the volatility of our stock price, we are not making strategic business
decisions based on an expectation that we will receive any cash from the exercise of warrants. However, we will use any cash proceeds
received from the exercise of warrants for general corporate and working capital purposes, which would increase our liquidity. We will
continue to evaluate the probability of warrant exercises and the merit of including potential cash proceeds from the exercise of the
warrants in our future liquidity projections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cash at&#160;June 30, 2025 totaled $7,966,500 as
compared to $7,827,487 at December 31, 2024, an increase of $139,013. <span style="background-color: white">The following table shows
Cardio&#8217;s cash flows from operating activities, investing activities and financing activities for the stated periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Six
    months ended June 30,</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; text-align: left">Net cash used in operating activities</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">2,971,566</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">2,443,450</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net cash used in investing activities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">83,132</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">271,010</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net cash provided by financing activities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,193,711</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,741,056</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="background-color: white"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="background-color: white"><i>Cash
Used in </i></span><i>Operating <span style="background-color: white">Activities</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cash used in operating activities for the six months
ended June 30, 2025 was $2,971,566 as compared to $2,443,450 for the six months ended June 30, 2024. The cash used in operations during
the six months ended June 30, 2025 is a function of net loss of $3,318,263 adjusted for the following non-cash operating items: depreciation
of $75,441, amortization of $139,022, $61,390 in stock-based compensation, a decrease of $5,685 in accounts receivable, a decrease of
$220,762 in prepaid expenses and other current assets, a decrease of $38,937 in accounts payable and accrued expenses and a decrease in
lease liability of $116,666.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The cash used in operations during the six months
ended June 30, 2024 is a function of net loss of $5,451,579 adjusted for the following non-cash operating items: depreciation of $39,579,
amortization of $69,877, $2,546,135 in stock-based compensation, an increase of $2,560 in accounts receivable, a decrease of $656,310
in prepaid expenses and other current assets, a decrease of $191,132 in accounts payable and accrued expenses and a decrease in lease
liability of $110,080.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i></i></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Cash Used in Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cash used in investing activities for the six months
ended June 30, 2025 was $83,132 compared to $271,010 for the six months ended June 30, 2024. The cash used in investing activities for
the six months ended June 30, 2025 and 2024 was due to purchases of property and equipment and patent costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Cash Provided by Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cash provided by financing activities for the six
months ended June 30, 2025 was $3,193,711 as compared to $2,741,056 for the six months ended June 30, 2024. Cash provided by financing
activities for the six months ended June 30, 2025 was due to $3,423,784 in net proceeds from the sale of common stock offset by $230,073
in payments of finance agreement. Cash provided by financing activities for the six months ended June 30, 2024 was due to $3,021,556 in
net proceeds from the sale of common stock and warrants offset by $280,500 in payments pursuant to a finance agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Financing Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 10pt">We did not have any
off-balance sheet arrangements as of June 30, 2025.</span><span style="font-size: 4pt">&#160;&#160;&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Contractual Obligations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of June 30, 2025, we do not have any ongoing
contractual obligations that would have a negative impact on liquidity and cash flows. However, if one or more of the following potential
claims that arise from contracts we have entered into were pursued against us, there is the potential that we could see a negative impact
on liquidity and cash flows, depending on the outcome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Prior Relationships of Cardio with Boustead Securities,
<span style="letter-spacing: -0.25pt">LLC</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i><span style="letter-spacing: -0.25pt">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">At the commencement of efforts to pursue what ultimately
ended in the terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the &#8220;Placement
Agent Agreement&#8221;), dated April 12, 2021, with Boustead Securities, LLC (&#8220;Boustead Securities&#8221;). This agreement was terminated
in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying escrow agreement relating
to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions of the closing deadline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Under the terminated Placement Agent Agreement,
Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead
Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with
any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company&#8217;s
exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#8220;right of first refusal&#8221;).
Cardio has taken the position that due to Boustead Securities&#8217; failure to perform as contemplated by the Placement Agent Agreement,
these provisions purporting to provide future rights are null and void.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 10pt">Boustead Securities
responded to the termination of the Placement Agent Agreement by disputing Legacy Cardio&#8217;s contention that it had not performed
under the Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its
response, Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio&#8217;s behalf. While Boustead
Securities&#8217; contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had
not made any such contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years
following the termination of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions.
Legacy Cardio strongly disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined,
with any potential party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has
no plans to do so at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that
the final outcome will not have a material adverse impact on its financial condition.</span><span style="font-size: 4pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i></i></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>The Benchmark Company, LLC Right of First Refusal</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company completed a business combination with
Mana on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark
Company, LLC (&#8220;Benchmark&#8221;) as its M&amp;A advisor. Upon closing of the business combination, Legacy Cardio assumed the contractual
engagement entered into by Mana. On November 14, 2022, Cardio and Benchmark entered into Amendment No. 1 Engagement Letter (the &#8220;Amendment
Engagement&#8221;). Pursuant to the Amendment Engagement, Benchmark has been granted a right of first refusal to act as lead or joint-lead
investment banker, lead or joint-lead book-runner and/or lead or joint-lead placement agent for all future public and private equity and
debt offerings through October 25, 2023. Based on the right of first refusal, Benchmark alleges that it is owed damages because the Company
entered into the Yorkville Convertible Debenture Transaction without first offering Benchmark the right to serve as the lead or joint-lead
placement agent for the transaction. The Company is evaluating the claim. No legal proceedings have been instigated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Demand Letter and Potential Mootness Fee Claim</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On June 25, 2022, a plaintiffs&#8217; securities
law firm sent a demand letter to the Company alleging that the Company&#8217;s Registration Statement on Form S-4 filed (the &#8220;S-4
Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May 31, 2022 omitted material information
with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures
in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S- 4 Registration
Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various
comments of the SEC staff and otherwise updated its disclosure. In October 2022, the SEC completed its review and declared the S-4 registration
statement effective on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs&#8217; securities law firm contacted the
Company&#8217;s counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022
demand letter. The Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any
respect and believes that no additional supplemental disclosures are material or required. The Company believes that the claims asserted
in the Demand Letter are without merit and that no further disclosure was required to supplement the S-4 Registration Statement under
applicable laws. As of the date of filing of this Quarterly Report on Form 10-Q, no lawsuit has been filed against the Company by that
firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however,
Cardio believes that the final outcome will not have a material adverse impact on its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Northland Securities, <span style="letter-spacing: -0.2pt">Inc.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In January 2024, following the Company&#8217;s
termination of its agreement with Yorkville and in connection with the Company&#8217;s recent at the market offering and/or its February
2024 private placement, a managing director of Northland Securities, Inc. (&#8220;Northland&#8221;) contacted the Company claiming the
right to be paid a fee of approximately $150,000 pursuant to the agreement of March 1, 2023 between the Company and Northland regarding
the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland would not proceed
with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville Securities
Purchase Agreement and the subsequent financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company cannot preclude the possibility that
claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require significant
time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i></i></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Directors and Officers Insurance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In connection with the Company&#8217;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>The <span style="background-color: white">University
of Iowa Research Foundation Exclusive License Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i><span style="background-color: white">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i><span style="background-color: white"></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company has a worldwide exclusive
license agreement with the University of Iowa Research Foundation (UIRF) relating to its patent and patent-pending technology (the &#8220;Exclusive
License Agreement&#8221;). Under the terms of the Exclusive License Agreement, the Company will have to pay each of: (1) 1% of either
the: (i) aggregate consideration (and trailing consideration, if any) for a liquidation event; or (ii) pre-money valuation for an initial
public offering, (the &#8220;Equity Rights&#8221;) (2) 2% of annual net sales, and (3) 15% of non-royalty fees paid to licensee if it
enters into one or more sublicensing agreements. Upon the Closing of the Business Combination, the Company issued 3,639 (109,170 prior
to the Reverse Stock Split) Shares of Common Stock to UIRF in accordance with the Equity Rights under the Exclusive License Agreement.
The Company has had minimal sales of $62,221 to date and has paid 2% or approximately $1,300 in total royalty fees to UIRF under the exclusive
license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Exclusive License Agreement entered
into with UIRF and those licenses granted under that license agreement terminate on the expiration of the patent rights licensed under
the license agreement, unless certain proprietary, non-patented technical information <span style="background-color: white">is still being
used by the Company, in which case the license agreement will not terminate until the date of termination of such use. The licenses under
the license agreement could terminate prior to the expiration of the licensed patent rights if the Company materially breaches its obligations
under the license agreement,&#160;including failing to pay the applicable license fees and any interest on such fees,&#160;and failing
to fully remedy such breach within the period specified in the license agreement, or if the Company enters liquidation, has a receiver
or administrator appointed over any assets related to the license agreement, ceases to carry on business, files for bankruptcy or if an
involuntary bankruptcy petition is filed against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical <span style="background-color: white">Accounting Policies
and Significant Judgments and Estimates</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#8217;s consolidated financial statements
are prepared in accordance with GAAP in the United&#160;States. The preparation of its consolidated financial&#160;statements&#160;and
related disclosures requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs
and expenses, and the disclosure of contingent assets and liabilities in Cardio&#8217;s financial statements. Cardio bases its estimates
on historical experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Cardio evaluates its estimates and assumptions on an ongoing basis. Cardio&#8217;s actual results may differ from
these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our senior management has reviewed the critical
accounting policies and estimates with the Audit Committee of our Board of Directors. For a description of the Company&#8217;s critical
accounting policies and estimates, refer to &#8220;Part II&#8212;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8221; in our most recent Annual Report on Form 10-K
for the year ended December 31, 2024, which was filed with the SEC on March 20, 2025. Critical accounting policies are those that are
most important to the portrayal of our financial condition, results of operations and cash flows and require management&#8217;s most difficult,
subjective and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.
If actual results were to differ significantly from estimates made, the reported results could be materially affected. There were no significant
changes to our critical accounting policies and estimates during the three and six months ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"></span></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="Business"></span><span style="background-color: white"><b>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>References in this report to &#8220;Cardio,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221; refer to Cardio Diagnostics Holdings, Inc. References to our &#8220;management&#8221;
or our &#8220;management team&#8221; refer to the officers and directors of Cardio Diagnostics Holdings, Inc.&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio Diagnostics, Inc. ("Legacy Cardio&#8221;)
was founded in 2017 in Coralville, Iowa by Meeshanthini (Meesha) Dogan, PhD, and Robert (Rob) Philibert, MD PhD. It was formed in January
2017 as an Iowa LLC and was subsequently incorporated as a Delaware C Corp in September 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio was formed to further develop and commercialize
a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (&#8220;CHD&#8221;),
stroke, heart failure and diabetes, by leveraging our Artificial Intelligence (&#8220;AI&#8221;)-driven Integrated Genetic-Epigenetic
Engine&#8482;. As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases.
Cardio aims to become one of the leading medical technology companies for enabling improved prevention, detection, treatment and management
of cardiovascular disease and associated co-morbidities. Cardio is transforming the approach to cardiovascular medicine from reactive
to proactive and hopes to accelerate the adoption of Precision Cardiovascular Medicine for all. We believe that incorporating our solutions
into routine clinical practice in and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to
develop some form of cardiovascular disease by 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio believes that it is the first company to
develop&#160;and&#160;commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value propositions for
multiple stakeholders including (1) patients, (2) clinicians, (3) hospitals/health systems, (4) employers and (5) payors. According to
the CDC, epigenetics is the study of how a person&#8217;s behaviors and environment can cause changes that affect the way a person&#8217;s
genes work. Unlike genetic changes, epigenetic changes are reversible and do not change one&#8217;s DNA sequence, but they can change
how a person&#8217;s body reads a DNA sequence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#160;launched&#160;its first clinical test,
Epi+Gen CHD&#8482;, a three-year symptomatic CHD risk assessment clinical blood test targeting CHD events, including heart attacks, in
2021 during the Covid-19 pandemic. As a result, the initial strategy for commercialization involved launching the test via telemedicine
and in smaller provider practices such as concierge medicine practices. The volume of tests through these channels were minimal, and as
the circumstances around Covid-19 pandemic improved, management re-vamped the Company&#8217;s go-to-market strategy to include other healthcare
verticals and stakeholders beyond patients and small providers, including larger provider organizations, group purchasing organizations,
employers, payors and life insurers. This new approach allowed Cardio to expand the reach of our solutions beyond the initial focus areas.
Beyond the launch of Epi+Gen CHD, in March 2023, we announced the launch of our second product, PrecisionCHD&#8482;, an integrated epigenetic-genetic
clinical blood test for the detection of coronary heart disease. The Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are coupled to our
Actionable Clinical Intelligence (&#8220;ACI&#8221;), a platform that offers new epigenetic and genetic insights to clinicians prescribing
our tests to personalize patient management and help improve chronic care management. In May 2023, we launched CardioInnovate360&#8482;,
a research-use-only (&#8220;RUO&#8221;) solution to support the discovery, development and validation of novel biopharmaceuticals for
the assessment and management of cardiovascular diseases. In February 2024, we announced the launch of HeartRisk&#8482;, a cardiovascular
disease risk intelligence platform. We believe that our Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests are categorized as laboratory-developed
tests, or &#8220;LDTs.&#8221; The new go-to-market strategy is also being implemented for these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Despite long partnership and sales cycles, in some
instance as long as 14 months, we were able to increase the reach of our solutions in 2024, generating revenue from provider organizations
and continued the development of a more robust sales and partnership pipeline. To further increase reach and potentially accelerate partnerships
and sales cycles, more seasoned sales personnel in the provider and employer verticals were hired in late 2024. In the first and second
quarters of 2025, our focus remained in driving adoption of our clinical solutions, predominantly among providers, channel partners and
employers. In addition, we made progress in the Medicare reimbursement process where we received preliminary gapfill pricing from the
Centers for Medicare and Medicaid for the Epi+Gen CHD and PrecisionCHD tests, onboarding a new employer client and in setting up our laboratory
facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a company in the early stages of its development,
the Company continuously reevaluates its business, the market in which it operates and potential new opportunities. The Company may seek
other alternatives within the healthcare field in order to grow its business and increase revenues. Such alternatives may include, but
not be limited to, combinations or strategic partnerships with other laboratory companies or with medical practices such as hospitalists
or behavioral health.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="font-size: 10pt">Key recent developments
include:</span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Recommended pricing for our two Current Procedural Terminology (&#8220;CPT&#8221;) Proprietary Laboratory Analysis (&#8220;PLA&#8221;) codes from the American Medical Association, 0440U for PrecisionCHD&#8482; and 0439U for Epi+Gen CHD&#8482;, at the Centers for Medicare and Medicaid Services&#8217; (&#8220;CMS&#8221;) Clinical Laboratory Fee Schedule (CLFS) annual meeting;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Expanded the availability of our Epi+Gen CHD&#8482; test to Family Medicine Specialists&#8217; retail clinical location at Meijer Supercenter;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Received Medicare pricing determination from Centers for Medicare and Medicaid Services (CMS) for PrecisionCHD&#8482; and Epi+Gen CHD&#8482;; and</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">We have entered into partnerships with seven new provider organizations. The new partners include specialized practices in Michigan, Illinois, Texas, Florida, California, and Connecticut, representing various medical specialties including concierge medicine, primary care, and precision medicine</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio expects that sales and partnership cycles
will continue to be long. Our ongoing strategy for expanding our business operations and increasing revenue generation include the following:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Develop additional products, including clinical tests for stroke, congestive heart failure and diabetes;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Expand clinical and health economics evidence portfolio to continue to demonstrate value of products and increase reach;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Leverage our newly-awarded CPT PLA codes;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Expand the adoption of our products across key channels, including health systems and self-insured employers, including for HeartRisk, Cardio&#8217;s new SaaS product;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Scale our internal operations capabilities with a focus on improving efficiency and reducing our cost of goods sold; and</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Pursue potential strategic partnership(s) and acquisition(s) of one or more synergistic companies.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry Background</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">According to the American Heart Association (&#8220;AHA&#8221;),
even though an estimated 80% of cardiovascular disease (&#8220;CVD&#8221;) is preventable, it remains the leading cause of death in the
United States and globally. The AHA also reported that over 650,000 deaths in the United States each year are attributable to heart disease,
which amounts to one in every four deaths. The Centers for Disease Control and Prevention (&#8220;CDC&#8221;) estimates that in the United
States, one person dies every 36 seconds from CVD. Unfortunately, the incidence of CVD is expected to continue to rise with the AHA projecting
that by 2035, nearly half of Americans will have some form of CVD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">CVD represents conditions that affect the heart
and blood vessels such as coronary heart disease (&#8220;CHD&#8221;), stroke, and congestive heart failure (&#8220;CHF&#8221;). CHD is
the most common type of heart disease and according to the CDC, was responsible for nearly 370,000 deaths in 2019. The National Center
for Health Statistics reported that the prevalence of CHD is approximately 6.7%, and according to the AHA, over 20 million adults aged
20 or older in the United States have CHD. CHD is also the major cause of heart attacks. According to the AHA, every 40 seconds, someone
in the United States has a heart attack, with over 800,000 Americans having a heart attack each year. The CDC reported that in 2020, stroke
was responsible for one in six CVD-related deaths. The AHA estimates that every year, nearly 800,000 Americans have a stroke which is
the leading cause of major long-term disability, with a stroke-related death occurring every 3.5 minutes. According to the AHA, over six
million adults have heart failure and nearly 380,000 deaths in 2018 were attributable to heart failure. There are numerous risk factors
that could increase an individual&#8217;s risk for CVD. Several key risk factors include diabetes, high blood cholesterol, and high blood
pressure. For example, according to the CDC, over 34 million adults have diabetes and according to Johns Hopkins Medicine, those with
diabetes are two to four times more likely to develop CVD. Alongside genetics, age, sex, and ethnicity, lifestyle factors such as smoking,
unhealthy diet, physical inactivity, and being overweight can also increase the risk for CVD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition to the enormous morbidity and mortality
associated with CVD, the economic burden of CVD is also staggering as depicted in the figure below from the Cardiovascular Disease: A
Costly Burden For America, Projections Through 2035 report by the AHA. CVD is the costliest disease in the United States and the economic
burden associated with CVD is expected to continue to soar. According to the CDC Foundation, every year, one in six United States healthcare
dollars is expended on CVD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><img src="image_009.jpg" alt="" style="height: 247.8pt; width: 280.8pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The AHA reports that in 2016, the cost of CVD was
$555 billion and is expected to rise to over $1 trillion by 2035. Of the $555 billion, $318 billion was associated with medical costs,
and the remaining $237 billion with indirect costs such as lost productivity. By 2035, the medical costs associated with CVD are expected
to increase 135% to $749 billion, while the indirect costs are expected to rise by 55% to $368 billion. Currently, among the various types
of CVD, the medical costs of CHD are the highest at $89 billion and are expected to rise to $215 billion by 2035 as depicted in the figure
below from the Cardiovascular Disease: A Costly Burden For America, Projections Through 2035 report by the AHA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><img src="image_010.jpg" alt="" style="height: 183pt; width: 330.6pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">To address this expected significant rise in human
health and economic burdens, the United States healthcare market is seeking more efficient and effective methods to better prevent, detect,
manage, and treat CVD. This same trend is playing out across developed nations around the globe as the burden of CVD continues to grow
due to a rise in major risk factors such as obesity, poor diet and Type 2 diabetes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">This is consistent with the cardiovascular diagnostic
testing market trends reported by Research and Markets in their Outlook on the Cardiovascular Diagnostic Testing Global Market to 2027
- Increasing Number of Insurance Providers Presents Opportunities press release published on July 4, 2022. They estimate that the Global
Cardiovascular Diagnostic Testing Market is estimated to grow from $8.47 billion in 2022 to $12.41 billion by 2027, with a CAGR of 7.94%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There are several healthcare tailwinds that are
driving this expected growth and are expected to support the large-scale adoption of our solutions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="text-align: left; width: 17px; line-height: 100%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.2pt; text-align: justify; line-height: 100%"><span style="font-size: 10pt; line-height: 100%"><b>The aging population:</b> According to the Population Reference Bureau, by 2060, the number of Americans aged 65 and over is projected to more than double from 46 million to over 98 million. This demographic shift will result in increased demand for healthcare services in general and for CVD specifically because the risk for CVD increases with age. According to the AHA, the risk for CVD at age 24 is about 20% and more than doubles to 50% by age 45, with 90% of those over the age of 80 having some form of CVD.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="text-align: left; width: 17px; padding-top: 4.3pt; line-height: 100%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.75pt"><span style="font-size: 10pt; line-height: 100%"><b>The rise of chronic diseases:</b> Chronic diseases such as heart disease, cancer, and diabetes are rising in the United States. The rise of these conditions is further driven by less-than-ideal lifestyle choices such as smoking, an unhealthy diet, and sedentary behavior. As a result, better predictive and diagnostic tools are needed to get ahead of these conditions alongside the need for improved treatment and management of these conditions.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="text-align: left; width: 17px; line-height: 100%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 12.35pt; line-height: 100%"><span style="font-size: 10pt; line-height: 100%"><b>The rise of costs associated with chronic diseases:</b> Chronic diseases, including heart disease and cancer continue to drive up healthcare costs, placing a growing financial burden on employers, insurers, and the healthcare system at large. In the United States, the direct and indirect costs associated with CVD is expected to climb as prevalence increases. The financial strain is particularly evident in employer-sponsored health plans, where CVD is a leading driver of high-cost claims, absenteeism, and reduced productivity. As healthcare costs rise, self-insured employers, benefits consultants, payers, and providers are actively seeking cost-effective solutions to mitigate the impact of CVD. This includes early detection strategies, precision diagnostics, and personalized prevention programs that can identify at-risk individuals before costly acute events occur.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px; line-height: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 12.35pt; line-height: 100%"><span style="font-size: 10pt; line-height: 100%"><b>The shift to value-based care:</b> The shift to value-based care drives healthcare providers to focus on quality rather than quantity of care. The shift to value-based care is a crucial driver of growth for Cardio because it incentivizes health care providers to focus on providing quality care rather than simply providing more care. Cardio believes providers can tackle the costliest and deadliest disease category with its solutions while reducing costs.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px; line-height: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.75pt"><span style="font-size: 10pt; line-height: 100%"><b>The growth of telemedicine:</b> Driven largely by the COVID-19 pandemic, telemedicine is a growing trend in healthcare, as it allows patients to receive care from providers remotely. Remote, telemedicine-based preventative programs and tests can serve those who are already undergoing routine screening, but more importantly, expand reach to most Americans who currently are not receiving preventative healthcare, including rural and underserved populations. our evidence-based solutions can be deployed remotely, which is expected to further drive adoption by patients and clinicians.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px; line-height: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.75pt"><span style="font-size: 10pt; line-height: 100%"><b>The adoption of Artificial Intelligence (AI):</b> AI is increasingly incorporated into many aspects of healthcare, including administrative tasks, diagnosis and treatment. AI has the potential to improve the quality of care while reducing costs. Machine learning, which is a type of AI, is instrumental to our cutting-edge solutions, powering their clinical performance and differentiating them from other technologies for CVD.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.75pt"><span style="font-size: 10pt"><b>The rise of patient engagement:</b> Thanks to technology, patients are becoming more engaged in their healthcare. They use online tools to research their conditions and treatments and are more likely to participate in their care. This includes demanding cutting-edge clinical tests that can help them better prevent chronic diseases such as CVD while improving the length and quality of life. As a result, healthcare providers and organizations that offer such services including our solutions are likely to have an edge over those who do not.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 8.75pt"><span style="font-size: 10pt"><b>Building compelling evidence.</b> Our AI-driven Integrated Genetic-Epigenetic Engine&#8482; enables rapid design, development, and launch of diagnostic solutions resulting from over a decade of research studies. Our solutions that result from this technology, including our Epi+Gen CHD&#8482; test for coronary heart disease event risk assessment and PrecisionCHD&#8482; for the earlier detection of coronary heart disease, were developed through rigorous studies that are peer-reviewed and published and others that are being prepared for peer-reviewed publication in collaboration with leading healthcare and research institutions. In addition to the superior sensitivity of the Epi+Gen CHD&#8482; and PrecisionCHD&#8482; tests, the evidence bases for both the PrecisionCHD&#8482; and Epi+Gen CHD&#8482; tests also include an economic case to drive a more holistic and compelling argument for adoption.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px; line-height: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 7.9pt; line-height: 100%"><span style="font-size: 10pt; line-height: 100%"><b>Engaging experts and key stakeholders.</b> At Cardio, we understand that engaging experts and key healthcare stakeholders is critical to realizing our solutions&#8217; full potential and ensuring that these solutions reach as many people as possible.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 7.3pt"><span style="font-size: 10pt"><b>Prioritizing and executing strategic acquisitions.</b> Our expertise at several intersections across biology, machine learning, lab assay development, and cardiovascular disease, provide an array of strategic acquisition opportunities to better serve the cardiovascular disease market by horizontally and vertically integrating across the cardiac care continuum.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 14.65pt"><span style="font-size: 10pt"><b>Prioritizing payor coverage. </b>We believe that to continue to grow the market traction of our solutions, it would require pursuing additional payor coverage. We are engaging the appropriate experts, building necessary evidence, and have a roadmap in place for this. As part of this priority, we are pursuing pilots and strategic collaborations. We expect that it will take six to twelve months to engage additional payors and potentially longer to secure additional coverage for our solutions.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td><span style="font-size: 10pt"><b>Evaluating FDA pathway.</b> Cardio is evaluating an FDA regulatory pathway to enable broader access to our tests.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 17.55pt"><span style="font-size: 10pt"><b>Targeting multiple revenue channels.</b> To ensure that our revenue stream is diversified, Cardio has and will continue to target multiple revenue channels for which our solutions have compelling value propositions. This strategy includes, but is not limited to providers, health systems, and employers.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 100%">&#8226;</span></td>
    <td style="padding-right: 10.45pt"><span style="font-size: 10pt"><b>Launching synergistic products.</b> To more fully address cardiovascular health, Cardio is leveraging our AI-driven Integrated Genetic-Epigenetic Engine&#8482; to develop a series of clinical tests for major types of cardiovascular disease and associated co-morbidities, including stroke, congestive heart failure and diabetes. We have also started to develop additional synergistic products other than new clinical blood tests. Our first such product, HeartRisk&#8482;, is a cardiovascular disease risk intelligence platform, designed to augment our clinical blood tests.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">At the core of Cardio is our proprietary AI-driven
Integrated Genetic-Epigenetic Engine&#8482;, an engine invented and built by three key employees/officers for over a decade. Our technology
enables rapid design, development and launch of new diagnostic solutions through the identification of robust integrated genetic-epigenetic
biomarkers and their translation into clinical tests for cardiovascular disease and associated co-morbidities. This Engine consists of
multiple layers. It begins with genome-wide genetic (single nucleotide polymorphisms or SNPs), genome-wide epigenetic (DNA methylation)
and clinical data points. Using high-performance computing, ML/AI techniques and deep domain expertise in medicine, molecular biology
and engineering, a panel of SNP-DNA methylation biomarkers and mined, modeled and translated into standalone laboratory assays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="image_011.jpg" alt="" style="height: 270.6pt; width: 468.6pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As a result, our products, which are clinical tests,
consist of two components. The first is a laboratory component, which involves epigenetic DNA biomarkers. Genetic biomarkers (&#8220;SNPs&#8221;)
represent an individual&#8217;s inherited risk for the disease, have been reported to drive less than 20% of the risk for cardiovascular
disease (Hou, K et al, Aug 2019, Nature Genetics) and do not change with intervention (<i>i.e.</i>, static). Epigenetic biomarkers (DNA
methylation) represent an individual&#8217;s acquired risk for the disease that is influenced by lifestyle and environment which is a
larger driver for cardiovascular risk compared to genetics, is largely confounded by genetics and has been shown to change over time with
intervention or changes in one&#8217;s lifestyle and environment (<i>i.e.</i>, dynamic). The second is an analytical component, which
involves applying a proprietary interpretive predictive machine learning model to predict risk and provide personalized insights to help
clinicians tailor patient management. The combination of biomarkers and predictive machine learning model is unique to each clinical test
we develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt/105% Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="image_012.jpg" alt="" style="height: 264pt; width: 468pt"/></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.65pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Products and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have and will continue to leverage our AI-driven
Integrated Genetic-Epigenetic Engine&#8482; to develop a series of clinical tests for cardiovascular disease. As of August 2025, we have
leveraged this Engine to develop two clinical products: Epi+Gen CHD&#8482; and PrecisionCHD&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that our first product, Epi+Gen CHD&#8482;,
is the first epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for a coronary heart disease (&#8220;CHD&#8221;)
event, including heart attacks, and our second product, PrecisionCHD&#8482;, is the first epigenetics-based clinical blood test for the
detection of CHD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Both Epi+Gen CHD and PrecisionCHD are accompanied
by our provider-facing Actionable Clinical Intelligence&#8482; platform, which maps a patient&#8217;s unique biomarker profile and other
information onto modifiable factors such as diabetes, hypertension, hypercholesterolemia, and smoking, known to be critical drivers of
coronary heart disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">CardioInnovate360&#8482; is a research use only
(RUO) solution we launched to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management
of cardiovascular diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In 2024, we launched our first software product,
HeartRisk&#8482;. HeartRisk&#8482; is a cardiovascular disease risk intelligence platform that combines insights from HIPAA-compliant
anonymized and aggregated clinical cardiovascular data obtained through our Epi+Gen CHD&#8482; and PrecisionCHD&#8482; clinical blood
tests, with industry and geographic data to enable real-time population-level cardiovascular disease (&#8220;CVD&#8221;) risk insights.
These insights are customized for the stakeholder implementing our clinical solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="image_013.jpg" alt="" style="height: 266.4pt; width: 468pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Clinicians&#8217; Current Approach to Cardiovascular
Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Currently, a patient&#8217;s risk for CVD is generally
assessed using two common lipid-based clinical tests known as Framingham Risk Score (FRS) and ASCVD Pooled Cohort Equation (PCE).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">FRS and PCE are 10-year CVD risk calculators that
aggregate common clinical variables such as cholesterol and diabetes, demographics and subjective, self-reported information such as smoking
status. For the early detection of CHD, tests that are routinely used in a provider setting include stress echocardiograms. These tests
have several limitations and are less effective for several reasons:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">In a peer-reviewed published study by Cardio in collaboration with Intermountain Healthcare (Dogan, Meeshanthini &amp; Knight, Stacey &amp; Dogan, Timur &amp; Knowlton, Kirk &amp; Philibert, Robert. (2021). External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease. Epigenomics. 13. 10.2217/epi-2021-0123), we found that for <span style="letter-spacing: -0.05pt">predicting the </span>three-year <span style="letter-spacing: -0.05pt">risk for a </span>coronary heart disease event such as a heart attack, the average sensitivity of FRS and PCE was 44% in men and 32% in women. This means that for every 100 men and 100 women deemed "at-risk&#8221; for a coronary heart disease event, the test only correctly identifies 44 men and 32 women. </span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 10.05pt"><span style="font-size: 10pt">In a peer-reviewed published study by Cardio in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics (Philibert, Robert &amp; Dogan, Timur &amp; Knight, Stacey &amp; Ahmad, Ferhaan &amp; Lau, Stanley &amp; Miles, George &amp; Knowlton, Kirk &amp; Dogan, Meeshanthini. (2023). Validation of integrated genetic-epigenetic test for the assessment of coronary heart disease. Journal of American Heart Association. 12:e030934. DOI: 10.1161/JAHA.123.030934), we found that the overall average area under the curve, sensitivity, and specificity in three independent test cohorts for detecting coronary heart disease were 82%, 79%, and 76%, respectively.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">In a peer-reviewed published study by Cardio in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics (Philibert, Robert &amp; Dogan, Timur &amp; Knight, Stacey &amp; Ahmed, Ferhaan &amp; Lau, Stanley &amp; Miles, George &amp; Knowlton, Kirk &amp; Dogan, Meeshanthini. (2023). Validation of an integrated genetic-epigenetic test for the assessment of coronary heart disease. Journal of American Heart Association. 10.1161/JAHA.123.030934), we found that for predicting the presence of coronary heart disease, PrecisionCHD had an 80% sensitivity for men and 76% sensitivity for women</span>.</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="padding-top: 1pt; width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1pt; vertical-align: bottom"><span style="font-size: 10pt">The fasting requirement for current tests could be cumbersome for patients to comply, and the lack of fasting could affect test results.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 1pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 1pt; vertical-align: bottom"><span style="font-size: 10pt">The patient care plan that results from these tests generally lack personalization.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 8pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 26.65pt; vertical-align: bottom"><span style="font-size: 10pt">Lipid-based risk assessment tests depend on self-reported, subjective information such as smoking status from patients, and inaccurate information could affect the accuracy of test results.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 16.9pt; vertical-align: bottom"><span style="font-size: 10pt">Undergoing these tests requires an in-person clinic visit to collect blood samples and other necessary data points such as blood pressure, which may delay or prevent access to primary prevention, e.g., for those who are unable to make time for the visit, have transportation issues or live in rural areas are likely to delay primary prevention altogether. Similarly, to undergo a stress echocardiogram for instance, an in-person visit is required, and such a visit can take weeks to schedule that could delay care for patients especially if they are experiencing symptoms such as chest pain.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-right: 16.9pt; vertical-align: bottom"><span style="font-size: 10pt">Commonly used risk assessment tests were also developed predominantly using data from men and therefore, may be less effective for women.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Epi+Gen CHD&#8482; is the Only Epigenetics-based
Clinical Test for Coronary Heart Disease <span style="letter-spacing: -0.05pt">Event </span>Risk Assessment&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Epi+Gen CHD&#8482; is a scientifically
backed clinical blood test that is based on an individual&#8217;s objective genetic and epigenetic DNA biomarkers for assessing the
three-year risk for a coronary heart disease event such as a heart attack. In a peer-reviewed study done in collaboration with
Intermountain Healthcare (Dogan, Meeshanthini &amp; Knight, Stacey &amp; Dogan, Timur &amp; Knowlton, Kirk &amp; Philibert, Robert.
(2021). External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease. Epigenomics.
13. 10.2217/epi-2021-0123), this test demonstrated a 76% and 78% sensitivity for men and women, respectively, for three-year CHD
risk. This means that for every 100 men and 100 women deemed "at-risk&#8221; for a coronary heart disease event, the test
correctly identifies 76 men and 78 women. In comparison, the average sensitivity of the Framingham Risk Score and the ASCVD Pooled
Cohort Equation was found to be 44% and 32% for men and women, respectively. The performance of the test in this study was evaluated
across two cohorts that were independent of each other. One cohort was used for the development of this test and the other was used
to independently validate the performance of the test, showing Epi+Gen CHD&#8482; to be approximately 1.7 times and 2.4 times more
sensitive than the current lipid-based clinical risk estimators in men and women, respectively. In another peer-reviewed study
focusing on the cost utility of Epi+Gen CHD&#8482; (Jung, Younsoo &amp; Frisvold, David &amp; Dogan, Timur &amp; Dogan, Meeshanthini
&amp; Philibert, Robert. (2021). Cost-utility analysis of an integrated genetic/epigenetic test for assessing risk for coronary
heart disease. Epigenomics. 13. 10.2217/epi-2021-0021), this test was associated with up to $42,000 in cost savings per quality
adjusted life year and improved survival compared to the ASCVD Pooled Cohort Equation. In another peer-reviewed study, (Philibert,
Willem &amp; Andersen, Allan &amp; Hoffman, Eric &amp; Philibert, Robert &amp; Dogan, Meeshanthini. (2021). The reversion of DNA
methylation at coronary heart disease risk loci in response to prevention therapy. Processes. 9, 699.
https://doi.org/10.3390/pr9040699), DNA methylation of this test was shown to change within 90 days of intervention in the form of
smoking cessation, demonstrating that this test could potentially also be leveraged to evaluate the effectiveness of
interventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><img src="image_014.jpg" alt="" style="height: 276pt; width: 483.6pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The blood-based version of this test was introduced
for market testing in 2021 The pricing of the test varies based on factors such as organization type and test volume. The price of the
test and revenue streams could change in the future depending on market forces and payor requirements, as well as on the customer and
the region in which the test is being sold. We are continuing to build additional clinical and health economics evidence to pursue payor
coverage. A key first step in expanding critical payor coverage is to have this test be assigned a CPT PLA code, and the American Medical
Association awarded the Epi+Gen CHD&#8482; a CPT PLA code, 0439U.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that the Epi+Gen CHD&#8482; test can
benefit numerous healthcare stakeholders. For instance, we believe that this test will enable clinicians to identify patients at-risk
in the near-term for CHD-related events, including a heart attack, and utilize actionable insights from this test to provide more personalized
care for their patients to help prevent the event and improve outcomes. These actionable insights are conveyed via our provider-facing
Actionable Clinical Intelligence&#8482; platform, which maps a patient&#8217;s unique biomarker profile and other information onto pathways
and modifiable drivers of coronary heart disease. In addition to clinicians, we believe that this test can enable healthcare organizations
and payors to reduce the cost of care, and employers to understand and better manage business risks including healthcare costs. Insights
for these stakeholders upon leveraging the Epi+Gen CHD&#8482; test are provided via our new software product, HeartRisk&#8482;, which
is a cardiovascular disease risk intelligence platform. The pricing for this platform will be customized based on the organization type
and size, and use case.<i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>PrecisionCHD&#8482; is the Only Epigenetics-based
Clinical Test for the Early Detection of Coronary Heart Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">PrecisionCHD&#8482; is a scientifically backed
clinical blood test that is based on an individual&#8217;s objective genetic and epigenetic DNA biomarkers for the detection of coronary
heart disease. In a peer-reviewed published study by Cardio in collaboration with Intermountain Healthcare and University of Iowa Hospitals
and Clinics (Philibert, Robert &amp; Dogan, Timur &amp; Knight, Stacey &amp; Ahmad, Ferhaan &amp; Lau, Stanley &amp; Miles, George &amp;
Knowlton, Kirk &amp; Dogan, Meeshanthini. (2023). Validation of integrated genetic-epigenetic test for the assessment of coronary heart
disease. Journal of American Heart Association. 12:e030934. DOI: 10.1161/JAHA.123.030934), this test demonstrated an overall average area
under the curve, sensitivity, and specificity in three independent test cohorts for detecting coronary heart disease of 82%, 79%, and
76%, respectively. The average sensitivity for men and women were 80% and 76%, respectively. This means that for every 100 men and 100
women deemed "to have&#8221; coronary heart disease, the test correctly identifies 80 men and 76 women. In comparison, the most commonly
used and least invasive test for detecting coronary heart disease, exercise ECG, has a sensitivity of only 58%. The performance of the
test in this study was evaluated across three cohorts that were independent of each other. One cohort was used for the development of
this test and the other two were used to independently validate the performance of the test. Based on the known sensitivity of exercise
ECG, PrecisionCHD&#8482; is approximately 1.4 times and 1.3 times more sensitive than an exercise ECG in men and women, respectively,
for detecting coronary heart disease. In another peer-reviewed study, (Broyles, Damon &amp; Philibert, Robert. (2023). Precision epigenetics
provides a scalable pathway for improving coronary heart disease care globally. Epigenomics. 10.2217/epi-2023-0233), the global scalability
of PrecisionCHD was outlined in comparison to commonly used coronary heart disease tests such as exercise ECG and CCTA. Similar to the
Epi+Gen CHD&#8482; test, a peer-reviewed study was conducted to evaluate if the DNA methylation biomarkers of PrecisionCHD could be potentially
leveraged to evaluate the effectiveness of interventions. In this peer-reviewed study, (Philibert, Robert &amp; Moody, Joanna &amp; Philibert,
Willem &amp; Dogan, Meeshanthini &amp; Hoffman, Eric. (2023). The reversion of epigenetic signature of coronary heart disease in response
to smoking cessation. Genes. 14, 1233. https://doi.org/10.3390/genes14061233), DNA methylation of this test was shown to change within
90 days of intervention in the form of smoking cessation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The blood-based version of this test was introduced
for market testing in 2023. The pricing of the test varies based on factors such as organization type and test volume. The American Medical
Association awarded the PrecisionCHD&#8482; a CPT PLA code, 0440U. The price of the test and revenue streams could change in the future
depending on market forces and payor requirements, as well as on the customer and the region in which the test is being sold. We are continuing
to build additional clinical and health economics evidence to pursue payor coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that the PrecisionCHD&#8482; test can
benefit numerous healthcare stakeholders. For instance, we believe that this test will enable clinicians to identify patients with CHD
with a simple blood test and utilize actionable insights from this test to provide more personalized care for their patients to help improve
outcomes. These actionable insights are conveyed via our provider-facing Actionable Clinical Intelligence&#8482; platform, which maps
a patient&#8217;s unique biomarker profile and other information onto modifiable factors such as diabetes, inflammation, hypercholesterolemia,
and smoking, known to be critical drivers of coronary heart disease. In addition to clinicians, we believe that this test can enable healthcare
organizations and payors to reduce the cost of care, and employers to understand and <span style="letter-spacing: -0.05pt">better </span>manage
business risks including healthcare cost. Insights for these stakeholders upon leveraging the PrecisionCHD&#8482; test are provided via
our new software product, HeartRisk&#8482;, which is a cardiovascular disease risk intelligence platform. The pricing for this platform
will be customized based on the organization type and size, and use case.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio intends to accelerate the adoption of Epi+Gen
CHD&#8482; and PrecisionCHD&#8482; by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="padding-right: 13.9pt; width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">developing strategic clinical partnerships to reach as many patients as possible;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">leveraging industry organizations to engage and educate providers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">launching a piloting program to for innovative providers and key strategic partners;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">developing strategic partnerships with other healthcare stakeholders such as payors and employers; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">developing a customized customer portal to reduce transaction friction.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio foresees potential opportunities to increase
the gross margin of the Epi+Gen CHD&#8482; and PrecisionCHD&#8482; by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#160;</td>
    <td style="padding-right: 13.9pt; width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">establishing a laboratory to potentially reduce cost associated with processing samples;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">processing patient samples in the laboratory in larger batches;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">shipping sample collection kits in larger batches; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 13.9pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="padding-right: 13.9pt"><span style="font-size: 10pt">increasing the level of automation to reduce manual processing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have completed a pre-submission with the FDA
pertaining to our PrecisionCHD product and have received feedback from the FDA on that submission. We may complete additional pre- submissions
to the FDA as we continue to evaluate FDA&#8217;s feedback and further develop our regulatory strategy. We have engaged outside expertise
for this process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Product Pipeline</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In March 2023, we announced the debut of the PrecisionCHD&#8482;
test, our second clinical blood test for the detection of CHD. In May 2023, we launched CardioInnovate360&#8482; a research-use- only
(RUO) solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular
diseases. In February 2024, we announced the launch of HeartRisk&#8482;, our first software product that is a cardiovascular disease risk
intelligence platform. We have several other tests in our product pipeline at various stages of development for congestive heart failure,
stroke and diabetes. However, as a company in the early stages of its development, we continuously reevaluate our business, the market
in which we operate and potential new opportunities. We may modify our product pipeline, seek other alternatives within the healthcare
field in order to grow the Company&#8217;s business and increase revenues. Such alternatives may include, but not be limited to, combinations
or strategic partnerships with other laboratory companies or with medical practices such as hospitalists or behavioral health.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Market Opportunity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardiovascular disease (&#8220;CVD&#8221;) is the
leading cause of death in the United States, accounting for one in four deaths. Despite being largely preventable, the American Heart
Association projects that by 2035, nearly 45% of Americans will have some form of CVD. One of the key ways to address the prevalence of
CVD is to shift the approach for CVD from reactive treatment to proactive prevention and earlier detection. As such, technologies that
can more precisely assess the risk for and detect CVD before symptoms emerge or a catastrophic cardiac event occurs becomes even more
critical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">According to Research and Markets in their Outlook
on the Cardiovascular Diagnostic Testing Global Market to 2027 - Increasing Number of Insurance Providers Presents Opportunities press
release published on July 4, 2022, the Global Cardiovascular Diagnostic Testing Market is estimated to grow from $8.47 billion in 2022
to $12.41 billion by 2027, with a CAGR of 7.94%. The increasing prevalence of cardiovascular diseases, technological advancements in cardiovascular
disease diagnostics, and the growing number of initiatives to promote cardiovascular disease testing are the major factors driving the
growth of this market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our principal mission is to enable better detection
of the presence and risk of major cardiovascular diseases through a series of clinical tests developed by leveraging our proprietary AI-driven
Integrated Genetic-Epigenetic Engine&#8482;. Our initial product, Epi+Gen CHD&#8482;, is a highly sensitive and accessible clinical test
for three-year coronary heart disease (&#8220;CHD&#8221;) event risk assessment, including risk for a heart attack. Our second product,
PrecisionCHD&#8482;, is a highly sensitive and accessible clinical test for the detection of CHD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Using data from the US Census Bureau, Cardio estimates
that 146 million adults could potentially benefit from our Epi+Gen CHD&#8482; test, 157 million adults for our PrecisionCHD test, 152
million adults for the congestive heart failure test, 153 million adults for the stroke test and 140 million adults for the diabetes test.
The pricing of each of our tests may vary, but the US addressable market equates to $51 billion for Epi+Gen CHD&#8482;, assuming a pricing
of $350/test, $134 billion for PrecisionCHD&#8482;, assuming a price of $850/test, $53 billion for congestive heart failure, assuming
a pricing of $350/test, $53 billion for stroke, assuming a pricing of $350/test and $49 billion for diabetes, assuming a pricing of $350/test
for a total US addressable market of $340 billion. This total addressable market evaluation also assumes that one patient could be tested
with multiple tests, and each test is administered to each patient a single time in a year although some patients may benefit from being
re-tested in less than a year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Go-To-Market Strategy for Epi+Gen CHD&#8482;
and PrecisionCHD&#8482;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our current go-to-market (&#8220;GTM&#8221;) strategy
is predominantly a product-led innovation growth strategy that emphasizes enterprise-wide adoption across key healthcare sub-verticals
with a particular emphasis on deeply centralized key opinion and health trend leaders like innovative providers, health systems, and employers.
This strategy is augmented with a bottom-up consumer- led sales focused on directly acquiring and retaining savvy and health-conscious
consumers interested in using the latest technologies to address their cardiovascular disease concerns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Healthcare Sub-Vertical Priorities for Epi+Gen
CHD&#8482; and PrecisionCHD&#8482;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">By assessing the risk for a heart attack early
and/or detecting CHD early to potentially avert a heart attack, we believe that the clinical and economic utility of the Epi+Gen CHD&#8482;
and PrecisionCHD&#8482; tests will support their commercial adoption. We believe that Epi+Gen CHD&#8482; and PrecisionCHD&#8482; can address
a significant addressable market opportunity even before these tests are covered and reimbursed by payors. While we believe that such
coverage and reimbursement would be necessary to gain widespread adoption, obtaining such coverage and reimbursement from federal and
private payors may take several years, if it is obtained at all. We intend to focus on the following key channels as part of our GTM strategy:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Innovative Health Systems</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As innovative health systems diversify their business
models and care delivery pathways, there is a renewed emphasis on using precision medical technologies to better manage expensive and
chronic conditions, including CHD. By assessing the risk for a CHD event including a heart attack before it occurs, Epi+Gen CHD&#8482;
has the potential to improve population health. We believe that the improved performance of our test compared to other risk calculators,
coupled with evidence of cost savings and enhanced survival, will drive the adoption of Epi+Gen CHD&#8482; by health systems to continue
improving the health of their patients. Similarly, with PrecisionCHD&#8482;, innovative health systems are able to help test their patients
detect CHD earlier with a simple blood test, potentially leading to better patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Physician-Directed Channels, Including Concierge Practices</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Early adoption is driven by practices committed
to innovation in medicine for patients who are more focused on preventive health and wellness and have the financial means to pay out-of-
pocket for concierge subscription services. There is a convergence in innovative providers, health-conscious consumers, and best-in-class
tests and technologies in concierge medicine practices or other similar practices to provide on-demand elite personalized and readily
accessible healthcare. With an estimated 2,000 to 5,000 concierge practices in the United States, there is robust growth in high-end healthcare
services with an equal demand for innovative diagnostic tools. Additionally, concierge practices are not price-sensitive, so reimbursement
is not a top priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: right; width: 28pt"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Employers</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;Early adoption in the employer space is
likely to be driven by self-insured employers and employers looking to provide employee perks relevant to health. Self-insured employers
are consistently seeking solutions to help manage their biggest cost centers such as heart disease. In a post-pandemic world, the health
and wellbeing of employees are also top-of-mind for many employers to ensure that their employees are healthy and productive. Employers
view healthcare investments as another investment in the business. Employers leveraging innovative diagnostic solutions can connect better
health for employees to drive overall business objectives and have a competitive advantage in managing business risks while attracting
and retaining talent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: right; width: 28pt"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Telemedicine and Marketplaces</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;Many Americans are concerned about being
proactive with their health needs. Understanding their personalized risk with tests at the forefront of medicine is crucial for those
with financial resources. According to the U.S. Census Bureau based on the 2020 census, there are nearly 44 million households that earn
$100,000 or more annually. We expect high-earning Americans who are proactive about their health to constitute the initial attainable
market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Sales and Marketing for Epi+Gen CHD&#8482;
and PrecisionCHD&#8482; with a Focus on Strategic Channel Partnerships</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">While our overall sales and marketing initiatives
will span the gamut across traditional, print, and digital media, our primary sales and marketing strategy consists of the branding, collaboration,
co-marketing, and co-sales opportunities involved in strategic channel partnerships. By prioritizing strategic channel partnerships, we
believe we can accelerate our market penetration into the key healthcare sub-verticals we intend to prioritize for our growth. The key
to our efforts is a well-defined and executed channel partnership integration strategy that will serve to accelerate the sales cycles
for each of our distribution channels. The sales cycles are generally defined as the period in which such distribution channel will turn
over its inventory of our tests, which may vary for each distribution channel. Utilizing and developing such strategic channel partnerships,
we believe, will generate revenue in a myriad of ways including larger contracts for our Epi+Gen CHD&#8482; and PrecisionCHD&#8482; clinical
blood tests, and bundling our solutions alongside other synergistic technologies, services, and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Strategic channel partnerships are key for the
growth of our solutions. There are several key revenue and strategy benefits to developing a robust channel partnership strategy, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Defensibility and Displacement</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Strategic channel partners may have exclusivity
agreements for Epi+Gen CHD&#8482; and PrecisionCHD&#8482;, which forecloses distribution channels to potential competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Distribution and Network Effects</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Channel partners under consideration for Epi+Gen
CHD&#8482; and PrecisionCHD&#8482; strategic partnerships have large, related healthcare and life science networks that we expect to leverage
as part of the relationship.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Bi-Directional Value</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The cardiovascular disease space is of paramount
concern to stakeholders across the healthcare continuum; the scale of the disease across the population and the associated costs ensures
that addressing cardiovascular disease from a payment, cost, patient outcome, and prevention standpoint for stakeholders across the spectrum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 28pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Pricing Differentiation</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The economics of each channel partnership can be
crafted independently to offer each strategic partner a per-unit cost relevant to the size of their network.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 14pt">&#8226;</span></td><td style="width: 5pt"/><td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Complementary Goods</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Bundling Epi+Gen CHD&#8482;, PrecisionCHD&#8482;,
HeartRisk&#8482; and future Cardio solutions alongside complementary clinical, analytics, treatment pathways, and services-consulting
for primary prevention optimization with key partners expands the ROI of the investment in our solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Hiring and Talent to Accelerate Growth</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our growth strategy will require investment in
internal and external healthcare enterprise sales, marketing and deep customer insights. By combining best-in-class revenue operations
technologies with seasoned healthcare sales and marketing experts, we believe we can quickly scale the selling approaches we have outlined
and validated to transform the cardiovascular healthcare experience, driving revenue and increased margins. New hires will be targeting
the entire continuum of revenue needs, including opportunity identification, campaign design, and execution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacture/Supply Chain</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The content of the sample collections kits for
both Epi+Gen CHD&#8482; and PrecisionCHD&#8482; are identical, and we rely on third-party suppliers for kit contents required to collect
and transport a blood sample to the lab for processing. These are commonly used supplies that are and can be sourced from multiple distributors.
Upon sourcing these contents, they are assembled into lancet- based and vacutainer-based sample collection kits internally and fulfilled.
We intend to maintain an inventory of fully assembled kits to meet expected demand for at least six months. However, since there are no
particular or unique assembly protocols and assembly is handled internally, the lead time to assemble additional sample collection kits
would be minimal after the contents are sourced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Proprietary genetic and DNA methylation components
are sourced from large manufacturers and manufactured under good manufacturing practices (&#8220;cGMP&#8221;). There are alternative manufacturers
for each of these components, and no additional lead time is expected. Laboratory assays that are manufactured under cGMP to specifications
are expected to be available to meet anticipated demand for at least six months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Both the Epi+Gen CHD&#8482; and PrecisionCHD&#8482;
clinical blood tests currently are offered as LDTs through an experienced laboratory with the appropriate Clinical Laboratory Improvement
Amendments of 1988 (&#8220;CLIA&#8221;) certification and state licensure. However, we are currently setting up an internal operational
hub that includes a CLIA laboratory. We anticipate completing this process in 2025. However, we are moving at a measured pace in order
to preserve resources, so the timing of completion of the internal CLIA laboratory could be delayed. We will continue to use the services
of our outside laboratory without interruption until our laboratory is operational.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Competitive Strengths</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Innovation is the key to success. In the rapidly
moving cardiac diagnostics space, we believe that we have the team, differentiated technology, and deep technical and business expertise
to deliver a market differentiating suite of products for our customers to address unmet clinical needs in the cardiovascular space and
help us dominate our market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The pillar of our strategy has been innovation,
from the onset with our technology development and intellectual property that account for future growth, to our commercialization and
partnership efforts that bring together key healthcare stakeholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that, among other reasons, the future
belongs to Cardio based on the following competitive strengths:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt"><i>Technology and products are strongly backed by science.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our technology and products stem from over a decade
of rigorous scientific research by the founding team in collaboration with other clinical and research experts from leading organizations.
Our founding team consist of experts in machine learning approaches in healthcare and in epigenetics with highly-cited peer-reviewed publications.
The technology and products are developed and validated with extensive clinical data. The key findings have been published after undergoing
stringent independent third-party peer review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 3.8pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 3.8pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Broad intellectual property portfolio protects our current and future products and their applications.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of August 2025, our patent portfolio includes
six patent families. In the first family of patents and patent applications owned solely by UIRF, which is exclusively licensed by Cardio,
there are granted patents in the US (two), EU (subsequently validated in the United Kingdom, France, Germany, Italy, Switzerland, Ireland
and Hong Kong), China, Australia, India, and Japan and other pending patent applications. The Company also has pending patent applications
in patent families two, three, four, five and six, pending PCT International applications, and almost forty patent applications pending
worldwide, and which are generally directed to methods and compositions for detecting biomarkers associated with cardiovascular disease
and diabetes for diagnosis and other applications. In addition, we have extensive trade secrets and know-how, including algorithms and
assay designs, that are critical for the continued development and improvement of our current and future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Big data and artificial intelligence (machine learning) expertise drive future product development.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our expertise in processing billions of clinical
genotypic, epigenetic and phenotypic data points to generate critical insights allows us to continue to develop innovative products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 38px">&#160;</td>
    <td style="width: 20px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Proprietary cutting-edge AI-driven Integrated Genetic-Epigenetic Engine&#8482; accelerates product development.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have built a proprietary AI-driven Integrated
Genetic-Epigenetic Engine&#8482; that is made up of layers of big data, our algorithms informed by biology and its expert domain knowledge
that was designed and built over the past decade and can be leveraged to enable rapid design, development and launch of new diagnostic
solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 3.75pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 3.75pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Multiple potential product offerings with strong value propositions for key healthcare stakeholders.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have built a robust product pipeline for various
types of cardiovascular disease and other indications that leverage our AI-driven Integrated Genetic-Epigenetic Engine&#8482; to continue
to build market traction. We believe that our current and future products have strong value propositions for various key stakeholders
in healthcare. As a result, we believe that our customers will adopt and champion our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 3.8pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 3.8pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Products that can potentially drive value in multiple ways.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe that our tests are the first epigenetics-based
clinical tests for heart disease. Unlike genetic biomarkers that are static, the DNA methylation (epigenetic) biomarkers included in our
products are generally dynamic. Therefore, DNA methylation biomarkers can change over time and as a result, in addition to initial assessment,
our products could potentially be used to personalize interventions and help monitor the effectiveness of these interventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 3.8pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 3.8pt; vertical-align: bottom"><span style="font-size: 10pt"><i>Commercial processes that are inherently scalable to meet demand.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our commercial pipeline is inherently scalable.
Laboratory testing kits consist of easy to synthesize oligonucleotide products, readily available PCR reagents, and can be kitted months
in advance. Our lancet and vacutainer-based sampling kits incorporate readily available components that can be sourced from several vendors.
Our propriety algorithms can be scaled and automated to process data from thousands of samples. In addition, the laboratory processes
can be automated and scaled by adding existing commercial equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 32px">&#160;</td>
    <td style="width: 17px; padding-top: 3.8pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 3.8pt; vertical-align: bottom"><span style="font-size: 10pt"><i>A leadership team of seasoned healthcare professionals and executives that is led by a visionary founder.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio is led by a management team with experience
in inventing innovative technologies, developing and commercializing clinical products, and building high growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Even though we believe that our solutions provide
significant advantages over solutions that are currently available from other sources, we expect continued intense competition. This includes
companies that are entering the cardiovascular diagnostics market or existing companies that are looking to capitalize on the same or
similar opportunities as Cardio is in the clinical and non-clinical spaces. Some of our potential and current competitors have longer
operating histories and have, or will have, substantially greater financial, technical, research, and other resources than we do, along
with larger, more established marketing, sales, distribution, and service organizations. This could enable our competitors to respond
more quickly or efficiently than it can to capture a larger market share, respond to changes in the regulatory landscape or adapt to meet
new trends in the market. Having access to more resources, these competitors may undertake more extensive research and development efforts,
substantially reduce the time to introducing new technologies, accelerate key hires to drive adoption of their technologies, deploy more
far-reaching marketing campaigns and implement a more aggressive pricing policy to build larger customer bases than we have. In some cases,
we are competing for the same resources our customers allocate for purchasing cardiovascular diagnostics products or for establishing
strategic partnerships. We expect new competitors to emerge and the intensity of competition to increase. There is a likelihood that our
competitors may develop solutions that are similar ours and ones that could achieve greater market acceptance than ours. This could attract
customers away from our solutions and reduce our market share. To compete effectively, we must scale our organization and infrastructure
appropriately and demonstrate that our products have superior value propositions, cost savings, and clinical performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The clinical cardiovascular diagnostic space is
perhaps the most intensely competitive market space in clinical medicine. Even though we believe our solutions offer significant advantages
to existing methods, we expect alternative biomarker assessment approaches to continue to exist and to be developed. With respect to coronary
heart disease (CHD) risk assessment and early detection, our competitors use a variety of technologies including genetic, serum lipid-based,
imaging, proteomic and "people tracking&#8221; approaches.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Genetic testing, both whole genome and more focused
panel modalities, is the first type of biomarker assessment and is used by many clinicians to assess lifetime risk for CHD. However, whereas
the scientific tenets for this approach are generally accepted, it does not identify when CHD might develop, and we believe that the relative
power of this method for predicting CHD as compared to its Epi+Gen CHD&#8482; test is limited. In addition, whereas the use of this test
may divert revenues for testing, this approach is in some respects complementary, and it is conceivable that some clinicians may elect
to get both forms of testing to have a more holistic assessment of both short term and lifetime risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The best-known biomarker approach is that embodied
by the American Heart Association/American College of Cardiology Atherosclerotic Cardiovascular Risk Calculator (referred to ASCVD risk
calculator or Pooled Cohort Equation). This method integrates laboratory assessment of serum lipids, blood pressure and self-reported
health variables to impute 10-year risk for all forms of atherosclerotic cardiovascular disease (mainly CHD, but also stroke and peripheral
artery disease) using a standard algebraic equation. This is the most commonly used method of assessing CHD risk and enjoys general acceptance
by the medical community. It is perhaps the most direct competitor for our Epi+Gen CHD&#8482; test. We believe that our test has superior
performance, does not require overnight fasting and will eventually provide greater information to the clinician than this current market
standard. In addition, we note that our test assesses risk over a three-year window rather than a 10-year window which it believes is
a more relevant period of time for patient management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Imaging modalities are also used to assess risk
for and detect CHD. Perhaps the most commonly used imaging method for predicting risk for CHD is Coronary Artery Calcium (&#8220;CAC&#8221;)
screening. In this method, a low intensity computed tomography (&#8220;CT&#8221;) scan is taken of the heart. Then using this data, the
amount of calcium laden plaque is determined and the result used to assess 10-year risk for CHD. Strengths of this approach include the
general acceptance of the medical community. Weaknesses include the necessity of exposing patients to x-ray radiation and the inability
of the CAC test to monitor patient response. In many ways, this test competes with our test. At the same time, we note that this test
is not yet recommended as a primary method for screening low risk individuals, uses a longer risk assessment window, and could actually
be used as secondary testing to evaluate patients who are not found to be at low risk using Epi+Gen CHD&#8482; or who are flagged for
CHD by the PrecisionCHD&#8482; test.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Proteomic methods, as exemplified by serologic
assessments of individual proteins such as c-reactive protein or of entire protein panels, such as that for the HART CADhs or CVE tests
from Prevencio are another risk assessment tool. The CADhs test is a good example of a proteomic competitor and predicts the one-year
risk for having &#8805;70% stenosis in a major coronary artery while another Prevencio test HART CVE, predicts one year risk for individuals
at risk for developing a major adverse cardiovascular event. Important differences between our tests and their offerings include the window
of prediction (three-year vs one-year), the type of technology employed (AI-guided interpretation of genotype and methylation sensitive
digital PCR results compared to algorithm interpretation of results from Luminex bead immunoassays). Because we believe that digital PCR
based methods are more scalable testing solutions than Luminex bead platforms, we believe that our approach has an advantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Finally, researchers have described methods to
use wearable devices, such as the Huami wrist device, to predict risk for cardiovascular disease. Although people doubtlessly use these
and similar methods derived from wearable devices to assess risk, their exact clinical market penetrance is currently low, and whether
they would pose as a direct competitor for our test remains uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">However, the aforementioned is only a snapshot
of the current market space in which we currently compete and which we intend to compete in the future. Our intellectual property claims
include methods to develop tests for coronary heart disease, as well as incident and prevalent heart failure, stroke and diabetes. The
test for prevalent coronary heart disease, whose basis was published in 2018, is well underway, and we expect this test to become a strong
competitor for other methods of establishing current CHD, such as exercise treadmill testing, and for monitoring response to CHD treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In summary, the cardiovascular diagnostic space
is extremely competitive and fast moving. We believe that the serum lipid, proteomic and to a certain extent, imaging-based modalities
are direct competitors for customers and enjoy both large existing market share and substantial financial backing. In addition, it is
clear that these existing alternative assessment strategies have significant degrees of scientific literature supporting their use, enjoy
backing from key medical constituencies for their use in certain circumstances, and have established strategies for obtaining third party
reimbursement. As the population ages, this competition is likely to increase. At the same time, we believe that there are important differences
between the current tests offered and our solutions with respect to clinical performance, window of clinical assessment, scalability,
capacity for assisting with interventions and response monitoring. However, the other technologies are not static, and we expect refinements
and/or combination of existing approaches to vigorously compete for customers in our business space. We will need to scale our efforts,
orient our organization appropriately and demonstrate that our products provide better value for our customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have made broad pending intellectual property
(&#8220;IP&#8221;) claims with respect to the use of epigenetic and gene-methylation interactions for the assessment and monitoring of
cardiovascular disease, specifically coronary heart disease, congestive heart failure and stroke, as well as diabetes. Our portfolio falls
into six patent families. The members of these patent families have been filed in the United States and a number of foreign jurisdictions
including the European Union, Japan, India, Australia, United Arab Emirates, Saudi Arabia, Canada and China. U.S., Patent Nos. 11,414,704
and 12,043,869, titled Compositions and Methods for Detecting Predisposition to Cardiovascular Disease, were issued in 2022 and 2024,
respectively, to the University of Iowa Research Foundation (&#8220;UIRF&#8221;), the co-inventors of which are Dr. Dogan and Dr. Philibert,
our Chief Executive Officer and Chief Medical Officer, respectively. The original patent family also includes patents granted by the European
Patent Office (subsequently validated in the United Kingdom, France, Germany, Italy, Switzerland, Ireland and Hong Kong), as well as China,
Australia, India and Japan, and a number of other pending applications. We have a worldwide exclusive license agreement with UIRF. Under
UIRF&#8217;s Inventions Policy, inventors are generally entitled to 25% of income from earnings from their inventions. Consequently, Dr.
Dogan and Dr. Philibert will benefit from this policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our issued and pending patents cover general methods
as well as key technological steps that enable these core approaches while facilitating the continued patenting of material included in
the patent applications. In addition to the technology licensed from UIRF, we have other patent applications pending relating to improvements
to our technology, which are potentially valuable and of possible strategic importance to the Company. We expect to continue to file new
patent applications to protect additional products and methodologies as they emerge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The initial work on our AI-driven Integrated Genetic-Epigenetic
Engine&#8482; is derived from work done by our founders while at the University of Iowa. Follow-on work on our core technology also is
derived from work done by our founders while at the University of Iowa but was furthered by our founders and Cardio&#8217;s Chief Technology
Officer independent of the University of Iowa. The follow-on work is described in our second, third, fourth, fifth and sixth families
of patent applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The initial work is described in the first family
of patents and patent applications and is generally directed to a number of single nucleotide polymorphism (&#8220;SNP&#8221;) biomarkers
and a number of methylation site biomarkers that are associated with the presence or the early onset of a number of cardiovascular diseases.
The first family of patents and patent applications is owned solely by UIRF and is exclusively licensed by Cardio. As of August 2025,
this family includes granted patents in the US (two), EU (subsequently validated in the United Kingdom, France, Germany, Italy, Switzerland,
Ireland and Hong Kong), China, Australia, India, and Japan and other pending patent applications. Any and all patents issuing in this
family will be solely owned by UIRF and, barring any changes to the UIRF exclusive license agreement, will fall under the exclusive license
to Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The first family is generally directed to biomarkers
associated with cardiovascular disease. This family includes two issued patents in the US as well as issued patents in the United Kingdom,
France, Germany, Italy, Switzerland, Ireland, Hong Kong, Australia, China, India, and Japan, and pending applications in Australia, Canada,
China, Europe, Hong Kong, Japan and the US. The issued claims in the original US patent and in Australia, China and India are directed
to methods and/or compositions (e.g., kits) for determining the methylation status of at least one CpG dinucleotide and the genotype of
at least one single-nucleotide polymorphism (SNP) that use or include at least one primer for detecting the presence or absence of methylation
in a particular region of the genome (referred to as cg12586707) and at least one primer for detecting the presence or absence of a SNP
in a particular region of the genome (referred to as rs11597065). The issued claims in the EP patent are similarly directed to compositions
(e.g., a kit) for determining the methylation status of at least one CpG dinucleotide and a genotype of at least one SNP that includes
at least one primer that detects the presence or absence of methylation in a particular region of the genome (referred to as cg26910465)
and at least one primer that detects a SNP in a particular region of the genome (referred to as rs10275666) or another SNP in linkage
disequilibrium with the first SNP. The claims that issued in the second U.S. patent are directed to methods for determining the methylation
status of at least one CpG dinucleotide and the genotype of at least one SNP that includes at least one primer that detects the presence
or absence of methylation in a particular region of the genome (referred to as cg11964099) and at least one primer that detects a SNP
in a particular region of the genome (referred to as rs9988960). This family of patents is in-licensed under an exclusive license agreement
with UIRF, and is expected to expire in 2037, absent any applicable patent term adjustments or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The second family is generally directed to biomarkers
associated with diabetes. This family includes pending applications in the U.S., Australia, United Arab Emirates, Canada, China, Europe,
Hong Kong, India, Japan, Saudi Arabia, and Singapore, with original claims directed to compositions (e.g., a kit) that include at least
one primer for determining the methylation status of at least one CpG dinucleotide from a group of five different methylation sites, or
a different CpG dinucleotide in linkage disequilibrium with one of the listed CpG dinucleotides, and at least one primer for determining
the genotype of at least one SNP from a group of five different SNPs, or a different SNP in linkage disequilibrium with one of the listed
SNPs. The pending applications also included original claims to methods of determining the presence of biomarkers associated with diabetes,
claims to a computer-readable medium for performing such methods, and claims to a system for determining the methylation status of at
least one CpG dinucleotide and the genotype of at least one SNP. This family is co-owned by Cardio  and UIRF, and the UIRF-owned
portion is in-licensed under the same exclusive license agreement as the first family. Patents issuing from this second family are expected
to expire in 2041, absent any applicable patent term adjustments or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The second family of patent applications is co-owned
by UIRF and Cardio, since Cardio expanded on and further refined the original research that was done at the University of Iowa. The ownership
of any and all patents that ultimately issue in this family will depend on the specific subject matter that is claimed in each issued
patent. For example, depending upon the specific biomarkers claimed and when those biomarkers were identified (e.g., during the initial
work at the University of Iowa or during the follow-on work at Cardio), ownership could lie solely with UIRF or Cardio, or ownership could
be shared between UIRF and Cardio (e.g., if a claimed biomarker was initially identified at the University of Iowa and its significance
with respect to diabetes was further refined by Cardio; or if one of the claimed biomarkers was identified at the University of Iowa and
another one of the claimed biomarkers was identified at Cardio).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The third family is generally directed to biomarkers
associated with predicting a three-year incidence of cardiovascular disease. This family includes applications pending in the U.S., Australia,
United Arab Emirates, Canada, China, Europe, Hong Kong, India, Japan, Saudi Arabia, and Singapore, with original claims directed to compositions
(e.g., a kit) that include at least one primer for determining the methylation status of at least one CpG dinucleotide from a group of
three different methylation sites, or a different CpG dinucleotide in linkage disequilibrium with one of the listed CpG dinucleotides,
and at least one primer for determining the genotype of at least one SNP from a group of five different SNPs, or a different SNP in linkage
disequilibrium with one of the listed SNPs. The pending applications also included original claims to methods of determining the presence
of biomarkers associated with three-year incidence of cardiovascular disease, claims to a computer-readable medium for performing such
methods, and claims to a system for determining the methylation status of at least one CpG dinucleotide and the genotype of a SNP. This
family of patents is owned exclusively by Cardio. Patents issuing from this third family are expected to expire in 2041, absent
any applicable patent term adjustments or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The fourth family is generally directed to computer
resources (e.g., a dashboard) designed by Cardio  for use by their stakeholders (e.g., patients, physicians, researchers, insurance
companies, etc.). The computer resources are designed to provide results as well as information and context related to Cardio
tests and the specific biomarkers that are used. The pending claims are directed to methods of displaying relevant information including
genetic marker test results as well as probability analysis (based on, e.g., the population, age, and/or gender of patients), and hyperlinks
to relevant literature. The pending application also includes claims to computer-readable media containing instructions for performing
such methods and computer systems for executing such instructions. This family currently includes an International PCT application and
is solely owned by Cardio. Patents issuing from this fourth family are expected to expire in 2044, absent any applicable patent term adjustments
or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The fifth family is generally directed to biomarkers
associated with detecting cardiovascular disease. The pending claims are directed to compositions (e.g., a kit) that include at least
one primer for determining the methylation status of at least one CpG dinucleotide from a group of six different methylation sites, or
a different CpG dinucleotide in linkage disequilibrium with one of the listed CpG dinucleotides, and at least one primer for determining
the genotype of at least one SNP from a group of ten different SNPs, or a different SNP in linkage disequilibrium with one of the listed
SNPs. The pending application also includes claims to methods of determining the presence of biomarkers associated with detecting cardiovascular
disease, claims to a computer- readable medium for performing such methods, and claims to a system for determining the methylation status
of at least one CpG dinucleotide and the genotype of a SNP. This family currently includes an International PCT application, a U.S. utility
application, and an Indian application and is solely owned by Cardio. Patents issuing from this fifth family are expected to expire in
2044, absent any applicable patent term adjustments or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The sixth family is generally directed to an algorithm
that can be used to predict mortality based on the methylation status of at least one CpG dinucleotide and/or information obtained from
cardio-imaging. The pending claims are directed to methods for predicting mortality based on the presence of cardiovascular disease that
include obtaining epigenetic data and/or image data and generating an output that includes a mortality risk assessment for the subject.
This family currently includes a pending US provisional application, which is owned solely by Cardio. Patents issuing from the sixth family
are expected to expire in 2045, absent any applicable patent term adjustments or extensions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Exclusive License Agreement entered into with
UIRF and those licenses granted under that license agreement terminate on the expiration of the patent rights licensed under the license
agreement, unless certain proprietary, non-patented technical information is still being used by Cardio, in which case the license agreement
will not terminate until the date of termination of such use. The licenses under the license agreement could terminate prior to the expiration
of the licensed patent rights if we materially breach our obligations under the license agreement, including failing to pay the applicable
license fees and any interest on such fees, and failing to fully remedy such breach within the period specified in the license agreement,
or if we enter liquidation, have a receiver or administrator appointed over any assets related to the license agreement, or if we cease
to carry on business, file for bankruptcy or if an involuntary bankruptcy petition is filed against Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Additionally, we have considerable IP in the form
of trade secrets, including bioinformatics and high-performance computing techniques and artificial intelligence and machine learning
algorithms used to identify genetic and epigenetic biomarkers for various products and to interpret genetic and epigenetic data from patient
samples to generate clinically actionable information, as well as the methods to develop new methylation sensitive assays. We protect
our proprietary information, which includes, but is not limited to, trade secrets, know-how, and copyrights. Our future success depends
on protecting that knowledge, obtaining trademarks on our products, copyright on key materials, and avoiding infringing on the IP rights
of others. Where appropriate, we will assess the operating space and acquire licenses for critical technologies that we do not possess
or cannot create. We continue to invest in technological innovation and will seek mutualistic and symbiotic licensing opportunities to
promote and maintain our competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In order to provide our products, we currently
use a variety of third party technologies including, for example, genotyping, digital methylation assessment and data processing technologies.
The terms of these agreements for the non-exclusive use of these technologies are subject to change without notice and could affect our
ability to deliver our solutions. In addition, from time to time, we may face claims from third parties asserting ownership of, or demanding
release of, the open-source software or derivative works that we developed using such software (which could include our proprietary source
code), or otherwise seeking to enforce the terms of the applicable open-source license. These claims could result in litigation that could
be costly to defend, have a negative effect on our operating results and financial condition or require us to devote additional research
and development resources to change our existing or future solutions. Responding to any infringement or noncompliance claim by an open-source
vendor, regardless of its validity, discovering certain open-source software code in our products, or a finding that we have breached
the terms of an open-source software license, could harm our business, results of operations and financial condition. In each case, we
would be required to either seek licenses to software or services from other parties and redesign our products to function with such other
parties&#8217; software or services or develop these components internally, which would result in increased costs and could result in
delays to product launches. Furthermore, we might be forced to limit the features available in our current or future solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The laboratory testing and healthcare industry
and the practice of medicine are extensively regulated at both the state and federal levels, and additionally, the practice of medicine
is similarly extensively regulated by the various states. Our ability to operate profitably will depend in part upon its ability, and
that of its vendor partners, to maintain all necessary licenses and to operate in compliance with applicable laws and rules. Those laws
and rules continue to evolve, and therefore we devote significant resources to monitoring relevant developments in FDA, CLIA, healthcare
and medical practice regulation. Those laws and rules include, but are not limited to, ones that govern the regulation of clinical laboratories
in general and the regulation of LDTs in particular. As discussed below, legislation has been introduced in Congress that, if enacted,
would substantially alter federal regulation of diagnostic tests, including LDTs. As the applicable laws and rules change, we are likely
to make conforming modifications in our business processes from time to time. In many jurisdictions where we operate, neither our current
nor our anticipated business model has been the subject of judicial or administrative interpretation. We cannot be assured that a review
of our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that
the laboratory and healthcare regulatory environment will not change in a way that restricts our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>State and Federal Regulatory Issues&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Clinical Laboratory Improvement Amendments
of 1988 and State Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Clinical laboratories are required to hold certain
federal and state licenses, certifications and permits to conduct our business. As to federal certifications, in 1988, Congress passed
the Clinical Laboratory Improvement Amendments of 1988, or (&#8220;CLIA&#8221;), establishing more rigorous quality standards for all
commercial laboratories that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention,
or treatment of disease or the assessment of the health of human beings. CLIA requires such laboratories to be certified by the federal
government and mandates compliance with various operational, personnel, facilities administration, validation, quality and proficiency
testing requirements intended to ensure the accuracy, reliability and timeliness of patient test results. CLIA certification is also a
prerequisite to be eligible to bill state and federal healthcare programs, as well as many commercial third- party payers, for laboratory
testing services. The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) regulates laboratories that perform testing on
individuals in the U.S. through CLIA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Laboratories must comply with all applicable CLIA
requirements. If a clinical laboratory is found not to comply with CLIA standards, the government may impose sanctions, limit or revoke
the laboratory&#8217;s CLIA certificate (and prohibit the owner, operator or laboratory director from owning, operating, or directing
a laboratory for two years following license revocation), subject the laboratory to a directed plan of correction, on-site monitoring,
civil monetary penalties, civil actions for injunctive relief, criminal penalties, or suspension or exclusion from the Medicare and Medicaid
programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">CLIA provides that a state may adopt laboratory
licensure requirements and regulations that are more stringent than those under federal law and requires compliance with such laws and
regulations. New York State in particular, has implemented its own more stringent laboratory regulatory requirements. State laws may require
the laboratory to obtain state licensure and/or laboratory personnel to meet certain qualifications, specify certain quality control procedures
or facility requirements, or prescribe record maintenance requirements. Moreover, several states impose the same or similar state requirements
on out-of-state laboratory testing specimens collected or received from, or test results reported back to, residents within that state.
Therefore, the laboratory is required to meet certain laboratory licensing requirements for those states in which we offer services or
from which we accept specimens and that have adopted regulations beyond CLIA. For more information on state licensing requirements, see
"&#8212; California Laboratory Licensing,&#8221; "&#8212; New York Laboratory Licensing&#8221; and "&#8212; Other State
Laboratory Licensing Laws.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>California Laboratory Licensing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition to federal certification requirements
for laboratories under CLIA, the laboratory is required under California law to maintain a California state license and comply with California
state laboratory laws and regulations. Similar to the federal CLIA regulations, the California state laboratory laws and regulations establish
standards for the operation of a clinical laboratory and performance of test services, including the education and experience requirements
of the laboratory director and personnel (including requirements for documentation of competency), equipment validations, and quality
Management practices. All testing personnel must maintain a California state license or be supervised by licensed personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Clinical laboratories are subject to both routine
and complaint-initiated on-site inspections by the state. If a clinical laboratory is found to be out of compliance with California laboratory
standards, the California Department of Public Health (&#8220;CDPH&#8221;), may suspend, restrict or revoke the California state laboratory
license to operate the clinical laboratory (and exclude persons or entities from owning, operating, or directing a laboratory for two
years following license revocation), assess civil money penalties, and/or impose specific corrective action plans, among other sanctions.
Clinical laboratories must also provide notice to CDPH of any changes in the ownership, directorship, name or location of the laboratory.
Failure to provide such notification may result in revocation of the state license and sanctions under the CLIA program. Any revocation
of a CLIA certificate or exclusion from participation in Medicare or Medicaid programs may result in suspension of the California state
laboratory license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>New York Laboratory Licensing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We currently do not conduct tests on specimens
originating from New York State. In order to test specimens originating from, and return results to New York State, a clinical laboratory
is required to obtain a New York state laboratory permit and comply with New York state laboratory laws and regulations. The New York
state laboratory laws, regulations and rules are equal to or more stringent than the CLIA regulations and establish standards for the
operation of a clinical laboratory and performance of test services, including education and experience requirements of a laboratory director
and personnel, physical requirements of a laboratory facility, equipment validations, and quality Management practices. The laboratory
director(s) must maintain a Certificate of Qualification issued by the New York State Department of Health (&#8220;NYS DOH&#8221;) in
the permitted test categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A clinical laboratory conducting tests on specimens
originating in New York is subject to proficiency testing and on-site survey inspections conducted by the Clinical Laboratory Evaluation
Program (&#8220;CLEP&#8221;) under the NYS DOH. If a laboratory is found to be out of compliance with New York&#8217;s CLEP standards,
the NYS DOH, may suspend, limit, revoke or annul the New York laboratory permit, censure the holder of the license or assess civil money
penalties. Statutory or regulatory noncompliance may result in a laboratory&#8217;s operator, owners and/or laboratory director being
found guilty of a misdemeanor under New York law. Clinical laboratories must also provide notice to CLEP of any changes in ownership,
directorship, name or location of the laboratory. Failure to provide such notification may result in revocation of the state license and
sanctions under the CLIA program. Any revocation of a CLIA certificate or exclusion from participation in the Medicare or Medicaid programs
may result in suspension of the New York laboratory permit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The NYS DOH also must approve each LDT before that
test is offered to patients located in New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Other State Laboratory Licensing <span style="letter-spacing: -0.2pt">Laws</span>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition to New York and California, certain
other states require licensing of out-of-state laboratories under certain circumstances. We have obtained licenses in the states that
we believe require us to do so and believe we are in compliance with applicable state laboratory licensing laws, including Maryland and
Pennsylvania. We currently do not conduct tests on specimens originating from Rhode Island.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Potential sanctions for violation of state statutes
and regulations can include significant monetary fines, the rejection of license applications, the suspension or loss of various licenses,
certificates and authorizations, and in some cases criminal penalties, which could harm our business. CLIA does not preempt state laws
that have established laboratory quality standards that are more stringent than federal law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Laboratory-Developed Tests</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The FDA generally considers an LDT to be a test
that is designed, manufactured, and used within a single laboratory that is certified under CLIA and meets the regulatory requirements
under CLIA to perform high complexity testing. LDTs are performed using a variety of laboratory instruments and reagents and may also
incorporate FDA-authorized in vitro diagnostics (&#8220;IVDs&#8221;) that the laboratory modifies in some way and validates for its new
use. The FDA has historically taken the position that it has the authority to regulate LDTs as medical devices under the Federal Food,
Drug and Cosmetic Act (&#8220;FDC Act&#8221;), but it has generally exercised enforcement discretion with regard to LDTs. This means that
even though the FDA believes it can impose regulatory requirements on LDTs, such as requirements to obtain premarket approval, de novo
authorization, or 510(k) clearance of LDTs, it has generally chosen not to enforce those requirements to date. Although FDA has generally
exercised enforcement discretion for LDTs, the FDA has stated it retains discretion to require compliance with premarket when FDA deems
it appropriate to address significant public health concerns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In years past, legislative proposals addressing
the FDA&#8217;s oversight of LDTs have been introduced. In June 2021, Congress introduced the VALID Act, which would have established
a new risk-based regulatory framework for in vitro clinical tests (&#8220;IVCTs&#8221;), a category which would have included IVDs, LDTs,
collection devices and instruments used with such tests. The VALID Act has never been passed into law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In May 2024, FDA published a final rule amending
the definition of an in vitro diagnostic (&#8220;IVD&#8221;) device to include tests manufactured by a clinical laboratory. Pursuant to
the rule, LDTs, <i>i.e.</i>, tests designed, manufactured, and used within a single CLIA-certified high complexity laboratory, would be
classified as medical devices subject to FDA regulation under the Federal Food, Drug, and Cosmetic Act. The final rule also announced
FDA&#8217;s intention to apply its medical device requirements to LDTs, including premarket authorization requirements (510(k), de novo
classification, or PMA) for each LDT performed by the laboratory, and to postmarket registration and listing, medical device reporting,
correction, removal, and recall, complaint handling, labeling, investigational device, and quality system requirements. If implemented,
the final rule would have substantially increased costs and regulatory burdens for many clinical laboratories in ways that could be expected
to adversely affect their ability to develop, perform, and offer LDTs. Two lawsuits challenging FDA&#8217;s authority to regulate LDTs
were filed in federal court, and on March 31, 2025, a federal court in Texas vacated the FDA final rule, thereby cancelling the rulemaking&#8217;s
associated requirements. The court held that laboratory developed tests do not meet the definition of a medical device under the Federal
Food, Drug, and Cosmetic (&#8220;FD&amp;C&#8221;) Act, and the FDA therefore lacks jurisdiction to regulate them. Laboratories no longer
need to comply with the regulatory changes that were set to take effect on May 6, 2025, or with the rulemaking&#8217;s other requirements.
The federal government did not seek a stay of the district court&#8217;s opinion and did not file an appeal of the ruling, which means
the district court decision remains in effect. The change in Administration, the current balance of power in Congress, and recent court
rulings make it unlikely that the FDA will be urged to redouble its efforts to regulate LDTs as medical devices for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As mentioned above, separately, CMS oversees clinical
laboratory operations through the CLIA program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulation by the U.S. Food and Drug Administration</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Should the FDA decide to no longer exercise enforcement
discretion for LDTs, LDTs would be subject to extensive regulation as medical devices under the FDC Act and its implementing regulations,
which govern, among other things, medical device development, testing, labeling, storage, premarket clearance or approval, advertising
and promotion and product sales and distribution. To be commercially distributed in the United States, medical devices, including some
collection devices used to collect samples for testing, and certain types of software, must receive from the FDA prior to marketing, unless
subject to an exemption, clearance of a premarket notification (&#8220;510(k) clearance&#8221;), premarket approval (&#8220;PMA&#8221;),
or a de novo authorization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">IVDs are a type of medical device that are intended
to be used in the diagnosis or detection of diseases or conditions, including a determination of the state of health, through collection,
preparation and examination of specimens taken from the human body. IVDs may be used to detect the presence of certain chemicals, genetic
information or other biomarkers related to diagnosis or detection of diseases or conditions. IVDs may include tests for disease prediction,
prognosis, diagnosis, and screening.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The FDC Act classifies medical devices into one
of three categories based on the risks associated with the device and the level of control necessary to provide reasonable assurance of
safety and effectiveness. Class I devices are deemed to be low risk and are subject to the fewest regulatory controls. Many Class I devices
are exempt from FDA premarket review requirements. Class II devices, including some software products to the extent that they qualify
as a device, are deemed to be moderate risk, and generally require clearance through the premarket notification, or 510(k) clearance,
process. Class III devices are generally the highest risk devices and are subject to the highest level of regulatory control to provide
reasonable assurance of the device's safety and effectiveness. Class III devices typically require a PMA by the FDA before they are marketed.
A clinical trial is almost always required to support a PMA application or de novo authorization and is sometimes required for 510(k)
clearance. All clinical studies of investigational devices must be conducted in compliance with any applicable FDA and Institutional Review
Board requirements. Devices that are exempt from FDA premarket review requirements must nonetheless comply with post-market general controls
as described below, unless the FDA has indicated otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>510(k) clearance pathway. </i>To obtain 510(k)
clearance, a manufacturer must submit a premarket notification demonstrating to the FDA&#8217;s satisfaction that the new device is substantially
equivalent to a &#8220;predicate device.&#8221; A predicate device is a legally marketed device to which a new device may be compared
to for a determination regarding substantial equivalence. A legally marketed device is a device that was previously 510(k)-cleared, a
device that received de novo authorization, or a device that was in commercial distribution before May 28, 1976 for which the FDA has
not called for submission of a PMA application. The FDA&#8217;s 510(k) clearance pathway usually takes from three to 12 months from submission,
but it can take longer, particularly for a novel type of product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>PMA pathway.</i> The PMA pathway requires proof
of the safety and effectiveness of the device to the FDA&#8217;s satisfaction. The PMA pathway is costly, lengthy, and uncertain. A PMA
application must provide extensive preclinical and clinical trial data as well as information about the device and its components regarding,
among other things, device design, manufacturing, and labeling. As part of its PMA review process, the FDA will typically inspect the
manufacturer&#8217;s facilities for compliance with QSR requirements, which impose extensive testing, control, documentation, and other
quality assurance procedures. The PMA review process typically takes one to three years from submission but can take longer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">De novo pathway. If no predicate device can be
identified, a device is automatically classified as Class III, requiring a PMA application. However, the FDA can reclassify, either on
its own initiative or in response to a request for de novo classification, for a device for which there was no predicate device if the
device is low- or moderate-risk. If the device is reclassified as Class II, the FDA will identify special controls that the manufacturer
must implement, which may include labeling, testing, performance standards, or other requirements. Subsequent applicants can rely upon
the de novo device as a predicate for a 510(k) clearance, unless the FDA exempts subsequent devices from the need for a 510(k). The de
novo route is intended to be less burdensome than the PMA process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Post-market general controls.</i> After a device,
including a device exempt from FDA premarket review, is placed on the market, numerous regulatory requirements apply. These include: the
QSR, labeling regulations, registration and listing, the Medical Device Reporting regulation (which requires that manufacturers report
to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause
or contribute to a death or serious injury if it were to recur), and the Reports of Corrections and Removals regulation (which requires
manufacturers to report to the FDA corrective actions made to, or removal of, products in the field, if such actions were initiated to
reduce a risk to health posed by the device or to remedy a violation of the FDC Act which may present a health risk). Depending on the
severity of the legal violation that led to correction or removal, the FDA may classify the manufacturer&#8217;s action as a recall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The FDA enforces compliance with its requirements
through inspection and market surveillance. If the FDA finds a violation, it can institute a wide variety of actions, ranging from an
untitled or warning letter sent to manufacturers to enforcement actions such as fines, injunctions, and civil penalties; recall or seizure
of products; operating restrictions, partial suspension or total shutdown of production; refusing requests for 510(k) clearance or PMA
approval of new products; withdrawal of PMAs already granted; and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The FDA has become increasingly active in addressing
the regulation of software used to support clinical decision making. In 2016, the 21st Century Cures Act, (the &#8220;Cures Act&#8221;),
among other things, amended the medical device definition in the FDC Act to exclude certain software from FDA regulation, including clinical
decision support (&#8220;CDS software&#8221;) that meets certain criteria. CDS software is exempt from the medical device definition if
it: (a) displays, analyzes or prints medical information about a patient or other medical information; (b) is intended for the purpose
of supporting or providing recommendations about a patient&#8217;s care to a health care professional, (&#8220;HCP&#8221;), user; and
(c) provides sufficient information about the basis for the recommendations to the HCP user, so that the HCP user does not rely primarily
on any of the recommendations to make a clinical decision about an individual patient; unless (d) the software function acquires, processes,
or analyzes a medical image, a signal from an in vitro diagnostic device, or a pattern or signal from a signal acquisition system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On September 28, 2022, the FDA issued a final guidance
document interpreting the Cures Act as it pertains to CDS software. Among other views expressed, the final guidance stated that software
functions that assess or interpret the clinical implications or clinical relevance of a signal or pattern, such as those that process
or analyze an electrochemical or photometric response generated by an assay and instrument to generate a clinical test result, are not
exempt from medical device regulation. The final guidance also stated that software functions that generate risk probabilities or risk
scores are not exempt because they provide a specific diagnostic, preventive, or treatment output.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Practice of Medicine; Fee-Splitting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We contract with various healthcare companies to
deliver services to patients. This contractual relationship is subject to various state laws, including those of New York, Texas and California,
that prohibit fee-splitting or the practice of medicine by lay entities or persons and are intended to prevent unlicensed persons from
interfering with or influencing the physician&#8217;s professional judgment. In addition, various state laws also generally prohibit the
sharing of professional services income with nonprofessional or business interests. Activities other than those directly related to the
delivery of healthcare may be considered an element of the practice of medicine in many states. Under the corporate practice of medicine
restrictions of certain states, decisions and activities such as scheduling, contracting, setting rates and the hiring and management
of non-clinical personnel may implicate the restrictions on the corporate practice of medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">State corporate practice of medicine and fee-splitting
laws vary from state to state and are not always consistent among states. In addition, these requirements are subject to broad powers
of interpretation and enforcement by state regulators. Some of these requirements may apply to any telemedicine company or provider organization
we contract with. Failure to comply with regulations could lead to adverse judicial or administrative action against us and/or the providers
we work with, civil or criminal penalties, receipt of cease-and-desist orders from state regulators, loss of provider licenses, the need
to make changes to the terms of engagement with any telemedicine company or provider organization we contract with that interfere with
our business and other materially adverse consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Federal and State Fraud and Abuse Laws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Healthcare Laws Generally</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The federal Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations,
which is collectively referred to as HIPAA, established several separate criminal penalties for making false or fraudulent claims to insurance
companies and other non- governmental payors of healthcare services. Under HIPAA, these two additional federal crimes are: "Healthcare
Fraud&#8221; and "False Statements Relating to Healthcare Matters.&#8221; The Healthcare Fraud statute prohibits knowingly and recklessly
executing a scheme or artifice to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony
and may result in fines, imprisonment or exclusion from government-sponsored programs. The False Statements Relating to Healthcare Matters
statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making
any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items
or services. A violation of this statute is a felony and may result in fines or imprisonment. This statute could be used by the government
to assert criminal liability if a healthcare provider knowingly fails to refund an overpayment. These provisions are intended to punish
some of the same conduct in the submission of claims to private payors as the federal False Claims Act covers in connection with governmental
health programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition, the Civil Monetary Penalties Law imposes
civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs
and employing or contracting with individuals or entities who are excluded from participation in federally funded healthcare programs.
Moreover, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and
deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection
of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary
penalties of up to $10,000 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles
for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can
impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised
waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection
efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular
patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles
offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes
to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Federal Stark <span style="letter-spacing: -0.25pt">Law</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i><span style="letter-spacing: -0.25pt">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are subject to the federal self-referral prohibitions,
commonly known as the Stark Law. Where applicable, this law prohibits a physician from referring Medicare patients to an entity providing
"designated health services&#8221; if the physician or a member of such physician&#8217;s immediate family has a "financial
relationship&#8221; with the entity, unless an exception applies. The penalties for violating the Stark Law include the denial of payment
for services ordered in violation of the statute, mandatory refunds of any sums paid for such services, civil penalties of up to $15,000
for each violation and twice the dollar value of each such service and possible exclusion from future participation in the federally-funded
healthcare programs. A person who engages in a scheme to circumvent the Stark Law&#8217;s prohibitions may be fined up to $100,000 for
each applicable arrangement or scheme. The Stark Law is a strict liability statute, which means proof of specific intent to violate the
law is not required. In addition, the government and some courts have taken the position that claims presented in violation of the various
statutes, including the Stark Law can be considered a violation of the federal False Claims Act (described below) based on the contention
that a provider impliedly certifies compliance with all applicable laws, regulations and other rules when submitting claims for reimbursement.
A determination of liability under the Stark Law could have a material adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Federal Anti-Kickback Statute</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are also subject to the federal Anti-Kickback
Statute. The Anti-Kickback Statute is broadly worded and prohibits the knowing and willful offer, payment, solicitation or receipt of
any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other governmental
programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental
programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering of any item or service
reimbursable under Medicare, Medicaid or other governmental programs. Certain federal courts have held that the Anti-Kickback Statute
can be violated if "one purpose&#8221; of a payment is to induce referrals. In addition, a person or entity does not need to have
actual knowledge of this statute or specific intent to violate it to have committed a violation, making it easier for the government to
prove that a defendant had the requisite state of mind or "scienter&#8221; required for a violation. Moreover, the government may
assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the False Claims Act, as discussed below. Violations of the Anti- Kickback Statute can result in exclusion from
Medicare, Medicaid or other governmental programs as well as civil and criminal penalties, including fines of $50,000 per violation and
three times the amount of the unlawful remuneration. Imposition of any of these remedies could have a material adverse effect on our business,
financial condition and results of operations. In addition to a few statutory exceptions, the U.S. Department of Health and Human Services
Office of Inspector General, or OIG, has published safe-harbor regulations that outline categories of activities that are deemed protected
from prosecution under the Anti-Kickback Statute provided all applicable criteria are met. The failure of a financial relationship to
meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute.
However, conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government
enforcement authorities, such as the OIG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>False Claims <span style="letter-spacing: -0.25pt">Act</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i><span style="letter-spacing: -0.25pt">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Both federal and state government agencies have
continued civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and their executives
and managers. Although there are a number of civil and criminal statutes that can be applied to healthcare providers, a significant number
of these investigations involve the federal False Claims Act. These investigations can be initiated not only by the government but also
by a private party asserting direct knowledge of fraud. These "qui tam&#8221; whistleblower lawsuits may be initiated against any
person or entity alleging such person or entity has knowingly or recklessly presented, or caused to be presented, a false or fraudulent
request for payment from the federal government or has made a false statement or used a false record to get a claim approved. In addition,
the improper retention of an overpayment for 60 days or more is also a basis for a False Claim Act action, even if the claim was originally
submitted appropriately. Penalties for False Claims Act violations include fines ranging from $5,500 to $11,000 for each false claim,
plus up to three times the amount of damages sustained by the federal government. A False Claims Act violation may provide the basis for
exclusion from the federally-funded healthcare programs. In addition, some states have adopted similar fraud, whistleblower and false
claims provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>State Fraud and Abuse <span style="letter-spacing: -0.2pt">Laws</span>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Several states in which we operate have also adopted
similar fraud and abuse laws as described above. The scope of these laws and the interpretations of them vary from state to state and
are enforced by state courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or
services reimbursed by any third-party payor, including commercial insurers, not just those reimbursed by a federally-funded healthcare
program. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our
ability to operate in these jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>State and Federal Health Information Privacy
and Security Laws&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There are numerous U.S. federal and state laws
and regulations related to the privacy and security of personally identifiable information, or PII, including health information. In particular,
HIPAA establishes privacy and security standards that limit the use and disclosure of protected health information, or PHI, and require
the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of
individually identifiable health information in electronic form. Since the effective date of the HIPAA Omnibus Final Rule on September
23, 2013, HIPAA&#8217;s requirements are also directly applicable to the independent contractors, agents and other "business associates&#8221;
of covered entities that create, receive, maintain or transmit PHI in connection with providing services to covered entities. Although
Cardio is a covered entity under HIPAA, Cardio is also a business associate of other covered entities when Cardio is working on behalf
of our affiliated medical groups.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Violations of HIPAA may result in civil and criminal
penalties. The civil penalties range from $100 to $50,000 per violation, with a cap of $1.5 million per year for violations of the same
standard during the same calendar year. However, a single breach incident can result in violations of multiple standards. Cardio must
also comply with HIPAA&#8217;s breach notification rule. Under the breach notification rule, covered entities must notify affected individuals
without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI.
In addition, notification must be provided to the HHS and the local media in cases where a breach affects more than 500 individuals. Breaches
affecting fewer than 500 individuals must be reported to HHS on an annual basis. The regulations also require business associates of covered
entities to notify the covered entity of breaches by the business associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">State attorneys general also have the right to
prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would
allow individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state
civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct
periodic compliance audits of HIPAA covered entities and their business associates for compliance. It also tasks HHS with establishing
a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary
Penalty fine paid by the violator. In light of the HIPAA Omnibus Final Rule, recent enforcement activity, and statements from HHS, we
expect increased federal and state HIPAA privacy and security enforcement efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">HIPAA also required HHS to adopt national standards
establishing electronic transaction standards that all healthcare providers must use when submitting or receiving certain healthcare transactions
electronically. On January 16, 2009, HHS released the final rule mandating that everyone covered by HIPAA must implement ICD-10 for medical
coding on October 1, 2013, which was subsequently extended to October 1, 2015 and is now in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Many states in which we operate and in which patients
reside also have laws that protect the privacy and security of sensitive and personal information, including health information. These
laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California,
in which we operate, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws
we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply
with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some,
unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition,
state laws are changing rapidly, and there is discussion of a new federal privacy law or federal breach notification law, to which we
may be subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition to HIPAA, state health information
privacy and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit
unfair privacy and security practices and deceptive statements about privacy and security and laws that place specific requirements on
certain types of activities, such as data security and texting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In recent years, there have been a number of well-publicized
data breaches involving the improper use and disclosure of PII and PHI. Many states have responded to these incidents by enacting laws
requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing
prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA and pursuant to the related contracts
that we enter into with our business associates, we must report breaches of unsecured PHI to our contractual partners following discovery
of the breach. Notification must also be made in certain circumstances to affected individuals, federal authorities and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>State Privacy <span style="letter-spacing: -0.2pt">Laws</span>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Various states have enacted laws governing the
privacy of personal information collected and used by businesses online. For example, California adopted the California Consumer Privacy
Act of 2018 ("CCPA&#8221;), which went into effect on January 1, 2020 and was recently amended by the California Privacy Rights Act
of 2020 which significantly modified the CCPA in ways that affect businesses. This law, in part, requires that companies make certain
disclosures to consumers via their privacy policies, or otherwise at the time the personal data is collected. We will have to determine
what personal data it is collecting from individuals and for what purposes, and to update its privacy policy every 12 months to make the
required disclosures, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees and Human Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As of August 31, 2025 we had 15 full-time employees,
and 2 part-time employees. Three of our employees hold Ph.D. or M.D. degrees. We also engage contractors and consultants from time to
time. None of our employees are represented by a labor union or covered under a collective bargaining agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our human capital resources objectives include,
identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees into our collaborative culture.
Our compensation program is designed to retain, motivate and attract highly qualified executives and talented employees and consultants.
We are committed to fostering a culture that supports diversity and an environment of mutual respect, equity and collaboration that helps
drive our business and our mission to become one of the leading medical technology companies for enabling improved prevention, detection,
treatment and management of cardiovascular disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We do not own any real estate or other physical
properties materially important to our operations. We currently maintain our principal executive offices at 311 West Superior Street,
Suite 444, Chicago, IL 60654 pursuant to a lease agreement. The cost for this space is approximately $13,000 per month with an unaffiliated
third party, which commenced on December 1, 2023 and expires three years later. We also maintain a laboratory at 2565 North Dodge, Suite
D, Iowa City, IA 52245 pursuant to a lease agreement. The cost for this space is approximately $8,505 per month with an unaffiliated third
party, the term of which commenced on December 1, 2023 and expires five years later. We consider our current office space, combined with
the other office space otherwise available to our executive officers, adequate for our current operations.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are not currently a party to any material litigation
or other legal proceedings brought against <span style="letter-spacing: -0.25pt">us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="letter-spacing: -0.25pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporation Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our corporate headquarters is located at 311
West Superior Street, Suite 444, Chicago IL. Our telephone number is (855) 226-9991 and our website address is cdio.ai. The information
contained on, or that can be accessed through, our website is not incorporated by reference in this Prospectus and does not form a part
of this Post-Effective Amendment or the Prospectus which forms a part thereof. The reference to our website address does not constitute
incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part
of this Registration Statement or the Prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging Growth Status</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are an &#8220;emerging growth company<i>,</i>&#8221;
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;),
and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities
registered under the Securities Exchange Act of 1934, as amended the &#8220;Exchange Act&#8221;), are required to comply with the new
or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period
and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have
elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application
dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an
emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible
because of the potential differences in accounting standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We will remain an emerging growth company until
the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have
total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market
value of our Common Stock held by non-affiliates equaled or exceeded $700 million as of June 30th of that fiscal year, and (2) the date
on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Additionally, we are a &#8220;smaller reporting
company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting
company until the last day of the fiscal year in which (1) the market value of our Common Stock held by non-affiliates equaled or exceeded
$250 million as of June 30th of that fiscal year, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal
year and the market value of our Common Stock held by non-affiliates equaled or exceeded $700 million as of June 30th of that fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="Management"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following table sets forth certain information,
including ages as of September 12, 2025, of our executive officers and members of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Age</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Position</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Executive Officers</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; text-align: left">Meeshanthini (Meesha) V. Dogan, PhD</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: center">&#160;</td><td style="width: 7%; font-size: 10pt; text-align: center">37</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 40%; font-size: 10pt; text-align: left">Chief Executive Officer and Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Robert (Rob) Philibert, MD PhD</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Chief Medical Officer and Director</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Elisa Luqman, JD MBA</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">61</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Chief Financial Officer</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Timur Dogan, PhD</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">37</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Chief Technology Officer</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 14.65pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-Employee Directors</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Warren Hosseinion, MD</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">53</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Non-Executive Chairman</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Wendy J. Betts</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">53</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Paul F. Burton</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">58</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Peter K. Fung, MD</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">69</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">James Intrater</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: center">61</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Director</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Biographical Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Executive Officers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following is a brief biography of each of our
executive officers:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Meeshanthini V. Dogan, PhD </i>has served as
our Chief Executive Officer and a director since inception. Together with Dr. Philibert, she is the Co-Founder of Legacy Cardio, with
over 15 years&#8217; experience in bridging medicine, engineering and artificial intelligence towards building solutions to fulfill unmet
clinical needs such as in cardiovascular disease prevention and management. Coming from a family with a two-generation history of heart
disease and having worked for an extensive time interacting with those affected by heart disease, she understands the pain points and
founded Legacy Cardio to help prevent others from experiencing its devastating impacts. Dr. Dogan is a pioneer in artificial intelligence/machine
learning-driven integrated genetic-epigenetic approaches, which includes highly cited publications, and platform presentations at the
American Heart Association and American Society of Human Genetics. She co-invented the patent-pending Integrated Genetic-Epigenetic Engine&#8482;
of Cardio  (six granted patents and numerous pending patents). In 2017, Dr. Dogan founded Legacy Cardio to commercialize this
technology through a series of patent-pending clinical tests towards making heart disease prevention and early detection more accessible,
personalized and precise. Under her leadership, Legacy Cardio was awarded the prestigious One To Watch award in 2020 by Nature and Merck,
the 2021 Clinical Diagnostics Solution of the Year from Biotech Breakthrough and Fast Company's Next Big Things in Tech 2022, has worked
its way to become a technology leader in cardiovascular diagnostics, launched four products, secured both dilutive and non-dilutive funding
and key relationships with world renowned healthcare organizations and key opinion leaders. Dr. Dogan holds a PhD degree in Biomedical
Engineering and BSE/MS degrees in Chemical Engineering from University of Iowa. She was named FLIK Woman Entrepreneur to Watch in 2021and
Cardiovascular Business 40 under 40. We believe that, as a co-founder of our Company and co-inventor of our Company&#8217;s key technologies
and products, as well as her leadership skills, Dr. Dogan is uniquely positioned to bring unmatched experience and insights into the boardroom
and to the daily operations of our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Robert Philibert, MD, PhD </i>has served as
our Chief Medical Officer and as a director since inception. Together with Dr. Dogan, he is a co-founder of Legacy Cardio. Dr. Philibert
graduated from the University of Iowa Medical Scientist Training Program and completed a residency in Psychiatry at the University of
Iowa. Between 1993 and 1998, he completed a Pharmacology Research Training Program (&#8220;PRAT&#8221;) Fellowship and a Staff Fellowship
at the National Institutes of Health while also serving in the United States Uniformed Public Health Service. In late 1998, he returned
to the University of Iowa where he now is a Professor of Psychiatry, with joint appointments in Neuroscience, Molecular Medicine and Biomedical
Engineering. He has published over 170 peer reviewed manuscripts and is the recipient of numerous NIH grant awards and both national and
international patents for his pioneering work in epigenetics. In particular, he is credited with discovering the epigenetic signatures
for cigarette and alcohol consumption. In 2009, he founded Behavioral Diagnostics, LLC, a leading provider of epigenetic testing services
which has introduced two epigenetic tests, Smoke Signature&#169; and Alcohol Signature&#8482; to the commercial market. Simultaneously,
he has licensed related non-core technologies to manufacturing partners while developing an ecosystem of key complementary service providers
in the clinical diagnostics space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Elisa Luqman, JD, MBA </i>has served as our
Chief Financial Officer on a part time basis since March 2021. In March 2021, Legacy Cardio and Ms. Luqman entered into a consulting agreement
under which she was retained to provide services in connection with a potential merger transaction. Since April 2022, Ms. Luqman has also
been serving as Chief Legal Officer (SEC) for Nutex Health, Inc. (&#8220;Nutex&#8221;), a physician-led, technology-enabled healthcare
services company. She attained that position upon the closing of a merger transaction in which her employer, Clinigence Holdings, Inc.
(&#8220;Clinigence"), was the surviving entity. She served as the Chief Financial Officer, Executive Vice President Finance and General
Counsel of Clinigence from October 2019 until the merger. She also served as a director of Clinigence from October 2019 to February 2021.
At Clinigence, Ms. Luqman was responsible for maintaining the corporation&#8217;s accounting records and statements, preparing its SEC
filings and overseeing compliance requirements. She was an integral member of the Clinigence team responsible for obtaining the company&#8217;s
NASDAQ listing and completing the reverse merger with Nutex. At Nutex Ms. Luqman continues to be responsible for preparing its SEC filings
and overseeing compliance requirements. Ms. Luqman co-founded bigVault Storage Technologies, a cloud- based file hosting company acquired
by Digi-Data Corporation in February 2006. From March 2006 through February 2009, Ms. Luqman was employed as Chief Operating Officer of
the Vault Services Division of Digi-Data Corporation, and subsequently during her tenure with Digi-Data Corporation she became General
Counsel for the entire corporation. In that capacity she was responsible for acquisitions, mergers, patents, customer, supplier, and employee
contracts, and worked very closely with Digi-Data&#8217;s outside counsel firms. In March 2009, Ms. Luqman rejoined iGambit Inc. (&#8220;IGMB&#8221;)
as Chief Financial Officer and General Counsel. Ms. Luqman has overseen and been responsible for IGMB&#8217;s SEC filings, FINRA filings
and public company compliance requirements from its initial Form 10 filing with the SEC in 2010 through its reverse merger with Clinigence
Holdings, Inc. in October 2019. Ms. Luqman received a BA degree, a JD in Law, and an MBA Degree in Finance from Hofstra University. Ms.
Luqman is a member of the bar in New York and New Jersey.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Timur Dogan </i>has served as our Chief Technology
Officer since May 2022. He has been employed by Legacy Cardio since August 2019, after obtaining his Ph.D., and was serving as its Senior
Data Scientist until he was promoted to CTO. Dr. Dogan was instrumental in developing and advancing the Integrated Genetic-Epigenetic
Engine&#8482; that is at the core of Cardio&#8217;s cardiovascular solutions. Along with the founding team, he is the co-inventor of several
patent-pending technologies in cardiovascular disease and diabetes. He holds a joint B.S.E./M.S. and Ph.D. degrees in Mechanical Engineering
from the University of Iowa where he researched complex fluid flows. He developed machine learning models on high-performance computing
systems using a mixture of low and high-fidelity numerical simulations and experiments to draw insights from non-linear physics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Non-Employee Members of the Board of Directors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following is a brief biography of each of our
non-employee directors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Warren Hosseinion, MD</i> has served as the
Company&#8217;s Non-Executive Chairman of the Board since the consummation of the Business Combination in October 2022. He was Legacy
Cardio&#8217;s Non-Executive Chairman of the Board from May 2022 and was on Legacy Cardio&#8217;s Board of Directors beginning in November
2020. In March 2021, Legacy Cardio and Dr. Hosseinion entered into a consulting agreement under which he was retained to provide services
in connection with a potential merger transaction. He continues to provide consulting services to the Company under that contract. He
is also currently the President and a director of Nutex Health, Inc. (Nasdaq: NUTX), positions he has held since April 2022. He also serves
as Chairman of the Board of Voyager Acquisition Corp. (Nasdaq: VACH), a position he has held since December 2023. In 2001, Dr. Hosseinion
co-founded Astrana Health, Inc. (Nasdaq: ASTH) (formerly, Apollo Medical Holdings, Inc. (Nasdaq: AMEH)) and served as a member of Astrana&#8217;s
Board of Directors from July 2008 to March 2019. He served as Astrana&#8217;s Chief Executive Officer from July 2008 to December 2017
and its Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion received his B.S. in Biology from the University of
San Francisco, his M.S. in Physiology and Biophysics from the Georgetown University Graduate School of Arts and Sciences, his Medical
Degree from the Georgetown University School of Medicine and completed his residency in internal medicine from the Los Angeles County-University
of Southern California Medical Center. Dr. Hosseinion&#8217;s experience as a physician, along with his background at Astrana and Nutex,
brings to our Board and our Company a depth of understanding of physician culture and the healthcare market, as well as a strong knowledge
of the public markets.<i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Wendy J. Betts&#160;</i><span style="color: #231F20">has
served as a member of the Company&#8217;s Board of Directors since</span> November 15, 2024. Since June 2024, Ms. Betts has been serving
as the Information Security Officer at Rotary International,&#160;where she is managing the cybersecurity department, which includes cyber
defense, cyber operations and deployment of strategic technology. Prior to that, she was the Director of Cybersecurity Strategy at United
Airlines from&#160;October 2022 to September 2023,&#160;where she managed the strategic initiatives for the cybersecurity program.&#160;From&#160;July
2019 to October 2022, Ms. Betts served as&#160;Senior Risk Manager at Bank of America,&#160;where she oversaw the second line work for
cybersecurity defense including SOC, Malware, DDoS and Cloud.&#160;From March 2010 to July 2019, Ms. Betts was employed by Northern Trust,
most recently serving as&#160;Vulnerability&#160;Manager,&#160;where she developed the Secure SDLC program and rolled out DevSecOps methodology
throughout the application development environment. Ms. Betts is continually active in the technology industry, where she is currently
a member of Information Systems Security Association (&#8220;ISSA&#8221;), Women in Cybersecurity (&#8220;WiCyS&#8221;), and Chief, the
private network for senior women executives.&#160;Ms. Betts earned her BA in Operations Management Information Systems from Northern Illinois
University and an MBA with an emphasis in finance from the Keller Graduate School of Management. She is a Certified Information Systems
Security Professional (&#8220;CISSP&#8221;) and Certified Cloud Security Professional (&#8220;CCSP&#8221;). She also serves as a Director
for the Luminarts Culture Foundation,&#160;an organization dedicated to supporting young artists through its competitive programs that
offer financial awards, artistic opportunities and mentoring that bridge the gap between education and career. Ms. Betts was nominated
due to her background and experience in cybersecurity,<b>&#160;</b>finance, and corporate leadership, all of which are areas of expertise
we believe bring valuable insights to our boardroom including&#160;with respect to&#160;cybersecurity oversight requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Paul F. Burton, JD, MBA </i>has served as a
member of the Company&#8217;s Board of Directors since December 2023. Since May 2021, Mr. Burton has served as the Managing Partner, of
2Flo Ventures, a start-up studio and early-stage healthcare investor. Through 2Flo Ventures, he provides strategic and financial advice
to healthcare companies. In 2010, he founded and continues to serve as Managing Principal of Burton Advisory, Inc., which provides strategic
and financial advice to healthcare companies, drawing from over 20 years of experience in corporate finance and strategic advisory services.
In connection therewith, since December 2018, Mr. Burton has been the Chief Executive Officer of Akan Biosciences, a biotech start-up
company developing regenerative medicinal therapeutics. From 2019 he also has been serving as the Chief Financial Officer of Temprian
Therapeutics. From 2019 through 2022 he served as the fractional CFO for both Cancer IQ and 4D Healthware. From 2019 through 2022, Mr.
Burton was also an Entrepreneur in Residence at Northwestern University, supporting students and faculty with healthcare-oriented commercialization
projects. Previously, he was the Chief Executive Officer of ResQ Pharma, Inc. In 2013 he co-founded Vivacelle Bio, Inc., where he served
as Chief Financial Officer and a member of its board of directors. Mr. Burton currently serves as a member of the Chicago Biomedical Consortium&#8217;s
VC Advisory Committee, as a member of MATTER, a Chicago-based healthcare incubator, and the Bunker Labs, an incubator started in Chicago
for U.S. military veterans. He also is a member of the Board of Directors of Millennium Beacon, a healthcare incubator based on the southside
of Chicago, seeking to serve overlooked populations. Prior thereto, Mr. Burton worked as an investment banking associate at Salomon Brothers
(now Citigroup Corporate &amp; Investment Bank). He also served as a United States Regular Army Commissioned Officer (Infantry). Mr. Burton
earned his JD and MBA from the University of Illinois at Urbana-Champaign and earned two Bachelor&#8217;s Degrees from the University
of Illinois at Chicago. He currently serves on the Board of Trustees of the Ravinia Festival, an internationally-renowned, not-for-profit
music festival. Mr. Burton was nominated due to his extensive experience in the working of numerous capacities with early-stage healthcare
companies as well as his corporate finance background, both of which are areas of expertise we believe bring invaluable insights to our
Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i></i></p>

<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Peter K. Fung, MD </i><span style="color: #231F20">has
served as a member of the Company&#8217;s Board of Directors since</span> November 15, 2024. Since 2004, Dr. Fung has served as the Director
of Cardiovascular Division of Beverly Hospital&#160;in Montebello, California. He is also the Director of Research and Education at Central
California Heart Institute&#160;in Fresno, California&#160;since&#160;1992&#160;and Director of Nuclear Cardiology at Central Cardiology
Medical Clinic&#160;in Bakersfield, California since&#160;1991. Earlier in his professional career from 1990 to 1997, Dr. Fung served
as Clinical Faculty at University of California Los Angeles (UCLA). He received&#160;his&#160;B.Sc. in&#160;Psychobiology in 1979 from
University of Southern California, his MD in 1983 from Stanford University School of Medicine, and was an Internal Medicine resident between
1983 and 1986 and Cardiology Fellow between 1986 and 1989 at Cedars-Sinai Medical Center/UCLA. His board certifications include Diplomat
of the American Board of Internal Medicine, Diplomat Subspecialty Board of Cardiovascular Disease, Fellow of American College of Cardiology,
Fellow of American College of Angiology and Diplomat of Subspecialty Board of Interventional Cardiology. His extensive clinical expertise
includes more than 5,000 cases of coronary angiography, more than 2,000 cases of&#160;percutaneous transluminal coronary angioplasty,
more than 400 cases of Peripheral Angiography, more than 200 cases of Peripheral Angioplasty including balloon and TEC devices, more than
100 cases of Carotid Angiography, more than 100 cases of Peripheral Stent placement, more than 100 cases of Renal Artery Stent Placement,
Rotational Artherectomy, Coronary TEC, Pacemaker Implantation, Laser Artherectomy, Stent Placement, Brachytherapy, and Abdominal Aortic
Aneurysm Percutaneous Repair/&amp; Grafting. Dr. Fung was selected to serve on our board of directors due to his extensive clinical experience
in cardiology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>James Intrater </i>is the director who was designated
by Mana, and he began his term upon Closing of the Business Combination in October 2022<i>. </i>Mr. Intrater is a senior materials and
process engineer with over 35 years of professional experience. He has worked in both commercial product development and on Federal R&amp;D
projects, including work for NASA, the U.S. Department of Defense, and the U.S. Department of Energy. Since June 2014, Mr. Intrater has
served as the president of IntraMont Technologies, a consumer health products development company. In addition, since May 2020, he has
also provided engineering consultancy services for Falcon AI, a private investment firm to evaluate potential portfolio investments. Mr.
Intrater has published numerous technical works and reports for various agencies of the federal government and in technical journals and
is listed as holder or co-holder of five patents, with another patent pending. Mr. Intrater received his Master of Science in Metallurgical
Engineering from the University of Tennessee and a Bachelor of Sciences in Ceramic Engineering from Rutgers University - College of Engineering.
Mr. Intrater was selected to serve as a member of our board of directors due to his significant experience developing healthcare-related
products as well as products in other industries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Other than Meeshanthini Dogan and Timur Dogan,
who are wife and husband, there are no family relationships among our executive officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="BoardMatters"></span><b>BOARD MATTERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has structured its corporate governance
in a manner that we believe closely aligns its interests with those of its stockholders. Notable features of this corporate governance
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 23.55pt; vertical-align: bottom"><span style="font-size: 10pt">Cardio has independent director representation on its audit, compensation and nominating and corporate governance committees, and its independent directors will meet regularly in executive sessions without the presence of its corporate officers or non-independent directors;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">at least one of its directors has qualified as an "audit committee financial expert&#8221; as defined by the SEC; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">it has and will implement a range of other corporate governance best practices, including a robust director education program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leadership Structure of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The roles of our Non-Executive Chairman and our
Chief Executive Officer have been separated. We believe that this is appropriate under current circumstances because it allows management
to make the operating decisions necessary to manage the business, while separating out oversight function of the Board and operating decisions.
We feel that this has provided an appropriate balance of operational focus, flexibility and oversight. We do not separately have a lead
independent director. Currently, Dr. Hosseinion serves as Non-executive Chairman of the Board, participates in setting the agenda of Board
and committee meetings, facilitating communications among members of the Board and management, and maintaining the focus and punctuality
of Board and committee meetings. Dr Hosseinion also currently leads the efforts in evaluating our Chief Executive Officer and in succession
planning, considering Board committee membership and leadership. He will be presiding at this Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background and Experience of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our nominating and corporate governance committee
is responsible for, among other things, identifying individuals qualified to become members of our board of directors, consistent with
criteria approved by our board of directors, overseeing succession planning for our Chief Executive Officer and other executive officers,
periodically reviewing our board of directors&#8217; leadership structure and recommending any proposed changes to our board of directors,
overseeing an annual evaluation of the effectiveness of our board of directors and its committees, and developing and recommending to
our Board of Directors a set of corporate governance guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition of the Board of Directors and Company Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#8217;s business and affairs are managed
under the direction of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company&#8217;s board consists of seven directors.
The board of directors are elected each year at the annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company officers are appointed by the board
of directors and serve at the discretion of the board of directors, rather than for specific terms of office, subject to the terms of
employment agreements, where applicable. The board of directors is authorized to appoint persons to the offices set forth in our bylaws
as it deems appropriate. The Company&#8217;s bylaws provide that our officers may consist of a Chairman of the Board, Chief Executive
Officer, Chief Financial Officer, President, one or more Vice Presidents, Secretary, Treasurer, one or more Assistant Secretaries and
such other offices as may be determined by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Nasdaq listing standards require that a majority
of our Board of Directors be independent. An &#8220;independent director&#8221; is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, stockholder or officer of an organization that has a relationship with the company).
The Company&#8217;s independent directors expect to have regularly scheduled meetings at which only independent directors are present.
Any affiliated transactions will be on terms no less favorable to the Company than could be obtained from independent parties. The Company&#8217;s
Board of Directors will review and approve all affiliated transactions with any interested director abstaining from such review and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Based on information provided by each director
concerning his or her background, employment and affiliations, the Board has determined that Paul F. Burton, James Intrater, Wendy J.
Betts, and Peter K. Fung, MD, representing four of the Company&#8217;s seven directors, do not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is an &#8220;independent
director&#8221; as defined under the listing standards of Nasdaq and applicable SEC rules. In making these determinations, the Company
Board considered the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances
that the Company Board deemed relevant in determining their independence, including the beneficial ownership of the Company capital stock
by each non- employee director, and the transactions involving them. See &#8220;<a href="#CertainRelationships">Certain Relationships and Related Persons Transactions</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Committees&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The standing committees of the Cardio Board consist
of an audit committee, a compensation committee and a nominating and corporate governance committee. The board of directors may from time
to time establish other committees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio&#8217;s chief executive officer and other
executive officers regularly report to the non-executive directors and the audit, the compensation and the nominating and corporate governance
committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation
of management controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Audit Committee</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has an audit committee consisting of Paul
F. Burton, James Intrater and Wendy J. Betts, with Mr. Burton serving as the chair of the committee. The Cardio Board has determined that
each member of the audit committee qualifies as an independent director under the independence requirements of the Sarbanes-Oxley Act,
Rule 10A-3 under the Exchange Act and Nasdaq listing requirements. The Cardio Board has determined that Mr. <span style="letter-spacing: -0.05pt">Burton
</span>qualifies as an &#8220;audit committee financial expert,&#8221; as defined in Item 407(d)(5) of Regulation S-K, and that he possesses
financial sophistication, as defined under the rules of Nasdaq. Mr. Burton was selected to serve on our Board and as the chair of our
audit committee due to his extensive experience working in numerous capacities with early-stage healthcare companies as well as his corporate
finance background, both of which are areas of expertise that bring invaluable insights to the Cardio boardroom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The audit committee&#8217;s responsibilities include,
among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 6.65pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the Board whether the audited financial statements should be included in our Form 10-K;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">discussing with management major risk assessment and risk Management policies;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px; padding-top: 0.05pt">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">monitoring the independence of the independent auditor;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by <span style="letter-spacing: -0.2pt">law;</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving all related-party transactions;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">inquiring and discussing with management our compliance with applicable laws and regulations;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">appointing or replacing the independent auditor;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 10.35pt; vertical-align: bottom"><span style="font-size: 10pt">determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between Management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving any annual or long-term incentive cash bonus or equity or other incentive plans in which our executive officers may participate;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 19.5pt; vertical-align: bottom"><span style="font-size: 10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">approving reimbursement of expenses incurred by our management team in identifying potential target businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The board of directors has adopted a written charter
for the audit committee that is available on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Compensation Committee</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has a compensation committee consisting
of Wendy Betts, James Intrater and Peter Fung, MD with Ms. Betts serving as chair of the committee. The Cardio Board has determined that
each member of the compensation committee qualifies as an independent director under the independence requirements of the Sarbanes-Oxley
Act, Rule 10A-3 under the Exchange Act and Nasdaq listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The compensation committee&#8217;s responsibilities
include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">establishing, reviewing, and approving our overall executive compensation philosophy and policies;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 30.7pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving the compensation of all of our other executive officers;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">approving reimbursement of expenses incurred by our management team in identifying potential target businesses.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing our executive compensation policies and plans;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 39.7pt; vertical-align: bottom"><span style="font-size: 10pt">receiving and evaluating performance target goals for the senior officers and employees (other than executive officers) and reviewing periodic reports from the CEO as to the performance and compensation of such senior officers and employees;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">implementing and administering our incentive compensation equity-based remuneration plans;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving any annual or long-term incentive cash bonus or equity or other incentive plans in which our executive officers may participate;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 0.45in; vertical-align: bottom"><span style="font-size: 10pt">reviewing and approving for our chief executive officer and other executive officers any employment agreements, severance arrangements, and change in control agreements or provisions;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 7.95pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and discussing with Management the Compensation Discussion and Analysis set forth in Securities and Exchange Commission Regulation S-K, Item 402, if required, and, based on such review and discussion, determine whether to recommend to the Board that the Compensation Discussion and Analysis be included in our annual report or proxy statement the annual meeting of stockholders;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">assisting management in complying with our proxy statement and annual report disclosure requirements;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">if required, producing a report on executive compensation to be included in our annual proxy statement;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 15.45pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing and recommending to the Board for approval the frequency with which we will conduct Say-on-Pay Votes, taking into account the results of the most recent stockholder advisory vote on frequency of Say-on-Pay Votes required by Section 14A of the Exchange Act, and review and recommend to the Board for approval the proposals regarding the Say- on-Pay Vote and the frequency of the Say-on-Pay Vote to be included in our proxy statements filed with the SEC;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">conducting an annual performance evaluation of the committee; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The board of directors has adopted a written charter
for the compensation committee that is available on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Compensation Committee Interlocks and Insider
Participation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">None of our executive officers serves as a member
of the compensation committee of the board of directors (or other committee performing equivalent functions) of any entity that has one
or more executive officers serving on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Nominating and Corporate Governance Committee</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has a nominating and corporate governance
committee consisting of James Intrater, Paul F. Burton and Peter K. Fung, MD with Mr. Intrater serving as chair of the committee. The
Cardio Board has determined that each member of the nominating and corporate governance committee qualifies as an independent director
under the independence requirements of the Sarbanes-Oxley Act, Rule 10A-3 under the Exchange Act and Nasdaq listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The nominating and corporate governance committee&#8217;s
responsibilities include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">review and assess and make recommendations to the board of directors regarding desired qualifications, expertise and characteristics sought of board members;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">identify, evaluate, select or make recommendations to the board of directors regarding nominees for election to the board of directors;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">develop policies and procedures for considering stockholder nominees for election to the board of directors;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">review the Company&#8217;s succession planning process for Company&#8217;s chief executive officer, and assist in evaluating potential successors to the chief executive officer;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">review and make recommendations to the board of directors regarding the composition, organization and governance of the board and its committees;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">review and make recommendations to the board of directors regarding corporate governance guidelines and corporate governance framework;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">oversee director orientation for new directors and continuing education for directors;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">oversee the evaluation of the performance of the board of directors and its committees;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">review and monitor compliance with the Company&#8217;s code of business conduct and ethics; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">administer policies and procedures for communications with the non-management members of the Company&#8217;s Board of Directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The board of directors has adopted a written charter
for the nominating and corporate governance committee that is available on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Guidelines for Selecting Director Nominees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The guidelines for selecting nominees generally
provide that persons to be nominated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">should have demonstrated notable or significant achievements in business, education or public service;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; padding-right: 6.65pt; vertical-align: bottom"><span style="font-size: 10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the Board of Directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The nominating and governance committee will consider
a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating
a person&#8217;s candidacy for membership on the Board of Directors. The nominating and governance committee may require certain skills
or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider
the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating and governance committee
does not distinguish among nominees recommended by stockholders and other persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company has adopted a written code of business
conduct and ethics that applies to its principal executive officer, principal financial or accounting officer or person serving similar
functions and all of our other employees and members of our board of directors. The code of ethics codifies the business and ethical principles
that govern all aspects of our business. Cardio intends to make any legally required disclosures regarding amendments to, or waivers of,
provisions of our code of ethics on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Conflicts of Interest</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Potential investors should be aware of the following
potential conflicts of interests:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom; padding-top: 0.05pt; padding-right: 12.4pt; text-align: left"><span style="font-size: 10pt">None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom; padding-top: 0.05pt; padding-right: 15.7pt; text-align: left"><span style="font-size: 10pt">In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our Management has pre-existing fiduciary duties and contractual obligations to such entities (as well as to us) and may have conflicts of interest in determining to which entity a particular business opportunity should be presented.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">Our officers and directors may in the future become affiliated with entities engaged in business activities similar to those intended to be conducted by our company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The conflicts described above may not be resolved
in our favor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">All ongoing and future transactions between us
and any of our management team or their respective affiliates, will be on terms believed by us to be no less favorable to us than are
available from unaffiliated third parties. Such transactions will require prior approval by a majority of our uninterested "independent&#8221;
directors or the members of our board of directors who do not have an interest in the transaction, in either case who had access, at our
expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our disinterested "independent&#8221;
directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect
to such a transaction from unaffiliated third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Limitation on Liability and Indemnification of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company intends to enter into indemnification
agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained
in the DGCL. These indemnification agreements, which have been authorized for execution by the Cardio board of directors, requires the
Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status
or service. These indemnification agreements also require the Company to advance all expenses reasonably and actually incurred by its
directors and executive officers in investigating or defending any such action, suit or proceeding. Our By-laws provide that Cardio must
indemnify and advance expenses to Cardio&#8217;s directors and officers to the fullest extent authorized by the DGCL. We believe that
these agreements and By-laws provisions are necessary to attract and retain qualified individuals to serve as directors and executive
officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio maintains insurance policies under which
its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in
connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which
they are parties by reason of being or having been its directors or officers. The coverage provided by these policies may apply whether
or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL. At present,
we are not aware of any pending litigation or proceeding involving any person who will be one of the Company&#8217;s directors or officers
or is or was one of its directors or officers, or is or was one of its directors or officers serving at its request as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought,
and we are not aware of any threatened litigation that may result in claims for indemnification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The DGCL authorizes corporations to limit or eliminate
the personal liability of directors of corporations and their stockholders for monetary damages for breaches of directors&#8217; fiduciary
duties, subject to certain exceptions. Our Second Amended and Restated Certificate of Incorporation includes a provision that eliminates
the personal liability of directors for damages for any breach of fiduciary duty as a director where, in civil proceedings, the person
acted in good faith and in a manner that person reasonably believed to be in or not opposed to the best interests of our Company or, in
criminal proceedings, where the person had no reasonable cause to believe that his or her conduct was unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The limitation of liability, advancement and indemnification
provisions in our Second Amended and Restated Certificate of Incorporation and our By-laws may discourage stockholders from bringing lawsuit
against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative
litigation against directors and officers, even though such an action, if successful, might otherwise benefit Cardio and our stockholders.
In addition, your investment may be adversely affected to the extent Cardio pays the costs of settlement and damage awards against directors
and officer pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There is currently no pending material litigation
or proceeding involving any of Cardio&#8217;s directors, officers, or employees for which indemnification is sought.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities Trading</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company has adopted a Securities Trading Policy
that governs the purchase, sale, and/or other dispositions of the Company's securities by our directors, officers and employees that are
reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing standards applicable to the
Company. A copy of our policy against insider trading is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the fiscal year ended
December 31, 2024. Our policy against insider trading prohibits directors, officers, employees and other covered persons from engaging
in transactions while aware of material nonpublic information about the Company. Directors, officers and certain other employees are subject
to pre-clearance requirements for all transactions in the Company&#8217;s securities and are generally prohibited from transacting in
the Company&#8217;s securities during designated blackout periods. Our policy against insider trading prohibits employees, officers and
directors from engaging in any speculative or hedging transactions in our securities. We prohibit transactions such as puts, calls, swaps,
forward sale contracts, and other derivatives or similar arrangements or instruments designed to hedge or offset decreases in the market
value of our securities. No employee, officer or director may engage in short sales of our securities, hold our securities in a margin
account, purchase shares of our stock on margin or pledge our securities as collateral for a loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="ExecutiveCompensation"></span><b>EXECUTIVE AND DIRECTOR COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">This section discusses the material components
of the executive compensation program for our executive officers who are named in the &#8220;2024 Summary Compensation Table&#8221; below.
For <span style="letter-spacing: -0.25pt">the </span>year ended December 31, 2024, our &#8220;named executive officers&#8221; (&#8220;NEOs&#8221;)
and their positions were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">Meeshanthini V. Dogan, Chief Executive Officer;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">Warren Hosseinion, Non-executive Chairman of the Board*; <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">Elisa Luqman, Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Timur Dogan, Chief Technology Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">*Dr. Hosseinion provides ongoing services to our
company as Chairman of the Board and as a consultant. As such, he is not an executive officer and would not be included in the executive
compensation tables or accompanying narrative as an NEO under SEC disclosure rules. However, because his contractual compensation is significant
and would be payable to him, even if he were no longer our Chairman, we are treating him as an NEO in the interest of full disclosure
of the compensation payable to the highest paid persons who work for our company. Dr. Hosseinion is not considered a Named Executive Officer
for any purpose other than the following disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2024 Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following table sets forth information concerning
the compensation of our named executive officers for fiscal years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Current Officers Name &amp; Principal Position</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Salary ($)</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Bonus</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Option Awards (2)</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>All Other Compensation ($)</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; letter-spacing: -0.25pt"><b>($)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%"><span style="font-size: 10pt"><b>Meeshanthini V. Dogan,</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 5%; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">1,004,656</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">11,000</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">1,315,656</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">CEO</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">341,640</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,253</span></td>
    <td><span style="font-size: 10pt">(1)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">648,893</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt"><b>Warren Hosseinion,</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75,349</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">375,349</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Chairman</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">155,291</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">455,291</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt"><b>Elisa Luqman,</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">275,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75,349</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">350,349</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">CFO</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">275,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">72,469</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">347,469</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt"><b>Timur Dogan,</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">502,328</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9,167</span></td>
    <td><span style="font-size: 10pt">(1)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">761,495</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">CTO</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">250,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">196,702</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">446,702</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10px">&#160;</td>
    <td style="width: 27px"><span style="font-size: 7pt">(1)</span></td>
    <td><span style="font-size: 10pt">All Other Compensation includes Cardio&#8217;s contribution to the Company&#8217;s 401(k) account on behalf of the executive and health and dental insurance coverage.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10px">&#160;</td>
    <td style="width: 27px; text-align: justify"><span style="font-size: 7pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Discretionary stock option grants made in 2024 and 2023 by the Compensation Committee. The 2024 amounts reflect the grant date fair values of performance awards based upon the Nasdaq adjusted closing stock price of $63.30 on the date of grant. The 2023 amounts reflect the grant date fair values of performance awards based upon the Nasdaq adjusted closing stock price of $37.80 on the date of grant. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative to the Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>2024 Base Salary</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The named executive officers receive a base salary
to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide
a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. In 2024, the base
salaries paid to each of Dr. Dogan, Dr. Hosseinion, Ms. Luqman and Mr. Dogan are set forth in the &#8220;Summary Compensation Table&#8221;
above in the column titled &#8220;Salary.&#8221; Each of the NEOs has entered into an employment agreement (or, in the case of Dr. Hosseinion,
a Non- Executive Chairman and Consulting Agreement), which became effective as of the Closing of the Business Combination. A brief summary
of those agreements is set forth below under the caption, &#8220;Agreements with Our Executive Officers and Non-Executive Chairman of
the Board.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Annual Bonuses&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We do not currently maintain an annual bonus program
for our employees, including our named executive officers. However, the employment agreements and, in the case of Dr. Hosseinion, his
Non-Executive Chairman and Consulting Agreement, provide that our named executive officers are eligible to receive an annual cash bonus
based on the extent to which, in the discretion of the Board, each such person achieves or exceeds specific and measurable individual
and Company performance objectives. The Board did not award any annual bonuses in 2023 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>Equity Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Cardio Diagnostics Holdings, Inc. 2022 Equity
Incentive Plan (the &#8220;2022 Equity Plan&#8221;), was adopted by the Mana Board of Directors and approved by the Mana stockholders
in connection with the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The 2022 Equity Plan, as originally adopted, provided
for the grant of up to 108,850 shares of Common Stock upon exercise of granted options, awards of restricted stock units, rewards of restricted
stock and other equity awards as may be determined by the Board of Directors. In the discretion of the Board, the number of shares of
Common Stock available under the 2022 Plan may be increased as of January 1 of each year, without additional stockholder approval. The
Board did not increase the aggregate number of shares available under the 2022 Equity Plan on January 1, 2023 but the 2022 Equity Plan
was increased by 35,349 shares as of January 1, 2024 and granted&#160;39,594&#160;options to management and employees,&#160;38,894&#160;of
which vested immediately with the remaining 700 options subject to 50% vesting on June 30, 2024 and 100% vesting on December 31, 2024.
Each option has an exercise price of $63.30 per share with an expiration date of January 23, 2034. Among the 700 options, 250 options
were vested on June 30, 2024, 167 options were vested on December 31, 2024 and 283 options were forfeited before vesting with the leaving
of the employees before December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">On June 30, 2024, we granted 1,012 stock options
to the board of directors, which vested <span style="background-color: white">immediately on grant date. </span>Each option has an exercise
price of&#160;$16.50&#160;per share with an expiration date of&#160;June 30, 2034. On September 30, 2024, we granted 2,492 stock options
to the board of directors, which vested <span style="background-color: white">immediately on grant date. </span>Each option has an exercise
price of&#160;$6.60&#160;per share with an expiration date of&#160;September 30, 2034. On November 14, 2024, we granted 524 stock options
to the board of directors, which vested <span style="background-color: white">immediately on grant date. </span>Each option has an exercise
price of&#160;$8.10&#160;per share with an expiration date of&#160;November 14, 2034. On December 31, 2024, we granted 454 stock options
to the board of directors, which vested immediately on grant date. Each option has an exercise price of&#160;$27.60&#160;per share with
an expiration date of&#160;December 31, 2034. In the future, we may grant cash and equity incentive awards to directors, employees (including
our named executive officers) and consultants in order to continue to attract, motivate and retain the talent for which we compete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A total of 96,088 shares were available for issuance
under the 2022 Equity Plan at June 30, 2025. At June 30, 2025, there were 128,860 options outstanding for the purchase of Common Stock,
all of which were vested and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Award Grant Practices</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our equity-based incentive awards are designed
to align our interests and the interests of our stockholders with those of our employees and consultants, including our Named Executive
Officers. The Board or Compensation Committee is responsible for approving equity grants. We grant equity awards to employees annually
upon achieving Company and personal milestones. Annual awards are typically granted in the first quarter of each year. Generally, our
equity awards granted to our Named Executive Officers vest immediately.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Board and Compensation Committee do not take
material nonpublic information into account when determining the timing and terms of equity-based awards, and the Company does not time
the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. For all stock option
awards, the exercise price is the closing price of our Common Stock on the Nasdaq Capital Market on the date of the grant. If the grant
date falls on a&#160;non-trading&#160;day, the exercise price is the closing price of our Common Stock on the Nasdaq Capital Market on
the last trading day preceding the date of grant. We have not timed the disclosure of material nonpublic information for the purpose of
affecting the value of executive compensation for any Named Executive Officer grants in fiscal year 2024.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation Recovery (&#8220;Clawback&#8221;) Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Effective October 2, 2023, we adopted a compensation
recovery policy (the &#8220;Clawback Policy&#8221;), which provides that if we are required to prepare an accounting restatement due to
any material non-compliance with financial reporting requirements under the federal securities laws, then the Board or a duly established
committee thereof may require certain officers, including our executive officers named in the Summary Compensation Table presented later
in this proxy statement (our &#8220;NEOs&#8221;), to repay or forfeit any &#8220;excess compensation&#8221; in the event it finds, in
its sole discretion, that the executive officer contributed to the circumstances requiring the restatement and that it involved either
(a)&#160;intentional misconduct or an intentional violation of any of the Company&#8217;s rules or applicable legal or regulatory requirements
or (b)&#160;fraud. &#8220;Excess compensation&#8221; refers to the pre-tax amount in excess of what would have been paid to the executive
officer under the accounting restatement of any incentive-based compensation that is granted, earned or vested based on the attainment
of a performance measure during the three-year period preceding the date on which we are required to prepare such accounting restatement.
The Clawback Policy applies to incentive-based compensation granted after the adoption of this policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Elements of Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Retirement <span style="letter-spacing: -0.2pt">Plan</span>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We maintain a 401(k) retirement savings plan for
our employees, including our named executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code allows
eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the
401(k) plan. We believe that providing a vehicle for tax- deferred retirement savings though our 401(k) plan adds to the overall desirability
of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with
our compensation policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Employee Benefits and Perquisites</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Health/Welfare Plans. All of our full-time employees,
including our named executive officers, are eligible to participate in our health and welfare plans, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43px">&#160;</td>
    <td style="width: 17px; padding-top: 0.05pt"><span style="font-size: 12pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">medical, dental and vision benefits;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.05pt"><span style="font-size: 12pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">medical and dependent care flexible spending accounts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-top: 0.05pt"><span style="font-size: 12pt">&#8226;</span></td>
    <td style="text-align: left; padding-top: 0.05pt; vertical-align: bottom"><span style="font-size: 10pt">life insurance and accidental death and dismemberment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We believe the benefits described above are necessary
and appropriate to provide a competitive compensation package to our employees, including our named executive officers. We do not provide
any perquisites to our named executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>No Tax Gross-<span style="letter-spacing: -0.25pt">Ups</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i><span style="letter-spacing: -0.25pt">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We do not make gross-up payments to cover our named
executive officers&#8217; personal income taxes that may pertain to any of the compensation or benefits paid or provided by our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End
Table&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the number of shares of common stock
underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2024. We have made no stock awards
under the 2022 Plan and accordingly, that portion of the table has been omitted. The numbers in the table have been adjusted to reflect
the 1-for-30 reverse stock split that was effected on May 12, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="17" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Option Awards</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid">
    <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>
    <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>
    <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>
    <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Number of Securities Underlying Unexercised Options (#)(1)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Option Exercise Price ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Option Expiration Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercisable</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Unexercisable</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 39%"><span style="font-size: 10pt">Meeshanthini V. Dogan</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">15,875</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">63.30</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">1/23/2034</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9,075</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">37.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6/23/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">22,848</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">117.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5/6/2032</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Warren Hosseinion</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,191</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">63.30</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1/23/2034</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,125</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">37.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6/23/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">11,424</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">117.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5/6/2032</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Elisa Luqman</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,191</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">63.30</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1/23/2034</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,925</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">37.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6/23/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5,712</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">117.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5/6/2032</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Timur Dogan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,938</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">63.30</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1/23/2034</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5,225</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">37.80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">6/23/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,353</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">117.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5/6/203</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreements with Our Executive Officers and
Non-Executive Chairman of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In connection with preparations for the Business
Combination, Cardio executed employment and consulting agreements as of May 27, 2022 with each person expected to be named an executive
officer or chairman of the combined entity. The agreements became effective upon Closing of the Business Combination. The principal terms
of each of agreements is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Employment Agreement between Cardio and Meeshanthini
V. Dogan (Chief Executive Officer)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Dr. Dogan&#8217;s five-year employment agreement
provides for (i) an annual base salary of $300,000, (ii) eligibility to receive an annual cash bonus based on the extent to which, in
the discretion of the Board, Dr. Dogan achieves or exceeds specific and measurable individual and Company performance objectives, and
(iii) eligibility to participate in any long-term incentive plan that is made available to similarly positioned executives, employee benefit
or group insurance plans maintained from time to time by Cardio. Long-term incentive plan awards may include cash, or equity awards settled
in shares of Company stock, including but not limited to stock options, restricted stock and performance shares. If Dr. Dogan were to
leave the Company as a "Good Leaver,&#8221; as defined in the employment agreement, terms of any long-term incentive award will be
deemed satisfied immediately prior to such termination and as such, all awards and grants will be deemed fully vested. In addition, Dr.
Dogan will be reimbursed for her reasonable and usual business expenses incurred on behalf of the Company. Severance benefits will be
payable in the event Dr. Dogan&#8217;s termination is either by the Company without cause or by her with "good reason,&#8221; as
defined in the agreement. In such event and in addition to accrued salary benefits as of the date of termination, the Company will pay
Dr. Dogan an amount equal to a (x) two times the sum of her most recent base salary and target annual bonus and (y) an amount in cash
equal to the Company&#8217;s premium amounts paid for her coverage under group medical, dental and vision programs for a period of 24
months. The agreement also contains customary confidentiality, non- solicitation, non-competition and cooperation provisions. The employment
agreement will automatically renew for an additional year following the initial term and any renewal term, unless either party provides
60-days&#8217; written notice before the end of the then-current term. The Company may terminate Dr. Dogan&#8217;s employment without
cause (as defined in the agreement) by providing 60 days&#8217; advance written notice. Dr. Dogan may terminate her employment for any
reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Non-Executive Chairman and Consulting Agreement
between Cardio and Warren Hosseinion</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has retained Dr. Hosseinion under a five-year
consulting agreement to serve as Non-Executive Chairman of the Board following the Merger and to provide other services as requested.
Upon expiration of such provision, the agreement may be renewed for an additional one-year term. In addition to his duties as Chairman,
the agreement provides that Dr. Hosseinion will provide consulting services assisting management in developing business strategy and business
plans, identifying business opportunities and identifying strategic relationships and strategies to further develop the Company&#8217;s
brand. In the event he is not reelected as Chairman of the Board, the terms of this agreement will continue strictly as a consulting services
agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Conversely, if his consulting services are terminated,
such termination will not affect his Chairman Services, provided that he remains eligible to serve as Chairman. For his Chairman services
and consulting services, the agreement provides for a fee of $300,000 per year payable in monthly installments of $25,000. In addition,
Dr. Hosseinion is entitled to be awarded any equity compensation otherwise payable to Board members in connection with their service on
the Board and to be reimbursed for all reasonable and necessary business expenses incurred in the performance of his consulting services
and Chairman services. If Dr. Hosseinion&#8217;s services are terminated by the Company other than for Cause (as defined in the agreement),
including any discharge without Cause, liquidation or dissolution of the Company, or a termination caused by death or Disability (as defined
in the agreement), the Company will pay Dr. Hosseinion (or his estate) the consulting fees equal to two times his annual consulting compensation,
payable within 60 days, in one lump sum, plus any expenses owing for periods prior to and including the date of termination of the consulting
services. The agreement also contains customary confidentiality, non-solicitation, non-disparagement and cooperation provisions. Either
party may terminate the agreement without cause after giving prior written notice to the other party. The agreement may be terminated
by the Company at any time for cause, as defined in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Employment Agreement between Cardio and Elisa
Luqman (Chief Financial Officer)&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Ms. Luqman&#8217;s five-year employment agreement
provides for (i) an annual base salary of $275,000, (ii) eligibility to receive an annual cash bonus based on the extent to which, in
the discretion of the Board, Ms. Luqman achieves or exceeds specific and measurable individual and Company performance objectives, and
(iii) eligibility to participate in any long-term incentive plan that is made available to similarly positioned executives, employee benefit
or group insurance plans maintained from time to time by Cardio. Long-term incentive plan awards may include cash, or equity awards settled
in shares of Company stock, including but not limited to stock options, restricted stock and performance shares. If Ms. Luqman were to
leave the Company as a "Good Leaver,&#8221; as defined in the employment agreement, terms of any long-term incentive award will be
deemed satisfied immediately prior to such termination and as such, all awards and grants will be deemed fully vested. In addition, Ms.
Luqman will be reimbursed for her reasonable and usual business expenses incurred on behalf of the Company. Severance benefits will be
payable in the event Ms. Luqman&#8217;s termination is either by the Company without cause or by her with "good reason,&#8221; as
defined in the agreement. In such event and in addition to accrued salary benefits as of the date of termination, the Company will pay
Ms. Luqman an amount equal to a (x) the sum of her most recent base salary and target annual bonus and (y) an amount in cash equal to
the Company&#8217;s premium amounts paid for her coverage under group medical, dental and vision programs for a period of 12 months, provided
that she has elected continued coverage under COBRA. The agreement also contains customary confidentiality, non-solicitation, non-competition
and cooperation provisions. The employment agreement will automatically renew for an additional year following the initial term and any
renewal term, unless either party provides 60-days&#8217; written notice before the end of the then-current term. The Company may terminate
Ms. Luqman&#8217;s employment without cause (as defined in the agreement) by providing 60 days&#8217; advance written notice. Ms. Luqman
may terminate her employment for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Employment Agreement between Cardio and Timur
Dogan (Chief Technical Officer)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Dr. Dogan&#8217;s five-year employment agreement
provides for (i) an annual base salary of $250,000, (ii) eligibility to receive an annual cash bonus based on the extent to which, in
the discretion of the Board, Dr. Dogan achieves or exceeds specific and measurable individual and Company performance objectives, and
(iii) eligibility to participate in any long-term incentive plan that is made available to similarly positioned executives, employee benefit
or group insurance plans maintained from time to time by Cardio. Long-term incentive plan awards may include cash, or equity awards settled
in shares of Company stock, including but not limited to stock options, restricted stock and performance shares. If Dr. Dogan were to
leave the Company as a &#8220;Good Leaver,&#8221; as defined in the employment agreement, terms of any long-term incentive award will
be deemed satisfied immediately prior to such termination and as such, all awards and grants will be deemed fully vested. In addition,
Dr. Dogan will be reimbursed for his reasonable and usual business expenses incurred on behalf of the Company. Severance benefits will
be payable in the event Dr. Dogan&#8217;s termination is either by the Company without cause or by him with &#8220;good reason,&#8221;
as defined in the agreement. In such event and in addition to accrued salary benefits as of the date of termination, the Company will
pay Dr. Dogan an amount equal to a (x) the sum of his most recent base salary and target annual bonus and (y) an amount in cash equal
to the Company&#8217;s premium amounts paid for his coverage under group medical, dental and vision programs for a period of 12 months,
provided that he has elected continued coverage under COBRA. The agreement also contains customary confidentiality, non-solicitation,
non-competition and cooperation provisions. The employment agreement will automatically renew for an additional year following the initial
term and any renewal term, unless either party provides 60-days&#8217; written notice before the end of the then-current term. The Company
may terminate Dr. Dogan&#8217;s employment without cause (as defined in the agreement) by providing 60 days&#8217; advance written notice.
Dr. Dogan may terminate his employment for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following individuals served as non-employee
directors of the Company for all or part of 2024 (other than Dr. Hosseinion, who, as discussed above, is being treated as an NEO for purposes
of the compensation disclosure in this Prospectus): Paul F. Burton, James Intrater, Stanley K. Lau, Oded Levy, Wendy J. Betts and Peter
K. Fung, MD. The following table sets forth information concerning the compensation for our non-employee directors for services rendered
during the year ended December 31, 2024. Additionally, we reimburse our non-employee directors for reasonable travel and other out-of-pocket
expenses incurred in connection with attending board of director and committee meetings or undertaking other business on behalf of Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold">Name</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Fees Earned or Paid in Cash ($)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Paul F. Burton</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right">25,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right">25,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right">50,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">James Intrater</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">25,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">25,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">50,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Wendy J. Betts (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,167</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,083</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,250</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Peter K. Fung, MD (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,167</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,083</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,250</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stanley K. Lau (2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,833</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,917</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">43,750</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Oded Levy (2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,833</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,917</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">43,750</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 47px; padding-bottom: 6pt; text-align: right"><span style="font-size: 7pt">(1)</span></td>
    <td style="width: 7px">&#160;</td>
    <td style="padding-bottom: 6pt; text-align: justify"><span style="font-size: 10pt">Wendy J. Betts and Peter K. Fung, MD were elected to the Board at the November 15, 2024 Annual Meeting of Stockholders.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 6pt; text-align: right; line-height: 102%"><span style="font-size: 7pt; line-height: 102%">(2)</span></td>
    <td>&#160;</td>
    <td style="padding-bottom: 6pt; text-align: justify; line-height: 102%"><span style="font-size: 10pt; line-height: 102%">Stanley K. Lau and Oded Levy did not stand for re-election at the 2024 Annual Meeting but did receive shares of Common Stock upon vesting and settlement of previously awarded RSUs on December 31, 2023 and January 22, 2024, and Stock Options awarded through November 14, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Narrative Disclosure to Non-Employee Director
Compensation Table</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">During 2024, Cardio compensated its non-employee,
independent directors for service as a director with a combination of Restricted Stock Units (&#8220;RSUs&#8221;) in the amount of $12,500,
Option Agreements in the amount of $12,500 and Cash payments in the amount of $25,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The RSUs were awarded on January 23, 2024 for $12,500
to compensate for one quarter of service. The RSUs were vested and settled on March 31, 2024 based on the closing price of our Common
Stock on March 31, 2024. Thereafter, on June 30, 2024, September 30, 2024, and December 31, 2024, each independent director received $8,333
in cash payments and $4,167 in Stock Options awards. The number of shares of Common Stock into which the Options may be exercised were
based on the closing price of our Common Stock on June 30, 2024, September 30, 2024 and December 31, 2024, respectively. Directors who
transitioned on or off the Board were compensated on a pro-rata basis for days of service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Non-employee directors are also eligible to be
granted options under the Company&#8217;s 2022 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Company reimburses its non-employee directors
for reasonable travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings or undertaking
other business on behalf of our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">As discussed below under &#8220;Certain Relationships
and Related Party Transactions," we have entered into indemnification agreements with, and obtained directors liability protection
for, covering our directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>Compensation of Other Members of the Board
of Directors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In fiscal 2024, Dr. Dogan, our co-founder and Chief
Executive Officer, and Dr. Hosseinion, our Non-Executive Chairman of the Board, were compensated as an employee and a consultant, respectively,
and did not receive any additional compensation for service on our Board. Their total 2024 compensation in all capacities is reflected
in the Summary Compensation Table. As noted in connection with the Summary Compensation Table above, Dr. Hosseinion&#8217;s compensation
is disclosed as though he is a Named Executive Officer in order to provide complete transparency as to the compensation he is paid by
us as Non-Executive Chairman and a consultant to our company. Robert Philibert, our co-founder, Chief Medical Officer and a director,
is not compensated for his service as a member of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Related Party Transactions Policy&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The audit committee of the board of directors had
adopted a policy setting forth the policies and procedures for its review and approval or ratification of &#8220;related party transactions.&#8221;
The policy provides that a &#8220;related party transaction&#8221; is defined in the policy as any consummated or proposed transaction
or series of transactions: (i)&#160;in which the Company was or is to be a participant; (ii)&#160;the amount of which exceeds (or is reasonably
expected to exceed) the lesser of $120,000 or 1% of the average of the Company&#8217;s total assets at year-end&#160;for&#160;the prior
two completed fiscal years in the aggregate over the duration of the transaction (without regard to profit or loss); and (iii)&#160;in
which a &#8220;related party&#8221; had, has or will have a direct or indirect material interest. &#8220;Related parties&#8221; under
this policy included: (i)&#160;Cardio&#8217;s directors,&#160;<span style="background-color: white">nominees</span>&#160;for director
or executive officers; (ii)&#160;any record or beneficial owner of more than 5% of any class of Cardio&#8217;s voting securities; (iii)&#160;any
immediate family member of any of the foregoing if the foregoing person is a natural person; and (iv)&#160;any other person who maybe
a &#8220;related person&#8221; pursuant to Item 404 of Regulation S-K under the Exchange Act. Pursuant to the policy, the audit committee
would consider (i)&#160;the relevant facts and circumstances of each related party transaction, including if the transaction is on terms
comparable to those that could be obtained&#160;in&#160;arm&#8217;s-length&#160;dealings&#160;with an unrelated third party, (ii)&#160;the
extent of the related party&#8217;s interest in the transaction, (iii)&#160;whether the transaction contravenes our code of ethics or
other policies, (iv)&#160;whether the audit committee believes the relationship underlying the transaction to be in the best interests
of Cardio and its stockholders and (v)&#160;the effect that the transaction may have on a director&#8217;s status as an independent member
of Cardio&#8217;s board and on his or her eligibility to serve on Cardio&#8217;s board&#8217;s committees. The policy requires that the
Company&#8217;s management present to the audit committee each proposed related party transaction, including all relevant facts and circumstances
relating thereto. Under the policy, the Company is permitted to consummate related party transactions only if the audit committee approves
or ratifies the transaction in accordance with the guidelines set forth in the policy. The policy does not permit any director or executive
officer to participate in the discussion of, or decision concerning, a related person transaction in which he or she is the related party.&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="CertainRelationships"></span><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There have been no transactions since January 1,
2024 to which we have been a party in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of
our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our
knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons
had or will have a direct or indirect material interest, other than transactions that are described under the section &#8220;Executive
and Director Compensation.&#8221;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Cardio has an exclusive, worldwide patent license
of the Core Technology from the University of Iowa Research Foundation (UIRF). Under UIRF&#8217;s Inventions Policy inventors are generally
entitled to 25% of income from earnings from their inventions. Consequently, Meeshanthini Dogan and Robert Philibert could benefit from
this policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Timur Dogan, the Company&#8217;s Chief Technology
Officer is the spouse of Meeshanthini (Meesha) Dogan, the Company&#8217;s Co-Founder, Chief Executive Officer and Director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">At the Closing of the Business Combination, Dr.
M. Dogan, Dr. Philibert, Ms. Luqman, and Dr. T. Dogan each entered into an Invention and Non-Disclosure Agreement. An integral part of
the Invention and Non-Disclosure Agreement is the disclosure by the employee of any discoveries, ideas, inventions, improvements, enhancements,
processes, methods, techniques, developments, software and works of authorship (&#8220;developments&#8221;) that were created, made, conceived
or reduced to practice by the employee prior to his or her employment by Cardio and that are not assigned to the Company. Dr. Philibert&#8217;s
agreement lists certain developments that are epigenetic methods unrelated to the current mission of Cardio and that were developed separate
and apart from Cardio. There is no assurance that as the Company broadens the scope of its products and services that one or more of Dr.
Philibert&#8217;s developments could be relevant. Under the agreement, all rights to the developments listed by Dr. Philibert are his
sole property and their use, if desired by the Company, would be in the sole discretion of Dr. Philibert, who is under no obligation to
license or otherwise grant permission to the Company to use them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Certificate of Incorporation, as amended, restated
and currently in effect, and our Bylaws provide for indemnification and advancement of expenses for our directors and officers to the
fullest extent permitted by Delaware law, subject to certain limited exceptions. We have entered into indemnification agreements with
each member of our Board and several of our officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Warren Hosseinion M.D., who serves as the Non-Executive
Chairman of the Board of the Company, is also a minority 10% owner of Altitude Capital Group LLC (&#8220;Altitude&#8221;), a separate
entity that has previously been engaged as the Placement Agent for a 2024 private placement. This ownership interest creates a potential
conflict of interest because Dr. Hosseinion may have a financial interest in the success of Altitude, which could affect his decision-making
with respect to retaining the services of Altitude for future transactions. However, the Company has established policies and procedures
designed to address and mitigate any potential conflicts of interest that may arise in connection with Dr. Hosseinion&#8217;s dual roles.
All material agreements and arrangements between the Company and Altitude have be reviewed and approved by the Company's independent Board
of Directors. Dr. Hosseinion did not receive any compensation in relation to the 2024 private placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="PrincipalStockholders"></span><b>PRINCIPAL STOCKHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following table sets forth information regarding
the beneficial ownership of the Company&#8217;s Common Stock as of September 12, 2025 by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="width: 96%"><span style="font-size: 10pt">each person known to the Company to be the beneficial owner of more than 5% of the Company&#8217;s Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">each person who is &#8220;named executive officer&#8221; or director of the Company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td><span style="font-size: 10pt">all of the Company&#8217;s executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Beneficial ownership is determined in accordance
with SEC rules and includes voting or investment power with respect to securities. Except as indicated by the footnotes below that the
persons named in the table below have, sole voting and investment power with respect to all stock that they beneficially own, subject
to applicable community property laws. All Company stock subject to options or warrants exercisable within 60&#160;days of the date of
the table are deemed to be outstanding and beneficially owned by the persons holding those options or warrants for the purpose of computing
the number of shares beneficially owned and the percentage ownership of that person. They are not, however, deemed to be outstanding and
beneficially owned for the purpose of computing the percentage ownership of any other person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Subject to the paragraph above, percentage
ownership of outstanding shares is based on 1,763,129 shares of the Company&#8217;s Common Stock outstanding on September 12,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: justify">Name and Address of Beneficial Owner(1)</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Amount and<br/> Nature of<br/> Beneficial<br/> Ownership</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Approximate<br/> Percentage of<br/> Outstanding<br/> Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-style: italic; text-align: left">Directors, Executive Officers and Greater than 5% Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left">Meeshanthini V. Dogan(2)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 14%; font-size: 10pt; text-align: right">121,773</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 14%; font-size: 10pt; text-align: right">6.7</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Timur Dogan(3)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">121,773</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6.7</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Robert Philibert(4)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">82,979</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4.6</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Warren Hosseinion(5)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,609</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1.2</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Wendy J. Betts(6)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,443</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Paul F. Burton(7)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,688</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Peter K. Fung(6)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,443</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">James Intrater(7)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,781</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Elisa Luqman(8)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">10,759</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">All Executive Officers and Directors as a Group (9 individuals)(9)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">250,475</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13.3</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>_________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>*&#160;</b>Less than 1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 2%; vertical-align: top">(<span style="font-size: 10pt">1)</span></td>
    <td style="width: 98%"><span style="font-size: 10pt">Unless otherwise noted, the address for the persons in the table is 311 West Superior Street, Suite 444, Chicago IL 60654.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">Meeshanthini Dogan, the Company&#8217;s Chief Executive Officer and Director, and Timur Dogan, the Company&#8217;s Chief Technology Officer, are married. The beneficial ownership of Meeshanthini Dogan reflected in the table includes the shares and options of Timur Dogan as required by Rule 13d-3(d)(1)(i) of the Exchange Act. Meeshanthini Dogan&#8217;s direct ownership is 52,882 shares of Common Stock and 47,798 shares issuable upon exercise of currently exercisable options, plus an additional 2,299 shares jointly owned with her husband. Timur Dogan&#8217;s direct ownership is 4,278 shares of Common Stock and 14,516 shares issuable upon exercise of currently exercisable options, plus the additional 2,299 jointly-owned shares. Dr. Dogan may be deemed to be the indirect beneficial owner of the securities owned by her husband; however, she disclaims beneficial ownership of the shares held indirectly, except to the extent of her pecuniary interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">Timur Dogan, the Company&#8217;s Chief Technology Officer, and Meeshanthini Dogan, the Company&#8217;s Chief Executive Officer and Director, are married. The beneficial ownership of Timur Dogan reflected in the table includes the shares and options of Meeshanthini Dogan as required by Rule 13d-3(d)(1)(i) of the Exchange Act. Timur Dogan&#8217;s direct ownership is 4,278 shares of Common Stock and 14,516 shares issuable upon exercise of currently exercisable options plus an additional 2,299 shares jointly owned with his wife. Meeshanthini Dogan&#8217;s direct ownership is 52,882 shares of Common Stock and 47,798 shares issuable upon exercise of currently exercisable options, plus the additional 2,299 jointly-owned shares. Dr. Dogan may be deemed to be the indirect beneficial owner of the securities owned by his wife; however, he disclaims beneficial ownership of the shares held indirectly, except to the extent of his pecuniary interest.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(4)</span></td>
    <td><span style="font-size: 10pt">Dr. Philibert directly owns 2,523 shares of Common Stock. His total also includes (i) 52,882 shares of Common Stock held of record by BD Holdings, Inc.; (ii) 471 shares of Common Stock held of record by Behavioral Diagnostics, LLC; (iii) 254 shares of Common Stock held of record by Ingrid Philibert, Dr. Philibert&#8217;s wife; and (iv) 26,849 shares issuable upon exercise of currently exercisable options. BD Holdings, Inc. is a corporation owned and controlled by Dr. Philibert, and Behavioral Diagnostics, LLC is a limited liability company also owned and controlled by Dr. Philibert. The address of both entities is 2500 Crosspark Road, Suite W245, Coralville, IA 52241. Dr. Philibert disclaims beneficial ownership of all such indirectly-owned shares except to the extent of his pecuniary interest. Also includes 26,849 shares of Common Stock issuable upon exercise of options that are currently exercisable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(5)</span></td>
    <td><span style="font-size: 10pt">Includes 16,740 shares of Common Stock issuable upon exercise of options that are currently exercisable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(6)</span></td>
    <td><span style="font-size: 10pt">Includes 2,443 shares of Common Stock issuable upon exercise of options that are currently exercisable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(7)</span></td>
    <td style="padding-left: 12.7pt; text-indent: -12.7pt"><span style="font-size: 10pt">Includes 3,394 shares of Common Stock issuable upon exercise of options that are currently exercisable. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(8)</span></td>
    <td style="padding-left: 12.7pt; text-indent: -12.7pt"><span style="font-size: 10pt">Includes 8,828 shares of Common Stock issuable upon exercise of options that are currently exercisable. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">(9)</span></td>
    <td style="padding-left: 12.95pt; text-indent: -12.95pt"><span style="font-size: 10pt">Includes 126,405 shares of Common Stock issuable upon exercise of options that are currently exercisable. </span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b><span id="SellingStockholders"></span>SELLING <span style="font-size: 10pt">STOCKHOLDERS</span><span style="font-size: 8pt">&#160;</span></b></span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following table details the name of the
Selling Stockholders, the number of shares of our Common Stock beneficially owned by the Selling Stockholders, and the number of shares
of our Common Stock being offered by the Selling Stockholders for sale under this prospectus. The percentage of shares of our Common
Stock beneficially owned by the Selling Stockholders following the offering of securities pursuant to this prospectus, is based on 1,785,601
shares of our Common Stock outstanding as of September 12, 2025, which includes 1,763,129 shares of our Common Stock outstanding as of
September 12, 2025 and assumes the exercise of warrants to purchase 22,472 shares of Common Stock issued to the Selling Stockholders
and the placement agent on February 9, 2024 in connection with the February 2, 2024 private placement of Units.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Selling Stockholders acquired the shares
of Common Stock and warrants in a private placement pursuant to exemptions from registration under Section&#160;4(a)(2) of the Securities
Act and Rule 506 of Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Information with respect to shares of Common
Stock owned beneficially after the offering assumes the sale of all of the shares of Common Stock offered under this prospectus and no
other purchases or sales of our Common Stock. The Selling Stockholders may offer and sell some, all or none of the shares of Common Stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have determined beneficial ownership in accordance
with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the
Selling Stockholders have sole voting and investment power with respect to all shares of Common Stock that they beneficially own, subject
to applicable community property laws. Except as otherwise described below, based on the information provided to us by the Selling Stockholders,
no Selling Stockholder is a broker-dealer or an affiliate of a broker-dealer.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number of Shares of<br/>
Common Stock Owned<br/>
Prior to Offering(1)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Maximum Number <br/>
of Shares of<br/>
Common Stock to<br/>
be Offered Pursuant to<br/>
this </b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number of Shares of<br/>
Common Stock Owned After Offering</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Percent</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;Prospectus(2)</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Percent</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 36%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enebybergs Revisionsbyra <br/>
&#160;&#160;&#160;&#160;&#160;AB(3)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,612</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,746</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,866</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henrik Gumaelius(4)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,806</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,872</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,934</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jedair Holdings Ltd(5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,198</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,746</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,452</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tommy Maartensson(6)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,970</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,236</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,734</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Olive or Twist AB(7)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,922</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,872</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,050</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan Saur(8)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,970</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,236</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,734</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristian Stensjo and<br/>
&#160;&#160;&#160;&#160;&#160;Pernilla Stensjo(9)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,612</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,746</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,866</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altitude Capital Group, <br/>
&#160;&#160;&#160;&#160;&#160;LLC(10)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,745</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,745</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares of Common Stock Owned Prior to the Offering includes, as to each selling stockholder,  both shares of Common Stock owned and any shares of Common Stock issuable upon exercise of warrants, all of which are currently exercisable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise noted below, includes shares of Common Stock sold in the private placement and an equal number of shares of Common Stock issuable upon exercise of warrants issued in the private placement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 3,156 shares issuable upon currently exercisable warrants. Enebybergs Revisionsbyra AB (&#8220;Enebybergs&#8221;) is an entity based in Sweden, the equity owner of which is an accredited investor. Lars Svantemark exercises voting and dispositive control over the securities owned by Enebybergs.</span></td></tr>
  </table>
<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 1,578 shares issuable upon currently exercisable warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 2,355 shares issuable upon currently exercisable warrants. Jediar Holdings Ltd (&#8220;Jediar&#8221;) is an entity based in Cyprus, the equity owners of which are accredited investors. Sofoklis Markidis and Orestis Livadas share investment and dispositive control over the securities owned by Jediar.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 8,185 shares issuable upon currently exercisable warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 1,285 shares issuable upon currently exercisable warrants. Olive or Twist AB (&#8220;Olive or Twist&#8221;) is an entity based in Sweden, the equity owner of which is an accredited investor. Joel Wahlstrom exercises voting and dispositive control over the securities owned by Olive or Twist. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 8,185 shares issuable upon currently exercisable warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 3,157 shares issuable upon currently exercisable warrants. Does not include 646 shares and 321 shares issuable upon exercise of currently exercisable warrants held by Kristian Stensjo separately. If the securities separately owned by Kristian Stensjo are included in the totals, the Shares Owned Before the Offering total 8,579 shares, including 3,478 shares issuable upon exercise of currently exercisable warrants, and the After Offering total is 4,833 shares beneficially owned.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Common Stock Owned Prior to Offering includes 3,745 shares issuable upon currently exercisable warrants. Altitude Capital Group, LLC was the placement agent for the private placement. The shares registered for resale under this prospectus are the shares issuable upon exercise of the placement agent warrants issued to Altitude Capital Group, LLC as partial compensation for services rendered. Michael S. DiMeo exercises voting and dispositive control over the securities owned by Altitude Capital Group, LLC. Warren Hosseinion, the Company&#8217;s Chairman of the Board, has a minority interest in Altitude Capital Group, LLC. Altitude Capital Group, LLC is <span style="color: #212529">registered with the SEC as a broker-dealer member of FINRA and SIPC and an SEC registered investment adviser.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="DescriptionOfSecurities"></span>DESCRIPTION OF SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><i>The following is a description of the capital
stock of Cardio Diagnostics Holdings, Inc. (&#8220;Cardio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;)
and certain provisions of our second amended and restated certificate of incorporation (the &#8220;certificate of incorporation&#8221;),
our bylaws (the &#8220;bylaws&#8221;) and the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), as well as the
terms of the warrants issued in our initial public offering (the &#8220;Public Warrants&#8221;). This description is summarized from,
and qualified in its entirety by reference to, our certificate of incorporation, bylaws, the warrant agreement, dated as of November 22,
2021 (the &#8220;Warrant Agreement&#8221;), by and between the Company and Continental Stock Transfer &amp; Trust Company, and the applicable
provisions of the DGCL. For a complete description, investors should refer to our certificate of incorporation, bylaws, and the warrant
agreement, all of which are filed as exhibits to the registration statement of which this Prospectus is a part.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our certificate of incorporation currently authorizes
the issuance of 300,000,000 shares of Common Stock, par value $0.00001 and 100,000,000 shares of preferred stock, par value $0.00001 per
share. As of September 12, 2025, 1,763,129 shares of Common Stock are outstanding. No shares of preferred stock are currently outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Voting Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Each holder of our Common Stock is entitled to
cast one vote per share. Holders of Common Stock are not entitled to cumulative voting rights. Except as otherwise required by law or
The Nasdaq Stock Market rules (or such other national stock exchange on which are Common Stock may then by listed), matters to be voted
on by stockholders must be approved by the vote of a majority of the votes cast with respect to the matter. Except as otherwise required
by the DGCL, our certificate of incorporation or the voting rights granted to the holders of any preferred stock we may subsequently issue,
the holders of outstanding shares of Common Stock and preferred stock entitled to vote thereon, if any, will vote as one class with respect
to all matters to be voted on by our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Dividend Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Each holder of our Common Stock is entitled to
the payment of dividends and other distributions (based on the number of shares of Common Stock held) as may be declared by our Board
of Directors out of our assets or funds legally available for dividends and other distributions. These rights are subject to the preferential
rights of the holders of our preferred stock, if any, and any contractual limitations on our ability to declare and pay dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Liquidation, Dissolution and Winding Up</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If we are involved in a voluntary or involuntary
liquidation, dissolution or winding up of our affairs or a similar event, each holder of our Common Stock will participate&#160;<i>pro
rata</i>&#160;in all assets remaining after payment of liabilities, subject to prior distribution rights of the holders of our preferred
stock, if any, then outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Other Matters</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Holders of shares of our Common Stock do not have
subscription, redemption or conversion rights. All outstanding shares of our Common Stock are validly issued, fully paid and non<b>-</b>assessable.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Holders of our Common Stock are entitled to one
vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors
by our stockholders shall be determined, in an uncontested election, by a majority of the votes cast by the stockholders entitled to vote
on the election and, in a contested election, by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders
of Common Stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential
dividend rights of any series of preferred stock that we may designate and issue in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our stockholders have no redemption, preemptive
or other subscription rights and there are no sinking fund or redemption provisions applicable to the shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In the event of our liquidation or dissolution,
the holders of Common Stock are entitled to receive an amount of our net assets available for distribution to stockholders after the payment
of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of Common Stock have no
preemptive, subscription, redemption or conversion rights. Our outstanding shares of Common Stock are validly issued, fully paid and nonassessable.
The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders
of shares of any series of preferred stock that we may designate and issue in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Preferred Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">There are no shares of preferred stock outstanding.
Our certificate of incorporation filed with the State of Delaware authorizes the issuance of 100,000,000 shares of preferred stock, $0.00001
par value per share, with such designation, rights and preferences as may be determined from time to time by our board of directors. Accordingly,
our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting
or other rights which could adversely affect the voting power or other rights of the holders of Common Stock. In addition, the preferred
stock could be utilized as a method of discouraging, delaying or preventing a change in control of us. Although we do not currently intend
to issue any shares of preferred stock, we reserve the right to do so in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Public Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Public Warrants are issued under&#160;that
certain warrant agreement dated November 22, 2021, by and between us and Continental Stock Transfer &amp; Trust Company, as warrant agent.
Pursuant to the warrant agreement, 30 Public Warrants entitle the registered holder to purchase one whole share of our Common Stock at
a price of $345.00 per share, subject to adjustment as discussed below. The Public Warrants will expire on October 25, 2027, which is
five years after completion of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We will not be obligated to deliver any shares
of Common Stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such warrant exercise unless a registration
statement under the Securities Act with respect to the shares of Common Stock underlying the warrants is then effective and a Prospectus
relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No Public Warrant
will be exercisable, and we will not be obligated to issue shares of Common Stock upon exercise of a Public Warrant, unless Common Stock
issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence
of the registered holder of the Public Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied
with respect to a Public Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no
value and expire worthless. In no event will we be required to net cash settle any Public Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A registration statement covering, among other
things, the resale of the Public Warrants and the shares of Common Stock issuable upon exercise of the Public Warrants, was originally
filed on December 12, 2022 and declared effective on January 24, 2023. The latest post-effective amendment to that registration statement
was declared effective on September 9, 2025. As specified in the warrant agreement, we are obligated to maintain a current Prospectus
relating to those shares of Common Stock until the warrants expire or are redeemed. During any period when we will have failed to maintain
an effective registration statement, warrantholders may exercise Public Warrants on a &#8220;cashless basis&#8221; in accordance with
Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not
be able to exercise their Public Warrants on a cashless basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We may call the warrants for redemption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; width: 96%; vertical-align: bottom"><span style="font-size: 10pt">in whole and not in part;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">at a price of $0.01 per warrant;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption (the &#8220;30-day&#160;redemption period&#8221;) to each warrantholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">if, and only if, the reported last sale price of Common Stock equals or exceeds $540.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrantholders.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have established the last of the redemption
criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise
price. If the foregoing conditions are satisfied, and we issue a notice of redemption of the Public Warrants, each warrantholder will
be entitled to exercise its Public Warrants prior to the scheduled redemption date. However, the price of Common Stock may fall below
the $540.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
as well as the $345.00 warrant exercise price after the redemption notice is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If and when the Public Warrants become redeemable
by us, we may not exercise our redemption right if the issuance of shares of Common Stock upon exercise of the Public Warrants is not
exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If we call the Public Warrants for redemption,
they may be exercised, for cash or on a &#8220;cashless basis&#8221; in accordance with the warrant agreement, at the option of a holder,
at any time after notice of redemption. The notice of redemption will contain the information necessary to calculate the number of shares
of Common Stock to be received in the event the holder has elected to exercise on a cashless basis. If a record holder has not followed
the procedures specified in the notice of redemption and has not surrendered his, her or its Public Warrant before the redemption date,
then on and after the redemption date the holder will have no further rights except to receive, upon surrender of the Public Warrants,
the cash redemption price specified of $0.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A holder of a Public Warrants may notify us in
writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such Public Warrants,
to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s
actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify) of the shares of Common
Stock outstanding immediately after giving effect to such exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If the number of outstanding shares of Common Stock
is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other similar event,
then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise
of each Public Warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. In addition, if we,
at any time while the Public Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other
assets to the holders of Common Stock on account of such shares of Common Stock (or other shares of our capital stock into which the Public
Warrants are convertible), other than in certain circumstances as described in the warrant agreement, then the warrant exercise price
will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of
any securities or other assets paid on each share of&#160;Common Stock&#160;in respect of such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">If the number of outstanding shares of our Common
Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar
event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number
of shares of Common Stock issuable on exercise of each Public Warrant will be decreased in proportion to such decrease in outstanding
shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Whenever the number of shares of Common Stock purchasable
upon the exercise of the Public Warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the
warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Common
Stock purchasable upon the exercise of the Public Warrants immediately prior to such adjustment, and (y) the denominator of which will
be the number of shares of Common Stock so purchasable immediately thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In case of any reclassification or reorganization
of the outstanding shares of Common Stock (other than those described above or that solely affects the par value of such shares of Common
Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in
which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of
Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety
or substantially as an entirety in connection with which we are dissolved, the holders of the Public Warrants will thereafter have the
right to purchase and receive, upon the basis and upon the terms and conditions specified in the Public Warrants and in lieu of the shares
of our Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and
amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger
or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Public Warrants would have received
if such holder had exercised their Public Warrants immediately prior to such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Public Warrants have been issued in registered
form under the warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and us. Investors should review
a copy of the warrant agreement, which is an exhibit to the registration statement of which this Prospectus is a part, for a complete
description of the terms and conditions applicable to the Public Warrants. The warrant agreement provides that the terms of the Public
Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval
by the holders of at least a majority of the then outstanding Public Warrants to make any change that adversely affects the interests
of the registered holders of Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The Public Warrants may be exercised upon surrender
of the Public Warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the
reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on
a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Public Warrants being exercised.
The warrantholders do not have the rights or privileges of holders of Common Stock and any voting rights until they exercise their Public
Warrants and receive shares of Common Stock. After the issuance of shares of Common Stock&#160;upon exercise of the&#160;Public Warrants,
each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">No fractional shares will be issued upon exercise
of the Public Warrants. If, upon exercise of the Public Warrants, a holder would be entitled to receive a fractional interest in a share,
we will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to the warrantholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Private Warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In addition to our Public Warrants, as of September
12, 2025, we have the following privately-issued warrants:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom; width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500,000 warrants, exercisable for 83,333 shares, sold to our former sponsor, which are exercisable through October 25, 2027 at $345.00 per share, subject to adjustment for stock splits, reverse stock splits and other similar events of recapitalization;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,293,391 warrants, exercisable for 43,113 shares, at $116.86
per share, subject to adjustment for stock splits, reverse stock splits and other similar events of recapitalization, which were sold
in a private placement or issued to the placement agent by Legacy Cardio in 2021 and 2022, having an expiration date five years from the
date of issuance;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">811,236 warrants, exercisable
    for 27,041 shares, at $186.36 per share, subject to adjustment for stock splits, reverse stock splits and other similar events of
    recapitalization, which were sold in a private placement or issued to the placement agent by Legacy Cardio in 2022, having an expiration
    date five years from the date of issuance; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">674,146 warrants, exercisable for 22,472 shares, at $53.40 per share, subject to adjustment for stock splits, reverse stock splits and other similar events of recapitalization, which were sold in a private placement or issued to the placement agent by us in 2024, having an expiration date six years from the date of issuance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have not paid any cash dividends on our shares
of Common Stock to date and do not intend to pay cash dividends prior to the completion of a business combination. The payment of cash
dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition
subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination will, subject to
the laws of the State of Delaware, be within the discretion of our then board of directors. It is the present intention of our board of
directors to retain all earnings, if any, for use in our business operations and, accordingly, our board of directors does not anticipate
declaring any cash dividends in the foreseeable future. In addition, our board of directors is not currently contemplating and does not
anticipate declaring any share dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Listing of Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Common Stock and Public Warrants are listed
on the Nasdaq Capital Market under the symbols &#8220;CDIO&#8221; and &#8220;CDIOW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Transfer Agent and Warrant Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The transfer agent for our Common Stock and warrant
agent for our Public Warrants is Continental Stock Transfer &amp; Trust Company, 1 State Street Plaza, New York, New York 10004.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certain Anti-Takeover Provisions of Delaware Law and our Amended
and Restated Certificate of Incorporation and By-Laws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We are subject to the provisions of Section 203
of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging
in a &#8220;business combination&#8221; with:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; width: 96%; vertical-align: bottom"><span style="font-size: 10pt">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">an affiliate of an interested stockholder; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">A &#8220;business combination&#8221; includes a
merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; width: 96%; vertical-align: bottom"><span style="font-size: 10pt">our board of directors approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of Common Stock; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">on or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our authorized but unissued Common Stock and preferred
stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including
future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved
Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest,
tender offer, merger or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exclusive Forum for Certain Lawsuits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our certificate of incorporation requires that,
unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall
be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought
on behalf of the company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee
of the company to the company or the company&#8217;s stockholders, (iii) any action asserting a claim against the company, its directors,
officers or employees arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or the bylaws,
or (iv) any action asserting a claim against the company, its directors, officers or employees governed by the internal affairs doctrine,
except for, as to each of (i) through (iv) above, (a) any claim as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum
other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction, and (b) any action or
claim arising under the Exchange Act or Securities Act of 1933, as amended. This provision may limit a stockholder&#8217;s ability to
bring a claim in a judicial forum that it finds favorable for disputes with the company and its directors, officers, or other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Special Meeting of Stockholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our bylaws provide that special meetings of our
stockholders may be called only by a majority vote of our board of directors, by our chief executive officer or by our chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Advance Notice Requirements for Stockholder Proposals and Director
Nominations; Conduct of Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our bylaws provide that stockholders seeking to
bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of
stockholders must provide timely notice of their intent in writing. To be timely, a stockholder&#8217;s notice will need to be delivered
to our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the
120th day prior to the scheduled date of the annual meeting of stockholders. Our bylaws also specify certain requirements as to the form
and content of a stockholders&#8217; meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting
of stockholders or from making nominations for directors at our annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our bylaws allow the chairman of the meeting at
a meeting of the stockholders to adopt rules&#160;and regulations for the conduct of meetings which may have the effect of precluding
the conduct of certain business at a meeting if the rules&#160;and regulations are not followed. These provisions may also defer, delay
or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise
attempting to influence or obtain control of us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stockholders&#8217; Derivative Actions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Under the DGCL, any of our stockholders may bring
an action in Cardio&#8217;s name to procure a judgment in Cardio&#8217;s favor, also known as a derivative action,&#160;<i>provided that&#160;</i>the
stockholder bringing the action is a holder of Cardio&#8217;s shares at the time of the transaction to which the action relates or such
stockholder&#8217;s stock thereafter devolved by operation of law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="PlanOfDistribution"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offered shares are being registered to permit
the Selling Stockholders (which as used herein means the persons listed in the table included in &#8220;Selling Stockholders&#8221; and
the pledgees, donees, transferees, assignees, successors and others who later come to hold any of the offered shares as a result of a
transfer not involving a public sale) to offer and sell such shares from time to time after the date of this prospectus. We will not receive
any of the proceeds from the sale by the Selling Stockholders of the shares of Common Stock. We will bear all fees and expenses incident
to our obligation to register the shares of Common Stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Selling Stockholder may, from time to time,
sell any or all of their shares of Common Stock covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading
facility on which the shares are traded or in private transactions. These sales may be at fixed prices, at prevailing market prices at
the time of the sale, at varying prices determined at the time of sale, or privately negotiated prices. A Selling Stockholder may use
any one or more of the following methods when selling shares:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more underwritten offerings;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"></p>

<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales, to the extent permitted by law;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such methods of sale; or&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#8226;</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may also sell the shares
of Common Stock under Rule 144 under the Securities Act, if available, rather than under this prospectus.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Broker-dealers engaged by the Selling Stockholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders
(or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated, but, except as set
forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance
with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA&#160;IM-2440-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of the shares of
Common Stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the shares of Common Stock in the course of hedging the positions
they assume. The Selling Stockholders may also sell the shares of Common Stock short and deliver these securities to close out their
short positions or to return borrowed shares in connection with such short sales, or loan or pledge the shares of Common Stock to
broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such
broker-dealer or other financial institution of shares of Common Stock offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If underwriters are used in a sale, an underwriting
agreement will be executed with the underwriter or underwriters at the time an agreement for the sale is reached. The applicable prospectus
supplement will set forth the managing underwriter or underwriters, as well as any other underwriter or underwriters, with respect to
a particular underwritten offering of securities, and will set forth the terms of the transactions, including compensation of the underwriters
and dealers and the public offering price, if applicable. The prospectus and the applicable prospectus supplement will be used by the
underwriters to resell the securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders and any
underwriters, broker-dealers or agents that are involved in selling the shares of Common Stock may be deemed to be
&#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions
received by such Selling Stockholders, broker-dealers or agents and any profit on the resale of the shares purchased by them may be
deemed to be underwriting commissions or discounts under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221;
within the meaning of Section&#160;2(11) of the Securities Act will be subject to the prospectus delivery requirements of the
Securities Act and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the
Securities Act&#160;and&#160;Rule&#160;10b-5&#160;under&#160;the Exchange Act. Each Selling Stockholders has informed us that it is
not a registered broker-dealer or an affiliate of a registered broker-dealer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to bear all of the expenses incurred
in connection with the registration of these shares. The&#160;Selling Stockholders&#160;will pay or assume discounts, commissions, fees
of underwriters,&#160;selling&#160;brokers or dealer managers and similar expenses, if any, incurred for the sale of the shares. In addition,
the placement agent agreement between Altitude Capital Group LLC and us provides for indemnification of the other party under certain
limited circumstances. There is no indemnity agreement between us and the investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders will be subject to the
prospectus delivery requirements of the Securities Act including Rule&#160;172 thereunder unless an exemption therefrom is available.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The shares of Common Stockwell be sold only through
registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the shares
of Common Stock covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption
from the registration or qualification requirement is available and is complied with.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under applicable rules&#160;and regulations under
the Exchange Act, any person engaged in the distribution of the shares of Common Stockman not simultaneously engage in market making activities
with respect to the shares of Common Stockford the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules&#160;and
regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of shares of Common Stockboy the Selling
Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them
of the need to deliver a copy of this prospectus at or prior to the time of the sale (including by compliance with Rule&#160;172 under
the Securities Act).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There can be no assurance that any Selling Stockholders will sell any
or all of the shares of Common Stock we registered on behalf of the Selling Stockholders pursuant to the registration statement of which
this prospectus forms a part.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once sold under the registration statement of which
this prospectus forms a part, the shares of Common Stock will be freely tradable in the hands of persons other than our affiliates.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September 12, 2025, we had 1,763,129 shares of Common Stock
outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restrictions on the Resale of our Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Rule 144</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Pursuant to Rule 144 promulgated by the SEC under
the Securities Act, as may be amended from time to time (&#8220;Rule 144&#8221;), a person who has beneficially owned restricted shares
of our Common Stock or Warrants for at least six months would be entitled to sell their securities provided that, (i)&#160;such person
is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii)&#160;we
are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required
reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports)
preceding the sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Persons who have beneficially owned restricted
shares of our Common Stock or Warrants for at least six months but who are our affiliates at the time of, or at any time during the three
months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month
period only a number of securities that does not exceed the greater of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom; width: 96%"><span style="font-size: 10pt">1% of the total number of shares of
    Common Stock then outstanding, or 17,631 shares as of September 12, 2025; or</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the average weekly reported trading volume of the Common Stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Sales by our affiliates under Rule 144 are also
limited by manner of sale provisions and notice requirements and to the availability of current public information about us.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Restrictions on the Use
of Rule 144 by Shell Companies or Former Shell Companies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Rule 144 is not available for the resale of securities
initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously
a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 2%"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom; width: 96%"><span style="font-size: 10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act;&#160;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form&#160;8-K;&#160;and&#160;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 14pt">&#8226;</span></td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Following the closing of the Business Combination
on October 25, 2022, we were no longer a shell company. We filed current Form 10-type information on Form 8-K on October 31, 2022. As
a result, with respect to any shares of Common Stock a Stockholder may hold that are restricted and have not been registered for resale
on a registration statement that is current and effective at the time such holder desires to sell, such holder is now able to sell its
securities, in each case pursuant to Rule 144 without registration, assuming we otherwise comply with the conditions set forth above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="CertainTaxEffects"></span></b></p>

<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="LegalMatters"></span>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The validity of the securities offered hereby
was passed upon for us by Shartsis Friese LLP, San Francisco, California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="Experts"></span>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The consolidated financial statements of the Company
as of December 31, 2023 and 2024, and for each of the years in the two-year period ended December 31, 2024, have been included herein
in reliance upon the report of Prager Metis CPAs LLC, independent registered public accounting firm, appearing elsewhere in this Prospectus,
upon the authority of said firm as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="WhereYouCanFind"></span>WHERE <span style="text-transform: uppercase">YOU
CAN FIND ADDITIONAL INFORMATION&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-transform: uppercase">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. We have also filed a registration statement on Form&#160;S-1,&#160;including exhibits,
under the Securities Act of 1933, as amended, with respect to securities offered by this Prospectus. This Prospectus is part of the registration
statement but does not contain all of the information included in the registration statement or the exhibits. Our SEC filings are available
to the public on the internet at a website maintained by the SEC located at http://www.sec.gov.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We also maintain an Internet website at www.cardiodiagnosticsinc.com.
Through our website, we make or will make available, free of charge, the following documents as soon as reasonably practicable after they
are electronically filed with, or furnished to, the SEC: our Annual Reports on Form 10-K; our proxy statements for our annual and special
stockholder meetings; our Quarterly Reports on Form 10-Q; our Current Reports on Form 8-K; Forms 3, 4 and 5 and Schedules 13D and 13G;
and amendments to those documents. The information contained on, or that may be accessed through, our website is not part of, and is not
incorporated into, this Prospectus.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt"><span style="color: #212529">If you would like
</span>additional <span style="color: #212529">copies of this Prospectus, you should contact us by telephone or in writing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt">Cardio
Diagnostics Holdings, Inc.<br/>
311 West Superior Street, Suite 444<br/>
Chicago, IL 60654<br/>
Phone: (855) 226-9991 </span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b><span id="FinancialStatements"></span>INDEX TO FINANCIAL
STATEMENTS</b></span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><b>Audited Financial Statements </b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; width: 4%; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt"><b>Years Ended December 31, 2024 and 2023</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  </table>



<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center"><b><span style="letter-spacing: 0pt"></span></b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 90%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_100">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <span title="Auditor Firm ID">273</span>)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_101">Consolidated Balance Sheets as of December 31, 2024 and 2023</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_102">Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_103">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_104">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_105">Notes to Consolidated Financial Statements</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center"><b><span style="letter-spacing: 0pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited Financial Statements</b></span></td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months Ended June 30, 2025 and 2024</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_0106">Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_0107">Condensed Consolidated Statements of
    Operations for the Three and Six Months Ended June 30, 2025 and 2024</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_0108">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Six Months Ended June 30, 2025 and 2024</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-26</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_0109">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-27</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_0110">Notes to Condensed Consolidated Financial Statements</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-28</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_100"></span>&#160;<b><span style="text-decoration: underline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Stockholders and the Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cardio Diagnostics Holdings, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Cardio Diagnostics Holdings, Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related consolidated
statements of operations, changes in stockholders&#8217; equity, and cash flows for the years ended December 31, 2024 and 2023, and the
related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements
present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for the years ended December 31, 2024 and 2023, in conformity with accounting principles
generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #212529"><i>/s/&#160;Prager Metis CPAs
LLC</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">We have served
as the Company&#8217;s auditor since 2021&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">Hackensack,
New Jersey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; background-color: white; color: #212529">March 20, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 116; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 6pt; margin-bottom: 0"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 1pt; margin-bottom: 0"><span id="a_101"></span><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 1pt"><b>DECEMBER 31,</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<table cellpadding="0" cellspacing="0" id="xdx_30D_111_zIIIbyyN976" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20241231" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20231231" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zYYIMEFio2L8" style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="text-decoration: underline">ASSETS</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zki4HXeTlocc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_i02I_maCzJxJ_zfWbFIXomKWd" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; padding-left: 6.95pt">Cash</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,827,487</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,283,523</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzJxJ_z2PRDnPlfS52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.6pt">Accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,612</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,960</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzJxJ_zf8bhgFHfmmg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Prepaid expenses and other current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,683</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,477,197</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i01TI_mtCzJxJ_maCzHJ8_zUpG5VICs1Fg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,790,782</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,765,680</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsNoncurrentAbstract_iB_zUPu8icdwYrc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Long-term assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzHJ8_zIaDGniVwm8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.95pt">Property and equipment, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,861</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571,873</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzHJ8_z5XjZrWdxKd4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.95pt">Right of use assets, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,397</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575,227</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maCzHJ8_ziSikyRGlIx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.95pt">Intangible assets, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,333</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssetsNoncurrent_i01I_maCzHJ8_z1of4XCfhByc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 6.95pt">Deposits</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherIntangibleAssetsNet_i01I_maCzHJ8_zHVVlfe0k1I3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Patent costs, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">701,089</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">515,402</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_iTI_mtCzHJ8_zhEBQ325oC1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,312</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,462,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zgvJ95JNCb8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: center; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS' EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zR4SbjOHtUEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzW4K_zmYjMK8qvlp" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.6pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,661</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,213</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzW4K_zCyvqzg6zSP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.95pt">Lease liability &#8211; current</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,270</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,929</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FinanceAgreementPayable_i02I_maCzW4K_zhD9utahbwd1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Finance agreement payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,764</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,000</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i01TI_mtCzW4K_maCzwlD_zjYF2A7QugWb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">631,695</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">841,142</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zA8jdq9xHL1k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesNoncurrent_i01I_pp0p0_maCzwlD_zZEmxMaEynrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Lease liability &#8211; long term</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,829</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">663,099</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_iTI_mtCzwlD_maCzsih_z8BkpmIhwEIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,057,524</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,504,241</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_iB_zJmQ8CJxgpQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;
    equity</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzNDn_zCd2xEJEZZhb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241231_pdd" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20231231_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000108" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000110" decimals="INF" unitRef="USDPShares">.00001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20241231_pdd" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20231231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20241231_pdd" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_c20241231_pdd" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_c20231231_pdd" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_c20231231_pdd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2024 and 2023,
    respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231_pdd" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20231231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000124" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000126" decimals="INF" unitRef="USDPShares">.00001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20241231_pdd" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20231231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; 45,944,039 and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20231231_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,540,409</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December
    31, 2024 and 2023, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--CommonStockValue_i01I_pp0d_maCzNDn_c20231231_zc7DfDIIpsPh" title="Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,740,269 and 1,531,468 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBCQUxBTkNFIFNIRUVUUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 6.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,309,162</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--AdditionalPaidInCapital_i01I_pp0d_maCzNDn_c20231231_zRlc7v84x2Hc" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBCQUxBTkNFIFNIRUVUUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,326,299</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzNDn_zq2oeg83TtD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 6.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,751,833</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,368,380</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iTI_mtCzNDn_maCzsih_zpn3lHswNesg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&#8217; equity</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557,788</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,124</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzsih_zWVPeWfimxCd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,312</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,462,365</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.8pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 116.45pt 0 116.85pt; text-align: center">See accompanying notes to
the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 116.45pt 0 116.85pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->




<p style="text-align: center; margin-top: 1pt; margin-bottom: 0"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="text-align: center; margin-top: 1pt; margin-bottom: 0"><span id="a_102"></span><span style="letter-spacing: 0pt"><b>CONSOLIDATED STATEMENTS OF OPERATIONS
</b></span><b></b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 1pt"><b>YEARS ENDED DECEMBER 31,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 1pt"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_zLVjQERB7bIc" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zlihwK7R8xkf" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zpkfD6IhCtfc" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_maCzIQs_zz1caLKxB602" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,890</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,065</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zwUID0ZPx2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_maCzmCK_zhlADosejal8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">Sales and marketing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-012024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,446</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-012023-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,514</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_maCzmCK_zwQqWdpCjeZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,125</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-012023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_maCzmCK_zLRmlTS9Dvqa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">General and administrative expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,169,458</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,936,646</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_maCzmCK_zWHlCoiORgY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 6.6pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_iT_mtCzmCK_msCzIQs_zWyYObQKK6z8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400,767</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,259,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_iT_mtCzIQs_maCzwBM_zpov09ImR957" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,365,877</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,242,459</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zNOatU0KvcJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfDerivativeLiability_i01_maCzHuZ_zL9iboJuCWA" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">Change in fair value of derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0175">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:ChangeInFairValueOfDerivativeLiability" contextRef="From2023-01-012023-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,406,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestIncomeOperating_i01_maCzHuZ_zkLBhPIWGXQe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2024-01-012024-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,068</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestExpense_i01N_di_msCzHuZ_z9G7URtAhsfj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6.95pt">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,640</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,735,013</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCzHuZ_zyOwWYaNw2c1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 6.95pt">Gain on extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,350</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 6.6pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherNonoperatingIncomeExpense_i01T_mtCzHuZ_maCzwBM_z8gKjUy55qx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total other income (expenses)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,576</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,134,375</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtCzwBM_maCz7f5_zAHXACKOMzZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,383,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,376,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_msCz7f5_z5zz4rH43ZP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0193">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0194">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCz7f5_zPNdYx3BDeCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,383,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,376,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareAbstract_iB_zGwQhqKpHInd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and fully diluted income (loss) per common share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net loss per common share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20240101__20241231_pdd" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_pdd" title="Net loss per common share, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000202" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000204" decimals="INF" sign="-" unitRef="USDPShares">.31</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_pdd" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_pdd" title="Net loss per common share, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000206" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000208" decimals="INF" sign="-" unitRef="USDPShares">.66</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and fully diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_pdd" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_pdd" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,892,705</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_pdd" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_pdd" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,685,133</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.45pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center">See accompanying notes to
the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.1pt 0 0">&#160;</p>


<!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05in 116.45pt 0 116.85pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS,
<span style="letter-spacing: -0.2pt">INC.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><span id="a_103"></span><span style="letter-spacing: 0pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><span style="letter-spacing: 0pt"><b>YEARS ENDED DECEMBER 31, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b>&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_zXvJpd7OTEv3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zbN1lWX1R3A4" style="font-size: 8pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zj4ZiIicUPia" style="font-size: 8pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zFmbMQFGp1m7" style="font-size: 8pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BA_zAyxQfYVabhd" style="font-size: 8pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">Additional Paid-in</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Totals</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zhL4jTDPdK64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%">Balances, December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQL0dPqVeuxh" title="Beginning balance, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,514,743</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,293,159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,991,546</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,301,708</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--WarrantsConvertedToCommonStock_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Warrants converted to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantsConvertedToCommonStockShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB1XmILQmMIa" title="Warrants converted to common stock, shares" style="text-align: right"><ix:nonFraction name="cdio:WarrantsConvertedToCommonStockShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:WarrantsConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:WarrantsConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:WarrantsConvertedToCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PlacementAgentFees_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Placement agent fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000233" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">315,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2023-01-012023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">315,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RestrictedStockAwardsVested_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Restricted stock awards vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--RestrictedStockAwardsVestedShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNeBHz1VWeb9" title="Restricted stock awards vested, shares" style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2023-01-012023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NotesPayableConvertedToCommonStock_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.85pt">Notes payable converted to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--NotesPayableConvertedToCommonStockShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z92vzPZUxbBi" title="Notes payable converted to common stock, shares" style="text-align: right"><ix:nonFraction name="cdio:NotesPayableConvertedToCommonStockShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,622,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:NotesPayableConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:NotesPayableConvertedToCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,604,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:NotesPayableConvertedToCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,604,952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CompensationForVestedStockOptions_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.85pt">Compensation for vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2023-01-012023-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,035,273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AdjustmentToLiabilitiesAssumedInMergerWithMana_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Adjustment to liabilities assumed in merger with Mana</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana" contextRef="From2023-01-012023-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,376,834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,376,834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zvFNDynMCSn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balances, December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuML0grU6PM5" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,540,409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,326,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,368,380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CommonStockAndWarrantsIssuedForCash_iP3us-gaap--SharesOutstanding_z2IUoorbwaD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Common stock and warrants issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--CommonStockAndWarrantsIssuedForCashShares_iP3custom--CommonStockAndWarrantsIssuedForCash_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrgq3QcMidVf" title="Common stock and warrants issued for cash, shares" style="text-align: right"><ix:nonFraction name="cdio:CommonStockAndWarrantsIssuedForCashShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,319,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CommonStockAndWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CommonStockAndWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,546,696</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CommonStockAndWarrantsIssuedForCash" contextRef="From2024-01-012024-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,546,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PlacementAgentFees_zEJOXwon3kqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Placement agent fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:PlacementAgentFees" contextRef="From2024-01-012024-12-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--RestrictedStockAwardsVested_zPcddxVxu8d7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.85pt">Restricted stock awards vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--RestrictedStockAwardsVestedShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6hFyb6dRoTh" title="Restricted stock awards vested, shares" style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CompensationForVestedStockOptions_zQqIyieXwdWi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Compensation for vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,515,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,515,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProfitLoss_zg9m9aYxVghj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 6.95pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,383,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,383,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zuWaotTVzz88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balances, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu2yyDZEsqf7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,944,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,309,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,751,833</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557,788</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt/1pt Times New Roman, Times, Serif; margin: 0 0 0 204.05pt; text-indent: 488.6pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="letter-spacing: 9.5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center">See accompanying notes to the consolidated
financial <span style="letter-spacing: 0pt">statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center"><span style="letter-spacing: 0pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO
DIAGNOSTICS HOLDINGS, INC. <span style="letter-spacing: 0pt"></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><span style="letter-spacing: 0pt"><b><span id="a_104"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 10pt; text-align: center"><span style="letter-spacing: 0pt"><b>YEARS
ENDED</b></span><b> DECEMBER 31,</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zHet2WFRSe55" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zQF1UxeJuZyf" style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zgoFd9R7Gca9" style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zbSbwti8Uinl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_maCzSym_za6FniNbBS54" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left; padding-left: 6.95pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,383,453</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,376,834</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Depreciation_i02_maCzSym_zffqmQygFl5b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20.95pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,790</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentForAmortization_i02_maCzSym_zIv9IhBa6kB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20.6pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2023-01-012023-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,830</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_maCzSym_z8NKkD4CfhR6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20.95pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,591,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,279,273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NoncashInterestExpense_i02_maCzSym_zBpjQMvLR5oj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20.95pt">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:NoncashInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,704,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfDerivativeLiabilities_i02N_di_msCzSym_zvjUHgub746l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20.95pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:ChangeInFairValueOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,406,220</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzSym_zLeA6jTbXOb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20.95pt">Gain on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,350</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zLWVCDaSD8Z8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 15.7pt">Changes in operating assets and liabilities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msCzSym_z98Bi0lxzlb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20.6pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,652</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,960</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msCzSym_zHoh3G8Swye5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20.95pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">915,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">758,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i02N_di_msCzSym_z9MmOFrpJLUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20.95pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,900</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzSym_ziGkTOnFp0ua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20.6pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,552</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">781,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzSym_zHDzxLqPVgO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20.95pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">223,929</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzSym_maCzxC2_zGzQ8zShAAjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20.95pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,993,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,672,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_za0kno377EI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzoP1_zwpwsRAd5KC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 6.95pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,765</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575,663</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--PaymentsForRightOfUseAsset_i01N_di_msCzoP1_zZq9qxoJg5Lk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Payments for right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="cdio:PaymentsForRightOfUseAsset" contextRef="From2023-01-012023-12-31" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCzoP1_zmuJbP0Bzxy1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    and trademark costs incurred</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,425</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,276</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzoP1_maCzxC2_zELUl4VUxOMa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 11pt; padding-left: 20.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET CASH
    USED IN INVESTING ACTIVITIES</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">404,190</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000370" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">794,291</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zweL1tJmbbli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH FLOWS
    FROM FINANCING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCz8Ms_za5PzpotBRkb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from sale of common stock and warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,546,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_i01_maCz8Ms_z64gepDXJMB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes payable, net of original issue discount of $<span id="xdx_906_ecustom--OriginalIssueDiscount_pp0p0_c20240101__20241231_zSa3F9ZSpebh" title="Original issue discount"><ix:nonFraction name="cdio:OriginalIssueDiscount" contextRef="From2024-01-012024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromWarrantExercises_i01_maCz8Ms_z3JokOq4hun8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from exercise
    of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--PaymentsToAcquireFinanceReceivable_i01N_di_msCz8Ms_zZ7aEzoe0kbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    of finance agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="cdio:PaymentsToAcquireFinanceReceivable" contextRef="From2024-01-012024-12-31" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,691</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="cdio:PaymentsToAcquireFinanceReceivable" contextRef="From2023-01-012023-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">942,532</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_ecustom--PaymentsOfPlacementAgentFee_i01N_di_msCz8Ms_zPJakhsPH2n7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 6.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    of placement agent fee</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="cdio:PaymentsOfPlacementAgentFee" contextRef="From2024-01-012024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="cdio:PaymentsOfPlacementAgentFee" contextRef="From2023-01-012023-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCz8Ms_maCzxC2_zvYbm6wuk7Ee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH PROVIDED BY FINANCING ACTIVITIES</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,941,258</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,632,468</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzxC2_z8A1Aklx3h39" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET INCREASE (DECREASE) IN
    CASH</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,543,964</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,833,998</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    &#8211; BEGINNING OF YEAR</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,283,523</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,117,521</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0_zqjjNvepKrHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    &#8211; END OF YEAR</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,827,487</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,283,523</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zrwM3RnTyDGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidDuringPeriodForAbstract_iB_zPaqjqWt1qk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Cash paid during the year for:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i01_zJNRwh8UDAr4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10.45pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zsgdWEsyI9qj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.45pt">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zce6UkUBnAdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6.95pt">Non-cash investing and financing activities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DebtDiscountRelatedToDerivativeLiability_i01_zkorw5b05Mrf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10.45pt">Debt discount related to derivative liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:DebtDiscountRelatedToDerivativeLiability" contextRef="From2023-01-012023-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NotePayableConvertedToCommonStock_i01_zWoV2Yof4E13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10.45pt">Notes payable converted to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:NotePayableConvertedToCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AdjustmentToLiabilitiesAssumedInAcquisition_i01_zm57hpsHDme2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10.1pt">Adjustment to liabilities assumed in acquisition</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:AdjustmentToLiabilitiesAssumedInAcquisition" contextRef="From2023-01-012023-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_i01_zUTp7TXLJMi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10.45pt">Financing agreement entered into for prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2024-01-012024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2023-01-012023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">467,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--RightOfUseAssetAddedToOperatingLease_i01_pp0p0_z59PILmf1nj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10.45pt">Right of use asset added for operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:RightOfUseAssetAddedToOperatingLease" contextRef="From2023-01-012023-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">642,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.05pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 116.45pt 0 116.85pt; text-align: center">See accompanying notes to the consolidated
financial <span style="letter-spacing: 0pt">statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.1pt 0 0">&#160;</p>


<!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0pt; text-align: center"><b>CARDIO
DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><span id="a_105"></span>Notes
to Consolidated Financial Statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>

<p id="xdx_04E_c20240101__20241231_zC3wO8ioj9ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.75pt 0 0"><b></b></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000434" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zd6hdXQ8Jgsg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
1 &#8211; <span id="xdx_827_z37jE7uRTpg9">Organization and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the &#8220;Company&#8221;) and its wholly-owned
subsidiary, Cardio Diagnostics, Inc. (&#8220;Legacy Cardio&#8221;). The Company was incorporated as Mana Capital Acquisition Corp. (&#8220;Mana&#8221;)
under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability
company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed
to develop and commercialize a patent-pending Artificial Intelligence (&#8220;AI&#8221;)-driven DNA biomarker testing technology (&#8220;Core
Technology&#8221;) for cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the
leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The
Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated
into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD),
stroke, heart failure and diabetes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Business
<span style="letter-spacing: 0pt">Combination</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On May 27, 2022, Mana, Mana Merger Sub, Inc.
(&#8220;Merger Sub&#8221;), a wholly-owned direct subsidiary of Mana, Meeshanthini Dogan, the Shareholders&#8217; Representative, and
Legacy Cardio entered into the Business Combination Agreement (the &#8220;Merger Agreement&#8221;). On October 25, 2022, pursuant to
the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana.
Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc.</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000436" name="cdio:MergerAgreementAndReverseRecapitalizationTextBlock"><p id="xdx_80B_ecustom--MergerAgreementAndReverseRecapitalizationTextBlock_zrZsdLZbQaM3" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Note
2 &#8211; <span id="xdx_829_zRZ5U0uGlsUb">Merger Agreement and Reverse Recapitalization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
discussed in Note 1, on October 25, 2022, the Company (formerly known as Mana) and Legacy Cardio entered into the Merger Agreement, which
has been accounted for as a reverse recapitalization in accordance with GAAP. Pursuant to the Merger Agreement, the Company acquired
cash of $<span id="xdx_903_eus-gaap--CashAcquiredFromAcquisition_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Cash Acquired from Acquisition"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2022-10-012022-10-25_custom_MergerAgreementMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,021</ix:nonFraction></span> and assumed liabilities of $<span id="xdx_900_eus-gaap--LiabilitiesAssumed1_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Liabilities assumed"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2022-10-012022-10-25_custom_MergerAgreementMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">928,500</ix:nonFraction></span> from Mana. The liabilities assumed <span style="letter-spacing: -0.25pt">of $<span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionPayablesAssumed1_c20221001__20221025__us-gaap--BusinessAcquisitionAxis__custom--TwoInvestmentBankersMember_pp0p0" title="Liabilities assumed payable"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" contextRef="From2022-10-012022-10-25_custom_TwoInvestmentBankersMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">928,500</ix:nonFraction></span>
were payable to two investment bankers and due on October 25, 2023. The assumed liabilities decreased to $<span id="xdx_90A_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zSaqstvLsjr6" title="Liabilities assumed"><span id="xdx_908_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zV0xJXhRWKhi" title="Liabilities assumed"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2023-03-012023-03-22" id="Fact000444" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2023-03-012023-03-22" id="Fact000446" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">854,475</ix:nonFraction></ix:nonFraction></span></span>, net of an early payment
discount of $<span id="xdx_90A_ecustom--EarlyPaymentDiscount_c20230301__20230322_pp0p0" title="Early payment discount"><ix:nonFraction name="cdio:EarlyPaymentDiscount" contextRef="From2023-03-012023-03-22" id="Fact000448" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,025</ix:nonFraction></span> issued by one of the two investment bankers on March 22, 2023. On March 27, 2023, the Company accepted the early
payment discount and paid Ladenburg the net balance due and payable of $<span id="xdx_902_eus-gaap--LoansPayable_c20230327_pp0p0" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-03-27" id="Fact000450" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">419,475</ix:nonFraction></span>. On October 24, 2023, the Company paid the remaining
post-merger liabilities balance of $<span id="xdx_901_ecustom--PostmergerLiabilitiesBalance_c20231024_pp0p0" title="Post-merger liabilities balance"><ix:nonFraction name="cdio:PostmergerLiabilitiesBalance" contextRef="AsOf2023-10-24" id="Fact000452" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">435,000</ix:nonFraction></span> to Benchmark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Mana&#8217;s
common stock had a redemption right in connection with the business combination. Mana&#8217;s stockholders exercised their right to redeem
<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20240101__20241231_pdd" title="Stock redeemed shares"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2024-01-012024-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,465,452</ix:nonFraction></span> shares of common stock, which constituted approximately <span id="xdx_90E_eus-gaap--DebtInstrumentRedemptionPricePercentage_c20240101__20241231_pdd" title="Redemption percentage"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="From2024-01-012024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">99.5</ix:nonFraction>%</span> of the shares with redemption rights, for cash at a redemption
price of approximately $<span id="xdx_902_ecustom--RedemptionPricePerShre_c20241231_pdd" title="Redemption price per shre"><ix:nonFraction name="cdio:RedemptionPricePerShre" contextRef="AsOf2024-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.10</ix:nonFraction></span> per share, for an aggregate redemption amount of $<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20241231_pp0p0" title="Redemption amount"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2024-01-012024-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,310,892</ix:nonFraction></span>. In accounting for the reverse recapitalization,
the Company&#8217;s legacy issued and outstanding <span id="xdx_904_ecustom--ReverseRecapitalizationShares_c20240101__20241231_pdd" title="Reverse recapitalization shares"><ix:nonFraction name="cdio:ReverseRecapitalizationShares" contextRef="From2024-01-012024-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,976,749</ix:nonFraction></span> shares of common stock were reversed and the Mana shares of common stock
totaling <span id="xdx_90E_ecustom--CommonSharesReversed_c20240101__20241231_pdd" title="Common shares reversed"><ix:nonFraction name="cdio:CommonSharesReversed" contextRef="From2024-01-012024-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,514,743</ix:nonFraction></span> were recorded, as described in Note 10. Transactions costs incurred in connection with the recapitalization totaled
$<span id="xdx_903_eus-gaap--RecapitalizationCosts_c20240101__20241231_pp0p0" title="Recapitalization cost"><ix:nonFraction name="us-gaap:RecapitalizationCosts" contextRef="From2024-01-012024-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,535,035</ix:nonFraction></span> and were recorded as a reduction to additional paid in <span style="letter-spacing: 0pt">capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Options: NewSection -->
    <div id="xdx_236_zo9EHbBBGOxi" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 7; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23E_zoZjAlh4RBU5" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
additional consideration for the transaction, Cardio will issue to each holder who was entitled to merger consideration at the Closing,
its <i>pro rata </i>proportion of up to 1,000,000 shares of our authorized but unissued common stock (the &#8220;Earnout Shares&#8221;
or &#8220;Contingently Issuable Common Stock&#8221;), if on or prior to the fourth anniversary of the Closing Date (the &#8220;Earnout
Period&#8221;), the VWAP of the Company&#8217;s Common Stock equals or exceeds four different price triggers for 30 of any 40 consecutive
trading days, as follows: (i) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $12.50 per share for the
stated period; (ii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $15.00 per share for the stated <span style="letter-spacing: 0pt">period;
(iii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $17.50 for the stated period; and (iv) one-quarter
of the Earnout Shares will be issued if the VWAP equals or exceeds $20.00 for the stated period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In
evaluating the accounting treatment for the earnout, we have concluded that the earnout is not a liability under Accounting Standards
Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity, is not subject to the accounting guidance under ASC 718,
Compensation&#8212;Stock Compensation, and is not subject to derivative accounting under ASC 815, Derivative and Hedging. As such, the
earnout is recognized in equity at fair value upon the closing of the Business Combination. As of the date of filing of this Annual Report
on Form 10-K, the Company&#8217;s common stock did not trade at equal to or greater than $12.50 for a period of at least 30 trading days
out of 40 consecutive trading days and the Company has not issued any Earnout Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000468" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_z96x6CklUkj1" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Note
3 &#8211; <span id="xdx_821_zHEdPJSos6R">Summary of Significant Accounting <span style="letter-spacing: 0pt">Policies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000470" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zDNg8b34BS05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zr8jCQLjXzu6">Principles
of <span style="letter-spacing: 0pt">Consolidation</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio. All intercompany
accounts and transactions have been <span style="letter-spacing: 0pt">eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000472" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zLNQ2uKwnaZ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zS1mDvUJESNd">Use
of Estimates in the Preparation of Financial <span style="letter-spacing: 0pt">Statements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.25pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could
differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000474" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z91QthiMFmrj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_868_zCxlZUH7zj8b">Fair
Value Measurements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company adopted the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures, </i>which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields
on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
1 &#8211; quoted prices in active markets for identical assets or <span style="letter-spacing: 0pt">liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on <span style="letter-spacing: 0pt">assumptions)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level
3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for
the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains
and losses for the years ended December 31, 2024 and 2023.</p>

<ix:exclude><p id="xdx_234_zmFAvPueXSg2" style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div id="xdx_235_zylrWJ4fG5Ab" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23C_zCiq7yt0wLDh" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC</b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000477" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span id="xdx_8B9_zQfF87metW1a" style="display: none">Schedule of fair value measurements</span><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Balance of derivative liabilities &#8211; beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" title="Balance of derivative liabilities - beginning of year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" title="Balance of derivative liabilities - beginning of year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Issued" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Issued" style="width: 14%; text-align: right"><ix:nonFraction name="cdio:DerivativeLiabilitiesIssued" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000485" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,192,672</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Converted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Converted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Converted" style="text-align: right">(<ix:nonFraction name="cdio:DerivativeLiabilitiesConverted" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000489" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,786,452</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in fair value recognized in operations" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in fair value recognized in operations" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="cdio:ChangeInFairValueRecognizedInOperations" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000493" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,406,220</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Balance of derivative liabilities &#8211; end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" title="Balance of derivative liabilities - end of year" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" title="Balance of derivative liabilities - end of year" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zhAz12pT12J7" style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the Company&#8217;s
derivative instruments that are measured at fair value on a recurring basis as of December 31, 2024 and 2023, for each fair value hierarchy
level:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000499" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zhbf4g3brmh7" style="display: none">Schedule of fair value hierarchy level</span></td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left">December 31, 2024</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Level I</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Derivative liabilities" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Level II</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Level III</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%">December 31, 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level II</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level III</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" title="Derivative liabilities" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zmS7sqkIBUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000525" name="cdio:ConvertibleInstrumentsPolicyTextBlock"><p id="xdx_841_ecustom--ConvertibleInstrumentsPolicyTextBlock_zTtsCCOGiFb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zY6ocY8PrD24">Convertible <span style="letter-spacing: 0pt">Instruments</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company evaluates and accounts for conversion options
embedded in convertible instruments in accordance with ASC 815, <i>Derivatives and Hedging <span style="letter-spacing: 0pt">Activities.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Applicable GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes
in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument
would be considered a derivative <span style="letter-spacing: 0pt">instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for
convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded
in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term
of the related debt to their stated date of redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000527" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z7k6YLTKgNKd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_zGtXQv2t4pl4">Revenue <span style="letter-spacing: 0pt">Recognition</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company offers its products, Epi+Gen CHD and PrecisionCHD, via telemedicine providers, provider organizations such as concierge practices,
longevity clinics, and risk-bearing provider organizations, and employer organizations. The Company is continuing to expand its markets
and payment optionality, and therefore, other organization types not listed below may be added, and from time-to-time, there may be additional
payment options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-size: 10pt; letter-spacing: 0pt">Telemedicine</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For telemedicine, the telemedicine
provider collects payments from patients upon completion of eligibility screening and test order. Patients then send their samples to
the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation and shares test
reports with the ordering healthcare provider. Revenue is recognized upon invoicing the telemedicine providers. Telemedicine providers
are invoiced at the end of each month for all tests completed since prior invoicing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 7.2pt"/><td style="width: 13.95pt"><span style="font-size: 7pt">&#8226;</span></td><td><span style="font-size: 10pt">Provider organizations</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For provider organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the provider organization type
and testing volume commitment. Upon ordering a test, a patient&#8217;s sample is sent to the lab for biomarker assessments. The Company
performs all quality control, analytical assessments and report generation and shares test reports with the ordering healthcare provider.
Revenue is recognized upon invoicing the provider organization. The provider organization is invoiced the agreed upon pricing at the end
of each month for all samples accepted or tests completed since prior invoicing.</p>

<ix:exclude><p id="xdx_23D_zowyCX5vmMHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div id="xdx_235_zy4Y3HcK8gY9" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zFthIisFylhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-size: 10pt">Employer organizations</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For employer organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing volume commitment. Patient
samples are sent to the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation
and shares test reports with the ordering healthcare provider. Revenue is recognized upon invoicing the employer organization. The employer
organization is invoiced the agreed upon pricing once a heart disease fair is completed or all testing is completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for revenue
under Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;, using
the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect
adjustment to the opening balance of accumulated deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company determines the measurement of revenue and the timing
of revenue recognition utilizing the following core principles:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"/><td style="width: 3%"><span style="font-size: 10pt">1.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the contract with a customer;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"/><td style="width: 3%"><span style="font-size: 10pt">2.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the performance obligations in the contract;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"/><td style="width: 3%"><span style="font-size: 10pt">3.</span></td><td style="width: 92%"><span style="font-size: 10pt">Determining
                                            the transaction price;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"/><td style="width: 3%"><span style="font-size: 10pt">4.</span></td><td style="width: 92%"><span style="font-size: 10pt">Allocating
                                            the transaction price to the performance obligations in the contract; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"/><td style="width: 3%"><span style="font-size: 10pt">5.</span></td><td style="width: 92%"><span style="font-size: 10pt">Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000531" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBbGafxvms2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zlmVP2BBeDid">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Research and development
costs are expensed as incurred. Research and development costs charged to operations for the years ended December 31, 2024 and 2023 were
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_pp0p0" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,125</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_pp0p0" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">145,182</ix:nonFraction></span>, <span style="letter-spacing: 0pt">respectively.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000537" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zTLvsQqGTBik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_862_zVf107pUc8y4">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company expenses advertising costs as incurred. Advertising
costs of $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20240101__20241231_pp0p0" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2024-01-012024-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">182,446</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20230101__20231231_pp0p0" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2023-01-012023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,514</ix:nonFraction></span> were charged to operations for the years ended December 31, 2024 and 2023, respectively.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000543" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJs1obmk6Fvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_ztokn6a3ZbA7">Cash
and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Cash and cash equivalents are comprised of
cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241231_z9AChdOqs003" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zfiDJ26ZzsVd" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000545" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000547" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any
cash equivalents as of December 31, 2024 and 2023. Cash is maintained at a major financial institution. Accounts held at U.S. financial
institutions are insured by the FDIC up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20241231_pp0p0" title="FDIC Insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>. The Company is exposed to credit risk in the event of default by the financial institutions
or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of December 31, 2024 and 2023, was approximately $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_zkcfnxA4Tm9f" title="Amount in excess of FDIC insurance"><ix:nonFraction name="cdio:AmountInExcessOfFdicInsurance" contextRef="AsOf2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million and $<span id="xdx_90C_ecustom--AmountInExcessOfFdicInsurance_iI_pp0p0_c20231231_zoEZpwfaSeCg" title="Amount in excess of FDIC insurance"><ix:nonFraction name="cdio:AmountInExcessOfFdicInsurance" contextRef="AsOf2023-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">933,523</ix:nonFraction></span>, respectively. The Company has not experienced any losses
on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk with regard
to these deposits is not significant.</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000555" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_z0c9VQPN9uAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_zjLAHRTGqYll">Accounts Receivable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Accounts receivable is stated
at invoiced amount, net of an allowance for doubtful accounts and bear no interest. An allowance for losses is established through a provision
for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely.
The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based
on evaluation of the collectability of the accounts and prior loss experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000557" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyanY13R5eG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_zH37bjb3G8H5">Property and Equipment</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000559" name="cdio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: top; text-align: left">
  <td><span id="xdx_8B8_zSC0gG9hqifc" style="display: none">Schedule of estimated lives</span></td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="width: 10%">&#160;</td>
  <td style="width: 40%">Office and computer equipment</td>
  <td style="width: 50%"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000561" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Furniture and fixtures</td>
  <td><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000563" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric> </span>years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Lab equipment</td>
  <td><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_LabEquipmentMember" format="ixt-sec:duryear" id="Fact000565" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Leasehold improvements</td>
  <td><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000567" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

</ix:nonNumeric><p id="xdx_8A9_z3ZZlPuyTwi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt">	</p>

<ix:exclude><p id="xdx_233_z7ceXcdPKCsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<ix:exclude><p id="xdx_23D_zDre69wyF8Yh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div id="xdx_239_zXEpemVJwF6" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_233_zdcUss8nwwab" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zuElqMNgZLP2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000572" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITHZUwl7a7j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_zD5TjXIatc38">Intangible <span style="letter-spacing: 0pt">Assets</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Intangible
assets are acquired individually or as part of a group of assets, and are initially recorded at cost. The cost of a group of assets acquired
in a transaction is allocated to the individual assets based on their relative fair values. Intangible assets are carried at cost less
accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line
method over the period of estimated useful life. The estimated useful life of the Company&#8217;s intangible assets (Know-how license)
is <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zCfcXVkoKSEe" title="Useful life"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000574" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> years. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets
might be impaired.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000576" name="cdio:PatentAndTrademarkCostsPolicyTextBlock"><p id="xdx_846_ecustom--PatentAndTrademarkCostsPolicyTextBlock_ze5KSEOQ1fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_864_zw0QsOV54Bfd">Patent Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company accounts for patents in accordance
with ASC 350-30, <i>General Intangibles Other than Goodwill</i>. The Company capitalizes patent costs representing legal fees associated
with filing patent applications and amortize them on a straight-line basis. The Company evaluates its patents&#8217; estimated useful
life and begins amortizing the patents when they are brought to the market or otherwise commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.95pt 0 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000578" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhZLkfI2Wpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_z7dyBmZQQyqd">Impairment
of Long-Lived <span style="letter-spacing: 0pt">Assets</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In accordance with ASC 360-10-35,
the Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value
might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit
of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present.
If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an
impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows
exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the
asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally
measured by the present value of the estimated cash flows.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000580" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zZVaUfZxgLMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_863_zxjoSA4ulfbc">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for leases
under ASC <i>842, &#8220;Leases&#8221;. </i>The Company determines if an arrangement is a lease or contains a lease at inception of the
arrangement. Operating lease liabilities are recognized based on the present value of the remaining lease payments, discounted using the
discount rate for the lease at the commencement date. As the rate implicit in the lease is not readily determinable for the operating
lease, the Company generally uses an incremental borrowing rate based on information available at the commencement date to determine the
present value of future lease payments. Operating lease right-of-use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right
to control the use of an identified asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease
payments arising from the lease. ROU assets are generally recognized based on the amount of the initial measurement of the lease liability.
Lease expense is recognized on a straight-line basis over the lease term. The Company elected to keep leases with an initial term of 12
months or less off the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ROU assets are reviewed for
impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance
in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. ROU assets are tested for impairment individually
or as part of an asset group if the cash flows related to the ROU assets are not independent from the cash flows of other assets and liabilities.
An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable
cash flows are largely independent of the cash flows of other groups of assets and liabilities.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000582" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJw8YL6Iavr" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zlTdxiM7gO0f">Stock-Based <span style="letter-spacing: 0pt">Compensation</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for its stock-based
awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires
the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value
on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company
uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing
model requires the input of highly subjective assumptions including the expected stock price volatility of the Company&#8217;s common
stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption
related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of
the Company&#8217;s stock options and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000584" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zzzlr7ysTP2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zfHg5iI9wen">Income
<span style="letter-spacing: 0pt">Taxes</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for income
taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company applies the provisions
of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the
Company&#8217;s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold
and measurement attribute for the financial statement recognition and measurement of a tax position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div id="xdx_231_zFLZekOYNZf6" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23D_zYBnVUOUkjV6" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zmAZBQr8V5Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000587" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5RenvA8vA4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86F_zXRvAiswOSKg">Recent Accounting <span style="letter-spacing: 0pt">Pronouncements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">We have reviewed other recent
accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated
financial statements as a result of future adoption.</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000589" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zwjm4gdBZQSf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
4 &#8211; <span id="xdx_82F_zXVeIf8VHBU1">Property and <span style="letter-spacing: 0pt">Equipment</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">Property and equipment are carried at cost and consist of the following at December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000591" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9ucvjRd8hu3" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8B9_znhDxlo6b4V7" style="display: none">Schedule of property and equipment</span>&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zdXSpYKrX3z1" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_z1ilcE0qeHli" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAENzR6H_zrB4cuUYLmce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,032</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAENzR6H_zfe8qFobm03j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2024-12-31" id="Fact000596" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAENzR6H_z2p6OR1LHEXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2024-12-31" id="Fact000599" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAENzR6H_zS9oqLLg4fEe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2024-12-31" id="Fact000602" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">502,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2023-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">482,170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzR6H_z5xKrDrjTYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,567</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzR6H_zDbXGo7IzTz" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">672,861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">571,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Leasehold improvements of $<span id="xdx_90C_eus-gaap--LeaseholdImprovementsGross_c20241231_pp0p0" title="Leasehold Improvements"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2024-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">502,155</ix:nonFraction></span> represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024. Depreciation expense of $<span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">113,777</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,790</ix:nonFraction></span>
was charged to operations for the years ended December 31, 2024 and 2023, respectively.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000617" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zbuxR5JbFRC7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
5 &#8211; <span id="xdx_828_zBzoa4Zewyz9">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
following table provides details associated with the Company&#8217;s acquired identifiable intangible assets at December 31, 2024 and
2023:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000619" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zc7Lz3Rjebf7" summary="xdx: Disclosure - Intangible Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8B1_zpyq01DYJWF5" style="display: none">Schedule of intangible assets</span>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20241231_z579V0nUMvE3" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20231231_zrO7yEGUaRhh" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzDBb_zYnczfGzJWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Know-how license</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact000622" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzDBb_zwhIMPpnEcFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,667</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,667</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzDBb_zYIW5sL1Yq8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000628" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Amortization expense charged to operations was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_pp0p0" title="Amortization expense"><span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_pp0p0" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></ix:nonFraction></span></span> for the
years ended December 31, 2024 and 2023, <span style="letter-spacing: 0pt">respectively.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000634" name="cdio:PatentAndTrademarkCostsTextBlock"><p id="xdx_806_ecustom--PatentAndTrademarkCostsTextBlock_zcrwGc6tWs0b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
6 &#8211; <span id="xdx_824_z5wdhx2Sfmvh">Patent <span style="letter-spacing: 0pt">Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2024, in the first family
of patents and patent applications owned solely by UIRF and is exclusively licensed by Cardio, there are seven granted patents (US (2),
EU, China, Australia, India and Hong Kong) and other pending patent applications. The Company has pending patent applications in patent
families two, three, four, five and six. Legal fees associated with the patents totaled $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zcFqIPzAR06h" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31_us-gaap_PatentsMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">701,089</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zykuNE1meSaa" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember" id="Fact000638" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">515,402</ix:nonFraction></span>, net of accumulated amortization
of $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zofvdqOAqYt3" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,920</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,182</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively and are presented in the consolidated balance sheets as patent costs.
Patents are amortized over their estimated useful lives of approximately 14 and <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgtwhQEcsZXi" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact000644" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span> years, respectively. Amortization expense charged to
operations was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-12-31_us-gaap_PatentsMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,738</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,182</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000650" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zWIUiVNtCZR1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
7 &#8211; <span id="xdx_823_zyECJSRl5J4h">Operating <span style="letter-spacing: 0pt">Leases</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company determines if
a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#8217;s
consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance
lease obligations, net of current portion in the Company&#8217;s consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ROU assets represent the right
to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.
ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.
In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement
date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments.
Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.
Leases with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 126 -->
    <div id="xdx_237_zqnOpHZtZQrj" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_235_z5w4qjMcjXw3" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In 2023, the Company entered
into a lease agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and
expiring on November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental
installments from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $<span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p0" title="Monthly rent payment"><ix:nonFraction name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" contextRef="From2023-08-022023-11-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,505</ix:nonFraction></span> ($<span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p0" title="Annually rent payment"><ix:nonFraction name="cdio:AnnuallyRentPayment" contextRef="From2023-08-022023-11-30" id="Fact000654" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,060</ix:nonFraction></span> annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#8220;TIA&#8221;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $<span id="xdx_906_ecustom--PremisesAllowance_c20240101__20241231_pp0p0" title="Premises allowance"><ix:nonFraction name="cdio:PremisesAllowance" contextRef="From2024-01-012024-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Pursuant to ASC Topic 842
Leases, the Company accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated
to be payable on December 1, 2023. The Company received the TIA from landlord in maximum amount of $<span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p0" title="Amount receivable"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2024-01-16" id="Fact000658" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,000</ix:nonFraction></span> on January 16, 2024 and recorded
a reimbursement receivable from landlord of $<span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p0" title="Reimbursement receivable"><ix:nonFraction name="cdio:ReimbursementReceivable" contextRef="AsOf2023-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,000</ix:nonFraction></span> as of December 31, 2023, which was included in Prepaid expenses and other current
assets on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company recorded ROU assets of $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p0" title="ROU assets"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">663,875</ix:nonFraction></span> and operating lease liabilities of $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p0" title="Operating lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">642,523</ix:nonFraction></span> at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be <span id="xdx_90B_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_pdd" title="Borrowing rate"><ix:nonFraction name="us-gaap:SubordinatedBorrowingInterestRate" contextRef="From2023-01-012023-12-31_custom_ChicagoMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.57</ix:nonFraction>%</span> for the Chicago lease and <span id="xdx_90F_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_pdd" title="Borrowing rate"><ix:nonFraction name="us-gaap:SubordinatedBorrowingInterestRate" contextRef="From2023-01-012023-12-31_stpr_IA" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.24</ix:nonFraction>%</span> for the Iowa
City lease, respectively, as the interest rate implicit in our lease is not readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
of December 31, 2024 and 2023, operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheets
as <span style="letter-spacing: 0pt">follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000670" name="cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zyoLYq3Im9od" summary="xdx: Disclosure - Operating Leases (Details)" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zADQOQFfRyfi" style="font-size: 8pt"><b style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20241231_zzRQXmMCDVHc" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_496_20231231_zNUIrXNUIwwf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">432,397</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,227</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">237,270</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,929</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zaTmatbFqhb4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,829</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000679" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">663,099</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zvpAVaPeTkg7" style="font: 10pt Times New Roman, Times, Serif; margin: 5.35pt 0 12pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As of December 31, 2024, the weighted-average
remaining lease terms of the two operating leases were <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zeFB5GFznR4a" title="Operating Lease, Weighted Average Remaining Lease Term"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_LeaseOneMember" format="ixt-sec:duryear" id="Fact000681" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.9</ix:nonNumeric></span> years and <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zfCRvCZNnXb3" title="Operating Lease, Weighted Average Remaining Lease Term"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_LeaseTwoMember" format="ixt-sec:duryear" id="Fact000683" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.9</ix:nonNumeric></span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000685" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIsC8qEhRhJ9" summary="xdx: Disclosure - Operating Leases (Details 1)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B5_zH4yu9sV5t5c" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20241231_pp0p0" title="2025" style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,611</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20241231_pp0p0" title="2026" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,152</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20241231_pp0p0" title="2027" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact000691" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,060</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20241231_pp0p0" title="2028" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,555</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20241231_pp0p0" title="Total minimum lease payments" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">706,378</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20241231_pp0p0" title="Less: Imputed interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000697" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,279</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20241231_pp0p0" title="Present value of lease liabilities" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000699" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">663,099</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At December 31, 2024, the Company had the
following future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom"><span style="display: none"></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20241231_zjx6NL5YA5E2" title="2025" style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,611</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20241231_zf7NWr1e7xch" title="2026" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,152</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20241231_z32BNlNXJWHc" title="2027" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact000705" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,060</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20241231_zhmSPc62i7bk" title="2028" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,555</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20241231_zuWuaIY5glDk" title="Total minimum lease payments" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000709" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">706,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zlrBoJ7IUXGf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 127 -->
    <div id="xdx_238_zKJkWLWWw0G2" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23F_zNAAk48DCLyc" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zCLN7o7IzBac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Consolidated rental expense for all operating
leases was $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_pp0p0" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,717</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20230101__20231231_pp0p0" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">138,266</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The following table summarizes the cash paid
and related right-of-use operating lease recognized for the years ended December 31, 2024 and 2023.</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000716" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zz2OC2XEo2sa" summary="xdx: Disclosure - Operating Leases (Details 2)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 8pt; font-weight: bold"><span id="xdx_8B7_zBl1bXJOS7i3" style="display: none">Schedule of cash paid and related right-of-use operating lease</span><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101_20241231" style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20230101_20231231" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zoPcBHLVkZSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Cash paid for amounts included in the measurement of
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating cash flows from operating leases</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">257,508</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,352</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB_zGppz3XnLuKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Right-of-use lease assets obtained in the exchange for
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating leases</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,929</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,950</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_zTO3SBrGpVb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000730" name="cdio:FinanceAgreementPayableTextBlock"><p id="xdx_803_ecustom--FinanceAgreementPayableTextBlock_zDvD2ZeOC3K7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
8 &#8211; <span id="xdx_82D_zamaU30TCmC4">Finance Agreement <span style="letter-spacing: 0pt">Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$<span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p0" title="Financing agreement entered into for prepaid insurance"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2023-10-012023-10-25" id="Fact000732" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">467,500</ix:nonFraction></span>&#160;is payable in 10 monthly installments plus interest at a rate of&#160;<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pdd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-10-012023-10-25" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.95</ix:nonFraction>%</span>&#160;through&#160;<span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_c20231025" title="Maturity date"><ix:nonNumeric contextRef="AsOf2023-10-25" format="ixt:datemonthdayyearen" id="Fact000736" name="us-gaap:LongTermDebtMaturityDate">August
25, 2024</ix:nonNumeric></span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p0" title="Prepaid expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2024-10-25" id="Fact000738" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">550,000</ix:nonFraction></span>&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $<span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p0" title="Financing agreement entered into for prepaid insurance"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2024-10-012024-10-25" id="Fact000740" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">383,455</ix:nonFraction></span> is payable in 10 monthly installments plus interest at a rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pdd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-10-012024-10-25" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.80</ix:nonFraction>%</span> through <span id="xdx_90C_eus-gaap--LongTermDebtMaturityDate_c20241025" title="Maturity date"><ix:nonNumeric contextRef="AsOf2024-10-25" format="ixt:datemonthdayyearen" id="Fact000744" name="us-gaap:LongTermDebtMaturityDate">August
25, 2025</ix:nonNumeric></span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p0" title="Prepaid expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2025-10-25" id="Fact000746" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">451,124</ix:nonFraction></span> has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Finance agreement payable for above two agreements
was $<span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p0" title="Finance agreement payable"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">306,764</ix:nonFraction></span> and $<span id="xdx_905_ecustom--FinanceAgreementPayable_c20231231_pp0p0" title="Finance agreement payable"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2023-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">374,000</ix:nonFraction></span> at December 31, 2024 and 2023, respectively. Unamortized balance of Directors and Officers insurance premiums
was $<span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p0" title="Unamortized balance"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,315</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--UnamortizedDebtIssuanceExpense_c20231231_pp0p0" title="Unamortized balance"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2023-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,041</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000756" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_803_eus-gaap--EarningsPerShareTextBlock_z5MscUNUo6L" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
9 &#8211; <span id="xdx_82D_z5qW3UYKl5R7">Earnings (Loss) Per Common <span style="letter-spacing: 0pt">Share</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates net income (loss) per common
share in accordance with ASC 260 &#8220;<i>Earnings Per Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net earnings (loss)
per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common
shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
and common stock warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2024
and 2023 as the result would be anti-dilutive.</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000758" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU8iRieUQ1Ld" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8BF_zY0CDmiHV3Y1" style="display: none">Schedule of anti dilutive earning per share</span>&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Years
    Ended December 31,</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Stock warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" title="Anti-dilutive shares" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_StockWarrantsMember" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,528,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" title="Anti-dilutive shares" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_StockWarrantsMember" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,854,620</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,594,202</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,584,599</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_pdd" title="Anti-dilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,122,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_pdd" title="Anti-dilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,439,219</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.5pt 0 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000772" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwtqmKaLZ10b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
10 &#8211; <span id="xdx_828_zw2TVCrEUToc">Stockholders&#8217; <span style="letter-spacing: 0pt">Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Stock <span style="letter-spacing: 0pt">Transactions</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Pursuant to the Business Combination Agreement on October
25, 2022, the Company issued the following <span style="letter-spacing: 0pt">securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Holders of conversion rights issued as a component of units
in Mana&#8217;s initial public offering (the &#8220;Public Rights&#8221;) were issued an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_IPOMember" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">928,571</ix:nonFraction></span> shares of the Company&#8217;s
common <span style="letter-spacing: 0pt">stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Holders of existing shares
of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the &#8220;Legacy Cardio Stockholders&#8221;)
received an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240101__20241231__dei--LegalEntityAxis__custom--LegacyCardioStockholdersMember_pp0p0" title="Number of shares received"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-01-012024-12-31_custom_LegacyCardioStockholdersMember" id="Fact000776" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,883,306</ix:nonFraction></span> shares of the Company&#8217;s Common Stock, calculated based on the <span style="color: #202529">exchange
ratio of 3.427259 pursuant to the Merger Agreement</span> (the &#8220;Exchange Ratio&#8221;) for each share of Legacy Cardio Common Stock
held or, in the case of the equity rights holder, that number of shares of the Company&#8217;s Common Stock equal to 1% of the Aggregate
Closing Merger Consideration, as defined in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Legacy Cardio Stockholders
received, in addition, an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20240101__20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pdd" title="Conversion of aggregate shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2024-01-012024-12-31_custom_LegacyCardioMember" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,334</ix:nonFraction></span> shares of the Company&#8217;s Common Stock (&#8220;Conversion Shares&#8221;) upon conversion
of an aggregate of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pp0p0" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_LegacyCardioMember" id="Fact000780" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">433,334</ix:nonFraction></span> in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such
amount in order to extend Mana&#8217;s duration through October 26, 2022 (the &#8220;Extension Notes&#8221;), which Conversion Shares
were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Mana public stockholders
(excluding Mana Capital, LLC, the SPAC sponsor (the &#8220;Sponsor&#8221;), and Mana&#8217;s former officers and directors) own 34,548
shares of the Company&#8217;s Common Stock and the Sponsor, Mana&#8217;s former officers and directors and certain permitted transferees
own <span id="xdx_90C_ecustom--NumberOfSharesTransferred_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ManasFormerOfficersAndDirectorsMember_pdd" title="Number of shares transferred"><ix:nonFraction name="cdio:NumberOfSharesTransferred" contextRef="From2024-01-012024-12-31_custom_ManasFormerOfficersAndDirectorsMember" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,625,000</ix:nonFraction></span> shares of the Company&#8217;s Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Immediately after giving effect to the Business Combination,
there were 9,514,743 issued and outstanding shares of the Company&#8217;s Common <span style="letter-spacing: 0pt">Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 128 -->
    <div id="xdx_230_zTXYjGjThwg8" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_239_zWWeDEwRinw9" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On October 25, 2022, in connection
with the approval of the Business Combination, the Company&#8217;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity
Incentive Plan (the &#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders
by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries,
to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of
Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations
of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock
Units, Stock Appreciation Rights, Performance Units and Performance Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
2022 Plan, as approved, permits the issuance of up to <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20241231__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Common stock issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_Plan2022Member" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,265,516</ix:nonFraction></span> shares of Common Stock (the &#8220;Share Reserve&#8221;) upon exercise
or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#8220;Evergreen Date&#8221;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the
Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January
1, 2023. In January 2024, the Compensation Committee approved an annual increase in the Share Reserve of <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Number of shares authorized"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" contextRef="AsOf2024-01-23_custom_Plan2022Member" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,060,458</ix:nonFraction></span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Common Stock <span style="letter-spacing: 0pt">Issued</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Private
Placement&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In connection with a private offering memorandum that the
Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with 7 accredited
investors (the &#8220;Subscription Agreements&#8221;), whereby the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,793</ix:nonFraction></span> units (&#8220;Units&#8221;), with
each Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Common stock , per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> par value (the &#8220;Common Stock&#8221;), and (ii)
one six year Common Stock purchase warrant (the &#8220;Warrants&#8221;), having an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRz4dkayTmki" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></span> per share (the &#8220;Private
Placement&#8221;). The Private Placement resulted in the issuance to investors of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,793</ix:nonFraction></span> shares of Common Stock and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,793</ix:nonFraction></span> Warrants.
The purchase price of the securities was $1.78 per Unit, resulting in gross proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember" id="Fact000798" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>, before deducting placement
agent fees (10% or $<span id="xdx_90E_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Placement agent fees"><ix:nonFraction name="cdio:PlacementAgentFee" contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember" id="Fact000800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working
capital and general corporate purposes. The Private Placement closed on February 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Private Placement, <span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalGroupLLCMember" title="Placement agent agreement description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalGroupLLCMember" id="Fact000802" name="cdio:PlacementAgentAgreementDescription">the
Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 112,353 shares of Common Stock at $1.78
per share through February 2, 2030 (the &#8220;Placement Agent Warrants&#8221;).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At-the-Market Issuance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In connection with an At-the-Market Issuance Sales Agreement
(the &#8220;Sales Agreement&#8221;) that the Company entered into with a placement agent on January 26, 2024, the Company sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,758,057</ix:nonFraction></span>
shares of Common Stock at various amounts per share to investors for gross proceeds totaling $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,546,949</ix:nonFraction></span> before deducting sales commissions
of $<span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Sales commissions"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember" id="Fact000808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">288,674</ix:nonFraction></span> to placement agent, during the year ended December 31, 2024. The Company also paid the placement agent a fee of $<span id="xdx_90B_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Placement agent fees"><ix:nonFraction name="cdio:PlacementAgentFee" contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember" id="Fact000810" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Other Common Stock Issuance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">During the year ended December 31, 2024, the Company issued
<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,568</ix:nonFraction></span> shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000814" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 31, 2024, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-03-31_custom_BoardOfDirectorsMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,212</ix:nonFraction></span> shares of Common
Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_custom_BoardOfDirectorsMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On March 2, 2023, a shareholder exercised warrants
in exchange for <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230301__20230302_pdd" title="Conversion of shares, shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-03-012023-03-02" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of Common Stock for proceeds of $<span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230301__20230302_pp0p0" title="Conversion of shares, Value"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2023-03-012023-03-02" id="Fact000822" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">390,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,375</ix:nonFraction></span> shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued
at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000826" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">251,172</ix:nonFraction></span> shares of Common Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted,
valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 129 -->
    <div id="xdx_23B_zjVHgVCik1C3" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_230_zi9KHi2STIPi" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the convertible notes payable
(see Note 11 below) the noteholders converted $<span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231_pdd" title="Conversion of shares, shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-01-012023-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> of principal balance to <span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230101__20231231_pp0p0" title="Conversion of shares, Value"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2023-01-012023-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,622,119</ix:nonFraction></span> shares of Common Stock during the year ended
December 31, 2023. The number of shares of Common Stock issued was determined based on the terms of the convertible notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 1, 2019, the Company issued warrants
to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20191001_pdd" title="Common stock issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2019-10-01" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500</ix:nonFraction></span> shares of Common Stock at the time of issuance.
The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the
warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the
next Qualified Equity Financing, or if the warrant became exercisable in connection with a Change in Control before the next Qualified
Equity Financing, the greater of the quotient obtained by dividing $150,000 by the Pre-financing Capitalization, and the price per share
paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation
of any Change of Control, or 15 years after the issuance of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In April 2022, the Company issued fully vested
warrants to investors as part of private placement subscription agreements pursuant to which the Company issued Common Stock. Each shareholder
received warrants to purchase 50% of the Common Stock issued at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30_us-gaap_StockOptionMember" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.90</ix:nonFraction></span> per share with an expiration date of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220401__20220430" title="Expiration date"><ix:nonNumeric contextRef="From2022-04-012022-04-30" format="ixt:datemonthdayyearen" id="Fact000840" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June 30,
2027</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of May 23, 2022, the Company issued fully
vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued Common
Stock. Each shareholder received warrants to purchase 50% of the Common Stock issued at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220523_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-23" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.21</ix:nonFraction></span> per share with an expiration
date of five years from the date of issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">All of the warrants issued by Legacy Cardio
were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2024, in
connection with the Private Placement as described above, the Company issued an aggregate of <span id="xdx_905_ecustom--WarrantsIssued_c20240101__20241231_pdd" title="Warrants issued"><ix:nonFraction name="cdio:WarrantsIssued" contextRef="From2024-01-012024-12-31" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,146</ix:nonFraction></span> warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Warrant
activity during the years ended December 31, 2024 and 2023 was as follows:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000846" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDCwURogRB1f" summary="xdx: Disclosure - Stockholders' Equity (Details)" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BB_zfAb4vTxNTi1" style="display: none">Schedule of warrant activity</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted
    Average Exercise<br/> Price</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>Weighted Average Remaining Contractual
                                                                                                Life</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2022</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1Q52kQUQ9E8" title="Warrants outstanding, beginning" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,954,620</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlPPXLz3nx6j" title="Weighted average exercise price outstanding, beginning" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.63</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfgzk0Lz0MC" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000852" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.46</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants exercised</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrants exercised" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.90</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,854,620</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9.70</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Uu5x01Apb1" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000858" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.72</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrants granted" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,146</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, granted" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,528,766</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9.08</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUZLGB7r6SId" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000864" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.91</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z6PpS9k3vC75" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p>

<ix:exclude><p id="xdx_233_zloXzwwecTil" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b></b></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_232_zYvUU24uESAi" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zSdOhAyzAEed" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline">Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 23, 2023, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-06-012023-06-23_custom_StockOptionsMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,000</ix:nonFraction></span>
stock options to management, which vested immediately on grant date. Each option has an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-23_custom_StockOptionsMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.26</ix:nonFraction></span> per share with an expiration
date of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"><ix:nonNumeric contextRef="From2023-06-012023-06-23_custom_StockOptionsMember" format="ixt:datemonthdayyearen" id="Fact000872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June 23, 2033</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_908_ecustom--StockOptionsValued_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" id="Fact000874" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,035,273</ix:nonFraction></span> at grant date based on the Black-Scholes Option
Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during
the year ended December 31, 2023, risk free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.41</ix:nonFraction>%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">176</ix:nonFraction>%</span> and an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionsMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.26</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On January 23, 2024, the Company authorized
an additional 1,060,458 shares to the Equity Incentive Plan Reserve (the &#8220;2022 Plan&#8221;) and granted 1,187,826 options to management
and employees, 1,166,826 of which vested immediately with the remaining 21,000 options subject to 50% vesting on June 30, 2024 and 100%
vesting on December 31, 2024. Each option has an exercise price of $2.11 per share with an expiration date of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" format="ixt:datemonthdayyearen" id="Fact000882" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">January 23, 2034</ix:nonNumeric></span>. The immediately
vested 1,166,826 stock options were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" id="Fact000884" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,461,404</ix:nonFraction></span> at grant date based on the Black-Scholes Option Pricing model. The following
assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the year ended December 31,
2024, risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.22</ix:nonFraction>%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">228</ix:nonFraction>%</span> and an exercise price of $2.11. For the remaining 21,000 options, 7,500 options
were vested on June 30, 2024, 5,000 options were vested on December 31, 2024 and 8,500 options were forfeited before vesting with the
leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at vesting date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these vested stock options during the
year ended December 31, 2024, risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction>%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">188</ix:nonFraction>%</span> and an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_N2022PlanMember_custom_StockOption1Member" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 30, 2024, the Company granted 30,300
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.55 per share
with an expiration date of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" format="ixt:datemonthdayyearen" id="Fact000896" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June 30, 2034</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_90C_ecustom--StockOptionsValued_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact000898" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,625</ix:nonFraction></span> at grant date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options
during the year ended December 31, 2024, risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction>%</span>, volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">188</ix:nonFraction>%</span> and an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On September 30, 2024, the Company granted
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-09-30_custom_StockOptionsMember" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,744</ix:nonFraction></span> stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.22 per
share with an expiration date of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_StockOptionsMember" format="ixt:datemonthdayyearen" id="Fact000908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">September 30, 2034</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_901_ecustom--StockOptionsValued_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-09-30_custom_StockOptionsMember" id="Fact000910" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,618</ix:nonFraction></span> at grant date based
on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-09-30_custom_StockOptionsMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.79</ix:nonFraction>%</span>, volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-09-30_custom_StockOptionsMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">184</ix:nonFraction>%</span> and an exercise price
of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-09-30_custom_StockOptionsMember" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.22</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On November 14, 2024, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-11-14_custom_StockOptionsMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,728</ix:nonFraction></span>
stock options to two independent directors of the board, which vested immediately on grant date. Each option has an exercise price of
$0.27 per share with an expiration date of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-11-14_custom_StockOptionsMember" format="ixt:datemonthdayyearen" id="Fact000920" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">November 14, 2034</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-11-14_custom_StockOptionsMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,125</ix:nonFraction></span> at grant date
based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-11-14_custom_StockOptionsMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.44</ix:nonFraction>%</span>, volatility of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-11-14_custom_StockOptionsMember" id="Fact000926" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">156</ix:nonFraction>%</span> and an exercise price
of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-11-14_custom_StockOptionsMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.27</ix:nonFraction></span>. The two independent directors did not stand for re-election at the 2024 Annual Meeting but did receive the options upon vesting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On December 31, 2024, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,632</ix:nonFraction></span>
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.92 per share
with an expiration date of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" format="ixt:datemonthdayyearen" id="Fact000932" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">December 31, 2034</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000934" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,289</ix:nonFraction></span> at grant date based on the
Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested
stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.58</ix:nonFraction>%</span>, volatility of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">146</ix:nonFraction>%</span> and an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></span>.</p>

<ix:exclude><p id="xdx_23A_z8LK3kmU1Pn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 131 -->
    <div id="xdx_23A_zh5sV3TZBihf" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_234_zEn6EXXTYgh4" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Option
activity during the years ended December 31, 2024 and 2023 was as follows:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000943" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUvpU5j4hnfl" summary="xdx: Disclosure - Stockholders' Equity (Details 1)" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zERaSKPPmM23" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Exercise&#160;Price</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Remaining Contractual Life (Years)</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; padding-left: 5.4pt">Options outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZWfO100pTS2" title="Options outstanding, beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_StockOptionsMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,759,599</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6doTkcJ0gzf" title="Weighted average exercise price outstanding, beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionsMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.90</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zgUrtRCBeDtf" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact000949" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.35</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">825,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price granted" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.26</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Options outstanding at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,584,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJpBEP5l7EGi" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" format="ixt-sec:duryear" id="Fact000955" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.71</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,322,231</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.93</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options expired or cancelled or forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0UGR8MEMLBa" title="Options expired or cancelled or forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,628</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, Options expired or cancelled or forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.93</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,594,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2.74</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzkJV3s72Ima" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" format="ixt-sec:duryear" id="Fact000965" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.12</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Options vested and exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,594,202</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.74</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zg6cru78mdZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000971" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z5SJdCUsAw6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"><b>Note 11 &#8211; <span id="xdx_820_zPuC4vamZWx5">Convertible Notes Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"><b><span style="letter-spacing: 0pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 8, 2023, the Company
entered into a securities purchase agreement (&#8220;Securities Purchase Agreement&#8221;) with YA II PN, Ltd., an investment fund managed
by Yorkville Advisors Global, LP (&#8220;Yorkville&#8221;) under which the Company agreed to sell and issue to Yorkville convertible debentures
(&#8220;Convertible Debentures&#8221;) in a gross aggregate principal amount of up to $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20230308_pp0n6" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-08" id="Fact000973" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11.2</ix:nonFraction></span> million (&#8220;Subscription Amount&#8221;).
The Convertible Debentures were convertible into shares of common stock of the Company and were subject to various contingencies being
satisfied as set forth in the Securities Purchase Agreement. The notes were convertible at any time through the maturity date, which,
in each case, was one year from the date of issuance. The conversion price was determined on the basis of <span id="xdx_90A_ecustom--ConversionPriceDeterminedPercentage_c20230308_pdd" title="Conversion price determined percentage"><ix:nonFraction name="cdio:ConversionPriceDeterminedPercentage" contextRef="AsOf2023-03-08" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">92</ix:nonFraction>%</span> of the two lowest VWAP (Volume
Weighted Average Prices) of the Common Stock during the prior seven trading day period, initially with a floor conversion price of $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20230307__20230308_pdd" title="Floor conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="From2023-03-072023-03-08" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>,
but subsequently lowered by mutual agreement of the parties to $<span id="xdx_90B_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20230307__20230308_pdd" title="Decrease floor conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2023-03-072023-03-08" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.20</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 8, 2023, the Company
issued and sold to Yorkville a Convertible Debenture in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentIssuedPrincipal_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_zdfCN7k7wKp9" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember" id="Fact000981" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million, for which it received $<span id="xdx_904_ecustom--PrincipalAmountReceived_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ziIxVvgFNrQ" title="Principal amount received"><ix:nonFraction name="cdio:PrincipalAmountReceived" contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember" id="Fact000983" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million, with
a $<span id="xdx_901_ecustom--DebtInstrumentOriginalIssueDiscount_pp0p0_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ztoQDNZJo29f" title="Debt Instrument original issue discount"><ix:nonFraction name="cdio:DebtInstrumentOriginalIssueDiscount" contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember" id="Fact000985" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> original issue discount (&#8220;OID&#8221;). Interest on the outstanding principal balance accrued at a rate of <span id="xdx_90B_eus-gaap--ShortTermDebtPercentageBearingFixedInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance accrues percentage"><ix:nonFraction name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction>%</span> and would
increase to <span id="xdx_905_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance remains uncured percentage"><ix:nonFraction name="us-gaap:ShortTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">15</ix:nonFraction>%</span> upon an Event of Default for so long as it remained uncured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company recorded a debt
discount related to identified embedded derivatives relating to the conversion features (see Note 12) based on fair values as of the inception
date of the Note. The calculated debt discount, including the OID, equaled the face of the Note and was amortized over the term of the
note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Yorkville fully converted the initial $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_z5n84HJU19c3" title="Conversion of convertible debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember" id="Fact000991" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span>
Convertible Debenture into an aggregate of <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Conversion of shares converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,622,119</ix:nonFraction></span> shares of Common Stock during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On January 4, 2024, the Company
and Yorkville terminated the Securities Purchase Agreement dated as of March 8, 2023, as amended, by the mutual consent of the parties,
effective as of January 4, 2024. The First Convertible Debenture was fully converted, and as of January 4, 2024, the obligation of the
Company to issue and sell, and Yorkville&#8217;s obligation to purchase, the Second Convertible Debenture was terminated. At the time
of termination, there were no outstanding borrowings, advance notices or shares of Common Stock to be issued under the Securities Purchase
Agreement. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the Securities Purchase
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 132 -->
    <div id="xdx_238_zjBemJNJ9YMa" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_232_zosOmcilDTKe" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000995" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_80C_eus-gaap--DerivativesAndFairValueTextBlock_zOloJLscBhxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
12 &#8211; <span id="xdx_829_z28Bg1hUmo3l">Derivative <span style="letter-spacing: 0pt">Liability</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company has determined
that the conversion feature embedded in the convertible notes described in Note 11 contain a potential variable conversion amount which
constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding
discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately
to interest expense at inception, which aggregated $4,692,672. The Company used the Binomial Black-Scholes Option Pricing model to value
the conversion features.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes
option-pricing model with the following assumption inputs:</p>
<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact000997" name="us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Derivative Liability (Details)" id="xdx_88C_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zITA2HDXmO6g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8B8_ziN7h3ix7bzh" style="display: none">Schedule of option liability</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Year Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span title="Annual dividend yield"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zWoG2cQUPHx" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: left">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span title="Expected life (years)"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zpUNdjQGHwUj" title="Expected life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact001001" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">1.0</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Risk-free interest rate"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.89</ix:nonFraction>%</span></span> - <span title="Risk-free interest rate"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.59</ix:nonFraction>%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Expected volatility"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">164</ix:nonFraction>%</span></span> - <span title="Expected volatility"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">187</ix:nonFraction>%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Exercise price">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact001011" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span></span> - <span title="Exercise price">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact001013" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.53</ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Stock price">$<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Stock price"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.22</ix:nonFraction></span></span> - <span title="Stock price">$<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Stock price"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.32</ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Based
upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40
to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance
date.&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001019" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zrddLXAWpkF9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
13 &#8211; <span id="xdx_82E_z5NG03DBmNMb">Income <span style="letter-spacing: 0pt">Taxes</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
reconciliation between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense
(benefit) for the years ended December 31, 2024 and 2023 is as follows:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001021" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkeEgAemkND" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zKXVVQApLLp5" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Statutory U.S. federal income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_zA4fmfMuoFHb" title="Statutory U.S. federal income tax rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20230101__20231231_zV4xHFQww82f" title="Statutory U.S. federal income tax rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">21.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">State income taxes, net of federal income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zauRogrk3fba" title="State income taxes, net of federal income tax benefit">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zfKHcofJHLd6" title="State income taxes, net of federal income tax benefit">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Tax effect of expenses that are not deductible for income tax purposes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Amortization of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20240101__20241231_z3xZ1eWVpzie" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" contextRef="From2024-01-012024-12-31" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20230101__20231231_zoe6I5d1lHn1" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" contextRef="From2023-01-012023-12-31" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">16.8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Change in fair value of derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20240101__20241231_zlNbhtfeSNvi" title="Change in fair value of derivative liability"><ix:nonFraction name="cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" contextRef="From2024-01-012024-12-31" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20230101__20231231_zrlAUN2OWe24" title="Change in fair value of derivative liability">(<ix:nonFraction name="cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" contextRef="From2023-01-012023-12-31" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">13.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20240101__20241231_zpsgVc7bgcX8" title="Stock based compensation"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-012024-12-31" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">6.3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20230101__20231231_zXWf4EPQ4pa5" title="Stock based compensation"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">2.7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20240101__20241231_zQ4nh9fiUQOg" title="Other">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextRef="From2024-01-012024-12-31" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20230101__20231231_zXmcFRScXv2b" title="Other">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextRef="From2023-01-012023-12-31" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">0.6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231_zzbWtQx1Kqr3" title="Change in Valuation Allowance"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">14.7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zMkTDce0G3Di" title="Change in Valuation Allowance"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">15.6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Effective tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20240101__20241231_zAxNr2oh5sQ1" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20230101__20231231_zUH8FsKfqPoi" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AB_zacfAkZFaQl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 1pt; text-indent: 0pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At
December 31, the significant components of the deferred tax assets (liabilities) are summarized below:</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001055" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzHApVvRgZg5" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_ziywFiCgO7t" style="display: none">Schedule of deferred income tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zyUAvWW9pP9k" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zq1KrWC4RGy2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzbaL_zwsm03zDW9Tj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Net operating losses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,580,034</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001061" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,222,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzbaL_zvaVmaa4mRhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001063" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,328</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,743</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGzbaL_zR381ADtVbK2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,169</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzbaL_maDTANz3eX_zOXBo4tjngGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,607,531</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,224,742</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_zupMAopM0D5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred Tax Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz3eX_zLDnL26YDvrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001075" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,607,531</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,224,742</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz3eX_zZhxdOk5e1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zn4rTrr8Rww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 133 -->
    <div id="xdx_233_zDFv4EMN10hc" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_233_zltdYWxDGpH3" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">As
of December 31, 2024, the Company had federal net operating loss carryforwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_FederalMember" id="Fact001081" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.2</ix:nonFraction></span> million which may be carried forward
indefinitely, and state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IA_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_stpr_IA" id="Fact001083" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.6</ix:nonFraction></span> million (Iowa) and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IL_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_stpr_IL" id="Fact001085" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.6</ix:nonFraction></span> million (Illinois), respectively
which expire at various dates from 2040 through 2044. These net operating loss carryforwards may be used to offset future taxable income
and thereby reduce the Company&#8217;s U.S. federal income taxes. The net operating losses may be subject to limitation under Internal
Revenue Code Section 382 should there be a greater than <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_c20240101__20241231_pdd" title="Tax ownership percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="From2024-01-012024-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">50</ix:nonFraction>%</span> change in ownership as determined under the regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In assessing the realization of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation
allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets
will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In accordance with ASC 740, a valuation allowance
must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration
of available positive and negative evidence, which includes, among other things, the Company&#8217;s most recent results of operations
and expected future profitability. Based on the Company&#8217;s cumulative losses in recent years, a full valuation allowance against
the Company&#8217;s deferred tax assets as of December 31, 2024 and 2023 respectively has been established as Management believes that
the Company will not more likely than not realize the benefit of those deferred tax assets. Therefore, <span id="xdx_909_ecustom--TaxProvision_iI_do_c20241231_z47qkGu7gRhj" title="Tax provision"><span id="xdx_90F_ecustom--TaxProvision_iI_do_c20231231_zGC2nCmKuAB8" title="Tax provision"><ix:nonFraction name="cdio:TaxProvision" contextRef="AsOf2024-12-31" id="Fact001089" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="cdio:TaxProvision" contextRef="AsOf2023-12-31" id="Fact001091" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> tax provision has been recorded
for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company complies with
the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits
claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize
the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination
by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant
uncertain tax positions requiring recognition under ASC 740-10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company is subject
to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or
any states in connection with income taxes. The Company&#8217;s tax years generally remain open to examination for all federal and state
income tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The
federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute
of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a
period within the statute of limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">The Company recognizes
interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. <span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zK7I2jDtHR54" title="Interest or penalties"><span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zdIvJaIhp8zl" title="Interest or penalties"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2024-01-012024-12-31" id="Fact001093" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact001095" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> interest or penalties
have been recorded for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On
March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic.
The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning
before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding
taxable years to generate a refund of previously paid income taxes. At present the Company does not expect that the NOL carryback provision
of the CARES Act will result in a material cash benefit to us.</p>

<ix:exclude><!-- Field: Page; Sequence: 134 -->
    <div id="xdx_238_zX4KM1mQoH74" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23C_z8AH5bdEPM88" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001097" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7PufVHyV2u" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
14 &#8211; <span id="xdx_826_zSkZfOyEPvZ5">Commitments and <span style="letter-spacing: 0pt">Contingencies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Prior
Relationship of Cardio with Boustead Securities, <span style="letter-spacing: -0.25pt">LLC</span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At the commencement of efforts
to pursue what ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services
Agreement (the &#8220;Placement Agent Agreement&#8221;), dated April 12, 2021, with Boustead Securities, LLC (&#8220;Boustead Securities&#8221;).
This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Under the terminated Placement
Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during
which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent
Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the
Company&#8217;s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#8220;right of
first refusal&#8221;). Cardio has taken the position that due to Boustead Securities&#8217; failure to perform as contemplated by the
Placement Agent Agreement, these provisions purporting to provide future rights are null and void.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Boustead Securities responded
to the termination of the Placement Agent Agreement by disputing Legacy Cardio&#8217;s contention that it had not performed under the
Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response,
Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio&#8217;s behalf. While Boustead Securities&#8217;
contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such
contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination
of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly
disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential
party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so
at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome
will not have a material adverse impact on its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">The Benchmark Company, LLC Right of First Refusal</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As noted in Note 1, the Company
completed the business combination on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13,
2022, Mana engaged The Benchmark Company, LLC (&#8220;Benchmark&#8221;) as its M&amp;A advisor. Upon closing of the business combination,
Legacy Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment
No. 1 Engagement Letter (the &#8220;Amendment Engagement&#8221;). <span id="xdx_904_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCRightOfFirstRefusalMember" title="Business combination reason, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" id="Fact001099" name="us-gaap:BusinessCombinationReasonForBusinessCombination">Pursuant to the Amendment Engagement, the parties agreed that the Company
would pay Benchmark $230,000 at the closing of the business combination and an additional $435,000 on October 25, 2023. Both of those
payments have been made in full. In addition, the Amendment Engagement provided that Benchmark has been granted a right of first refusal
to act as lead or joint-lead investment banker, lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future
public and private equity and debt offerings through October 25, 2023.</ix:nonNumeric></span> Based on the right of first refusal, Benchmark alleges that it
is owed damages because the Company entered into the Yorkville Convertible Debenture Transaction (see Note 11) without first offering
Benchmark the right to serve as the lead or joint-lead placement agent for the transaction. The Company is evaluating the claim. No legal
proceedings have been instigated.</p>

<ix:exclude><p id="xdx_232_zpWC02wzz2N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 135 -->
    <div id="xdx_232_zZy0FNFNwyt8" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_233_znV2BDBtR9dj" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Demand Letter and Potential Mootness Fee <span style="letter-spacing: 0pt">Claim</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On
June 25, 2022, a plaintiffs&#8217; securities law firm sent a demand letter to the Company alleging that the Company&#8217;s Registration
Statement on Form S-4 filed (the &#8220;S-4 Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of
Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto,
the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022
and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2022,
the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023,
plaintiffs&#8217; securities law firm contacted the Company&#8217;s counsel asking who will be negotiating a mootness fee relating to
the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement,
as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required.
The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement
the S-4 Registration Statement under applicable laws. As of the date of filing of this Annual Report on Form 10-K, no lawsuit has been
filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution
cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Northland Securities, Inc.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In January 2024, following
the Company&#8217;s termination of its agreement with Yorkville and in connection with the Company&#8217;s recent at the market offering
and/or its February 2024 private placement, a managing director of Northland Securities, Inc. (&#8220;Northland&#8221;) contacted the
Company claiming the right to be paid a fee of approximately $<span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p0" title="Termination fee"><ix:nonFraction name="cdio:TerminationFee" contextRef="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember" id="Fact001102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> pursuant to the agreement of March 1, 2023 between the Company and
Northland regarding the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland
would not proceed with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville
Securities Purchase Agreement and the subsequent financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company cannot preclude
the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could
potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing
on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Directors and Officers Insurance</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Company&#8217;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Notice of Non-Compliance with Nasdaq
Listing Requirements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On June 3, 2024,
Cardio Diagnostics Holdings, Inc. (the &#8220;Company&#8221;) received a letter (the &#8220;First Nasdaq Bid Price Letter&#8221;) from The
Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2),
because the minimum bid price of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) had closed below the minimum $<span id="xdx_906_ecustom--CommonStockBidPrice_c20240603_pdd" title="Common stock bid price"><ix:nonFraction name="cdio:CommonStockBidPrice" contextRef="AsOf2024-06-03" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per
share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price
Requirement&#8221;). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, or until December 2, 2024, to regain compliance.&#160;On December 4, 2024 (the &#8220;Second Nasdaq Bid Price Letter&#8221;), Nasdaq
notified the Company that Nasdaq&#8217;s Staff has determined that the Company is eligible for an additional 180 calendar day period,
or until June 2, 2025, to regain compliance (the "Second Compliance Period&#8221;). The determination is based on the Company&#8217;s
meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing
on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company&#8217;s written notice of its intention
to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. If the Company chooses to
implement a reverse stock split, it must complete the split no later than ten business days prior to the end of the Second Compliance
Period in order to timely regain compliance. As of the date of this report the Common Stock has not regained compliance with the Minimum
Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">If we fail to
regain compliance with the minimum bid requirement within the cure period (or extended cure period) or if we fail to continue to meet
all applicable continued listing requirements for Nasdaq in the future, Nasdaq could delist our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 136 -->
    <div id="xdx_239_zXbMsBe1jC22" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_233_z8WuN1RM1vP6" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, <span style="letter-spacing: -0.2pt">INC.</span></b></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; text-align: center">Notes to Consolidated Financial Statements</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">Years Ended December 31, 2024 and 2023</p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-12-31" escape="true" id="Fact001106" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zY9AM4GHUcW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&#160;<b>Note 15 &#8211; <span id="xdx_825_z3skOqY1fdz">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company evaluated its December 31, 2024 consolidated financial statements
for subsequent events through the date the consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Sales of the Company&#8217;s Common Stock may
be made pursuant to the Sales Agreement up to an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250201__20250207__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zQpiMK8Ymcvg" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-02-012025-02-07_custom_SalesAgreementMember" id="Fact001108" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,476,508</ix:nonFraction></span> under the Company&#8217;s Registration Statement on Form
S-3 filed on February 7, 2025 (File No. 333-284775), declared effective by the SEC on February 14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Common
Stock Issued</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-20_custom_SalesAgreementMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,201,377</ix:nonFraction></span> shares of Common
Stock for gross proceeds totaling $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-03-20_custom_SalesAgreementMember" id="Fact001112" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,511,042</ix:nonFraction></span> under the At-the-Market Issuance Sales Agreement as of the date of this report.</p>

</ix:nonNumeric><p id="xdx_81C_zBsWTnbLXMAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 137; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 23; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>CARDIO DIAGNOSTICS HOLDINGS,
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="a_0106"></span>CONDENSED CONSOLIDATED
BALANCE SHEETS</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>(unaudited)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zReJuSZkeSM6" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20250630_zpcrFlnrl23h" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z1nyPxbHnya2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,<br/> 2025</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">December 31,<br/> 2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zrohCNLrPldl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrentAbstract_iB_zorYC2gD3vAk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_iI_pp0d_maACzo5u_zceWDUMUXYCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">&#160;&#160;&#160;&#160;Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-06-30" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,966,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,827,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_iI_pp0d_maACzo5u_ze35JiTUxLeg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-06-30" id="Fact001123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,927</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0d_maACzo5u_zrRvpySwqS3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-06-30" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723,921</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_iTI_pp0d_mtACzo5u_maAz04B_zTVTHpVB7RHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" id="Fact001129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,703,348</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,790,782</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsNoncurrentAbstract_iB_zkUD8Z3TWd07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_maAz04B_zRlwSajtw3P" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact001135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0d_maAz04B_zXxHJ3UgJtUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Right of use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,298</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,397</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0d_maAz04B_zSh2ah3tVsHa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepositsAssetsNoncurrent_iI_pp0d_maAz04B_znYx9xTAPzHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-06-30" id="Fact001144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherIntangibleAssetsNet_iI_pp0d_maAz04B_zP5eucMMPkmg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,148</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">701,089</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_iTI_pp0d_mtAz04B_zAQ5Yn9PGLz4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,396,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zcbrRawvcTXa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center">LIABILITIES AND STOCKHOLDERS' EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zAt2utVMKhPe" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0d_maLCzjoI_zWMX8Y8PRAD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact001159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,661</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0d_maLCzjoI_zQUmwPuy9mJ" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Lease liability - current</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact001162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,270</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FinanceAgreementPayable_i02I_pp0d_maLCzjoI_ziMLVX705mFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Finance agreement payable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2025-06-30" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,691</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2024-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,764</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i01TI_pp0d_mtLCzjoI_maLzfEY_zMwB7rW2RIA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,597</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">631,695</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zrrxlOyRrCNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrent_i01I_pp0d_maLzfEY_zZ00Gd0sftAg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Lease liability &#8211; long term</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-06-30" id="Fact001174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,829</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_iTI_pp0d_mtLzfEY_maLASEzbrq_zyORcM3uRCc4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30" id="Fact001177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,848</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact001178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,057,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB_z6gpCuNDeHO6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i01I_pp0d_maSEzAAn_zmqOzAyeJYF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 20pt">Preferred stock, $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630_zz0Z0elrug0c" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241231_pd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact001186" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001188" decimals="INF" unitRef="USDPShares">.00001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized - <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20250630_pd" title="Preferred stock, shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20241231_pd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <br/> <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_c20250630_pd" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20250630_pd" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20241231_pd" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_c20241231_pd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of June 30, 2025 and <br/> December 31, 2024, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1183">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i01I_pp0d_maSEzAAn_zFmnmKHh96Da" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 20pt">Common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630_pd" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231_pd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact001205" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001207" decimals="INF" unitRef="USDPShares">.00001</ix:nonFraction></ix:nonFraction></span></span>
    par value; authorized - <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20250630_pn5" title="Common stock, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20241231_pd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact001209" format="ixt:numdotdecimal" decimals="-5" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <br/> <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20250630_pd" title="Common stock, shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20250630_pd" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,740,269</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_c20241231_pd" title="Common stock, shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_c20241231_pd" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,531,468</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of <br/>
    June 30, 2025 and December 31, 2024, respectively<span id="xdx_F46_zJx3xo7D1Um1">*</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_iI_pp0d_maSEzAAn_zHCwiTTHcE9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,794,778</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,309,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0d_maSEzAAn_zHG5TmE1q4v1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact001224" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,070,096</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,751,833</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iTI_pp0d_mtSEzAAn_maLASEzbrq_zP3qKwJGvTdf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total stockholders' equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-06-30" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,724,699</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557,788</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0d_mtLASEzbrq_zEjW7XFx1MW7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,396,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span id="xdx_F03_zd9Z9EG4QcC5" style="font-family: Symbol; font-size: 8pt">*</span></td>
    <td><span id="xdx_F1D_zBWbNqfGmVsd" style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:footnote id="Footnote001232" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; background-color: white">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 138 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;&#160;<b>CARDIO DIAGNOSTICS
HOLDINGS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="a_0107"></span>CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>(unaudited)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zUtK3S2uvAT5" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20250401__20250630_zdzHrMljaDVi" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240401__20240630_zeP6BUd9aOu5" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20250630_z7oMLVbKbZv7" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240630_zpYntP0Lwk3i" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">THREE
    MONTHS<br/> ENDED<br/> JUNE 30,</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">SIX
    MONTHS<br/> ENDED<br/> JUNE 30,</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_maCznCB_zlMtLaYUdzFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; padding-bottom: 1pt">Revenue</td><td style="width: 1%; font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-04-012025-06-30" id="Fact001234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,475</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-012024-06-30" id="Fact001235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,870</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-06-30" id="Fact001236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,415</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-06-30" id="Fact001237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,798</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zS8hqdjqqhIa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_iP3us-gaap--OperatingExpensesAbstract_maCzUJI_maCzmCK_z61Ybnk9Ugof" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;&#160;&#160;&#160;Selling, general and administrative expenses</td><td style="padding-bottom: 1pt; font-size: 9pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012025-06-30" id="Fact001244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,686,174</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 9pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact001245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,290,330</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 9pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact001246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,317,674</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 9pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30" id="Fact001247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,464,306</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_iT_mtCzUJI_msCznCB_zOk2PGqecoU6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-04-012025-06-30" id="Fact001249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,686,174</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-012024-06-30" id="Fact001250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,290,330</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-06-30" id="Fact001251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,317,674</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-06-30" id="Fact001252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,464,306</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtCznCB_maCznY7_zOihf0D5Hpob" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact001254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,678,699</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact001255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,282,460</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact001256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,309,259</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact001257" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,440,508</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zLilmkYqeZsc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestIncomeOperating_i01_pp0d_maCzv17_zV9hrGfMjasa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;&#160;&#160;&#160;Interest income</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2025-04-012025-06-30" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2024-04-012024-06-30" id="Fact001265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2025-01-01to2025-06-30" id="Fact001266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2024-01-012024-06-30" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">563</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01N_pp0d_di_msCzv17_zt9aqbzQfqG7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Interest expense</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-04-012025-06-30" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,690</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-04-012024-06-30" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,817</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-01-01to2025-06-30" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,381</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-06-30" id="Fact001272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,634</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01T_mtCzv17_maCznY7_zP1287pfdvUh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total other income (expenses)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012025-06-30" id="Fact001274" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,500</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact001275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact001276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,004</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-06-30" id="Fact001277" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,071</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtCznY7_maCzlH9_zhiHMDkTfjBe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss before provision for income taxes</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-04-012025-06-30" id="Fact001279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,683,199</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-012024-06-30" id="Fact001280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-06-30" id="Fact001281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,318,263</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt">&#160;</td>
    <td style="font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-06-30" id="Fact001282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></td><td style="font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_msCzlH9_zLcn4PI12dOh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1286">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1287">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzlH9_zjtJk5nElFi2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact001289" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,683,199</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact001290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact001291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,318,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact001292" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareAbstract_iB_zPUDQACYQDUg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Basic and fully diluted income (loss) per common share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Net loss per common share*</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250401__20250630_fKg_____zFMg1jvZMjGa" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_fKg_____zkzAFSURqbA8" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-04-012025-06-30" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-012025-06-30" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.97</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20240401__20240630_fKg_____zhawj9KZJqXc" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_fKg_____zQKJZJQ99OEf" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.71</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20250101__20250630_fKg_____zXrLxWt9OCl8" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_fKg_____zWRWEnzlPEx8" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-06-30" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-06-30" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.94</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20240101__20240630_fKg_____zVWcrg15ZNk3" title="Net loss per common share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_fKg_____z2cQcluJA2Xj" title="Net loss per common share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.49</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and fully diluted*</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_fKg_____zVapQgTlwFi" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_fKg_____zmGIgKXd8Gs" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,739,045</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_fKg_____zfyFOfKcIxLd" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_fKg_____z154xY3njjT2" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">753,587</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_fKg_____zqZkBnVt9Wic" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_fKg_____z2zDidAyoJp6" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-06-30" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-06-30" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,712,741</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">&#160;</td><td style="font-size: 9pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 9pt; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_fKg_____zFsbIanEwkWe" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_fKg_____zBarl97jkOI3" title="Weighted average common shares outstanding, fully diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">728,081</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; font-size: 9pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span id="xdx_F06_zp1uu06B1Oh1" style="font-family: Symbol; font-size: 8pt">*</span></td>
    <td><span id="xdx_F11_zazsPLZWmZSi" style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:footnote id="Footnote001330" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</ix:footnote></span></td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">The accompanying notes are
an integral part of these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 139 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 4pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 4pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>CARDIO DIAGNOSTICS HOLDINGS,
INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_0108"></span><b>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended June 30, 2025 and 2024</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>(unaudited)</b></span><span style="font-size: 10pt">&#160;</span><span style="font-size: 9pt">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_z7lYxVXVPCug" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzmmuov8XV7c">&#160;</td><td>&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z3oBZt8xElY3" style="font: 9pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zdIEpoQQYSk6">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B9_zT9iIDEGmQvi">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Additional</b></span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Common
    stock</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Paid-in</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares*</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount<span id="xdx_F57_zSpyCKdTtVu1">*</span></b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Capital</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Deficit</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Totals</b></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_43C_c20250101__20250331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zYlypEIBq5v6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 35%; padding-left: 5.4pt">Balances, Dec<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ember
    31, 2024</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--ShareOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zoBcAue1rRQd" title="Beginning balance, shares" style="font: 9pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,531,468</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,309,606</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact001334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,751,833</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact001335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557,788</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3custom--ShareOutstanding_zkZwggK2u4Wg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Common
    stock issued for cash, net of issuance costs</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--CommonStockIssuedForCashShares_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zBxeYllXt0Vh" title="Common stock issued for cash, net of issuance costs, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CommonStockIssuedForCashShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">206,713</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,423,782</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31" id="Fact001342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,423,784</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--RestrictedStockAwardsVested_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Restricted
    stock awards vested</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--RestrictedStockAwardsVestedShares_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zoLkV76G3vn6" title="Restricted stock awards vested, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">502</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-01-012025-03-31" id="Fact001349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--CompensationForVestedStockOptions_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Compensation
    for vested stock options</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1353">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,612</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-01-012025-03-31" id="Fact001356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,612</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1358">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1359">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,635,064</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-03-31" id="Fact001361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,635,064</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20250401__20250630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zTT7lB7qxTK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances,
    March 31, 2025</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--ShareOutstanding_iS_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zkUWnwZymUQe" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,738,683</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact001363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,764,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact001365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,386,897</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-03-31" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,377,120</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--RestrictedStockAwardsVested_zmzXzIsEHxW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Restricted
    stock awards vested</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--RestrictedStockAwardsVestedShares_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zjfHkzeshRO2" title="Restricted stock awards vested, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,559</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1370">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1372">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2025-04-012025-06-30" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--CompensationForVestedStockOptions_z3Y5sMkTsBHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Compensation
    for vested stock options</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1377">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,778</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1379">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2025-04-012025-06-30" id="Fact001380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,778</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--FractionalSharesAdjustment_iP3custom--CompensationForVestedStockOptions_zugxNlAFcacg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Fractional
    shares adjustment</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--FractionalSharesAdjustmentShares_iP3custom--FractionalSharesAdjustment_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zXKpKzlxarXl" title="Fractional shares adjustment, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:FractionalSharesAdjustmentShares" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1382">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProfitLoss_zMf7Gc04DQZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1389">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1390">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact001391" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,683,199</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-04-012025-06-30" id="Fact001392" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,683,199</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_432_c20250401__20250630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z2MQqyPnTKL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances,
    June 30, 2025</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--ShareOutstanding_iE_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zKFWTQM0j2H9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,740,269</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,794,778</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,070,096</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-06-30" id="Fact001397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,724,699</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20240101__20240331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zvQ2Q4HanbAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances,
    December 31, 2023</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareOutstanding_iS_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____z88E0FROlX56" title="Beginning balance, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">684,680</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,326,497</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact001403" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,368,380</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact001404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,958,124</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zAxpl1iJeeDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Common
    stock and warrants issued for cash, net of issuance costs</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--CommonStockIssuedForCashShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zrJKZFrI9yA1" title="Common stock issued for cash, net of issuance costs, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CommonStockIssuedForCashShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,963</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1408">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,722,857</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1410">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,722,857</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--RestrictedStockAwardsVested_zetPmvdYlpU3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Restricted
    stock awards vested</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--RestrictedStockAwardsVestedShares_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____z9qhmWByshff" title="Restricted stock awards vested, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,323</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1415">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1417">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-01-012024-03-31" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--CompensationForVestedStockOptions_zuoy3t8TQFO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Compensation
    for vested stock options</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1422">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,461,404</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1424">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-01-012024-03-31" id="Fact001425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,461,404</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_zEvViMkvMDJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1427">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1428">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact001429" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,163,584</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-03-31" id="Fact001430" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,163,584</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_434_c20240401__20240630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zHNFvT60Pu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances,
    March 31, 2024</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--ShareOutstanding_iS_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zGBYQkXBOcgl" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact001437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">720,966</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,568,758</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,531,964</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-03-31" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,036,801</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zCguXEZx5bA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Common
    stock issued for cash</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--CommonStockIssuedForCashShares_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zc3B2LpECljb" title="Common stock issued for cash, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CommonStockIssuedForCashShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,822</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,298,698</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1441">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30" id="Fact001442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,298,699</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--RestrictedStockAwardsVested_zm4MGzIMtHx3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Restricted
    stock awards vested</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--RestrictedStockAwardsVestedShares_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____z9bY20bINX6c" title="Restricted stock awards vested, shares" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVestedShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact001451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1446">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1448">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:RestrictedStockAwardsVested" contextRef="From2024-04-012024-06-30" id="Fact001449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CompensationForVestedStockOptions_zoJlqNcmp1Bl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Compensation
    for vested stock options</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1453">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,731</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1455">&#8212;</span></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:CompensationForVestedStockOptions" contextRef="From2024-04-012024-06-30" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,731</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_zfGuEYPIjpqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1458">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1459">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012024-06-30" id="Fact001461" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20240401__20240630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zeO54gSeI679" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances,
    June 30, 2024</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--ShareOutstanding_iE_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____z6NbNcmIcMQj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cdio:ShareOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">777,103</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact001464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,894,187</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,819,959</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-06-30" id="Fact001466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,074,236</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span id="xdx_F09_zS7J36R7CfTb" style="font-family: Symbol; font-size: 8pt">*</span></td>
    <td><span id="xdx_F17_znLLGaBKs43j" style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:footnote id="Footnote001469" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.</ix:footnote></span></td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 140 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_0109"></span><b>CONDENSED CONSOLIDATED&#160;STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>(unaudited)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zGd6Ouulafxj" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20250630_zPeVSLzW8LCg" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240630_zuG6q8hvy692" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended June 30,</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zUsZqa08K344" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_pp0d_maNCPBUz7MG_zCVoLj0Oif7f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; text-indent: 10pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact001474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,318,263</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact001475" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zXIx1dGzN9yj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Adjustments to reconcile net loss to net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_pp0d_maNCPBUz7MG_zcjIcAl2OPPd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-06-30" id="Fact001480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,441</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-06-30" id="Fact001481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentForAmortization_i02_pp0d_maNCPBUz7MG_zwkIjSBRpXX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2025-01-01to2025-06-30" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-06-30" id="Fact001484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,877</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_pp0d_maNCPBUz7MG_zbxTgkp8p4g8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-06-30" id="Fact001486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,546,135</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zpqct8InEEHl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pp0d_di_msNCPBUz7MG_zK4NeYnl9Gm6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-06-30" id="Fact001492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,685</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-06-30" id="Fact001493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,560</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pp0d_di_msNCPBUz7MG_zr1rqaHsKJw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-06-30" id="Fact001495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">220,762</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-06-30" id="Fact001496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">656,310</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_pp0d_maNCPBUz7MG_z6rmzV3ufHMh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-06-30" id="Fact001498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,937</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-06-30" id="Fact001499" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">191,132</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_pp0d_maNCPBUz7MG_z2MIYcdFWQVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-06-30" id="Fact001501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,666</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-06-30" id="Fact001502" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,080</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_pp0d_mtNCPBUz7MG_maCCERCzao2_zTeLLDRM4F1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN OPERATING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact001504" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,971,566</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-06-30" id="Fact001505" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,443,450</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zLsYWtIOf1re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0d_di_msNCPBUzXwH_zoqILTVU0A91" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Purchases of property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-06-30" id="Fact001510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,483</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-06-30" id="Fact001511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,881</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0d_di_msNCPBUzXwH_z2lYjF1Ma7Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs incurred</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2025-01-01to2025-06-30" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,649</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-012024-06-30" id="Fact001514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,129</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_pp0d_mtNCPBUzXwH_maCCERCzao2_zWMgpO0ynJK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN INVESTING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact001516" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,132</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-06-30" id="Fact001517" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,010</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_znuCEuemJY78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_pp0d_maNCPBUzFMa_zYIhC4wnDG9l" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Proceeds from sale of common stock and warrants, net of issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-06-30" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,423,784</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-06-30" id="Fact001523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,021,556</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PaymentsToAcquireFinanceReceivable_i01N_pp0d_di_msNCPBUzFMa_z17wh5T0ALWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Payments of finance agreement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cdio:PaymentsToAcquireFinanceReceivable" contextRef="From2025-01-01to2025-06-30" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,073</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cdio:PaymentsToAcquireFinanceReceivable" contextRef="From2024-01-012024-06-30" id="Fact001526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0d_mtNCPBUzFMa_maCCERCzao2_zcekKBUaK09i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact001528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,193,711</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-06-30" id="Fact001529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,741,056</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0d_mtCCERCzao2_zGIdRpdDLbPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">NET INCREASE IN CASH</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-01to2025-06-30" id="Fact001531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,013</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-06-30" id="Fact001532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,596</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">CASH - BEGINNING OF PERIOD</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,827,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact001535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,283,523</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">CASH - END OF PERIOD</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" id="Fact001537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,966,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact001538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,119</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z8nUqQqMUkp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CashPaidDuringPeriodForAbstract_iB_zOfPNsuMmUN6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;Interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-06-30" id="Fact001546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,381</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-06-30" id="Fact001547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,634</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1549">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b>&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 141 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b><span id="a_0110"></span>NOTES TO CONDENSED CONSOLIDATED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p id="xdx_04D_c20250101__20250630_zBPTvbx87nB" style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001552" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zK9kI5JM98pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 - <span id="xdx_828_zr0p1iZr6SJ2">Organization and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements presented
are those of Cardio Diagnostics Holdings, Inc., (the &#8220;Company&#8221;) and its wholly-owned subsidiary, Cardio Diagnostics, Inc.
(&#8220;Legacy Cardio&#8221;). The Company was incorporated as Mana Capital Acquisition Corp. (&#8220;Mana&#8221;) under the laws of the
state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics,
LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed to develop and commercialize
a patent-pending Artificial Intelligence (&#8220;AI&#8221;)-driven DNA biomarker testing technology (&#8220;Core Technology&#8221;) for
cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the leading medical technology
companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the
approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for
major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure and
diabetes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Interim Financial Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following (a)  consolidated balance sheet
as of December 31, 2024, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim
financial statements of the Company as of and for the period ended June 30, 2025 have been prepared in accordance with the instructions
to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for
complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative
of results that may be expected for the year ending December 31, 2025 or any future periods. These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December
31, 2024 included in the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on March 20, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Reverse Stock Split</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company held its annual meeting of stockholders
on November 15, 2024, where the Company&#8217;s stockholders approved a reverse stock split at a ratio within a range of&#160;<span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250101__20250630_z4fc6rvNoeK8" title="Reverse stock split" class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact001554" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-5
and&#160;1-for-40</ix:nonNumeric></span> and granted the Company&#8217;s Board of Directors the discretion to determine the timing and ratio of the split within
such range.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On April 10, 2025, the Company&#8217;s Board
of Directors determined to effect the reverse stock split of the common stock at a&#160;1-for-30 ratio (the "Reverse Stock Split&#8221;)
and approved the filing of a Certificate of Amendment (the "Certificate of Amendment&#8221;) to the Third Amended and Restated Certificate
of Incorporation of the Company to effect the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On May 12, 2025, the Company filed the Certificate
of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, effective immediately after the close of trading
on Nasdaq on May 12, 2025 (the "Effective Time&#8221;). At the Effective Time, every 30 shares of issued and outstanding common stock
automatically combined into one issued share of common stock, with no change in par value. No fractional shares were issued as a result
of the Reverse Stock Split. Instead of issuing fractional shares, the Company rounded shares up or down to the nearest whole number as
determined by DTC at the participant level. The Reverse Stock Split did not modify any voting rights or other terms of the common stock.
The Company&#8217;s common stock began trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the open of the
markets on May 13, 2025. The Reverse Stock Split was implemented for the purpose of regaining compliance with the minimum bid price requirement
for continued listing of the Company&#8217;s common stock on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As a result of the Reverse Stock Split,
the number of shares of common stock outstanding was reduced from&#160;52,160,487&#160;shares to&#160;<span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20250512_zLEhJFGXBrK" title="Common stock, shares outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-05-12" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,738,683</ix:nonFraction></span>&#160;shares,
exclusive of 27 whole shares issued for rounding up fractional shares (which was issued in May 2025), and the number of authorized
shares of common stock remains&#160;<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pn5n6_c20250630_zUXvz5lEfOXi" title="Common stock, shares authorized" class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact001558" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">300</ix:nonFraction></span>&#160;million
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise indicated, all  issued,
and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted
to reflect the&#160;1-for-30 Reverse Stock Split for all prior periods presented.&#160;Proportionate adjustments for the Reverse Stock
Split were made to the exercise prices and number of shares issuable under the Company&#8217;s equity incentive plans, and the number
of shares underlying outstanding equity awards, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The impacts of the Reverse Stock Split were applied
retroactively for all periods presented in accordance with applicable guidance, less the number of rounded whole shares issued for fractional
shares on May 12, 2025. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following
tables may not foot due to rounding.</p>

<ix:exclude><p id="xdx_23F_zBluQ2OshWQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 142; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 28; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zkYIAPoBjOg9" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates changes in equity,
as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse Stock Split retroactively adjusted for the
periods presented:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001561" name="us-gaap:ScheduleOfSubsequentEventsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSubsequentEventsTextBlock_zpYZjRGCbUsd" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zt84fx4y3b03" style="display: none">Schedule of subsequent events</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>June 30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_ecustom--CommonStockShares_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z0P94rZzChEg" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,313,070</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(<ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001565" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">22,535,967</ix:nonFraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">777,103</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Common stock - amount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--CommonStockValues_iI_pp0d_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbJTmqYMjgwe" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(<ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,893,962</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,894,187</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>March
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlCGB6q1lAo5" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember" id="Fact001581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,628,974</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zY3KZL3tZji5" title="Common stock - shares">(<ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">20,908,008</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z3wGkOP3IwR6" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-03-31_custom_AsRevisedMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">720,966</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zepu5rMhFSc4" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z9WxqGHZVmEe" title="Common stock - amount">(<ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember" id="Fact001589" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_zpisezl81zd6" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-03-31_custom_AsRevisedMember" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzlGBn0KrMzl" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,568,549</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zWf6HDeIzXd8" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z4DbKHEBQAm1" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-03-31_custom_AsRevisedMember" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,568,758</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,944,039</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(<ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001601" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">44,412,571</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2024-12-31_custom_AsRevisedMember" id="Fact001603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,531,468</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001605" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(<ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">444</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2024-12-31_custom_AsRevisedMember" id="Fact001609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,309,162</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31_custom_AsRevisedMember" id="Fact001615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,309,606</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,540,409</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(<ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001619" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">19,855,729</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"><ix:nonFraction name="cdio:CommonStockShares" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">684,680</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(<ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001625" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">198</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"><ix:nonFraction name="cdio:CommonStockValues" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,326,299</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,326,497</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z6w6NjRtD9K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates changes in loss per
share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse
Stock Split retroactively adjusted for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001635" name="cdio:ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_zpY1nXvhMbNf" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 1)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BD_z3AbVHx5SOmg" style="display: none">Schedule of loss per share and weighted average shares outstanding</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss attributable to common shareholders</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001637" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001641" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares used to compute basic and
    diluted EPS</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zi6jVSxtJug4" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6xhhlWAEj0d" title="Weighted average common shares outstanding, fully diluted"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,842,422</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_90D_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(<ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001647" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001649" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">21,114,341</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">728,081</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss per share - basic and diluted</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001655" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001657" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001659" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001661" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.24</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001663" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001665" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.49</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Three
    months ended June 30, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 5.4pt">Loss attributable to common shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001667" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLoss_pp0d_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z608DvtVr0Z7" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1669">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_AsRevisedMember" id="Fact001671" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Weighted average shares used to compute basic and diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, fully diluted"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,607,618</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(<ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001677" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001679" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">21,854,031</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_custom_AsRevisedMember" id="Fact001681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="cdio:WeightedAverageCommonSharesOutstandingFullyDiluted" contextRef="From2024-04-012024-06-30_custom_AsRevisedMember" id="Fact001683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">753,587</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001685" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001687" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.06</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001691" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.65</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30_custom_AsRevisedMember" id="Fact001693" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30_custom_AsRevisedMember" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.71</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zz5rjvTplPx" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation
of diluted shares outstanding because the effect would be anti-dilutive:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001697" name="cdio:ScheduleOWarrantsExercisableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOWarrantsExercisableTextBlock_zCu6qmEE8mZ7" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 2)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8B9_zja0MIWV8Jai" style="display: none">Schedule of warrants exercisable</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock options</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBUuIFKhWLKa" title="Common stock options"><ix:nonFraction name="cdio:CommonStockOptions" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001699" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,796,725</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock options">(<ix:nonFraction name="cdio:CommonStockOptions" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001701" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,670,168</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock options"><ix:nonFraction name="cdio:CommonStockOptions" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,557</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZGhGby5IEQ5" title="Common stock warrants"><ix:nonFraction name="cdio:CommonStockWarrants" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,528,766</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock warrants">(<ix:nonFraction name="cdio:CommonStockWarrants" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001707" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">8,244,474</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock warrants"><ix:nonFraction name="cdio:CommonStockWarrants" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001709" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zEieOGR6BSG6" style="font: 9pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zrUCUW4mI222" style="font: 9pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 143 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 29; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_234_zgCnUIxhvOZ2" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Stock options were adjusted retroactively to
give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001712" name="cdio:ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_zcFHdmLaMnQh" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 3)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B4_zBHOArNBgO1e" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zR616nd98ZTb" title="Options outstanding, beginning"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001714" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,584,599</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3uOjSwFxC44" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001716" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z34kfibtIwt3" title="Options outstanding, beginning">(<ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001718" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,498,446</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zJ9SSnoR0Jw1" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001720" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">88.66</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zSPbPGFxKZEi" title="Options outstanding, beginning"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,153</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zD9reunbj5qa" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001724" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">91.72</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGG3WxZZQ3B8" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,218,126</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001728" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options granted">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001730" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,177,522</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.07</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,604</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">62.14</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    cancelled</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmBHkmjywouk" title="Options cancelled">(<ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">6,000</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price cancelled"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z7OmQWfrVAIk" title="Options cancelled"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,800</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price cancelled"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.19</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zIuYcGYDcfwl" title="Options cancelled">(<ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">200</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price cancelled"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5AzGUcG24hc" title="Options outstanding, ending"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,796,725</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6Yi8BjVYlTc" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001752" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.74</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zYSYNxFVGy3b" title="Options outstanding, ending">(<ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001754" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,670,168</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z8ArIw1NhnG7" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001756" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79.53</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zWcFEIPqnHTb" title="Options outstanding, ending"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,557</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_z6RrXAsbfll8" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001760" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.27</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--OptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ywNTqRtCih" title="Options vested and exercisable"><ix:nonFraction name="cdio:OptionsVestedAndExercisable" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,789,225</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zk6bfUxx9En8" title="Weighted average exercise price outstanding, Options vested and exercisable"><ix:nonFraction name="cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001764" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.74</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options vested and exercisable">(<ix:nonFraction name="cdio:OptionsVestedAndExercisable" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,662,918</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"><ix:nonFraction name="cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79.53</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options vested and exercisable"><ix:nonFraction name="cdio:OptionsVestedAndExercisable" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,307</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"><ix:nonFraction name="cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001772" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.27</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AB_zM3n5OyRUNv3" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Warrants were adjusted
retroactively to give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001774" name="cdio:ScheduleOfWarrantsAdjustmentsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfWarrantsAdjustmentsTableTextBlock_zDY4zYb0EIta" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 4)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B8_zY1wGgYEBwWj" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at December 31, 2023</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKWqwhAdgGcj" title="Warrants outstanding, beginning"><ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,854,620</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z17giM8MmWsb" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact001778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ztOJEeRGXhE8" title="Warrants outstanding, beginning">(<ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001780" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">7,592,799</ix:nonFraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zqDQ5IDT7xq7" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember" id="Fact001782" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">281.35</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zEnRBiZbAVni" title="Warrants outstanding, beginning"><ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">261,821</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zQ7RLz7NP28a" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_AsRevisedMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">291.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhH8hkXhTj78" title="Warrants granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,146</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price, granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ziFj1lIFLsy6" title="Warrants granted">(<ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001792" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">651,675</ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.62</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zqFWAjVDb1Ub" title="Warrants granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,471</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2024-01-012024-06-30_custom_AsRevisedMember" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">53.40</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants cancelled</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFfFZymhHLTc" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zywJi7N2dSv1" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx1gjKa7t7ue" title="Warrants outstanding, ending"><ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,528,766</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zT9MFQyIVsw4" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember" id="Fact001814" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.08</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zZRxYowVaOJ7" title="Warrants outstanding, ending">(<ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001816" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">8,244,474</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zLFD4vn8jDak" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember" id="Fact001818" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">263.18</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zpZZgfUzQoed" title="Warrants outstanding, ending"><ix:nonFraction name="cdio:ClassOfWarrantOrRightOutstandings" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zrYGbwhJwujk" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_AsRevisedMember" id="Fact001822" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">272.26</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zv1vLxFagL05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001824" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zXnzAM93Vftf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; <span id="xdx_82D_zvNMoO0pTkIc">Summary of Significant Accounting
Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001826" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zl60xhPDXMab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zYwROa3I9txl">Principles of Consolidation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio.&#160;All intercompany accounts and transactions have been
eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001828" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_zsYjArLjRd73" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_z9vhkwplhIGc">Use of Estimates in the Preparation of Financial
Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p>

<p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001830" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNWmy4gcCel4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zBAIFoxhFVF9">Segments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;), who is our chief executive officer, for making operating decisions and assessing
performance as the source for determining the Company&#8217;s reportable segments. Management, including the CODM, reviews operating results
solely by monthly revenue and operating results of the Company and, as such, the Company has determined that the Company has one operating
segment (product testing) as defined by ASC Topic 280 &#8220;Segment Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One hundred percent of the Company&#8217;s revenues
are generated from products tests for major types of cardiovascular disease, and therefore the Company has one operating segment for financial
reporting purposes. The Company&#8217;s principal products are its Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD assesses the risk for
a coronary heart disease event, including a heart attack, in the next three years. PrecisionCHD aids in diagnosing and managing coronary
heart disease. The tests can be paid for by provider organizations, patients, and/or employers. Customers are generally charged for tests
utilized for the minimum committed test volume and the pricing can vary based on organization type, size and volume.</p>

<ix:exclude><p id="xdx_231_zvWrsIB8CsUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 144 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 30; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_235_zh3FvvhlNg9f" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment information is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001833" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><span id="xdx_8BB_zGDkB6bUDBQc" style="display: none">Schedule of segment information</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#8203;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">December&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">&#160;&#160;&#160;&#160;Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,966,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,827,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,927</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723,921</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current segment assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,703,348</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,790,782</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Right of use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,298</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001857" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,397</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsCurrent" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,850</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,148</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">701,089</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total segment assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,396,547</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember" id="Fact001869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,615,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment operating results are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Revenue</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" title="Revenues" style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember" id="Fact001871" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" title="Revenues" style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember" id="Fact001873" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,798</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001875" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001877" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,798</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-left: 5.4pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cdio:PayrollAndRelatedCosts" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:PayrollAndRelatedCosts" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,387,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RentAndFacilityExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,854</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:RentAndFacilityExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001886" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:ConsultingAndContractorExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:ConsultingAndContractorExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:InsuranceExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:InsuranceExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,558</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:FilingFeesExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:FilingFeesExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:TransferAgentExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:TransferAgentExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:SoftwareAndWebComputingExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:SoftwareAndWebComputingExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,488</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:BoardCompensationExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:BoardCompensationExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:InvestorRelationsExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:InvestorRelationsExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zPhum7r27AA7">(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:OtherSegmentItems" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="cdio:OtherSegmentItems" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,004</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,071</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember" id="Fact001927" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,318,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember" id="Fact001928" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,451,579</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right">(a)</td><td style="width: 5pt"/><td id="xdx_F18_zwvtHqID77o7" style="text-align: justify"><ix:footnote id="Footnote001929" xml:lang="en-US">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_z4n0ZsIqNjog" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z7mufLI5o0u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 145 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 31; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_236_zM005yhoaoPb" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z0Yn4dUzwD6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Three Months
    Ended June 30</b></span>,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" title="Revenues" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember" id="Fact001934" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,475</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" title="Revenues" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember" id="Fact001936" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,870</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" title="Revenues" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001938" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,475</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" title="Revenues" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001940" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,870</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:PayrollAndRelatedCosts" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,471</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:PayrollAndRelatedCosts" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,245</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:RentAndFacilityExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,461</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:RentAndFacilityExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,744</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,736</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:ConsultingAndContractorExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,905</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:ConsultingAndContractorExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,499</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:InsuranceExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,263</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:InsuranceExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,821</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:FilingFeesExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,159</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:FilingFeesExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,804</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:TransferAgentExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,554</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:TransferAgentExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,587</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:SoftwareAndWebComputingExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:SoftwareAndWebComputingExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:BoardCompensationExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,778</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:BoardCompensationExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,958</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:InvestorRelationsExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,750</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:InvestorRelationsExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,429</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zcYwFIWWI5Gk">(a)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:OtherSegmentItems" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001975" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,742</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cdio:OtherSegmentItems" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,456</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,096</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001981" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,043</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001982" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,779</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,794</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,535</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember" id="Fact001990" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,683,199</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember" id="Fact001991" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,287,995</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt"><ix:footnote id="Footnote001992" xml:lang="en-US">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</ix:footnote></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_8A1_zCqMEGDYcDLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zvppydljKrM" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 146 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 32; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23F_zU0e91MN1Jp5" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zw4iyr1wW8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001996" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2mAdQMUlbFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_z8pJAsGR6pv6">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
Research and development costs charged to operations for the six months ended June 30, 2025 and 2024 were $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630_pp0p" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-06-30" id="Fact001998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,296</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_pp0p" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30" id="Fact002000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,120</ix:nonFraction></span>, respectively,
and for the three months ended June 30, 2025 and 2024 were $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20250401__20250630_pp0p" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012025-06-30" id="Fact002002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,096</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_pp0p" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30" id="Fact002004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,280</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002006" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zl5jecmfnhNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_znG9dE2Sv5dk">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses advertising costs as incurred.
Advertising costs of $<span id="xdx_909_eus-gaap--AdvertisingExpense_c20250101__20250630_pp0p" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2025-01-01to2025-06-30" id="Fact002008" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,435</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20240101__20240630_pp0p" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2024-01-012024-06-30" id="Fact002010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,181</ix:nonFraction></span> were charged to operations for the six months ended June 30, 2025 and 2024, respectively, and
of $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20250401__20250630_pp0p" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2025-04-012025-06-30" id="Fact002012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,615</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20240401__20240630_pp0p" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2024-04-012024-06-30" id="Fact002014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,779</ix:nonFraction></span> for the three months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002016" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCcjix61MV8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_z3nIqiyDjCoc">Cash and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are comprised of cash and
highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zjINRfafLPR1" title="Cash equivalents"><span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20241231_zkGi9ZqE3K91" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact002018" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact002020" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any cash equivalents
as of June 30, 2025 and December 31, 2024. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions
are insured by the FDIC up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20250630_pp0p" title="FDIC Insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-06-30" id="Fact002022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. The Company is exposed to credit risk in the event of default by the financial institutions or
the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of June 30, 2025 and December 31, 2024 was approximately $<span id="xdx_906_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20250630_zwLs3JyT22I9" title="Amount in excess of FDIC insurance"><ix:nonFraction name="cdio:AmountInExcessOfFdicInsurance" contextRef="AsOf2025-06-30" id="Fact002024" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.6</ix:nonFraction></span> million and $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_z9zOPeI3oJ0k" title="Amount in excess of FDIC insurance"><ix:nonFraction name="cdio:AmountInExcessOfFdicInsurance" contextRef="AsOf2024-12-31" id="Fact002026" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million, respectively. The Company has not experienced
any losses on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk
with regard to these deposits is not significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002028" name="cdio:ReclassificationPolicyTextBlock"><p id="xdx_844_ecustom--ReclassificationPolicyTextBlock_zP6QjNBgUMaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zggMIIs6RLqk">Reclassification</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified
to conform with the current period presentation. On the condensed consolidated statements of changes in stockholders&#8217; equity and
cash flows, payment of placement agent fee has been combined with common stock and warrants issued for cash rather than being separated
out, to present net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002030" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZeQL7AYBsje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_zZ2vRqjKSUWj">Recent Accounting Pronouncements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily
through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income
tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is
effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the
impact that ASU 2023-09 will have on the condensed consolidated financial statements and its plan for adoption, including the adoption
date and transition method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Disaggregation of Income Statement Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the FASB issued ASU No. 2024-03,
&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&#8221;, which requires disaggregated disclosure of income statement expenses for public business entities.
ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying
any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee
compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses
and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods
beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance
can be applied prospectively with an option for retrospective application. Early adoption is also permitted. We are currently evaluating
the provisions of this ASU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed other recent accounting pronouncements
and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial
statements as a result of future adoption.</p>

<ix:exclude><p id="xdx_23D_zSFzdBlhicp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zlUyr5VCSqYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 147 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 33; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23C_ziFuY9jC4MY8" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002034" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2Nile72S6Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; <span id="xdx_825_z8chcBPXzx55">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are carried at cost and consist
of the following at June 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002036" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3PtcAmmUii" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5QIunZAOLc7" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zLPYcwrjG5a5" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zfasNjvyN0h1" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0d_maPPAENzAGD_zlMCiNM2Btx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Office and computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2025-06-30" id="Fact002038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,264</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact002039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,032</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pp0d_maPPAENzAGD_z81QV8y8prOl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2025-06-30" id="Fact002041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,069</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2024-12-31" id="Fact002042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,818</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0d_maPPAENzAGD_zly4O7Rx1KBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2025-06-30" id="Fact002044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,423</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2024-12-31" id="Fact002045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,423</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_pp0d_maPPAENzAGD_zxtNEfehQQ5b" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2025-06-30" id="Fact002047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">502,155</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2024-12-31" id="Fact002048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">502,155</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_msPPAENzAGD_zFVT9ph36CP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact002050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,008</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact002051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,567</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0d_mtPPAENzAGD_z7JAVJAVIeR" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;&#160;Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact002053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact002054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leasehold improvements of $<span id="xdx_902_eus-gaap--LeaseholdImprovementsGross_c20250630_pp0p" title="Leasehold Improvements"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2025-06-30" id="Fact002056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">502,155</ix:nonFraction></span> represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense of $<span id="xdx_907_eus-gaap--Depreciation_c20250101__20250630_pp0p" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-06-30" id="Fact002058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,441</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_c20240101__20240630_pp0p" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-06-30" id="Fact002060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,579</ix:nonFraction></span> was charged
to operations for the six months ended June 30, 2025 and 2024, respectively, and of $<span id="xdx_902_eus-gaap--Depreciation_c20250401__20250630_pp0p" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-04-012025-06-30" id="Fact002062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,785</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--Depreciation_c20240401__20240630_pp0p" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-04-012024-06-30" id="Fact002064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,992</ix:nonFraction></span> for the three months ended June
30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002066" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zY6U7MoBlpad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; <span id="xdx_82E_zCBGHDr1yqi5">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides details associated with
the Company&#8217;s acquired identifiable intangible assets at June 30, 2025 and December 31, 2024:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002068" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsomD40dIqVh" summary="xdx: Disclosure - Intangible Assets (Details)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B4_zxMHN2bNC403" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zUmaSQaoeAR2" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zO7pRLBhVoV1" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzF5l_zeSLq06VrdX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Know-how license</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-06-30" id="Fact002070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" id="Fact002071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzF5l_zGrk2x9OgeV1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-06-30" id="Fact002073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact002074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzF5l_zrlwhrfsnpc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact002077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense charged to operations was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630_pp0p" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-06-30" id="Fact002079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240630_pp0p" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-06-30" id="Fact002081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span> for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630_pp0p" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-04-012025-06-30" id="Fact002083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240401__20240630_pp0p" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-04-012024-06-30" id="Fact002085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> for the three months ended June 30, 2025
and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002087" name="cdio:PatentAndTrademarkCostsTextBlock"><p id="xdx_800_ecustom--PatentAndTrademarkCostsTextBlock_z2ywE5Nusa6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_82A_zVQTP5XVMP">Patent Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2025, in the first family of
patents and patent applications owned solely by UIRF which is exclusively licensed by Cardio, there are eight granted patents (US
(2), EU, China, Australia, India, Hong Kong and Japan) and other pending patent applications. The Company has pending patent
applications in patent families two, three, four, five and six. Legal fees associated with the patents totaled $<span id="xdx_90C_eus-gaap--LegalFees_c20250101__20250630_pp0p" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-01to2025-06-30" id="Fact002089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,148</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--LegalFees_c20240101__20240630_pp0p" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-06-30" id="Fact002091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">701,089</ix:nonFraction></span>, net of accumulated
amortization of $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-06-30_us-gaap_PatentsMember" id="Fact002093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,510</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,920</ix:nonFraction></span>
as of June 30, 2025 and December 31, 2024, respectively and are presented in the condensed consolidated balance sheets as patent
costs. Patents are amortized over their estimated useful lives of approximately <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zolxFMgzKVHc" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact002097" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">14</ix:nonNumeric></span>
and <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1AitjJ5h3L7" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact002099" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span>
years, respectively. Amortization expense charged to operations was $<span id="xdx_909_eus-gaap--AdjustmentForAmortization_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2025-01-012025-06-30_us-gaap_PatentsMember" id="Fact002101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,590</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-06-30_us-gaap_PatentsMember" id="Fact002103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,587</ix:nonFraction></span>
for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2025-04-012025-06-30_us-gaap_PatentsMember" id="Fact002105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,152</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--AdjustmentForAmortization_c20240401__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-04-012024-06-30_us-gaap_PatentsMember" id="Fact002107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">794</ix:nonFraction></span>
for the three months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002109" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_z2Uj1dtFNXEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; <span id="xdx_825_zeOBvS5n7AH9">Operating Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">The Company determines if a contract is, or
contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current
portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#8217;s consolidated balance
sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations,
net of current portion in the Company&#8217;s condensed consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">ROU assets represent the right to use an underlying
asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and
lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition,
ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and
exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms
include options to extend or terminate&#160;the lease when it is reasonably certain that the Company will exercise that option. Leases
with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">In 2023, the Company entered into a lease
agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and expiring on
November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental installments
from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.</p>

<ix:exclude><p id="xdx_233_zXAunFw0j2U" style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 148 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 34; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_23A_z0EOkjlA5VAa" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $<span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p" title="Monthly rent payment"><ix:nonFraction name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" contextRef="From2023-08-022023-11-30" id="Fact002112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,505</ix:nonFraction></span> ($<span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p" title="Annually rent payment"><ix:nonFraction name="cdio:AnnuallyRentPayment" contextRef="From2023-08-022023-11-30" id="Fact002114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,060</ix:nonFraction></span> annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#8220;TIA&#8221;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $<span id="xdx_902_ecustom--PremisesAllowance_c20250101__20250630_pp0p" title="Premises allowance"><ix:nonFraction name="cdio:PremisesAllowance" contextRef="From2025-01-01to2025-06-30" id="Fact002116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">Pursuant to ASC Topic 842 Leases, the Company
accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated to be payable on December
1, 2023. The Company received the TIA from landlord in maximum amount of $<span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p" title="Amount receivable"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2024-01-16" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,000</ix:nonFraction></span> on January 16, 2024 and recorded a reimbursement receivable
from landlord of $<span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p" title="Reimbursement receivable"><ix:nonFraction name="cdio:ReimbursementReceivable" contextRef="AsOf2023-12-31" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,000</ix:nonFraction></span> as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">During the year ended December 31, 2023, the
Company recorded ROU assets of $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p" title="ROU assets"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,875</ix:nonFraction></span> and operating lease liabilities of $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p" title="Operating lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact002124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">642,523</ix:nonFraction></span> at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be <span id="xdx_902_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_zaeVzAhFJKkb" title="Borrowing rate"><ix:nonFraction name="us-gaap:SubordinatedBorrowingInterestRate" contextRef="From2023-01-012023-12-31_custom_ChicagoMember" id="Fact002126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.57</ix:nonFraction>%</span> for Chicago lease and <span id="xdx_900_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_zspWYz9z8Kzf" title="Borrowing rate"><ix:nonFraction name="us-gaap:SubordinatedBorrowingInterestRate" contextRef="From2023-01-012023-12-31_stpr_IA" id="Fact002128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.24</ix:nonFraction>%</span> for Iowa City
lease, respectively, as the interest rate implicit in our lease is not readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0pt; text-align: justify">As of June
30, 2025 and December 31, 2024, operating lease ROU assets and operating lease liabilities are recorded on the condensed consolidated
balance sheets as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002130" name="cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zNtVTQFk8b56" summary="xdx: Disclosure - Operating Leases (Details)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B8_z9dBFAE1NiV7" style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_c20250630_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" id="Fact002131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,298</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20241231_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact002132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,397</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_c20250630_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact002133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,182</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_c20241231_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact002134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20250630_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="Fact002135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,251</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20241231_pp0p"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact002136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,829</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zx2IisfyivP5" style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">As of June 30, 2025, the
weighted-average remaining lease terms of the two operating leases were <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zC4jPIJ7t9Db"><ix:nonNumeric contextRef="AsOf2025-06-30_custom_LeaseOneMember" format="ixt-sec:duryear" id="Fact002137" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.42</ix:nonNumeric> </span>years
and <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zWAY2UZMusj"><ix:nonNumeric contextRef="AsOf2025-06-30_custom_LeaseTwoMember" format="ixt-sec:duryear" id="Fact002138" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.42</ix:nonNumeric></span>
years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002140" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zh5iJedn1Ybl" summary="xdx: Disclosure - Operating Leases (Details 1)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B0_zFoADQYAUHi9" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_c20250630_zsMfhNSLQSG7" title="2025 (remaining period)"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_c20250630_zZtYySMFLxlj" title="2026"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-06-30" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_c20250630_zgMIsXczn6Wj" title="2027"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-06-30" id="Fact002146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,060</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_c20250630_zSmbhAe3Hxsg" title="2028"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-06-30" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0d_c20250630_zSvUnCBTwA34" title="Total minimum lease payments"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" id="Fact002150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,725</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0d_c20250630_zSvnyIqZocr2" title="Less: Imputed interest"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" id="Fact002152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,292</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0d_c20250630_z4pHZmPwSRT6" title="Present value of lease liabilities"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-06-30" id="Fact002154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,433</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">At June 30, 2025, the Company had the following
future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_zaj12noFBQb1" title="2025 (remaining period)" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" id="Fact002156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,958</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zeObSfRyjXk5" title="2026" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-06-30" id="Fact002158" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,152</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20250630_z2dvVzmsSMSh" title="2027" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-06-30" id="Fact002160" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,060</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20250630_z5J4jQGmjp7b" title="2028" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-06-30" id="Fact002162" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,555</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_zKF4aZT1pbmd" title="Total minimum lease payments" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" id="Fact002164" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">576,725</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zswGVDPHbb81" style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">Consolidated rental expense for all operating
leases was $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20250101__20250630_pp0p" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-01to2025-06-30" id="Fact002166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,525</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20240630_pp0p" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-06-30" id="Fact002168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,398</ix:nonFraction></span> for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_c20250401__20250630_pp0p" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-04-012025-06-30" id="Fact002170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,939</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240401__20240630_pp0p" title="Rental expense for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-04-012024-06-30" id="Fact002172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,582</ix:nonFraction></span> for the three months
ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">The following table summarizes the cash paid
and related right-of-use operating lease recognized for the six months ended June 30, 2025 and 2024.</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002174" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zdGAm3EDPqp2" summary="xdx: Disclosure - Operating Leases (Details 2)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8BF_zqedldmhoi5e" style="display: none">Schedule of cash paid and related right-of-use operating lease</span>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20250101__20250630_z6GuhX4DZPOf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101__20240630_zgOdrKJIYLF8" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zppCJdUm5oQ7" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-01-01to2025-06-30" id="Fact002179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,653</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-06-30" id="Fact002180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,112</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ReductionOfLeaseLiabilitiesAbstract_i01B_zzKziDeNIiZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reduction of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2025-01-01to2025-06-30" id="Fact002185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,666</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-012024-06-30" id="Fact002186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,080</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z24vbAqljPof" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:exclude><p id="xdx_23A_zTGiySdQbOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_ztfKn16FSfo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 149 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 35; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_231_zT1hPVDq6Zld" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z6IAgZY5WKA" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002191" name="cdio:FinanceAgreementPayableTextBlock"><p id="xdx_809_ecustom--FinanceAgreementPayableTextBlock_zxKOWPizo3m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7 &#8211; <span id="xdx_820_zSwJcOPtVmO3">Finance Agreement Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$<span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p" title="Financing agreement entered into for prepaid insurance"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2023-10-012023-10-25" id="Fact002193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">467,500</ix:nonFraction></span>&#160;is payable in 10 monthly installments plus interest at a rate of&#160;<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-10-012023-10-25" id="Fact002195" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.95</ix:nonFraction>%</span>&#160;through&#160;<span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20231025_zgPx5S3jAOHg" title="Maturity date"><ix:nonNumeric contextRef="AsOf2023-10-25" format="ixt:datemonthdayyearen" id="Fact002197" name="us-gaap:LongTermDebtMaturityDate">August
25, 2024</ix:nonNumeric></span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p" title="Prepaid expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2024-10-25" id="Fact002199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></span>&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024. As of October 31, 2024, this finance agreement has been paid in full and insurance premiums
have been fully amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $<span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p" title="Financing agreement entered into for prepaid insurance"><ix:nonFraction name="cdio:FinancingAgreementEnteredIntoForPrepaidInsurance" contextRef="From2024-10-012024-10-25" id="Fact002201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,455</ix:nonFraction></span> is payable in 10 monthly installments plus interest at a rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-10-012024-10-25" id="Fact002203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">8.80</ix:nonFraction>%</span> through <span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20241025_zGyVLeKxCET9" title="Maturity date"><ix:nonNumeric contextRef="AsOf2024-10-25" format="ixt:datemonthdayyearen" id="Fact002205" name="us-gaap:LongTermDebtMaturityDate">August
25, 2025</ix:nonNumeric></span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p" title="Prepaid expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2025-10-25" id="Fact002207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,124</ix:nonFraction></span> has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Finance agreement payable for this agreement
was $<span id="xdx_90E_ecustom--FinanceAgreementPayable_c20250630_pp0p" title="Finance agreement payable"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2025-06-30" id="Fact002209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,691</ix:nonFraction></span> and $<span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p" title="Finance agreement payable"><ix:nonFraction name="cdio:FinanceAgreementPayable" contextRef="AsOf2024-12-31" id="Fact002211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,764</ix:nonFraction></span> at June 30, 2025 and December 31, 2024, respectively. Unamortized balance of Directors and Officers insurance
premiums was $<span id="xdx_904_eus-gaap--UnamortizedDebtIssuanceExpense_c20250630_pp0p" title="Unamortized balance"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2025-06-30" id="Fact002213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,607</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p" title="Unamortized balance"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2024-12-31" id="Fact002215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,315</ix:nonFraction></span> as of June 30, 2025 and December 31, 2024, respectively.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002217" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zIMc6IP9XQDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 - <span id="xdx_823_zApgRt5G9qXg">Earnings (Loss) Per Common Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates net income (loss) per
common share in accordance with ASC 260 &#8220;<i>Earnings Per Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net
earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted
average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include
outstanding common stock options and common stock warrants presented below
on a post-reverse stock split basis, have not been included in the computation of
diluted net loss per share for the six months ended June 30, 2025 and 2024 as the result would be anti-dilutive.</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002219" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSAErrEj71d4" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BE_zZlr10vxVjo5" style="display: none">Schedule of anti dilutive earning per share</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June
    30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 66%; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_custom_StockWarrantsMember" id="Fact002221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_StockWarrantsMember" id="Fact002223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember" id="Fact002225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,860</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember" id="Fact002227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,557</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total shares excluded from calculation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-06-30" id="Fact002229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_pd" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30" id="Fact002231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">410,849</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002233" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zGur66SZ7Dg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; <span id="xdx_824_zDlZUxFxRE03">Stockholders&#8217; Equity</span></b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Stock Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 25, 2022, in connection with the approval
of the Business Combination, the Company&#8217;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan
(the &#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing
eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to
increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common
Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the
Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units,
Stock Appreciation Rights, Performance Units and Performance Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan, as approved, permits the issuance
of up to <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630__us-gaap--PlanNameAxis__custom--N2022PlanMember_zkAIl0v4Hta" title="Common stock issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-06-30_custom_N2022PlanMember" id="Fact002235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108,851</ix:nonFraction></span> shares (3,265,516 prior to the Reverse Stock Split) of Common Stock (the &#8220;Share Reserve&#8221;) upon exercise or
conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#8220;Evergreen Date&#8221;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation
Committee, which administers the 2022 Plan, in its sole discretion. In January 2024, the Compensation Committee approved an annual increase
in the Share Reserve of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsBiKgClq0W8" title="Number of shares authorized"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" contextRef="AsOf2024-01-23_custom_N2022PlanMember" id="Fact002237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,349</ix:nonFraction></span> shares (1,060,458 prior to the Reverse Stock Split). On March 31, 2025, the Compensation Committee approved
an increase in the Share Reserve of <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--N2022PlanMember_zl6bp0UFxZh3" title="Number of shares authorized"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" contextRef="AsOf2025-03-31_custom_N2022PlanMember" id="Fact002239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,721</ix:nonFraction></span> shares (2,871,638 prior to the Reverse Stock Split).</p>

<ix:exclude><p id="xdx_236_zCGNXmXHe3Ql" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 150 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 36; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_236_zhRCgMIIAv7a" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>Private Placement&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with a private offering memorandum
that the Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with
7 accredited investors (the &#8220;Subscription Agreements&#8221;), whereby the Company issued a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLrkUVlopqxj" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact002242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,727</ix:nonFraction></span> units (&#8220;Units&#8221;)
(561,793 prior to the Reverse Stock Split), with each Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Common stock , per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact002244" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></span> par
value (the &#8220;Common Stock&#8221;), and (ii) one six year Common Stock purchase warrant (the &#8220;Warrants&#8221;), having an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember" id="Fact002246" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">53.40</ix:nonFraction></span> per share ($1.78 prior to the Reverse Stock Split) (the &#8220;Private Placement&#8221;). The Private Placement resulted
in the issuance to investors of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNaO9M2qbZ3g" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact002248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,727</ix:nonFraction></span> shares (561,793 prior to the Reverse Stock Split) of Common Stock and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXc69KzAyn9a" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember" id="Fact002250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,727</ix:nonFraction></span> Warrants (561,793
prior to the Reverse Stock Split) during the six months ended June 30, 2024. The purchase price of the securities was $53.40 per Unit
($1.78 prior to the Reverse Stock Split), resulting in gross proceeds to the Company of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember" id="Fact002252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>, before deducting placement agent fees
(10% or $<span id="xdx_902_ecustom--PlacementAgentFee_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Placement agent fees"><ix:nonFraction name="cdio:PlacementAgentFee" contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember" id="Fact002254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working capital
and general corporate purposes. The Private Placement closed on February 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Private Placement, the
<span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalMember_zIyqMHCp9yH" title="Placement agent agreement description"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalMember" id="Fact002256" name="cdio:PlacementAgentAgreementDescription">Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 3,745 shares (112,353 prior to the Reverse
Stock Split) of Common Stock at $53.40 per share ($1.78 prior to the Reverse Stock Split) through February 2, 2030 (the &#8220;Placement
Agent Warrants&#8221;).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>At-the-Market Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with an At-the-Market Issuance
Sales Agreement (the &#8220;Sales Agreement&#8221;) that the Company entered into with a placement agent on January 26, 2024, the Company
sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUy9Q6Z7q5Rk" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">206,713</ix:nonFraction></span> shares (6,201,377 prior to the Reverse Stock Split) of Common Stock at various amounts per share to investors for gross proceeds
totaling $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUgkjQeigyV2" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,511,040</ix:nonFraction></span> before deducting sales commissions of $<span id="xdx_904_eus-gaap--SalesCommissionsAndFees_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zL8Db4352JNj" title="Sales commissions"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,256</ix:nonFraction></span> to the placement agent, during the six months ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="background-color: white">In
connection with the Sales Agreement, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2iH191Vz27k" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,058</ix:nonFraction></span>
common shares </span>(2,161,737 prior to the Reverse Stock Split) <span style="background-color: white">at various amounts per share
to investors for gross proceeds totaling $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zF0NuSAhNK3b" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,176,556</ix:nonFraction></span>,
before deducting sales commissions of $<span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zfdPghkpdd4c" title="Sales commissions"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,399</ix:nonFraction></span>
to placement agent, during the six months ended June 30, 2024 (among which&#160;55,822&#160;shares of common stock (1,674,654 prior to the Reverse Stock Split) were sold for gross
proceeds totaling $1,298,699&#160;before deducting sales commissions of $32,452&#160;to placement agent during the three months ended
June 30, 2024). The Company also paid the placement agent a fee of $<span id="xdx_903_ecustom--PlacementAgentFee_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zghdApbIp2a2" title="Placement agent fees"><ix:nonFraction name="cdio:PlacementAgentFee" contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember" id="Fact002270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>Other Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the three and six months ended June
30, 2025, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,559</ix:nonFraction></span> shares and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,061</ix:nonFraction></span> shares (on a Reverse Stock Split-adjusted basis) of Common Stock to a consultant for
services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the three and six months ended June
30, 2024, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315</ix:nonFraction></span> common shares (9,442 prior to the Reverse Stock Split) and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">464</ix:nonFraction></span> shares (13,919 prior to the Reverse Stock
Split) to 2 consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On March 31, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zSDyvkZpqSQ9" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember" id="Fact002288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,174</ix:nonFraction></span>
shares (35,212 prior to the Reverse Stock Split) of Common Stock to the board of directors for services pursuant to vesting of Restricted
Stock Units granted, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0d_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zedwpLnUm6H8" title="Stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember" id="Fact002290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2025 and 2024,
in connection with the Private Placement as described above, the Company issued an aggregate of <span id="xdx_901_ecustom--WarrantsIssued_c20250101__20250630_pd" title="Warrants issued"><ix:nonFraction name="cdio:WarrantsIssued" contextRef="From2025-01-01to2025-06-30" id="Fact002292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_903_ecustom--WarrantsIssued_c20240101__20240630_pd" title="Warrants issued"><ix:nonFraction name="cdio:WarrantsIssued" contextRef="From2024-01-012024-06-30" id="Fact002294" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,471</ix:nonFraction></span> warrants (674,146 prior to
the Reverse Stock Split), respectively.</p>

<ix:exclude><p id="xdx_236_zDFIppJoGMmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zFKtoCJk97C8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 151 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 37; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_232_zZjfx6XXaR0g" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Warrant activity during the six months ended June
30, 2025 and 2024 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002298" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlEGX7ePw5aj" summary="xdx: Disclosure - Stockholders' Equity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b><span id="xdx_8BB_zoCoP1sUAfHb" style="display: none">Schedule of warrant activity</span>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>Warrants Outstanding</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted<br/> <span style="font-family: Times New Roman, Times, Serif">Average
    Exercise Price</span></b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted Average
    Remaining<br/> <span style="font-family: Times New Roman, Times, Serif">Contractual Life (Years)</span></b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAOwo5LhTg8" title="Warrants outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">261,821</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4RmJlBL6xab" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002302" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">291.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfGOYs1XZSpj" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact002304" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.72</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6O41bVQa3z3" title="Warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" id="Fact002306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,471</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pJZNJXcx5a" title="Weighted average exercise price, granted"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" id="Fact002308" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">53.40</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCtPHsMVVXa" title="Warrants outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact002310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HzCSIdJjkd" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact002312" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">272.26</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lbY9PQTUak" title="Weighted average remaining contractual life" style="padding-bottom: 2.5pt; text-align: center"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact002314" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.41</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs5JHNeyCwB1" title="Warrants outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyLySFuh2kD9" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002318" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">272.26</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGh30EF5wXjf" title="Weighted average remaining contractual life" style="text-align: center"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact002320" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.91</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">No warrant activity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLG9eYUxUuj" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2322">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzAo7Rvt5Cr1" title="Warrants outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-06-30_us-gaap_WarrantMember" id="Fact002326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,292</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdg2D1KlSxVh" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-30_us-gaap_WarrantMember" id="Fact002328" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">272.26</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNyh32gO7w" title="Weighted average remaining contractual life" style="padding-bottom: 2.5pt; text-align: center"><ix:nonNumeric contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact002330" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.41</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zVlmPyeYasC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;<span style="text-decoration: underline">Options</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On January 23, 2024, the Company authorized
an additional <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares authorized"><ix:nonFraction name="cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" contextRef="AsOf2024-01-23_custom_N2022PlanMember" id="Fact002332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,349</ix:nonFraction></span> shares (1,060,458 prior to the Reverse Stock Split) to the Equity Incentive Plan Reserve (the &#8220;2022 Plan&#8221;)
and granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zu5cmimglaj" title="Number of shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-01-23_custom_N2022PlanMember_custom_StockOptionsMember" id="Fact002334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,594</ix:nonFraction></span> options (1,187,826 prior to the Reverse Stock Split) to management and employees, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" id="Fact002336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,894</ix:nonFraction></span> (1,166,826 prior to the Reverse
Stock Split) of which vested immediately with the remaining 700 options (21,000 prior to the Reverse Stock Split) subject to 50% vesting
on June 30, 2024 and 100% vesting on December 31, 2024. Each option has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-23_custom_N2022PlanMember" id="Fact002338" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span> per share ($2.11 prior to the Reverse
Stock Split) with an expiration date of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zMFZCl0RHRU6" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" format="ixt:datemonthdayyearen" id="Fact002340" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">January 23, 2034</ix:nonNumeric></span>. The immediately vested <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of stock option vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" id="Fact002342" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,894</ix:nonFraction></span> stock options (1,166,826 prior to the Reverse
Stock Split) were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-01-23_custom_N2022PlanMember" id="Fact002344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,461,404</ix:nonFraction></span> at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized
in the Black-Scholes valuation of these immediately vested stock options during the six months ended June 30, 2024, risk free interest
rate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zQ20NdqxEqo1" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.22</ix:nonFraction>%</span>, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLfHNJndiWl3" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002348" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">228</ix:nonFraction>%</span> and an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_z0wqn6cB2tJh" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002350" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span> ($2.11 prior to the Reverse Stock Split). For the remaining 700 options
(21,000 prior to the Reverse Stock Split), 250 options (7,500 prior to the Reverse Stock Split) were vested on June 30, 2024, 167 options
(5,000 prior to the Reverse Stock Split) were vested on December 31, 2024 and 283 options (8,500 prior to the Reverse Stock Split) were
forfeited before vesting with the leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at
vesting date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of
these vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsrsmU3hBnrb" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002352" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction>%</span>, volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zNO39uuRkL7j" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002354" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">188</ix:nonFraction>%</span> and an exercise
price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLCZyLHqCDte" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_StockOptionsMember_custom_N2022PlanMember" id="Fact002356" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span> ($2.11 prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2025, the Company authorized an
additional 95,721 shares (2,871,638 prior to the Reverse Stock Split) to the 2022 Plan and granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-31_custom_StockOptionsMember" id="Fact002358" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,524</ix:nonFraction></span>
stock options (75,756 prior to the Reverse Stock Split) to the board of directors, which vested immediately on grant date. Each
option has an exercise price of $9.90 per share ($0.33 prior to the Reverse Stock Split) with an expiration date of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBoXVlSUKYR3" title="Expiration date"><ix:nonNumeric contextRef="From2025-01-012025-03-31_custom_StockOptionsMember" format="ixt:datemonthdayyearen" id="Fact002360" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">March
31, 2035</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_90C_ecustom--StockOptionsValued_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2025-01-012025-03-31_custom_StockOptionsMember" id="Fact002362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,612</ix:nonFraction></span>
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the six months ended June 30, 2025, risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-03-31_custom_StockOptionsMember" id="Fact002364" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.3908</ix:nonFraction>%</span>,
volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-03-31_custom_StockOptionsMember" id="Fact002366" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">148</ix:nonFraction>%</span>
and an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-03-31_custom_StockOptionsMember" id="Fact002368" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.90</ix:nonFraction></span>
($0.33 prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2025, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,944</ix:nonFraction></span>
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $3.60 per
share with an expiration date of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlVfbBiRRbQ6" title="Expiration date"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" format="ixt:datemonthdayyearen" id="Fact002372" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June
30, 2035</ix:nonNumeric></span>. These immediately vested stock options were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,778</ix:nonFraction></span>
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the three and six months ended June 30, 2025, risk free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002376" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.39</ix:nonFraction>%</span>,
volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002378" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">161</ix:nonFraction>%</span>
and an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-06-30_custom_StockOptionsMember" id="Fact002380" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2024, the Company granted&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z59sAkIXF6Ta" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,012</ix:nonFraction></span>&#160;stock options
(30,300 prior to the Reverse Stock Split) to the board of directors, which vested&#160;immediately on grant date.&#160;Each option has
an exercise price of&#160;$16.50&#160;per share ($0.55 prior to the Reverse Stock Split) with an expiration date of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z5HCp0vha9cl" title="Expiration date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" format="ixt:datemonthdayyearen" id="Fact002384" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June 30, 2034</ix:nonNumeric></span>.
These immediately vested stock options were valued at $<span id="xdx_90F_ecustom--StockOptionsValued_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqDHpmpsf856" title="Stock options valued"><ix:nonFraction name="cdio:StockOptionsValued" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,625</ix:nonFraction></span>&#160;at grant date based on the Black-Scholes Option Pricing model. The
following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the three and six
months ended June 30, 2024, risk free interest rate of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLhmXluWXUt4" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002388" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction>%</span>, volatility of&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJrgvVaAVFEd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002390" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">188</ix:nonFraction>%</span>&#160;and an exercise price of $16.50 ($<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zK2IDTX5v0ok" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact002392" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>
prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zL3qhuNroOAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 152 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 38; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_233_zlBplyA28zq8" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><p id="xdx_237_zjVuw7Gd9xvd" style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p></ix:exclude>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt">Option activity during the six months ended June 30, 2025 and
2024 was as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002396" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGs7bIHxLQp5" summary="xdx: Disclosure - Stockholders' Equity (Details 1)" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;<span id="xdx_8BB_zNmBnhfV8Laa" style="display: none">Schedule of option activity</span></span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>Options
                                            Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Remaining Contractual Life (Years)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOJXjWefUdP" title="Options outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionsMember" id="Fact002398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,153</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDg6ZJOPgxC" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionsMember" id="Fact002400" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">91.72</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUJy2BcWHZUh" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140" format="ixt-sec:duryear" id="Fact002402" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.71</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,604</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zKMj6jOusIGh" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002406" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">62.14</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV6AelXyevyi" title="Options expired or cancelled or forfeited">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, expired or cancelled or forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" id="Fact002410" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTSo3OHqjMq8" title="Options outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact002412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,557</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHjMIUWBPHih" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact002414" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.27</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTvB6JrirWF6" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187" format="ixt-sec:duryear" id="Fact002416" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.65</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z4n1IAOkDHk7" title="Options vested and exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact002418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,307</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUtjp5Js5eOg" title="Weighted average exercise price vested and exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact002420" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.27</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding at
    December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcngGi4b9jza" title="Options outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact002422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,807</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zspxLpDaEV05" title="Weighted average exercise price outstanding, beginning"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_StockOptionsMember" id="Fact002424" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.25</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCUQxp6NVIoi" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218" format="ixt-sec:duryear" id="Fact002426" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.12</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9neLI2AIYX3" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002428" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,468</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDk7Orw9n4h9" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002430" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.28</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zklXVoomkO6e" title="Options expired or cancelled or forfeited">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002432" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">415</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOV21jIxGlHe" title="Weighted average exercise price, expired or cancelled or forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" id="Fact002434" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zyNHHYaSm7y4" title="Options outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_StockOptionsMember" id="Fact002436" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,860</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqN8Dz80y938" title="Weighted average exercise price outstanding, ending"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_StockOptionsMember" id="Fact002438" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76.66</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zolOFlBzQHxi" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328" format="ixt-sec:duryear" id="Fact002440" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.80</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqiYmyE5a4zf" title="Options vested and exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_StockOptionsMember" id="Fact002442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,860</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zx5LSZ3zbR6j" title="Weighted average exercise price vested and exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_StockOptionsMember" id="Fact002444" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76.66</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

</ix:nonNumeric><p id="xdx_8AE_z0LUweIq7Wsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002446" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zShBwFWPfXQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; <span id="xdx_82B_zsatqx1pURcg">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Prior Relationship of Cardio with Boustead
Securities, LLC</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">At the commencement of efforts to pursue what
ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the
&#8220;Placement Agent Agreement&#8221;), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities&#8221;). This
agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Under the terminated Placement Agent Agreement,
Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead
Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with
any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company&#8217;s
exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#8220;right of first refusal&#8221;).
Cardio has taken the position that due to Boustead Securities&#8217; failure to perform as contemplated by the Placement Agent Agreement,
these provisions purporting to provide future rights are null and void.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Boustead Securities responded to the termination
of the Placement Agent Agreement by disputing Legacy Cardio&#8217;s contention that it had not performed under the Placement Agent Agreement
because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included
a list of funds that they had supposedly contacted on Legacy Cardio&#8217;s behalf. While Boustead Securities&#8217; contention appears
to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions,
Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent
Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this
position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly
was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the
tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material
adverse impact on its financial condition.</p>

<ix:exclude><p id="xdx_230_z1ASySE2ntF" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 153 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Value: 39; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div id="xdx_230_z1gnErol51cd" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CARDIO DIAGNOSTICS HOLDINGS, INC.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>NOTES TO CONDENSED CONSOLIDATED</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: center"><b>FINANCIAL STATEMENTS</b></p><p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">The Benchmark Company, LLC Right of First
Refusal</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company completed the business combination
on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark
Company, LLC (&#8220;Benchmark&#8221;) as its M&amp;A advisor. Upon closing of the business combination, Legacy Cardio assumed the contractual
engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment No. 1 Engagement Letter (the &#8220;Amendment
Engagement&#8221;). <span id="xdx_90C_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20250101__20250630__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCMember_zyDTS55FLA34" title="Business Combination, Reason for Business Combination"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_TheBenchmarkCompanyLLCMember" id="Fact002449" name="us-gaap:BusinessCombinationReasonForBusinessCombination">Pursuant to the Amendment Engagement, the parties agreed that the Company would pay Benchmark $230,000 at the closing
of the business combination and an additional $435,000 on October 25, 2023. Both of those payments have been made in full. In addition,
the Amendment Engagement provided that Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker,
lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings
through October 25, 2023.</ix:nonNumeric></span> Based on the right of first refusal, Benchmark alleges that it is owed damages because the Company entered into
the Yorkville Convertible Debenture Transaction without first offering Benchmark the right to serve as the lead or joint-lead placement
agent for the transaction. The Company is evaluating the claim. No legal proceedings have been instigated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Demand Letter and Potential Mootness
Fee Claim</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 25, 2022, a plaintiffs&#8217; securities
law firm sent a demand letter to the Company alleging that the Company&#8217;s Registration Statement on Form S-4 filed (the &#8220;S-4
Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May 31, 2022 omitted material information
with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures
in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration
Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various
comments of the SEC staff and otherwise updated its disclosure. In October 2022, the SEC completed its review and declared the S-4 registration
statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs&#8217; securities law firm contacted the Company&#8217;s
counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The
Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that
no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are
without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the
date of filing of this Annual Report on Form 10-K, no lawsuit has been filed against the Company by that firm. The firm has indicated
its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the
final outcome will not have a material adverse impact on its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Northland Securities, Inc.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In January 2024, following the Company&#8217;s
termination of its agreement with Yorkville and in connection with the Company&#8217;s recent at the market offering and/or its February
2024 private placement, a managing director of Northland Securities, Inc. (&#8220;Northland&#8221;) contacted the Company claiming the
right to be paid a fee of approximately $<span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p" title="Termination fee"><ix:nonFraction name="cdio:TerminationFee" contextRef="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember" id="Fact002451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> pursuant to the agreement of March 1, 2023 between the Company and Northland regarding
the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland would not proceed
with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville Securities
Purchase Agreement and the subsequent financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company cannot preclude the possibility
that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require
significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Directors and Officers Insurance</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Company&#8217;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">The University of Iowa Research Foundation
Exclusive License Agreement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="background-color: white">The Company
has a worldwide exclusive license agreement with the University of Iowa Research Foundation (UIRF) relating to its patent and patent-pending
technology (the &#8220;Exclusive License Agreement&#8221;). Under the terms of the Exclusive License Agreement, the Company will have
to pay each of: (1) 1% of either the: (i) aggregate consideration (and trailing consideration, if any) for a liquidation event; or (ii)
pre-money valuation for an initial public offering, (the &#8220;Equity Rights&#8221;) (2) 2% of annual net sales, and (3) 15% of non-royalty
fees paid to licensee if it enters into one or more sublicensing agreements. Upon the Closing of the Business Combination, the Company
issued 3,639 (109,170 prior to the Reverse Stock Split) Shares of Common Stock to UIRF in accordance with the Equity Rights under the
Exclusive License Agreement. The Company has had minimal sales of $<span style="background-color: white">62,221</span> to date and has paid 2% or <span style="background-color: white">approximately $1,300</span> in total royalty fees to UIRF
under the exclusive license.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact002453" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zqPowa0bV8Od" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; <span id="xdx_82A_zenWtyxGfFVj">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated its June 30, 2025 condensed
consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Subsequent to
June 30, 2025, the Company sold </span><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250701__20250715_pd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-012025-07-15" id="Fact002455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,860</ix:nonFraction></span> <span style="background-color: white">common shares for gross proceeds totaling </span>$<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250715_pp0p" title="Proceeds from common shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-07-012025-07-15" id="Fact002457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,912</ix:nonFraction></span>
<span style="background-color: white">under the </span>At-the-Market&#160;Issuance <span style="background-color: white">Sales Agreement
as of the date of this report.</span></p>

</ix:nonNumeric><p id="xdx_816_zzoHzuKscX64" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 3pt; margin-bottom: 0">F-40</p>

<!-- Field: Page; Sequence: 154; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;13. Other Expenses of Issuance and Distribution.&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The estimated expenses payable by us in connection
with the offering described in this registration statement (other than the underwriting discount and commissions) will be as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 84%; padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">SEC registration fee</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">6,605.61</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">Accounting fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">Legal fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">Printing and engraving expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">Miscellaneous</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">**</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">**</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">_________</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">*</span></td>
    <td colspan="2"><span style="font-size: 10pt">Previously paid.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td colspan="2">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimates not presently known.&#160;</p>
    <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-size: 10pt"><b>Item&#160;14.</b></span></td>
    <td><span style="font-size: 10pt"><b>Indemnification of Directors and Officers.&#160;</b></span></td></tr>
  <tr>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 92%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Our Charter provides that our officers and directors
will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. In addition,
our Charter provides that our directors will not be personally liable for monetary damages to us or our stockholders for breaches of their
fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally
violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper
personal benefit from their actions as directors.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">We have or intend to enter into agreements with
our officers and directors to provide contractual indemnification in addition to the indemnification provided for in the Charter. Our
Bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions,
regardless of whether Delaware law would permit such indemnification. We have purchased a policy of directors&#8217; and officers&#8217;
liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances
and insures us against our obligations to indemnify our officers and directors. Our officers and directors have agreed to waive (and any
other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right,
title, interest or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for
any reason whatsoever, including with respect to such indemnification.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">These provisions may discourage stockholders from
bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the
likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit
us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement
and damage awards against officers and directors pursuant to these indemnification provisions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 155; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;15.</b></span></td>
    <td><span style="font-size: 10pt"><b>Recent Sales of Unregistered Securities.&#160;</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Set forth below is information regarding shares
of capital stock issued by us within the past three years. Also included is the consideration received by us for such shares and information
relating to the section of the Securities Act, or rule of SEC, under which exemption from registration was claimed. The Company issued
the securities under Section&#160;4(a)(2) of the Securities Act and/or Rule&#160;506 of Regulation&#160;D promulgated under the Securities
Act, as a transaction not requiring registration under Section&#160;5 of the Securities Act. In each instance, the party or parties receiving
the securities represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection
with any distribution, and appropriate restrictive legends were affixed to the certificates representing the securities (or reflected
in restricted book entry with the Company&#8217;s transfer agent). The parties also had adequate access, through business or other relationships,
to information about the Company. No underwriting discounts, brokerage fees or commissions were paid with respect to such sales, unless
otherwise noted below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In March, 2023, the Company closed on the issuance
and sale to one accredited investor of a convertible debenture in the principal amount of $5.0 million, for aggregate proceeds of $4.5
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">In February 2024, the Company closed on the offer
and sale to seven accredited investors who purchased an aggregate of 18,727 units, with each unit consisting of (i) one share of the Company&#8217;s
Common Stock, and (ii) one six-year Common Stock purchase warrant, having an exercise price of $53.40 per share. The private placement
resulted in the issuance to investors of 18,727 shares of Common Stock and warrants to purchase an additional 18,727 in an unregistered
offering of securities. The purchase price of the securities was $53.40 per unit, resulting in gross proceeds to the Company of $1,000,000,
before deducting placement agent fees and other offering expenses. In connection this offering, the placement agent received a warrant
to purchase 3,745 shares of Common Stock at $53.40 per share, which is exercisable through February 2, 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 156 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;16.</b></span></td>
    <td><span style="font-size: 10pt"><b>Exhibits and Financial Statement Schedules.&#160;</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">The following is a list of exhibits filed as part
of the registration statement or are incorporated herein by reference into the registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-size: 8pt; color: #212529"><b>Exhibit Number</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 70%; text-align: center"><span style="font-size: 8pt; color: #212529"><b>Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 4%; text-align: center"><span style="font-size: 8pt; color: #212529"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: center"><span style="font-size: 8pt; color: #212529"><b>Exhibit</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%; text-align: center"><span style="font-size: 8pt; color: #212529"><b>Filing<br/>
Dat</b></span><span style="font-size: 10pt; color: #212529">e</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: 18.8pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">2.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322000718/ex2x1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders (included as Annex A to the Proxy Statement/Prospectus)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">2.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">5/31/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">2.2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001114/ex2x1.htm" style="-sec-extract: exhibit">Amendment dated September 15, 2022 to Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">2.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">9/15/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">2.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001382/ex2x3.htm" style="-sec-extract: exhibit">Waiver Agreement dated as of October 25, 2022 with respect to Agreement and Plan of Merger dated as of May 27, 2022, as amended on September 15, 2022</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">2.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10/31/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">3.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997323000793/ex3x1.htm" style="-sec-extract: exhibit">Third Amended and Restated Certificate of Incorporation of Cardio Diagnostics Holdings, Inc., dated May 30, 2023</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">3.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">5/30/23</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">3.2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex3x3.htm" style="-sec-extract: exhibit">By-laws</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">3.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10/19/21</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">4.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex4x2.htm" style="-sec-extract: exhibit">Specimen Stock Certificate</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-1/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">11/10/21</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">4.2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex4z1.htm" style="-sec-extract: exhibit">Specimen Warrant Certificate (contained in Exhibit 4.3)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">11/26/21</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">4.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex4z1.htm" style="-sec-extract: exhibit">Warrant Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">11/26/21</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">4.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997324000172/ex4x1.htm" style="-sec-extract: exhibit">Form of Private Placement Warrant</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">2/2/24</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">4.5</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997324000480/ex4x5.htm" style="-sec-extract: exhibit">Description of Securities</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">4/1/24</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">5.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997324001610/ex5x1.htm" style="-sec-extract: exhibit">Legal Opinion of Shartsis Friese LLP</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11/22/24</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322000710/ex10x8.htm" style="-sec-extract: exhibit">Form of Non-Competition and Non-Solicitation Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.8</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">5/31/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.2#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335023000338/cdio_ex10z1.htm" style="-sec-extract: exhibit">Form of Board of Directors Agreement, dated June 19, 2023</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">6/22/23</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x6.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated November 22, 2021, by and among the Company, the Sponsor and other holders party thereto</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">11/26/21</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.4#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997324000480/ex10x4.htm" style="-sec-extract: exhibit">Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan and related forms of agreements</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;10.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">4/1/24</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.5#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000113626122000381/exh10-5.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">12/12/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.6#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x13.htm" style="-sec-extract: exhibit">Employment Agreement, executed as of May 27, 2022, between Cardio Diagnostics, Inc. and Meeshanthini Dogan</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.13</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.7#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x14.htm" style="-sec-extract: exhibit">Employment Agreement, executed as of May 27, 2022, between Cardio Diagnostics, Inc. and Robert Philibert</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.14</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.8#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x15.htm" style="-sec-extract: exhibit">Employment Agreement, executed as of May 27, 2022, between Cardio Diagnostics, Inc. and Elisa Luqman</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.15</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.9#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x16.htm" style="-sec-extract: exhibit">Employment Agreement, executed as of May 27, 2022, between Cardio Diagnostics, Inc. and Timur Dogan</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.16</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.10#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x17.htm" style="-sec-extract: exhibit">Employment Agreement, executed as of May 18, 2022, between Cardio Diagnostics, Inc. and Khullani Abdullahi</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.17</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.11#</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x18.htm" style="-sec-extract: exhibit">Non-Executive Chairman and Consulting Agreement between Cardio Diagnostics, Inc. and Warren Hosseinion</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.18</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.12</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001019/ex10x11.htm" style="-sec-extract: exhibit">Exclusive License Agreement between Cardio Diagnostics, LLC and the University of Iowa Research Foundation dated May 2, 2017</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.11</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/23/22</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.13</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997322001117/ex10x19.htm" style="-sec-extract: exhibit">First Amendment to Exclusive License Agreement between Cardio Diagnostics, Inc. and the University of Iowa Research Foundation dated September 2, 2022</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">S-4/A</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.19</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">9/15/22</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.14</span><span style="font-size: 10pt">&#167;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997323001160/ex10x1.htm" style="-sec-extract: exhibit">Lease Agreement, dated July 20, 2023, between the Registrant and 246 Group LC dba North Point Crossing</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/14/23</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.15</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997323001160/ex10x2.htm" style="-sec-extract: exhibit">Office Building Lease Agreement, dated June 15, 2023, between the Registrant and 311 W. Superior, L.L.C.</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">8/14/23</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">10.16</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997323000412/ex10x18.htm" style="-sec-extract: exhibit">Engagement Letter, dated as of May 13, 2022, between Mana Capital Acquisition Corp. and The Benchmark Company, LLC </a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">10.18</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt; color: #212529">3/31/23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 157 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 10%"><span style="font-size: 10pt; color: #212529">10.17</span></td>
    <td style="vertical-align: bottom; width: 71%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997323000412/ex10x19.htm" style="-sec-extract: exhibit">Amendment No. 1 to Engagement Letter, dated November 14, 2022, between the Registrant and The Benchmark Company, LLC </a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 3%; text-align: center"><span style="font-size: 10pt; color: #212529">10-K</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: center"><span style="font-size: 10pt; color: #212529">10.19</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 8%; text-align: center"><span style="font-size: 10pt; color: #212529">3/31/23</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.18</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997324000130/ex1x2.htm" style="-sec-extract: exhibit">At the Market Offering Agreement, dated January 26, 2024, between Cardio Diagnostics Holdings, Inc. and Craig-Hallum Capital Group, LLC</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">S-3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1/26/24</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">23.1*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="ex23x1.htm">Consent of Prager Metis CPAs LLC, independent registered public accounting firm</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">24.1*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="#poa">Power of Attorney (included on page II-7 hereof)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.INS*+</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.SCH*+</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema Document.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.CAL*+</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.DEF*+</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.LAB*+</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">101.PRE*+</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt; color: #212529">104*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: #212529">Cover Page Interactive Date File (embedded with the Inline XBRL document)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-family: Calibri, Helvetica, Sans-Serif">&#160;</span><span style="font-size: 10pt">107</span></td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000113626122000381/ex-filingfees.htm" style="-sec-extract: exhibit">Filing Fee Table</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;107</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;11/22/24</span></td></tr>
  </table>
<p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&#160;________</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt">*</span></td>
    <td colspan="4" style="vertical-align: top"><span style="font-size: 10pt">Filed herewith.</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt">Indicates a management contract or compensatory plan, contract or arrangement.</span></td>
    <td colspan="4">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; line-height: 105%"><span style="font-size: 10pt; line-height: 105%">&#167;</span></td>
    <td colspan="5" style="vertical-align: top"><span style="font-size: 10pt">Certain of the exhibits or schedules to this Exhibit have been omitted in accordance with Regulation&#160;S-K&#160;Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request; provided, however, that the Registrant may request confidential treatment pursuant to Rule&#160;24b-2&#160;of the Exchange Act, as amended, for any schedule or exhibit so furnished.</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">+</span><span style="font-family: Calibri, Helvetica, Sans-Serif">&#160;&#160;</span></td>
    <td colspan="5" style="vertical-align: top"><span style="font-size: 10pt">Furnished herewith. Pursuant to Rule&#160;406T of Regulation&#160;S-T, the Interactive Data Files on Exhibit&#160;101 hereto are deemed not filed or part of a registration statement or Prospectus for purposes of Sections&#160;11 or 12 of the Securities Act of 1933, as amended,&#160;are deemed not filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended,&#160;and otherwise are not subject to liability under those sections. &#160;</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 54%">&#160;</td>
    <td style="width: 25%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 158 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><br/>
<span style="font-size: 10pt"><b>Item&#160;17. Undertakings.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 40pt; text-indent: 0pt; text-align: justify">(a)&#160;&#160;&#160;&#160;The
undersigned registrant hereby undertakes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">(1)&#160;&#160;&#160;&#160;To file, during any
period in which offers or sales are being made, a post-effective amendment to this registration statement:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(i)&#160;&#160;&#160;&#160;To include any Prospectus
required by Section&#160;10(a)(3) of the Securities Act of 1933;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(ii)&#160;&#160;&#160;&#160;To reflect in the
Prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of Prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221;
table in the effective registration statement; and&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(iii)&#160;&#160;&#160;&#160;To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to
such information in the registration statement;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">(2)&#160;&#160;&#160;&#160;That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">(3)&#160;&#160;&#160;&#160;To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">(4)&#160;&#160;&#160;&#160;That, for the purpose
of determining liability under the Securities Act of 1933 to any purchaser, each Prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than registration statements relying on Rule 430B or other than Prospectuses filed
in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after
effectiveness. Provided, however, that no statement made in a registration statement or Prospectus that is part of the registration&#160;statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or Prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement
that was made in the registration statement or Prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">(5)&#160;&#160;&#160;&#160;That, for the purpose
of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to
such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(i)&#160;&#160;&#160;&#160;Any preliminary Prospectus
or Prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(ii)&#160;&#160;&#160;&#160;Any free writing
Prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt"></p>

<!-- Field: Page; Sequence: 159 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(iii)&#160;&#160;&#160;&#160;The portion of any
other free writing Prospectus relating to the offering containing material information about the undersigned registrant or its securities
provided by or on behalf of the undersigned registrant; and&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">(iv)&#160;&#160;&#160;&#160;Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 79.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(b)&#160;&#160;&#160;&#160;Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 160 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;SIGNATURES&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Chicago, Illinois, on the  16th day of September, 2025.&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr>
    <td style="width: 16%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 83%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="padding-left: 12pt; text-indent: -12pt"><span style="font-size: 10pt"><b>Cardio Diagnostics Holdings, Inc.</b></span></td></tr>
  <tr>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">By:</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Meeshanthini V. Dogan</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Name:</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;&#160;Meeshanthini V. Dogan</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Title:</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;&#160;Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="poa"></span>POWER OF ATTORNEY AND SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">KNOW ALL MEN BY THESE PRESENTS, that of the undersigned
constitutes and appoints Meeshanthini V. Dogan and Elisa Luqman, and each of them, her true and&#160;lawful&#160;attorney-in-fact&#160;and&#160;agent,
with full power of substitution and revocation, for her and in her name, place and stead, in any and all capacities, to execute any or
all amendments including any post-effective amendments and supplements to this Registration Statement, and any additional Registration
Statement filed pursuant to Rule&#160;462(b), and to file the same, with all exhibits thereto, and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto&#160;said&#160;attorney-in-fact&#160;and&#160;agent full power and authority
to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as she might or
could do in person, hereby ratifying and confirming all that&#160;said&#160;attorney-in-fact&#160;and&#160;agent, or her substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates
indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 36%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 44%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="text-align: center; width: 18%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 8pt"><b>Position</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 8pt"><b>Date</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Meeshanthini
    V. Dogan</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Meeshanthini V. Dogan</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer, Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(principal executive officer)</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Elisa Luqman</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elisa Luqman</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(principal financial officer and principal accounting
    officer)</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/
    Warren Hosseinion</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warren Hosseinion</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director, Chair</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Wendy J.
    Betts</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wendy J. Betts</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Paul F.
    Burton</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul F. Burton</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Peter K.
    Fung</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Peter K. Fung</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ James Intrater</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James Intrater</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">/s/ Robert
    Philibert</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">September 16, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert Philibert</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 161 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23x1.htm
<DESCRIPTION>CONSENT OF PRAGER METIS CPAS LLC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 23.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the inclusion in this Post-Effective
Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-283419) of our report dated March 20, 2025 with respect to our
audit of the consolidated financial statements of Cardio Diagnostics Holdings, Inc. as of and for the years ended December 31, 2024 and
2023, which appears in such Registration Statement. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo;
in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Prager Metis CPAs, LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hackensack, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 16, 2025</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        #<     0   -P    !  .@ 0 #     0 !  "@
M @ $     0   <J@ P $     0   *      _^T .%!H;W1O<VAO<" S+C
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MW0 $ !W_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH
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M$#K7X _!C_@XA_8\\?ZG#I'Q,TGQ5X(,I(-]J%O'>V4?H'DLGE<9/&=F!U)
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M[0M0^#?CZUN;73/A7XVO8+^74)I9=TVL W4WFV2.^_RPIW3.3. A"._YG_\
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M'M+G'%?O]\"O@QX(_9_^%FD_"CX>VJ6VFZ7;+&I &^>4C,L\I'WI)7RSMZG
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M/23I'@_P!&X:^^V7.MR(.=EO'$T )]-SR?+Z[3Z&OU#_ &<O#^H>%O@/X/\
M#NJHT5U:>'=/AN8G^\DJP)O0_P"Z<C\*_2^(Y2JY'E]>OK*\DGU<5_D?S+X:
MTX87CK/\%@]*+C3FTME-K6RV5]6SW*BBBOS0_IH**** "BBB@ HHHH ****
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MQ%N8S&MZ;=@UO;6\+\K:H>6/1CD<EF-?T$(BH@C7H!C'H!38(HX5$4*JJ*
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M.*P=55(2V:=T_F24445SGI!11D=*,CK0 4444 %%%% '_]3^_?MQ7R?^V/\
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M?_@KY^PV\>N_';2AXS\*VS@WUVT:7D20JOS$W=NJS18'.^1-N>O%>1?M*_\
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M &[?^"E=EIW[6G_!*'XT:YIVGZK#!9>/?A1J&M-8S>%-:CA7>81M<&"?;N
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M3[$U\[?\$5?@+X>\&_LY/\;;BVA;6?%E_<"*]*@R1Z;9.;>*!6/(7S$D<@$
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MH8Z+<98B,5YQO*Q_0?X9\-Z'X0T&T\,>&;6*ST^QMTMK.U@4)'%%&NU551C
M %='@8W#KBHDY'T%/.X#'/UK^?)-R=V[L_N2G2C"*A35DMDNA_-]_P %&_#&
MF_ O]LKPU\6_""+:27RV.O7/D_(#=6-T$E< < O"%#'N<YK]A_VQ?C!?_"C]
MEWQ!X\T%S%J$NGQ6>G2 X9+B_98$D7WC\SS/^ U^2W_!9W*_$OPLR]1X=O6'
MU$P-?H#_ ,%!_#=]XB_8CN[BS#N=-BTO4Y509)BBDC$C'V1&+L?1:_9<50AB
M,-D<\1K=M-OLI+0_CK+\=7P./XTH8!<O)&,TE_-*,KM=MCPW_@E-^SQX>L?
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M+)$Q'!:-PR,1QD'''-5M._8+_9/TR_74[;P5I#2(P=!)&70,/]ELC]*^EO\
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M.6(HX2*IVMR[W7F^_F?22\*<PKY%++L9F]25?FY_:IVM):I)+[/D?E-\./\
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M6=:I4FYSF].:4M].B/_7_OXHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %* 78# 2(  A$! Q$!_\0
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MX<K?#K_H=];_ ._"?XU^C?\ GK1_GK0!^<G_  Y6^'7_ $.^M_\ ?A/\:/\
MARM\.O\ H=];_P"_"?XU^C?^>M'^>M2!^<G_  Y6^'7_ $.^M_\ ?A/\:/\
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M,('SEF(W;O48Z5Y'X1_9%\9:+\&_B7H6J:S;:EXGUS%AI%[CBVL(SB&(Y[
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M0V&9!SBOE?\ 9DT^U\7_ !I^-?B;6X4G\2V>M_V9"\Z[VM;9%(C55/8CG(I
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MLB..C*1D'\C5VO!/V,_$5YXB^!.EK>R;WTJ[N=-#?WTC?"_H<?A7O*C:  ,
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M\#?#7PW&MSP0:-=P72WR(-\DD<A?&/0Y(KW)(B@^\2>3DTV:#>%P3\ISQZT
M?&OA3X0>-=>^._QEU[PEXHO/!-S)>6MJ'EM1+;74?DGYU!'WE/IWKJI?V+5T
MC2?"D_AGQ3/IOC+P_>RZBVM7<*SK>3S#$CO&> ?3'3M7TY%"=[,5$8)R HQS
MW)]:F\K_ &C_ (_6@#Y?'['FJZCJ/C.]UOQ_?:M+XOT^.SU-G@4!9(V!C>(8
M^4 9&!ZUWWQ&_9^'C/0/",5AKUQH/B7PEL;2=<MU!=<1A&$@/#*P'*]*]D*$
M_P 6/I3?*.T MGZB@#PG2?V<+WQ!I/BFW^(GBJY\82^(;,6,N%$4,$2G*M$@
MX5L\YZ\5Q>K?L;^)_%VDZ)H/B+XIZEJ?AW0KV"\TVW^SJLA\I@428X^8 #%?
M5)@5FS[8QV-/V#GDY]?2@#GO$WA6'Q;X5U/0;YF6RO[.2TF,9PRA@02*\&3]
MD*_F^&OAW0KCQO=?\))X6NC<>'_$,,*K)9Q\@1D=&&..:^F/+)ZMQQC'6E6'
M"XW,3_>SS0!X?\+?V?\ 4=!\?3^.O&_BN3QGXL^R_8+*X\H1PVD.<D(@XW$\
MD]:ZOXU?!72?C5X3BT?499[&\M9EN]/U6T;;/97*_=D4_P QWKT@*%&!3/*'
M&#C'2@#YEN_V8O&WQ!_LW2OB1\39O$WA&RDCDFTFTM5@-^Z$%1.PZC(!('!K
MN?%?P+N-2^+?AGQWH6NOHC:5:_V;<:>L8,4]I_SSP?NX]J]>6#;N.]B6YZ]/
MI3VCW$G/48QVH \4T?\ 9RL]+^"WBCX<#5IGL]8GN)C>,@W1K,P;8/7&*S-=
M_9KU'3KK0=>\$>+'\,^*M,TJ'1I[V6!98+VW0 +YBGN,<8KWUH0VWMM.0.U!
MA4X]1P".PH \#D_9>>\T/0+;5O%U_K&JV.OKXCNKZ] ;[1.!C:B]$4=@*]T6
M.3"$_>49Z]/;\JL^4N,8XSG\:!&1SD9(YXZT ?+6E?LF>./!TWB6V\)?%J]T
M/2=<U&343;K:1M)"SG+[6(KHA^R!X=LOA7#X0T[4;V*<ZQ%K-_K%PV^ZOKA&
MW,[D]B>W05]!A/FR>>PXY%-6#;C)W8XR>N* /GKQM^SEXKU;7?$LOA_XASZ5
MX=\4<ZEI5] MP$8KM8PEL[<CMTS5:Y_9.;PG!X:O?AOXIG\(:]H6GC2FO)X5
MFCO;?);]ZI')!8D'WKZ/:(L#R,>F.*01;0 #P.-N.,4 ?-GB#]D6XU[P5I5O
M/XUOY?&&G:Q_;L'B"X02)]HP<CRC\JI@GC%10_LF:]JWC2[\4^)/B+?W^I:E
MI3:7>O9H(0JY)0P$<H03GWKZ9\E=Q(XSQQ2?9PJG:?F(QN;F@#YST;]E_P 0
M:KXM\,ZEX\\=R^+;#PK,;C2[=K=8Y#(5*YF<#)^4]!P:KM^RMXCT:;4M \,_
M$B\T/P#J5RUU/H\<"&XAWMND6*7&0&/XU]*^2.O4]O:@0+W'UQ0!X'XP^ /B
MB3Q%=:CX+^(=UH-KJ%DNGWFE:A"+FV8*H421JV=KD9R>]=Y\$_A)8_!'P#IW
MA339Y;JV@9I9;J8 -+,QRQP. #7H/DC>&/44&/Y3@^] 'QM??L]ZCXE;X@?"
MAM2OO#FFWFL)XETW4H(P]O/&QS);OGJ-V3BO7OA]\)_'WAG7++^UOB!#K?AZ
MU@-N^D)8I$I7;MP-HXXKV-K;;RHYQCD9')YI]JIC&#DCU;K0!\NZA^Q?>K9Z
MCX5T[Q[?V/PQU*^-]=>&UA5F 9MSQ*^,A&;J*]>^)?P=LOB#\)[SP'#+_9%A
M)#%;02PKEHHTQMZ^F*]*:/=WP?4=:0H3WP?7VH \E^*/P.;Q_P"&O#MGI_B"
M\T37O#VR73M7@ZK(JA?G3[K CL:X)OA1JWPLC\2_$[Q5KUSX^\?G2GL+%8H!
M''!&<_NX$ X+$\FOI;RNN3GI4;6P9<%B1G=\V#S0!YG^S=\/)/AE\&- T>=3
M]O9&O+K/7SI6+MGW&0/PKU)%V@_6H5C=)"P;@G)']*L+G'-0 M%%% !1115(
M#\/_ /@L#_R==_W"+;_T&BC_ (+ _P#)UW_<(MO_ $&BF!]2_P#!%/\ Y(SX
MX_["T7_H#5^C=?G)_P $4_\ DC/CC_L+1?\ H#5^C=2 4444@"BBB@!,T?C2
M-24 +GWI<BFT4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "D)].:6B@!!GO1^%+10 4444 (>E)MIU% !1110 4444 %%
M%%4@/P__ ."P/_)UW_<(MO\ T&BC_@L#_P G7?\ <(MO_0:*8'U+_P $4_\
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MP)\(-6N-4\/:8ZZI,GE+=W<S3211?\\T)Z+[5ZG@9(Z$4S:C=3^/:J \<O\
M]D;X9:CXS'B6?0-UU]H^VM9B5A9O<?\ /5H<X+9YS7L4<852HX [?A4HV\8Y
M%)D*6_SVH \@_9C7=\.[S/\ T%[O_P!#KU]8Q7D7[,7_ "3R\_["]W_Z'7KZ
M]*E@(J[5Q3J**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%%4@/P_\ ^"P/_)UW_<(MO_0:*/\
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M (+ _P#)UW_<(MO_ $&BC_@L#_R==_W"+;_T&BF!]2_\$4_^2,^./^PM%_Z
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MK \C_9A^;X=WA/7^UKO_ -#KUM8PK[N^,5Y)^R^<?#N\_P"PO=_^AUZ_U%0
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M/_)UW_<(MO\ T&BF!]2_\$4_^2,^./\ L+1?^@-7Z,]#7YS?\$4_^2,^./\
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M ^E?C\ZO+*UC[NMF=.C-PDM4?LEO%+N!K\;O^&NOC%_T/%U_WS1_PUS\8_\
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M***HU"BBBL@$?_52?[A_E7ZI_L0_\F[>'OHW\Z_*Q_\ 52?[A_E7ZI?L0_\
M)NWA_P"C?SKU\!U]4?FG'/\ N4/4_/CXD_\ )2/%7_82G_F:YVNB^)'_ "4G
MQ5_V$Y_YFN=K^@*/\*'HC^.,1_'J>H4445L8A1110 5]/_\ !/?_ )*YK/\
MV#__ &:OF"OI_P#X)[_\E<UG_L'_ /LU>5F?^YUST\J_WND4/^"H7_(]>#?^
MO63^=?%B\;J^TO\ @J%_R/O@O_KUD_G7Q;_$:_%ZOQGKX_\ WB?J%%%%9'E!
M1110-;BIU'UK0\+_ /(W>'_^PC%_Z'6>G4?6M#PO_P C=X?_ .PC%_Z'072^
M,_=/2_\ D'6O_7%?_014Y^_4&E_\@ZU_ZXK_ .@BIS]^O41^EQV1.OW12TB_
M=%+28PHHHIH#\/\ _@L#_P G7?\ <(MO_0:*/^"P/_)UW_<(MO\ T&BF!]2_
M\$4_^2,^./\ L+1?^@-7Z-#I7YR_\$4_^2,^./\ L+1?^@-7Z-#I4@4KRSAO
MD:&>(30.I5XVY1@?[P[UQO\ PIKP&N\-X/T/YSEO]$4Y_2N_VCTHQZ<4@,7P
MQX6T?PE8-:Z-I5KI-N3N,%I&$4GUP*VZ;M%.H *0G%+4<G4 #)IH!=P[]*-Z
M>HK!\5>+-)\':#>:SK-]'I^F6H)FFF.,8[#U)KS;X+?M/>!_CS=7MIX;O9(=
M3M7?.GWB^7)+&O'F(#U6J ]HRM(/O-7E<W[2'PXM?&I\*S>+]/CUI)OLYMVD
M C\X](B_3?[5Z<KLL9)P#R<#MQTH \G_ &8/^2=WG_87N_\ T.O8!TKQW]EM
M]_PYO23_ ,Q>[_\ 0Z]CJ6 T]Z^<?V\_^3=M=_X!_P"A"OHX]Z^</V]/^3=M
M>^J?^A"LZCM39ZF5_P"_4O4_+=?N#Z"EI%^ZOT%+7S'-N?TW#X4%%%%0:!11
M10 A_P!3+_N'^5?JE^P__P FZZ!]&K\K'_U<G^XW\J_5+]A\C_AG30?]UJ];
M ?&?F?''^XK_ !'Y\_$?_DI'BG_L)3_S-<[71?$C_DI'BG_L)3_SKG:_?\+_
M  ('\;5_XD_5A11170<ZW"BBB@U ]!7T[_P3Y_Y*[K/_ &#_ /V:OF(]!7T]
M_P $^2/^%N:S_P!@_P#]FKR,T_W.?H>GE7^^4C/_ ."H7_(]^#/^O5_YU\7_
M ,35]H_\%0_^1\\&?]>LG\Z^+OXFK\8J?&SU<?\ [S,2BBBH1YL@HHHI] 6X
M=U^O]:T?#'_(U^'O^PC%_P"AUG=A]1_.M+PU_P C;H(]-0BQ_P!]TRZ7QG[H
MZ7\VF6@_Z8I_Z"*MJ-M4]*8?V9:#^+R4_P#015ZO2/T> X=32;QNQ36!Z[MN
M#DUCMXDT^/Q.FAFX_P")G);FZ$/I&"!G\S4LU-RBD'2EIH#\/_\ @L#_ ,G7
M?]PBV_\ 0:*/^"P/_)UW_<(MO_0:*8'U+_P13_Y(SXX_["T7_H#5^C=?G)_P
M13_Y(SXX_P"PM%_Z U?HW4@%%%%( HHHH *@N1NCVX.&."1V]ZGJ*=2ZA02N
M>"10!XC^U9\-;[XJ_#VUTG2M5L=/UNVU&"_L8K]L07<T3AA P[AL8KYS^#_Q
M$&G:]+!XY\!)X6\;LNHKH>O:>H%M<3!#YMMD>G88KZV^,WPCL_C!X5CTBYO;
MK2;JUG6]L-4LWQ):SH<JWN/45XO\%OV7?$FC>*+/Q!\3O%"^);G1;RXETBTM
M[=8XE:48:=\=6(H \[T+P-X=N/\ @G-J6I2:?"^H2V\NL27^P><MWYX;S0YY
M!R/6OL#X5ZE=:S\+?"E[>,7O;C2+>61V_C9HAR?<]:\"D_8SU9K._P#"-G\0
M;RU^%U]?G4)] CMU\W!<.UNKGI&6 XKZAL-,ATW3+>RM8A#;6\:Q0QQ_+L51
M@#]*=P/G#X%_&+PS\/?"^IZ)XAN;BPU*+5KF1H_LLC JS<$';S7I(_:>^'HZ
MZO,/K9R__$UZ>UG#,VZ2&-V]64&D_L^V'(MX0?\ KF*0'F'_  T[\._^@S+_
M . <O_Q->'?MA?&7PKX]^"6LZ1H=S=:A?S%0D,-G(2<'/]VOL V<.#^XB_[X
M%0"TMD)S!'N]T'--QYTT;T*TL/6C5BKM'X>C3=5VI_Q(M7^Z,_Z#)Z?2D_L[
M5!UT+5__  !D_P *_<A8(CC]T@^BBG&")1RB?]\BO,^I13/O8\9XR-ER)GX:
M_P!GZG_T M8_\ )/\*/[/U/_ * 6L?\ @!)_A7[E>1%_=7_OD4>1%_=7_OD5
M7U*)I_KMC/\ GVC\-/[/U7_H!:O_ . ,G^%._LW53_S M7_\ 9/\*_<KR5_Y
MXK^0I/)7_G@GY"CZE$/]=L;_ ,^XGX:2:;JOER :#K#,5. +&3'\J_1#]DKX
MS>%?!7P/T?2M8NKJSU*'*O;26D@?GVVU]<M;QM@F%<_04Q]/@?DV\)^L8KHH
MT%1?,CY[-N(*^;4O958V]#\=O'MY-J/COQ%>6>E:I<VD^HR,DJV4G(8]>E87
M^F_] 35__ &3_"OVG6SC086")1U(5!UI_D1_\\U_[Y%?8TN(*U*"A&-['YE+
M(:4I.3EN?BN%O?\ H"ZQ_P" $G^%(PO1TT35_P#P!D_PK]JO(C_YYK^0I/L\
M9_@7_OD5K_K)7_Y](G^P*/<_%4?;?^@)J_\ X R?X4[;>?\ 0%UC_P  )/\
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M12B[IGD.G?M)_#^WMK=6U><,L2*5^QR\$*!_=J[_ ,-/?#S_ *"\P_[=)?\
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MH ST.::'(..U2*V[MBK$H]T'-+@TJ]:=2N.R(]M&VG9]Z,^]%V%EV&EMM+G
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MA7\Y-% ']&W_  VY\#/^BFZ'_P!_&_PH_P"&W/@9_P!%-T/_ +^-_A7\Y-%
M']&W_#;GP,_Z*;H?_?QO\*/^&W/@9_T4W0_^_C?X5_.310!_1M_PVY\#/^BF
MZ'_W\;_"D_X;;^!G_13=#_[^-_A7\Y5% ']&O_#;?P,_Z*;H?_?QO\*/^&V_
M@9_T4W0_^_C?X5_.510!_1M_PVY\#/\ HINA_P#?QO\ "C_AMSX&?]%-T/\
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/6"\@?2BOD(?ZO\:* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #T ;D# 2(  A$! Q$!_\0
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M_8F^&GCWQAJ^MWPUJR@UV>*ZUO0].U:6WTW5I4^Z]U;K\KM_Z%71:_\ LO\
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MZE_\?JO?_ SP_#8SR)JGBO<L;,O_ !5>I>G_ %\5Z?5+5/\ D%7O_7%__0:
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M67D_P?-^]MW?_P >J0/?:*\W_P"%4Z]_T5/Q?_WQIW_R)1_PJG7O^BI^+_\
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M )!5[_UQ?_T&N$_X53KW_14_%_\ WQIW_P B57U'X6:XFG7;?\+0\7M^Z?\
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MK\1O%,4L-IIA:X5+#?+N2?A\VNWY?]G^]7H/_"J=>_Z*GXO_ .^-._\ D2K
M\<U?]C;Q5?:CH_B>Q^-.O:;\1[6PN-(O_%::9:L^HV,LN](I(/N*T7\+KBB/
M]A'3_".G>"9/AQXXUCP#XH\+V,VG)K\5O%>O?PSN99OM$4HVLS2LS_[->Q_\
M*IU[_HJ?B_\ [XT[_P"1*/\ A5.O?]%3\7_]\:=_\B5 'B]C^PA:^&-!T*7P
MC\1O$OAKQ[INH7.J7'BU D[:E/<_\?'VFU;]TZM_"O\ #7JGP ^ -E\"M&UM
M?[9O?%/B7Q!J+ZIK?B#4MJS7UPW&=B_*BJOW5%:G_"J=>_Z*GXO_ .^-._\
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M_B)XS^)7A#Q+\0]7\,K:>$;BXO;#3_#-G<!Y[B6!X-TTLK_=5';Y%7YF]-M
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M_P"G*WH \:_X*B?\F+?$W_N%_P#ITM:_ .OW\_X*B?\ )BWQ-_[A?_ITM:_
M.K _:C_@BO\ \FL^*O\ L<KK_P!(K*OH+X<:)XUOM2\>2:!XKTO2+#_A*K[_
M $:ZT-KI]WR;OWOVA/\ T&OGW_@BO_R:SXJ_['*Z_P#2*RKZS^"/W?'O_8W:
MC_[)4@3?\(Q\4?\ H?\ 0O\ PEG_ /DVC_A&/BC_ -#_ *%_X2S_ /R;7GEM
MK_Q!^.'CWQI:>%O%J>!/"GA/4_[$2ZMM+@O;O4;]8E>=F\_*Q1)YJ+M5=S?/
M\XK,\7?%[X@_"?1_AXOCV_T'2)+GQK_8>J:VI2*TU'3/LT[I=%6?_179E3<N
M[Y&1OX&J@/5O^$8^*/\ T/\ H7_A+/\ _)M'_",?%'_H?]"_\)9__DVN%UK]
MHK2=:^.?PM\+^"O&.@^(--UHZLVL6^EW<%ZZK!:"2'+(S>5\W_?5>?\ PU\0
M?'7QI\!+#XH67Q!TK5-0FLY[\>%]0\/11VDZQN_[@3Q.LJ%E3[_S?[M 'O7_
M  C'Q1_Z'_0O_"6?_P"3:/\ A&/BC_T/^A?^$L__ ,FUL_"[QY:_%'X=>&O%
MMC"]O::YIT&H11RXW1^8@;8?=<UUU0!YQ_PC'Q1_Z'_0O_"6?_Y-H_X1CXH_
M]#_H7_A+/_\ )M>CT4 ><?\ ",?%'_H?]"_\)9__ )-H_P"$8^*/_0_Z%_X2
MS_\ R;7H]% 'G'_",?%'_H?]"_\ "6?_ .3:/^$8^*/_ $/^A?\ A+/_ /)M
M>CT4 ><?\(Q\4?\ H?\ 0O\ PEG_ /DVC_A&/BC_ -#_ *%_X2S_ /R;7H]%
M 'G'_",?%'_H?]"_\)9__DVC_A&/BC_T/^A?^$L__P FUZ/10!YQ_P (Q\4?
M^A_T+_PEG_\ DVC_ (1CXH_]#_H7_A+/_P#)M>CT4 ><?\(Q\4?^A_T+_P )
M9_\ Y-H_X1CXH_\ 0_Z%_P"$L_\ \FUZ/10!YQ_PC'Q1_P"A_P!"_P#"6?\
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MW^>565#*J>A7+4 >R_\ ",?%'_H?]"_\)9__ )-H_P"$8^*/_0_Z%_X2S_\
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M_P#@VO/_ )%H^W_%_P#Z W@G_P &UY_\BT >E45YK]O^+_\ T!O!/_@VO/\
MY%H^W_%__H#>"?\ P;7G_P BT >E45YK]O\ B_\ ] ;P3_X-KS_Y%H^W_%__
M * W@G_P;7G_ ,BT >E45YK]O^+_ /T!O!/_ (-KS_Y%H^W_ !?_ .@-X)_\
M&UY_\BT >E45YK]O^+__ $!O!/\ X-KS_P"1:/M_Q?\ ^@-X)_\ !M>?_(M
M'I5%>:_;_B__ - ;P3_X-KS_ .1:/M_Q?_Z W@G_ ,&UY_\ (M 'I54M4_Y!
M5[_UQ?\ ]!K@OM_Q?_Z W@G_ ,&UY_\ (M5M1OOBY]@NMVB^"=OE/N_XFUY_
M=_Z]: +_ ,$(Y9?@1X$CCE\J5O#UDJRJN[:WV=?FKYME^$?Q1^('Q:TD>+/"
M&C0:UHDNB7$GQ)M+E$>6*SN+AY7M8EBW)+=)^ZEB/R*K_P :[*]7^#%Y\4D^
M$/@A;+2O![V7]BV?D27&IW:NR>2FW<OV?[U=K]O^+_\ T!O!/_@VO/\ Y%H
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M&UOX=L-'\*W:Z=J.N>)(IY_M5_L65K>WAB=/DB1T#RNWWG^53M-5/^%Z>,]
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MH'@+]H3X4>(O 7@:PT;3[)=636+W3H5B5$>UV0;_ /@=1?LI?LL^$_"'PO\
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MR5U:O /^"*__ ":SXJ_['*Z_](K*OK/X(_=\>_\ 8W:C_P"R5("_\+$\>?\
M1)]2_P#!U8?_ !VC_A8GCS_HD^I?^#JP_P#CM<AJ?QX\7:SXM\6Z5\/?A]%X
MLM/"ET+#4KR\UI;!IKL1)*\$$?E/O*I*GS.57<WMFM+1?VHO!NI:O\/=*GDD
MT;4_&EC+>VUCJK);7-GLV8CN(F;>CNS,B_WF1L4@-W_A8GCS_HD^I?\ @ZL/
M_CM'_"Q/'G_1)]2_\'5A_P#':WY_B;X0MTNS)XJT5$M;;[9<,VHQ 16^_9YK
M?/\ *F[Y=W]ZN=\;_'#0O#OP]M_%^AW-GXOTR;4K+3DFTJ^BDB9I[J*WW>:N
MY?D\W=M_V: '_P#"Q/'G_1)]2_\ !U8?_':/^%B>//\ HD^I?^#JP_\ CM=?
M-XJT:UN]0MIM8L(KC3X%NKR*2Z4-:Q<_/+_=3Y6^9J3PQXV\/^.-.^W^'-:T
M[7[#=Y9N]+NX[B(-_=WHQ&: .1_X6)X\_P"B3ZE_X.K#_P".T?\ "Q/'G_1)
M]2_\'5A_\=KTRB@#S/\ X6)X\_Z)/J7_ (.K#_X[1_PL3QY_T2?4O_!U8?\
MQVO3** /,_\ A8GCS_HD^I?^#JP_^.T?\+$\>?\ 1)]2_P#!U8?_ !VO3**
M/,_^%B>//^B3ZE_X.K#_ ..T?\+$\>?]$GU+_P '5A_\=KTRB@#S/_A8GCS_
M *)/J7_@ZL/_ ([1_P +$\>?]$GU+_P=6'_QVO3** /,_P#A8GCS_HD^I?\
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MAK.B?VQF74HGN(F\WR_*\G[S+_%YOW?X: +O_"Q/'G_1)]2_\'5A_P#':/\
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MH ],HKS/_A><'_0C^./_  GY:/\ A><'_0C^./\ PGY: /3**\S_ .%YP?\
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M^+/&.M^//!/BG4-&ELI?$=EX>6^&LV<5[+]EM[JU2)_(O_*='5]B_P"M=?\
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M?#;4(IOC!<7ND17BV]TSZG+!\O\ :"7L6[=]G2+S?OKM7;%M_@H _16BBBH
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M_:KN?#OB(Z_87-Q+IU]H_P!GNKBU,6IQ>2[B-V7S5^8_NWV[E;NM?&_B1_\
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MW&I:8DS+:W$O][<O1_XU57_BKXV\++\,K;]G.74M!U"/_A?<6N72:.D-T_\
M;!O_ .TI?*B@BW;OLS+]Y$7RMA??_%4 ?>>L?%RQT#5K+3]3TG5[.2_\0Q^'
M;.6:U58KJ5[=YQ*AW_-%L1UW?WU^[2_#GXP6'Q1L-%U#2-'UB+2]7TO^U;?4
M+JU5+=5\WR_*9MW$O\6W^[7S??SM)\5KI6D9POQNLU7>V[;_ ,2#^&O+/"^H
M>);/X5Z0WA.>]36%^#<[P?V<'^T*G]J)YKQ+_P ]?*W[/XMU6!^D*R*^[:RM
MMIV]=VW/S>E?#R1_##3/'OA5/@9?6MS9W/A[5IO%"Z'>//$]A]B;[/+>_/\
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M7W:[K1?&>D>)-8\0:7I]Y]HO]"N4M;^(1L/(E:))57G[WR.K?+ZUT5 'E_\
MPTG\.?\ H95_\ [C_P"-4?\ #2?PY_Z&5?\ P#N/_C5>H44 >7_\-)_#G_H9
M5_\  .X_^-4?\-)_#G_H95_\ [C_ .-5ZA10!Y?_ ,-)_#G_ *&5?_ .X_\
MC5'_  TG\.?^AE7_ , [C_XU7J%% 'E__#2?PY_Z&5?_  #N/_C5'_#2?PY_
MZ&5?_ .X_P#C5>H44 >7_P##2?PY_P"AE7_P#N/_ (U1_P -)_#G_H95_P#
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M(_,7]Y:Z#P;_ ,EP^)'_ %YZ1_Z!<5F_%_\ :0\'_!>YT^QUZ>]N=6O7B?\
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M?^AE7_P#N/\ XU1_PTG\.?\ H95_\ [C_P"-5ZA10!Y?_P -)_#G_H95_P#
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M_@?_ *''P_\ ^#2#_P"*H_X6OX'_ .AQ\/\ _@T@_P#BJ .LHKD_^%K^!_\
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M<0W]NCW+*H1&=MWS?*JK^% 'H-%<G_PM?P/_ -#CX?\ _!I!_P#%4?\ "U_
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MX=TW0EU#P?%HNE2Q7%EIZ7-LMO:R1/OC9$W;596^;BNF_P"%K^!_^AQ\/_\
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MC9I<VHBMI4?>KQ+N^5E;YLBNC_X6OX'_ .AQ\/\ _@T@_P#BJ@#K*\X^//\
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M/_8P:-_Z<K>@#QK_ (*B?\F+?$W_ +A?_ITM:_ .OW\_X*B?\F+?$W_N%_\
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MI_[TDKLS-5:;]G#X>M9_$*V_L-TB^($GF^(]E[.IO&QM^]O_ '?WF^YMJ?\
MX9K^&?\ T*-G_P!]R?\ Q5'_  S7\,_^A1L_^^Y/_BJ +NM?!7P5XC^$Q^&E
M_H44O@C[%%IXTE9G15@BV;$WJV_Y=B?-NW<=:\T\3?L#? _QEK<VKZQX1FO=
M4ECB@EN#K%XKNL42Q1AMLHZ(BUWW_#-?PS_Z%&S_ .^Y/_BJ/^&:_AG_ -"C
M9_\ ?<G_ ,50!=TWX)^#M+^$3_#.UTMX_!;V,NG'3C<RM_H\F[>GF;M_\3?Q
M50L?V<?AYIVN>!M8A\.QKJ7@FQ.FZ#<&XE9[.#9LV??^?Y>/GW=:=_PS7\,_
M^A1L_P#ON3_XJC_AFOX9_P#0HV?_ 'W)_P#%4 <YK'['7PDU_P #3>#+WPJT
MWAR76I?$+VAO[I?]/D)WR[O-W?Q?=^[[5C>'/V#/@CX6&J_V;X2D@_M;3I]*
MO=VJWDOFVTOWT^>4]=H^:N\_X9K^&?\ T*-G_P!]R?\ Q5'_  S7\,_^A1L_
M^^Y/_BJ .*\$?L(? WX=^)=/U_1? =NNJ6+>9:S7MY<77D/_ 'D65V7=7H]A
M\&_"%A\1/$/CB/2 ?$?B"TBL=3NY979+F"-=J(T3-LZ?[-9O_#-?PS_Z%&S_
M .^Y/_BJ/^&:_AG_ -"C9_\ ?<G_ ,50!PGAW]@KX'>%_&D'B>P\$01WMM/]
MJM[22[N);*"?C]ZMNS^4K<?W:],\%_"3PK\/?$WBO7]!TPV6L^*;U;W5[MYY
M97N95&U/O,=JKN/RKA>:SO\ AFOX9_\ 0HV?_?<G_P 51_PS7\,_^A1L_P#O
MN3_XJ@#D/$G[%'P:\96^I0:GX0>:#4M8DU^YB34+J*-K]TV/,JK*-NY>R_+[
M5T/P:_9@^&_P!U+5+_P+H,FCW>I1);W+/?7%QO56+*/WKOM^]5[_ (9K^&?_
M $*-G_WW)_\ %4?\,U_#/_H4;/\ [[D_^*H POC+^R)\+/CQK4.M^+O#1GUJ
M*+R/[2L;N6SN)8N?W3M$R[U]FKHK3X!_#VQ^%!^&\'A'3U\$&/RFT?RLQ/SO
MW-_%NW_-N^]NYJ+_ (9K^&?_ $*-G_WW)_\ %4?\,U_#/_H4;/\ [[D_^*H
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MM*HOE[2@&U?NXK$_X9K^&?\ T*-G_P!]R?\ Q5'_  S7\,_^A1L_^^Y/_BJ
M.>\#?L@?"KX<^([K7-#\,^1J,MFVGQ/<7T\Z6D#+M:.W65V\A6_V*FTO]DCX
M6:+8Z39VOAGR;;3-"O/#EI']MG;R["Z9FN(1\_S;M[_,?FYZUM_\,U_#/_H4
M;/\ [[D_^*H_X9K^&?\ T*-G_P!]R?\ Q5 %?1OV<?ASH6IZ%?67AQ/M.B:
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M $*-G_WW)_\ %4 >FUYQ\>?^1(LO^P_HW_IRMZA_X9K^&?\ T*-G_P!]R?\
MQ5/L?V>/AWI>H6M]:^%+)+JUF2X@?YG*2*VY6^9NN: /'?\ @J)_R8M\3?\
MN%_^G2UK\ Z_?S_@J)_R8M\3?^X7_P"G2UK\ ZL#T#PC\;/B)\-K";2_"/C[
MQ/X6TV2Y>62TT36+BSBDDVHGF,D3JI?:J#=C.%'I6M_PUE\;_P#HL?C_ /\
M"HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[
M110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#
M67QO_P"BQ^/_ /PJ+[_X[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\
MHL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\
M_"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#67QO_P"BQ^/_ /PJ+[_X
M[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?
M&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ
M^/\ _P *B^_^.T44 '_#67QO_P"BQ^/_ /PJ+[_X[1_PUE\;_P#HL?C_ /\
M"HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[
M110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#
M67QO_P"BQ^/_ /PJ+[_X[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\
MHL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\
M_"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#67QO_P"BQ^/_ /PJ+[_X
M[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?
M&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ
M^/\ _P *B^_^.T44 '_#67QO_P"BQ^/_ /PJ+[_X[1_PUE\;_P#HL?C_ /\
M"HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[
M110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#
M67QO_P"BQ^/_ /PJ+[_X[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\
MHL?C_P#\*B^_^.T?\-9?&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\
M_"HOO_CM'_#67QO_ .BQ^/\ _P *B^_^.T44 '_#67QO_P"BQ^/_ /PJ+[_X
M[1_PUE\;_P#HL?C_ /\ "HOO_CM%% !_PUE\;_\ HL?C_P#\*B^_^.T?\-9?
M&_\ Z+'X_P#_  J+[_X[110 ?\-9?&__ *+'X_\ _"HOO_CM'_#67QO_ .BQ
M^/\ _P *B^_^.T44 5O%/Q]^*'C30K[1?$7Q*\7^(-&N2%GTW5==N;FVF"$2
2)NC=RIPR*PR.H%>9444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'D T4# 2(  A$! Q$!_\0
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M !1110 4U_NTZF'[M  .E&[%<[XY\7:9X#\-:CK^L71L].L(#--*$+$C. H
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M'@7[./PP\7_&[X6#QA?_ !N^(^DZS/J=_&MO8ZC ;2,174D: 1R0MD851@N
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M8!))SPHJ_<>,/$N@PWWA&+6VNM0_MNST>QUR]CC\V&&>(2>9* -LDBJKA20
M[-'D=:[WX8>'P]K'XJNH)++6-9TNRCN[1,+%;F-#A44_=Y<@CM5C5?A9H^LG
MQ";SSV.LR0SS9DQY$D2JL;Q$8*E2H;.>M2ZJYFA/"U/9*5/XGUN]NVYQ^IZ;
MK7PSN='U.W\3ZMKEE=ZE;6%]8ZO*DNY9Y!&)8RJ*8W5F4E0=I"L,9%96HWFI
M6%[J=UXGUOQ/H=Q'<R^5=6$:R:;'#N;RR L9& FTL9?XMPW<<=]IGPJM[;6+
M34-2UG5M?>P.ZTBU.5#'"_/[S:B('8 _>;)'8U7O?A!%>"[M$\0:Y;Z1=LS2
MV$<Z,A5SEE5V0NJDDD@,#R>U-5(HQK8:O*,90BTD[6O<P=:\+?VM\6+22/7M
M4@CN=--RKVERJK&!(BX3Y>%/7&3R3S27?BC67UO6]*M[[RYI]=AL+::1586L
M1M8Y'V\=^2"1C)KM-7^'=KJ<^GS6E]=Z+/80&UBEL2@_=<?(1(K#' [9S3+K
MX9:9=1:ND[SRRZE<1W;R;]KQ3)&B*RLOW3B,<XK15XW3ET5CG>7UX.HJ*Y>9
MW=GOI'[MOQ,]?"&N^';&^ETOQ#J.KW1MI/*M=5\MT>;;\C;@B[>>HS@\<=:Y
M[PAJ+V&MZ<NIZ_XFL[^=PKVVKPH(+A^Z+^[V+@]-K9QBNNM?AO&AN#J&MZQJ
M@DA,*B>X$0C0]2/+"<_[1R>E0V?POCCO;,WNMZOJ]I8NLUO:WDD?EAQ]TLRJ
MK/C_ &B1[FLXSBHN[O\ (W^JU^>$J<.5+SN=Y;*4C(/J>I)_4]:*+5/+0J"6
MYSDGG\:*X+WU/IE=KWMQUPBOG=RNW!'8CT->;0?L[?#"V\3CQ#%X!\/0ZWYO
MFB_33XEF\S^]N SN]Z]0HH3G%^Y*WIU]1F;J6EVFLZ?<V%_;0WEE<H8YH)D#
M)(I&"&!XQ7'>&?@5\/?!0MTT'P7H>D"WN?MD8M;&-"LV"OF*1T."1GWKT.BA
M2J15E(-#$L_#&E6.MW^LVUA;Q:M>I''=7J(%EG2/A%9NX4<5/K6A:?XCTJ[T
MW5;2+4=.ND,<UM/&'CE0\E2#U!_I6I11KH!G65E!I]I%:VL*0VL*K'%'$H55
M51A54#H !C'M7-:Q\)/!NO6NMP:GX8TJ]MM:F2XU*&XM59;R1,;)) ?O,N.M
M=M125U+F3[;76P]U8X[P7\,?"7P\-X_AGP[IGA]KPHUS_9]JD'GE,[=^T<XW
M''?FNI\H%,,<C')Q^>?6K%%#]Y\TG=BTM8\O_P"&;/A8]Z;Q_AYX;>Z,AF\V
M32H6;>6)+$[2<Y/6NZNM!L+W2)]*FLX'TN>%K:2S:,&%H6&UD*X'!&1CWK6H
MK252<G=L5D8<'AO3(- 30XK&!-'2V%FMB(E\E;<)L$6S^[L^3%%GX:TJS\/1
M:';V%M#HL=L+./3DB58EA"[?+V]-H7C%;E%9-.6["R,3P]X9TOPEH=KH^BV%
MOI6F6B[8+2SC$<40R3A%' &2?S-<G=_ 7X=:EXO'B>[\$:'/XAWB3^TI+&+S
MMX_BW8SN]Z]'HJDY1;<7:_K_ )CT,74/"^DZMJNF:E>:?;W.H:87-E<RQ;I+
M8NH5RA/W<@ 9]J9<>&=+F\0P:Z^F6\FLV]L]I%>F,&5(696:,,><,RJ?PK=H
MIIM*P&#XJ\(:+XVT6;2/$&FVFLZ9,R&2SOX1+$Y5@RDJ>." 16-X;^#W@KP?
M::G::%X5TG2;75(A!?PV=FD:W*!=JA\=0%)&/>NWHIJ4EHF*R.:N_!&@7WA8
M>%I](LY/#HMEM!IC0J;?REP H3T&%Q]*B\5^ O#7CK14T?Q#H6GZUI2,'2PO
MK=)8U8 [<*> 0":ZJBIYIK52!I,Y'7_ASX7\4^&8?#FK:!I^JZ#"D:1Z?=VR
M26\8083:AX&!@#'I63#\*=*\(?#[6_#G@"RL/!4EW:3Q6LVFVZQ+#.Z,JS87
M&64D'\*]$IK=:$YIWO\ U>^VP678^'M&^#OC'2/!MMX9U3]FSP/XEUV"T^SW
M/BJXU^#R+^?&&NI ]N9\NWSL.3GC/3'T'\!_@G%\,/AEX"T776M=:\2>%[&2
MTM]6V[S )>72%G^;;@!!G'RH.*]<V@GFG[1734KSJQ<9;/7J)12./\=?##PE
M\3[""S\5>'=.\0VD#>9%#J%NL@C8CJN>G3\:72?AAX3T._TN_P!/\.:98WNF
M6K6-E<6]HB/;6['<T<9 R%SSCU)/>NO Q2US7EIKI\_^&*:3W1R&D_#;POH7
MB;4/$.G>'M.TW7-01DN]2M;9([BX#,&(=U^8\@'FLC4_@+\.M8\7#Q1=^"-"
MNO$*R>=_:,MC&TQD_O[L<MGN>:]&HHYJE[\SZ=7T^8K(Y[Q3X,T/QSHT^C^(
M=+M=:TN;;YEG?1++$2.GRFLGPQ\'_!?@?[!_PC_AC2M':PCDCM&L;1(VA5R#
M(J^F['/TKMZ*:G44>7F"VMS(UC0[#Q'IEWIFIVT-]IMRC13VTR!HY4/8CTKS
MQOV7?A&>#\-O#.,!1C3(OIQ@>F:]:HIQG4AI"32OLOU'H>!?$#X)7/C3]H3P
M7X@GTO3K[P5IOAO4M(U"VNL.&>9H/*40E3E<1M]*],\"?#/PG\,M.ET[PGX>
MT[PY92OYLD.F6Z1*[=F;CD^GY5UW<T9[4Y5*DHJ+>Q*BM3PKX\?!_5-:^%3>
M'?AW9Z3IK+JD&HW.B7#M:V>KPB;?<6DLB*2OF@G+8.3P1BO$_%WP$\3_ !9T
MZU\/6/P&\)_"><WEM<GQ;!JMM--8K%,KLUJEM"K&1@FT%BG#-DGI7W#LHV#T
MS6T,54I?#O\ Y[]K_.X.*.$\<_"#P3\3GM7\6>%=(\2/: ^3-J%G'*\?.25)
M!QR36I=> /#M]X7_ .$8GT6QE\.&(0G23 GV?RP00H3 & 0#]173XQVQ3EZ5
MR)SLES:)WZ_YV*T[&'K7A;2/$EE;V>K:=;:A;6\\5Q%#<Q*Z+-&P:-P/52H(
M^M9GC;X:^%OB5IL=CXJ\/V'B&VB8,D6HVR2A3TR 1QD8_"NPHI^\MG_7R"R.
M>\)^#=#\#Z'!I'A_2;31=-MSF.ST^%88A^ XK+T?X2^#- .MC3/"^E6"ZVK+
MJ0MK1(_M@;.?-Q][[S=?[U=K134IK:6^X:'-WW@;0-2\+CPU=Z/97/AY8$MQ
MIDUNK6XB485 G8  "J'@3X3^#_AA'<P>$_#6F>'([I@\XTVV6'S2.F['X5V=
M%4IS2Y;Z"MK<KQC@EN3D\_K7(^/?A!X)^**VP\6^%]*\1?9CF!M1M$E:+/7:
M6!(KMJ*B%Z<KPT]!O7<Y#0/AMX6\(7%I/H?AW3M*ELK1K&W>RMDB,5N6#F)<
M ?*6 ./7-9/B?X"_#SQCXDBU_6_!6AZMJ\;*POKFQ1Y<J?E.2.H]Z]%HI\U1
M/F4G?O=_YA9=C!U3POI.LOIK7NG6M[)ILZW-DTT(?[-* 55D'\) )&:DOO#&
ME:EJVGZG=6%O<:AIH?['=2QAY+?> &V$]"0!DUM44DK=0>IP7C?X*^ _B;>6
M]YXJ\(:/XAN;=2D<NH6B3,%/49(Y'?'N:Z./PWIB:&=%&GVRZ2(?LXL1"H@$
M>,;-@XVX[5M454I3DDG)NVVKT_$-#BM.^$?@K2?#+>'+'PMI-IHC7(NSI\%H
MJ0&<8(D*#C/RKS["K7C7X;^%_B3IB:;XHT'3_$%BKB5(-1MEF1&'0X;IUQ75
MT4*4ULQ61@>$/!6@^ =$BT?PWI%GH>EQ,62SL(5BC4GJ=J\9JAXW^%WA+XCB
MU'BGPYIGB%;7<8%U&U281;AABH8'!.!7744DY)\T6T^Z"QY[X4^!OP^\$:TF
ML>'?!>BZ)JL:- EY86,<4RHV PW #&0!D>U=/HWAK2O#<5TFF:?;6"W=Q)=W
M'V>(*)9Y.7E('4GN:VZ:W6J<Y2=Y.X]#P#X]_!G5]3\"^'=(^'^EZ/+I6DZL
MFH7W@Z]D^RV.M6^6+6[2!'VDR.)!E=I91NXKRC4O@1XE^).M^&4M?@EX7^#Z
MZ3K5KJDWB:#5()[U$A<,T-O%:Q)G>%"?,ZJ%QPW0?:NW-&RNB&)JT[<KU6WS
MW]2;'.P^"=!AAUJ--(M%36W9M2 @3%VQ0(6E&/F)4 <^M.NO!.A7_AH>';G2
MK270E@6U&FO$IMUB7;M0)T  5<"NB48%+7-S2[_\.4<SXL\">'?'.BG1_$&B
M6.L:4=N;&^MUEB&WIA3P#[U'X)^'/AGX;Z4VF>%=!T_P]IY8NUOI]N(E8GO@
M=3[^WM7544FYN+C?3Y_YAHAD?0Y&"33Z**2T ****8!1110 4444 %%%% !1
M110 4U^E.I#TH :1G%(4!!!Z$8H7..*=\WM0 R.-8EVKT%.SBE^;VH^;VHWW
M!:" YHI?F]J/F]J5D E%+\WM1\WM18!*:RY-/^;VH^;VHL@NR/91LJ3YO:CY
MO:BR[!=D>R@IBI/F]J/F]J=D*U]R!XP3GO[5@7/@#PS=:M_:MQH6GR:ED,+E
MK=3)GUW5TWS>U'S>U-.VQ$J<9+9%>) JX' [<5)M'K4GS>U'S>U3;6Y=D1A1
MG&:0@ XS4OS>U'S>U.R'H1E1B@IQ4GS>U'S>U*R C* X.<4;/?-2?-[4G/>F
M BC%%/7I10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1112N 4444P
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI7 ****8!1114L HHHI
MH HHHI@%%%%*X!1110 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?>)9]<T:_P#'$%U #J,&GLMEMFO H586<L0L;A1EN>M$J$HNS#E/I9>E'%?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*SOXKR+S8'25#]UXW# TY4ZE-7DF9T<51Q#:HSC*V]FG;[C.U/P=HFK^'I=
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MC9))YJKNW,IVL>IJ?PS\-?"?@W5M1U+0_"^C:+J6HG=>WVFZ=%;3739R3(R
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M?F^>4E1QCY5NK_>?;G_!-7XDR0ZMXA\#7,@,4L:ZE9*>SC"2C_OG97W\APH
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ML>K$,1D_6H[<XN8?^NB?^A"N_P#CSX5D\+_$K40B[;?42+N%_4L3N'Y@_G7
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M[Q$9R>KC%OIK)7Z#RM)8>48Z+FDE\F2J<Y^M.IJ?=%.KQEHCV0HHHI@%%%%
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M74$EGT6\@A:")-[N)6C"GY03UR>F*;\.?VY?A!\5?$>D:#H7B*Y^WZQD:?\
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M>+;\BEIW[$/AF)MU[XAUB\ .2B".)6_)=WY&O4?!'P/\%> 7$ND:);+> ?\
M'W/NEF_[Z<D@>PP.3ZUS5]^U;\-='T7QWJ>HZ\]FG@B]_L[6X)[619H)F.(U
M1"@:02' C*@AQT/6L?Q[^V]\)_AMXGNO#OB#5=5M-6MK2"]N;>'1[N7[-#+&
M)$9V2,A/E/(8@CO14KXBJO>;#"Y)EV"ESX>BHL]Z@BPIR>^>W]*?P#UKPCQK
M^VK\)O C^'4U#7[F[/B'31JVFG2=,N;W[5:DD>8!$CG&01@@$8.:@\1?MP?"
M?PKIOAB]O]3U81^([6:]TV&'0[R6:6.)RDC-$D9=,,#]Y17)[*IO8]NU]SZ
M#8]Z4-FOG_7_ -N#X1>'/ VA^,9_$%S<^'=8-PEM>V>G7$RH\&WS5E"(3$PW
MCA\=:S[K]O3X/V/@>W\77&L:O%H,UZVFI=RZ#>KF<(KA<>5D JZX8#!Y&>#3
M5.H[776P6/I'=2$YKP7Q_P#MH?"OX97>G6NN:Q>PW5UIZ:H]K:Z7<3R6=HX!
M66Y1%)A7!'+XJ7XD?MD?"WX8:MI6EZWK-\U_JFG)JMI'I^DW5V7MGX23]U&V
MW/TI*,VTK!8]OFZBO OVE?\ D>OA'_V'8_YK7KO@7QMI7Q'\)Z;XET1YY-*U
M*+SK=KFWD@D*YQS'( R\@\$"O(?VEO\ D>_A'_V'H_YK75A-*WR?Y-'SV?:8
M&7^*'_I43Z#B^Z?J:?3(ON#\?YT^N0^@&-][\*@G^^OX?SJ=OO?A4$_WU_#^
M=1+9_P!=Q=4?)/P#_P"3X_CA_P!></\ Z&E?7(^[^-?(WP#_ .3X_CA_UYP_
M^AI7UR/N_C7OYQ_'A_U[I_\ I!XV5_P7_CG^9*O2G4U>E.KPD>T%%%%,!C]<
MTUL$UA^/?&FD?#KPCJWB;7KAK31]+MVN;J=49RD8ZG:N2?P%>2_#[]M/X2_%
M#59-.T+7[D7_ -ADU&*'4-+N;0W$")O=HO-1?-PHR0I-+DG-72V&D>O>(?#F
MF^)K1['5M-M=5L)%P]M>1+)&WL58$'\J\*\3_L$?!WQ)+)-;^'[C0)7Y)T>]
MDB4'_9C8E%^@%7/AU^W-\'OB;XBTG1-$\0WAOM7;R].^VZ7=6T5W*!_JXYI(
MPC,>@&[)P:L>(OVV_@_X5\>3^$]1\4-'?VUVMA=7D-G/)8VEPW2*2Y5#$C9&
M,,W!ZUUT:N+PK;HSE%^3.6MA*%?2I!/Y'#G_ ()O?"]=I;5/$[@'[OVZ$9^I
M\H?H:[KP;^Q3\'_!%Q'=6_A&+5;Q#N2?5[B2[P?78[%,_1:?\2OVS/A7\(_&
MUQX7\3:Y>6VL06T5W/':Z9<W,<4,@RKM+&A55[Y) KKH?C]X&OO$/@K0[36X
MM1O?&EM/=:&UK&TD-['#&9)&#@%5PJGJ>U;U,PS&M'EJUI-/S.>&68.D^:G2
MBGZ'=:?90V%LEO!$D$,8VI'&H"J.P ' %6UP&QFO*KO]IKX<:9H7CC6;_P 1
MQV6F>"[[^S=;N+F.2,6]P%4^6HQF0G>H&P').*Y/2_VXOA)J_A?6M;M=6U/R
M]&E@AO;(Z)>+>P>?GRF^S>6)-K;2=P!''->;[.<=M;[W/22MHM#Z&7ZYI:\6
M^"O[6'P[_:!U2YL? ^I7NHRV\'VAI)M-GMX2N[:0LKQA68'((!KV:([E)[9(
MZ8Z<?TI\O+H(?1110 Q^HJ"3[S?2IWZBH)/O-]*F?PO^NY#V^?ZGRA\$O^3Y
M_C1_V#+;_P!"CKZR7_5U\F_!+_D^?XT?]@RV_P#0HZ^LE_U=>UFW\6G_ (*?
M_I)Y65_P9?XY_F2I]T4ZFI]T4ZO'/8"BBB@ HHHH **** "BBB@"-_OK45Q_
MJI/^!?R-2O\ ?6HKC_52?\"_D:7_  /S,Y_#+T_1GA?[+O\ Q[^+O^PS+_2O
M=8ON_P# J\*_9=_X]_%W_89E_I7NL7W?^!5ZF8?[U+Y?DCYGAK_D54?6?_I4
MR<=*6D'2EKRSZE!4<N-ISP"#G\JDIK+DTQGP/^UA\+O$>L_M66OBI? OCKQ1
MX8;PJ-.,W@74A8W N//+!))/,3,>TG*\@DKG-<9J'P\^+?A+X ? '0+OX::W
MK>H^%?%D/B*2VT2.W\VSTVVF+1V\Q5E'VIU*ME002.N<@?I5LHQBMU7:2CV'
M<^$/'O@/XD^!/BI\7H=&\'^+-7TSXG2V&HZ;K_A#4XK*YTNZBC$;07,C@^7'
MD<L WRY&TYROI7A'PG\0M8_8!O?#GBVVU*_^(UWX9U"TN8-1F\V\GG;S@BL^
M3N)5HQ]XCG':OJ7;FC94.JW;R"Y\!_#KP1\3/B8G[/6@:S\-=5\#Z-\)X;2[
MU+5];NH0;Z:VL_($5M#$69@Q&XLQ&.F.:XF7]G3X]3^&'^+@F*>(I?'K>-O^
M$!?2(_[33$IME0WGFYV_90"(0,8;UK],ME&RK]M(+GS;\0/!OB3Q!^U_\$O%
MT&B7)\/Z;HFLQ:E>;?W=E)-#'Y:.<CEB"/J*\(^-'[,?Q<_:$\;_ !S\217T
M7A"QG@@\/Z+INH:8+J?4[:R9;F-X9O.7[.)+D;@VUN<G'RU^A.RC94JI).Z"
MYQ'P3U?7]>^%'A._\4Z5-HGB2;38#J-A<??AN @$@/\ P('TKNJ11@4M9MWU
M$%%%%("-_OK44_\ JI?H:E?[ZU%/_JI?H:E_Y?F9S^&7I^C/!OV;O]=XW_[#
M<U>^)]Q/K7@?[-W^N\;_ /8;FKWQ/N)]:];,?]Z?]=$?+\+_ /(KI>L__3DQ
M[=?QK,\3?\B]J?\ UZR_^@FM-NOXUF>)O^1>U/\ Z]9?_037F0^./JOS1]%B
M?]WJ>DO_ $F1YO\ LOC_ (M'I/\ UWG_ /0S7EO_  4A\.:KXJ^!6B:?HT5\
M]Y)XKTK$NGVYFEMAYI_?@#)&SKG&/6O4_P!E_P#Y)%I7_7>?_P!#->N'I7?C
MY<N.JM?S,XLH_P"1?0_PH^$?#W@KQ%\#_P!LZ\\2>*/%'BGXA:18?#J]NIM:
MU#3E>2$)<QN;:);>,*[,$W!,;CSCO7B_P[T37KO]CKX7W<7AC7]1?X<^/XM:
M\0:&^G31SSV?VIYBT,3@>;\C+E1G!+#&0:_2;XB_%#PE\)]'75_&/B+3O#6F
M,XB6ZU&X$*LYZ*N?O'V_&LX_';X?#P /''_"9Z)_PAV=O]M_;4%KNSC'F9P3
MG^$<UBJT^Q[)\0ZM\1_'7Q6U/X[)9MXAUGP%K/@74+K23JOA%-*E\[<RI:I(
M )9UC4[0SD9)88P 33T/X(>-O"MG^R)J^H^+_%?BFP;4-,FD\/:A8QK;:&OV
M'< /+0.@C'[KYS@U]RZ1\??AWKO@&]\:V/C71+OPI8_\?>KPWB-;6YRHQ(W\
M/++U]:T=7^+G@KP]H^AZOJ/BG2[#2M>DAATJ\N+I%CO7E ,0B/\ 'N!&*'7E
M:W*!\N?M._#/XN6'[,OQB7Q9X^C^(\%[IR+IFC:=X;CLI;9_M"D'?&S-+\G&
M"O.*CNOV6_%EMX2UOXA>.OB#??$7Q)8^!K_1]&L$T&+3EM$G@/F*5B+-*_5/
MF .,\5]!:]^U-\(_"WBBY\-ZO\1O#>F:]:S"WGT^[U!(I(I#CY"#T)R./>NO
MMOB+X8N]?UC1(==L9-8TBVCO-0LUG4R6L+J2LC>BD9Y]*E5)I;!<^!/V1O$E
MU#\/5\*WOB;XDZIJ+^";BQ3PQK?AMK72["5+;<WD7'E#<5V/&@)Y$F*YSX%_
M#7QYINI?LJ0?$34]:UKX>%7U+2=-L]%6V_L'5XE/V:*[=09'C(8D,_)8-T0-
M7W3J_P"U=\'?#]MI=QJ7Q+\-V<&J6HO;&2>_2-;B$2-%YBMW7S$=<^JMZ4D_
M[6/P=M['2+Z7XE>&X[35=_V"9M00+<[9#&Y3^]AQBK]I-MNVX'S[^Q'\'_%]
MM-K_ (IN_&WB70=(A\9:S(W@Z2UC2RND:5PLAW1^80VY6R#CY>*\3U=-:\._
MLQ_$']FV\\!^)=0^)NM>(;A;&6WTIY+*\2:]6=+S[5]P($7JQ!&SG"Y8?HWI
M_P 6?!VJ:KXBTRS\2Z;=:AX;02ZQ:QW*F2Q0J6#2K_""H+9]JS-<^/7P[\,^
M"M-\8ZMXUT73_#&IA6L=4N;U(XKH'.#&21O[' Z9K-U)I[ ?"/Q:^&WQAL_B
M7\>;WP%K5YI]YIW@K28+J Z,MTGB!8[5HYXXIY!D2 ;V79EF9@-H(%2>(?V>
M(?B#XC^"VC^!(-<TN#2?AO<7WAK5]1A:.?3]6AN89H/M#;/D?S<AQ@  G QB
MOT3\&>-=!^(.@0:YX;UBRUW2+C/E7MA.LT3_ $921^%5?&?Q&\,?#Z724\2:
M_8:$=6NEL;$7TZQ&YG;[L<>?O-[>]:?6*KDH);#/SY\)>"?$O[)_B?XU:E:6
M.KZ[XG?X?V-U=:K:PR3?VGKUS/*9ID;8-V)I"5[A5%7/@%\*?B=^SC\8/ -G
MXF\,Z)!H7B+P?-X7DF\-?:+E3/!NNDFO0Z?++(\C@D<') Z5][:C\2/"VD>+
M[3PK>Z_86WB2[MI+V#2Y9U6X>! =\JIW4;6R?:K7@[QKH/Q \-VOB'PUJ]KK
M6AWBL;>_L9?,AEVN4.U^APRL#[BD\14WDMQ7/R-7X*^//A[^SK\/M;T/0-2E
MTOQM=6MIXLTD6DAGMKVRU:22VOO+ )!>)=A&W  !SSQ]/6/CP_LQ?&WX]0^,
M? ?B/Q2?&^IP:IH<FD:2UY#JD/E;!:F0#"&-CM(D( ST&>?L33?B;X9U>]\6
M06NK1L?"\I@UF0JRQV<@B$I5G8;20C!B!T!!JG9?&_P#??#^X\<P>+](G\'6
MY<3:Y%=*UHA5]K9DZ?>(%*5:4HWL!\&?&C4=4T;]KK4_$,U_\0OAC8ZAX/TR
M*)_"&@_VC,L@)=[68*DBKL!_AP/E_/[[T76(O$'PEM=2ADNY8KG2A(LFH0&"
MX;,762,J-K>HQ5KX??$OPO\ %/0FUGPCKUAXBTH3M;F[TZ82Q"10"R[AW^8'
M\16KXF&/#FJ?]>TG_H)I.HY3A%]&OS1RXK^#/_#+\I'G7[+7_)(['_KXF_\
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M\I'G'[+W_)(M)_Z[S_\ H9KUT5Y%^R__ ,DBTK_KO/\ ^AFO7175F'^^UO\
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M2/F>&O\ D54?6?\ Z5,G'2EI!TI:\L^I04444QA1110 4444 %%%% !1110
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M7+F0MW8N2Q]S7L40PNW&-O' P/PK*K/VEK"'T445F QZR_$W_(NZE_U[2?\
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M-NOXUF>)O^1>U/\ Z]9?_037ETU^\3\U^:/HL3_N]3TE^4CSC]E__DD.D_\
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M\_>H[6*[U975\$1(?*DW*=HW5+XO\,^,8_!_@[6[CX?:O9_$.3PI_9@T_2=
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M8?[U+Y?E$^:X9_Y%5'UG_P"E3,7QWXGMO!/A+6O$5Z'>TTFQFO9(T(!8(I;
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M^6X7_P"172]9_P#IR8]NOXUF>)O^1>U/_KUE_P#036FW7\:S/$W_ "+VI_\
M7K+_ .@FO,A\<?5?FCZ+$_[O4])?^DR/-_V8/^20Z7_UWF_]#-9O[8GQTU;]
MG3X':OXUT;PV?$UW;30P&W8L(84D;:99=O.P<#CNRUI_LO\ _)(M*_Z[S_\
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MEWHELFJ:BLL:Z?<QHLEL5$:CR_W,;;C\^8U!8@* U* 71VOP9;=\)?!7)_Y
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MR?=J%_N_A6<MG_7<75'R1\ _^3X_CA_UYP_^AI7UROW#]:^1O@!_R>_\;O\
MKSA_]"2OKI?N_C7NYQ_'A_@I_P#I!XV5?P9?XY_F/4?**P/%OC70O ]E%?\
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MRCVNOM=;,^\M]&^OA3_A:7C][#[8-=U,VR2>6;H % <#Y<COR#^-0K\8_'*
MJ/$NH#GJ77G\ZAY!B-??CIYC?B1EJY+T*MY:[1VO9/XMM_N/O'?1OKX,/QB\
M;@G'B:^7/)^9.:=;_%OQY-<1QP>(]0FGD.U8XP&9OH IYJGP_B([SC^/:X0\
M1\OFTE0J:MK[-]/+FUOH?=[2<XI5; KX2N_BYX\M;AX9O$6HV\T9VO'(R[@?
M?(&#4'_"X?&X;=_PD]]N_O93-$>'\1)K]Y&S7?\ X GXDY;&RE1J)WLTU%-6
MWOKT/O7?1OKX*_X7#XWR?^*FOCGJ<I1_PN'QQ_T,M]^:4O[ K?\ /R/W_P#
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M_P +C\;_ /0S7_\ WTE/_5+%_P#/R'_DW^0?Z\X'_GU/\/\ ,^[-]&^OA/\
MX7#XW/\ S,U__P!])1_PN#QO_P!#-?\ _?24_P#5+%_\_8?^3?Y"_P!>L!_S
M[G^'^9]V;Z-]?"G_  N#QN/^9GO_ /OI*/\ A</C?_H9[_\ [Z2E_JGBO^?L
M/_)O\A_Z\X'_ )]3_#_,^Z]]&^OA,_&+QN/^9GO_ /OI*/\ A<?C?_H9K_\
M[Z2C_5+%_P#/V'_DW^0?Z\X'_GU/\/\ ,^ZF?)%9OB8Y\.ZG_P!>TG_H)KXG
M_P"%P^-R<_\ "37_ -=R4R7XL^,[E6BE\1WCQNI#(V"&'<<54>$L7&2DZD+*
MSW?3Y>1E5XUP=6E*,*4[M26R[-=_,^E?V6O^21V/_7Q/_P"AUZ[7D'[+9)^%
M5OG)7[3-MSZ9']<UZ\.E?+YDK8RK_B9]GDW_ "+J%U;W5O\ ,CE^\/I7SO\
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M];,,O^7;_ _: IGU_"C9_LD_6OQB/Q^^*"-AO'GB-AC.#J<HI%_: ^)^X_\
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M1_6O!:MD6%]'_P"E,5N_UK'\6_\ (KZM_P!>TO\ Z :V3U-8_BK_ )%K5/\
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M=M0*C*2D(I,,;@\%N"0U;4'[2]II'Q;TWQ/;:/JU_HMII4VER6FLZZ]U/()
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M?16_E0MW\OS,:OP2]/T9^>&L_P#(=U7_ *_9_P#T8U4ZN:U_R'=5_P"OV?\
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M,GO6']L/FY86M>VZUW.K_5?DI\]6I)R]FY)<MO>O!);O;G^Y'A[2* <$ #D
M''J>?RKH?%/A"[\'R:9'?2P.-1LX[Z(0<X1\XS[Y!KW;Q5X;N[WP#XWTK4[8
M7<VEVJ-;&+2OL\<9V_\ +%_X^,9K9M_[6O/$O@>R318+SP]>>'XTU&XGM58
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M]5Y/AQXZ>R@M)-#U=K!/]5;2-F.(^R;^/6OO#R:/(^;-']OU;W5./W>5A_\
M$.<*HV^LSZ[J+W^7].S/@EOA/XS8_P#(L:C]=J\^_+TG_"I?&?\ T+.H_P#?
M*?\ Q=??6RC95?ZQ8C^2)C_Q#++NE:7W1_R/@7_A4WC/_H6=1_[X0_\ L]*/
MA-XT )'AG4/^_:?_ !=?>[)S3?*);(-+_6+$?R1#_B&67_\ /^7W1_R/!OV9
M_#&K^&-'UB'5[";3Y9KU7C290"1M49X)XXKWI.B?04\J=O-. P*^?Q.(>*J.
MK)6;/TO*<MAE.#IX*G*\872;WU=^@C5D^)(6N-!U".-2\C6\@55ZL=IP*V*9
MY=<\6X24ET=STZE-5(2@^JL?!4'PJ\9,G'AK4"P.&(C7K^+#VIS?"GQH#_R+
M.H_]^T_^+K[SV4;*^S7%F*BE%4HZ=[GYY+@C"SDY.M+7ML?!?_"JO&G_ $+.
MH_\ ?M/_ (NC_A57C7_H6=1_[]I_\77WILHV57^M^*_Y\P^Y_P"9/^HV%_Y_
M3/@O_A57C7_H6-1_[]I_\71_PJKQK_T+&H_]^T_^+K[TV4;*?^M^*_Y\P_'_
M #'_ *CX;_G_ #_#_(^#/^%5>-?^A8U'_OVG_P 71_PJKQK_ -"QJ7_?M/\
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M /)% 'U#17R\?VW;\_\ - /B\!Z_V'"?Y7%'_#;UR/O? ;XN#W.@Q?\ QXT
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M2_']CJERVH^'KNUCC@2.5&8NZ8^](E 'WO&NU2,YYSS[\T^F1#Y3SD$\4^@
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M1"A*]QWKE)_V:M%\P1PZQJL.F7,L,NJ:>/),>HB&Z:YB61O+R@5W*GRRI90
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M@ HHHH **** "BBFN<"@!U%4-2U2TTJW:[OKF*TM8AEIIY B+]22!7.K\7?
MQ'_(Y^'_ *G5(/\ XJA*4DW&+8KKN=C17'GXN>!O^AR\/_\ @T@_^*I/^%N>
M!O\ H<O#_P#X-(/_ (JJY)_RL#L:*X__ (6[X&_Z'+P__P"#2#_XJC_A;O@;
M_H<_#_\ X-(/_BJ.2?6+^X5T=A17''XN>!<_\CEX?S_V%(/_ (JC_A;O@;_H
M<O#_ /X-(/\ XJERS_E?W/\ R"Z[G8T5QX^+O@;_ *'/P_\ ^#2#_P"*H_X6
M[X&_Z'/P_P#^#2#_ .*I\E3^5_<.Z[G845Q__"W/ W_0Y^'O_!I!_P#%4?\
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M_P 52<9K[+^X+KN=?17'_P#"W/ P_P"9S\/_ /@T@_\ BJ/^%N^!O^AS\/\
M_@T@_P#BJ:A-_9?W!==SL**X_P#X6[X&_P"AS\/_ /@T@_\ BJ/^%N^!O^AS
M\/?^#2#_ .*HY*G\K"Z[G845Q_\ PMWP-_T.?A[_ ,&D'_Q5'_"W? W_ $.?
MA[_P:0?_ !5')4_E877<["BN./Q=\#Y_Y'/P_P#^#2#_ .*H_P"%N^!_^AS\
M/_\ @T@_^*J;2ZQ?W/\ R"Z[G8T5QX^+O@;_ *'/P_\ ^#2#_P"*H_X6[X&_
MZ'/P]_X-(/\ XJFH5']E_<_\@NNYV%%<<?B[X&S_ ,CGX?\ _!I!_P#%4?\
M"W? _P#T.?A__P &D'_Q5+EFMXO[G_D%UW.QHKCO^%N^!N_C+P__ .#2#_XJ
MC_A;G@;_ *'+P_\ ^#2#_P"*JN2;^R_N#YG8T5Q__"W/ W_0Y^'Q_P!Q2#_X
MJC_A;G@;_H<_#_\ X-(/_BJ7+-?9?W!==SL**X__ (6YX&_Z'/P__P"#2#_X
MJC_A;O@;_H<_#_\ X-(/_BJ?+/\ E?W!==SL**X__A;O@;_H<_#_ /X-(/\
MXJC_ (6[X&_Z'/P]_P"#2#_XJCDJ?RL+KN=A17'_ /"W? Q_YG/P]_X-(/\
MXJC_ (6YX&_Z'/P]_P"#2#_XJCDG_*PN=A17'_\ "W? W_0Y^'__  :0?_%4
M?\+=\#?]#GX?_P#!I!_\51RS_E?W!==SL**X\_%WP/\ ]#GX>_\ !I!_\52?
M\+=\#_\ 0Y^'O_!I!_\ %5-I?RO[G_D%UW.QHKCQ\7/ Y'_(Y^'O_!I!_P#%
M4?\ "W/ W_0Y^'__  :0?_%4)2?V7]S"Z[G845Q__"W? W_0Y^'_ /P:0?\
MQ5'_  MSP,?^9S\/_P#@T@_^*JG&:^R_N"Z[G845QX^+?@8?\SGX>_\ !I!_
M\51_PMSP-_T.?A__ ,&D'_Q5+EE_*_N"Z[G845Q__"W? W_0Y^'_ /P:0?\
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MQ)YV#^M.IFF(IXEM4;I+:S3V>N]AQHQDKN1\1S_#V:+X>1^-&32?[#?46TL
M7</VGS@A<YA7YMN O/3.:Y]K:S1F#QVZD<G,: 8]OR[U]A_#SX^:;8_#GP)X
MYU\>'7\0I\1_^)OIUO:P*ZZ3)9&VF_T=.?)6-C@GY0X4^M>B>&=5^$OPO^+G
MAWX?V6O:!J-GHNB:S?Z5XA%Q;-:_VS=7#&T!N64Q++';JJHT@95;M4K-)T7)
M3H7_ *^?<E44]>8_/9H;$0B0+;"-C@/M6K_A_P ,R>+=9T_2M(LH+[4=0F6W
MM85"+YDK<*-QPH_.ONCQ-\4-#\.ZA\4M8MSX6TWQO9^ K,I=1W]CJ37NJ+<@
MB4^6B0/=!2K,(U(&0<<UX;^U9'I?Q'^/FAOH&HZ TVO:-I$EY>VUU%#9)>O%
MB=Y'3Y(SD+NR 1QQS730S.567LU2M=7O:_1NWX"E145?F/*OBG\&/$WP4UNV
MT;QQX?A\/ZI=0BX@@>>";='N9=V8V8#+(PP3GCITK"T'PE=^)[35;K2=*_M"
MVTNT-_?R6Z(1:VP8*9F]@V!_P*OO;XJ>,M!\,_M _M">,=)\1^$=3;5? ]M<
M^';A;^UO4:[A2WB";#E?.#1,53!+*%/>KG_"XM.MO%7Q'M_#7BWPEINL^+/A
MEI=]YT[6D=K<ZVJL)E=R-BR&+K&0!R,KP">..<553BW1NW;OU+="*=N8_.D0
M6DC[!#;F7J41%!'_ -:KVG>&[G5[#4K[3](EOK'2T$NH7-K;;HK-2<(TSA2J
M D$9?@XXYK[S\7^,O #?LR6UGHD7AW5O"TWA&"V;3+C4[2&XM]<$A\R5;;R3
M</=$XRR':Z_=&.:[7XN7%X/!]YH>DII=_H>GZGX?OM5L+?5;!+?PU:6KH9Y%
MM(P)?+<Y\P7/ #$]ZJ6=2C+E]DKWMN^_]?.R!4$]>8_,DK8!-^RT"],E$VYQ
MGT'K^M:^F^$+S5]#UG6K'2?M6E:+'%-J%ZD2&*S$L@CB+GT=SM'^[7W7I7Q+
ML_$/[0OQ?UO3O%WA?P_!X6C^S>';738=-MCJ%F]T'GDBO)U:/@8+'&Y@^P=!
M5CQ7\1-'T:/]ISP_\/?%G@W3K;7[/3-;\.I'/:BVG5AB]5&8;#)Y88"(\JS#
M:.0:N6<34U!4=?=Z?S;].G];"]@OYC\]A%:-*42*W+*/N$+D#M^E=-H'PQU'
MQ/X%\2^+].L;*;0O#LD$6HR>8JR1O,2L>U?XN0:^V_C+XU^'%U\ ULM*C\/:
MGX"?2]'32[*/5+)+ZPN%DC^TF&V\K[3Y^-_F;W^Z#QCK;_:8\:Z;=?";XSV$
M/BWP/?:!?7.C-X/TS0+RU%R+)9$WJ5B ;Y3N.ULGYNN"*(9S4JRA!4;7DU>U
M]G:XG025^8^2_AI^R;\3?C%X<37_  ;X)36]):9[<W:W%M OF)MW +)*O'S*
M>%/4\]AY?J^CIH.L7VEW]O;VE]93O:7-N=N8YD?##<"5^\K8]:^VO@0_A7Q%
M^R/H.@:I;_#O7=3LO$M[=OI7CCQ+_97D1LB*)E",&.1D88$<UW7[/D(\%_";
MX2M<ZOX)TG0(-?\ $5MXGFU>6V;[=8QW,B%+:21"9EX&-AR05KG>;U*;J*M#
MFL[)<MAJBFD[[GP'KGP]NO#O@[PYXHO(],&E:\)_L.RYC>?]P_EN98EYCZ'D
M\5FZGX;ET73["_U#2'L+#4(VFL+F\MC#'>1*2&>)V^^,@C<O&0>X-?>'P8NO
M!.H6WP7.B-X>SI]IXSN)FGD@2;3(C>L;&>7>"L;+&RF/SN.:[2;7X8?B@NN>
M(I=/M-5NO <6F>!_$U]K>G31:K<6T[&\FBN0C6D-PRM$N O1.O/"6=^SGR2I
MKY_\,7]77\Q^9IAL(U!=;=00"'*J2P(R.?QH:/3XU5F2V"L<*VU>37WKK7Q=
MT#PI)\=M<\.CPGH_B/[=X6^Q1PW5I?P2S;R+N>WPB([!3^\,0P&#$UW/AOQ9
M\.-+\>?%J;PA?^&5\3W/BBQO#(VI:?:6][I'V2(S)'-/&\9B,WG&5(AN.170
M\Y=N9X?^ON,U03^T?G;9> =1U70[;6[?25719]3CT1-4D"K:_;9%WK"[=!E/
MF);@*M-\<>#7^'_BO4= U=-.74+*<PR-9S17$3MU^21>&&" 3ZY':OLF^^+>
MEZS^SOXG\.:!K/AG1=,L/B3'-+X<^TVQ!T1G1B+8L 98_-PVY0,(KCH*[#5/
M$^D?VQ\2A\*_$_P\T3Q+-XW+ZI=^(I+0VMUHC6RA1$7!62'>/F2+YB2:/[5J
MIR?LM$]K=+I7>GGY@Z"2^(_/&.PAED2)+-'FD=8EB$2N79CA5 VDDD],<UZ5
MX\_96^)?PP\*0>(_%'@2ZTK1)2B_:7>&5H&;[OG",N\7_ P.HKK_ (;?%#X6
M>$?$OP]OY/!,]MKVB>)+2_U/Q-!J#O:301W)9WBM2!@8*F-?X0JU[%\0_ O@
M*Q\%_&S6]=\5^'=?U'7-3;7M*N-!\6M+<:G:R7:MY4MD&6/=''(X7.2&!_NB
MM<3F52G54?9V7^&]Q1HI_:/AY8;&0G:EL67.1M7((X.1GCIVQ]*<D-E+N*PV
MS%1D_*M?I'\:?'?@&\O?"\=C-X0O_"1\5:!+X=O8=5LL:=9B6'SPEM&BS)$0
M&\P3,0&7/:N?UKXG?#SQ7J-VOCJ\\+7F@:!\7W33H8(H$VZ.0Q\P)$N98-S!
MG?!4DEB3DXQ_MIM<RP_]?<-T4M.<^#/#/A:?QGK=CH^@Z8-7U:]D\J"QMHE>
M29L9*H/7 Y]JU+SX;7UAX%/BVYAT]-*&J2:,\7G1_:EG1"S P_>"C &X<9!]
M*_0+4OC-H7A#X]_"BZU75?#,-U'KFH6\WB6#5].NG_LJ0'R8IEMH@(8BWE^6
M6.Y=LG8FN(\)>*O!)M-$F^)>K^%]4U'_ (7!>7.I3QRVTT4L!T_;!,0G6U\W
MR]S#Y>,]*%FU:HHS5&R]/-KMY#]BOYCX0BM[61@T<4$C X C ?#9^4<8ZD=S
M7KWB_P#8Z^*OP_\ !-YXM\0>!/[.\.64"7%Q?&\LG$<;;=K;!*6&2R]1FMO]
MJ?4/%&I^)?#TWB_Q+X.\2:N$F6.7PF86DMX/M&(EN9(!L)VC]V,\+G->_?M@
M6WA/QG'<^*-&3X97[0PZ4[Z[9^*/,UN01^4LD0LT)B;H4(!X7<<5K6S*H_8R
MC&W,FWH^G3=;BA23<DWL? \<=E)E0ML[C.0@4MUP>OOFNJ\!_"O5_B5J%C;:
M%I$3V]W?IIO]IW4:P6$5PREDBEN6^1&(!POWCD#JRU]S?%?Q]X7^(^H?%/PT
M)O"6MV>G^,_#'_"+6-M% PN%EGA6\\LPCS)E*[T;;DA"^!QSW'CW57NO'7@5
M[JYTG5/A_H/Q ^T:CJ\NL:=-9Z1$\,D,-DT%N%$<6[;M:<!U8#/-<]7.YK14
ME%^;?;H5'#WUN?E[J&GVNEZC=:?.MH;FUF>"3:4D&Y6*G#CAAQ@,O! R*@:.
MSC8)Y5ON(+!"JY/! (Z8()XY]:_0WX,?%#PGX?NOA#X?GUCPE'H.JZUXHMO$
MHO!:,3:%[A[5)I&YCC8A63. X"X/6J/P]\6^ =*_97T73K%/#=]I,.@ZC;^(
M]'U'5;&VF?459O*E,<D3W$DIPAA,;X^Z/X:T>=3BN5T-;VO;_@ J$>5MR/E0
M?LJ?$:;37U"W\'K?Z:EHE^]WI]U:7"16\D33)-)LD/EH\:LR[^2",5Y6Z6(P
MS1P1;OF&Y0#R?0DG\_Y5W]A\;_'-CI=K8V_B2X@MHK&"Q$,<857@BMV@2.0#
M[X$;-QV.37T-^P[XB\-Z#X)\:Q0W>DV'CQ]0L9+?^U+VTLWFTU>)HDFNXWBP
M6'[Q -Q0C':N^KBZV$H.O."DK]FOU,(P4GN?';QV,>-\5JI(R!A<D>N*1X;*
M-@KQVRLXRNY%!'I@=^AK] _ _P 7?"?A*R@;P]/X2T./4OC++%=V2R6ETD6D
MRVJ+*\<CJ"L#2*P5U"C:2 >*W?@3>^ /"T6I0S>,?"G_  AVO^)]=@O]&GET
M^*"UC+,EIY[2 SS(QVM&T3!%##<:\^6<R]FY*AL[;;_@;>P7\Q\">*_AI?\
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MC,'!4Z<M$FE==SDGAJ<Y.3ZGX_G_ ()6_&@X_P!(\,-QWOG_ /B*3_AU=\:
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M*C%)<3YC?XE]WFF+ZG2/Q^/_  2N^,[XWR^%R>5RU\^,'''W/I6UJ7_!-_\
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M)\G[(;SS9(\)Y6U&//TD2DN?BKX<M)[:*344:29E3$:EMI+;<G'0$_RJY:^
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M.I%Z>E+6=AA11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL
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M4GU.[T'3[C4&QFYGMT+X",BY^B.R?1C4>J?#3PCK!C-]X<TRY*.6026R<,0
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MP/RNK3?=YY&./XO3[GP;H-V)DFTBQE27SO-5K=2K^<NR4D=RRC:?49'>J/\
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MZ3#ID^DPIIZZ@NJ-;6Z*B33AMWSKCY@Q^]ZX%2K\+_"'F+./#>E&54$2N+1
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MHHK1; %%%%, HHHJ6 4444@"D(S114@ &*6BBJ 0C- &***I +1113 ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %K H0# 2(  A$! Q$!_\0
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MFT7PUHVN^'M'TR74+Q[S5Y;6Z_=!G=8HEMW5_E7NZU<(2J2Y8A+W2Q_PR?\
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M[%;3[Y79MH^:X9?^^:WO&7QD\$?#LV"^)?%>D:$U\N^V&H7J0F5?[PW'[O\
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MOP!_X2]C_P#&J#^R?\$?^B.> /\ PE['_P"-5%X(^-L>H-XIL?&]G9^"M?\
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M?#6G:-=6-MIUS?70@>Z:>U25PVYOX6?%5&C4E\,0YHQ-?_AD[X(_]$;\ ?\
MA+V/_P :H_X9.^"/_1&_ '_A+V/_ ,:KU&.59HEDB971EW*R_P 535D4>4?\
M,G?!'_HC?@#_ ,)>Q_\ C5'_  R=\$?^B-^ /_"7L?\ XU7J]% 'E'_#)WP1
M_P"B-^ /_"7L?_C5'_#)WP1_Z(WX _\ "7L?_C5>KT4 >4?\,G?!'_HC?@#_
M ,)>Q_\ C5'_  R=\$?^B-^ /_"7L?\ XU7J]% 'E'_#)WP1_P"B-^ /_"7L
M?_C5'_#)WP1_Z(WX _\ "7L?_C5>KT4 >4?\,G?!'_HC?@#_ ,)>Q_\ C5'_
M  R=\$?^B-^ /_"7L?\ XU7J]4]0^TK8W!M%5KD1MY2M]W=_#F@#Q:_^ _[.
M.C:C#IM_\._A=9:E*/W5K<:'IT4TG^ZC)NIT7P%_9RFUI]%3X=?"U]93[VGI
MH6G?:%_[9[-WZ5PFOZ7:_P##)M[J>A6,=[KEU#$WB2]EMDGOUE\Y/[2:0,K_
M +U,2_)_!M^3[JT[X7Z7X<O?V<-8U'Q+;VB^&HY9IM+U18E6?RMJ>5+;R_?9
M_/WK$_WF_=;=W!;O^K+DY[_:Y3#VDN8]3_X90^"./^2.> /_  E['_XU1_PR
MA\$<?\D<\ ?^$O8__&JY^:X\1^-+_P"'O@W6]2OM&DN_#TFL:XUC(;6XO)XO
ML\36XD7YHDWSL[;<-\JKG&ZMC5--L/@7:2:EH0UC49=2GM]*LO#]WJLLMK+=
M2R[4??/O:+K\S+\NU?N,W7E]ETOJ7S%K_AD_X(?]$;\ ?^$O8_\ QJC_ (9/
M^"'_ $1OP!_X2]C_ /&JYGQA\;O&WPV_M%/$?A/2KB:'0;W6;:?2=49H;AH)
M;=/LY\R)65O](SN^[6Y>>/O'UOJ.FZ"_A[06\4:F)[N!(]2E:TL[.'RO-:=_
M*W,V^:)%5%^?=N^3::KV,K7%[2):_P"&3_@A_P!$;\ ?^$O8_P#QJC_AD[X(
M_P#1&_ '_A+V/_QJO.=#\=^(+3XI:O;^*;:2SG7Q'IUF+>RUB4VD2_V7<2M*
MOR)OB?;_ *IU^_\ [JUVFG_%OQ,^F:1XJO\ PW8VW@S5Y+9(C%?,VH6T5RZI
M;SRILV$-O3<JMN3?_'MIRHRB1[:)H?\ #*'P1/3X.^ ?_"7L?_C5*?V4/@C_
M -$<\ ?^$O8__&JY;X:_#8>+_ *ZPWB+Q)IOB.:\OP-2M]:N7\MEO)57]P[M
M$R?*OR;-M0>"?C3J.H6EM>_V7)?^(]6L=*CAMQ?O':SSR_:M[HC;UABVV\LN
MY=S.FWK\E5]7?O<OV3#ZU&/)*7VCK!^RC\$O^B0> ?\ PE['_P"-4[_AE#X)
M'_FD'@+_ ,)>Q_\ C54=1^+7B?POK=SI.N>&;1[HV4<UI-IM^S174LMU';Q1
M?.B^7\\J[F/'-,UWXK>+/!\[VNJ^'=-N;N2WCGLH]/U!MEP[74$#H6>)=NSS
MT;=_%N[4HX><MB)8ZC#XO_22\_[*GP1# ?\ "H? *Y[?\(O8_P#QJG-^RE\$
MMI_XL_X"&.I_X1BR_P#C52S?$K6?"]U=67B'1;=]0:!;BR32[DNMTS2I (F,
MBKL8/+'\Q^7:_P#L\ON?'WB#PR[PZ[HEN\T]K//9)I=T93.\2[C"=R*=Y7&&
M_P!ENG2CV,V1+,</#XG_ .2_#_B*O_#*OP2Z#X.> 21U_P"*8L>/_(5#?LJ?
M!-5!_P"%-^ &/H?#%C_\:JI=_$'5-3\%>)I["?1I;K3[3SDDL+QY3%E6.2K1
M9#<<;OO8/2M35?&5SX=U*W;4[,S:@UBY6&QO&$3LTT4<:A6"_,S2*-Q^[^-:
M?5I;'*\XH?\ ;O\ -_V]*/G_ "D*_LH?!(_\T;\ ?^$Q8_\ QJE/[*'P2/\
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MV3?^36?@Y_V)NC?^D45>KT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BW_P6B_Y
M.D\+_P#8FVO_ *6WU%'_  6B_P"3I/"__8FVO_I;?44 ?J;^R;_R:S\'/^Q-
MT;_TBBKU>O*/V3?^36?@Y_V)NC?^D45>KT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/'(B;YE_WEZK^-= &W#CK7B24HOED?9TZL*L?:4Y<T22BBBI-@HHHH ****
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M]ZG*G1$>]^&/VG] \3:S\.]&ET+Q'HFK>-?[12UL=7L/L\UF]BFZ=9U9N/\
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M +3/_%7OW[/_ ,']2\.?!?XC:KX>MQ+\2_[)NX-+NU_UMK.UJVR*(_PMYO\
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M $BBKU>O*/V3?^36?@Y_V)NC?^D45>KT %%%% !1110 4444 %%%% !1110
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MP%X6TW[$MQK^F7%S/+<YS]GC>9\1?[6[Y6_V?^!5Y]H/C'2O"7BS1;G4M/\
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M.V-VW_/=XP''_ EYK[/#<1OV?LL?2YT?DF-X%=*K[?*,1[/[7++X?^W9=/\
MR8^*?&'[1'CCQT^GB\T:P\ZRF\Z-X()4^?\ VOGJEXG\8_$#XG6[1^(M7E^Q
M%L)I6GKL20>FU/O?\"W5]EQ?L_\ P_AD+CPW"A_N^?*5_P#0JZG1/!>B>&D!
MTG2K2P;'WH8E#?G70\^RVC&'U;#_  _U_>-I</\ $N84XX;,,?\ NO\ M[_[
M4^1?A/\ LFZEXHFBOO$R/HVA+\RV(^6ZG^O_ #R7_P >K['TC1['0=.MM.TZ
MUCM+*U3RX88AM1%] *TLX W'K[4T+\C<5\KC<PKYA4]I69]ODV0X3(Z7LL-\
M7VI?:D4M3TNSUO39[*]MX[RSN%\N2"5<K(OH17R'\7?V5M2T-WU'PB'U/2AE
MFTPMB>W_ -T_\M5]OO\ ^]7V2!E%&,^M.SP<&IP>.K8"?/18\YR'!9Y2]GBH
M^]]F7VHGYK>$_&GB+X:>()+_ $MGT^_BB:T=+J+=B+=NVLK?[JUT?B?XW^(?
M%VOZ!KU_!I_V_1I_M$'E1.BN_3YOG]*^RO%^G>!M9U*SL/%7]B'4;G(M;349
M(Q/)_P!<]QW'_@-<C)\!?A?>RR2VND63Q6UPT=ZT5X^V':C;E?Y_E_AXKW*F
M/RC&K_;,+_>_[>_\E/@:7#O$^62MEF9>[\.LI?#_ "_:Z?RGS)XX^./BKXBV
MC6.KW4,FF[@WV:W@6-2W_H=;?PR_9[\1^/+B.XGADT70\[GN9TVO(O\ TR0_
M^A?=KZ2T?3_A5X%EM);1_#.FRW42RVTTMU$))$;[K(S-N*G_ &:]425'0&,[
MU/W2*=;/84H\F I<AMAN!Z^*J0KY]BI5N7[/O<O_ )-_[;&)SO@WP7I7@#18
M=)T>W6"VC')_B=O[S'^)O>NAFA697CD421L-K*W?BILD]\_A2;@0>>*^3E*4
MI<TC]5I4:=&G&E2CRQB?'WQN_8_FCNI];\ QJ%?YY]%=MH7'_/!NW?Y/^^:^
M=K36_$_@:6_TM9[_ $<W"^7>6$NZ))?]Z)J_41I6C5<#.>U8WB7P5HOC&)8=
M9TNSU*(?=6[A63;],U]-AL[FJ2H8V/M8'YWF7!].K6^MY75]A5_K^7WHGP[X
M'_:@\5^"O"FG^'[*+3)+*QB$4+3V[LQ7\'KG/%OQA\5>-]1>]O=3,,C)Y6VR
M4P+M^[M^7K]ZOLJ;]F'X:S %?#48)_YYW$J+^6^MWPU\'O!?A2Y1].\,V%M=
M)TF,7F./^!-FNVEF>5X77#X<\'$\+\0YG+DS#'<T>;F^U+_M[:/YGR)\+/V<
MO$'Q$N([FZ@DT30 0SW<PVO*I_YY)_[-]VOM+P;X&TCX?Z'!I.BVBP6L8Y_O
M2-_>8]V]ZZ56^134<B 1G*8'IGK7@X_-,1F$OWC]W^4^XR+AK Y!"]+WJG\T
MOZ]TM4445XY]B%%%% !1110 4444 %%%% 'XM_\ !:+_ ).D\+_]B;:_^EM]
M11_P6B_Y.D\+_P#8FVO_ *6WU% 'ZF_LF_\ )K/P<_[$W1O_ $BBKU>O*/V3
M?^36?@Y_V)NC?^D45>KT %5+VX:SLYYUBDNFC5F$40R[?[*U;HH \<_9F^.>
MI?'[P!=>(]1\$ZOX"E@U"6P73]94B654"'S5RJ_+\Q7[OWD:M6/XH7&M_%*Y
M\'Z+8QC^RMDNJW6HS^0QC9-R_9H/ORKED'F_+%]Y=S,"M>F8]:R-3\-:7J^I
MZ;?WEA;W-[I\C26<\L>Z2W=EVL4;^'*G%5S1Y@/GC6_%?B_PK!XMGT?Q=?\
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M?\G2>%_^Q-M?_2V^HH_X+1?\G2>%_P#L3;7_ -+;ZB@#]3?V3?\ DUGX.?\
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MKPQ:?$WE:EJ4#?ZYOXH4;^[_ 'F_BZ=/O=^$PM7&U?94SQLTS.AE5#V]?_\
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MWEV5Y.W_ !YM_!$S?\\__0?]WI]'_'+XQQ?#'2([73Q'<^(+Q3]FA<_+&O\
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MD%PS?\>C>G_7+_T&LL=E5"O0^MY;_P" G-DW$^+P.+_LC/OC_G_^2_\ DO\
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M$:7VI1,GA33''VM_^?F7M OM_>_V3_MU^A_C&TDN_">L6L2%GELYD51W9E;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'XM_P#!:+_DZ3PO_P!B;:_^EM]11_P6B_Y.D\+_ /8FVO\
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MB@#%V^(/^>^F_P#?B3_XNC;X@_Y[Z;_WXD_^+K:HH Q=OB#_ )[Z;_WXD_\
MBZ-OB#_GOIO_ 'XD_P#BZVJ* ,7;X@_Y[Z;_ -^)/_BZ-OB#_GOIO_?B3_XN
MMJB@#%V^(/\ GOIO_?B3_P"+HV^(/^>^F_\ ?B3_ .+K:HH Q=OB#_GOIO\
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MPCHG[06D_"*XMK^37M1MTF%^D:&R@E9)98H)7+;EE=('95V\BK/QA_:0\+?
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MKOC_ /'C1/V>_ ?_  E.N6&HZK UU'9P:?I4*RW=S,^XA$1F4'Y5=^OW4:O
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MZ1H/A2Q\&P7%U"T2W]RLSW5Q+#N^]$GF(F_[K-NV_=KZ2KDJ1C&7ND!1114
M%%%% !1110 4444 %%%% #,<48[4O85\.?MG?M(>-_ ?Q0MO"_A36'T"UM+"
M*\N)8H8I)9Y)'?\ OHWRJB5TX;#5<75]E2W.:O6AAX>TF?<5'8^E?%_BO]J'
M7O%'[&TWBG3Y_P"R_%3WT6AWUW8_)Y,N\;Y8O[N^/:?]C?\ [-<A^PO\<?$4
MOQ*?P3KFL7FKZ;JMK+-9_;[AIW@GB^=MKO\ -M9=WR_[%=2RZNZ%6NOL&'UV
ME[2%+^8_0*BBBO,/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&F/I_P!J_?O:3PP2QL[P*DK[Y3\L#/M\IU^9MN<_5/VEM4M(-,M=)\/?V_K
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MRX6))8G_ +K_ 'T?_OJOJC]J+Q=#\2?V>?A;XJC"^;?ZC;RL=OW6:UF\U/\
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MODW8VE6,\TOY1'7T5S/AOQ79Z]JVM:<D;P7NER1B57V_O8I$WQ2H5^\C?/\
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M/F5N7^\W1OT]]WXG?\/1OVG?^BF?^4#2_P#Y&H_X>C?M._\ 13/_ "@:7_\
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M:)&2-5V[/S^:J5Q\./%#.;E?'NH->QHQBW0(D1?YMN]%^7;7XF_\/1OVG?\
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8'<O8VT.V%9)'5 L4:K@-(YZ9^:BI __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '( R(# 2(  A$! Q$!_\0
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M_>Q19^=D>+:Z?>KHJ1I3JU&[+5M:_P!VZ_R%=G:S?'WQ=\// 7CW7/B=\/\
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MW\5<Y^T"NL^'/CA\&_&UIX7UOQ-I.BQZS;7T>@VOVBX@:YBMTB9DW?=^1_\
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M=<)+#XTU82I_SUEWU[;\+/\ @H!XJ\/W<4'C&QBU[3OXKBR_=7"_[6W[K?\
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M[2]NT7Q7N)2,I/;0,M>5O]Q_]VOI?]JGP<]WI>F^(K>+>UBWD7>W^&)ONO\
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M@ I.]+2=Z /G']G[_DYW]I+_ +">C?\ I!7T6M?.G[/W_)SO[27_ &$]&_\
M2"OHM:[,9_%7^&/_ *3$RB24445QFH4444 %%%% !1110 4444 %(WW32TC?
M=- 'S/\ MV32I^SOXHV_Q^0C?^!"5^6A.6XK]??VH/!LGCWX+^+=(MUWW$]B
M[1)_TU3]ZO\ Z!7Y";_,C ;Y"*_6^#JBE@ZM-=):KLNY^8\5P<<33F]FK'H5
MG\)K1?#FCZKKWC+3O#IUB![JSM);&YNF:)96BW.T43*OS(WRUWNA>)M'^!O@
M:31=6MH_&FC>)6_MFPFM$\JUU#:DMK]GNHIT\V)4E3>K1;6_VJJ_#?XF+X,^
M!7V:Y\2>*-.D_M]O*MO#.II!*B?9U;YU?^#=_P"/5UGQ&^)7A&Q^(GBJ/Q'^
M^U266PEL]6U;18-<=+/[$G^C^5.R+%\[M+N3[V]JZ\5/%5:LZ=:/-%-O2ZO:
MUNG2YP8>-"G3YZ+M+3L][^?D>?\ PQ\>7?B_XV>#;6YM;73]"N47PP-'T[>E
MK'8W*M%+$JLS,^[S6E9G;=N^:N3^#^DCQ)XR7PI<7US#I^NJ]E+]DEVI).JL
MUNS_ -Y4E5&VU[U\-?'/@IY];UZ#5](TV+1-/ENEU4_#^QMFL[F7]U:RK+$[
M-O65U;;_ !;6KCM-\4Z=XL^-WPJ6'68_%.NV%RO]J^)(K/[*E_\ O=R?)M5F
MV1?+N9/F_P" TJ5:?/42HN-H^?Q)-J6W2_6_J7*BE3@Y54_FMGNM_P#ACY^=
M73>KKL=6^9/]JOIC_@GQ<RQ?'JZC5OW4NAW&[_@,L6ROG+4Y?M6JW<J_ZEYW
M9=O]W=7V#_P3A\&RWGB;Q1XI>/\ <PP1:;$_]YF;S7_] 3_OJO1SZHH957D^
MJLO\SCR:FYYE3C'2SO\ \ _1.T_X]UJ:F0_ZI?I3Z_"3]F"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B)  J"\MTFCV5<I
M&^Z:/46NZW/E+X^_">>"\F\1:3#O_P"?R%%^?_KJO_LU>"G(/RU^BE]IT=XF
MUQ7@WQ'_ &=+35+B:_T5_P"S;MOG:'_EE*W_ ++7UV59S&E%4<1TZGXIQ9P3
M/%U98[*UK/XH=WW3Z?<>9?!#6_".C7FK/XM2Q>.5(OLWVN'S<-@[_P"#Z5[0
MOQ#^#W]F_P!G^9I8LO-^T?9_L3[?-_O;=GWJ^=-;^%_BK0I66?2)YD3_ ):V
MG[U/_':Q/[!U7?M_LR^W_P#7JW_Q%>MB,%A,7)U'6>OF?$X+.\VX?PRP/U):
M*UY0;?G>S5[Z;]CO_CGK7A#6M0TIO""VB0Q1R_:/L,'E<93;_!ZYKS#[E=;H
MGPK\5:\R>1I$\*/_ ,M;O]TE>W_#K]G&RTB6.]UMSJ-TOS+$%V6\7_ ?XO\
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M[3P-[>WA_P"!+_,[E?K4;Q*P^[FN)7XU>!1_S-.G_P#?RG'XV>!O^AIT\?\
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M"^O87;VL;_XE_F=BD8"$*>/6G*HVX!S7&_\ "[/ O_0SZ?\ ]_*/^%V>!?\
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M,*O!P*!SG!_2OD#_ (>9_#__ *%GQ-_W[@_^.T[_ (>8_#\_\RWXC_[]P?\
MQVLWD>9O_EP[>@_[9R_=UE<^OZ*^/A_P4P^'O_0N>)O^_4'_ ,=H_P"'F/P^
M_P"A:\2_]^X/_CM"R3,WMAY?=_P2O[:R];UD?8-%?'Q_X*8?#X]?#?B3/_7.
M#_X[2'_@IA\/3_S+?B7_ +]P?_':O^Q,RZ4)!_;. _Y^H^PJ*^/O^'F/P]_Z
M%SQ)_P!^H/\ X[0G_!2WX>2,H;P]XD13_'Y$'_QVG_8>:?\ 0/+[F/\ MG ?
M\_D?8-/KAOA=\6/#'Q@\,Q:[X7U!+ZR9MK\%7B?^XZ_PM7:_PFO$G&5*3IS5
MI+H>K"I"K%2@[IDE%%%(T"BBB@ HHHH **** "BBB@ HHHH 8WRJ:S]4N6M-
M/N9U&YHXV=?^^:T&YS61X@&=$OC_ -,9/_0:I:NQSUFX4FX]#X GN[_Q3K+7
M,WF7NIZA)NX^9F9OX$K5O_AKXJTJTN+V^\/:A9VL"EI+B6/*JO\ >JK\/O\
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M)%8R?9H$?A8U7G*UF0_#7Q9<V<5W'X<U":WEC\Q94CW[E_O5)\7ACXC>*O\
MK[EKV/6==T/PR?A[?ZCXEU;39+;2H+@:;9HS17*J%^]QS7Z]+'5L!@\-3PD5
M>2N]&_L\W?Y?B?@<,#2S'&8NIC)OW7:^FGO<O5/IK^!\ZNFQG5EV.GWD?Y*;
M7LIU;P_=^!/$OC:[\+6NH7<OB!E@@N'V[594^]M_[ZV_WJV](\*^$]%T'P?#
MJ-II\MKK%B\]W+-;3RW4KLN[]TZ?*NVNN>>.G'FG1DG=QWZJ-Y=>FWF<D,@E
M5ERTZL7IS;/9RY8O;KN^Q\_?+FM27PUJ$7AZ'7)+<)I4TS0QS^:OS2+G'R_>
M[&O3;?3]'\)>"/#][9^&[;Q?+K%Y<P-/.&WM&KE(E7;]UF2J]GHNE-\.?#5Q
M?:5,D<OB:6*XMX-[R>7\_P"ZHGG#;ARQ:M*WV==[]=-M#.&2Q2J.4T[QYMGI
M>UD_=\];;'F&EZ?-JVH6MA:QB6YN9%BCB+[-S-3M6TFZT34;G3[Z-(+NVD\N
M10^\*U>T^(O#NF7^L>%[W3=/T)M%.O0V@GTZ*6&X5"XVQRJWU'S5#JFC:9X:
ML_'?B!/#]OK=[;:XEC!9W09HK>,[?F"_[6[]:PCGJDU+D=G]F_\ >Y=[_/8W
MJ</2IPG%RC>/VM;/W>;^6^QXC3H86N)4CCB::5FV*B+N=FKWK5O!7AWPSKOC
MV=-$MKVWLM'@U&+3YW;;!(P?<O\ >5<H*N>&=*T@?$KP!JMMIEIID^K://<_
M98!MB-PJ#;MS_OO6CX@IN/-&#?N\V_7EYK;_ (E+AVKS<LII>]R[=.;EOMWZ
M?+?0\2UOP7X@\.627FJZ'>:?:-_RVGCRG_ _[G_ ZKW'AK5[+68M*N--N(M3
MGV^59L/WK;ONUOZO<>.9]%\2I=MJCZ9YW^G_ &C=M0[QMQN_#[E>U^+4\))\
M=]%_M(ZJ-?#6WD);A?LN[#;-_P#%ZTJN;8C#0Y9*,])/W>9_#:WWW^1-')\)
MBI7BY05XKWK+XN;R\M.]^A\_6'@?Q#J\]Y!9Z)=W4MI)Y%RL8 \N7^ZU0CPG
MK,FL?V0-(NEU,IYB6<L>V5Q]6KV.:;48O"GQ>DTQKM+XZZFU[3=YO\']SYJS
M?&NM:AH_@SX8:QJL;S>)[-I9S]M_UK1[OEW?Q?W*QI9SBJU51BHW>EKN]^12
MVO\ #K:YM5R3!TJ3JR<[)<U]+6YW"U[?%I>WR/+[OPAK>F12SW6DW<,44?FR
MS.OR*N[;NW?[U>J?LL:Y=V_C.]TI'8V-S;-.8MWRJR_Q)_WU7G\WQ(UB;PXV
MA,8O[.:V^R^1\WR_,K;O][Y:[#]EWCXI<=?L,O\ [)6V:*O4RRO+&12:5U8P
MRAX6GFV'6"G)INSO;_(^Q:***_&C^A0HHHH **** "D[TM)WH ^<?V?O^3G?
MVDO^PGHW_I!7T6M?.G[/W_)SO[27_83T;_T@KZ+6NS&?Q5_AC_Z3$RB24445
MQFH4444 1[OF6O(OVJ=5N-*_9Z\>7-I*T-PNES('3[R[OE_]FKUD##DUX_\
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M:[D>PM&:2VM?DVQLWWF_\?-?9W_"C_ ?_0LVGYO_ /%4?\*/\!_]"S:?F_\
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MSI63K6NZEXBOFO=4O9M0N638);AMWR5]F_\ "B_ G_0M6?Y-_C2_\*)\!_\
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M3G?VDO\ L)Z-_P"D%?1:U\Z?L_?\G._M)?\ 83T;_P!(*^BUKLQG\5?X8_\
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MP^#(IC-XGO)5U!9%TPEHKB5A!\ZM/OWK$UQAE_@^\FWRME7[.?\ ,3<]WO/
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M%#_$NR(R,S?W/DW?>IM]XRT*WCMUEU&VFFO+:6:UBAD5I;J*-=TOE;?O_P#
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M3MM+11<!N!ZU#-;Q7,3Q2(KQ.NUD9<JRU/NI:FR AB@6)%1%"(J[551]VI"
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MNV54S7$:9^T'K6G>'HM7UNPT^2T\C3;V=[(O^XBOK65HE^?_ *>$BB_W9?\
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M"3S^Q^"OB:UT+0+>+3M*2YTJ\E:S280-$D3>1\]PBQ(LLO[E_P!]%Y4J_P#
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M*LW'QAL([NXL[70]:O;A=3_LN!;:&(?;)U1I9?*WR+\J(C,S/M_V=S4^:IV
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M39GTSX0>&-*-QML);A[H723O=W4D_FBY6)9]V]OX_(B_7^\U<3K'B?Q7X?\
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M.45@HJ($>OZ4%@?XL_A5/3<+KN2T5"C*R]:"-G3Y:-]@NGJMB:BBB@84444
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MB@ HHHH **** "BBB@ HHHH ;NHW4ZBE8 HHHI@%%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRE-U?H)K_A#P_J/QP^/WBC4$L)M=T*WTY=/?4]+;58;1)(?GG^RI\TOW=O\
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M:BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHIC??H ?14*8 Z8_&G<&@$[[$E%0^8*/,%.Q',B:BH?-'I1YH]*+#
MYEW)J*@\P>E'F#THLPYEW)Z*@\P>E'F#THLPYEW)Z*A\T>E'FCTHL',NY!-$
M)4(W9S[5\Y_M*?L[I\0[?^VM%5(?$%NNSYOE2Z7^X_\ M?W6KZ3\P5'*D<WW
MJWH5JF'J*I3=FCSL;@Z&84)8>NDXR_!]T?DAJNE7>BZG<6.H6LMA?0-MEM[A
M=KK76:1\:/&OAS2+72]/UYDT^S7RH(I;."?RE_NJTD3-MK]!/'OP9\-?$2V6
M/6=,@NW1=L4OW94_W6KPO6OV&M)>=FT[7=0LT;^"5$EK[:EG.&Q"M7IV^7_!
M/Q[$<&9IA*C66U.:#\TF?/B?M#?$-'W+XC"-_"RZ99JZ_P#D*O/9YFFD\UGW
MNS[][_.[-7U]9?L-6KW"_:_$M[-%_<2U1=W_  *O6/A]^S;X2^'<L5S9:4MQ
M?)]V]OCYDJ?[G]VD\WP5!-THIW,:/!V<XR26)J*,5UYKGA/[-G[-5W=:A:>*
M/%ELUO#$5EL]+N%^9G_AEE_]E2OM2RM%MH%4=:+:!+9?E%6/-'I7QV+Q-3%U
M'.;T?0_8,KRW#Y3A_84+:ZM]W_70FHJ'S!1Y@KDL>OS(FHJ#S!Z4>8/2BS'S
M+N3T5!Y@]*/,'I19AS+N3T5!Y@]*/,'I19AS+N3T5!Y@]*/,'I19AS+N3T5!
MYOM2[\_PY_&BSZA==":BH]U/7I2&G<6BBB@84444 %%%% !1110 4444 %%%
M% !1110 4G>EI.] 'SC^S]_R<[^TE_V$]&_](*^BUKYT_9^_Y.=_:2_[">C?
M^D%?1:UV8S^*O\,?_28F422BBBN,U"BBB@ HHHH **** "BBB@#\C?VU_!&H
M^"_VA/$EU?PLECKTOV^QN&3"3IL3>B-_>1OO?\ _OUY+JGC77M=;1VU'6[V^
M;1HU@T][B3=]CB79M6+^[MVK7[6>*/!FA>-=-^P:_HUEK-ENW_9[Z!9D#?WL
M-7$?\,M_"4?\T^T#_P  EKZRAGE.-*FJL+N"M^%CY6ODU2524J<K<SO^-S\G
M+/XK^-+#Q;/XHM?%FJP^(YU$,VJI<_OY$'1&_O)\G\52Q?&;QW%XK?Q3'XQU
M<^(6C\AM3-SOE:/KY7]S;_LU^KO_  RW\)?^B?:!_P" 2T?\,M_"7_HGV@?^
M 2UT?VW@O^?3VML1_9.)_GZW/RB_X7'X[^UV=U_PFFM/<V-S+>6TSW;.\$\B
M.LK+O^ZS*[K_ ,#K(T/QIKOA?77UO1M;O=+UI]V_4+6=EE?=][>W^U7ZZ_\
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MS4X.HTY_#[L=>G;O_F?0_P#PW/>?]"9#_P"#-O\ XS1_PW/>?]"9#_X,V_\
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M?WJY-1114'2%%%% !1110 4444 %%%% !1110 4444 %)WI:3O0!\X_L_?\
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M[O*<-_WUN_AHY8_S"/1[SP]X2@O=.CGTO23<+?.UFKPIO2Z96G;;_=?"E_\
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M=ODEB_W+C;_!6+;_  J\9W%QX9&M6=SJ=];2Z-+_ &@^L,RVGD70ENU96?\
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M7[VWT^5DBDEN&MXHGX^5VG1HO]^I5^.WA@_9&4:F$EC2><'3Y1]B5I7@_?\
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MHL\MPBKN7Y-KRL-W]W_:^>O80,5G.,.@Q:***0!1110 4444 %%%% !1110
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M_P"5^SD%SUVBO/?%/CK4M)U+3X]-T6XOK*>!Y9KOR6VPN6VQ+^C[_P"[\O\
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MP5\1:K/KMQ</()=1N&E$EQ<QQ>?;RW\5QY4JK%YNZ*!/*R\K;=F$^5JN:E\
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MG%2YJEUV2^Z*1,8DE%%%<Q04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 W
MFCFBBIL3<3@]ZAE@CGV^8BOM;<NX=***TVV+Y434445%O,@*,-112L41);)$
MS,L:H[?>95^]4M%%.5R I>:**;0Q****=A#NG>H98DG4K(JNC?PLM%%)(L>B
M[%VK3N:**5B0YHYHHHL%QU%%%,H**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "F/110!DV6A:=INI:A?VEA;VM]?LCWD\42J]PRKM7>W\6U:U6HHI
M7NKL(DE%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %P H4# 2(  A$! Q$!_\0
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M/ZM!>R7/B*?RDFM(E:*S3S8HEEN&+?)&TL\46[^\]7"$JDN6),I<I#_PR?\
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MFQM_BW>;_P".UU_VN'[08/,3SU7=Y>[YMM$E*/O!<\Q_X9/^"6?^2.> <?\
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M$O8__&J/^&3O@C_T1OP!_P"$O8__ !JO3OM4(N/(\Q/M&W=Y6[YMM<Q9^/\
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M_%.-*K*4H<OO1'S1MS$O_#)_P2'7X.^ ?_"7L?\ XU2_\,G_  1_Z(YX _\
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MBRQ-]UD;<K5AGQSX?C\26OA[^V[#^W+N)[BWT\7*&>2)3\[JG4JM*SD!Q?\
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M1V1T+2+_ %V:YM%O3##LB,,;,RKYC2,JJVY'7;G/R-Z53H3CT,EC\//X9?\
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MO8DSM=H'Y5]OWL4 ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?E5_P %S>GP2_[C?_MA11_P7-Z?!+_N-_\
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MNI>*8?B-:>*]8&@W%XVGW>I*ZR7"13I%$+6W5%B7M%YJW!D_C^[C[U'-+;F
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M[<S6TZQ7+JT46;.W\U(MOW5\[S?E_P :Q<;$GHE%%%0 4444 %%%% !1110
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M\56?VK1]6LM6MO\ GK8W*3I_WTIHE"2]Z43.-2,O=YC:HHHH- HHHH ****
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MX4\0VNO>);K2]2M-$@MQIEJMGLBM7@\UOM$LLKNSLOFOM7Y53[W+_,MJQO\
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MF_\ )K/P<_[$W1O_ $BBKU>O*/V3?^36?@Y_V)NC?^D45>KT %%%% !1110
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M_P "KU=/88KG?%L*7%MIRO$)0NH6S?/:2S[?G^]\GW?]]OE7^*M85ZD8V_\
MMC"6'IRES'&)\"(-<FBD\:^(]7\<1HV[^S]0:*#3\]MUM B)+_VUWUZA!;QV
ML2QQHL42+M557:JK4V<4NZE.I.IN.G2C2^$=11169L%%%% "=!7$^./A9X?^
M(2VLNK63IJ%F=UGJEE.]M>VS?],IT*NO^[]TUVN[BDZBG%RA+FB1*,9^[(\H
M'PO\<Z>3#IWQ4U,V@&$75=*L[J5!_P!=%1-W_ J4? :#7YDD\;^)M7\=)&V[
M^S[YHK?3\_[5K B)+_VUWUV7BZ)+BULT>(3?\3&U8(]K+./]:GS?)]W_ 'S\
MJ_Q5TNVK]M,R^KTR*""*TB2*)%BBC7:J*NU56IZ**S.@**** "BBB@#@OB)\
M(?#GQ,CM)-:L'?4[!M]CJ]C</:W]FW_3*XC*NHY^[G:V!N!KE1\(?B'IG[C2
M/C-JWV-1\JZWHMG>RI_VU18MW_ ]U>S<5S?BY$ELK5&B$P-]:MM>TEN!Q*G\
M*_=_WS\J]6XK159J/*3RQ/.Q^SA!XFECD^(GBW7/B%$AW?V5J#16NEL?]NT@
M1$E_[:[Z]>M;6*QMXX((DAAB4+''$FU57^ZM6N*6E.I*?Q"C'E"BBBH+"BBB
M@ KS_P")'P?\+?%.&S;7-.=]4T\F33M8LIWM=0L7_O07,3+*GT#;6_B!KT"B
ME%\H'B!^#'Q*T@>3HOQQUDV0&%37M#L;^5/^VJI$S?\  ]U-?]F>'Q4\<GQ*
M\9^(/B2B_,=(U!XK/26]-]G;(B2_]MO,KTOQBBW-C!&\8F'VZV;8]I+./]:G
M\*?^A'Y5_BKIJTYY%<S*5K9V^FVL-O;PQV]O$BQQQ1KM557[JJM7:**@D***
M* "BBB@ HHHH _*K_@N;T^"7_<;_ /;"BC_@N;T^"7_<;_\ ;"B@#[^_9-_Y
M-9^#G_8FZ-_Z115ZO7E'[)O_ ":S\'/^Q-T;_P!(HJ]7H **** "BBB@ HHH
MH **** "BBB@#F]5B9_%.@R"&5U07&Z1+9)53Y5^]*WS1?\  ?O5TE<SJ\*O
MXLT"1HT=T6Y*N]JSNORK]V5?EC_X%][H*Z:@ HHHH **** "BBB@ HHHH **
M** .;\7PFXL+,"&24B]MVVI:K<?\M5^;:WW?]_\ AZUTE<QXPB233K&-T2<K
M?6K;)+9[C_EJOS;5^[_OGY5KIZ "BBB@ HHHH **** "BBB@#G/%NWR=*W[?
M^0G!MW^;_?\ ^F7_ +/\G]ZNCKFO%<ZQKI(:40[]2@3YIY8=_)^7*?>_W&^5
MJZ6@ HHHH **** "BBB@ KF_&/E^1I7F8_Y"=M]_SO[_ /TR_P#9_D_O5TE<
MWXJ=88-+WRB+?J,"?/<RP[_G^[\GWO\ =;Y6_BH Z2BBB@ HHHH **** "BB
MB@#F_&&W[+IF[;C^T;;;O\[^_P#],_\ V?Y/[U=)7-^+66&WTO=,(M^H0+\]
MS+%N^;[OR?>_W6^5OXJZ2@ HHHH **** "BBB@ KG/&6W[#IV[&/[2MOO^;_
M ,]5_P">?_LWR?WJZ.N;\7/Y-KIO[P1!]0MD^>YEBS\_^Q][_=;Y6_BH Z2B
MBB@ HHHH **** "BBB@#F_&6S^SK;=C_ (_[7[_F_P#/5/\ GE\W_?7R?W_E
MS725S7BZ18+2P+/Y1.HVP&^YE@S^]7_GG][_ '#\K=&XKI: "BBB@ HHHH *
M*** "BBB@#\JO^"YO3X)?]QO_P!L**/^"YO3X)?]QO\ ]L** /O[]DW_ )-9
M^#G_ &)NC?\ I%%7J]>4?LF_\FL_!S_L3=&_](HJ]7H **** "BBB@ HHHH
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MNV_-_N?Q5T1S7XD^-_\ @JM\=?%.IB;2+[1_"=FDJM';6&G)+]W^%VGW[O\
MQVO4?@)_P5Z\3Z5JUMI_Q7TBUUC1Y'VOK&CP>1=09_B:+[DJ^R[&_P!ZO3EE
MU>,.>QK[&1^L]%8OA?Q3I7C;P[INO:%?PZII&HP+<6MW;MN26)N5<5M5YAD%
M%%% !1110 4444 ?E5_P7-Z?!+_N-_\ MA11_P %S>GP2_[C?_MA10!]_?LF
M_P#)K/P<_P"Q-T;_ -(HJ]7KRC]DW_DUGX.?]B;HW_I%%7J] !1110 4444
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M_!S_ +$W1O\ TBBKU>O*/V3?^36?@Y_V)NC?^D45>KT %%%% !1110 4444
M%%%% 'EGQ"\&ZE_:%KXL\+HIU_3U9'MR<"\@.-T+$\=LKQUJIX&_X0?QU;3/
M'H6G+JL1S=6-U;(ES"^>=ZE?UKU$.0QPN"O7GI7'^+_AAX?\777VR\LY(+]/
M]5J-G*T,Z<?WE/Z&NVG73A[.K[O]Z)\MBLNE3KRQ6%C&7-\4)?#S?S1ERRY9
M?S?9EU][WBCJ'PY\,0^(-)C7P_IA5UFW;M.9R,*O1U^5/^!=>U:5Y\/?"-C;
M//<:'I5M;QC<TDEN@5?QQ7$WWPWUO3/$>AV]I\2=2MTE6?8MVB22D[5^[\FU
MO^!],_+6VGP,T^^E%QXBUG5/%#[MRQ7\N(%/_7)<+6S<4KNM?_P(PY*L_<IY
M=&,O[WL^7_R52E_Y*<H([?XI3-H/AR"/2_ MM*3J-_;1>4NH,#Q#&%P=N00S
M U[=;6J6T:B.,1C 4(I^Z!3=/LX;&UBAMXDBB5=JQH,*JU,ZLT9+Q;B?X=V,
M5SU:OM/=C\)ZN P+PO-5JRYJLOB^S'^[&,?LQC_]M+4NT445R'MA1110 444
M4 >0?&'PWJVGZKIGCKPY;M-J^C[TNK12#]LM6P&3']Y?O+[_ %KH_#VOZ!\6
MO#JW5NR7ME+M8QOD212#^%NZ.M=H=S,P/RCC%>3>)/@OG69/$'A75)?">O/S
M+);IO@NC_P!-(B=OXUZU*K3K4XTZTN64?AE^/++_ -MET]#Y;%86OA:TJ^%C
M[2%3XZ?_ +='[/\ BC+XO4W-0\)Z5X>LX18V:(TE[;%I)(I[EOEE&W[K;E^O
MW5Y9N,UI-X \-_;3?-8KNW^9C<_E[M^[=LSMSN^;I7FNL77Q/TFV@76=.T'5
M(/M$217-O?R6;/)N_=;@/5OX?NUJ?V-\7?$_^CWFI:1X2L&^^VG*;BZ_X"S?
M*M:.A5@Y3GB8_P"+F_R]XRECL/.,:4,'4ER_9]GR_P#DTI<I<^+/Q#O+:X7P
MCX97[7XMU%?*2*-A_HL; 9GDX^4!2>?6NI^'G@NU\!^#K#2;5O,^S1X>;!'F
M.6+,V/<DU4^'WPPTGP#'*+.&6YO;HEKO4;N3S+BX;U=J[7Y!]_G=^M<E?$TU
M36'PWP[\W\TO_D?Y3NP6"KRQ$\=C7^\^&,?LPC_[=*7VI?\ ;JTWM4445P'T
M 4444 1%1D>U>;?%SX-:7\6M-B%PS66J6W-O?1+N=?\ 9;/WE]J])! 'M0P.
M.N/PK2G4G0G[6E\1QXO"4,=0EA\1'FA(^&=8_9=\=Z-=Q0V]C;ZQ%+)Y:SVT
M^"/]M]WW:[+P)^R#J,EW'<^++R&WLU^8Z?9-O:7_ &7?^'_@%?2'BB!9;[0B
M\:S;;_=EK6679^[?YMR<1_[S?+702Q[E V[AZ9Q7NU,]QM2'(V?#4>!,EHUO
M:\LI?W92]TAT[3;;2K*"TLX4MK6!5CBBB7:J*O115W&/:@<4,V/K7SY^AI<O
MNQ'4444B@HHHH \7_:&_9J\/?M :!%#?L^G:W9AC8ZK @9XB?X67^./U6OAG
MQ7^P1\6M!OD@LK2PUZWE?RX[FRN0I'^TZR;=M?J2G(QVKG?%,2376A!HA-LU
M!6^:VEEV?*_S93[G^\WRU[V79_CLKA[*E/W?[QX>-R;"X^?M*L?>/AKX1_\
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M?^D45>KUY1^R;_R:S\'/^Q-T;_TBBKU>@ HHHH **** "BBB@ HHHH ****
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M[_K_ (T?V]IO_01M/^_Z_P"-<)[YH45FGQ#I:?>U.T_[_K2?\))I/_04LO\
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M=/$+^:\'V:PE5&;;_K<W$NU_D4_-\O%?1@.!15<H_$2+1117. 4444 %%%%
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M=4C(=#O@N8Q^\A;U4_TKZ/(,VAE6,]K4UC+W9'PW%N02S_+_ &5/^)#WH_\
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M\4<#RM'%\VUFV+_L/M7[S;>*Z>N'\5_"?0_&.H&\U)KMYOLSVH$4^S:K]?\
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MEU\D6^)_](_V$_O?P5-<Z5JNFRR^?8ZA9RP;7E\V*57BW?<W_P!W?5>PJ_\
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M_P!C[Z?)4MM\!_#VII9,VKW>B?VC>>4KRQ/+%9[M2>U^RR_ND5947Y][RK_
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M2GNM3M8K&[2=)73=HOVKY]R_/$\O\"[?X_F_AKP^_P#[<FBBT&>VN=FAM/\
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M_/J7_DI7U*I_.?A[_P )KX@2:X==<U#?/>17\_\ I+_O;J+=Y4K?[2;FVO\
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M/ID+DKGK7 _&OP+>_$KX9ZSX<L)H;>[O4C5)9V^5"LJ/S\K?W?2O+/$'Q0^
MWB*:TEG^.WA&*2VM5LU\KQ3IP1XU8/\ ,N[GYE7_ +Y%5M;^*OP7UC6X[O\
MX: \(QVK2M/+;#Q;9_>W;DV_O^-M72<:=2-2,OA,:D/:QE3E'XBY\0OV6[S5
MF63P]X@N[:^DMM5EO-3O)A]HN;RYBMXT+[8]OE;8 C*BK\OW?FYJSI_[/FL6
M_B"U2W;2;301KUCK[RQS2M=6K6UK%!]CB^7YH_W.W>S_ ''==E06_P 8/@C;
M:7+9+^T'X:",V]9AXQL_,5MCK][S?5]W_ %J&/XM_!<S%O\ AHK0G4!MB?\
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M_A46/_QV@#U>BO*/^&L?@C_T63P!_P"%18__ !VC_AK'X(_]%D\ ?^%18_\
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M18__ !VC_AK'X(_]%D\ ?^%18_\ QV@#U>BO*/\ AK'X(_\ 19/ '_A46/\
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M1\5? _Q0;X2?\(?XN\/^+Q8_VO\ :O[%U:WNA;[_ +%LWF)VV[MCXW==IHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cdio-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aAps7xRiXgen8uEYHMsSaSCabPtx517aZkhvmh2bRkK7yQmSH9qWCYueacWcU0F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cdio="http://cdio.ai/20250630" elementFormDefault="qualified" targetNamespace="http://cdio.ai/20250630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cdio.ai/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
          <link:definition>999008 - Disclosure - Organization and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" id="MergerAgreementAndReverseRecapitalization">
          <link:definition>999009 - Disclosure - Merger Agreement and Reverse Recapitalization</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999011 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999012 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PatentCosts" id="PatentCosts">
          <link:definition>999013 - Disclosure - Patent Costs</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeases" id="OperatingLeases">
          <link:definition>999014 - Disclosure - Operating Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/FinanceAgreementPayable" id="FinanceAgreementPayable">
          <link:definition>999015 - Disclosure - Finance Agreement Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/EarningsLossPerCommonShare" id="EarningsLossPerCommonShare">
          <link:definition>999016 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999017 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
          <link:definition>999018 - Disclosure - Convertible Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/DerivativeLiability" id="DerivativeLiability">
          <link:definition>999019 - Disclosure - Derivative Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999024 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999025 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999026 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeasesTables" id="OperatingLeasesTables">
          <link:definition>999027 - Disclosure - Operating Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/EarningsLossPerCommonShareTables" id="EarningsLossPerCommonShareTables">
          <link:definition>999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999029 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/DerivativeLiabilityTables" id="DerivativeLiabilityTables">
          <link:definition>999030 - Disclosure - Derivative Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999031 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SubsequentEventsTables" id="SubsequentEventsTables">
          <link:definition>999032 - Disclosure - Subsequent Events (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" id="MergerAgreementAndReverseRecapitalizationDetailsNarrative">
          <link:definition>999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
          <link:definition>999034 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
          <link:definition>999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" id="SummaryOfSignificantAccountingPoliciesDetails2">
          <link:definition>999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
          <link:definition>999038 - Disclosure - Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999039 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
          <link:definition>999040 - Disclosure - Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>999041 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/PatentCostsDetailsNarrative" id="PatentCostsDetailsNarrative">
          <link:definition>999042 - Disclosure - Patent Costs (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeasesDetails" id="OperatingLeasesDetails">
          <link:definition>999043 - Disclosure - Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeasesDetails1" id="OperatingLeasesDetails1">
          <link:definition>999044 - Disclosure - Operating Leases (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeasesDetails2" id="OperatingLeasesDetails2">
          <link:definition>999045 - Disclosure - Operating Leases (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>999046 - Disclosure - Operating Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" id="FinanceAgreementPayableDetailsNarrative">
          <link:definition>999047 - Disclosure - Finance Agreement Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/EarningsLossPerCommonShareDetails" id="EarningsLossPerCommonShareDetails">
          <link:definition>999048 - Disclosure - Earnings (Loss) Per Common Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
          <link:definition>999049 - Disclosure - Stockholders' Equity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
          <link:definition>999050 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999051 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
          <link:definition>999052 - Disclosure - Convertible Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/DerivativeLiabilityDetails" id="DerivativeLiabilityDetails">
          <link:definition>999053 - Disclosure - Derivative Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>999054 - Disclosure - Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>999055 - Disclosure - Income Taxes (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999056 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999057 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999058 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" id="OrganizationAndBasisOfPresentationDetails">
          <link:definition>999059 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" id="OrganizationAndBasisOfPresentationDetails1">
          <link:definition>999060 - Disclosure - Organization and Basis of Presentation (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" id="OrganizationAndBasisOfPresentationDetails2">
          <link:definition>999061 - Disclosure - Organization and Basis of Presentation (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" id="OrganizationAndBasisOfPresentationDetails3">
          <link:definition>999062 - Disclosure - Organization and Basis of Presentation (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" id="OrganizationAndBasisOfPresentationDetails4">
          <link:definition>999063 - Disclosure - Organization and Basis of Presentation (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" id="SummaryOfSignificantAccountingPoliciesDetails3">
          <link:definition>999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
          <link:definition>999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cdio-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdio-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdio-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdio-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
    <element id="cdio_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TwoInvestmentBankersMember" name="TwoInvestmentBankersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ChicagoMember" name="ChicagoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_LeaseOneMember" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_LeaseTwoMember" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_StockWarrantsMember" name="StockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_LegacyCardioStockholdersMember" name="LegacyCardioStockholdersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_LegacyCardioMember" name="LegacyCardioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ManasFormerOfficersAndDirectorsMember" name="ManasFormerOfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_Plan2022Member" name="Plan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_SevenAccreditedInvestorsMember" name="SevenAccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PlacementAgentAgreementMember" name="PlacementAgentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AltitudeCapitalGroupLLCMember" name="AltitudeCapitalGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CraigHallumCapitalGroupLLCMember" name="CraigHallumCapitalGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_N2022PlanMember" name="N2022PlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_StockOption1Member" name="StockOption1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AltitudeCapitalMember" name="AltitudeCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AtTheMarketIssuanceMember" name="AtTheMarketIssuanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_YorkvilleConvertibleDebentureMember" name="YorkvilleConvertibleDebentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" name="TheBenchmarkCompanyLLCRightOfFirstRefusalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NorthlandSecuritiesMember" name="NorthlandSecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TheBenchmarkCompanyLLCMember" name="TheBenchmarkCompanyLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ImpactOfReverseStockSplitMember" name="ImpactOfReverseStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AsRevisedMember" name="AsRevisedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ReportableSegmentsMember" name="ReportableSegmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ProductTestSalesMember" name="ProductTestSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FinanceAgreementPayable" name="FinanceAgreementPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockAndWarrantsIssuedForCash" name="CommonStockAndWarrantsIssuedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockAndWarrantsIssuedForCashShares" name="CommonStockAndWarrantsIssuedForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareOutstanding" name="ShareOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockIssuedForCashShares" name="CommonStockIssuedForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WarrantsConvertedToCommonStock" name="WarrantsConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WarrantsConvertedToCommonStockShares" name="WarrantsConvertedToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PlacementAgentFees" name="PlacementAgentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RestrictedStockAwardsVested" name="RestrictedStockAwardsVested" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RestrictedStockAwardsVestedShares" name="RestrictedStockAwardsVestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NotesPayableConvertedToCommonStock" name="NotesPayableConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NotesPayableConvertedToCommonStockShares" name="NotesPayableConvertedToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CompensationForVestedStockOptions" name="CompensationForVestedStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FractionalSharesAdjustment" name="FractionalSharesAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FractionalSharesAdjustmentShares" name="FractionalSharesAdjustmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" name="AdjustmentToLiabilitiesAssumedInMergerWithMana" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ChangeInFairValueOfDerivativeLiabilities" name="ChangeInFairValueOfDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PaymentsForRightOfUseAsset" name="PaymentsForRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PaymentsToAcquireFinanceReceivable" name="PaymentsToAcquireFinanceReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PaymentsOfPlacementAgentFee" name="PaymentsOfPlacementAgentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CashPaidDuringPeriodForAbstract" name="CashPaidDuringPeriodForAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DebtDiscountRelatedToDerivativeLiability" name="DebtDiscountRelatedToDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NotePayableConvertedToCommonStock" name="NotePayableConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AdjustmentToLiabilitiesAssumedInAcquisition" name="AdjustmentToLiabilitiesAssumedInAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" name="FinancingAgreementEnteredIntoForPrepaidInsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RightOfUseAssetAddedToOperatingLease" name="RightOfUseAssetAddedToOperatingLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_OriginalIssueDiscount" name="OriginalIssueDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" name="DisclosureMergerAgreementAndReverseRecapitalizationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_MergerAgreementAndReverseRecapitalizationTextBlock" name="MergerAgreementAndReverseRecapitalizationTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DisclosurePatentCostsAbstract" name="DisclosurePatentCostsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PatentAndTrademarkCostsTextBlock" name="PatentAndTrademarkCostsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DisclosureFinanceAgreementPayableAbstract" name="DisclosureFinanceAgreementPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FinanceAgreementPayableTextBlock" name="FinanceAgreementPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DisclosureDerivativeLiabilityAbstract" name="DisclosureDerivativeLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ConvertibleInstrumentsPolicyTextBlock" name="ConvertibleInstrumentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PatentAndTrademarkCostsPolicyTextBlock" name="PatentAndTrademarkCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ReclassificationPolicyTextBlock" name="ReclassificationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" name="ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOWarrantsExercisableTextBlock" name="ScheduleOWarrantsExercisableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" name="ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" name="ScheduleOfWarrantsAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_EarlyPaymentDiscount" name="EarlyPaymentDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PostmergerLiabilitiesBalance" name="PostmergerLiabilitiesBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RedemptionPricePerShre" name="RedemptionPricePerShre" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ReverseRecapitalizationShares" name="ReverseRecapitalizationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonSharesReversed" name="CommonSharesReversed" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DerivativeLiabilitiesIssued" name="DerivativeLiabilitiesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DerivativeLiabilitiesConverted" name="DerivativeLiabilitiesConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ChangeInFairValueRecognizedInOperations" name="ChangeInFairValueRecognizedInOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AmountInExcessOfFdicInsurance" name="AmountInExcessOfFdicInsurance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" name="RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ReductionOfLeaseLiabilitiesAbstract" name="ReductionOfLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_AnnuallyRentPayment" name="AnnuallyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PremisesAllowance" name="PremisesAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ReimbursementReceivable" name="ReimbursementReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_NumberOfSharesTransferred" name="NumberOfSharesTransferred" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PlacementAgentFee" name="PlacementAgentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PlacementAgentAgreementDescription" name="PlacementAgentAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WarrantsIssued" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_StockOptionsValued" name="StockOptionsValued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ConversionPriceDeterminedPercentage" name="ConversionPriceDeterminedPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PrincipalAmountReceived" name="PrincipalAmountReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_DebtInstrumentOriginalIssueDiscount" name="DebtInstrumentOriginalIssueDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TaxProvision" name="TaxProvision" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TerminationFee" name="TerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockBidPrice" name="CommonStockBidPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockShares" name="CommonStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockValues" name="CommonStockValues" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WeightedAverageCommonSharesOutstandingBasic" name="WeightedAverageCommonSharesOutstandingBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" name="WeightedAverageCommonSharesOutstandingFullyDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockOptions" name="CommonStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_CommonStockWarrants" name="CommonStockWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_OptionsVestedAndExercisable" name="OptionsVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" name="WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ClassOfWarrantOrRightOutstandings" name="ClassOfWarrantOrRightOutstandings" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WarrantsCancelled" name="WarrantsCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_WeightedAverageExercisePriceCancelled" name="WeightedAverageExercisePriceCancelled" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_PayrollAndRelatedCosts" name="PayrollAndRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_RentAndFacilityExpense" name="RentAndFacilityExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_ConsultingAndContractorExpense" name="ConsultingAndContractorExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_InsuranceExpense" name="InsuranceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_FilingFeesExpense" name="FilingFeesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_TransferAgentExpense" name="TransferAgentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_SoftwareAndWebComputingExpense" name="SoftwareAndWebComputingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_BoardCompensationExpense" name="BoardCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_InvestorRelationsExpense" name="InvestorRelationsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="cdio_OtherSegmentItems" name="OtherSegmentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cdio-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#Cover" roleURI="http://cdio.ai/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentation" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalization" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipment" roleURI="http://cdio.ai/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssets" roleURI="http://cdio.ai/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCosts" roleURI="http://cdio.ai/role/PatentCosts" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeases" roleURI="http://cdio.ai/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayable" roleURI="http://cdio.ai/role/FinanceAgreementPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShare" roleURI="http://cdio.ai/role/EarningsLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquity" roleURI="http://cdio.ai/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayable" roleURI="http://cdio.ai/role/ConvertibleNotesPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiability" roleURI="http://cdio.ai/role/DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxes" roleURI="http://cdio.ai/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingencies" roleURI="http://cdio.ai/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEvents" roleURI="http://cdio.ai/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://cdio.ai/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsTables" roleURI="http://cdio.ai/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesTables" roleURI="http://cdio.ai/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareTables" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityTables" roleURI="http://cdio.ai/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityTables" roleURI="http://cdio.ai/role/DerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesTables" roleURI="http://cdio.ai/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsTables" roleURI="http://cdio.ai/role/SubsequentEventsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalizationDetailsNarrative" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetails" roleURI="http://cdio.ai/role/IntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCostsDetailsNarrative" roleURI="http://cdio.ai/role/PatentCostsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails" roleURI="http://cdio.ai/role/OperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails1" roleURI="http://cdio.ai/role/OperatingLeasesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails2" roleURI="http://cdio.ai/role/OperatingLeasesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetailsNarrative" roleURI="http://cdio.ai/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayableDetailsNarrative" roleURI="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareDetails" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails" roleURI="http://cdio.ai/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails1" roleURI="http://cdio.ai/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cdio.ai/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayableDetailsNarrative" roleURI="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityDetails" roleURI="http://cdio.ai/role/DerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails" roleURI="http://cdio.ai/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails1" roleURI="http://cdio.ai/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cdio.ai/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cdio.ai/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails1" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails2" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails3" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails4" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayable" xlink:label="loc_cdioFinanceAgreementPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cdioFinanceAgreementPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_cdioChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_cdioChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NoncashInterestExpense" xlink:label="loc_cdioNoncashInterestExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cdioNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_cdioChangeInFairValueOfDerivativeLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cdioChangeInFairValueOfDerivativeLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsForRightOfUseAsset" xlink:label="loc_cdioPaymentsForRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_cdioPaymentsForRightOfUseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsToAcquireFinanceReceivable" xlink:label="loc_cdioPaymentsToAcquireFinanceReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cdioPaymentsToAcquireFinanceReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsOfPlacementAgentFee" xlink:label="loc_cdioPaymentsOfPlacementAgentFee" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cdioPaymentsOfPlacementAgentFee" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentation" xlink:title="999008 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" xlink:title="999009 - Disclosure - Merger Agreement and Reverse Recapitalization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipment" xlink:title="999011 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssets" xlink:title="999012 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCosts" xlink:title="999013 - Disclosure - Patent Costs" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeases" xlink:title="999014 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayable" xlink:title="999015 - Disclosure - Finance Agreement Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShare" xlink:title="999016 - Disclosure - Earnings (Loss) Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayable" xlink:title="999018 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiability" xlink:title="999019 - Disclosure - Derivative Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentTables" xlink:title="999025 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsTables" xlink:title="999026 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesTables" xlink:title="999027 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareTables" xlink:title="999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityTables" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityTables" xlink:title="999030 - Disclosure - Derivative Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesTables" xlink:title="999031 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsTables" xlink:title="999032 - Disclosure - Subsequent Events (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" xlink:title="999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaapConstructionInProgressGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapConstructionInProgressGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999039 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetails" xlink:title="999040 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCostsDetailsNarrative" xlink:title="999042 - Disclosure - Patent Costs (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails" xlink:title="999043 - Disclosure - Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails1" xlink:title="999044 - Disclosure - Operating Leases (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails2" xlink:title="999045 - Disclosure - Operating Leases (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetailsNarrative" xlink:title="999046 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" xlink:title="999047 - Disclosure - Finance Agreement Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareDetails" xlink:title="999048 - Disclosure - Earnings (Loss) Per Common Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails" xlink:title="999049 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails1" xlink:title="999050 - Disclosure - Stockholders&apos; Equity (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetailsNarrative" xlink:title="999051 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999052 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityDetails" xlink:title="999053 - Disclosure - Derivative Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails" xlink:title="999054 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails1" xlink:title="999055 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsDetailsNarrative" xlink:title="999058 - Disclosure - Subsequent Events (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" xlink:title="999059 - Disclosure - Organization and Basis of Presentation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" xlink:title="999060 - Disclosure - Organization and Basis of Presentation (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" xlink:title="999061 - Disclosure - Organization and Basis of Presentation (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" xlink:title="999062 - Disclosure - Organization and Basis of Presentation (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" xlink:title="999063 - Disclosure - Organization and Basis of Presentation (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cdio-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#Cover" roleURI="http://cdio.ai/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentation" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalization" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipment" roleURI="http://cdio.ai/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssets" roleURI="http://cdio.ai/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCosts" roleURI="http://cdio.ai/role/PatentCosts" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeases" roleURI="http://cdio.ai/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayable" roleURI="http://cdio.ai/role/FinanceAgreementPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShare" roleURI="http://cdio.ai/role/EarningsLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquity" roleURI="http://cdio.ai/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayable" roleURI="http://cdio.ai/role/ConvertibleNotesPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiability" roleURI="http://cdio.ai/role/DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxes" roleURI="http://cdio.ai/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingencies" roleURI="http://cdio.ai/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEvents" roleURI="http://cdio.ai/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://cdio.ai/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsTables" roleURI="http://cdio.ai/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesTables" roleURI="http://cdio.ai/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareTables" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityTables" roleURI="http://cdio.ai/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityTables" roleURI="http://cdio.ai/role/DerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesTables" roleURI="http://cdio.ai/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsTables" roleURI="http://cdio.ai/role/SubsequentEventsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalizationDetailsNarrative" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetails" roleURI="http://cdio.ai/role/IntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCostsDetailsNarrative" roleURI="http://cdio.ai/role/PatentCostsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails" roleURI="http://cdio.ai/role/OperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails1" roleURI="http://cdio.ai/role/OperatingLeasesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails2" roleURI="http://cdio.ai/role/OperatingLeasesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetailsNarrative" roleURI="http://cdio.ai/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayableDetailsNarrative" roleURI="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareDetails" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails" roleURI="http://cdio.ai/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails1" roleURI="http://cdio.ai/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cdio.ai/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayableDetailsNarrative" roleURI="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityDetails" roleURI="http://cdio.ai/role/DerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails" roleURI="http://cdio.ai/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails1" roleURI="http://cdio.ai/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cdio.ai/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cdio.ai/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails1" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails2" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails3" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails4" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCash" xlink:label="loc_cdioCommonStockAndWarrantsIssuedForCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockAndWarrantsIssuedForCash_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCashShares" xlink:label="loc_cdioCommonStockAndWarrantsIssuedForCashShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockAndWarrantsIssuedForCashShares_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareOutstanding" xlink:label="loc_cdioShareOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareOutstanding_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockIssuedForCashShares" xlink:label="loc_cdioCommonStockIssuedForCashShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockIssuedForCashShares_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStock" xlink:label="loc_cdioWarrantsConvertedToCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsConvertedToCommonStock_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStockShares" xlink:label="loc_cdioWarrantsConvertedToCommonStockShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsConvertedToCommonStockShares_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFees" xlink:label="loc_cdioPlacementAgentFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioPlacementAgentFees_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVested" xlink:label="loc_cdioRestrictedStockAwardsVested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioRestrictedStockAwardsVested_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVestedShares" xlink:label="loc_cdioRestrictedStockAwardsVestedShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioRestrictedStockAwardsVestedShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStock" xlink:label="loc_cdioNotesPayableConvertedToCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioNotesPayableConvertedToCommonStock_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStockShares" xlink:label="loc_cdioNotesPayableConvertedToCommonStockShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioNotesPayableConvertedToCommonStockShares_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CompensationForVestedStockOptions" xlink:label="loc_cdioCompensationForVestedStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCompensationForVestedStockOptions_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustment" xlink:label="loc_cdioFractionalSharesAdjustment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioFractionalSharesAdjustment_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustmentShares" xlink:label="loc_cdioFractionalSharesAdjustmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioFractionalSharesAdjustmentShares_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" xlink:label="loc_cdioAdjustmentToLiabilitiesAssumedInMergerWithMana_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioAdjustmentToLiabilitiesAssumedInMergerWithMana_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentation" xlink:title="999008 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" xlink:title="999009 - Disclosure - Merger Agreement and Reverse Recapitalization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipment" xlink:title="999011 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssets" xlink:title="999012 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCosts" xlink:title="999013 - Disclosure - Patent Costs" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeases" xlink:title="999014 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayable" xlink:title="999015 - Disclosure - Finance Agreement Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShare" xlink:title="999016 - Disclosure - Earnings (Loss) Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayable" xlink:title="999018 - Disclosure - Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiability" xlink:title="999019 - Disclosure - Derivative Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentTables" xlink:title="999025 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsTables" xlink:title="999026 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesTables" xlink:title="999027 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareTables" xlink:title="999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityTables" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityTables" xlink:title="999030 - Disclosure - Derivative Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesTables" xlink:title="999031 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsTables" xlink:title="999032 - Disclosure - Subsequent Events (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" xlink:title="999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_MergerAgreementMember" xlink:label="loc_cdioMergerAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioMergerAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TwoInvestmentBankersMember" xlink:label="loc_cdioTwoInvestmentBankersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTwoInvestmentBankersMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAcquiredFromAcquisition_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionPayablesAssumed1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionPayablesAssumed1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_EarlyPaymentDiscount" xlink:label="loc_cdioEarlyPaymentDiscount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioEarlyPaymentDiscount_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLoansPayable_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PostmergerLiabilitiesBalance" xlink:label="loc_cdioPostmergerLiabilitiesBalance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioPostmergerLiabilitiesBalance_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaapDebtInstrumentRedemptionPricePercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionPricePercentage_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RedemptionPricePerShre" xlink:label="loc_cdioRedemptionPricePerShre_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioRedemptionPricePerShre_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReverseRecapitalizationShares" xlink:label="loc_cdioReverseRecapitalizationShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioReverseRecapitalizationShares_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonSharesReversed" xlink:label="loc_cdioCommonSharesReversed_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioCommonSharesReversed_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRecapitalizationCosts_80" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesIssued" xlink:label="loc_cdioDerivativeLiabilitiesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioDerivativeLiabilitiesIssued_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesConverted" xlink:label="loc_cdioDerivativeLiabilitiesConverted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioDerivativeLiabilitiesConverted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueRecognizedInOperations" xlink:label="loc_cdioChangeInFairValueRecognizedInOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioChangeInFairValueRecognizedInOperations_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LabEquipmentMember" xlink:label="loc_cdioLabEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cdioLabEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999039 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetails" xlink:title="999040 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCostsDetailsNarrative" xlink:title="999042 - Disclosure - Patent Costs (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapLegalFees_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_120" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails" xlink:title="999043 - Disclosure - Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails1" xlink:title="999044 - Disclosure - Operating Leases (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails2" xlink:title="999045 - Disclosure - Operating Leases (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetailsNarrative" xlink:title="999046 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChicagoMember" xlink:label="loc_cdioChicagoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_cdioChicagoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IA" xlink:label="loc_stprIA_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIA_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseOneMember" xlink:label="loc_cdioLeaseOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_cdioLeaseOneMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseTwoMember" xlink:label="loc_cdioLeaseTwoMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_cdioLeaseTwoMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AnnuallyRentPayment" xlink:label="loc_cdioAnnuallyRentPayment_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioAnnuallyRentPayment_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PremisesAllowance" xlink:label="loc_cdioPremisesAllowance_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioPremisesAllowance_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapReceivablesNetCurrent_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReimbursementReceivable" xlink:label="loc_cdioReimbursementReceivable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioReimbursementReceivable_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="loc_us-gaapSubordinatedBorrowingInterestRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubordinatedBorrowingInterestRate_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_160" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" xlink:title="999047 - Disclosure - Finance Agreement Payable (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareDetails" xlink:title="999048 - Disclosure - Earnings (Loss) Per Common Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockWarrantsMember" xlink:label="loc_cdioStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cdioStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cdioStockOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails" xlink:title="999049 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails1" xlink:title="999050 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetailsNarrative" xlink:title="999051 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioStockholdersMember" xlink:label="loc_cdioLegacyCardioStockholdersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_cdioLegacyCardioStockholdersMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioMember" xlink:label="loc_cdioLegacyCardioMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioLegacyCardioMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ManasFormerOfficersAndDirectorsMember" xlink:label="loc_cdioManasFormerOfficersAndDirectorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioManasFormerOfficersAndDirectorsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardOfDirectorsMember" xlink:label="loc_cdioBoardOfDirectorsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioBoardOfDirectorsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_Plan2022Member" xlink:label="loc_cdioPlan2022Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cdioPlan2022Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_N2022PlanMember" xlink:label="loc_cdioN2022PlanMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cdioN2022PlanMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SevenAccreditedInvestorsMember" xlink:label="loc_cdioSevenAccreditedInvestorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioSevenAccreditedInvestorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalGroupLLCMember" xlink:label="loc_cdioAltitudeCapitalGroupLLCMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioAltitudeCapitalGroupLLCMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CraigHallumCapitalGroupLLCMember" xlink:label="loc_cdioCraigHallumCapitalGroupLLCMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioCraigHallumCapitalGroupLLCMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalMember" xlink:label="loc_cdioAltitudeCapitalMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioAltitudeCapitalMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementMember" xlink:label="loc_cdioPlacementAgentAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioPlacementAgentAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SalesAgreementMember" xlink:label="loc_cdioSalesAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioSalesAgreementMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOptionsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOption1Member" xlink:label="loc_cdioStockOption1Member_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOption1Member_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AtTheMarketIssuanceMember" xlink:label="loc_cdioAtTheMarketIssuanceMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioAtTheMarketIssuanceMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_690" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_690" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_690" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NumberOfSharesTransferred" xlink:label="loc_cdioNumberOfSharesTransferred_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioNumberOfSharesTransferred_690" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_690" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_690" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_690" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFee" xlink:label="loc_cdioPlacementAgentFee_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioPlacementAgentFee_690" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementDescription" xlink:label="loc_cdioPlacementAgentAgreementDescription_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioPlacementAgentAgreementDescription_690" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees_690" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_690" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_690" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_690" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1_690" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_690" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsIssued" xlink:label="loc_cdioWarrantsIssued_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioWarrantsIssued_690" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_690" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsValued" xlink:label="loc_cdioStockOptionsValued_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioStockOptionsValued_690" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_690" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_690" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_690" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_690" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_690" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_690" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999052 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_YorkvilleConvertibleDebentureMember" xlink:label="loc_cdioYorkvilleConvertibleDebentureMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cdioYorkvilleConvertibleDebentureMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_YorkvilleConvertibleDebentureMember" xlink:label="loc_cdioYorkvilleConvertibleDebentureMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioYorkvilleConvertibleDebentureMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConversionPriceDeterminedPercentage" xlink:label="loc_cdioConversionPriceDeterminedPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioConversionPriceDeterminedPercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PrincipalAmountReceived" xlink:label="loc_cdioPrincipalAmountReceived_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioPrincipalAmountReceived_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_cdioDebtInstrumentOriginalIssueDiscount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioDebtInstrumentOriginalIssueDiscount_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapShortTermDebtPercentageBearingFixedInterestRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtPercentageBearingFixedInterestRate_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapShortTermDebtPercentageBearingVariableInterestRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtPercentageBearingVariableInterestRate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityDetails" xlink:title="999053 - Disclosure - Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails" xlink:title="999054 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails1" xlink:title="999055 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FederalMember" xlink:label="loc_cdioFederalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_cdioFederalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapGeographicDistributionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IA" xlink:label="loc_stprIA_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIA_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="loc_stprIL_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIL_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TaxProvision" xlink:label="loc_cdioTaxProvision_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_cdioTaxProvision_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" xlink:label="loc_cdioTheBenchmarkCompanyLLCRightOfFirstRefusalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTheBenchmarkCompanyLLCRightOfFirstRefusalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCMember" xlink:label="loc_cdioTheBenchmarkCompanyLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTheBenchmarkCompanyLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NorthlandSecuritiesMember" xlink:label="loc_cdioNorthlandSecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cdioNorthlandSecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaapBusinessCombinationReasonForBusinessCombination_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationReasonForBusinessCombination_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TerminationFee" xlink:label="loc_cdioTerminationFee_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_cdioTerminationFee_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockBidPrice" xlink:label="loc_cdioCommonStockBidPrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_cdioCommonStockBidPrice_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsDetailsNarrative" xlink:title="999058 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SalesAgreementMember" xlink:label="loc_cdioSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" xlink:title="999059 - Disclosure - Organization and Basis of Presentation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockShares" xlink:label="loc_cdioCommonStockShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockShares_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockValues" xlink:label="loc_cdioCommonStockValues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockValues_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" xlink:title="999060 - Disclosure - Organization and Basis of Presentation (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingBasic" xlink:label="loc_cdioWeightedAverageCommonSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageCommonSharesOutstandingBasic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" xlink:label="loc_cdioWeightedAverageCommonSharesOutstandingFullyDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageCommonSharesOutstandingFullyDiluted_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" xlink:title="999061 - Disclosure - Organization and Basis of Presentation (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockOptions" xlink:label="loc_cdioCommonStockOptions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockOptions_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockWarrants" xlink:label="loc_cdioCommonStockWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockWarrants_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" xlink:title="999062 - Disclosure - Organization and Basis of Presentation (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OptionsVestedAndExercisable" xlink:label="loc_cdioOptionsVestedAndExercisable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioOptionsVestedAndExercisable_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" xlink:label="loc_cdioWeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" xlink:title="999063 - Disclosure - Organization and Basis of Presentation (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ClassOfWarrantOrRightOutstandings" xlink:label="loc_cdioClassOfWarrantOrRightOutstandings_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioClassOfWarrantOrRightOutstandings_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsCancelled" xlink:label="loc_cdioWarrantsCancelled_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsCancelled_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceCancelled" xlink:label="loc_cdioWeightedAverageExercisePriceCancelled_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageExercisePriceCancelled_100" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReportableSegmentsMember" xlink:label="loc_cdioReportableSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cdioReportableSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ProductTestSalesMember" xlink:label="loc_cdioProductTestSalesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cdioProductTestSalesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapCash_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAccountsReceivableNet_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsCurrent_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaapIntangibleAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapIntangibleAssetsCurrent_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapDepositsAssets_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapFiniteLivedPatentsGross_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapAssets_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PayrollAndRelatedCosts" xlink:label="loc_cdioPayrollAndRelatedCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioPayrollAndRelatedCosts_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RentAndFacilityExpense" xlink:label="loc_cdioRentAndFacilityExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioRentAndFacilityExpense_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapProfessionalFees_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConsultingAndContractorExpense" xlink:label="loc_cdioConsultingAndContractorExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioConsultingAndContractorExpense_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InsuranceExpense" xlink:label="loc_cdioInsuranceExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioInsuranceExpense_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FilingFeesExpense" xlink:label="loc_cdioFilingFeesExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioFilingFeesExpense_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TransferAgentExpense" xlink:label="loc_cdioTransferAgentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioTransferAgentExpense_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SoftwareAndWebComputingExpense" xlink:label="loc_cdioSoftwareAndWebComputingExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioSoftwareAndWebComputingExpense_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardCompensationExpense" xlink:label="loc_cdioBoardCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioBoardCompensationExpense_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InvestorRelationsExpense" xlink:label="loc_cdioInvestorRelationsExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioInvestorRelationsExpense_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OtherSegmentItems" xlink:label="loc_cdioOtherSegmentItems_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_cdioOtherSegmentItems_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpense_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOptionsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOption1Member" xlink:label="loc_cdioStockOption1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOption1Member" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AtTheMarketIssuanceMember" xlink:label="loc_cdioAtTheMarketIssuanceMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioAtTheMarketIssuanceMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cdio-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_MergerAgreementMember" xlink:label="cdio_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_MergerAgreementMember" xlink:to="cdio_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TwoInvestmentBankersMember" xlink:label="cdio_TwoInvestmentBankersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TwoInvestmentBankersMember" xlink:to="cdio_TwoInvestmentBankersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TwoInvestmentBankersMember_lbl" xml:lang="en-US">Two investment bankers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LabEquipmentMember" xlink:label="cdio_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_LabEquipmentMember" xlink:to="cdio_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_LabEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChicagoMember" xlink:label="cdio_ChicagoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ChicagoMember" xlink:to="cdio_ChicagoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ChicagoMember_lbl" xml:lang="en-US">Chicago [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IA" xlink:label="stpr_IA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IA" xlink:to="stpr_IA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_IA_lbl" xml:lang="en-US">IOWA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseOneMember" xlink:label="cdio_LeaseOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_LeaseOneMember" xlink:to="cdio_LeaseOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_LeaseOneMember_lbl" xml:lang="en-US">Lease one [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseTwoMember" xlink:label="cdio_LeaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_LeaseTwoMember" xlink:to="cdio_LeaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_LeaseTwoMember_lbl" xml:lang="en-US">Lease two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockWarrantsMember" xlink:label="cdio_StockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_StockWarrantsMember" xlink:to="cdio_StockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_StockWarrantsMember_lbl" xml:lang="en-US">Stock warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="cdio_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_StockOptionsMember" xlink:to="cdio_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_StockOptionsMember_lbl" xml:lang="en-US">Stock options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioStockholdersMember" xlink:label="cdio_LegacyCardioStockholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_LegacyCardioStockholdersMember" xlink:to="cdio_LegacyCardioStockholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_LegacyCardioStockholdersMember_lbl" xml:lang="en-US">Legacy Cardio Stockholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioMember" xlink:label="cdio_LegacyCardioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_LegacyCardioMember" xlink:to="cdio_LegacyCardioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_LegacyCardioMember_lbl" xml:lang="en-US">Legacy Cardio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ManasFormerOfficersAndDirectorsMember" xlink:label="cdio_ManasFormerOfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ManasFormerOfficersAndDirectorsMember" xlink:to="cdio_ManasFormerOfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ManasFormerOfficersAndDirectorsMember_lbl" xml:lang="en-US">Mana&#146;s former officers and directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_Plan2022Member" xlink:label="cdio_Plan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_Plan2022Member" xlink:to="cdio_Plan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_Plan2022Member_lbl" xml:lang="en-US">Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SevenAccreditedInvestorsMember" xlink:label="cdio_SevenAccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_SevenAccreditedInvestorsMember" xlink:to="cdio_SevenAccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_SevenAccreditedInvestorsMember_lbl" xml:lang="en-US">7 accredited investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementMember" xlink:label="cdio_PlacementAgentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PlacementAgentAgreementMember" xlink:to="cdio_PlacementAgentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PlacementAgentAgreementMember_lbl" xml:lang="en-US">Placement Agent Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalGroupLLCMember" xlink:label="cdio_AltitudeCapitalGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AltitudeCapitalGroupLLCMember" xlink:to="cdio_AltitudeCapitalGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AltitudeCapitalGroupLLCMember_lbl" xml:lang="en-US">Altitude Capital Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CraigHallumCapitalGroupLLCMember" xlink:label="cdio_CraigHallumCapitalGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CraigHallumCapitalGroupLLCMember" xlink:to="cdio_CraigHallumCapitalGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CraigHallumCapitalGroupLLCMember_lbl" xml:lang="en-US">Craig Hallum Capital Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SalesAgreementMember" xlink:label="cdio_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_SalesAgreementMember" xlink:to="cdio_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardOfDirectorsMember" xlink:label="cdio_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_BoardOfDirectorsMember" xlink:to="cdio_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_N2022PlanMember" xlink:label="cdio_N2022PlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_N2022PlanMember" xlink:to="cdio_N2022PlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_N2022PlanMember_lbl" xml:lang="en-US">2022 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOption1Member" xlink:label="cdio_StockOption1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_StockOption1Member" xlink:to="cdio_StockOption1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_StockOption1Member_lbl" xml:lang="en-US">Stock Option #1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalMember" xlink:label="cdio_AltitudeCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AltitudeCapitalMember" xlink:to="cdio_AltitudeCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AltitudeCapitalMember_lbl" xml:lang="en-US">Altitude Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AtTheMarketIssuanceMember" xlink:label="cdio_AtTheMarketIssuanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AtTheMarketIssuanceMember" xlink:to="cdio_AtTheMarketIssuanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AtTheMarketIssuanceMember_lbl" xml:lang="en-US">At The Market Issuance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_YorkvilleConvertibleDebentureMember" xlink:label="cdio_YorkvilleConvertibleDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_YorkvilleConvertibleDebentureMember" xlink:to="cdio_YorkvilleConvertibleDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_YorkvilleConvertibleDebentureMember_lbl" xml:lang="en-US">Yorkville Convertible Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FederalMember" xlink:label="cdio_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FederalMember" xlink:to="cdio_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="stpr_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IL" xlink:to="stpr_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_IL_lbl" xml:lang="en-US">ILLINOIS</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" xlink:label="cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" xlink:to="cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember_lbl" xml:lang="en-US">The Benchmark Company LLC Right Of First Refusal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NorthlandSecuritiesMember" xlink:label="cdio_NorthlandSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NorthlandSecuritiesMember" xlink:to="cdio_NorthlandSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NorthlandSecuritiesMember_lbl" xml:lang="en-US">Northland Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCMember" xlink:label="cdio_TheBenchmarkCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TheBenchmarkCompanyLLCMember" xlink:to="cdio_TheBenchmarkCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TheBenchmarkCompanyLLCMember_lbl" xml:lang="en-US">The Benchmark Company L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="cdio_ImpactOfReverseStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ImpactOfReverseStockSplitMember" xlink:to="cdio_ImpactOfReverseStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ImpactOfReverseStockSplitMember_lbl" xml:lang="en-US">Impact of Reverse Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="cdio_AsRevisedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AsRevisedMember" xlink:to="cdio_AsRevisedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AsRevisedMember_lbl" xml:lang="en-US">As Revised [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReportableSegmentsMember" xlink:label="cdio_ReportableSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ReportableSegmentsMember" xlink:to="cdio_ReportableSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ReportableSegmentsMember_lbl" xml:lang="en-US">Reportable segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ProductTestSalesMember" xlink:label="cdio_ProductTestSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ProductTestSalesMember" xlink:to="cdio_ProductTestSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ProductTestSalesMember_lbl" xml:lang="en-US">Product Test Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Right of use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Patent costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Lease liability - current</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayable" xlink:label="cdio_FinanceAgreementPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FinanceAgreementPayable" xlink:to="cdio_FinanceAgreementPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FinanceAgreementPayable_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Finance agreement payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;Lease liability &#8211; long term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,740,269 and 1,531,468 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiability" xlink:label="cdio_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ChangeInFairValueOfDerivativeLiability" xlink:to="cdio_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="us-gaap_InterestIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOperating" xlink:to="us-gaap_InterestIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOperating_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Basic and fully diluted income (loss) per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, fully diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCash" xlink:label="cdio_CommonStockAndWarrantsIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockAndWarrantsIssuedForCash" xlink:to="cdio_CommonStockAndWarrantsIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockAndWarrantsIssuedForCash_lbl" xml:lang="en-US">Common stock and warrants issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCashShares" xlink:label="cdio_CommonStockAndWarrantsIssuedForCashShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockAndWarrantsIssuedForCashShares" xlink:to="cdio_CommonStockAndWarrantsIssuedForCashShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockAndWarrantsIssuedForCashShares_lbl" xml:lang="en-US">Common stock and warrants issued for cash, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareOutstanding" xlink:label="cdio_ShareOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareOutstanding" xlink:to="cdio_ShareOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cdio_ShareOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Common stock issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockIssuedForCashShares" xlink:label="cdio_CommonStockIssuedForCashShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockIssuedForCashShares" xlink:to="cdio_CommonStockIssuedForCashShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockIssuedForCashShares_lbl" xml:lang="en-US">Common stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStock" xlink:label="cdio_WarrantsConvertedToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WarrantsConvertedToCommonStock" xlink:to="cdio_WarrantsConvertedToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WarrantsConvertedToCommonStock_lbl" xml:lang="en-US">Warrants converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStockShares" xlink:label="cdio_WarrantsConvertedToCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WarrantsConvertedToCommonStockShares" xlink:to="cdio_WarrantsConvertedToCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WarrantsConvertedToCommonStockShares_lbl" xml:lang="en-US">Warrants converted to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFees" xlink:label="cdio_PlacementAgentFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PlacementAgentFees" xlink:to="cdio_PlacementAgentFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PlacementAgentFees_lbl" xml:lang="en-US">Placement agent fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVested" xlink:label="cdio_RestrictedStockAwardsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RestrictedStockAwardsVested" xlink:to="cdio_RestrictedStockAwardsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RestrictedStockAwardsVested_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVestedShares" xlink:label="cdio_RestrictedStockAwardsVestedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RestrictedStockAwardsVestedShares" xlink:to="cdio_RestrictedStockAwardsVestedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RestrictedStockAwardsVestedShares_lbl" xml:lang="en-US">Restricted stock awards vested, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStock" xlink:label="cdio_NotesPayableConvertedToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NotesPayableConvertedToCommonStock" xlink:to="cdio_NotesPayableConvertedToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NotesPayableConvertedToCommonStock_lbl" xml:lang="en-US">Notes payable converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStockShares" xlink:label="cdio_NotesPayableConvertedToCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NotesPayableConvertedToCommonStockShares" xlink:to="cdio_NotesPayableConvertedToCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NotesPayableConvertedToCommonStockShares_lbl" xml:lang="en-US">Notes payable converted to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CompensationForVestedStockOptions" xlink:label="cdio_CompensationForVestedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CompensationForVestedStockOptions" xlink:to="cdio_CompensationForVestedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CompensationForVestedStockOptions_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Compensation for vested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustment" xlink:label="cdio_FractionalSharesAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FractionalSharesAdjustment" xlink:to="cdio_FractionalSharesAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FractionalSharesAdjustment_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Fractional shares adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustmentShares" xlink:label="cdio_FractionalSharesAdjustmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FractionalSharesAdjustmentShares" xlink:to="cdio_FractionalSharesAdjustmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FractionalSharesAdjustmentShares_lbl" xml:lang="en-US">Fractional shares adjustment, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" xlink:label="cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" xlink:to="cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana_lbl" xml:lang="en-US">Adjustment to liabilities assumed in merger with Mana</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareOutstanding" xlink:to="cdio_ShareOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cdio_ShareOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NoncashInterestExpense" xlink:label="cdio_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NoncashInterestExpense" xlink:to="cdio_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NoncashInterestExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiabilities" xlink:label="cdio_ChangeInFairValueOfDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ChangeInFairValueOfDerivativeLiabilities" xlink:to="cdio_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cdio_ChangeInFairValueOfDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsForRightOfUseAsset" xlink:label="cdio_PaymentsForRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsForRightOfUseAsset" xlink:to="cdio_PaymentsForRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cdio_PaymentsForRightOfUseAsset_lbl" xml:lang="en-US">Payments for right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Patent costs incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Proceeds from sale of common stock and warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable, net of original issue discount of $500,000</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsToAcquireFinanceReceivable" xlink:label="cdio_PaymentsToAcquireFinanceReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsToAcquireFinanceReceivable" xlink:to="cdio_PaymentsToAcquireFinanceReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cdio_PaymentsToAcquireFinanceReceivable_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Payments of finance agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsOfPlacementAgentFee" xlink:label="cdio_PaymentsOfPlacementAgentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsOfPlacementAgentFee" xlink:to="cdio_PaymentsOfPlacementAgentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cdio_PaymentsOfPlacementAgentFee_lbl" xml:lang="en-US">Payments of placement agent fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE IN CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH - BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH - END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CashPaidDuringPeriodForAbstract" xlink:label="cdio_CashPaidDuringPeriodForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CashPaidDuringPeriodForAbstract" xlink:to="cdio_CashPaidDuringPeriodForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DebtDiscountRelatedToDerivativeLiability" xlink:label="cdio_DebtDiscountRelatedToDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DebtDiscountRelatedToDerivativeLiability" xlink:to="cdio_DebtDiscountRelatedToDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DebtDiscountRelatedToDerivativeLiability_lbl" xml:lang="en-US">Debt discount related to derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotePayableConvertedToCommonStock" xlink:label="cdio_NotePayableConvertedToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NotePayableConvertedToCommonStock" xlink:to="cdio_NotePayableConvertedToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_NotePayableConvertedToCommonStock_lbl" xml:lang="en-US">Notes payable converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AdjustmentToLiabilitiesAssumedInAcquisition" xlink:label="cdio_AdjustmentToLiabilitiesAssumedInAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AdjustmentToLiabilitiesAssumedInAcquisition" xlink:to="cdio_AdjustmentToLiabilitiesAssumedInAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AdjustmentToLiabilitiesAssumedInAcquisition_lbl" xml:lang="en-US">Adjustment to liabilities assumed in acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" xlink:label="cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" xlink:to="cdio_FinancingAgreementEnteredIntoForPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FinancingAgreementEnteredIntoForPrepaidInsurance_lbl" xml:lang="en-US">Financing agreement entered into for prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RightOfUseAssetAddedToOperatingLease" xlink:label="cdio_RightOfUseAssetAddedToOperatingLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RightOfUseAssetAddedToOperatingLease" xlink:to="cdio_RightOfUseAssetAddedToOperatingLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RightOfUseAssetAddedToOperatingLease_lbl" xml:lang="en-US">Right of use asset added for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OriginalIssueDiscount" xlink:label="cdio_OriginalIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_OriginalIssueDiscount" xlink:to="cdio_OriginalIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_OriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:label="cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:to="cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract_lbl" xml:lang="en-US">Merger Agreement And Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_MergerAgreementAndReverseRecapitalizationTextBlock" xlink:label="cdio_MergerAgreementAndReverseRecapitalizationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_MergerAgreementAndReverseRecapitalizationTextBlock" xlink:to="cdio_MergerAgreementAndReverseRecapitalizationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_MergerAgreementAndReverseRecapitalizationTextBlock_lbl" xml:lang="en-US">Merger Agreement and Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosurePatentCostsAbstract" xlink:label="cdio_DisclosurePatentCostsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DisclosurePatentCostsAbstract" xlink:to="cdio_DisclosurePatentCostsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DisclosurePatentCostsAbstract_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PatentAndTrademarkCostsTextBlock" xlink:label="cdio_PatentAndTrademarkCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PatentAndTrademarkCostsTextBlock" xlink:to="cdio_PatentAndTrademarkCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_PatentAndTrademarkCostsTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="cdio_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DisclosureOperatingLeasesAbstract" xlink:to="cdio_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureFinanceAgreementPayableAbstract" xlink:label="cdio_DisclosureFinanceAgreementPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DisclosureFinanceAgreementPayableAbstract" xlink:to="cdio_DisclosureFinanceAgreementPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DisclosureFinanceAgreementPayableAbstract_lbl" xml:lang="en-US">Finance Agreement Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayableTextBlock" xlink:label="cdio_FinanceAgreementPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FinanceAgreementPayableTextBlock" xlink:to="cdio_FinanceAgreementPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_FinanceAgreementPayableTextBlock_lbl" xml:lang="en-US">Finance Agreement Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureDerivativeLiabilityAbstract" xlink:label="cdio_DisclosureDerivativeLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DisclosureDerivativeLiabilityAbstract" xlink:to="cdio_DisclosureDerivativeLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DisclosureDerivativeLiabilityAbstract_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConvertibleInstrumentsPolicyTextBlock" xlink:label="cdio_ConvertibleInstrumentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ConvertibleInstrumentsPolicyTextBlock" xlink:to="cdio_ConvertibleInstrumentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ConvertibleInstrumentsPolicyTextBlock_lbl" xml:lang="en-US">Convertible Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PatentAndTrademarkCostsPolicyTextBlock" xlink:label="cdio_PatentAndTrademarkCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PatentAndTrademarkCostsPolicyTextBlock" xlink:to="cdio_PatentAndTrademarkCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_PatentAndTrademarkCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReclassificationPolicyTextBlock" xlink:label="cdio_ReclassificationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ReclassificationPolicyTextBlock" xlink:to="cdio_ReclassificationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ReclassificationPolicyTextBlock_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value hierarchy level</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease ROU assets and operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum payments due</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of cash paid and related right-of-use operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti dilutive earning per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xml:lang="en-US">Schedule of subsequent events</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" xlink:label="cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" xlink:to="cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of loss per share and weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOWarrantsExercisableTextBlock" xlink:label="cdio_ScheduleOWarrantsExercisableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOWarrantsExercisableTextBlock" xlink:to="cdio_ScheduleOWarrantsExercisableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOWarrantsExercisableTextBlock_lbl" xml:lang="en-US">Schedule of warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" xlink:label="cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" xlink:to="cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" xlink:label="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" xlink:to="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl" xml:lang="en-US">Liabilities assumed payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_EarlyPaymentDiscount" xlink:label="cdio_EarlyPaymentDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_EarlyPaymentDiscount" xlink:to="cdio_EarlyPaymentDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_EarlyPaymentDiscount_lbl" xml:lang="en-US">Early payment discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PostmergerLiabilitiesBalance" xlink:label="cdio_PostmergerLiabilitiesBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PostmergerLiabilitiesBalance" xlink:to="cdio_PostmergerLiabilitiesBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PostmergerLiabilitiesBalance_lbl" xml:lang="en-US">Post-merger liabilities balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Stock redeemed shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Redemption percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RedemptionPricePerShre" xlink:label="cdio_RedemptionPricePerShre" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RedemptionPricePerShre" xlink:to="cdio_RedemptionPricePerShre_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RedemptionPricePerShre_lbl" xml:lang="en-US">Redemption price per shre</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Redemption amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReverseRecapitalizationShares" xlink:label="cdio_ReverseRecapitalizationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ReverseRecapitalizationShares" xlink:to="cdio_ReverseRecapitalizationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ReverseRecapitalizationShares_lbl" xml:lang="en-US">Reverse recapitalization shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonSharesReversed" xlink:label="cdio_CommonSharesReversed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonSharesReversed" xlink:to="cdio_CommonSharesReversed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonSharesReversed_lbl" xml:lang="en-US">Common shares reversed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Recapitalization cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xml:lang="en-US">Balance of derivative liabilities - beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesIssued" xlink:label="cdio_DerivativeLiabilitiesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DerivativeLiabilitiesIssued" xlink:to="cdio_DerivativeLiabilitiesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DerivativeLiabilitiesIssued_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesConverted" xlink:label="cdio_DerivativeLiabilitiesConverted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DerivativeLiabilitiesConverted" xlink:to="cdio_DerivativeLiabilitiesConverted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DerivativeLiabilitiesConverted_lbl" xml:lang="en-US">Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueRecognizedInOperations" xlink:label="cdio_ChangeInFairValueRecognizedInOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ChangeInFairValueRecognizedInOperations" xlink:to="cdio_ChangeInFairValueRecognizedInOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ChangeInFairValueRecognizedInOperations_lbl" xml:lang="en-US">Change in fair value recognized in operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_2_lbl" xml:lang="en-US">Balance of derivative liabilities - end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC Insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AmountInExcessOfFdicInsurance" xlink:label="cdio_AmountInExcessOfFdicInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AmountInExcessOfFdicInsurance" xlink:to="cdio_AmountInExcessOfFdicInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AmountInExcessOfFdicInsurance_lbl" xml:lang="en-US">Amount in excess of FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Office and computer equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Lab equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">&#160;&#160;Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Know-how license</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentForAmortization_2_lbl" xml:lang="en-US">Amortization expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Operating lease right-of-use assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025 (remaining period)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:label="cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Right-of-use lease assets obtained in the exchange for lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReductionOfLeaseLiabilitiesAbstract" xlink:label="cdio_ReductionOfLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ReductionOfLeaseLiabilitiesAbstract" xlink:to="cdio_ReductionOfLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ReductionOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Reduction of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl" xml:lang="en-US">Monthly rent payment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AnnuallyRentPayment" xlink:label="cdio_AnnuallyRentPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_AnnuallyRentPayment" xlink:to="cdio_AnnuallyRentPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_AnnuallyRentPayment_lbl" xml:lang="en-US">Annually rent payment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PremisesAllowance" xlink:label="cdio_PremisesAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PremisesAllowance" xlink:to="cdio_PremisesAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PremisesAllowance_lbl" xml:lang="en-US">Premises allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Amount receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReimbursementReceivable" xlink:label="cdio_ReimbursementReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ReimbursementReceivable" xlink:to="cdio_ReimbursementReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ReimbursementReceivable_lbl" xml:lang="en-US">Reimbursement receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">ROU assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xml:lang="en-US">Borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Rental expense for operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FinanceAgreementPayable" xlink:to="cdio_FinanceAgreementPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_FinanceAgreementPayable_2_lbl" xml:lang="en-US">Finance agreement payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US">Unamortized balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" xlink:label="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" xlink:to="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:label="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:to="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options expired or cancelled or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options expired or cancelled or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired or cancelled or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Number of shares received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NumberOfSharesTransferred" xlink:label="cdio_NumberOfSharesTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NumberOfSharesTransferred" xlink:to="cdio_NumberOfSharesTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NumberOfSharesTransferred_lbl" xml:lang="en-US">Number of shares transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_lbl" xml:lang="en-US">Number of shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock , per value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFee" xlink:label="cdio_PlacementAgentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PlacementAgentFee" xlink:to="cdio_PlacementAgentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PlacementAgentFee_lbl" xml:lang="en-US">Placement agent fees</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementDescription" xlink:label="cdio_PlacementAgentAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PlacementAgentAgreementDescription" xlink:to="cdio_PlacementAgentAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PlacementAgentAgreementDescription_lbl" xml:lang="en-US">Placement agent agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Sales commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued for services, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of shares, Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsIssued" xlink:label="cdio_WarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WarrantsIssued" xlink:to="cdio_WarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WarrantsIssued_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsValued" xlink:label="cdio_StockOptionsValued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_StockOptionsValued" xlink:to="cdio_StockOptionsValued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_StockOptionsValued_lbl" xml:lang="en-US">Stock options valued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of stock option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConversionPriceDeterminedPercentage" xlink:label="cdio_ConversionPriceDeterminedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ConversionPriceDeterminedPercentage" xlink:to="cdio_ConversionPriceDeterminedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ConversionPriceDeterminedPercentage_lbl" xml:lang="en-US">Conversion price determined percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Floor conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Decrease floor conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PrincipalAmountReceived" xlink:label="cdio_PrincipalAmountReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PrincipalAmountReceived" xlink:to="cdio_PrincipalAmountReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PrincipalAmountReceived_lbl" xml:lang="en-US">Principal amount received</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DebtInstrumentOriginalIssueDiscount" xlink:label="cdio_DebtInstrumentOriginalIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_DebtInstrumentOriginalIssueDiscount" xlink:to="cdio_DebtInstrumentOriginalIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_DebtInstrumentOriginalIssueDiscount_lbl" xml:lang="en-US">Debt Instrument original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Interest outstanding principal balance accrues percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Interest outstanding principal balance remains uncured percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Conversion of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Annual dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory U.S. federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:to="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Tax ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TaxProvision" xlink:label="cdio_TaxProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TaxProvision" xlink:to="cdio_TaxProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TaxProvision_lbl" xml:lang="en-US">Tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="us-gaap_BusinessCombinationReasonForBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:to="us-gaap_BusinessCombinationReasonForBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationReasonForBusinessCombination_lbl" xml:lang="en-US">Business Combination, Reason for Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TerminationFee" xlink:label="cdio_TerminationFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TerminationFee" xlink:to="cdio_TerminationFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TerminationFee_lbl" xml:lang="en-US">Termination fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockBidPrice" xlink:label="cdio_CommonStockBidPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockBidPrice" xlink:to="cdio_CommonStockBidPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockBidPrice_lbl" xml:lang="en-US">Common stock bid price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockShares" xlink:label="cdio_CommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockShares" xlink:to="cdio_CommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockShares_lbl" xml:lang="en-US">Common stock - shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockValues" xlink:label="cdio_CommonStockValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockValues" xlink:to="cdio_CommonStockValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockValues_lbl" xml:lang="en-US">Common stock - amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Loss attributable to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingBasic" xlink:label="cdio_WeightedAverageCommonSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageCommonSharesOutstandingBasic" xlink:to="cdio_WeightedAverageCommonSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_WeightedAverageCommonSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" xlink:label="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" xlink:to="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding, fully diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockOptions" xlink:label="cdio_CommonStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockOptions" xlink:to="cdio_CommonStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockOptions_lbl" xml:lang="en-US">Common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockWarrants" xlink:label="cdio_CommonStockWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_CommonStockWarrants" xlink:to="cdio_CommonStockWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_CommonStockWarrants_lbl" xml:lang="en-US">Common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_lbl" xml:lang="en-US">Options cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OptionsVestedAndExercisable" xlink:label="cdio_OptionsVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_OptionsVestedAndExercisable" xlink:to="cdio_OptionsVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_OptionsVestedAndExercisable_lbl" xml:lang="en-US">Options vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" xlink:label="cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" xlink:to="cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_lbl" xml:lang="en-US">Weighted average exercise price outstanding, Options vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ClassOfWarrantOrRightOutstandings" xlink:label="cdio_ClassOfWarrantOrRightOutstandings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ClassOfWarrantOrRightOutstandings" xlink:to="cdio_ClassOfWarrantOrRightOutstandings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cdio_ClassOfWarrantOrRightOutstandings_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsCancelled" xlink:label="cdio_WarrantsCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WarrantsCancelled" xlink:to="cdio_WarrantsCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WarrantsCancelled_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceCancelled" xlink:label="cdio_WeightedAverageExercisePriceCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageExercisePriceCancelled" xlink:to="cdio_WeightedAverageExercisePriceCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WeightedAverageExercisePriceCancelled_lbl" xml:lang="en-US">Weighted average exercise price, cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ClassOfWarrantOrRightOutstandings" xlink:to="cdio_ClassOfWarrantOrRightOutstandings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cdio_ClassOfWarrantOrRightOutstandings_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_2_lbl" xml:lang="en-US">Current Segment assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Total current segment assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_2_lbl" xml:lang="en-US">Long-term segment assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="us-gaap_IntangibleAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;Patent costs, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total segment assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_2_lbl" xml:lang="en-US">Segment Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PayrollAndRelatedCosts" xlink:label="cdio_PayrollAndRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PayrollAndRelatedCosts" xlink:to="cdio_PayrollAndRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PayrollAndRelatedCosts_lbl" xml:lang="en-US">&#160;&#160;&#160;Payroll and related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RentAndFacilityExpense" xlink:label="cdio_RentAndFacilityExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_RentAndFacilityExpense" xlink:to="cdio_RentAndFacilityExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_RentAndFacilityExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Rent and facility expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">&#160;&#160;&#160;Legal and professional expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConsultingAndContractorExpense" xlink:label="cdio_ConsultingAndContractorExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ConsultingAndContractorExpense" xlink:to="cdio_ConsultingAndContractorExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ConsultingAndContractorExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Consulting and contractor expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InsuranceExpense" xlink:label="cdio_InsuranceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_InsuranceExpense" xlink:to="cdio_InsuranceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_InsuranceExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Insurance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FilingFeesExpense" xlink:label="cdio_FilingFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FilingFeesExpense" xlink:to="cdio_FilingFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FilingFeesExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Filing fees expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TransferAgentExpense" xlink:label="cdio_TransferAgentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_TransferAgentExpense" xlink:to="cdio_TransferAgentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_TransferAgentExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Transfer agent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SoftwareAndWebComputingExpense" xlink:label="cdio_SoftwareAndWebComputingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_SoftwareAndWebComputingExpense" xlink:to="cdio_SoftwareAndWebComputingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_SoftwareAndWebComputingExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Software and web computing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardCompensationExpense" xlink:label="cdio_BoardCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_BoardCompensationExpense" xlink:to="cdio_BoardCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_BoardCompensationExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Board compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InvestorRelationsExpense" xlink:label="cdio_InvestorRelationsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_InvestorRelationsExpense" xlink:to="cdio_InvestorRelationsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_InvestorRelationsExpense_lbl" xml:lang="en-US">&#160;&#160;&#160;Investor relations expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OtherSegmentItems" xlink:label="cdio_OtherSegmentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_OtherSegmentItems" xlink:to="cdio_OtherSegmentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_OtherSegmentItems_lbl" xml:lang="en-US">&#160;&#160;&#160;Other segment items</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Sales and marketing expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">&#160;&#160;&#160;Interest expense, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Total Segment Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareOutstanding" xlink:to="cdio_ShareOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareOutstanding_3_lbl" xml:lang="en-US">ShareOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ChangeInFairValueOfDerivativeLiabilities" xlink:to="cdio_ChangeInFairValueOfDerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ChangeInFairValueOfDerivativeLiabilities_2_lbl" xml:lang="en-US">ChangeInFairValueOfDerivativeLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsForRightOfUseAsset" xlink:to="cdio_PaymentsForRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PaymentsForRightOfUseAsset_2_lbl" xml:lang="en-US">PaymentsForRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsToAcquireFinanceReceivable" xlink:to="cdio_PaymentsToAcquireFinanceReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PaymentsToAcquireFinanceReceivable_2_lbl" xml:lang="en-US">PaymentsToAcquireFinanceReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PaymentsOfPlacementAgentFee" xlink:to="cdio_PaymentsOfPlacementAgentFee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PaymentsOfPlacementAgentFee_2_lbl" xml:lang="en-US">PaymentsOfPlacementAgentFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_NotePayableConvertedToCommonStock" xlink:to="cdio_NotePayableConvertedToCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_NotePayableConvertedToCommonStock_2_lbl" xml:lang="en-US">NotePayableConvertedToCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PatentAndTrademarkCostsTextBlock" xlink:to="cdio_PatentAndTrademarkCostsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PatentAndTrademarkCostsTextBlock_2_lbl" xml:lang="en-US">PatentAndTrademarkCostsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_FinanceAgreementPayableTextBlock" xlink:to="cdio_FinanceAgreementPayableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_FinanceAgreementPayableTextBlock_2_lbl" xml:lang="en-US">FinanceAgreementPayableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_PatentAndTrademarkCostsPolicyTextBlock" xlink:to="cdio_PatentAndTrademarkCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_PatentAndTrademarkCostsPolicyTextBlock_2_lbl" xml:lang="en-US">PatentAndTrademarkCostsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_2_lbl" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" xlink:to="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock_2_lbl" xml:lang="en-US">ScheduleOfWarrantsAdjustmentsTableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3_lbl" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_2_lbl" xml:lang="en-US">Debt Instrument, Issued, Principal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:to="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageCommonSharesOutstandingBasic" xlink:to="cdio_WeightedAverageCommonSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WeightedAverageCommonSharesOutstandingBasic_2_lbl" xml:lang="en-US">WeightedAverageCommonSharesOutstandingBasic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" xlink:to="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_WeightedAverageCommonSharesOutstandingFullyDiluted_2_lbl" xml:lang="en-US">WeightedAverageCommonSharesOutstandingFullyDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_OptionsVestedAndExercisable" xlink:to="cdio_OptionsVestedAndExercisable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_OptionsVestedAndExercisable_2_lbl" xml:lang="en-US">OptionsVestedAndExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ClassOfWarrantOrRightOutstandings" xlink:to="cdio_ClassOfWarrantOrRightOutstandings_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ClassOfWarrantOrRightOutstandings_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightOutstandings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:to="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_2_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsCurrent_2_lbl" xml:lang="en-US">Intangible Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_2_lbl" xml:lang="en-US">Deposits Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_2_lbl" xml:lang="en-US">Finite-Lived Patents, Gross</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cdio-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#Cover" roleURI="http://cdio.ai/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentation" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalization" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipment" roleURI="http://cdio.ai/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssets" roleURI="http://cdio.ai/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCosts" roleURI="http://cdio.ai/role/PatentCosts" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeases" roleURI="http://cdio.ai/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayable" roleURI="http://cdio.ai/role/FinanceAgreementPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShare" roleURI="http://cdio.ai/role/EarningsLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquity" roleURI="http://cdio.ai/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayable" roleURI="http://cdio.ai/role/ConvertibleNotesPayable" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiability" roleURI="http://cdio.ai/role/DerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxes" roleURI="http://cdio.ai/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingencies" roleURI="http://cdio.ai/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEvents" roleURI="http://cdio.ai/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://cdio.ai/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsTables" roleURI="http://cdio.ai/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesTables" roleURI="http://cdio.ai/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareTables" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityTables" roleURI="http://cdio.ai/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityTables" roleURI="http://cdio.ai/role/DerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesTables" roleURI="http://cdio.ai/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsTables" roleURI="http://cdio.ai/role/SubsequentEventsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#MergerAgreementAndReverseRecapitalizationDetailsNarrative" roleURI="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetails" roleURI="http://cdio.ai/role/IntangibleAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#PatentCostsDetailsNarrative" roleURI="http://cdio.ai/role/PatentCostsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails" roleURI="http://cdio.ai/role/OperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails1" roleURI="http://cdio.ai/role/OperatingLeasesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetails2" roleURI="http://cdio.ai/role/OperatingLeasesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OperatingLeasesDetailsNarrative" roleURI="http://cdio.ai/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#FinanceAgreementPayableDetailsNarrative" roleURI="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#EarningsLossPerCommonShareDetails" roleURI="http://cdio.ai/role/EarningsLossPerCommonShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails" roleURI="http://cdio.ai/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetails1" roleURI="http://cdio.ai/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://cdio.ai/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#ConvertibleNotesPayableDetailsNarrative" roleURI="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#DerivativeLiabilityDetails" roleURI="http://cdio.ai/role/DerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails" roleURI="http://cdio.ai/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetails1" roleURI="http://cdio.ai/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://cdio.ai/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://cdio.ai/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails1" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails2" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails3" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetails4" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="cdio-20250630.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" roleURI="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayable" xlink:label="loc_cdioFinanceAgreementPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_cdioFinanceAgreementPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_cdioChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_cdioChangeInFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCash" xlink:label="loc_cdioCommonStockAndWarrantsIssuedForCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockAndWarrantsIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockAndWarrantsIssuedForCashShares" xlink:label="loc_cdioCommonStockAndWarrantsIssuedForCashShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockAndWarrantsIssuedForCashShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareOutstanding" xlink:label="loc_cdioShareOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockIssuedForCashShares" xlink:label="loc_cdioCommonStockIssuedForCashShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockIssuedForCashShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStock" xlink:label="loc_cdioWarrantsConvertedToCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsConvertedToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsConvertedToCommonStockShares" xlink:label="loc_cdioWarrantsConvertedToCommonStockShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsConvertedToCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFees" xlink:label="loc_cdioPlacementAgentFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioPlacementAgentFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVested" xlink:label="loc_cdioRestrictedStockAwardsVested" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioRestrictedStockAwardsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RestrictedStockAwardsVestedShares" xlink:label="loc_cdioRestrictedStockAwardsVestedShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioRestrictedStockAwardsVestedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStock" xlink:label="loc_cdioNotesPayableConvertedToCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioNotesPayableConvertedToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotesPayableConvertedToCommonStockShares" xlink:label="loc_cdioNotesPayableConvertedToCommonStockShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioNotesPayableConvertedToCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CompensationForVestedStockOptions" xlink:label="loc_cdioCompensationForVestedStockOptions" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCompensationForVestedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustment" xlink:label="loc_cdioFractionalSharesAdjustment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioFractionalSharesAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FractionalSharesAdjustmentShares" xlink:label="loc_cdioFractionalSharesAdjustmentShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioFractionalSharesAdjustmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana" xlink:label="loc_cdioAdjustmentToLiabilitiesAssumedInMergerWithMana" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioAdjustmentToLiabilitiesAssumedInMergerWithMana" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareOutstanding" xlink:label="loc_cdioShareOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NoncashInterestExpense" xlink:label="loc_cdioNoncashInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_cdioNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_cdioChangeInFairValueOfDerivativeLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_cdioChangeInFairValueOfDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsForRightOfUseAsset" xlink:label="loc_cdioPaymentsForRightOfUseAsset" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_cdioPaymentsForRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsToAcquireFinanceReceivable" xlink:label="loc_cdioPaymentsToAcquireFinanceReceivable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cdioPaymentsToAcquireFinanceReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PaymentsOfPlacementAgentFee" xlink:label="loc_cdioPaymentsOfPlacementAgentFee" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_cdioPaymentsOfPlacementAgentFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CashPaidDuringPeriodForAbstract" xlink:label="loc_cdioCashPaidDuringPeriodForAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_cdioCashPaidDuringPeriodForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioCashPaidDuringPeriodForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioCashPaidDuringPeriodForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DebtDiscountRelatedToDerivativeLiability" xlink:label="loc_cdioDebtDiscountRelatedToDerivativeLiability" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cdioDebtDiscountRelatedToDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NotePayableConvertedToCommonStock" xlink:label="loc_cdioNotePayableConvertedToCommonStock" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cdioNotePayableConvertedToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AdjustmentToLiabilitiesAssumedInAcquisition" xlink:label="loc_cdioAdjustmentToLiabilitiesAssumedInAcquisition" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cdioAdjustmentToLiabilitiesAssumedInAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" xlink:label="loc_cdioFinancingAgreementEnteredIntoForPrepaidInsurance" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cdioFinancingAgreementEnteredIntoForPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RightOfUseAssetAddedToOperatingLease" xlink:label="loc_cdioRightOfUseAssetAddedToOperatingLease" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_cdioRightOfUseAssetAddedToOperatingLease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OriginalIssueDiscount" xlink:label="loc_cdioOriginalIssueDiscount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_cdioOriginalIssueDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentation" xlink:title="999008 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalization" xlink:title="999009 - Disclosure - Merger Agreement and Reverse Recapitalization">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:label="loc_cdioDisclosureMergerAgreementAndReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_MergerAgreementAndReverseRecapitalizationTextBlock" xlink:label="loc_cdioMergerAgreementAndReverseRecapitalizationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:to="loc_cdioMergerAgreementAndReverseRecapitalizationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipment" xlink:title="999011 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssets" xlink:title="999012 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCosts" xlink:title="999013 - Disclosure - Patent Costs">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosurePatentCostsAbstract" xlink:label="loc_cdioDisclosurePatentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PatentAndTrademarkCostsTextBlock" xlink:label="loc_cdioPatentAndTrademarkCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosurePatentCostsAbstract" xlink:to="loc_cdioPatentAndTrademarkCostsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeases" xlink:title="999014 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayable" xlink:title="999015 - Disclosure - Finance Agreement Payable">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureFinanceAgreementPayableAbstract" xlink:label="loc_cdioDisclosureFinanceAgreementPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayableTextBlock" xlink:label="loc_cdioFinanceAgreementPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_cdioFinanceAgreementPayableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShare" xlink:title="999016 - Disclosure - Earnings (Loss) Per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquity" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayable" xlink:title="999018 - Disclosure - Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiability" xlink:title="999019 - Disclosure - Derivative Liability">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_cdioDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConvertibleInstrumentsPolicyTextBlock" xlink:label="loc_cdioConvertibleInstrumentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cdioConvertibleInstrumentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PatentAndTrademarkCostsPolicyTextBlock" xlink:label="loc_cdioPatentAndTrademarkCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cdioPatentAndTrademarkCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReclassificationPolicyTextBlock" xlink:label="loc_cdioReclassificationPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cdioReclassificationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_cdioScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cdioScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentTables" xlink:title="999025 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsTables" xlink:title="999026 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesTables" xlink:title="999027 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_cdioScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_cdioScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareTables" xlink:title="999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityTables" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityTables" xlink:title="999030 - Disclosure - Derivative Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_cdioDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueOptionQuantitativeDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapFairValueOptionQuantitativeDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesTables" xlink:title="999031 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsTables" xlink:title="999032 - Disclosure - Subsequent Events (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="loc_us-gaapScheduleOfSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfSubsequentEventsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" xlink:label="loc_cdioScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_cdioScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOWarrantsExercisableTextBlock" xlink:label="loc_cdioScheduleOWarrantsExercisableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_cdioScheduleOWarrantsExercisableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" xlink:label="loc_cdioScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_cdioScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock" xlink:label="loc_cdioScheduleOfWarrantsAdjustmentsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_cdioScheduleOfWarrantsAdjustmentsTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" xlink:title="999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:label="loc_cdioDisclosureMergerAgreementAndReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureMergerAgreementAndReverseRecapitalizationAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_MergerAgreementMember" xlink:label="loc_cdioMergerAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TwoInvestmentBankersMember" xlink:label="loc_cdioTwoInvestmentBankersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTwoInvestmentBankersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionPayablesAssumed1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_EarlyPaymentDiscount" xlink:label="loc_cdioEarlyPaymentDiscount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioEarlyPaymentDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PostmergerLiabilitiesBalance" xlink:label="loc_cdioPostmergerLiabilitiesBalance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioPostmergerLiabilitiesBalance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaapDebtInstrumentRedemptionPricePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RedemptionPricePerShre" xlink:label="loc_cdioRedemptionPricePerShre" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioRedemptionPricePerShre" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReverseRecapitalizationShares" xlink:label="loc_cdioReverseRecapitalizationShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioReverseRecapitalizationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonSharesReversed" xlink:label="loc_cdioCommonSharesReversed" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_cdioCommonSharesReversed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesIssued" xlink:label="loc_cdioDerivativeLiabilitiesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioDerivativeLiabilitiesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DerivativeLiabilitiesConverted" xlink:label="loc_cdioDerivativeLiabilitiesConverted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioDerivativeLiabilitiesConverted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChangeInFairValueRecognizedInOperations" xlink:label="loc_cdioChangeInFairValueRecognizedInOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_cdioChangeInFairValueRecognizedInOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LabEquipmentMember" xlink:label="loc_cdioLabEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_cdioLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AmountInExcessOfFdicInsurance" xlink:label="loc_cdioAmountInExcessOfFdicInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_cdioAmountInExcessOfFdicInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaapConstructionInProgressGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapConstructionInProgressGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999039 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetails" xlink:title="999040 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/PatentCostsDetailsNarrative" xlink:title="999042 - Disclosure - Patent Costs (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosurePatentCostsAbstract" xlink:label="loc_cdioDisclosurePatentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosurePatentCostsAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails" xlink:title="999043 - Disclosure - Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails1" xlink:title="999044 - Disclosure - Operating Leases (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetails2" xlink:title="999045 - Disclosure - Operating Leases (Details 2)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_cdioCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_cdioCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:label="loc_cdioRightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_cdioRightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioRightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReductionOfLeaseLiabilitiesAbstract" xlink:label="loc_cdioReductionOfLeaseLiabilitiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioRightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="loc_cdioReductionOfLeaseLiabilitiesAbstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OperatingLeasesDetailsNarrative" xlink:title="999046 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureOperatingLeasesAbstract" xlink:label="loc_cdioDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ChicagoMember" xlink:label="loc_cdioChicagoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_cdioChicagoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IA" xlink:label="loc_stprIA" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseOneMember" xlink:label="loc_cdioLeaseOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_cdioLeaseOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LeaseTwoMember" xlink:label="loc_cdioLeaseTwoMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_cdioLeaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AnnuallyRentPayment" xlink:label="loc_cdioAnnuallyRentPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioAnnuallyRentPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PremisesAllowance" xlink:label="loc_cdioPremisesAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioPremisesAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReimbursementReceivable" xlink:label="loc_cdioReimbursementReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioReimbursementReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="loc_us-gaapSubordinatedBorrowingInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubordinatedBorrowingInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative" xlink:title="999047 - Disclosure - Finance Agreement Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureFinanceAgreementPayableAbstract" xlink:label="loc_cdioDisclosureFinanceAgreementPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinancingAgreementEnteredIntoForPrepaidInsurance" xlink:label="loc_cdioFinancingAgreementEnteredIntoForPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_cdioFinancingAgreementEnteredIntoForPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="loc_us-gaapLongTermDebtMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_us-gaapLongTermDebtMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FinanceAgreementPayable" xlink:label="loc_cdioFinanceAgreementPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_cdioFinanceAgreementPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaapUnamortizedDebtIssuanceExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureFinanceAgreementPayableAbstract" xlink:to="loc_us-gaapUnamortizedDebtIssuanceExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/EarningsLossPerCommonShareDetails" xlink:title="999048 - Disclosure - Earnings (Loss) Per Common Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockWarrantsMember" xlink:label="loc_cdioStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cdioStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cdioStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails" xlink:title="999049 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetails1" xlink:title="999050 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/StockholdersEquityDetailsNarrative" xlink:title="999051 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioStockholdersMember" xlink:label="loc_cdioLegacyCardioStockholdersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_cdioLegacyCardioStockholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_LegacyCardioMember" xlink:label="loc_cdioLegacyCardioMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioLegacyCardioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ManasFormerOfficersAndDirectorsMember" xlink:label="loc_cdioManasFormerOfficersAndDirectorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioManasFormerOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardOfDirectorsMember" xlink:label="loc_cdioBoardOfDirectorsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cdioBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_Plan2022Member" xlink:label="loc_cdioPlan2022Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cdioPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_N2022PlanMember" xlink:label="loc_cdioN2022PlanMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cdioN2022PlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SevenAccreditedInvestorsMember" xlink:label="loc_cdioSevenAccreditedInvestorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioSevenAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalGroupLLCMember" xlink:label="loc_cdioAltitudeCapitalGroupLLCMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioAltitudeCapitalGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CraigHallumCapitalGroupLLCMember" xlink:label="loc_cdioCraigHallumCapitalGroupLLCMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioCraigHallumCapitalGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AltitudeCapitalMember" xlink:label="loc_cdioAltitudeCapitalMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cdioAltitudeCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementMember" xlink:label="loc_cdioPlacementAgentAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioPlacementAgentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SalesAgreementMember" xlink:label="loc_cdioSalesAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsMember" xlink:label="loc_cdioStockOptionsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOption1Member" xlink:label="loc_cdioStockOption1Member" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioStockOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AtTheMarketIssuanceMember" xlink:label="loc_cdioAtTheMarketIssuanceMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cdioAtTheMarketIssuanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NumberOfSharesTransferred" xlink:label="loc_cdioNumberOfSharesTransferred" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioNumberOfSharesTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentFee" xlink:label="loc_cdioPlacementAgentFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioPlacementAgentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PlacementAgentAgreementDescription" xlink:label="loc_cdioPlacementAgentAgreementDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioPlacementAgentAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsIssued" xlink:label="loc_cdioWarrantsIssued" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_StockOptionsValued" xlink:label="loc_cdioStockOptionsValued" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_cdioStockOptionsValued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999052 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_YorkvilleConvertibleDebentureMember" xlink:label="loc_cdioYorkvilleConvertibleDebentureMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_cdioYorkvilleConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_YorkvilleConvertibleDebentureMember" xlink:label="loc_cdioYorkvilleConvertibleDebentureMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioYorkvilleConvertibleDebentureMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConversionPriceDeterminedPercentage" xlink:label="loc_cdioConversionPriceDeterminedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioConversionPriceDeterminedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PrincipalAmountReceived" xlink:label="loc_cdioPrincipalAmountReceived" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioPrincipalAmountReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_cdioDebtInstrumentOriginalIssueDiscount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_cdioDebtInstrumentOriginalIssueDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapShortTermDebtPercentageBearingFixedInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapShortTermDebtPercentageBearingVariableInterestRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/DerivativeLiabilityDetails" xlink:title="999053 - Disclosure - Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_DisclosureDerivativeLiabilityAbstract" xlink:label="loc_cdioDisclosureDerivativeLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdioDisclosureDerivativeLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails" xlink:title="999054 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="loc_cdioEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_cdioEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetails1" xlink:title="999055 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FederalMember" xlink:label="loc_cdioFederalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_cdioFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapGeographicDistributionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IA" xlink:label="loc_stprIA" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="loc_stprIL" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_stprIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TaxProvision" xlink:label="loc_cdioTaxProvision" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_cdioTaxProvision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999057 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember" xlink:label="loc_cdioTheBenchmarkCompanyLLCRightOfFirstRefusalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTheBenchmarkCompanyLLCRightOfFirstRefusalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TheBenchmarkCompanyLLCMember" xlink:label="loc_cdioTheBenchmarkCompanyLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_cdioTheBenchmarkCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_NorthlandSecuritiesMember" xlink:label="loc_cdioNorthlandSecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_cdioNorthlandSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaapBusinessCombinationReasonForBusinessCombination" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationReasonForBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TerminationFee" xlink:label="loc_cdioTerminationFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_cdioTerminationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockBidPrice" xlink:label="loc_cdioCommonStockBidPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_cdioCommonStockBidPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SubsequentEventsDetailsNarrative" xlink:title="999058 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SalesAgreementMember" xlink:label="loc_cdioSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_cdioSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails" xlink:title="999059 - Disclosure - Organization and Basis of Presentation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockShares" xlink:label="loc_cdioCommonStockShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockValues" xlink:label="loc_cdioCommonStockValues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockValues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1" xlink:title="999060 - Disclosure - Organization and Basis of Presentation (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingBasic" xlink:label="loc_cdioWeightedAverageCommonSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageCommonSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageCommonSharesOutstandingFullyDiluted" xlink:label="loc_cdioWeightedAverageCommonSharesOutstandingFullyDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageCommonSharesOutstandingFullyDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2" xlink:title="999061 - Disclosure - Organization and Basis of Presentation (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockOptions" xlink:label="loc_cdioCommonStockOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_CommonStockWarrants" xlink:label="loc_cdioCommonStockWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioCommonStockWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3" xlink:title="999062 - Disclosure - Organization and Basis of Presentation (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OptionsVestedAndExercisable" xlink:label="loc_cdioOptionsVestedAndExercisable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioOptionsVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" xlink:label="loc_cdioWeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4" xlink:title="999063 - Disclosure - Organization and Basis of Presentation (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ImpactOfReverseStockSplitMember" xlink:label="loc_cdioImpactOfReverseStockSplitMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioImpactOfReverseStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_AsRevisedMember" xlink:label="loc_cdioAsRevisedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_cdioAsRevisedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ClassOfWarrantOrRightOutstandings" xlink:label="loc_cdioClassOfWarrantOrRightOutstandings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioClassOfWarrantOrRightOutstandings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:label="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:label="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WarrantsCancelled" xlink:label="loc_cdioWarrantsCancelled" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWarrantsCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_WeightedAverageExercisePriceCancelled" xlink:label="loc_cdioWeightedAverageExercisePriceCancelled" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioWeightedAverageExercisePriceCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ClassOfWarrantOrRightOutstandings" xlink:label="loc_cdioClassOfWarrantOrRightOutstandings_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cdioClassOfWarrantOrRightOutstandings_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ReportableSegmentsMember" xlink:label="loc_cdioReportableSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_cdioReportableSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ProductTestSalesMember" xlink:label="loc_cdioProductTestSalesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_cdioProductTestSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaapIntangibleAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_PayrollAndRelatedCosts" xlink:label="loc_cdioPayrollAndRelatedCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioPayrollAndRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_RentAndFacilityExpense" xlink:label="loc_cdioRentAndFacilityExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioRentAndFacilityExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_ConsultingAndContractorExpense" xlink:label="loc_cdioConsultingAndContractorExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioConsultingAndContractorExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InsuranceExpense" xlink:label="loc_cdioInsuranceExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioInsuranceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_FilingFeesExpense" xlink:label="loc_cdioFilingFeesExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioFilingFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_TransferAgentExpense" xlink:label="loc_cdioTransferAgentExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioTransferAgentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_SoftwareAndWebComputingExpense" xlink:label="loc_cdioSoftwareAndWebComputingExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioSoftwareAndWebComputingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_BoardCompensationExpense" xlink:label="loc_cdioBoardCompensationExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioBoardCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_InvestorRelationsExpense" xlink:label="loc_cdioInvestorRelationsExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioInvestorRelationsExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdio-20250630.xsd#cdio_OtherSegmentItems" xlink:label="loc_cdioOtherSegmentItems" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_cdioOtherSegmentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Post-Effective
Amendment No. 1 (this &#8220;Post-Effective Amendment&#8221;) to the Registration Statement on Form S-1 (File No. 333-283419) of
Cardio Diagnostics Holdings, Inc. (the &#8220;Company,&#8221; &#8220;Cardio,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;), which
was originally declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on December 3, 2024 (the
&#8220;Original Registration Statement&#8221;) is being filed to update the Original Registration Statement and the Prospectus
contained therein with information from the registrant&#8217;s Annual Report on Form 10-K for the year ended&#160;December 31, 2024,
which was filed with the SEC on March 20, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025, which was
filed on August&#160;14, 2025, and to update certain other information in the Original Registration Statement. Unless otherwise
noted, all of the share and price per share information in this Post- Effective Amendment has been adjusted to reflect the 1-for-30
reverse stock split implemented by the Company on May 12, 2025. The audited financial statements included herein have not been
adjusted for the reverse stock split. Certain pre-reverse stock split information included in the Form 10-Q for the period ended
June 30, 2025 has been omitted in this Post-Effective Amendment.

&#160;

This Post-Effective Amendment contains an updated
prospectus (the &#8220;Prospectus&#8221;) relating to the offer and sale of the securities registered by the Original Registration Statement.
No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time
of the initial filing of the Original Registration Statement on November 22, 2024.
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIO DIAGNOSTICS HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001870144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">6770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0925574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">311 West Superior Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-9991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">311 West Superior Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-9991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Meeshanthini V. Dogan, Ph.D.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">&#160;&#160;&#160;&#160;Cash</a></td>
<td class="nump">$ 7,966,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,827,487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,283,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">&#160;&#160;&#160;&#160;Accounts receivable</a></td>
<td class="nump">12,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">723,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">944,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,477,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,703,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,790,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,765,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;&#160;&#160;&#160;Property and equipment, net</a></td>
<td class="nump">621,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">672,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">571,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">&#160;&#160;&#160;&#160;Right of use assets, net</a></td>
<td class="nump">347,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">432,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">575,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">&#160;&#160;&#160;&#160;Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">&#160;&#160;&#160;&#160;Deposits</a></td>
<td class="nump">12,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">&#160;&#160;&#160;&#160;Patent costs, net</a></td>
<td class="nump">711,148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">701,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">515,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,615,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,462,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</a></td>
<td class="nump">48,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">87,661<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">243,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">&#160;&#160;&#160;&#160;Lease liability - current</a></td>
<td class="nump">244,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">237,270<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">223,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FinanceAgreementPayable', window );">&#160;&#160;&#160;&#160;Finance agreement payable</a></td>
<td class="nump">76,691<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">306,764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">374,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">369,597<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">631,695<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">841,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">&#160;&#160;&#160;Lease liability &#8211; long term</a></td>
<td class="nump">302,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">425,829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">663,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">671,848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,057,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,504,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,740,269 and 1,531,468 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">&#160;&#160;&#160;&#160;Additional paid-in capital</a></td>
<td class="nump">35,794,778<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,309,606<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,326,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">&#160;&#160;&#160;&#160;Accumulated deficit</a></td>
<td class="num">(26,070,096)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,751,833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,368,380)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">9,724,699<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,557,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,958,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,615,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,462,365<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FinanceAgreementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FinanceAgreementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">1,740,269<span></span>
</td>
<td class="nump">1,531,468<span></span>
</td>
<td class="nump">20,540,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">1,740,269<span></span>
</td>
<td class="nump">1,531,468<span></span>
</td>
<td class="nump">20,540,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 7,475<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 34,890<span></span>
</td>
<td class="nump">$ 17,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">&#160;&#160;&#160;&#160;Selling, general and administrative expenses</a></td>
<td class="nump">1,686,174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,290,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,317,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,464,306<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,446<span></span>
</td>
<td class="nump">158,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,125<span></span>
</td>
<td class="nump">145,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,169,458<span></span>
</td>
<td class="nump">6,936,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,738<span></span>
</td>
<td class="nump">19,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,686,174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,290,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,317,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,464,306<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,400,767<span></span>
</td>
<td class="nump">7,259,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,678,699)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,282,460)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,309,259)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,440,508)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,365,877)<span></span>
</td>
<td class="num">(7,242,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,406,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">&#160;&#160;&#160;&#160;Interest income</a></td>
<td class="nump">190<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">&#160;&#160;&#160;&#160;Interest expense</a></td>
<td class="num">(4,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,817)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,381)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,634)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,640)<span></span>
</td>
<td class="num">(6,735,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">193,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expenses)</a></td>
<td class="num">(4,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,004)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,071)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,576)<span></span>
</td>
<td class="num">(1,134,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(1,683,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,318,263)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,383,453)<span></span>
</td>
<td class="num">(8,376,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,683,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,318,263)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (8,383,453)<span></span>
</td>
<td class="num">$ (8,376,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and fully diluted income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">1,739,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">753,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,712,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">728,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">26,892,705<span></span>
</td>
<td class="nump">12,685,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, fully diluted</a></td>
<td class="nump">1,739,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">753,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,712,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">728,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">26,892,705<span></span>
</td>
<td class="nump">12,685,133<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,293,159<span></span>
</td>
<td class="num">$ (5,991,546)<span></span>
</td>
<td class="nump">$ 4,301,708<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,514,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsConvertedToCommonStock', window );">Warrants converted to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">389,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsConvertedToCommonStockShares', window );">Warrants converted to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentFees', window );">Placement agent fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(315,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(315,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">243,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">244,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_NotesPayableConvertedToCommonStock', window );">Notes payable converted to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 106<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,604,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,604,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_NotesPayableConvertedToCommonStockShares', window );">Notes payable converted to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,622,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,035,273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,035,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana', window );">Adjustment to liabilities assumed in merger with Mana</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74,025<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">74,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,376,834)<span></span>
</td>
<td class="num">(8,376,834)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,326,299<span></span>
</td>
<td class="num">(14,368,380)<span></span>
</td>
<td class="nump">2,958,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,540,409<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,326,497<span></span>
</td>
<td class="num">(14,368,380)<span></span>
</td>
<td class="nump">2,958,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">684,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;&#160;&#160;&#160;Common stock issued for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,722,857<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,722,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockIssuedForCashShares', window );">Common stock issued for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,963<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,461,404<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,461,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,163,584)<span></span>
</td>
<td class="num">(4,163,584)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,568,758<span></span>
</td>
<td class="num">(18,531,964)<span></span>
</td>
<td class="nump">3,036,801<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">720,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,326,299<span></span>
</td>
<td class="num">(14,368,380)<span></span>
</td>
<td class="nump">2,958,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,540,409<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockAndWarrantsIssuedForCash', window );">Common stock and warrants issued for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,546,696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,546,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockAndWarrantsIssuedForCashShares', window );">Common stock and warrants issued for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,319,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,326,497<span></span>
</td>
<td class="num">(14,368,380)<span></span>
</td>
<td class="nump">2,958,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">684,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentFees', window );">Placement agent fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(155,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">75,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,780<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,515,168<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,515,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,383,453)<span></span>
</td>
<td class="num">(8,383,453)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 459<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,309,162<span></span>
</td>
<td class="num">(22,751,833)<span></span>
</td>
<td class="nump">9,557,788<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,944,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,309,606<span></span>
</td>
<td class="num">(22,751,833)<span></span>
</td>
<td class="nump">9,557,788<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,531,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,568,758<span></span>
</td>
<td class="num">(18,531,964)<span></span>
</td>
<td class="nump">3,036,801<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">720,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;&#160;&#160;&#160;Common stock issued for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,298,698<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,298,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockIssuedForCashShares', window );">Common stock issued for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">55,822<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,731<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,287,995)<span></span>
</td>
<td class="num">(1,287,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,894,187<span></span>
</td>
<td class="num">(19,819,959)<span></span>
</td>
<td class="nump">3,074,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">777,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,309,606<span></span>
</td>
<td class="num">(22,751,833)<span></span>
</td>
<td class="nump">9,557,788<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,531,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;&#160;&#160;&#160;Common stock issued for cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,423,782<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,423,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockIssuedForCashShares', window );">Common stock issued for cash, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">206,713<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,612<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,635,064)<span></span>
</td>
<td class="num">(1,635,064)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">35,764,000<span></span>
</td>
<td class="num">(24,386,897)<span></span>
</td>
<td class="nump">11,377,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,738,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVested', window );">&#160;&#160;&#160;&#160;Restricted stock awards vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RestrictedStockAwardsVestedShares', window );">Restricted stock awards vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CompensationForVestedStockOptions', window );">&#160;&#160;&#160;&#160;Compensation for vested stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,778<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FractionalSharesAdjustment', window );">&#160;&#160;&#160;&#160;Fractional shares adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FractionalSharesAdjustmentShares', window );">Fractional shares adjustment, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">&#160;&#160;&#160;&#160;Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,683,199)<span></span>
</td>
<td class="num">(1,683,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 35,794,778<span></span>
</td>
<td class="num">$ (26,070,096)<span></span>
</td>
<td class="nump">$ 9,724,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareOutstanding', window );">Ending balance, shares at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,740,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockAndWarrantsIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockAndWarrantsIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockAndWarrantsIssuedForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockAndWarrantsIssuedForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockIssuedForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockIssuedForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CompensationForVestedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CompensationForVestedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FractionalSharesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FractionalSharesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FractionalSharesAdjustmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FractionalSharesAdjustmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_NotesPayableConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_NotesPayableConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_NotesPayableConvertedToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_NotesPayableConvertedToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RestrictedStockAwardsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RestrictedStockAwardsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RestrictedStockAwardsVestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RestrictedStockAwardsVestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WarrantsConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WarrantsConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WarrantsConvertedToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WarrantsConvertedToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,318,263)<span></span>
</td>
<td class="num">$ (5,451,579)<span></span>
</td>
<td class="num">$ (8,383,453)<span></span>
</td>
<td class="num">$ (8,376,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation</a></td>
<td class="nump">75,441<span></span>
</td>
<td class="nump">39,579<span></span>
</td>
<td class="nump">113,777<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization</a></td>
<td class="nump">139,022<span></span>
</td>
<td class="nump">69,877<span></span>
</td>
<td class="nump">162,568<span></span>
</td>
<td class="nump">107,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation expense</a></td>
<td class="nump">61,390<span></span>
</td>
<td class="nump">2,546,135<span></span>
</td>
<td class="nump">2,591,168<span></span>
</td>
<td class="nump">1,279,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,704,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,406,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(193,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="num">(2,560)<span></span>
</td>
<td class="num">(13,652)<span></span>
</td>
<td class="num">(4,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">220,762<span></span>
</td>
<td class="nump">656,310<span></span>
</td>
<td class="nump">915,969<span></span>
</td>
<td class="nump">758,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</a></td>
<td class="num">(38,937)<span></span>
</td>
<td class="num">(191,132)<span></span>
</td>
<td class="num">(155,552)<span></span>
</td>
<td class="num">(781,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lease liability</a></td>
<td class="num">(116,666)<span></span>
</td>
<td class="num">(110,080)<span></span>
</td>
<td class="num">(223,929)<span></span>
</td>
<td class="nump">244,505<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(2,971,566)<span></span>
</td>
<td class="num">(2,443,450)<span></span>
</td>
<td class="num">(4,993,104)<span></span>
</td>
<td class="num">(5,672,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">&#160;&#160;&#160;&#160;Purchases of property and equipment</a></td>
<td class="num">(24,483)<span></span>
</td>
<td class="num">(187,881)<span></span>
</td>
<td class="num">(214,765)<span></span>
</td>
<td class="num">(575,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PaymentsForRightOfUseAsset', window );">Payments for right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">&#160;&#160;&#160;&#160;Patent costs incurred</a></td>
<td class="num">(58,649)<span></span>
</td>
<td class="num">(83,129)<span></span>
</td>
<td class="num">(189,425)<span></span>
</td>
<td class="num">(197,276)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(83,132)<span></span>
</td>
<td class="num">(271,010)<span></span>
</td>
<td class="num">(404,190)<span></span>
</td>
<td class="num">(794,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">&#160;&#160;&#160;&#160;Proceeds from sale of common stock and warrants, net of issuance costs</a></td>
<td class="nump">3,423,784<span></span>
</td>
<td class="nump">3,021,556<span></span>
</td>
<td class="nump">12,546,949<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable, net of original issue discount of $500,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PaymentsToAcquireFinanceReceivable', window );">&#160;&#160;&#160;&#160;Payments of finance agreement</a></td>
<td class="num">(230,073)<span></span>
</td>
<td class="num">(280,500)<span></span>
</td>
<td class="num">(450,691)<span></span>
</td>
<td class="num">(942,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PaymentsOfPlacementAgentFee', window );">Payments of placement agent fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
<td class="num">(315,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">3,193,711<span></span>
</td>
<td class="nump">2,741,056<span></span>
</td>
<td class="nump">11,941,258<span></span>
</td>
<td class="nump">3,632,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE IN CASH</a></td>
<td class="nump">139,013<span></span>
</td>
<td class="nump">26,596<span></span>
</td>
<td class="nump">6,543,964<span></span>
</td>
<td class="num">(2,833,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH - BEGINNING OF PERIOD</a></td>
<td class="nump">7,827,487<span></span>
</td>
<td class="nump">1,283,523<span></span>
</td>
<td class="nump">1,283,523<span></span>
</td>
<td class="nump">4,117,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH - END OF PERIOD</a></td>
<td class="nump">7,966,500<span></span>
</td>
<td class="nump">1,310,119<span></span>
</td>
<td class="nump">7,827,487<span></span>
</td>
<td class="nump">1,283,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">&#160;&#160;&#160;&#160;&#160;&#160;Interest</a></td>
<td class="nump">9,381<span></span>
</td>
<td class="nump">11,634<span></span>
</td>
<td class="nump">18,640<span></span>
</td>
<td class="nump">30,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DebtDiscountRelatedToDerivativeLiability', window );">Debt discount related to derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_NotePayableConvertedToCommonStock', window );">Notes payable converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_AdjustmentToLiabilitiesAssumedInAcquisition', window );">Adjustment to liabilities assumed in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">74,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FinancingAgreementEnteredIntoForPrepaidInsurance', window );">Financing agreement entered into for prepaid insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,455<span></span>
</td>
<td class="nump">467,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RightOfUseAssetAddedToOperatingLease', window );">Right of use asset added for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 642,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_AdjustmentToLiabilitiesAssumedInAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_AdjustmentToLiabilitiesAssumedInAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DebtDiscountRelatedToDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DebtDiscountRelatedToDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FinancingAgreementEnteredIntoForPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FinancingAgreementEnteredIntoForPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_NotePayableConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_NotePayableConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PaymentsForRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PaymentsForRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PaymentsOfPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PaymentsOfPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PaymentsToAcquireFinanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PaymentsToAcquireFinanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RightOfUseAssetAddedToOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RightOfUseAssetAddedToOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_OriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_OriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_OriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zK9kI5JM98pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 - <span id="xdx_828_zr0p1iZr6SJ2">Organization and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements presented
are those of Cardio Diagnostics Holdings, Inc., (the &#8220;Company&#8221;) and its wholly-owned subsidiary, Cardio Diagnostics, Inc.
(&#8220;Legacy Cardio&#8221;). The Company was incorporated as Mana Capital Acquisition Corp. (&#8220;Mana&#8221;) under the laws of the
state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics,
LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed to develop and commercialize
a patent-pending Artificial Intelligence (&#8220;AI&#8221;)-driven DNA biomarker testing technology (&#8220;Core Technology&#8221;) for
cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the leading medical technology
companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the
approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for
major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure and
diabetes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Interim Financial Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following (a)  consolidated balance sheet
as of December 31, 2024, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim
financial statements of the Company as of and for the period ended June 30, 2025 have been prepared in accordance with the instructions
to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for
complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative
of results that may be expected for the year ending December 31, 2025 or any future periods. These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December
31, 2024 included in the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on March 20, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Reverse Stock Split</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company held its annual meeting of stockholders
on November 15, 2024, where the Company&#8217;s stockholders approved a reverse stock split at a ratio within a range of&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250101__20250630_z4fc6rvNoeK8" title="Reverse stock split">1-for-5
and&#160;1-for-40</span> and granted the Company&#8217;s Board of Directors the discretion to determine the timing and ratio of the split within
such range.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On April 10, 2025, the Company&#8217;s Board
of Directors determined to effect the reverse stock split of the common stock at a&#160;1-for-30 ratio (the "Reverse Stock Split&#8221;)
and approved the filing of a Certificate of Amendment (the "Certificate of Amendment&#8221;) to the Third Amended and Restated Certificate
of Incorporation of the Company to effect the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On May 12, 2025, the Company filed the Certificate
of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, effective immediately after the close of trading
on Nasdaq on May 12, 2025 (the "Effective Time&#8221;). At the Effective Time, every 30 shares of issued and outstanding common stock
automatically combined into one issued share of common stock, with no change in par value. No fractional shares were issued as a result
of the Reverse Stock Split. Instead of issuing fractional shares, the Company rounded shares up or down to the nearest whole number as
determined by DTC at the participant level. The Reverse Stock Split did not modify any voting rights or other terms of the common stock.
The Company&#8217;s common stock began trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the open of the
markets on May 13, 2025. The Reverse Stock Split was implemented for the purpose of regaining compliance with the minimum bid price requirement
for continued listing of the Company&#8217;s common stock on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As a result of the Reverse Stock Split,
the number of shares of common stock outstanding was reduced from&#160;52,160,487&#160;shares to&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20250512_zLEhJFGXBrK" title="Common stock, shares outstanding">1,738,683</span>&#160;shares,
exclusive of 27 whole shares issued for rounding up fractional shares (which was issued in May 2025), and the number of authorized
shares of common stock remains&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pn5n6_c20250630_zUXvz5lEfOXi" title="Common stock, shares authorized">300</span>&#160;million
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise indicated, all  issued,
and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted
to reflect the&#160;1-for-30 Reverse Stock Split for all prior periods presented.&#160;Proportionate adjustments for the Reverse Stock
Split were made to the exercise prices and number of shares issuable under the Company&#8217;s equity incentive plans, and the number
of shares underlying outstanding equity awards, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The impacts of the Reverse Stock Split were applied
retroactively for all periods presented in accordance with applicable guidance, less the number of rounded whole shares issued for fractional
shares on May 12, 2025. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following
tables may not foot due to rounding.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates changes in equity,
as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse Stock Split retroactively adjusted for the
periods presented:</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSubsequentEventsTextBlock_zpYZjRGCbUsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zt84fx4y3b03" style="display: none">Schedule of subsequent events</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>June 30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_ecustom--CommonStockShares_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z0P94rZzChEg" title="Common stock - shares">23,313,070</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(22,535,967</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">777,103</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Common stock - amount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--CommonStockValues_iI_pp0d_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbJTmqYMjgwe" title="Common stock - amount">233</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(225</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">22,893,962</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">225</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">22,894,187</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>March
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlCGB6q1lAo5" title="Common stock - shares">21,628,974</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zY3KZL3tZji5" title="Common stock - shares">(20,908,008</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z3wGkOP3IwR6" title="Common stock - shares">720,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zepu5rMhFSc4" title="Common stock - amount">216</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z9WxqGHZVmEe" title="Common stock - amount">(209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_zpisezl81zd6" title="Common stock - amount">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzlGBn0KrMzl" title="Additional paid-in capital">21,568,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zWf6HDeIzXd8" title="Additional paid-in capital">209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z4DbKHEBQAm1" title="Additional paid-in capital">21,568,758</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares">45,944,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(44,412,571</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">1,531,468</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount">459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">32,309,162</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">32,309,606</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares">20,540,409</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(19,855,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">684,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount">205</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">17,326,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">17,326,497</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z6w6NjRtD9K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates changes in loss per
share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse
Stock Split retroactively adjusted for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_zpY1nXvhMbNf" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BD_z3AbVHx5SOmg" style="display: none">Schedule of loss per share and weighted average shares outstanding</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss attributable to common shareholders</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(5,451,579</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(5,451,579</span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares used to compute basic and
    diluted EPS</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zi6jVSxtJug4" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6xhhlWAEj0d" title="Weighted average common shares outstanding, fully diluted">21,842,422</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_90D_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(21,114,341</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted">728,081</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss per share - basic and diluted</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(0.25</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(7.24</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(7.49</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Three
    months ended June 30, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 5.4pt">Loss attributable to common shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(1,287,995</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLoss_pp0d_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z608DvtVr0Z7" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1669">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(1,287,995</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Weighted average shares used to compute basic and diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, fully diluted">22,607,618</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(21,854,031</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted">753,587</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(0.06</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(1.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(1.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


<p id="xdx_8AC_zz5rjvTplPx" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation
of diluted shares outstanding because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOWarrantsExercisableTextBlock_zCu6qmEE8mZ7" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 2)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8B9_zja0MIWV8Jai" style="display: none">Schedule of warrants exercisable</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock options</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBUuIFKhWLKa" title="Common stock options">3,796,725</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock options">(3,670,168</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock options">126,557</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZGhGby5IEQ5" title="Common stock warrants">8,528,766</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock warrants">(8,244,474</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock warrants">284,292</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zEieOGR6BSG6" style="font: 9pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Stock options were adjusted retroactively to
give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_zcFHdmLaMnQh" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B4_zBHOArNBgO1e" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zR616nd98ZTb" title="Options outstanding, beginning">2,584,599</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3uOjSwFxC44" title="Weighted average exercise price outstanding, beginning">3.06</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z34kfibtIwt3" title="Options outstanding, beginning">(2,498,446</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zJ9SSnoR0Jw1" title="Weighted average exercise price outstanding, beginning">88.66</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zSPbPGFxKZEi" title="Options outstanding, beginning">86,153</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zD9reunbj5qa" title="Weighted average exercise price outstanding, beginning">91.72</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGG3WxZZQ3B8" title="Options granted">1,218,126</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price granted">2.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options granted">(1,177,522</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price granted">60.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options granted">40,604</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price granted">62.14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    cancelled</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmBHkmjywouk" title="Options cancelled">(6,000</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price cancelled">2.11</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z7OmQWfrVAIk" title="Options cancelled">5,800</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price cancelled">61.19</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zIuYcGYDcfwl" title="Options cancelled">(200</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price cancelled">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5AzGUcG24hc" title="Options outstanding, ending">3,796,725</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6Yi8BjVYlTc" title="Weighted average exercise price outstanding, ending">2.74</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zYSYNxFVGy3b" title="Options outstanding, ending">(3,670,168</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z8ArIw1NhnG7" title="Weighted average exercise price outstanding, ending">79.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zWcFEIPqnHTb" title="Options outstanding, ending">126,557</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_z6RrXAsbfll8" title="Weighted average exercise price outstanding, ending">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--OptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ywNTqRtCih" title="Options vested and exercisable">3,789,225</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zk6bfUxx9En8" title="Weighted average exercise price outstanding, Options vested and exercisable">2.74</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options vested and exercisable">(3,662,918</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable">79.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options vested and exercisable">126,307</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p id="xdx_8AB_zM3n5OyRUNv3" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Warrants were adjusted
retroactively to give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfWarrantsAdjustmentsTableTextBlock_zDY4zYb0EIta" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B8_zY1wGgYEBwWj" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at December 31, 2023</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKWqwhAdgGcj" title="Warrants outstanding, beginning">7,854,620</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z17giM8MmWsb" title="Weighted average exercise price outstanding, beginning">9.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ztOJEeRGXhE8" title="Warrants outstanding, beginning">(7,592,799</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zqDQ5IDT7xq7" title="Weighted average exercise price outstanding, beginning">281.35</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zEnRBiZbAVni" title="Warrants outstanding, beginning">261,821</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zQ7RLz7NP28a" title="Weighted average exercise price outstanding, beginning">291.05</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhH8hkXhTj78" title="Warrants granted">674,146</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price, granted">1.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ziFj1lIFLsy6" title="Warrants granted">(651,675</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, granted">51.62</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zqFWAjVDb1Ub" title="Warrants granted">22,471</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, granted">53.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants cancelled</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFfFZymhHLTc" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zywJi7N2dSv1" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx1gjKa7t7ue" title="Warrants outstanding, ending">8,528,766</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zT9MFQyIVsw4" title="Weighted average exercise price outstanding, ending">9.08</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zZRxYowVaOJ7" title="Warrants outstanding, ending">(8,244,474</span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zLFD4vn8jDak" title="Weighted average exercise price outstanding, ending">263.18</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zpZZgfUzQoed" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zrYGbwhJwujk" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A6_zv1vLxFagL05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zd6hdXQ8Jgsg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
1 &#8211; <span id="xdx_827_z37jE7uRTpg9">Organization and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the &#8220;Company&#8221;) and its wholly-owned
subsidiary, Cardio Diagnostics, Inc. (&#8220;Legacy Cardio&#8221;). The Company was incorporated as Mana Capital Acquisition Corp. (&#8220;Mana&#8221;)
under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability
company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed
to develop and commercialize a patent-pending Artificial Intelligence (&#8220;AI&#8221;)-driven DNA biomarker testing technology (&#8220;Core
Technology&#8221;) for cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the
leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The
Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated
into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD),
stroke, heart failure and diabetes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Business
<span style="letter-spacing: 0pt">Combination</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On May 27, 2022, Mana, Mana Merger Sub, Inc.
(&#8220;Merger Sub&#8221;), a wholly-owned direct subsidiary of Mana, Meeshanthini Dogan, the Shareholders&#8217; Representative, and
Legacy Cardio entered into the Business Combination Agreement (the &#8220;Merger Agreement&#8221;). On October 25, 2022, pursuant to
the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana.
Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger Agreement and Reverse Recapitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract', window );"><strong>Merger Agreement And Reverse Recapitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_MergerAgreementAndReverseRecapitalizationTextBlock', window );">Merger Agreement and Reverse Recapitalization</a></td>
<td class="text"><p id="xdx_80B_ecustom--MergerAgreementAndReverseRecapitalizationTextBlock_zrZsdLZbQaM3" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Note
2 &#8211; <span id="xdx_829_zRZ5U0uGlsUb">Merger Agreement and Reverse Recapitalization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
discussed in Note 1, on October 25, 2022, the Company (formerly known as Mana) and Legacy Cardio entered into the Merger Agreement, which
has been accounted for as a reverse recapitalization in accordance with GAAP. Pursuant to the Merger Agreement, the Company acquired
cash of $<span id="xdx_903_eus-gaap--CashAcquiredFromAcquisition_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Cash Acquired from Acquisition">4,021</span> and assumed liabilities of $<span id="xdx_900_eus-gaap--LiabilitiesAssumed1_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Liabilities assumed">928,500</span> from Mana. The liabilities assumed <span style="letter-spacing: -0.25pt">of $<span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionPayablesAssumed1_c20221001__20221025__us-gaap--BusinessAcquisitionAxis__custom--TwoInvestmentBankersMember_pp0p0" title="Liabilities assumed payable">928,500</span>
were payable to two investment bankers and due on October 25, 2023. The assumed liabilities decreased to $<span id="xdx_90A_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zSaqstvLsjr6" title="Liabilities assumed"><span id="xdx_908_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zV0xJXhRWKhi" title="Liabilities assumed">854,475</span></span>, net of an early payment
discount of $<span id="xdx_90A_ecustom--EarlyPaymentDiscount_c20230301__20230322_pp0p0" title="Early payment discount">74,025</span> issued by one of the two investment bankers on March 22, 2023. On March 27, 2023, the Company accepted the early
payment discount and paid Ladenburg the net balance due and payable of $<span id="xdx_902_eus-gaap--LoansPayable_c20230327_pp0p0" title="Loans payable">419,475</span>. On October 24, 2023, the Company paid the remaining
post-merger liabilities balance of $<span id="xdx_901_ecustom--PostmergerLiabilitiesBalance_c20231024_pp0p0" title="Post-merger liabilities balance">435,000</span> to Benchmark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Mana&#8217;s
common stock had a redemption right in connection with the business combination. Mana&#8217;s stockholders exercised their right to redeem
<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20240101__20241231_pdd" title="Stock redeemed shares">6,465,452</span> shares of common stock, which constituted approximately <span id="xdx_90E_eus-gaap--DebtInstrumentRedemptionPricePercentage_c20240101__20241231_pdd" title="Redemption percentage">99.5%</span> of the shares with redemption rights, for cash at a redemption
price of approximately $<span id="xdx_902_ecustom--RedemptionPricePerShre_c20241231_pdd" title="Redemption price per shre">10.10</span> per share, for an aggregate redemption amount of $<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20241231_pp0p0" title="Redemption amount">65,310,892</span>. In accounting for the reverse recapitalization,
the Company&#8217;s legacy issued and outstanding <span id="xdx_904_ecustom--ReverseRecapitalizationShares_c20240101__20241231_pdd" title="Reverse recapitalization shares">1,976,749</span> shares of common stock were reversed and the Mana shares of common stock
totaling <span id="xdx_90E_ecustom--CommonSharesReversed_c20240101__20241231_pdd" title="Common shares reversed">9,514,743</span> were recorded, as described in Note 10. Transactions costs incurred in connection with the recapitalization totaled
$<span id="xdx_903_eus-gaap--RecapitalizationCosts_c20240101__20241231_pp0p0" title="Recapitalization cost">1,535,035</span> and were recorded as a reduction to additional paid in <span style="letter-spacing: 0pt">capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
additional consideration for the transaction, Cardio will issue to each holder who was entitled to merger consideration at the Closing,
its <i>pro rata </i>proportion of up to 1,000,000 shares of our authorized but unissued common stock (the &#8220;Earnout Shares&#8221;
or &#8220;Contingently Issuable Common Stock&#8221;), if on or prior to the fourth anniversary of the Closing Date (the &#8220;Earnout
Period&#8221;), the VWAP of the Company&#8217;s Common Stock equals or exceeds four different price triggers for 30 of any 40 consecutive
trading days, as follows: (i) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $12.50 per share for the
stated period; (ii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $15.00 per share for the stated <span style="letter-spacing: 0pt">period;
(iii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $17.50 for the stated period; and (iv) one-quarter
of the Earnout Shares will be issued if the VWAP equals or exceeds $20.00 for the stated period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In
evaluating the accounting treatment for the earnout, we have concluded that the earnout is not a liability under Accounting Standards
Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity, is not subject to the accounting guidance under ASC 718,
Compensation&#8212;Stock Compensation, and is not subject to derivative accounting under ASC 815, Derivative and Hedging. As such, the
earnout is recognized in equity at fair value upon the closing of the Business Combination. As of the date of filing of this Annual Report
on Form 10-K, the Company&#8217;s common stock did not trade at equal to or greater than $12.50 for a period of at least 30 trading days
out of 40 consecutive trading days and the Company has not issued any Earnout Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_MergerAgreementAndReverseRecapitalizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_MergerAgreementAndReverseRecapitalizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zXnzAM93Vftf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; <span id="xdx_82D_zvNMoO0pTkIc">Summary of Significant Accounting
Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zl60xhPDXMab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zYwROa3I9txl">Principles of Consolidation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio.&#160;All intercompany accounts and transactions have been
eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zsYjArLjRd73" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_z9vhkwplhIGc">Use of Estimates in the Preparation of Financial
Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p>

<p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNWmy4gcCel4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zBAIFoxhFVF9">Segments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;), who is our chief executive officer, for making operating decisions and assessing
performance as the source for determining the Company&#8217;s reportable segments. Management, including the CODM, reviews operating results
solely by monthly revenue and operating results of the Company and, as such, the Company has determined that the Company has one operating
segment (product testing) as defined by ASC Topic 280 &#8220;Segment Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One hundred percent of the Company&#8217;s revenues
are generated from products tests for major types of cardiovascular disease, and therefore the Company has one operating segment for financial
reporting purposes. The Company&#8217;s principal products are its Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD assesses the risk for
a coronary heart disease event, including a heart attack, in the next three years. PrecisionCHD aids in diagnosing and managing coronary
heart disease. The tests can be paid for by provider organizations, patients, and/or employers. Customers are generally charged for tests
utilized for the minimum committed test volume and the pricing can vary based on organization type, size and volume.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment information is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><span id="xdx_8BB_zGDkB6bUDBQc" style="display: none">Schedule of segment information</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#8203;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">December&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">&#160;&#160;&#160;&#160;Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,966,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,827,487</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,927</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">723,921</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">944,683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current segment assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,703,348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,790,782</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">621,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">672,861</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Right of use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">347,298</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">432,397</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">711,148</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">701,089</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total segment assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,396,547</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,615,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment operating results are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Revenue</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">8,415</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">23,798</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">8,415</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">23,798</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-left: 5.4pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">961,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$&#160;</td><td style="text-align: right">3,387,020</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,222</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,473</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396,277</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,558</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,957</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,153</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,488</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,958</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zPhum7r27AA7">(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,120</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,181</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,587</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,004</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,318,263</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,451,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right">(a)</td><td style="width: 5pt"></td><td id="xdx_F18_zwvtHqID77o7" style="text-align: justify">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Three Months
    Ended June 30</b></span>,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">360,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">451,245</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">89,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">209,744</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">165,905</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158,263</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">181,821</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,159</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,554</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101,723</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zcYwFIWWI5Gk">(a)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">136,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">129,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">163,096</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57,779</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,794</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,535</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,683,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,287,995</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_8A1_zCqMEGDYcDLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>







<p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2mAdQMUlbFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_z8pJAsGR6pv6">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
Research and development costs charged to operations for the six months ended June 30, 2025 and 2024 were $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630_pp0p" title="Research and development expense">165,296</span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_pp0p" title="Research and development expense">18,120</span>, respectively,
and for the three months ended June 30, 2025 and 2024 were $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20250401__20250630_pp0p" title="Research and development expense">163,096</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_pp0p" title="Research and development expense">7,280</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zl5jecmfnhNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_znG9dE2Sv5dk">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses advertising costs as incurred.
Advertising costs of $<span id="xdx_909_eus-gaap--AdvertisingExpense_c20250101__20250630_pp0p" title="Advertising costs">50,435</span> and $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20240101__20240630_pp0p" title="Advertising costs">92,181</span> were charged to operations for the six months ended June 30, 2025 and 2024, respectively, and
of $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20250401__20250630_pp0p" title="Advertising costs">8,615</span> and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20240401__20240630_pp0p" title="Advertising costs">57,779</span> for the three months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCcjix61MV8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_z3nIqiyDjCoc">Cash and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are comprised of cash and
highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zjINRfafLPR1" title="Cash equivalents"><span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20241231_zkGi9ZqE3K91" title="Cash equivalents">no</span></span>t have any cash equivalents
as of June 30, 2025 and December 31, 2024. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions
are insured by the FDIC up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20250630_pp0p" title="FDIC Insured limit">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions or
the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of June 30, 2025 and December 31, 2024 was approximately $<span id="xdx_906_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20250630_zwLs3JyT22I9" title="Amount in excess of FDIC insurance">7.6</span> million and $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_z9zOPeI3oJ0k" title="Amount in excess of FDIC insurance">7.5</span> million, respectively. The Company has not experienced
any losses on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk
with regard to these deposits is not significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_ecustom--ReclassificationPolicyTextBlock_zP6QjNBgUMaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zggMIIs6RLqk">Reclassification</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified
to conform with the current period presentation. On the condensed consolidated statements of changes in stockholders&#8217; equity and
cash flows, payment of placement agent fee has been combined with common stock and warrants issued for cash rather than being separated
out, to present net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZeQL7AYBsje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_zZ2vRqjKSUWj">Recent Accounting Pronouncements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily
through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income
tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is
effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the
impact that ASU 2023-09 will have on the condensed consolidated financial statements and its plan for adoption, including the adoption
date and transition method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Disaggregation of Income Statement Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the FASB issued ASU No. 2024-03,
&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&#8221;, which requires disaggregated disclosure of income statement expenses for public business entities.
ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying
any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee
compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses
and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods
beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance
can be applied prospectively with an option for retrospective application. Early adoption is also permitted. We are currently evaluating
the provisions of this ASU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed other recent accounting pronouncements
and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial
statements as a result of future adoption.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_z96x6CklUkj1" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Note
3 &#8211; <span id="xdx_821_zHEdPJSos6R">Summary of Significant Accounting <span style="letter-spacing: 0pt">Policies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zDNg8b34BS05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zr8jCQLjXzu6">Principles
of <span style="letter-spacing: 0pt">Consolidation</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio. All intercompany
accounts and transactions have been <span style="letter-spacing: 0pt">eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zLNQ2uKwnaZ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zS1mDvUJESNd">Use
of Estimates in the Preparation of Financial <span style="letter-spacing: 0pt">Statements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.25pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could
differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z91QthiMFmrj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_868_zCxlZUH7zj8b">Fair
Value Measurements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company adopted the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures, </i>which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields
on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
1 &#8211; quoted prices in active markets for identical assets or <span style="letter-spacing: 0pt">liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on <span style="letter-spacing: 0pt">assumptions)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level
3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for
the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains
and losses for the years ended December 31, 2024 and 2023.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span id="xdx_8B9_zQfF87metW1a" style="display: none">Schedule of fair value measurements</span><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Balance of derivative liabilities &#8211; beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued">9,192,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Converted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted">(3,786,452</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations">(5,406,220</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Balance of derivative liabilities &#8211; end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AC_zhAz12pT12J7" style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the Company&#8217;s
derivative instruments that are measured at fair value on a recurring basis as of December 31, 2024 and 2023, for each fair value hierarchy
level:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zhbf4g3brmh7" style="display: none">Schedule of fair value hierarchy level</span></td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left">December 31, 2024</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Level I</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Level II</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Level III</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%">December 31, 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level II</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level III</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zmS7sqkIBUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p id="xdx_841_ecustom--ConvertibleInstrumentsPolicyTextBlock_zTtsCCOGiFb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zY6ocY8PrD24">Convertible <span style="letter-spacing: 0pt">Instruments</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company evaluates and accounts for conversion options
embedded in convertible instruments in accordance with ASC 815, <i>Derivatives and Hedging <span style="letter-spacing: 0pt">Activities.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Applicable GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes
in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument
would be considered a derivative <span style="letter-spacing: 0pt">instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for
convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded
in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term
of the related debt to their stated date of redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</p>

<p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z7k6YLTKgNKd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_zGtXQv2t4pl4">Revenue <span style="letter-spacing: 0pt">Recognition</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company offers its products, Epi+Gen CHD and PrecisionCHD, via telemedicine providers, provider organizations such as concierge practices,
longevity clinics, and risk-bearing provider organizations, and employer organizations. The Company is continuing to expand its markets
and payment optionality, and therefore, other organization types not listed below may be added, and from time-to-time, there may be additional
payment options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt; letter-spacing: 0pt">Telemedicine</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For telemedicine, the telemedicine
provider collects payments from patients upon completion of eligibility screening and test order. Patients then send their samples to
the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation and shares test
reports with the ordering healthcare provider. Revenue is recognized upon invoicing the telemedicine providers. Telemedicine providers
are invoiced at the end of each month for all tests completed since prior invoicing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 7.2pt"></td><td style="width: 13.95pt"><span style="font-size: 7pt">&#8226;</span></td><td><span style="font-size: 10pt">Provider organizations</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For provider organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the provider organization type
and testing volume commitment. Upon ordering a test, a patient&#8217;s sample is sent to the lab for biomarker assessments. The Company
performs all quality control, analytical assessments and report generation and shares test reports with the ordering healthcare provider.
Revenue is recognized upon invoicing the provider organization. The provider organization is invoiced the agreed upon pricing at the end
of each month for all samples accepted or tests completed since prior invoicing.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Employer organizations</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For employer organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing volume commitment. Patient
samples are sent to the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation
and shares test reports with the ordering healthcare provider. Revenue is recognized upon invoicing the employer organization. The employer
organization is invoiced the agreed upon pricing once a heart disease fair is completed or all testing is completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for revenue
under Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;, using
the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect
adjustment to the opening balance of accumulated deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company determines the measurement of revenue and the timing
of revenue recognition utilizing the following core principles:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">1.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the contract with a customer;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">2.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the performance obligations in the contract;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">3.</span></td><td style="width: 92%"><span style="font-size: 10pt">Determining
                                            the transaction price;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">4.</span></td><td style="width: 92%"><span style="font-size: 10pt">Allocating
                                            the transaction price to the performance obligations in the contract; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">5.</span></td><td style="width: 92%"><span style="font-size: 10pt">Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBbGafxvms2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zlmVP2BBeDid">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Research and development
costs are expensed as incurred. Research and development costs charged to operations for the years ended December 31, 2024 and 2023 were
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_pp0p0" title="Research and development expense">29,125</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_pp0p0" title="Research and development expense">145,182</span>, <span style="letter-spacing: 0pt">respectively.</span></p>

<p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zTLvsQqGTBik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_862_zVf107pUc8y4">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company expenses advertising costs as incurred. Advertising
costs of $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20240101__20241231_pp0p0" title="Advertising costs">182,446</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20230101__20231231_pp0p0" title="Advertising costs">158,514</span> were charged to operations for the years ended December 31, 2024 and 2023, respectively.</p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJs1obmk6Fvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_ztokn6a3ZbA7">Cash
and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Cash and cash equivalents are comprised of
cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241231_z9AChdOqs003" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zfiDJ26ZzsVd" title="Cash equivalents">no</span></span>t have any
cash equivalents as of December 31, 2024 and 2023. Cash is maintained at a major financial institution. Accounts held at U.S. financial
institutions are insured by the FDIC up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20241231_pp0p0" title="FDIC Insured limit">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions
or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of December 31, 2024 and 2023, was approximately $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_zkcfnxA4Tm9f" title="Amount in excess of FDIC insurance">7.5</span> million and $<span id="xdx_90C_ecustom--AmountInExcessOfFdicInsurance_iI_pp0p0_c20231231_zoEZpwfaSeCg" title="Amount in excess of FDIC insurance">933,523</span>, respectively. The Company has not experienced any losses
on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk with regard
to these deposits is not significant.</p>



<p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_z0c9VQPN9uAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_zjLAHRTGqYll">Accounts Receivable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Accounts receivable is stated
at invoiced amount, net of an allowance for doubtful accounts and bear no interest. An allowance for losses is established through a provision
for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely.
The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based
on evaluation of the collectability of the accounts and prior loss experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0"></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyanY13R5eG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_zH37bjb3G8H5">Property and Equipment</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)">
<tr style="vertical-align: top; text-align: left">
  <td><span id="xdx_8B8_zSC0gG9hqifc" style="display: none">Schedule of estimated lives</span></td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="width: 10%">&#160;</td>
  <td style="width: 40%">Office and computer equipment</td>
  <td style="width: 50%"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives">5</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Furniture and fixtures</td>
  <td><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives">7 </span>years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Lab equipment</td>
  <td><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Leasehold improvements</td>
  <td><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<p id="xdx_8A9_z3ZZlPuyTwi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt">	</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>







<p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITHZUwl7a7j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_zD5TjXIatc38">Intangible <span style="letter-spacing: 0pt">Assets</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Intangible
assets are acquired individually or as part of a group of assets, and are initially recorded at cost. The cost of a group of assets acquired
in a transaction is allocated to the individual assets based on their relative fair values. Intangible assets are carried at cost less
accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line
method over the period of estimated useful life. The estimated useful life of the Company&#8217;s intangible assets (Know-how license)
is <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zCfcXVkoKSEe" title="Useful life">5</span> years. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets
might be impaired.</p>

<p id="xdx_846_ecustom--PatentAndTrademarkCostsPolicyTextBlock_ze5KSEOQ1fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_864_zw0QsOV54Bfd">Patent Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company accounts for patents in accordance
with ASC 350-30, <i>General Intangibles Other than Goodwill</i>. The Company capitalizes patent costs representing legal fees associated
with filing patent applications and amortize them on a straight-line basis. The Company evaluates its patents&#8217; estimated useful
life and begins amortizing the patents when they are brought to the market or otherwise commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.95pt 0 0"></p>

<p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhZLkfI2Wpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_z7dyBmZQQyqd">Impairment
of Long-Lived <span style="letter-spacing: 0pt">Assets</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In accordance with ASC 360-10-35,
the Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value
might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit
of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present.
If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an
impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows
exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the
asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally
measured by the present value of the estimated cash flows.</p>

<p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zZVaUfZxgLMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_863_zxjoSA4ulfbc">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for leases
under ASC <i>842, &#8220;Leases&#8221;. </i>The Company determines if an arrangement is a lease or contains a lease at inception of the
arrangement. Operating lease liabilities are recognized based on the present value of the remaining lease payments, discounted using the
discount rate for the lease at the commencement date. As the rate implicit in the lease is not readily determinable for the operating
lease, the Company generally uses an incremental borrowing rate based on information available at the commencement date to determine the
present value of future lease payments. Operating lease right-of-use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right
to control the use of an identified asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease
payments arising from the lease. ROU assets are generally recognized based on the amount of the initial measurement of the lease liability.
Lease expense is recognized on a straight-line basis over the lease term. The Company elected to keep leases with an initial term of 12
months or less off the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ROU assets are reviewed for
impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance
in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. ROU assets are tested for impairment individually
or as part of an asset group if the cash flows related to the ROU assets are not independent from the cash flows of other assets and liabilities.
An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable
cash flows are largely independent of the cash flows of other groups of assets and liabilities.</p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJw8YL6Iavr" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zlTdxiM7gO0f">Stock-Based <span style="letter-spacing: 0pt">Compensation</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for its stock-based
awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires
the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value
on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company
uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing
model requires the input of highly subjective assumptions including the expected stock price volatility of the Company&#8217;s common
stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption
related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of
the Company&#8217;s stock options and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zzzlr7ysTP2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zfHg5iI9wen">Income
<span style="letter-spacing: 0pt">Taxes</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for income
taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company applies the provisions
of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the
Company&#8217;s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold
and measurement attribute for the financial statement recognition and measurement of a tax position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5RenvA8vA4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86F_zXRvAiswOSKg">Recent Accounting <span style="letter-spacing: 0pt">Pronouncements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">We have reviewed other recent
accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated
financial statements as a result of future adoption.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2Nile72S6Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; <span id="xdx_825_z8chcBPXzx55">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are carried at cost and consist
of the following at June 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3PtcAmmUii" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5QIunZAOLc7" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zLPYcwrjG5a5" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zfasNjvyN0h1" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0d_maPPAENzAGD_zlMCiNM2Btx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Office and computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,264</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21,032</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pp0d_maPPAENzAGD_z81QV8y8prOl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">113,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,818</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0d_maPPAENzAGD_zly4O7Rx1KBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,423</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,423</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_pp0d_maPPAENzAGD_zxtNEfehQQ5b" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">502,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">502,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_msPPAENzAGD_zFVT9ph36CP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(193,008</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(117,567</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0d_mtPPAENzAGD_z7JAVJAVIeR" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;&#160;Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">621,903</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">672,861</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leasehold improvements of $<span id="xdx_902_eus-gaap--LeaseholdImprovementsGross_c20250630_pp0p" title="Leasehold Improvements">502,155</span> represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense of $<span id="xdx_907_eus-gaap--Depreciation_c20250101__20250630_pp0p" title="Depreciation expense">75,441</span> and $<span id="xdx_909_eus-gaap--Depreciation_c20240101__20240630_pp0p" title="Depreciation expense">39,579</span> was charged
to operations for the six months ended June 30, 2025 and 2024, respectively, and of $<span id="xdx_902_eus-gaap--Depreciation_c20250401__20250630_pp0p" title="Depreciation expense">37,785</span> and $<span id="xdx_904_eus-gaap--Depreciation_c20240401__20240630_pp0p" title="Depreciation expense">35,992</span> for the three months ended June
30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zwjm4gdBZQSf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
4 &#8211; <span id="xdx_82F_zXVeIf8VHBU1">Property and <span style="letter-spacing: 0pt">Equipment</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">Property and equipment are carried at cost and consist of the following at December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9ucvjRd8hu3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8B9_znhDxlo6b4V7" style="display: none">Schedule of property and equipment</span>&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zdXSpYKrX3z1" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_z1ilcE0qeHli" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAENzR6H_zrB4cuUYLmce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">21,032</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAENzR6H_zfe8qFobm03j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,099</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAENzR6H_z2p6OR1LHEXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAENzR6H_zS9oqLLg4fEe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,170</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzR6H_z5xKrDrjTYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(117,567</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,790</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzR6H_zDbXGo7IzTz" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">672,861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">571,873</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Leasehold improvements of $<span id="xdx_90C_eus-gaap--LeaseholdImprovementsGross_c20241231_pp0p0" title="Leasehold Improvements">502,155</span> represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024. Depreciation expense of $<span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231_pp0p0" title="Depreciation expense">113,777</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_pp0p0" title="Depreciation expense">3,790</span>
was charged to operations for the years ended December 31, 2024 and 2023, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zY6U7MoBlpad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; <span id="xdx_82E_zCBGHDr1yqi5">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides details associated with
the Company&#8217;s acquired identifiable intangible assets at June 30, 2025 and December 31, 2024:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsomD40dIqVh" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B4_zxMHN2bNC403" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zUmaSQaoeAR2" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zO7pRLBhVoV1" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzF5l_zeSLq06VrdX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Know-how license</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">80,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">80,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzF5l_zGrk2x9OgeV1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(80,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(74,667</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzF5l_zrlwhrfsnpc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,333</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense charged to operations was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630_pp0p" title="Amortization expense">5,333</span>
and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240630_pp0p" title="Amortization expense">8,000</span> for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630_pp0p" title="Amortization expense">1,333</span> and $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240401__20240630_pp0p" title="Amortization expense">4,000</span> for the three months ended June 30, 2025
and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zbuxR5JbFRC7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
5 &#8211; <span id="xdx_828_zBzoa4Zewyz9">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
following table provides details associated with the Company&#8217;s acquired identifiable intangible assets at December 31, 2024 and
2023:</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zc7Lz3Rjebf7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8B1_zpyq01DYJWF5" style="display: none">Schedule of intangible assets</span>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20241231_z579V0nUMvE3" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20231231_zrO7yEGUaRhh" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzDBb_zYnczfGzJWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Know-how license</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">80,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">80,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzDBb_zwhIMPpnEcFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(74,667</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,667</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzDBb_zYIW5sL1Yq8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Amortization expense charged to operations was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_pp0p0" title="Amortization expense"><span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_pp0p0" title="Amortization expense">16,000</span></span> for the
years ended December 31, 2024 and 2023, <span style="letter-spacing: 0pt">respectively.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent Costs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosurePatentCostsAbstract', window );"><strong>Patent Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PatentAndTrademarkCostsTextBlock', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_800_ecustom--PatentAndTrademarkCostsTextBlock_z2ywE5Nusa6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_82A_zVQTP5XVMP">Patent Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2025, in the first family of
patents and patent applications owned solely by UIRF which is exclusively licensed by Cardio, there are eight granted patents (US
(2), EU, China, Australia, India, Hong Kong and Japan) and other pending patent applications. The Company has pending patent
applications in patent families two, three, four, five and six. Legal fees associated with the patents totaled $<span id="xdx_90C_eus-gaap--LegalFees_c20250101__20250630_pp0p" title="Legal fees">711,148</span>
and $<span id="xdx_90E_eus-gaap--LegalFees_c20240101__20240630_pp0p" title="Legal fees">701,089</span>, net of accumulated
amortization of $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization">55,510</span>
and $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization">6,920</span>
as of June 30, 2025 and December 31, 2024, respectively and are presented in the condensed consolidated balance sheets as patent
costs. Patents are amortized over their estimated useful lives of approximately <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zolxFMgzKVHc" title="Estimated useful lives">14</span>
and <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1AitjJ5h3L7" title="Estimated useful lives">15</span>
years, respectively. Amortization expense charged to operations was $<span id="xdx_909_eus-gaap--AdjustmentForAmortization_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses">48,590</span>
and $<span id="xdx_90B_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses">1,587</span>
for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses">7,152</span>
and $<span id="xdx_908_eus-gaap--AdjustmentForAmortization_c20240401__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses">794</span>
for the three months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_806_ecustom--PatentAndTrademarkCostsTextBlock_zcrwGc6tWs0b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
6 &#8211; <span id="xdx_824_z5wdhx2Sfmvh">Patent <span style="letter-spacing: 0pt">Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2024, in the first family
of patents and patent applications owned solely by UIRF and is exclusively licensed by Cardio, there are seven granted patents (US (2),
EU, China, Australia, India and Hong Kong) and other pending patent applications. The Company has pending patent applications in patent
families two, three, four, five and six. Legal fees associated with the patents totaled $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zcFqIPzAR06h" title="Legal fees">701,089</span> and $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zykuNE1meSaa" title="Legal fees">515,402</span>, net of accumulated amortization
of $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zofvdqOAqYt3" title="Accumulated amortization">6,920</span> and $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Accumulated amortization">3,182</span> as of December 31, 2024 and 2023, respectively and are presented in the consolidated balance sheets as patent costs.
Patents are amortized over their estimated useful lives of approximately 14 and <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgtwhQEcsZXi" title="Estimated useful lives">15</span> years, respectively. Amortization expense charged to
operations was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses">3,738</span> and $<span id="xdx_90F_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses">3,182</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosurePatentCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosurePatentCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PatentAndTrademarkCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PatentAndTrademarkCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_z2Uj1dtFNXEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; <span id="xdx_825_zeOBvS5n7AH9">Operating Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">The Company determines if a contract is, or
contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current
portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#8217;s consolidated balance
sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations,
net of current portion in the Company&#8217;s condensed consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">ROU assets represent the right to use an underlying
asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and
lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition,
ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and
exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms
include options to extend or terminate&#160;the lease when it is reasonably certain that the Company will exercise that option. Leases
with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">In 2023, the Company entered into a lease
agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and expiring on
November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental installments
from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $<span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p" title="Monthly rent payment">8,505</span> ($<span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p" title="Annually rent payment">102,060</span> annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#8220;TIA&#8221;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $<span id="xdx_902_ecustom--PremisesAllowance_c20250101__20250630_pp0p" title="Premises allowance">253,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">Pursuant to ASC Topic 842 Leases, the Company
accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated to be payable on December
1, 2023. The Company received the TIA from landlord in maximum amount of $<span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p" title="Amount receivable">253,000</span> on January 16, 2024 and recorded a reimbursement receivable
from landlord of $<span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p" title="Reimbursement receivable">253,000</span> as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">During the year ended December 31, 2023, the
Company recorded ROU assets of $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p" title="ROU assets">663,875</span> and operating lease liabilities of $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p" title="Operating lease liabilities">642,523</span> at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be <span id="xdx_902_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_zaeVzAhFJKkb" title="Borrowing rate">4.57%</span> for Chicago lease and <span id="xdx_900_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_zspWYz9z8Kzf" title="Borrowing rate">4.24%</span> for Iowa City
lease, respectively, as the interest rate implicit in our lease is not readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0pt; text-align: justify">As of June
30, 2025 and December 31, 2024, operating lease ROU assets and operating lease liabilities are recorded on the condensed consolidated
balance sheets as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zNtVTQFk8b56" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B8_z9dBFAE1NiV7" style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_c20250630_pp0p">347,298</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20241231_pp0p">432,397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_c20250630_pp0p">244,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_c20241231_pp0p">237,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20250630_pp0p">302,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20241231_pp0p">425,829</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zx2IisfyivP5" style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">As of June 30, 2025, the
weighted-average remaining lease terms of the two operating leases were <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zC4jPIJ7t9Db">1.42 </span>years
and <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zWAY2UZMusj">3.42</span>
years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zh5iJedn1Ybl" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B0_zFoADQYAUHi9" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_c20250630_zsMfhNSLQSG7" title="2025 (remaining period)">130,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_c20250630_zZtYySMFLxlj" title="2026">250,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_c20250630_zgMIsXczn6Wj" title="2027">102,060</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_c20250630_zSmbhAe3Hxsg" title="2028">93,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0d_c20250630_zSvUnCBTwA34" title="Total minimum lease payments">576,725</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0d_c20250630_zSvnyIqZocr2" title="Less: Imputed interest">30,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0d_c20250630_z4pHZmPwSRT6" title="Present value of lease liabilities">546,433</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">At June 30, 2025, the Company had the following
future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_zaj12noFBQb1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025 (remaining period)">130,958</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zeObSfRyjXk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">250,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20250630_z2dvVzmsSMSh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">102,060</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20250630_z5J4jQGmjp7b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">93,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_zKF4aZT1pbmd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total minimum lease payments">576,725</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zswGVDPHbb81" style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">Consolidated rental expense for all operating
leases was $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20250101__20250630_pp0p" title="Rental expense for operating leases">126,525</span> and $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20240630_pp0p" title="Rental expense for operating leases">91,398</span> for the six months ended June 30, 2025 and 2024, respectively, and $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_c20250401__20250630_pp0p" title="Rental expense for operating leases">68,939</span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240401__20240630_pp0p" title="Rental expense for operating leases">55,582</span> for the three months
ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify">The following table summarizes the cash paid
and related right-of-use operating lease recognized for the six months ended June 30, 2025 and 2024.</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zdGAm3EDPqp2" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8BF_zqedldmhoi5e" style="display: none">Schedule of cash paid and related right-of-use operating lease</span>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20250101__20250630_z6GuhX4DZPOf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101__20240630_zgOdrKJIYLF8" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zppCJdUm5oQ7" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">129,653</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">128,112</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ReductionOfLeaseLiabilitiesAbstract_i01B_zzKziDeNIiZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reduction of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">116,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">110,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z24vbAqljPof" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>









<span></span>
</td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zWIUiVNtCZR1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
7 &#8211; <span id="xdx_823_zyECJSRl5J4h">Operating <span style="letter-spacing: 0pt">Leases</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company determines if
a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#8217;s
consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance
lease obligations, net of current portion in the Company&#8217;s consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ROU assets represent the right
to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.
ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.
In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement
date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments.
Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.
Leases with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In 2023, the Company entered
into a lease agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and
expiring on November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental
installments from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $<span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p0" title="Monthly rent payment">8,505</span> ($<span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p0" title="Annually rent payment">102,060</span> annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#8220;TIA&#8221;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $<span id="xdx_906_ecustom--PremisesAllowance_c20240101__20241231_pp0p0" title="Premises allowance">253,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Pursuant to ASC Topic 842
Leases, the Company accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated
to be payable on December 1, 2023. The Company received the TIA from landlord in maximum amount of $<span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p0" title="Amount receivable">253,000</span> on January 16, 2024 and recorded
a reimbursement receivable from landlord of $<span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p0" title="Reimbursement receivable">253,000</span> as of December 31, 2023, which was included in Prepaid expenses and other current
assets on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company recorded ROU assets of $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p0" title="ROU assets">663,875</span> and operating lease liabilities of $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p0" title="Operating lease liabilities">642,523</span> at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be <span id="xdx_90B_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_pdd" title="Borrowing rate">4.57%</span> for the Chicago lease and <span id="xdx_90F_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_pdd" title="Borrowing rate">4.24%</span> for the Iowa
City lease, respectively, as the interest rate implicit in our lease is not readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As
of December 31, 2024 and 2023, operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheets
as <span style="letter-spacing: 0pt">follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zyoLYq3Im9od" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zADQOQFfRyfi" style="font-size: 8pt"><b style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20241231_zzRQXmMCDVHc" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_496_20231231_zNUIrXNUIwwf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">432,397</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">575,227</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">237,270</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">223,929</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zaTmatbFqhb4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">425,829</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">663,099</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zvpAVaPeTkg7" style="font: 10pt Times New Roman, Times, Serif; margin: 5.35pt 0 12pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As of December 31, 2024, the weighted-average
remaining lease terms of the two operating leases were <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zeFB5GFznR4a" title="Operating Lease, Weighted Average Remaining Lease Term">1.9</span> years and <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zfCRvCZNnXb3" title="Operating Lease, Weighted Average Remaining Lease Term">3.9</span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIsC8qEhRhJ9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B5_zH4yu9sV5t5c" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20241231_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="2025">260,611</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2026">250,152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2027">102,060</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028">93,555</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="Total minimum lease payments">706,378</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less: Imputed interest">43,279</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20241231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Present value of lease liabilities">663,099</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At December 31, 2024, the Company had the
following future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom"><span style="display: none"></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20241231_zjx6NL5YA5E2" style="width: 14%; font-size: 10pt; text-align: right" title="2025">260,611</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20241231_zf7NWr1e7xch" style="font-size: 10pt; text-align: right" title="2026">250,152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20241231_z32BNlNXJWHc" style="font-size: 10pt; text-align: right" title="2027">102,060</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20241231_zhmSPc62i7bk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028">93,555</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20241231_zuWuaIY5glDk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total minimum lease payments">706,378</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zlrBoJ7IUXGf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Consolidated rental expense for all operating
leases was $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_pp0p0" title="Rental expense for operating leases">204,717</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20230101__20231231_pp0p0" title="Rental expense for operating leases">138,266</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The following table summarizes the cash paid
and related right-of-use operating lease recognized for the years ended December 31, 2024 and 2023.</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zz2OC2XEo2sa" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 8pt; font-weight: bold"><span id="xdx_8B7_zBl1bXJOS7i3" style="display: none">Schedule of cash paid and related right-of-use operating lease</span><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101_20241231" style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20230101_20231231" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zoPcBHLVkZSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Cash paid for amounts included in the measurement of
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating cash flows from operating leases</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">257,508</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">21,352</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB_zGppz3XnLuKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Right-of-use lease assets obtained in the exchange for
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating leases</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">223,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">4,950</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p id="xdx_8A1_zTO3SBrGpVb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Agreement Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureFinanceAgreementPayableAbstract', window );"><strong>Finance Agreement Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FinanceAgreementPayableTextBlock', window );">Finance Agreement Payable</a></td>
<td class="text"><p id="xdx_809_ecustom--FinanceAgreementPayableTextBlock_zxKOWPizo3m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7 &#8211; <span id="xdx_820_zSwJcOPtVmO3">Finance Agreement Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$<span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p" title="Financing agreement entered into for prepaid insurance">467,500</span>&#160;is payable in 10 monthly installments plus interest at a rate of&#160;<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pd" title="Interest rate">8.95%</span>&#160;through&#160;<span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20231025_zgPx5S3jAOHg" title="Maturity date">August
25, 2024</span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p" title="Prepaid expenses">550,000</span>&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024. As of October 31, 2024, this finance agreement has been paid in full and insurance premiums
have been fully amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $<span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p" title="Financing agreement entered into for prepaid insurance">383,455</span> is payable in 10 monthly installments plus interest at a rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pd" title="Interest rate">8.80%</span> through <span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20241025_zGyVLeKxCET9" title="Maturity date">August
25, 2025</span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p" title="Prepaid expenses">451,124</span> has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Finance agreement payable for this agreement
was $<span id="xdx_90E_ecustom--FinanceAgreementPayable_c20250630_pp0p" title="Finance agreement payable">76,691</span> and $<span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p" title="Finance agreement payable">306,764</span> at June 30, 2025 and December 31, 2024, respectively. Unamortized balance of Directors and Officers insurance
premiums was $<span id="xdx_904_eus-gaap--UnamortizedDebtIssuanceExpense_c20250630_pp0p" title="Unamortized balance">144,607</span> and $<span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p" title="Unamortized balance">368,315</span> as of June 30, 2025 and December 31, 2024, respectively.</p>

<span></span>
</td>
<td class="text"><p id="xdx_803_ecustom--FinanceAgreementPayableTextBlock_zDvD2ZeOC3K7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
8 &#8211; <span id="xdx_82D_zamaU30TCmC4">Finance Agreement <span style="letter-spacing: 0pt">Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$<span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p0" title="Financing agreement entered into for prepaid insurance">467,500</span>&#160;is payable in 10 monthly installments plus interest at a rate of&#160;<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pdd" title="Interest rate">8.95%</span>&#160;through&#160;<span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_c20231025" title="Maturity date">August
25, 2024</span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p0" title="Prepaid expenses">550,000</span>&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $<span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p0" title="Financing agreement entered into for prepaid insurance">383,455</span> is payable in 10 monthly installments plus interest at a rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pdd" title="Interest rate">8.80%</span> through <span id="xdx_90C_eus-gaap--LongTermDebtMaturityDate_c20241025" title="Maturity date">August
25, 2025</span>. Accordingly, Directors and Officers insurance premiums of $<span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p0" title="Prepaid expenses">451,124</span> has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Finance agreement payable for above two agreements
was $<span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p0" title="Finance agreement payable">306,764</span> and $<span id="xdx_905_ecustom--FinanceAgreementPayable_c20231231_pp0p0" title="Finance agreement payable">374,000</span> at December 31, 2024 and 2023, respectively. Unamortized balance of Directors and Officers insurance premiums
was $<span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p0" title="Unamortized balance">368,315</span> and $<span id="xdx_900_eus-gaap--UnamortizedDebtIssuanceExpense_c20231231_pp0p0" title="Unamortized balance">449,041</span> as of December 31, 2024 and 2023, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureFinanceAgreementPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureFinanceAgreementPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FinanceAgreementPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FinanceAgreementPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and fully diluted income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zIMc6IP9XQDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 - <span id="xdx_823_zApgRt5G9qXg">Earnings (Loss) Per Common Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates net income (loss) per
common share in accordance with ASC 260 &#8220;<i>Earnings Per Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net
earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted
average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include
outstanding common stock options and common stock warrants presented below
on a post-reverse stock split basis, have not been included in the computation of
diluted net loss per share for the six months ended June 30, 2025 and 2024 as the result would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSAErrEj71d4" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BE_zZlr10vxVjo5" style="display: none">Schedule of anti dilutive earning per share</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June
    30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 66%; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares">284,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares">284,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares">128,860</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares">126,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total shares excluded from calculation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_pd" title="Anti-dilutive shares">413,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_pd" title="Anti-dilutive shares">410,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--EarningsPerShareTextBlock_z5MscUNUo6L" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
9 &#8211; <span id="xdx_82D_z5qW3UYKl5R7">Earnings (Loss) Per Common <span style="letter-spacing: 0pt">Share</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates net income (loss) per common
share in accordance with ASC 260 &#8220;<i>Earnings Per Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net earnings (loss)
per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common
shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
and common stock warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2024
and 2023 as the result would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU8iRieUQ1Ld" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8BF_zY0CDmiHV3Y1" style="display: none">Schedule of anti dilutive earning per share</span>&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Years
    Ended December 31,</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Stock warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares">8,528,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares">7,854,620</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">3,594,202</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2,584,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">12,122,968</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">10,439,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 2.5pt 0 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zGur66SZ7Dg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; <span id="xdx_824_zDlZUxFxRE03">Stockholders&#8217; Equity</span></b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Stock Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 25, 2022, in connection with the approval
of the Business Combination, the Company&#8217;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan
(the &#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing
eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to
increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common
Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the
Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units,
Stock Appreciation Rights, Performance Units and Performance Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan, as approved, permits the issuance
of up to <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630__us-gaap--PlanNameAxis__custom--N2022PlanMember_zkAIl0v4Hta" title="Common stock issuance">108,851</span> shares (3,265,516 prior to the Reverse Stock Split) of Common Stock (the &#8220;Share Reserve&#8221;) upon exercise or
conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#8220;Evergreen Date&#8221;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation
Committee, which administers the 2022 Plan, in its sole discretion. In January 2024, the Compensation Committee approved an annual increase
in the Share Reserve of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsBiKgClq0W8" title="Number of shares authorized">35,349</span> shares (1,060,458 prior to the Reverse Stock Split). On March 31, 2025, the Compensation Committee approved
an increase in the Share Reserve of <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--N2022PlanMember_zl6bp0UFxZh3" title="Number of shares authorized">95,721</span> shares (2,871,638 prior to the Reverse Stock Split).</p>



<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>Private Placement&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with a private offering memorandum
that the Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with
7 accredited investors (the &#8220;Subscription Agreements&#8221;), whereby the Company issued a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLrkUVlopqxj" title="Number of shares issued">18,727</span> units (&#8220;Units&#8221;)
(561,793 prior to the Reverse Stock Split), with each Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Common stock , per value">0.00001</span> par
value (the &#8220;Common Stock&#8221;), and (ii) one six year Common Stock purchase warrant (the &#8220;Warrants&#8221;), having an exercise
price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Warrant exercise price">53.40</span> per share ($1.78 prior to the Reverse Stock Split) (the &#8220;Private Placement&#8221;). The Private Placement resulted
in the issuance to investors of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNaO9M2qbZ3g" title="Number of shares issued">18,727</span> shares (561,793 prior to the Reverse Stock Split) of Common Stock and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXc69KzAyn9a" title="Number of shares issued">18,727</span> Warrants (561,793
prior to the Reverse Stock Split) during the six months ended June 30, 2024. The purchase price of the securities was $53.40 per Unit
($1.78 prior to the Reverse Stock Split), resulting in gross proceeds to the Company of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Proceeds from issuance of common stock">1,000,000</span>, before deducting placement agent fees
(10% or $<span id="xdx_902_ecustom--PlacementAgentFee_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Placement agent fees">100,000</span>) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working capital
and general corporate purposes. The Private Placement closed on February 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Private Placement, the
<span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalMember_zIyqMHCp9yH" title="Placement agent agreement description">Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 3,745 shares (112,353 prior to the Reverse
Stock Split) of Common Stock at $53.40 per share ($1.78 prior to the Reverse Stock Split) through February 2, 2030 (the &#8220;Placement
Agent Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>At-the-Market Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with an At-the-Market Issuance
Sales Agreement (the &#8220;Sales Agreement&#8221;) that the Company entered into with a placement agent on January 26, 2024, the Company
sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUy9Q6Z7q5Rk" title="Number of shares issued">206,713</span> shares (6,201,377 prior to the Reverse Stock Split) of Common Stock at various amounts per share to investors for gross proceeds
totaling $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUgkjQeigyV2" title="Proceeds from issuance of common stock">3,511,040</span> before deducting sales commissions of $<span id="xdx_904_eus-gaap--SalesCommissionsAndFees_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zL8Db4352JNj" title="Sales commissions">87,256</span> to the placement agent, during the six months ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="background-color: white">In
connection with the Sales Agreement, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2iH191Vz27k" title="Number of shares issued">72,058</span>
common shares </span>(2,161,737 prior to the Reverse Stock Split) <span style="background-color: white">at various amounts per share
to investors for gross proceeds totaling $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zF0NuSAhNK3b" title="Proceeds from issuance of common stock">2,176,556</span>,
before deducting sales commissions of $<span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zfdPghkpdd4c" title="Sales commissions">54,399</span>
to placement agent, during the six months ended June 30, 2024 (among which&#160;55,822&#160;shares of common stock (1,674,654 prior to the Reverse Stock Split) were sold for gross
proceeds totaling $1,298,699&#160;before deducting sales commissions of $32,452&#160;to placement agent during the three months ended
June 30, 2024). The Company also paid the placement agent a fee of $<span id="xdx_903_ecustom--PlacementAgentFee_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zghdApbIp2a2" title="Placement agent fees">55,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><i>Other Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the three and six months ended June
30, 2025, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares">1,559</span> shares and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares">2,061</span> shares (on a Reverse Stock Split-adjusted basis) of Common Stock to a consultant for
services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount">6,000</span> and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount">12,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the three and six months ended June
30, 2024, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares">315</span> common shares (9,442 prior to the Reverse Stock Split) and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares">464</span> shares (13,919 prior to the Reverse Stock
Split) to 2 consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount">6,000</span> and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount">14,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On March 31, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zSDyvkZpqSQ9" title="Stock issued for services, shares">1,174</span>
shares (35,212 prior to the Reverse Stock Split) of Common Stock to the board of directors for services pursuant to vesting of Restricted
Stock Units granted, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0d_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zedwpLnUm6H8" title="Stock issued for services, amount">50,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2025 and 2024,
in connection with the Private Placement as described above, the Company issued an aggregate of <span id="xdx_901_ecustom--WarrantsIssued_c20250101__20250630_pd" title="Warrants issued">0</span> and <span id="xdx_903_ecustom--WarrantsIssued_c20240101__20240630_pd" title="Warrants issued">22,471</span> warrants (674,146 prior to
the Reverse Stock Split), respectively.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Warrant activity during the six months ended June
30, 2025 and 2024 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlEGX7ePw5aj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b><span id="xdx_8BB_zoCoP1sUAfHb" style="display: none">Schedule of warrant activity</span>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>Warrants Outstanding</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted<br/> <span style="font-family: Times New Roman, Times, Serif">Average
    Exercise Price</span></b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted Average
    Remaining<br/> <span style="font-family: Times New Roman, Times, Serif">Contractual Life (Years)</span></b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAOwo5LhTg8" title="Warrants outstanding, beginning">261,821</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4RmJlBL6xab" title="Weighted average exercise price outstanding, beginning">291.05</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfGOYs1XZSpj" title="Weighted average remaining contractual life">3.72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6O41bVQa3z3" title="Warrants granted">22,471</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pJZNJXcx5a" title="Weighted average exercise price, granted">53.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCtPHsMVVXa" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HzCSIdJjkd" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lbY9PQTUak" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life">3.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs5JHNeyCwB1" title="Warrants outstanding, beginning">284,292</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyLySFuh2kD9" title="Weighted average exercise price outstanding, beginning">272.26</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGh30EF5wXjf" style="text-align: center" title="Weighted average remaining contractual life">2.91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">No warrant activity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLG9eYUxUuj" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2322">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzAo7Rvt5Cr1" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdg2D1KlSxVh" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNyh32gO7w" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life">2.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A6_zVlmPyeYasC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;<span style="text-decoration: underline">Options</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On January 23, 2024, the Company authorized
an additional <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares authorized">35,349</span> shares (1,060,458 prior to the Reverse Stock Split) to the Equity Incentive Plan Reserve (the &#8220;2022 Plan&#8221;)
and granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zu5cmimglaj" title="Number of shares granted">39,594</span> options (1,187,826 prior to the Reverse Stock Split) to management and employees, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares granted">38,894</span> (1,166,826 prior to the Reverse
Stock Split) of which vested immediately with the remaining 700 options (21,000 prior to the Reverse Stock Split) subject to 50% vesting
on June 30, 2024 and 100% vesting on December 31, 2024. Each option has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Warrant exercise price">63.30</span> per share ($2.11 prior to the Reverse
Stock Split) with an expiration date of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zMFZCl0RHRU6" title="Expiration date">January 23, 2034</span>. The immediately vested <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of stock option vested">38,894</span> stock options (1,166,826 prior to the Reverse
Stock Split) were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p" title="Stock options valued">2,461,404</span> at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized
in the Black-Scholes valuation of these immediately vested stock options during the six months ended June 30, 2024, risk free interest
rate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zQ20NdqxEqo1" title="Risk free interest rate">5.22%</span>, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLfHNJndiWl3" title="Volatility">228%</span> and an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_z0wqn6cB2tJh" title="Exercise price">63.30</span> ($2.11 prior to the Reverse Stock Split). For the remaining 700 options
(21,000 prior to the Reverse Stock Split), 250 options (7,500 prior to the Reverse Stock Split) were vested on June 30, 2024, 167 options
(5,000 prior to the Reverse Stock Split) were vested on December 31, 2024 and 283 options (8,500 prior to the Reverse Stock Split) were
forfeited before vesting with the leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at
vesting date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of
these vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsrsmU3hBnrb" title="Risk free interest rate">4.40%</span>, volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zNO39uuRkL7j" title="Volatility">188%</span> and an exercise
price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLCZyLHqCDte" title="Exercise price">63.30</span> ($2.11 prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2025, the Company authorized an
additional 95,721 shares (2,871,638 prior to the Reverse Stock Split) to the 2022 Plan and granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted">2,524</span>
stock options (75,756 prior to the Reverse Stock Split) to the board of directors, which vested immediately on grant date. Each
option has an exercise price of $9.90 per share ($0.33 prior to the Reverse Stock Split) with an expiration date of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBoXVlSUKYR3" title="Expiration date">March
31, 2035</span>. These immediately vested stock options were valued at $<span id="xdx_90C_ecustom--StockOptionsValued_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued">24,612</span>
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the six months ended June 30, 2025, risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate">4.3908%</span>,
volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility">148%</span>
and an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price">9.90</span>
($0.33 prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2025, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted">6,944</span>
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $3.60 per
share with an expiration date of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlVfbBiRRbQ6" title="Expiration date">June
30, 2035</span>. These immediately vested stock options were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued">24,778</span>
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the three and six months ended June 30, 2025, risk free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate">4.39%</span>,
volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility">161%</span>
and an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price">3.60</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2024, the Company granted&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z59sAkIXF6Ta" title="Options granted">1,012</span>&#160;stock options
(30,300 prior to the Reverse Stock Split) to the board of directors, which vested&#160;immediately on grant date.&#160;Each option has
an exercise price of&#160;$16.50&#160;per share ($0.55 prior to the Reverse Stock Split) with an expiration date of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z5HCp0vha9cl" title="Expiration date">June 30, 2034</span>.
These immediately vested stock options were valued at $<span id="xdx_90F_ecustom--StockOptionsValued_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqDHpmpsf856" title="Stock options valued">16,625</span>&#160;at grant date based on the Black-Scholes Option Pricing model. The
following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the three and six
months ended June 30, 2024, risk free interest rate of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLhmXluWXUt4" title="Risk free interest rate">4.40%</span>, volatility of&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJrgvVaAVFEd" title="Volatility">188%</span>&#160;and an exercise price of $16.50 ($<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zK2IDTX5v0ok" title="Exercise price">0.55</span>
prior to the Reverse Stock Split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>









<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt">Option activity during the six months ended June 30, 2025 and
2024 was as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGs7bIHxLQp5" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;<span id="xdx_8BB_zNmBnhfV8Laa" style="display: none">Schedule of option activity</span></span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>Options
                                            Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Remaining Contractual Life (Years)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOJXjWefUdP" title="Options outstanding, beginning">86,153</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDg6ZJOPgxC" title="Weighted average exercise price outstanding, beginning">91.72</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUJy2BcWHZUh" title="Weighted average remaining contractual life">8.71</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted">40,604</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zKMj6jOusIGh" title="Weighted average exercise price, granted">62.14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV6AelXyevyi" title="Options expired or cancelled or forfeited">(200</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, expired or cancelled or forfeited">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTSo3OHqjMq8" title="Options outstanding, ending">126,557</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHjMIUWBPHih" title="Weighted average exercise price outstanding, ending">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTvB6JrirWF6" title="Weighted average remaining contractual life">8.65</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z4n1IAOkDHk7" title="Options vested and exercisable">126,307</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUtjp5Js5eOg" title="Weighted average exercise price vested and exercisable">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding at
    December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcngGi4b9jza" title="Options outstanding, beginning">119,807</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zspxLpDaEV05" title="Weighted average exercise price outstanding, beginning">82.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCUQxp6NVIoi" title="Weighted average remaining contractual life">8.12</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9neLI2AIYX3" title="Options granted">9,468</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDk7Orw9n4h9" title="Weighted average exercise price, granted">5.28</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zklXVoomkO6e" title="Options expired or cancelled or forfeited">(415</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOV21jIxGlHe" title="Weighted average exercise price, expired or cancelled or forfeited">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zyNHHYaSm7y4" title="Options outstanding, ending">128,860</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqN8Dz80y938" title="Weighted average exercise price outstanding, ending">76.66</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zolOFlBzQHxi" title="Weighted average remaining contractual life">7.80</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqiYmyE5a4zf" title="Options vested and exercisable">128,860</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zx5LSZ3zbR6j" title="Weighted average exercise price vested and exercisable">76.66</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p id="xdx_8AE_z0LUweIq7Wsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwtqmKaLZ10b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
10 &#8211; <span id="xdx_828_zw2TVCrEUToc">Stockholders&#8217; <span style="letter-spacing: 0pt">Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Stock <span style="letter-spacing: 0pt">Transactions</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Pursuant to the Business Combination Agreement on October
25, 2022, the Company issued the following <span style="letter-spacing: 0pt">securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Holders of conversion rights issued as a component of units
in Mana&#8217;s initial public offering (the &#8220;Public Rights&#8221;) were issued an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Number of shares issued">928,571</span> shares of the Company&#8217;s
common <span style="letter-spacing: 0pt">stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Holders of existing shares
of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the &#8220;Legacy Cardio Stockholders&#8221;)
received an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240101__20241231__dei--LegalEntityAxis__custom--LegacyCardioStockholdersMember_pp0p0" title="Number of shares received">6,883,306</span> shares of the Company&#8217;s Common Stock, calculated based on the <span style="color: #202529">exchange
ratio of 3.427259 pursuant to the Merger Agreement</span> (the &#8220;Exchange Ratio&#8221;) for each share of Legacy Cardio Common Stock
held or, in the case of the equity rights holder, that number of shares of the Company&#8217;s Common Stock equal to 1% of the Aggregate
Closing Merger Consideration, as defined in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Legacy Cardio Stockholders
received, in addition, an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20240101__20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pdd" title="Conversion of aggregate shares">43,334</span> shares of the Company&#8217;s Common Stock (&#8220;Conversion Shares&#8221;) upon conversion
of an aggregate of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pp0p0" title="Principal amount">433,334</span> in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such
amount in order to extend Mana&#8217;s duration through October 26, 2022 (the &#8220;Extension Notes&#8221;), which Conversion Shares
were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Mana public stockholders
(excluding Mana Capital, LLC, the SPAC sponsor (the &#8220;Sponsor&#8221;), and Mana&#8217;s former officers and directors) own 34,548
shares of the Company&#8217;s Common Stock and the Sponsor, Mana&#8217;s former officers and directors and certain permitted transferees
own <span id="xdx_90C_ecustom--NumberOfSharesTransferred_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ManasFormerOfficersAndDirectorsMember_pdd" title="Number of shares transferred">1,625,000</span> shares of the Company&#8217;s Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Immediately after giving effect to the Business Combination,
there were 9,514,743 issued and outstanding shares of the Company&#8217;s Common <span style="letter-spacing: 0pt">Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On October 25, 2022, in connection
with the approval of the Business Combination, the Company&#8217;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity
Incentive Plan (the &#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders
by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries,
to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of
Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations
of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock
Units, Stock Appreciation Rights, Performance Units and Performance Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
2022 Plan, as approved, permits the issuance of up to <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20241231__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Common stock issuance">3,265,516</span> shares of Common Stock (the &#8220;Share Reserve&#8221;) upon exercise
or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#8220;Evergreen Date&#8221;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the
Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January
1, 2023. In January 2024, the Compensation Committee approved an annual increase in the Share Reserve of <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Number of shares authorized">1,060,458</span> shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Common Stock <span style="letter-spacing: 0pt">Issued</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Private
Placement&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In connection with a private offering memorandum that the
Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with 7 accredited
investors (the &#8220;Subscription Agreements&#8221;), whereby the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of shares issued">561,793</span> units (&#8220;Units&#8221;), with
each Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Common stock , per value">0.00001</span> par value (the &#8220;Common Stock&#8221;), and (ii)
one six year Common Stock purchase warrant (the &#8220;Warrants&#8221;), having an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRz4dkayTmki" title="Warrant exercise price">1.78</span> per share (the &#8220;Private
Placement&#8221;). The Private Placement resulted in the issuance to investors of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares issued">561,793</span> shares of Common Stock and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares issued">561,793</span> Warrants.
The purchase price of the securities was $1.78 per Unit, resulting in gross proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock">1,000,000</span>, before deducting placement
agent fees (10% or $<span id="xdx_90E_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Placement agent fees">100,000</span>) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working
capital and general corporate purposes. The Private Placement closed on February 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Private Placement, <span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalGroupLLCMember" title="Placement agent agreement description">the
Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 112,353 shares of Common Stock at $1.78
per share through February 2, 2030 (the &#8220;Placement Agent Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At-the-Market Issuance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In connection with an At-the-Market Issuance Sales Agreement
(the &#8220;Sales Agreement&#8221;) that the Company entered into with a placement agent on January 26, 2024, the Company sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of shares issued">24,758,057</span>
shares of Common Stock at various amounts per share to investors for gross proceeds totaling $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock">11,546,949</span> before deducting sales commissions
of $<span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Sales commissions">288,674</span> to placement agent, during the year ended December 31, 2024. The Company also paid the placement agent a fee of $<span id="xdx_90B_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Placement agent fees">55,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Other Common Stock Issuance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">During the year ended December 31, 2024, the Company issued
<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares">48,568</span> shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount">26,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 31, 2024, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares">35,212</span> shares of Common
Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount">50,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On March 2, 2023, a shareholder exercised warrants
in exchange for <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230301__20230302_pdd" title="Conversion of shares, shares">100,000</span> shares of Common Stock for proceeds of $<span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230301__20230302_pp0p0" title="Conversion of shares, Value">390,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares">52,375</span> shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued
at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount">44,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2023, the
Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares">251,172</span> shares of Common Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted,
valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount">200,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the convertible notes payable
(see Note 11 below) the noteholders converted $<span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231_pdd" title="Conversion of shares, shares">5,000,000</span> of principal balance to <span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230101__20231231_pp0p0" title="Conversion of shares, Value">10,622,119</span> shares of Common Stock during the year ended
December 31, 2023. The number of shares of Common Stock issued was determined based on the terms of the convertible notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On October 1, 2019, the Company issued warrants
to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20191001_pdd" title="Common stock issuance">22,500</span> shares of Common Stock at the time of issuance.
The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the
warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the
next Qualified Equity Financing, or if the warrant became exercisable in connection with a Change in Control before the next Qualified
Equity Financing, the greater of the quotient obtained by dividing $150,000 by the Pre-financing Capitalization, and the price per share
paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation
of any Change of Control, or 15 years after the issuance of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In April 2022, the Company issued fully vested
warrants to investors as part of private placement subscription agreements pursuant to which the Company issued Common Stock. Each shareholder
received warrants to purchase 50% of the Common Stock issued at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Warrant exercise price">3.90</span> per share with an expiration date of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220401__20220430" title="Expiration date">June 30,
2027</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of May 23, 2022, the Company issued fully
vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued Common
Stock. Each shareholder received warrants to purchase 50% of the Common Stock issued at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220523_pdd" title="Warrant exercise price">6.21</span> per share with an expiration
date of five years from the date of issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">All of the warrants issued by Legacy Cardio
were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the year ended December 31, 2024, in
connection with the Private Placement as described above, the Company issued an aggregate of <span id="xdx_905_ecustom--WarrantsIssued_c20240101__20241231_pdd" title="Warrants issued">674,146</span> warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Warrant
activity during the years ended December 31, 2024 and 2023 was as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDCwURogRB1f" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BB_zfAb4vTxNTi1" style="display: none">Schedule of warrant activity</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted
    Average Exercise<br/> Price</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>Weighted Average Remaining Contractual
                                                                                                Life</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2022</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1Q52kQUQ9E8" style="width: 12%; font-size: 10pt; text-align: right" title="Warrants outstanding, beginning">7,954,620</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlPPXLz3nx6j" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price outstanding, beginning">9.63</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfgzk0Lz0MC" title="Weighted average remaining contractual life">4.46</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants exercised</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised">(100,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised">3.90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,854,620</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9.70</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Uu5x01Apb1" title="Weighted average remaining contractual life">3.72</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants granted">674,146</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, granted">1.78</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,528,766</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9.08</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUZLGB7r6SId" title="Weighted average remaining contractual life">2.91</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z6PpS9k3vC75" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"><span style="letter-spacing: 0pt"><b>&#160;</b></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline">Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 23, 2023, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted">825,000</span>
stock options to management, which vested immediately on grant date. Each option has an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Warrant exercise price">1.26</span> per share with an expiration
date of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date">June 23, 2033</span>. These immediately vested stock options were valued at $<span id="xdx_908_ecustom--StockOptionsValued_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued">1,035,273</span> at grant date based on the Black-Scholes Option
Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during
the year ended December 31, 2023, risk free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">5.41%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility">176%</span> and an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price">1.26</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On January 23, 2024, the Company authorized
an additional 1,060,458 shares to the Equity Incentive Plan Reserve (the &#8220;2022 Plan&#8221;) and granted 1,187,826 options to management
and employees, 1,166,826 of which vested immediately with the remaining 21,000 options subject to 50% vesting on June 30, 2024 and 100%
vesting on December 31, 2024. Each option has an exercise price of $2.11 per share with an expiration date of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember" title="Expiration date">January 23, 2034</span>. The immediately
vested 1,166,826 stock options were valued at $<span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p0" title="Stock options valued">2,461,404</span> at grant date based on the Black-Scholes Option Pricing model. The following
assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the year ended December 31,
2024, risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Risk free interest rate">5.22%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Volatility">228%</span> and an exercise price of $2.11. For the remaining 21,000 options, 7,500 options
were vested on June 30, 2024, 5,000 options were vested on December 31, 2024 and 8,500 options were forfeited before vesting with the
leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at vesting date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these vested stock options during the
year ended December 31, 2024, risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Risk free interest rate">4.40%</span>, volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Volatility">188%</span> and an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Exercise price">2.11</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 30, 2024, the Company granted 30,300
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.55 per share
with an expiration date of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date">June 30, 2034</span>. These immediately vested stock options were valued at $<span id="xdx_90C_ecustom--StockOptionsValued_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued">16,625</span> at grant date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options
during the year ended December 31, 2024, risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">4.40%</span>, volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility">188%</span> and an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price">0.55</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On September 30, 2024, the Company granted
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted">74,744</span> stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.22 per
share with an expiration date of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date">September 30, 2034</span>. These immediately vested stock options were valued at $<span id="xdx_901_ecustom--StockOptionsValued_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued">16,618</span> at grant date based
on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">3.79%</span>, volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility">184%</span> and an exercise price
of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price">0.22</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On November 14, 2024, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted">15,728</span>
stock options to two independent directors of the board, which vested immediately on grant date. Each option has an exercise price of
$0.27 per share with an expiration date of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date">November 14, 2034</span>. These immediately vested stock options were valued at $<span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued">4,125</span> at grant date
based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">4.44%</span>, volatility of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility">156%</span> and an exercise price
of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price">0.27</span>. The two independent directors did not stand for re-election at the 2024 Annual Meeting but did receive the options upon vesting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On December 31, 2024, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted">13,632</span>
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.92 per share
with an expiration date of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date">December 31, 2034</span>. These immediately vested stock options were valued at $<span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued">12,289</span> at grant date based on the
Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested
stock options during the year ended December 31, 2024, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">4.58%</span>, volatility of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility">146%</span> and an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price">0.92</span>.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Option
activity during the years ended December 31, 2024 and 2023 was as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUvpU5j4hnfl" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zERaSKPPmM23" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Exercise&#160;Price</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Remaining Contractual Life (Years)</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; padding-left: 5.4pt">Options outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZWfO100pTS2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning">1,759,599</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6doTkcJ0gzf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">3.90</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zgUrtRCBeDtf" title="Weighted average remaining contractual life">9.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted">825,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted">1.26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Options outstanding at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,584,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJpBEP5l7EGi" title="Weighted average remaining contractual life">8.71</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted">1,322,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted">1.93</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options expired or cancelled or forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0UGR8MEMLBa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options expired or cancelled or forfeited">(312,628</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options expired or cancelled or forfeited">1.93</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,594,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2.74</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzkJV3s72Ima" title="Weighted average remaining contractual life">8.12</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Options vested and exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options vested and exercisable">3,594,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price vested and exercisable">2.74</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zg6cru78mdZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z5SJdCUsAw6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"><b>Note 11 &#8211; <span id="xdx_820_zPuC4vamZWx5">Convertible Notes Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"><b><span style="letter-spacing: 0pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 8, 2023, the Company
entered into a securities purchase agreement (&#8220;Securities Purchase Agreement&#8221;) with YA II PN, Ltd., an investment fund managed
by Yorkville Advisors Global, LP (&#8220;Yorkville&#8221;) under which the Company agreed to sell and issue to Yorkville convertible debentures
(&#8220;Convertible Debentures&#8221;) in a gross aggregate principal amount of up to $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20230308_pp0n6" title="Principal amount">11.2</span> million (&#8220;Subscription Amount&#8221;).
The Convertible Debentures were convertible into shares of common stock of the Company and were subject to various contingencies being
satisfied as set forth in the Securities Purchase Agreement. The notes were convertible at any time through the maturity date, which,
in each case, was one year from the date of issuance. The conversion price was determined on the basis of <span id="xdx_90A_ecustom--ConversionPriceDeterminedPercentage_c20230308_pdd" title="Conversion price determined percentage">92%</span> of the two lowest VWAP (Volume
Weighted Average Prices) of the Common Stock during the prior seven trading day period, initially with a floor conversion price of $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20230307__20230308_pdd" title="Floor conversion price">0.55</span>,
but subsequently lowered by mutual agreement of the parties to $<span id="xdx_90B_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20230307__20230308_pdd" title="Decrease floor conversion price">0.20</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On March 8, 2023, the Company
issued and sold to Yorkville a Convertible Debenture in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentIssuedPrincipal_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_zdfCN7k7wKp9" title="Principal amount">5.0</span> million, for which it received $<span id="xdx_904_ecustom--PrincipalAmountReceived_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ziIxVvgFNrQ" title="Principal amount received">4.5</span> million, with
a $<span id="xdx_901_ecustom--DebtInstrumentOriginalIssueDiscount_pp0p0_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ztoQDNZJo29f" title="Debt Instrument original issue discount">500,000</span> original issue discount (&#8220;OID&#8221;). Interest on the outstanding principal balance accrued at a rate of <span id="xdx_90B_eus-gaap--ShortTermDebtPercentageBearingFixedInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance accrues percentage">0%</span> and would
increase to <span id="xdx_905_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance remains uncured percentage">15%</span> upon an Event of Default for so long as it remained uncured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company recorded a debt
discount related to identified embedded derivatives relating to the conversion features (see Note 12) based on fair values as of the inception
date of the Note. The calculated debt discount, including the OID, equaled the face of the Note and was amortized over the term of the
note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Yorkville fully converted the initial $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_z5n84HJU19c3" title="Conversion of convertible debt">5,000,000</span>
Convertible Debenture into an aggregate of <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Conversion of shares converted">10,622,119</span> shares of Common Stock during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On January 4, 2024, the Company
and Yorkville terminated the Securities Purchase Agreement dated as of March 8, 2023, as amended, by the mutual consent of the parties,
effective as of January 4, 2024. The First Convertible Debenture was fully converted, and as of January 4, 2024, the obligation of the
Company to issue and sell, and Yorkville&#8217;s obligation to purchase, the Second Convertible Debenture was terminated. At the time
of termination, there were no outstanding borrowings, advance notices or shares of Common Stock to be issued under the Securities Purchase
Agreement. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the Securities Purchase
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DerivativesAndFairValueTextBlock_zOloJLscBhxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
12 &#8211; <span id="xdx_829_z28Bg1hUmo3l">Derivative <span style="letter-spacing: 0pt">Liability</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company has determined
that the conversion feature embedded in the convertible notes described in Note 11 contain a potential variable conversion amount which
constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding
discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately
to interest expense at inception, which aggregated $4,692,672. The Company used the Binomial Black-Scholes Option Pricing model to value
the conversion features.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes
option-pricing model with the following assumption inputs:</p>
<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zITA2HDXmO6g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8B8_ziN7h3ix7bzh" style="display: none">Schedule of option liability</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Year Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span title="Annual dividend yield"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zWoG2cQUPHx" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: left">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span title="Expected life (years)"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zpUNdjQGHwUj" title="Expected life (years)">1.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Risk-free interest rate"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk-free interest rate">4.89%</span></span> - <span title="Risk-free interest rate"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Risk-free interest rate">5.59%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Expected volatility"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility">164%</span></span> - <span title="Expected volatility"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Expected volatility">187%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Exercise price">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price">0.19</span></span> - <span title="Exercise price">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price">3.53</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Stock price">$<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Stock price">0.22</span></span> - <span title="Stock price">$<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Stock price">5.32</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Based
upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40
to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance
date.&#160;</p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zrddLXAWpkF9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
13 &#8211; <span id="xdx_82E_z5NG03DBmNMb">Income <span style="letter-spacing: 0pt">Taxes</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
reconciliation between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense
(benefit) for the years ended December 31, 2024 and 2023 is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkeEgAemkND" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zKXVVQApLLp5" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Statutory U.S. federal income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_zA4fmfMuoFHb" title="Statutory U.S. federal income tax rate">(21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20230101__20231231_zV4xHFQww82f" title="Statutory U.S. federal income tax rate">(21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">State income taxes, net of federal income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zauRogrk3fba" title="State income taxes, net of federal income tax benefit">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zfKHcofJHLd6" title="State income taxes, net of federal income tax benefit">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Tax effect of expenses that are not deductible for income tax purposes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Amortization of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20240101__20241231_z3xZ1eWVpzie" title="Amortization of debt discount">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20230101__20231231_zoe6I5d1lHn1" title="Amortization of debt discount">16.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Change in fair value of derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20240101__20241231_zlNbhtfeSNvi" title="Change in fair value of derivative liability">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20230101__20231231_zrlAUN2OWe24" title="Change in fair value of derivative liability">(13.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20240101__20241231_zpsgVc7bgcX8" title="Stock based compensation">6.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20230101__20231231_zXWf4EPQ4pa5" title="Stock based compensation">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20240101__20241231_zQ4nh9fiUQOg" title="Other">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20230101__20231231_zXmcFRScXv2b" title="Other">(0.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231_zzbWtQx1Kqr3" title="Change in Valuation Allowance">14.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zMkTDce0G3Di" title="Change in Valuation Allowance">15.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Effective tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20240101__20241231_zAxNr2oh5sQ1" title="Effective tax rate">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20230101__20231231_zUH8FsKfqPoi" title="Effective tax rate">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>



<p id="xdx_8AB_zacfAkZFaQl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 1pt; text-indent: 0pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At
December 31, the significant components of the deferred tax assets (liabilities) are summarized below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzHApVvRgZg5" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_ziywFiCgO7t" style="display: none">Schedule of deferred income tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zyUAvWW9pP9k" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zq1KrWC4RGy2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzbaL_zwsm03zDW9Tj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Net operating losses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,580,034</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,222,999</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzbaL_zvaVmaa4mRhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,328</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,743</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGzbaL_zR381ADtVbK2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzbaL_maDTANz3eX_zOXBo4tjngGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,607,531</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,224,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_zupMAopM0D5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred Tax Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz3eX_zLDnL26YDvrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,607,531</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,224,742</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz3eX_zZhxdOk5e1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zn4rTrr8Rww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">As
of December 31, 2024, the Company had federal net operating loss carryforwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards">17.2</span> million which may be carried forward
indefinitely, and state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IA_pn5n6" title="Operating loss carryforwards">12.6</span> million (Iowa) and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IL_pn5n6" title="Operating loss carryforwards">16.6</span> million (Illinois), respectively
which expire at various dates from 2040 through 2044. These net operating loss carryforwards may be used to offset future taxable income
and thereby reduce the Company&#8217;s U.S. federal income taxes. The net operating losses may be subject to limitation under Internal
Revenue Code Section 382 should there be a greater than <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_c20240101__20241231_pdd" title="Tax ownership percentage">50%</span> change in ownership as determined under the regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In assessing the realization of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation
allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets
will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In accordance with ASC 740, a valuation allowance
must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration
of available positive and negative evidence, which includes, among other things, the Company&#8217;s most recent results of operations
and expected future profitability. Based on the Company&#8217;s cumulative losses in recent years, a full valuation allowance against
the Company&#8217;s deferred tax assets as of December 31, 2024 and 2023 respectively has been established as Management believes that
the Company will not more likely than not realize the benefit of those deferred tax assets. Therefore, <span id="xdx_909_ecustom--TaxProvision_iI_do_c20241231_z47qkGu7gRhj" title="Tax provision"><span id="xdx_90F_ecustom--TaxProvision_iI_do_c20231231_zGC2nCmKuAB8" title="Tax provision">no</span></span> tax provision has been recorded
for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company complies with
the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits
claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize
the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination
by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant
uncertain tax positions requiring recognition under ASC 740-10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company is subject
to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or
any states in connection with income taxes. The Company&#8217;s tax years generally remain open to examination for all federal and state
income tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The
federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute
of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a
period within the statute of limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">The Company recognizes
interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. <span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zK7I2jDtHR54" title="Interest or penalties"><span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zdIvJaIhp8zl" title="Interest or penalties">No</span></span> interest or penalties
have been recorded for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On
March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic.
The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning
before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding
taxable years to generate a refund of previously paid income taxes. At present the Company does not expect that the NOL carryback provision
of the CARES Act will result in a material cash benefit to us.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zShBwFWPfXQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; <span id="xdx_82B_zsatqx1pURcg">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Prior Relationship of Cardio with Boustead
Securities, LLC</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">At the commencement of efforts to pursue what
ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the
&#8220;Placement Agent Agreement&#8221;), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities&#8221;). This
agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Under the terminated Placement Agent Agreement,
Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead
Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with
any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company&#8217;s
exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#8220;right of first refusal&#8221;).
Cardio has taken the position that due to Boustead Securities&#8217; failure to perform as contemplated by the Placement Agent Agreement,
these provisions purporting to provide future rights are null and void.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Boustead Securities responded to the termination
of the Placement Agent Agreement by disputing Legacy Cardio&#8217;s contention that it had not performed under the Placement Agent Agreement
because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included
a list of funds that they had supposedly contacted on Legacy Cardio&#8217;s behalf. While Boustead Securities&#8217; contention appears
to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions,
Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent
Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this
position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly
was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the
tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material
adverse impact on its financial condition.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">The Benchmark Company, LLC Right of First
Refusal</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company completed the business combination
on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark
Company, LLC (&#8220;Benchmark&#8221;) as its M&amp;A advisor. Upon closing of the business combination, Legacy Cardio assumed the contractual
engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment No. 1 Engagement Letter (the &#8220;Amendment
Engagement&#8221;). <span id="xdx_90C_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20250101__20250630__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCMember_zyDTS55FLA34" title="Business Combination, Reason for Business Combination">Pursuant to the Amendment Engagement, the parties agreed that the Company would pay Benchmark $230,000 at the closing
of the business combination and an additional $435,000 on October 25, 2023. Both of those payments have been made in full. In addition,
the Amendment Engagement provided that Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker,
lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings
through October 25, 2023.</span> Based on the right of first refusal, Benchmark alleges that it is owed damages because the Company entered into
the Yorkville Convertible Debenture Transaction without first offering Benchmark the right to serve as the lead or joint-lead placement
agent for the transaction. The Company is evaluating the claim. No legal proceedings have been instigated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Demand Letter and Potential Mootness
Fee Claim</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 25, 2022, a plaintiffs&#8217; securities
law firm sent a demand letter to the Company alleging that the Company&#8217;s Registration Statement on Form S-4 filed (the &#8220;S-4
Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May 31, 2022 omitted material information
with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures
in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration
Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various
comments of the SEC staff and otherwise updated its disclosure. In October 2022, the SEC completed its review and declared the S-4 registration
statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs&#8217; securities law firm contacted the Company&#8217;s
counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The
Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that
no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are
without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the
date of filing of this Annual Report on Form 10-K, no lawsuit has been filed against the Company by that firm. The firm has indicated
its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the
final outcome will not have a material adverse impact on its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Northland Securities, Inc.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In January 2024, following the Company&#8217;s
termination of its agreement with Yorkville and in connection with the Company&#8217;s recent at the market offering and/or its February
2024 private placement, a managing director of Northland Securities, Inc. (&#8220;Northland&#8221;) contacted the Company claiming the
right to be paid a fee of approximately $<span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p" title="Termination fee">150,000</span> pursuant to the agreement of March 1, 2023 between the Company and Northland regarding
the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland would not proceed
with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville Securities
Purchase Agreement and the subsequent financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company cannot preclude the possibility
that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require
significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Directors and Officers Insurance</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Company&#8217;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">The University of Iowa Research Foundation
Exclusive License Agreement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="background-color: white">The Company
has a worldwide exclusive license agreement with the University of Iowa Research Foundation (UIRF) relating to its patent and patent-pending
technology (the &#8220;Exclusive License Agreement&#8221;). Under the terms of the Exclusive License Agreement, the Company will have
to pay each of: (1) 1% of either the: (i) aggregate consideration (and trailing consideration, if any) for a liquidation event; or (ii)
pre-money valuation for an initial public offering, (the &#8220;Equity Rights&#8221;) (2) 2% of annual net sales, and (3) 15% of non-royalty
fees paid to licensee if it enters into one or more sublicensing agreements. Upon the Closing of the Business Combination, the Company
issued 3,639 (109,170 prior to the Reverse Stock Split) Shares of Common Stock to UIRF in accordance with the Equity Rights under the
Exclusive License Agreement. The Company has had minimal sales of $<span style="background-color: white">62,221</span> to date and has paid 2% or <span style="background-color: white">approximately $1,300</span> in total royalty fees to UIRF
under the exclusive license.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7PufVHyV2u" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>Note
14 &#8211; <span id="xdx_826_zSkZfOyEPvZ5">Commitments and <span style="letter-spacing: 0pt">Contingencies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Prior
Relationship of Cardio with Boustead Securities, <span style="letter-spacing: -0.25pt">LLC</span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At the commencement of efforts
to pursue what ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services
Agreement (the &#8220;Placement Agent Agreement&#8221;), dated April 12, 2021, with Boustead Securities, LLC (&#8220;Boustead Securities&#8221;).
This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Under the terminated Placement
Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during
which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent
Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the
Company&#8217;s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#8220;right of
first refusal&#8221;). Cardio has taken the position that due to Boustead Securities&#8217; failure to perform as contemplated by the
Placement Agent Agreement, these provisions purporting to provide future rights are null and void.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Boustead Securities responded
to the termination of the Placement Agent Agreement by disputing Legacy Cardio&#8217;s contention that it had not performed under the
Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response,
Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio&#8217;s behalf. While Boustead Securities&#8217;
contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such
contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination
of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly
disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential
party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so
at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome
will not have a material adverse impact on its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">The Benchmark Company, LLC Right of First Refusal</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">As noted in Note 1, the Company
completed the business combination on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13,
2022, Mana engaged The Benchmark Company, LLC (&#8220;Benchmark&#8221;) as its M&amp;A advisor. Upon closing of the business combination,
Legacy Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment
No. 1 Engagement Letter (the &#8220;Amendment Engagement&#8221;). <span id="xdx_904_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCRightOfFirstRefusalMember" title="Business combination reason, description">Pursuant to the Amendment Engagement, the parties agreed that the Company
would pay Benchmark $230,000 at the closing of the business combination and an additional $435,000 on October 25, 2023. Both of those
payments have been made in full. In addition, the Amendment Engagement provided that Benchmark has been granted a right of first refusal
to act as lead or joint-lead investment banker, lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future
public and private equity and debt offerings through October 25, 2023.</span> Based on the right of first refusal, Benchmark alleges that it
is owed damages because the Company entered into the Yorkville Convertible Debenture Transaction (see Note 11) without first offering
Benchmark the right to serve as the lead or joint-lead placement agent for the transaction. The Company is evaluating the claim. No legal
proceedings have been instigated.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Demand Letter and Potential Mootness Fee <span style="letter-spacing: 0pt">Claim</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On
June 25, 2022, a plaintiffs&#8217; securities law firm sent a demand letter to the Company alleging that the Company&#8217;s Registration
Statement on Form S-4 filed (the &#8220;S-4 Registration Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of
Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto,
the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022
and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2022,
the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023,
plaintiffs&#8217; securities law firm contacted the Company&#8217;s counsel asking who will be negotiating a mootness fee relating to
the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement,
as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required.
The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement
the S-4 Registration Statement under applicable laws. As of the date of filing of this Annual Report on Form 10-K, no lawsuit has been
filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution
cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Northland Securities, Inc.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In January 2024, following
the Company&#8217;s termination of its agreement with Yorkville and in connection with the Company&#8217;s recent at the market offering
and/or its February 2024 private placement, a managing director of Northland Securities, Inc. (&#8220;Northland&#8221;) contacted the
Company claiming the right to be paid a fee of approximately $<span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p0" title="Termination fee">150,000</span> pursuant to the agreement of March 1, 2023 between the Company and
Northland regarding the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland
would not proceed with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville
Securities Purchase Agreement and the subsequent financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company cannot preclude
the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could
potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing
on its business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Directors and Officers Insurance</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In connection with the Company&#8217;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline">Notice of Non-Compliance with Nasdaq
Listing Requirements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">On June 3, 2024,
Cardio Diagnostics Holdings, Inc. (the &#8220;Company&#8221;) received a letter (the &#8220;First Nasdaq Bid Price Letter&#8221;) from The
Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2),
because the minimum bid price of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) had closed below the minimum $<span id="xdx_906_ecustom--CommonStockBidPrice_c20240603_pdd" title="Common stock bid price">1.00</span> per
share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price
Requirement&#8221;). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, or until December 2, 2024, to regain compliance.&#160;On December 4, 2024 (the &#8220;Second Nasdaq Bid Price Letter&#8221;), Nasdaq
notified the Company that Nasdaq&#8217;s Staff has determined that the Company is eligible for an additional 180 calendar day period,
or until June 2, 2025, to regain compliance (the "Second Compliance Period&#8221;). The determination is based on the Company&#8217;s
meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing
on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company&#8217;s written notice of its intention
to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. If the Company chooses to
implement a reverse stock split, it must complete the split no later than ten business days prior to the end of the Second Compliance
Period in order to timely regain compliance. As of the date of this report the Common Stock has not regained compliance with the Minimum
Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">If we fail to
regain compliance with the minimum bid requirement within the cure period (or extended cure period) or if we fail to continue to meet
all applicable continued listing requirements for Nasdaq in the future, Nasdaq could delist our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zqPowa0bV8Od" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; <span id="xdx_82A_zenWtyxGfFVj">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated its June 30, 2025 condensed
consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Subsequent to
June 30, 2025, the Company sold </span><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250701__20250715_pd" title="Number of common stock sold">22,860</span> <span style="background-color: white">common shares for gross proceeds totaling </span>$<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250715_pp0p" title="Proceeds from common shares">103,912</span>
<span style="background-color: white">under the </span>At-the-Market&#160;Issuance <span style="background-color: white">Sales Agreement
as of the date of this report.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zY9AM4GHUcW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&#160;<b>Note 15 &#8211; <span id="xdx_825_z3skOqY1fdz">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company evaluated its December 31, 2024 consolidated financial statements
for subsequent events through the date the consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Sales of the Company&#8217;s Common Stock may
be made pursuant to the Sales Agreement up to an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250201__20250207__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zQpiMK8Ymcvg" title="Proceeds from issuance of common stock">9,476,508</span> under the Company&#8217;s Registration Statement on Form
S-3 filed on February 7, 2025 (File No. 333-284775), declared effective by the SEC on February 14, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline">Common
Stock Issued</span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of common stock issued">6,201,377</span> shares of Common
Stock for gross proceeds totaling $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock">3,511,042</span> under the At-the-Market Issuance Sales Agreement as of the date of this report.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zl60xhPDXMab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zYwROa3I9txl">Principles of Consolidation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio.&#160;All intercompany accounts and transactions have been
eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zDNg8b34BS05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zr8jCQLjXzu6">Principles
of <span style="letter-spacing: 0pt">Consolidation</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio. All intercompany
accounts and transactions have been <span style="letter-spacing: 0pt">eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zsYjArLjRd73" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_z9vhkwplhIGc">Use of Estimates in the Preparation of Financial
Statements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p>

<p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zLNQ2uKwnaZ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zS1mDvUJESNd">Use
of Estimates in the Preparation of Financial <span style="letter-spacing: 0pt">Statements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.25pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could
differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z91QthiMFmrj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_868_zCxlZUH7zj8b">Fair
Value Measurements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company adopted the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures, </i>which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields
on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
1 &#8211; quoted prices in active markets for identical assets or <span style="letter-spacing: 0pt">liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Level 3 &#8211; inputs that
are unobservable (for example cash flow modeling inputs based on <span style="letter-spacing: 0pt">assumptions)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level
3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for
the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains
and losses for the years ended December 31, 2024 and 2023.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span id="xdx_8B9_zQfF87metW1a" style="display: none">Schedule of fair value measurements</span><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Balance of derivative liabilities &#8211; beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued">9,192,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Converted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted">(3,786,452</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations">(5,406,220</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Balance of derivative liabilities &#8211; end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AC_zhAz12pT12J7" style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the Company&#8217;s
derivative instruments that are measured at fair value on a recurring basis as of December 31, 2024 and 2023, for each fair value hierarchy
level:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zhbf4g3brmh7" style="display: none">Schedule of fair value hierarchy level</span></td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left">December 31, 2024</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Level I</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Level II</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Level III</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%">December 31, 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level II</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level III</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zmS7sqkIBUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ConvertibleInstrumentsPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--ConvertibleInstrumentsPolicyTextBlock_zTtsCCOGiFb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zY6ocY8PrD24">Convertible <span style="letter-spacing: 0pt">Instruments</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company evaluates and accounts for conversion options
embedded in convertible instruments in accordance with ASC 815, <i>Derivatives and Hedging <span style="letter-spacing: 0pt">Activities.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Applicable GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes
in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument
would be considered a derivative <span style="letter-spacing: 0pt">instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for
convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded
in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term
of the related debt to their stated date of redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z7k6YLTKgNKd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_zGtXQv2t4pl4">Revenue <span style="letter-spacing: 0pt">Recognition</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company offers its products, Epi+Gen CHD and PrecisionCHD, via telemedicine providers, provider organizations such as concierge practices,
longevity clinics, and risk-bearing provider organizations, and employer organizations. The Company is continuing to expand its markets
and payment optionality, and therefore, other organization types not listed below may be added, and from time-to-time, there may be additional
payment options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt; letter-spacing: 0pt">Telemedicine</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For telemedicine, the telemedicine
provider collects payments from patients upon completion of eligibility screening and test order. Patients then send their samples to
the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation and shares test
reports with the ordering healthcare provider. Revenue is recognized upon invoicing the telemedicine providers. Telemedicine providers
are invoiced at the end of each month for all tests completed since prior invoicing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 7.2pt"></td><td style="width: 13.95pt"><span style="font-size: 7pt">&#8226;</span></td><td><span style="font-size: 10pt">Provider organizations</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For provider organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the provider organization type
and testing volume commitment. Upon ordering a test, a patient&#8217;s sample is sent to the lab for biomarker assessments. The Company
performs all quality control, analytical assessments and report generation and shares test reports with the ordering healthcare provider.
Revenue is recognized upon invoicing the provider organization. The provider organization is invoiced the agreed upon pricing at the end
of each month for all samples accepted or tests completed since prior invoicing.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt">&#8226;</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Employer organizations</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">For employer organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing volume commitment. Patient
samples are sent to the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation
and shares test reports with the ordering healthcare provider. Revenue is recognized upon invoicing the employer organization. The employer
organization is invoiced the agreed upon pricing once a heart disease fair is completed or all testing is completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for revenue
under Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;, using
the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect
adjustment to the opening balance of accumulated deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company determines the measurement of revenue and the timing
of revenue recognition utilizing the following core principles:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">1.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the contract with a customer;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">2.</span></td><td style="width: 92%"><span style="font-size: 10pt">Identifying
                                            the performance obligations in the contract;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">3.</span></td><td style="width: 92%"><span style="font-size: 10pt">Determining
                                            the transaction price;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">4.</span></td><td style="width: 92%"><span style="font-size: 10pt">Allocating
                                            the transaction price to the performance obligations in the contract; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5%"></td><td style="width: 3%"><span style="font-size: 10pt">5.</span></td><td style="width: 92%"><span style="font-size: 10pt">Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2mAdQMUlbFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_z8pJAsGR6pv6">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
Research and development costs charged to operations for the six months ended June 30, 2025 and 2024 were $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630_pp0p" title="Research and development expense">165,296</span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_pp0p" title="Research and development expense">18,120</span>, respectively,
and for the three months ended June 30, 2025 and 2024 were $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20250401__20250630_pp0p" title="Research and development expense">163,096</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_pp0p" title="Research and development expense">7,280</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBbGafxvms2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zlmVP2BBeDid">Research and Development</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Research and development
costs are expensed as incurred. Research and development costs charged to operations for the years ended December 31, 2024 and 2023 were
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_pp0p0" title="Research and development expense">29,125</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_pp0p0" title="Research and development expense">145,182</span>, <span style="letter-spacing: 0pt">respectively.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zl5jecmfnhNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_znG9dE2Sv5dk">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses advertising costs as incurred.
Advertising costs of $<span id="xdx_909_eus-gaap--AdvertisingExpense_c20250101__20250630_pp0p" title="Advertising costs">50,435</span> and $<span id="xdx_90B_eus-gaap--AdvertisingExpense_c20240101__20240630_pp0p" title="Advertising costs">92,181</span> were charged to operations for the six months ended June 30, 2025 and 2024, respectively, and
of $<span id="xdx_90E_eus-gaap--AdvertisingExpense_c20250401__20250630_pp0p" title="Advertising costs">8,615</span> and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20240401__20240630_pp0p" title="Advertising costs">57,779</span> for the three months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zTLvsQqGTBik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_862_zVf107pUc8y4">Advertising Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company expenses advertising costs as incurred. Advertising
costs of $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20240101__20241231_pp0p0" title="Advertising costs">182,446</span> and $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20230101__20231231_pp0p0" title="Advertising costs">158,514</span> were charged to operations for the years ended December 31, 2024 and 2023, respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCcjix61MV8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_z3nIqiyDjCoc">Cash and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are comprised of cash and
highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zjINRfafLPR1" title="Cash equivalents"><span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20241231_zkGi9ZqE3K91" title="Cash equivalents">no</span></span>t have any cash equivalents
as of June 30, 2025 and December 31, 2024. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions
are insured by the FDIC up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20250630_pp0p" title="FDIC Insured limit">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions or
the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of June 30, 2025 and December 31, 2024 was approximately $<span id="xdx_906_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20250630_zwLs3JyT22I9" title="Amount in excess of FDIC insurance">7.6</span> million and $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_z9zOPeI3oJ0k" title="Amount in excess of FDIC insurance">7.5</span> million, respectively. The Company has not experienced
any losses on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk
with regard to these deposits is not significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJs1obmk6Fvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_ztokn6a3ZbA7">Cash
and Cash Equivalents</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Cash and cash equivalents are comprised of
cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241231_z9AChdOqs003" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zfiDJ26ZzsVd" title="Cash equivalents">no</span></span>t have any
cash equivalents as of December 31, 2024 and 2023. Cash is maintained at a major financial institution. Accounts held at U.S. financial
institutions are insured by the FDIC up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20241231_pp0p0" title="FDIC Insured limit">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions
or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#8217;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of December 31, 2024 and 2023, was approximately $<span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_zkcfnxA4Tm9f" title="Amount in excess of FDIC insurance">7.5</span> million and $<span id="xdx_90C_ecustom--AmountInExcessOfFdicInsurance_iI_pp0p0_c20231231_zoEZpwfaSeCg" title="Amount in excess of FDIC insurance">933,523</span>, respectively. The Company has not experienced any losses
on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk with regard
to these deposits is not significant.</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_z0c9VQPN9uAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_865_zjLAHRTGqYll">Accounts Receivable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Accounts receivable is stated
at invoiced amount, net of an allowance for doubtful accounts and bear no interest. An allowance for losses is established through a provision
for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely.
The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based
on evaluation of the collectability of the accounts and prior loss experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyanY13R5eG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_869_zH37bjb3G8H5">Property and Equipment</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)">
<tr style="vertical-align: top; text-align: left">
  <td><span id="xdx_8B8_zSC0gG9hqifc" style="display: none">Schedule of estimated lives</span></td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="width: 10%">&#160;</td>
  <td style="width: 40%">Office and computer equipment</td>
  <td style="width: 50%"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives">5</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Furniture and fixtures</td>
  <td><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives">7 </span>years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Lab equipment</td>
  <td><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Leasehold improvements</td>
  <td><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<p id="xdx_8A9_z3ZZlPuyTwi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt">	</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>







<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITHZUwl7a7j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_zD5TjXIatc38">Intangible <span style="letter-spacing: 0pt">Assets</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Intangible
assets are acquired individually or as part of a group of assets, and are initially recorded at cost. The cost of a group of assets acquired
in a transaction is allocated to the individual assets based on their relative fair values. Intangible assets are carried at cost less
accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line
method over the period of estimated useful life. The estimated useful life of the Company&#8217;s intangible assets (Know-how license)
is <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zCfcXVkoKSEe" title="Useful life">5</span> years. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets
might be impaired.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PatentAndTrademarkCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_846_ecustom--PatentAndTrademarkCostsPolicyTextBlock_ze5KSEOQ1fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_864_zw0QsOV54Bfd">Patent Costs</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company accounts for patents in accordance
with ASC 350-30, <i>General Intangibles Other than Goodwill</i>. The Company capitalizes patent costs representing legal fees associated
with filing patent applications and amortize them on a straight-line basis. The Company evaluates its patents&#8217; estimated useful
life and begins amortizing the patents when they are brought to the market or otherwise commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.95pt 0 0"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhZLkfI2Wpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_z7dyBmZQQyqd">Impairment
of Long-Lived <span style="letter-spacing: 0pt">Assets</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In accordance with ASC 360-10-35,
the Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value
might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit
of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present.
If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an
impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows
exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the
asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally
measured by the present value of the estimated cash flows.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zZVaUfZxgLMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="letter-spacing: 0pt"><b><span style="text-decoration: underline"><span id="xdx_863_zxjoSA4ulfbc">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for leases
under ASC <i>842, &#8220;Leases&#8221;. </i>The Company determines if an arrangement is a lease or contains a lease at inception of the
arrangement. Operating lease liabilities are recognized based on the present value of the remaining lease payments, discounted using the
discount rate for the lease at the commencement date. As the rate implicit in the lease is not readily determinable for the operating
lease, the Company generally uses an incremental borrowing rate based on information available at the commencement date to determine the
present value of future lease payments. Operating lease right-of-use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right
to control the use of an identified asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease
payments arising from the lease. ROU assets are generally recognized based on the amount of the initial measurement of the lease liability.
Lease expense is recognized on a straight-line basis over the lease term. The Company elected to keep leases with an initial term of 12
months or less off the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">ROU assets are reviewed for
impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance
in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. ROU assets are tested for impairment individually
or as part of an asset group if the cash flows related to the ROU assets are not independent from the cash flows of other assets and liabilities.
An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable
cash flows are largely independent of the cash flows of other groups of assets and liabilities.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJw8YL6Iavr" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zlTdxiM7gO0f">Stock-Based <span style="letter-spacing: 0pt">Compensation</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for its stock-based
awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires
the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value
on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company
uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing
model requires the input of highly subjective assumptions including the expected stock price volatility of the Company&#8217;s common
stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption
related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of
the Company&#8217;s stock options and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zzzlr7ysTP2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86E_zfHg5iI9wen">Income
<span style="letter-spacing: 0pt">Taxes</span></span></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company accounts for income
taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">The Company applies the provisions
of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the
Company&#8217;s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold
and measurement attribute for the financial statement recognition and measurement of a tax position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5RenvA8vA4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86F_zXRvAiswOSKg">Recent Accounting <span style="letter-spacing: 0pt">Pronouncements</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">We have reviewed other recent
accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated
financial statements as a result of future adoption.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNWmy4gcCel4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zBAIFoxhFVF9">Segments</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the &#8220;management approach&#8221;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s
chief operating decision maker (&#8220;CODM&#8221;), who is our chief executive officer, for making operating decisions and assessing
performance as the source for determining the Company&#8217;s reportable segments. Management, including the CODM, reviews operating results
solely by monthly revenue and operating results of the Company and, as such, the Company has determined that the Company has one operating
segment (product testing) as defined by ASC Topic 280 &#8220;Segment Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One hundred percent of the Company&#8217;s revenues
are generated from products tests for major types of cardiovascular disease, and therefore the Company has one operating segment for financial
reporting purposes. The Company&#8217;s principal products are its Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD assesses the risk for
a coronary heart disease event, including a heart attack, in the next three years. PrecisionCHD aids in diagnosing and managing coronary
heart disease. The tests can be paid for by provider organizations, patients, and/or employers. Customers are generally charged for tests
utilized for the minimum committed test volume and the pricing can vary based on organization type, size and volume.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment information is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><span id="xdx_8BB_zGDkB6bUDBQc" style="display: none">Schedule of segment information</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#8203;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">December&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">&#160;&#160;&#160;&#160;Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,966,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,827,487</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,927</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">723,921</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">944,683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current segment assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,703,348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,790,782</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">621,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">672,861</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Right of use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">347,298</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">432,397</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">711,148</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">701,089</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total segment assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,396,547</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,615,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment operating results are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Revenue</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">8,415</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">23,798</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">8,415</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">23,798</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-left: 5.4pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">961,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$&#160;</td><td style="text-align: right">3,387,020</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,222</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,473</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396,277</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,558</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,957</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,153</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,488</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,958</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zPhum7r27AA7">(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,120</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,181</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,587</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,004</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,318,263</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,451,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right">(a)</td><td style="width: 5pt"></td><td id="xdx_F18_zwvtHqID77o7" style="text-align: justify">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Three Months
    Ended June 30</b></span>,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">360,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">451,245</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">89,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">209,744</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">165,905</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158,263</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">181,821</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,159</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,554</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101,723</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zcYwFIWWI5Gk">(a)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">136,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">129,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">163,096</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57,779</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,794</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,535</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,683,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,287,995</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_8A1_zCqMEGDYcDLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>







<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ReclassificationPolicyTextBlock', window );">Reclassification</a></td>
<td class="text"><p id="xdx_844_ecustom--ReclassificationPolicyTextBlock_zP6QjNBgUMaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zggMIIs6RLqk">Reclassification</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified
to conform with the current period presentation. On the condensed consolidated statements of changes in stockholders&#8217; equity and
cash flows, payment of placement agent fee has been combined with common stock and warrants issued for cash rather than being separated
out, to present net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZeQL7AYBsje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_zZ2vRqjKSUWj">Recent Accounting Pronouncements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily
through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income
tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is
effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the
impact that ASU 2023-09 will have on the condensed consolidated financial statements and its plan for adoption, including the adoption
date and transition method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Disaggregation of Income Statement Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the FASB issued ASU No. 2024-03,
&#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&#8221;, which requires disaggregated disclosure of income statement expenses for public business entities.
ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying
any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee
compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses
and, in annual reporting periods, an entity&#8217;s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods
beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance
can be applied prospectively with an option for retrospective application. Early adoption is also permitted. We are currently evaluating
the provisions of this ASU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed other recent accounting pronouncements
and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial
statements as a result of future adoption.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ConvertibleInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ConvertibleInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PatentAndTrademarkCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PatentAndTrademarkCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ReclassificationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ReclassificationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of fair value measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span id="xdx_8B9_zQfF87metW1a" style="display: none">Schedule of fair value measurements</span><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Balance of derivative liabilities &#8211; beginning of year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued">9,192,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Converted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted">(3,786,452</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations">(5,406,220</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Balance of derivative liabilities &#8211; end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value hierarchy level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"><span id="xdx_8B3_zhbf4g3brmh7" style="display: none">Schedule of fair value hierarchy level</span></td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold">&#160;</td>
    <td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left">December 31, 2024</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Level I</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Level II</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Level III</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%">December 31, 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level II</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Level III</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of estimated lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)">
<tr style="vertical-align: top; text-align: left">
  <td><span id="xdx_8B8_zSC0gG9hqifc" style="display: none">Schedule of estimated lives</span></td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="width: 10%">&#160;</td>
  <td style="width: 40%">Office and computer equipment</td>
  <td style="width: 50%"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives">5</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Furniture and fixtures</td>
  <td><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives">7 </span>years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Lab equipment</td>
  <td><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Leasehold improvements</td>
  <td><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives">7</span> years</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><span id="xdx_8BB_zGDkB6bUDBQc" style="display: none">Schedule of segment information</span></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#8203;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">December&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">&#160;&#160;&#160;&#160;Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,966,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,827,487</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,927</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">723,921</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">944,683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current segment assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,703,348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,790,782</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term segment assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">621,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">672,861</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Right of use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">347,298</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">432,397</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;&#160;&#160;&#160;Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1859">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,850</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Patent costs, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">711,148</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">701,089</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total segment assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,396,547</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,615,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reportable segment operating results are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Revenue</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">8,415</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues">23,798</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">8,415</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">23,798</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-left: 5.4pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">961,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$&#160;</td><td style="text-align: right">3,387,020</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,222</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,473</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396,277</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,558</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,957</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,153</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,488</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,958</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zPhum7r27AA7">(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,120</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,181</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,587</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,004</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,318,263</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,451,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right">(a)</td><td style="width: 5pt"></td><td id="xdx_F18_zwvtHqID77o7" style="text-align: justify">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Three Months
    Ended June 30</b></span>,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Product Test sales</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,475</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues">7,870</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Segment Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Payroll and related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">360,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">451,245</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Rent and facility expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">89,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Legal and professional expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">209,744</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Consulting and contractor expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">165,905</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">173,499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158,263</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">181,821</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Filing fees expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,159</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Transfer agent expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,554</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Software and web computing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101,723</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Board compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Investor relations expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">&#160;&#160;&#160;Other segment items <sup id="xdx_F41_zcYwFIWWI5Gk">(a)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">136,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">129,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">163,096</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Sales and marketing expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57,779</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,794</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;&#160;Interest expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,535</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Segment Net Income (Loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,683,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,287,995</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3PtcAmmUii" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B1_z5QIunZAOLc7" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zLPYcwrjG5a5" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zfasNjvyN0h1" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0d_maPPAENzAGD_zlMCiNM2Btx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Office and computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,264</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">21,032</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pp0d_maPPAENzAGD_z81QV8y8prOl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">113,069</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">96,818</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0d_maPPAENzAGD_zly4O7Rx1KBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,423</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170,423</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_pp0d_maPPAENzAGD_zxtNEfehQQ5b" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">502,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">502,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_msPPAENzAGD_zFVT9ph36CP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(193,008</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(117,567</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0d_mtPPAENzAGD_z7JAVJAVIeR" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;&#160;Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">621,903</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">672,861</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9ucvjRd8hu3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8B9_znhDxlo6b4V7" style="display: none">Schedule of property and equipment</span>&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zdXSpYKrX3z1" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_z1ilcE0qeHli" style="font-weight: bold; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAENzR6H_zrB4cuUYLmce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">21,032</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAENzR6H_zfe8qFobm03j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,099</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAENzR6H_z2p6OR1LHEXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAENzR6H_zS9oqLLg4fEe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,170</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzR6H_z5xKrDrjTYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(117,567</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,790</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzR6H_zDbXGo7IzTz" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">672,861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">571,873</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsomD40dIqVh" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B4_zxMHN2bNC403" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zUmaSQaoeAR2" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20241231_zO7pRLBhVoV1" style="text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzF5l_zeSLq06VrdX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Know-how license</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">80,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">80,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzF5l_zGrk2x9OgeV1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(80,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(74,667</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzF5l_zrlwhrfsnpc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,333</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zc7Lz3Rjebf7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8B1_zpyq01DYJWF5" style="display: none">Schedule of intangible assets</span>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20241231_z579V0nUMvE3" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_493_20231231_zrO7yEGUaRhh" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzDBb_zYnczfGzJWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Know-how license</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">80,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">80,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzDBb_zwhIMPpnEcFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(74,667</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,667</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzDBb_zYIW5sL1Yq8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of operating lease ROU assets and operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zNtVTQFk8b56" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B8_z9dBFAE1NiV7" style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_c20250630_pp0p">347,298</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20241231_pp0p">432,397</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_c20250630_pp0p">244,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_c20241231_pp0p">237,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20250630_pp0p">302,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20241231_pp0p">425,829</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zyoLYq3Im9od" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zADQOQFfRyfi" style="font-size: 8pt"><b style="display: none">Schedule of operating lease ROU assets and operating lease liabilities</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20241231_zzRQXmMCDVHc" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_496_20231231_zNUIrXNUIwwf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Operating Leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease right-of-use assets, net</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">432,397</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">575,227</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Current portion of operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">237,270</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">223,929</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zaTmatbFqhb4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;Operating lease liabilities, net of current portion</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">425,829</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">663,099</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments due</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zh5iJedn1Ybl" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B0_zFoADQYAUHi9" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_c20250630_zsMfhNSLQSG7" title="2025 (remaining period)">130,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_c20250630_zZtYySMFLxlj" title="2026">250,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_c20250630_zgMIsXczn6Wj" title="2027">102,060</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_c20250630_zSmbhAe3Hxsg" title="2028">93,555</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0d_c20250630_zSvUnCBTwA34" title="Total minimum lease payments">576,725</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0d_c20250630_zSvnyIqZocr2" title="Less: Imputed interest">30,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0d_c20250630_z4pHZmPwSRT6" title="Present value of lease liabilities">546,433</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify">At June 30, 2025, the Company had the following
future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 81%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 (remaining period)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_zaj12noFBQb1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025 (remaining period)">130,958</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zeObSfRyjXk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">250,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20250630_z2dvVzmsSMSh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">102,060</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20250630_z5J4jQGmjp7b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">93,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_zKF4aZT1pbmd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total minimum lease payments">576,725</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIsC8qEhRhJ9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left"><span id="xdx_8B5_zH4yu9sV5t5c" style="display: none">Schedule of future minimum payments due</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20241231_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="2025">260,611</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2026">250,152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2027">102,060</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028">93,555</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total lease payments</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="Total minimum lease payments">706,378</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Less: Imputed interest</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less: Imputed interest">43,279</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Present value of lease liabilities</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20241231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Present value of lease liabilities">663,099</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">At December 31, 2024, the Company had the
following future minimum payments due under the non-cancelable lease:</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; vertical-align: bottom"><span style="display: none"></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; width: 81%; font-size: 10pt; text-align: left">2025</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20241231_zjx6NL5YA5E2" style="width: 14%; font-size: 10pt; text-align: right" title="2025">260,611</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20241231_zf7NWr1e7xch" style="font-size: 10pt; text-align: right" title="2026">250,152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="vertical-align: bottom; font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20241231_z32BNlNXJWHc" style="font-size: 10pt; text-align: right" title="2027">102,060</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left">2028</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20241231_zhmSPc62i7bk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028">93,555</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20241231_zuWuaIY5glDk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total minimum lease payments">706,378</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of cash paid and related right-of-use operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zdGAm3EDPqp2" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b><span id="xdx_8BF_zqedldmhoi5e" style="display: none">Schedule of cash paid and related right-of-use operating lease</span>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20250101__20250630_z6GuhX4DZPOf" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101__20240630_zgOdrKJIYLF8" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six
    Months Ended June 30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zppCJdUm5oQ7" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">129,653</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">128,112</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ReductionOfLeaseLiabilitiesAbstract_i01B_zzKziDeNIiZ2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reduction of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">116,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">110,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zz2OC2XEo2sa" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 8pt; font-weight: bold"><span id="xdx_8B7_zBl1bXJOS7i3" style="display: none">Schedule of cash paid and related right-of-use operating lease</span><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20240101_20241231" style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_492_20230101_20231231" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Years Ended December 31,</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 8pt; font-weight: bold"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zoPcBHLVkZSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Cash paid for amounts included in the measurement of
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating cash flows from operating leases</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">257,508</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">21,352</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB_zGppz3XnLuKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Right-of-use lease assets obtained in the exchange for
    lease liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Operating leases</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">223,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">4,950</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and fully diluted income (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti dilutive earning per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSAErrEj71d4" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BE_zZlr10vxVjo5" style="display: none">Schedule of anti dilutive earning per share</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Six Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>June
    30,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2025</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 66%; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares">284,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares">284,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares">128,860</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares">126,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total shares excluded from calculation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_pd" title="Anti-dilutive shares">413,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_pd" title="Anti-dilutive shares">410,849</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU8iRieUQ1Ld" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt"><span id="xdx_8BF_zY0CDmiHV3Y1" style="display: none">Schedule of anti dilutive earning per share</span>&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Years
    Ended December 31,</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 11pt"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2024</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">2023</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Stock warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares">8,528,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares">7,854,620</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">3,594,202</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2,584,599</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">12,122,968</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">10,439,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlEGX7ePw5aj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b><span id="xdx_8BB_zoCoP1sUAfHb" style="display: none">Schedule of warrant activity</span>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>Warrants Outstanding</b></span></td><td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted<br/> <span style="font-family: Times New Roman, Times, Serif">Average
    Exercise Price</span></b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted Average
    Remaining<br/> <span style="font-family: Times New Roman, Times, Serif">Contractual Life (Years)</span></b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAOwo5LhTg8" title="Warrants outstanding, beginning">261,821</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4RmJlBL6xab" title="Weighted average exercise price outstanding, beginning">291.05</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfGOYs1XZSpj" title="Weighted average remaining contractual life">3.72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6O41bVQa3z3" title="Warrants granted">22,471</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pJZNJXcx5a" title="Weighted average exercise price, granted">53.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCtPHsMVVXa" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HzCSIdJjkd" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lbY9PQTUak" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life">3.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs5JHNeyCwB1" title="Warrants outstanding, beginning">284,292</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyLySFuh2kD9" title="Weighted average exercise price outstanding, beginning">272.26</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGh30EF5wXjf" style="text-align: center" title="Weighted average remaining contractual life">2.91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">No warrant activity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLG9eYUxUuj" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl2322">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-size: 12pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzAo7Rvt5Cr1" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdg2D1KlSxVh" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNyh32gO7w" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life">2.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDCwURogRB1f" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BB_zfAb4vTxNTi1" style="display: none">Schedule of warrant activity</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted
    Average Exercise<br/> Price</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>Weighted Average Remaining Contractual
                                                                                                Life</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2022</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1Q52kQUQ9E8" style="width: 12%; font-size: 10pt; text-align: right" title="Warrants outstanding, beginning">7,954,620</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlPPXLz3nx6j" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price outstanding, beginning">9.63</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfgzk0Lz0MC" title="Weighted average remaining contractual life">4.46</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants exercised</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised">(100,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised">3.90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,854,620</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9.70</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Uu5x01Apb1" title="Weighted average remaining contractual life">3.72</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Warrants granted</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants granted">674,146</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, granted">1.78</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Warrants outstanding at December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,528,766</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9.08</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUZLGB7r6SId" title="Weighted average remaining contractual life">2.91</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGs7bIHxLQp5" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;<span id="xdx_8BB_zNmBnhfV8Laa" style="display: none">Schedule of option activity</span></span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>Options
                                            Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"><b>Weighted
    Average Remaining Contractual Life (Years)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOJXjWefUdP" title="Options outstanding, beginning">86,153</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDg6ZJOPgxC" title="Weighted average exercise price outstanding, beginning">91.72</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUJy2BcWHZUh" title="Weighted average remaining contractual life">8.71</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted">40,604</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zKMj6jOusIGh" title="Weighted average exercise price, granted">62.14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV6AelXyevyi" title="Options expired or cancelled or forfeited">(200</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, expired or cancelled or forfeited">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTSo3OHqjMq8" title="Options outstanding, ending">126,557</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHjMIUWBPHih" title="Weighted average exercise price outstanding, ending">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTvB6JrirWF6" title="Weighted average remaining contractual life">8.65</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z4n1IAOkDHk7" title="Options vested and exercisable">126,307</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUtjp5Js5eOg" title="Weighted average exercise price vested and exercisable">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding at
    December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcngGi4b9jza" title="Options outstanding, beginning">119,807</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zspxLpDaEV05" title="Weighted average exercise price outstanding, beginning">82.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCUQxp6NVIoi" title="Weighted average remaining contractual life">8.12</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9neLI2AIYX3" title="Options granted">9,468</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDk7Orw9n4h9" title="Weighted average exercise price, granted">5.28</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    expired or cancelled or forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zklXVoomkO6e" title="Options expired or cancelled or forfeited">(415</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOV21jIxGlHe" title="Weighted average exercise price, expired or cancelled or forfeited">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zyNHHYaSm7y4" title="Options outstanding, ending">128,860</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqN8Dz80y938" title="Weighted average exercise price outstanding, ending">76.66</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zolOFlBzQHxi" title="Weighted average remaining contractual life">7.80</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqiYmyE5a4zf" title="Options vested and exercisable">128,860</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zx5LSZ3zbR6j" title="Weighted average exercise price vested and exercisable">76.66</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUvpU5j4hnfl" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zERaSKPPmM23" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Exercise&#160;Price</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Weighted
    Average Remaining Contractual Life (Years)</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; padding-left: 5.4pt">Options outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZWfO100pTS2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning">1,759,599</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6doTkcJ0gzf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">3.90</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zgUrtRCBeDtf" title="Weighted average remaining contractual life">9.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted">825,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted">1.26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Options outstanding at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,584,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJpBEP5l7EGi" title="Weighted average remaining contractual life">8.71</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Options granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted">1,322,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted">1.93</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options expired or cancelled or forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0UGR8MEMLBa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options expired or cancelled or forfeited">(312,628</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options expired or cancelled or forfeited">1.93</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Options outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,594,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2.74</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzkJV3s72Ima" title="Weighted average remaining contractual life">8.12</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Options vested and exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options vested and exercisable">3,594,202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price vested and exercisable">2.74</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureDerivativeLiabilityAbstract', window );"><strong>Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock', window );">Schedule of option liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zITA2HDXmO6g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8B8_ziN7h3ix7bzh" style="display: none">Schedule of option liability</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Year Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span title="Annual dividend yield"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zWoG2cQUPHx" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: left">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span title="Expected life (years)"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zpUNdjQGHwUj" title="Expected life (years)">1.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Risk-free interest rate"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk-free interest rate">4.89%</span></span> - <span title="Risk-free interest rate"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Risk-free interest rate">5.59%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&#160;<span title="Expected volatility"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility">164%</span></span> - <span title="Expected volatility"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Expected volatility">187%</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Exercise price">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price">0.19</span></span> - <span title="Exercise price">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price">3.53</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"><span title="Stock price">$<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Stock price">0.22</span></span> - <span title="Stock price">$<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Stock price">5.32</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureDerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureDerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about asset and liability measured at fair value under fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkeEgAemkND" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zKXVVQApLLp5" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Years Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 8pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">Statutory U.S. federal income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_zA4fmfMuoFHb" title="Statutory U.S. federal income tax rate">(21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20230101__20231231_zV4xHFQww82f" title="Statutory U.S. federal income tax rate">(21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">State income taxes, net of federal income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zauRogrk3fba" title="State income taxes, net of federal income tax benefit">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zfKHcofJHLd6" title="State income taxes, net of federal income tax benefit">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Tax effect of expenses that are not deductible for income tax purposes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Amortization of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20240101__20241231_z3xZ1eWVpzie" title="Amortization of debt discount">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20230101__20231231_zoe6I5d1lHn1" title="Amortization of debt discount">16.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Change in fair value of derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20240101__20241231_zlNbhtfeSNvi" title="Change in fair value of derivative liability">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20230101__20231231_zrlAUN2OWe24" title="Change in fair value of derivative liability">(13.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20240101__20241231_zpsgVc7bgcX8" title="Stock based compensation">6.3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20230101__20231231_zXWf4EPQ4pa5" title="Stock based compensation">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20240101__20241231_zQ4nh9fiUQOg" title="Other">(0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20230101__20231231_zXmcFRScXv2b" title="Other">(0.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231_zzbWtQx1Kqr3" title="Change in Valuation Allowance">14.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zMkTDce0G3Di" title="Change in Valuation Allowance">15.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Effective tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20240101__20241231_zAxNr2oh5sQ1" title="Effective tax rate">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20230101__20231231_zUH8FsKfqPoi" title="Effective tax rate">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzHApVvRgZg5" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_ziywFiCgO7t" style="display: none">Schedule of deferred income tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zyUAvWW9pP9k" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zq1KrWC4RGy2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzbaL_zwsm03zDW9Tj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Net operating losses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,580,034</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4,222,999</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzbaL_zvaVmaa4mRhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,328</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,743</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGzbaL_zR381ADtVbK2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzbaL_maDTANz3eX_zOXBo4tjngGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;&#160;&#160;&#160;Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,607,531</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,224,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_zupMAopM0D5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred Tax Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz3eX_zLDnL26YDvrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Valuation Allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,607,531</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,224,742</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz3eX_zZhxdOk5e1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span>&#160;&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">Schedule of subsequent events</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSubsequentEventsTextBlock_zpYZjRGCbUsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zt84fx4y3b03" style="display: none">Schedule of subsequent events</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>June 30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90C_ecustom--CommonStockShares_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z0P94rZzChEg" title="Common stock - shares">23,313,070</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(22,535,967</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">777,103</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Common stock - amount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--CommonStockValues_iI_pp0d_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbJTmqYMjgwe" title="Common stock - amount">233</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(225</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">22,893,962</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">225</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">22,894,187</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>March
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlCGB6q1lAo5" title="Common stock - shares">21,628,974</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zY3KZL3tZji5" title="Common stock - shares">(20,908,008</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z3wGkOP3IwR6" title="Common stock - shares">720,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zepu5rMhFSc4" title="Common stock - amount">216</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z9WxqGHZVmEe" title="Common stock - amount">(209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_zpisezl81zd6" title="Common stock - amount">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzlGBn0KrMzl" title="Additional paid-in capital">21,568,549</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zWf6HDeIzXd8" title="Additional paid-in capital">209</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z4DbKHEBQAm1" title="Additional paid-in capital">21,568,758</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90D_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares">45,944,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(44,412,571</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_903_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">1,531,468</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount">459</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">32,309,162</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">32,309,606</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>December
    31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Common stock - shares</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares">20,540,409</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_908_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares">(19,855,729</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares">684,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Common stock - amount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount">205</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount">(198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital">17,326,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital">198</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital">17,326,497</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock', window );">Schedule of loss per share and weighted average shares outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_zpY1nXvhMbNf" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 1)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8BD_z3AbVHx5SOmg" style="display: none">Schedule of loss per share and weighted average shares outstanding</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss attributable to common shareholders</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(5,451,579</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(5,451,579</span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares used to compute basic and
    diluted EPS</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zi6jVSxtJug4" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6xhhlWAEj0d" title="Weighted average common shares outstanding, fully diluted">21,842,422</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_90D_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(21,114,341</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted">728,081</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Loss per share - basic and diluted</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(0.25</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(7.24</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(7.49</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Three
    months ended June 30, 2024</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Stock
    Split</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 5.4pt">Loss attributable to common shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders">(1,287,995</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLoss_pp0d_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z608DvtVr0Z7" title="Loss attributable to common shareholders"><span style="-sec-ix-hidden: xdx2ixbrl1669">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders">(1,287,995</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Weighted average shares used to compute basic and diluted EPS</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, fully diluted">22,607,618</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted">(21,854,031</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"><span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted">753,587</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted">(0.06</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted">(1.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted">(1.71</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOWarrantsExercisableTextBlock', window );">Schedule of warrants exercisable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOWarrantsExercisableTextBlock_zCu6qmEE8mZ7" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 2)">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt"><b><span id="xdx_8B9_zja0MIWV8Jai" style="display: none">Schedule of warrants exercisable</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Six months ended June
    30, 2024</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As Previously</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>As</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Stock Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock options</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBUuIFKhWLKa" title="Common stock options">3,796,725</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock options">(3,670,168</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock options">126,557</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">Common stock warrants</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZGhGby5IEQ5" title="Common stock warrants">8,528,766</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock warrants">(8,244,474</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock warrants">284,292</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock', window );">Schedule of Warrants adjustment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_zcFHdmLaMnQh" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B4_zBHOArNBgO1e" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding
    at December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zR616nd98ZTb" title="Options outstanding, beginning">2,584,599</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3uOjSwFxC44" title="Weighted average exercise price outstanding, beginning">3.06</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z34kfibtIwt3" title="Options outstanding, beginning">(2,498,446</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zJ9SSnoR0Jw1" title="Weighted average exercise price outstanding, beginning">88.66</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zSPbPGFxKZEi" title="Options outstanding, beginning">86,153</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zD9reunbj5qa" title="Weighted average exercise price outstanding, beginning">91.72</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGG3WxZZQ3B8" title="Options granted">1,218,126</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price granted">2.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options granted">(1,177,522</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price granted">60.07</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options granted">40,604</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price granted">62.14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Options
    cancelled</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmBHkmjywouk" title="Options cancelled">(6,000</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price cancelled">2.11</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z7OmQWfrVAIk" title="Options cancelled">5,800</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price cancelled">61.19</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zIuYcGYDcfwl" title="Options cancelled">(200</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price cancelled">63.30</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5AzGUcG24hc" title="Options outstanding, ending">3,796,725</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6Yi8BjVYlTc" title="Weighted average exercise price outstanding, ending">2.74</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zYSYNxFVGy3b" title="Options outstanding, ending">(3,670,168</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z8ArIw1NhnG7" title="Weighted average exercise price outstanding, ending">79.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zWcFEIPqnHTb" title="Options outstanding, ending">126,557</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_z6RrXAsbfll8" title="Weighted average exercise price outstanding, ending">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and exercisable at June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_903_ecustom--OptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ywNTqRtCih" title="Options vested and exercisable">3,789,225</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zk6bfUxx9En8" title="Weighted average exercise price outstanding, Options vested and exercisable">2.74</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90F_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options vested and exercisable">(3,662,918</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable">79.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_907_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options vested and exercisable">126,307</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable">82.27</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock', window );">Schedule of Warrants adjustment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfWarrantsAdjustmentsTableTextBlock_zDY4zYb0EIta" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 4)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B8_zY1wGgYEBwWj" style="display: none">Schedule of Warrants adjustment</span></b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 12pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Previously Reported</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Impact of Reverse Stock
    Split</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>As Revised</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Weighted Average</b></span></td><td><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Exercise Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at December 31, 2023</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKWqwhAdgGcj" title="Warrants outstanding, beginning">7,854,620</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z17giM8MmWsb" title="Weighted average exercise price outstanding, beginning">9.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ztOJEeRGXhE8" title="Warrants outstanding, beginning">(7,592,799</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zqDQ5IDT7xq7" title="Weighted average exercise price outstanding, beginning">281.35</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zEnRBiZbAVni" title="Warrants outstanding, beginning">261,821</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zQ7RLz7NP28a" title="Weighted average exercise price outstanding, beginning">291.05</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhH8hkXhTj78" title="Warrants granted">674,146</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price, granted">1.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ziFj1lIFLsy6" title="Warrants granted">(651,675</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, granted">51.62</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zqFWAjVDb1Ub" title="Warrants granted">22,471</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, granted">53.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">&#160;&#160;Warrants cancelled</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFfFZymhHLTc" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zywJi7N2dSv1" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Warrants outstanding at June 30, 2024</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx1gjKa7t7ue" title="Warrants outstanding, ending">8,528,766</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zT9MFQyIVsw4" title="Weighted average exercise price outstanding, ending">9.08</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zZRxYowVaOJ7" title="Warrants outstanding, ending">(8,244,474</span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zLFD4vn8jDak" title="Weighted average exercise price outstanding, ending">263.18</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zpZZgfUzQoed" title="Warrants outstanding, ending">284,292</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zrYGbwhJwujk" title="Weighted average exercise price outstanding, ending">272.26</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOWarrantsExercisableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOWarrantsExercisableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger Agreement and Reverse Recapitalization (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="nump">$ 854,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_EarlyPaymentDiscount', window );">Early payment discount</a></td>
<td class="nump">$ 74,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PostmergerLiabilitiesBalance', window );">Post-merger liabilities balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Stock redeemed shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,465,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RedemptionPricePerShre', window );">Redemption price per shre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,310,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ReverseRecapitalizationShares', window );">Reverse recapitalization shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonSharesReversed', window );">Common shares reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,514,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Recapitalization cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,535,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdio_TwoInvestmentBankersMember', window );">Two investment bankers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Liabilities assumed payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 928,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cdio_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 928,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonSharesReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonSharesReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_EarlyPaymentDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_EarlyPaymentDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PostmergerLiabilitiesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PostmergerLiabilitiesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RedemptionPricePerShre">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RedemptionPricePerShre</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ReverseRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ReverseRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdio_TwoInvestmentBankersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdio_TwoInvestmentBankersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdio_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdio_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Balance of derivative liabilities - beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DerivativeLiabilitiesIssued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,192,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DerivativeLiabilitiesConverted', window );">Converted</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,786,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ChangeInFairValueRecognizedInOperations', window );">Change in fair value recognized in operations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,406,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Balance of derivative liabilities - end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ChangeInFairValueRecognizedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ChangeInFairValueRecognizedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DerivativeLiabilitiesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DerivativeLiabilitiesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DerivativeLiabilitiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DerivativeLiabilitiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cdio_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cdio_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cdio_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 163,096<span></span>
</td>
<td class="nump">$ 7,280<span></span>
</td>
<td class="nump">$ 165,296<span></span>
</td>
<td class="nump">$ 18,120<span></span>
</td>
<td class="nump">$ 29,125<span></span>
</td>
<td class="nump">$ 145,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">8,615<span></span>
</td>
<td class="nump">$ 57,779<span></span>
</td>
<td class="nump">50,435<span></span>
</td>
<td class="nump">$ 92,181<span></span>
</td>
<td class="nump">182,446<span></span>
</td>
<td class="nump">158,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC Insured limit</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_AmountInExcessOfFdicInsurance', window );">Amount in excess of FDIC insurance</a></td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 933,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_AmountInExcessOfFdicInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_AmountInExcessOfFdicInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Office and computer equipment</a></td>
<td class="nump">$ 29,264<span></span>
</td>
<td class="nump">$ 21,032<span></span>
</td>
<td class="nump">$ 17,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">113,069<span></span>
</td>
<td class="nump">96,818<span></span>
</td>
<td class="nump">76,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Lab equipment</a></td>
<td class="nump">170,423<span></span>
</td>
<td class="nump">170,423<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Leasehold improvements</a></td>
<td class="nump">502,155<span></span>
</td>
<td class="nump">502,155<span></span>
</td>
<td class="nump">482,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(193,008)<span></span>
</td>
<td class="num">(117,567)<span></span>
</td>
<td class="num">(3,790)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;&#160;Total</a></td>
<td class="nump">$ 621,903<span></span>
</td>
<td class="nump">$ 672,861<span></span>
</td>
<td class="nump">$ 571,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements</a></td>
<td class="nump">$ 502,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 502,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 502,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 37,785<span></span>
</td>
<td class="nump">$ 35,992<span></span>
</td>
<td class="nump">$ 75,441<span></span>
</td>
<td class="nump">$ 39,579<span></span>
</td>
<td class="nump">$ 113,777<span></span>
</td>
<td class="nump">$ 3,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Know-how license</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(74,667)<span></span>
</td>
<td class="num">(58,667)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="nump">$ 21,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patent Costs (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,148<span></span>
</td>
<td class="nump">$ 701,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,667<span></span>
</td>
<td class="nump">$ 58,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,022<span></span>
</td>
<td class="nump">69,877<span></span>
</td>
<td class="nump">$ 162,568<span></span>
</td>
<td class="nump">107,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,089<span></span>
</td>
<td class="nump">515,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 55,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,920<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expenses</a></td>
<td class="nump">$ 7,152<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 48,590<span></span>
</td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">&#160;&#160;&#160;Operating lease right-of-use assets, net</a></td>
<td class="nump">$ 347,298<span></span>
</td>
<td class="nump">$ 432,397<span></span>
</td>
<td class="nump">$ 575,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">&#160;&#160;&#160;Current portion of operating lease liabilities</a></td>
<td class="nump">244,182<span></span>
</td>
<td class="nump">237,270<span></span>
</td>
<td class="nump">223,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">&#160;&#160;&#160;Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 302,251<span></span>
</td>
<td class="nump">$ 425,829<span></span>
</td>
<td class="nump">$ 663,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025 (remaining period)</a></td>
<td class="nump">$ 130,958<span></span>
</td>
<td class="nump">$ 260,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">250,152<span></span>
</td>
<td class="nump">250,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">102,060<span></span>
</td>
<td class="nump">102,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">93,555<span></span>
</td>
<td class="nump">93,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">576,725<span></span>
</td>
<td class="nump">706,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">30,292<span></span>
</td>
<td class="nump">43,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 546,433<span></span>
</td>
<td class="nump">$ 663,099<span></span>
</td>
<td class="nump">$ 642,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 129,653<span></span>
</td>
<td class="nump">$ 128,112<span></span>
</td>
<td class="nump">$ 257,508<span></span>
</td>
<td class="nump">$ 21,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract', window );"><strong>Right-of-use lease assets obtained in the exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 116,666<span></span>
</td>
<td class="nump">$ 110,080<span></span>
</td>
<td class="nump">$ 223,929<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments', window );">Monthly rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_AnnuallyRentPayment', window );">Annually rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PremisesAllowance', window );">Premises allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ReimbursementReceivable', window );">Reimbursement receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 546,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,099<span></span>
</td>
<td class="nump">642,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense for operating leases</a></td>
<td class="nump">$ 68,939<span></span>
</td>
<td class="nump">$ 55,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,525<span></span>
</td>
<td class="nump">$ 91,398<span></span>
</td>
<td class="nump">$ 204,717<span></span>
</td>
<td class="nump">$ 138,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cdio_LeaseOneMember', window );">Lease one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cdio_LeaseTwoMember', window );">Lease two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=cdio_ChicagoMember', window );">Chicago [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=stpr_IA', window );">IOWA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_AnnuallyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_AnnuallyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PremisesAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PremisesAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ReimbursementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ReimbursementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481295/840-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cdio_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cdio_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cdio_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cdio_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=cdio_ChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=cdio_ChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Agreement Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 25, 2024</div></th>
<th class="th"><div>Oct. 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 25, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DisclosureFinanceAgreementPayableAbstract', window );"><strong>Finance Agreement Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FinancingAgreementEnteredIntoForPrepaidInsurance', window );">Financing agreement entered into for prepaid insurance</a></td>
<td class="nump">$ 383,455<span></span>
</td>
<td class="nump">$ 467,500<span></span>
</td>
<td class="nump">$ 383,455<span></span>
</td>
<td class="nump">$ 467,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 25,  2025<span></span>
</td>
<td class="text">Aug. 25,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FinanceAgreementPayable', window );">Finance agreement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,764<span></span>
</td>
<td class="nump">374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,315<span></span>
</td>
<td class="nump">$ 449,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DisclosureFinanceAgreementPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DisclosureFinanceAgreementPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FinanceAgreementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FinanceAgreementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FinancingAgreementEnteredIntoForPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FinancingAgreementEnteredIntoForPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">413,152<span></span>
</td>
<td class="nump">410,849<span></span>
</td>
<td class="nump">12,122,968<span></span>
</td>
<td class="nump">10,439,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockWarrantsMember', window );">Stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">8,528,766<span></span>
</td>
<td class="nump">7,854,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">128,860<span></span>
</td>
<td class="nump">126,557<span></span>
</td>
<td class="nump">3,594,202<span></span>
</td>
<td class="nump">2,584,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdio_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning</a></td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">261,821<span></span>
</td>
<td class="nump">261,821<span></span>
</td>
<td class="nump">7,954,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, beginning</a></td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 291.05<span></span>
</td>
<td class="nump">$ 291.05<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 4 months 28 days<span></span>
</td>
<td class="text">3 years 4 months 28 days<span></span>
</td>
<td class="text">2 years 10 months 28 days<span></span>
</td>
<td class="text">3 years 8 months 19 days<span></span>
</td>
<td class="text">4 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,471<span></span>
</td>
<td class="nump">674,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 53.40<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending</a></td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">284,292<span></span>
</td>
<td class="nump">261,821<span></span>
</td>
<td class="nump">7,954,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, ending</a></td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 291.05<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1) - Stock options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="nump">119,807<span></span>
</td>
<td class="nump">86,153<span></span>
</td>
<td class="nump">86,153<span></span>
</td>
<td class="nump">1,759,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning</a></td>
<td class="nump">$ 82.25<span></span>
</td>
<td class="nump">$ 91.72<span></span>
</td>
<td class="nump">$ 91.72<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 7 months 24 days<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">9 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">9,468<span></span>
</td>
<td class="nump">40,604<span></span>
</td>
<td class="nump">1,322,231<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 62.14<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired or cancelled or forfeited</a></td>
<td class="num">(415)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="num">(312,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options expired or cancelled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable</a></td>
<td class="nump">128,860<span></span>
</td>
<td class="nump">126,307<span></span>
</td>
<td class="nump">3,594,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price vested and exercisable</a></td>
<td class="nump">$ 76.66<span></span>
</td>
<td class="nump">$ 82.27<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired or cancelled or forfeited</a></td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">128,860<span></span>
</td>
<td class="nump">126,557<span></span>
</td>
<td class="nump">119,807<span></span>
</td>
<td class="nump">86,153<span></span>
</td>
<td class="nump">1,759,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending</a></td>
<td class="nump">$ 76.66<span></span>
</td>
<td class="nump">$ 82.27<span></span>
</td>
<td class="nump">$ 82.25<span></span>
</td>
<td class="nump">$ 91.72<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdio_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdio_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Jun. 23, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 23, 2022</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock , per value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 103,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of shares, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,622,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,568<span></span>
</td>
<td class="nump">52,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdio_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 23,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2035<span></span>
</td>
<td class="text">Jun. 30,  2034<span></span>
</td>
<td class="text">Sep. 30,  2034<span></span>
</td>
<td class="text">Nov. 14,  2034<span></span>
</td>
<td class="text">Dec. 31,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,944<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">74,744<span></span>
</td>
<td class="nump">15,728<span></span>
</td>
<td class="nump">13,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_StockOptionsValued', window );">Stock options valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,778<span></span>
</td>
<td class="nump">$ 16,625<span></span>
</td>
<td class="nump">$ 16,618<span></span>
</td>
<td class="nump">$ 4,125<span></span>
</td>
<td class="nump">$ 12,289<span></span>
</td>
<td class="nump">$ 1,035,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3908%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">4.44%<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">5.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161.00%<span></span>
</td>
<td class="nump">188.00%<span></span>
</td>
<td class="nump">184.00%<span></span>
</td>
<td class="nump">156.00%<span></span>
</td>
<td class="nump">146.00%<span></span>
</td>
<td class="nump">176.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="nump">$ 9.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,468<span></span>
</td>
<td class="nump">40,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,231<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,201,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,476,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,511,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember', window );">Sales Agreement [Member] | At The Market Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,511,040<span></span>
</td>
<td class="nump">$ 2,176,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentFee', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,256<span></span>
</td>
<td class="nump">$ 54,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,713<span></span>
</td>
<td class="nump">72,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272.26<span></span>
</td>
<td class="nump">$ 291.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_SevenAccreditedInvestorsMember', window );">7 accredited investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentFee', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalGroupLLCMember', window );">Altitude Capital Group LLC [Member] | Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentAgreementDescription', window );">Placement agent agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 112,353 shares of Common Stock at $1.78
per share through February 2, 2030 (the &#8220;Placement Agent Warrants&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_CraigHallumCapitalGroupLLCMember', window );">Craig Hallum Capital Group LLC [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,758,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,546,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentFee', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalMember', window );">Altitude Capital [Member] | Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PlacementAgentAgreementDescription', window );">Placement agent agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#8220;Altitude Capital&#8221;
or the &#8220;Placement Agent&#8221;). The Company&#8217;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 3,745 shares (112,353 prior to the Reverse
Stock Split) of Common Stock at $53.40 per share ($1.78 prior to the Reverse Stock Split) through February 2, 2030 (the &#8220;Placement
Agent Warrants&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdio_Plan2022Member', window );">Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,265,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdio_N2022PlanMember', window );">2022 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 23,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_StockOptionsValued', window );">Stock options valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,461,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of stock option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdio_N2022PlanMember', window );">2022 Plan [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdio_N2022PlanMember', window );">2022 Plan [Member] | Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdio_N2022PlanMember', window );">2022 Plan [Member] | Stock Option #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cdio_LegacyCardioMember', window );">Legacy Cardio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cdio_ManasFormerOfficersAndDirectorsMember', window );">Mana&#146;s former officers and directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_NumberOfSharesTransferred', window );">Number of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cdio_BoardOfDirectorsMember', window );">Board of directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=cdio_LegacyCardioStockholdersMember', window );">Legacy Cardio Stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Number of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,883,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 7 accredited investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock , per value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 7 accredited investors [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 7 accredited investors [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_NumberOfSharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_NumberOfSharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PlacementAgentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PlacementAgentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_StockOptionsValued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_StockOptionsValued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdio_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdio_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdio_AtTheMarketIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdio_AtTheMarketIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_SevenAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_SevenAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdio_PlacementAgentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdio_PlacementAgentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_CraigHallumCapitalGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_CraigHallumCapitalGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cdio_AltitudeCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdio_Plan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdio_Plan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdio_N2022PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdio_N2022PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdio_StockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdio_StockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cdio_LegacyCardioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cdio_LegacyCardioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cdio_ManasFormerOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cdio_ManasFormerOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cdio_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cdio_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cdio_LegacyCardioStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cdio_LegacyCardioStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ConversionPriceDeterminedPercentage', window );">Conversion price determined percentage</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Floor conversion price</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Decrease floor conversion price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdio_YorkvilleConvertibleDebentureMember', window );">Yorkville Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,622,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=cdio_YorkvilleConvertibleDebentureMember', window );">Yorkville Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PrincipalAmountReceived', window );">Principal amount received</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_DebtInstrumentOriginalIssueDiscount', window );">Debt Instrument original issue discount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Interest outstanding principal balance accrues percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingVariableInterestRate', window );">Interest outstanding principal balance remains uncured percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ConversionPriceDeterminedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ConversionPriceDeterminedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_DebtInstrumentOriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_DebtInstrumentOriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PrincipalAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PrincipalAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdio_YorkvilleConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdio_YorkvilleConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cdio_YorkvilleConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cdio_YorkvilleConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">164.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">5.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">187.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory U.S. federal income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal income tax benefit</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization', window );">Amortization of debt discount</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(13.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Other</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">&#160;&#160;&#160;&#160;Net operating losses</a></td>
<td class="nump">$ 5,580,034<span></span>
</td>
<td class="nump">$ 4,222,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">&#160;&#160;&#160;&#160;Other</a></td>
<td class="nump">2,328<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">&#160;&#160;&#160;&#160;Property and equipment</a></td>
<td class="nump">25,169<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">&#160;&#160;&#160;&#160;Total deferred tax assets</a></td>
<td class="nump">5,607,531<span></span>
</td>
<td class="nump">4,224,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(5,607,531)<span></span>
</td>
<td class="num">(4,224,742)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Tax ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_TaxProvision', window );">Tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=stpr_IA', window );">IOWA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=stpr_IL', window );">ILLINOIS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cdio_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_TaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_TaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cdio_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cdio_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockBidPrice', window );">Common stock bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdio_NorthlandSecuritiesMember', window );">Northland Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_TerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember', window );">The Benchmark Company LLC Right Of First Refusal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationReasonForBusinessCombination', window );">Business Combination, Reason for Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Amendment Engagement, the parties agreed that the Company
would pay Benchmark $230,000 at the closing of the business combination and an additional $435,000 on October 25, 2023. Both of those
payments have been made in full. In addition, the Amendment Engagement provided that Benchmark has been granted a right of first refusal
to act as lead or joint-lead investment banker, lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future
public and private equity and debt offerings through October 25, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCMember', window );">The Benchmark Company L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationReasonForBusinessCombination', window );">Business Combination, Reason for Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Amendment Engagement, the parties agreed that the Company would pay Benchmark $230,000 at the closing
of the business combination and an additional $435,000 on October 25, 2023. Both of those payments have been made in full. In addition,
the Amendment Engagement provided that Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker,
lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings
through October 25, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationReasonForBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationReasonForBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdio_NorthlandSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdio_NorthlandSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdio_TheBenchmarkCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common shares</a></td>
<td class="nump">$ 103,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="nump">22,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,476,508<span></span>
</td>
<td class="nump">$ 3,511,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,201,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">$ 35,794,778<span></span>
</td>
<td class="nump">$ 32,309,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,326,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockShares', window );">Common stock - shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,944,039<span></span>
</td>
<td class="nump">23,313,070<span></span>
</td>
<td class="nump">21,628,974<span></span>
</td>
<td class="nump">20,540,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockValues', window );">Common stock - amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,309,162<span></span>
</td>
<td class="nump">$ 22,893,962<span></span>
</td>
<td class="nump">$ 21,568,549<span></span>
</td>
<td class="nump">$ 17,326,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember', window );">Impact of Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockShares', window );">Common stock - shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,412,571)<span></span>
</td>
<td class="num">(22,535,967)<span></span>
</td>
<td class="num">(20,908,008)<span></span>
</td>
<td class="num">(19,855,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockValues', window );">Common stock - amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (444)<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_AsRevisedMember', window );">As Revised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockShares', window );">Common stock - shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,531,468<span></span>
</td>
<td class="nump">777,103<span></span>
</td>
<td class="nump">720,966<span></span>
</td>
<td class="nump">684,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockValues', window );">Common stock - amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,309,606<span></span>
</td>
<td class="nump">$ 22,894,187<span></span>
</td>
<td class="nump">$ 21,568,758<span></span>
</td>
<td class="nump">$ 17,326,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_AsRevisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_AsRevisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common shareholders</a></td>
<td class="num">$ (1,683,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,318,263)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (8,383,453)<span></span>
</td>
<td class="num">$ (8,376,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,607,618<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,842,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingFullyDiluted', window );">Weighted average common shares outstanding, fully diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,607,618<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,842,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember', window );">Impact of Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,854,031)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,114,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingFullyDiluted', window );">Weighted average common shares outstanding, fully diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,854,031)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,114,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.65)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7.24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.65)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7.24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_AsRevisedMember', window );">As Revised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">753,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">728,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageCommonSharesOutstandingFullyDiluted', window );">Weighted average common shares outstanding, fully diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">753,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">728,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (7.49)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WeightedAverageCommonSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WeightedAverageCommonSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WeightedAverageCommonSharesOutstandingFullyDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WeightedAverageCommonSharesOutstandingFullyDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_AsRevisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_AsRevisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details 2)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockOptions', window );">Common stock options</a></td>
<td class="nump">3,796,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockWarrants', window );">Common stock warrants</a></td>
<td class="nump">8,528,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember', window );">Impact of Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockOptions', window );">Common stock options</a></td>
<td class="num">(3,670,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockWarrants', window );">Common stock warrants</a></td>
<td class="num">(8,244,474)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_AsRevisedMember', window );">As Revised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockOptions', window );">Common stock options</a></td>
<td class="nump">126,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_CommonStockWarrants', window );">Common stock warrants</a></td>
<td class="nump">284,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_AsRevisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_AsRevisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details 3)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, beginning | shares</a></td>
<td class="nump">2,584,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 3.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="nump">1,218,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod', window );">Options cancelled | shares</a></td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled | $ / shares</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, ending | shares</a></td>
<td class="nump">3,796,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_OptionsVestedAndExercisable', window );">Options vested and exercisable | shares</a></td>
<td class="nump">3,789,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable', window );">Weighted average exercise price outstanding, Options vested and exercisable | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember', window );">Impact of Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, beginning | shares</a></td>
<td class="num">(2,498,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 88.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="num">(1,177,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td>
<td class="nump">$ 60.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod', window );">Options cancelled | shares</a></td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled | $ / shares</a></td>
<td class="nump">$ 61.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, ending | shares</a></td>
<td class="num">(3,670,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 79.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_OptionsVestedAndExercisable', window );">Options vested and exercisable | shares</a></td>
<td class="num">(3,662,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable', window );">Weighted average exercise price outstanding, Options vested and exercisable | $ / shares</a></td>
<td class="nump">$ 79.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_AsRevisedMember', window );">As Revised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, beginning | shares</a></td>
<td class="nump">86,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 91.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="nump">40,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td>
<td class="nump">$ 62.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod', window );">Options cancelled | shares</a></td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled | $ / shares</a></td>
<td class="nump">$ 63.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Options outstanding, ending | shares</a></td>
<td class="nump">126,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 82.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_OptionsVestedAndExercisable', window );">Options vested and exercisable | shares</a></td>
<td class="nump">126,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable', window );">Weighted average exercise price outstanding, Options vested and exercisable | $ / shares</a></td>
<td class="nump">$ 82.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_OptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_OptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_AsRevisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_AsRevisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details 4)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, beginning | shares</a></td>
<td class="nump">7,854,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 9.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted', window );">Warrants granted | shares</a></td>
<td class="nump">674,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 1.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsCancelled', window );">Warrants cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceCancelled', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, ending | shares</a></td>
<td class="nump">8,528,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 9.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember', window );">Impact of Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, beginning | shares</a></td>
<td class="num">(7,592,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 281.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted', window );">Warrants granted | shares</a></td>
<td class="num">(651,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 51.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsCancelled', window );">Warrants cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceCancelled', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, ending | shares</a></td>
<td class="num">(8,244,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 263.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=cdio_AsRevisedMember', window );">As Revised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, beginning | shares</a></td>
<td class="nump">261,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 291.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted', window );">Warrants granted | shares</a></td>
<td class="nump">22,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 53.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WarrantsCancelled', window );">Warrants cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_WeightedAverageExercisePriceCancelled', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ClassOfWarrantOrRightOutstandings', window );">Warrants outstanding, ending | shares</a></td>
<td class="nump">284,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="nump">$ 272.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ClassOfWarrantOrRightOutstandings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ClassOfWarrantOrRightOutstandings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_WeightedAverageExercisePriceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_WeightedAverageExercisePriceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_ImpactOfReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=cdio_AsRevisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=cdio_AsRevisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Current Segment assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">&#160;&#160;&#160;&#160;Cash</a></td>
<td class="nump">$ 7,966,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,966,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,827,487<span></span>
</td>
<td class="nump">$ 1,283,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">723,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">723,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">944,683<span></span>
</td>
<td class="nump">1,477,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current segment assets</a></td>
<td class="nump">8,703,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,703,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,790,782<span></span>
</td>
<td class="nump">2,765,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term segment assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;&#160;&#160;&#160;Property and equipment, net</a></td>
<td class="nump">621,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">621,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">672,861<span></span>
</td>
<td class="nump">571,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">&#160;&#160;&#160;&#160;Right of use assets, net</a></td>
<td class="nump">347,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">347,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">432,397<span></span>
</td>
<td class="nump">575,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total segment assets</a></td>
<td class="nump">10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,615,312<span></span>
</td>
<td class="nump">4,462,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">7,475<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34,890<span></span>
</td>
<td class="nump">17,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Segment Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">&#160;&#160;&#160;Research and development expense</a></td>
<td class="nump">163,096<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,125<span></span>
</td>
<td class="nump">145,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">&#160;&#160;&#160;Sales and marketing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,446<span></span>
</td>
<td class="nump">158,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">&#160;&#160;&#160;Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,738<span></span>
</td>
<td class="nump">19,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">&#160;&#160;&#160;Interest expense, net</a></td>
<td class="nump">4,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,817<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,640<span></span>
</td>
<td class="nump">6,735,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Segment Net Income (Loss)</a></td>
<td class="num">(1,683,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,318,263)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,383,453)<span></span>
</td>
<td class="num">$ (8,376,834)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cdio_ReportableSegmentsMember', window );">Reportable segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Current Segment assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">&#160;&#160;&#160;&#160;Cash</a></td>
<td class="nump">7,966,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,966,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,827,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">&#160;&#160;&#160;&#160;Accounts receivable</a></td>
<td class="nump">12,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">723,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">723,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">944,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current segment assets</a></td>
<td class="nump">8,703,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,703,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,790,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term segment assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;&#160;&#160;&#160;Property and equipment, net</a></td>
<td class="nump">621,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">621,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">672,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">&#160;&#160;&#160;&#160;Right of use assets, net</a></td>
<td class="nump">347,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">347,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">432,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">&#160;&#160;&#160;&#160;Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">&#160;&#160;&#160;&#160;Deposits</a></td>
<td class="nump">12,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">&#160;&#160;&#160;&#160;Patent costs, net</a></td>
<td class="nump">711,148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">711,148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">701,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total segment assets</a></td>
<td class="nump">10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,396,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,615,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">7,475<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Segment Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_PayrollAndRelatedCosts', window );">&#160;&#160;&#160;Payroll and related costs</a></td>
<td class="nump">360,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">451,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">961,517<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,387,020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_RentAndFacilityExpense', window );">&#160;&#160;&#160;Rent and facility expense</a></td>
<td class="nump">89,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">59,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">155,854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">101,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">&#160;&#160;&#160;Legal and professional expense</a></td>
<td class="nump">209,744<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">94,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">511,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">444,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_ConsultingAndContractorExpense', window );">&#160;&#160;&#160;Consulting and contractor expense</a></td>
<td class="nump">165,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">173,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">326,707<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">396,277<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_InsuranceExpense', window );">&#160;&#160;&#160;Insurance expense</a></td>
<td class="nump">158,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">314,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">363,558<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_FilingFeesExpense', window );">&#160;&#160;&#160;Filing fees expense</a></td>
<td class="nump">22,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_TransferAgentExpense', window );">&#160;&#160;&#160;Transfer agent expense</a></td>
<td class="nump">5,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_SoftwareAndWebComputingExpense', window );">&#160;&#160;&#160;Software and web computing expense</a></td>
<td class="nump">101,723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,314<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_BoardCompensationExpense', window );">&#160;&#160;&#160;Board compensation expense</a></td>
<td class="nump">49,778<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49,958<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99,390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99,958<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_InvestorRelationsExpense', window );">&#160;&#160;&#160;Investor relations expense</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,429<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdio_OtherSegmentItems', window );">&#160;&#160;&#160;Other segment items</a></td>
<td class="nump">136,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">129,456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">233,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">249,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">&#160;&#160;&#160;Research and development expense</a></td>
<td class="nump">163,096<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">&#160;&#160;&#160;Sales and marketing expense</a></td>
<td class="nump">211,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">57,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">252,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">&#160;&#160;&#160;Amortization expense</a></td>
<td class="nump">8,485<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">53,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">&#160;&#160;&#160;Interest expense, net</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total Segment Net Income (Loss)</a></td>
<td class="num">(1,683,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,287,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,318,263)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,451,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cdio_ReportableSegmentsMember', window );">Reportable segments [Member] | Product Test Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term segment assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,475<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_BoardCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_BoardCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_ConsultingAndContractorExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_ConsultingAndContractorExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_FilingFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_FilingFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_InvestorRelationsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_InvestorRelationsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_OtherSegmentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_OtherSegmentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_PayrollAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_PayrollAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_RentAndFacilityExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_RentAndFacilityExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_SoftwareAndWebComputingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_SoftwareAndWebComputingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdio_TransferAgentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdio_TransferAgentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cdio_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cdio_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdio_ProductTestSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdio_ProductTestSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-5
and&#160;1-for-40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,740,269<span></span>
</td>
<td class="nump">1,738,683<span></span>
</td>
<td class="nump">1,531,468<span></span>
</td>
<td class="nump">20,540,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>233</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Merger Agreement and Reverse Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/MergerAgreementAndReverseRecapitalization</Role>
      <ShortName>Merger Agreement and Reverse Recapitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Patent Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PatentCosts</Role>
      <ShortName>Patent Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Finance Agreement Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/FinanceAgreementPayable</Role>
      <ShortName>Finance Agreement Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/EarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cdio.ai/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/IntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/OperatingLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/EarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/EarningsLossPerCommonShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/DerivativeLiability</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Subsequent Events (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SubsequentEventsTables</Role>
      <ShortName>Subsequent Events (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cdio.ai/role/SubsequentEvents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative</Role>
      <ShortName>Merger Agreement and Reverse Recapitalization (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/MergerAgreementAndReverseRecapitalization</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/PropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/PropertyAndEquipmentTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/IntangibleAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Patent Costs (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/PatentCostsDetailsNarrative</Role>
      <ShortName>Patent Costs (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/PatentCosts</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OperatingLeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Operating Leases (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeasesDetails1</Role>
      <ShortName>Operating Leases (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OperatingLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Operating Leases (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeasesDetails2</Role>
      <ShortName>Operating Leases (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OperatingLeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OperatingLeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Finance Agreement Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative</Role>
      <ShortName>Finance Agreement Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/FinanceAgreementPayable</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Earnings (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/EarningsLossPerCommonShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/EarningsLossPerCommonShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/StockholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/ConvertibleNotesPayable</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/DerivativeLiabilityDetails</Role>
      <ShortName>Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/DerivativeLiabilityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/IncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/IncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/CommitmentsAndContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SubsequentEventsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Organization and Basis of Presentation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1</Role>
      <ShortName>Organization and Basis of Presentation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Organization and Basis of Presentation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2</Role>
      <ShortName>Organization and Basis of Presentation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Organization and Basis of Presentation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3</Role>
      <ShortName>Organization and Basis of Presentation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Organization and Basis of Presentation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4</Role>
      <ShortName>Organization and Basis of Presentation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cdio_posam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cdio.ai/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cdio-20250630.xsd</File>
    <File>cdio-20250630_cal.xml</File>
    <File>cdio-20250630_def.xml</File>
    <File>cdio-20250630_lab.xml</File>
    <File>cdio-20250630_pre.xml</File>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="cdio_posam.htm">cdio_posam.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="968">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cdio_posam.htm": {
   "nsprefix": "cdio",
   "nsuri": "http://cdio.ai/20250630",
   "dts": {
    "schema": {
     "local": [
      "cdio-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cdio-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdio-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdio-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdio-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cdio_posam.htm"
     ]
    }
   },
   "keyStandard": 250,
   "keyCustom": 92,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 31,
   "hidden": {
    "total": 121,
    "http://cdio.ai/20250630": 53,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://fasb.org/us-gaap/2024": 65
   },
   "contextCount": 233,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 550,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 968,
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://cdio.ai/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "cdio:OriginalIssueDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "cdio:OriginalIssueDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentation",
     "longName": "999008 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cdio.ai/role/MergerAgreementAndReverseRecapitalization",
     "longName": "999009 - Disclosure - Merger Agreement and Reverse Recapitalization",
     "shortName": "Merger Agreement and Reverse Recapitalization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "cdio:MergerAgreementAndReverseRecapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "cdio:MergerAgreementAndReverseRecapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cdio.ai/role/PropertyAndEquipment",
     "longName": "999011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cdio.ai/role/IntangibleAssets",
     "longName": "999012 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cdio.ai/role/PatentCosts",
     "longName": "999013 - Disclosure - Patent Costs",
     "shortName": "Patent Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:PatentAndTrademarkCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:PatentAndTrademarkCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cdio.ai/role/OperatingLeases",
     "longName": "999014 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cdio.ai/role/FinanceAgreementPayable",
     "longName": "999015 - Disclosure - Finance Agreement Payable",
     "shortName": "Finance Agreement Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:FinanceAgreementPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:FinanceAgreementPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cdio.ai/role/EarningsLossPerCommonShare",
     "longName": "999016 - Disclosure - Earnings (Loss) Per Common Share",
     "shortName": "Earnings (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cdio.ai/role/StockholdersEquity",
     "longName": "999017 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cdio.ai/role/ConvertibleNotesPayable",
     "longName": "999018 - Disclosure - Convertible Notes Payable",
     "shortName": "Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cdio.ai/role/DerivativeLiability",
     "longName": "999019 - Disclosure - Derivative Liability",
     "shortName": "Derivative Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cdio.ai/role/IncomeTaxes",
     "longName": "999020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cdio.ai/role/CommitmentsAndContingencies",
     "longName": "999021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cdio.ai/role/SubsequentEvents",
     "longName": "999022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999024 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cdio.ai/role/PropertyAndEquipmentTables",
     "longName": "999025 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cdio.ai/role/IntangibleAssetsTables",
     "longName": "999026 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cdio.ai/role/OperatingLeasesTables",
     "longName": "999027 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cdio.ai/role/EarningsLossPerCommonShareTables",
     "longName": "999028 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cdio.ai/role/StockholdersEquityTables",
     "longName": "999029 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cdio.ai/role/DerivativeLiabilityTables",
     "longName": "999030 - Disclosure - Derivative Liability (Tables)",
     "shortName": "Derivative Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cdio.ai/role/IncomeTaxesTables",
     "longName": "999031 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cdio.ai/role/SubsequentEventsTables",
     "longName": "999032 - Disclosure - Subsequent Events (Tables)",
     "shortName": "Subsequent Events (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative",
     "longName": "999033 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)",
     "shortName": "Merger Agreement and Reverse Recapitalization (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-03-012023-03-22",
      "name": "us-gaap:LiabilitiesAssumed1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "cdio:MergerAgreementAndReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-03-012023-03-22",
      "name": "us-gaap:LiabilitiesAssumed1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "cdio:MergerAgreementAndReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "999034 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "cdio:DerivativeLiabilitiesIssued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "cdio:DerivativeLiabilitiesIssued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1",
     "longName": "999035 - Disclosure - Summary of Significant Accounting Policies (Details 1)",
     "shortName": "Summary of Significant Accounting Policies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2",
     "longName": "999036 - Disclosure - Summary of Significant Accounting Policies (Details 2)",
     "shortName": "Summary of Significant Accounting Policies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_OfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_OfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999037 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://cdio.ai/role/PropertyAndEquipmentDetails",
     "longName": "999038 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999039 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LeaseholdImprovementsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LeaseholdImprovementsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://cdio.ai/role/IntangibleAssetsDetails",
     "longName": "999040 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cdio.ai/role/IntangibleAssetsDetailsNarrative",
     "longName": "999041 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cdio.ai/role/PatentCostsDetailsNarrative",
     "longName": "999042 - Disclosure - Patent Costs (Details Narrative)",
     "shortName": "Patent Costs (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cdio:PatentAndTrademarkCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cdio:PatentAndTrademarkCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cdio.ai/role/OperatingLeasesDetails",
     "longName": "999043 - Disclosure - Operating Leases (Details)",
     "shortName": "Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://cdio.ai/role/OperatingLeasesDetails1",
     "longName": "999044 - Disclosure - Operating Leases (Details 1)",
     "shortName": "Operating Leases (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cdio.ai/role/OperatingLeasesDetails2",
     "longName": "999045 - Disclosure - Operating Leases (Details 2)",
     "shortName": "Operating Leases (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cdio.ai/role/OperatingLeasesDetailsNarrative",
     "longName": "999046 - Disclosure - Operating Leases (Details Narrative)",
     "shortName": "Operating Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-08-022023-11-30",
      "name": "us-gaap:SaleLeasebackTransactionMonthlyRentalPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-022023-11-30",
      "name": "us-gaap:SaleLeasebackTransactionMonthlyRentalPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative",
     "longName": "999047 - Disclosure - Finance Agreement Payable (Details Narrative)",
     "shortName": "Finance Agreement Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-10-25",
      "name": "cdio:FinancingAgreementEnteredIntoForPrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cdio:FinanceAgreementPayableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-10-25",
      "name": "cdio:FinancingAgreementEnteredIntoForPrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "cdio:FinanceAgreementPayableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cdio.ai/role/EarningsLossPerCommonShareDetails",
     "longName": "999048 - Disclosure - Earnings (Loss) Per Common Share (Details)",
     "shortName": "Earnings (Loss) Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cdio.ai/role/StockholdersEquityDetails",
     "longName": "999049 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_us-gaap_WarrantMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://cdio.ai/role/StockholdersEquityDetails1",
     "longName": "999050 - Disclosure - Stockholders' Equity (Details 1)",
     "shortName": "Stockholders' Equity (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_StockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_custom_StockOptionsMember51358328",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
     "longName": "999051 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-03-08",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2019-10-01",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative",
     "longName": "999052 - Disclosure - Convertible Notes Payable (Details Narrative)",
     "shortName": "Convertible Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-03-08",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-08",
      "name": "cdio:ConversionPriceDeterminedPercentage",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://cdio.ai/role/DerivativeLiabilityDetails",
     "longName": "999053 - Disclosure - Derivative Liability (Details)",
     "shortName": "Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://cdio.ai/role/IncomeTaxesDetails",
     "longName": "999054 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://cdio.ai/role/IncomeTaxesDetails1",
     "longName": "999055 - Disclosure - Income Taxes (Details 1)",
     "shortName": "Income Taxes (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cdio.ai/role/IncomeTaxesDetailsNarrative",
     "longName": "999056 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationDeductions",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationDeductions",
      "unitRef": "Ratio",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999057 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-03",
      "name": "cdio:CommonStockBidPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-03",
      "name": "cdio:CommonStockBidPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cdio.ai/role/SubsequentEventsDetailsNarrative",
     "longName": "999058 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-07-15",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-07-15",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
     "longName": "999059 - Disclosure - Organization and Basis of Presentation (Details)",
     "shortName": "Organization and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:AdditionalPaidInCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:CommonStockShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsequentEventsTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
     "longName": "999060 - Disclosure - Organization and Basis of Presentation (Details 1)",
     "shortName": "Organization and Basis of Presentation (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
     "longName": "999061 - Disclosure - Organization and Basis of Presentation (Details 2)",
     "shortName": "Organization and Basis of Presentation (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:CommonStockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOWarrantsExercisableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:CommonStockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOWarrantsExercisableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
     "longName": "999062 - Disclosure - Organization and Basis of Presentation (Details 3)",
     "shortName": "Organization and Basis of Presentation (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4",
     "longName": "999063 - Disclosure - Organization and Basis of Presentation (Details 4)",
     "shortName": "Organization and Basis of Presentation (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:ClassOfWarrantOrRightOutstandings",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfWarrantsAdjustmentsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember",
      "name": "cdio:ClassOfWarrantOrRightOutstandings",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdio:ScheduleOfWarrantsAdjustmentsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3",
     "longName": "999064 - Disclosure - Summary of Significant Accounting Policies (Details 3)",
     "shortName": "Summary of Significant Accounting Policies (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ReportableSegmentsMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "longName": "999065 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdio_posam.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r642",
      "r700",
      "r851",
      "r852"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r133",
      "r510"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r690",
      "r884"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r747",
      "r748",
      "r749",
      "r751",
      "r820",
      "r887"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows",
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "verboseLabel": "Amortization expenses",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cdio_AdjustmentToLiabilitiesAssumedInAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AdjustmentToLiabilitiesAssumedInAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to liabilities assumed in acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_AdjustmentToLiabilitiesAssumedInMergerWithMana": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AdjustmentToLiabilitiesAssumedInMergerWithMana",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to liabilities assumed in merger with Mana"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising costs",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r679"
     ]
    },
    "cdio_AltitudeCapitalGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AltitudeCapitalGroupLLCMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Altitude Capital Group LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_AltitudeCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AltitudeCapitalMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Altitude Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r251",
      "r258",
      "r668"
     ]
    },
    "cdio_AmountInExcessOfFdicInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AmountInExcessOfFdicInsurance",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount in excess of FDIC insurance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "cdio_AnnuallyRentPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AnnuallyRentPayment",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annually rent payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "cdio_AsRevisedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AsRevisedMember",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "As Revised [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Total segment assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r135",
      "r158",
      "r191",
      "r194",
      "r219",
      "r222",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r417",
      "r421",
      "r451",
      "r501",
      "r593",
      "r662",
      "r663",
      "r690",
      "r708",
      "r782",
      "r783",
      "r839"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS",
        "verboseLabel": "Current Segment assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Total current segment assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r137",
      "r158",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r417",
      "r421",
      "r451",
      "r690",
      "r782",
      "r783",
      "r839"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term assets",
        "verboseLabel": "Long-term segment assets"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_AtTheMarketIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "AtTheMarketIssuanceMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Issuance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "cdio_BoardCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "BoardCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "cdio_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative",
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r412",
      "r676",
      "r677"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative",
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r412",
      "r676",
      "r677"
     ]
    },
    "us-gaap_BusinessCombinationReasonForBusinessCombination": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationReasonForBusinessCombination",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Reason for Business Combination",
        "documentation": "This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r503",
      "r560",
      "r586",
      "r690",
      "r708",
      "r737"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r132",
      "r650"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH - BEGINNING OF PERIOD",
        "periodEndLabel": "CASH - END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r65",
      "r154"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE IN CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r65"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC Insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CashPaidDuringPeriodForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CashPaidDuringPeriodForAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ChangeInFairValueOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ChangeInFairValueOfDerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liability",
        "label": "ChangeInFairValueOfDerivativeLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ChangeInFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ChangeInFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ChangeInFairValueRecognizedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ChangeInFairValueRecognizedInOperations",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value recognized in operations"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ChicagoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ChicagoMember",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chicago [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4",
      "http://cdio.ai/role/StockholdersEquityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning",
        "periodEndLabel": "Weighted average exercise price outstanding, ending",
        "label": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning",
        "periodEndLabel": "Warrants outstanding, ending",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ClassOfWarrantOrRightOutstandings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ClassOfWarrantOrRightOutstandings",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning",
        "periodEndLabel": "Warrants outstanding, ending",
        "label": "ClassOfWarrantOrRightOutstandings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r279",
      "r280",
      "r643",
      "r774",
      "r779"
     ]
    },
    "cdio_CommonSharesReversed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonSharesReversed",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares reversed"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CommonStockAndWarrantsIssuedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockAndWarrantsIssuedForCash",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and warrants issued for cash"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CommonStockAndWarrantsIssuedForCashShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockAndWarrantsIssuedForCashShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and warrants issued for cash, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CommonStockBidPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockBidPrice",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock bid price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease floor conversion price",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor conversion price",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "cdio_CommonStockIssuedForCashShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockIssuedForCashShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r747",
      "r748",
      "r751",
      "r820",
      "r882",
      "r887"
     ]
    },
    "cdio_CommonStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockOptions",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock , per value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "cdio_CommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockShares",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r578"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r54",
      "r578",
      "r599",
      "r887",
      "r888"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,740,269 and 1,531,468 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r505",
      "r690"
     ]
    },
    "cdio_CommonStockValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockValues",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - amount"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CommonStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CommonStockWarrants",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CompensationForVestedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CompensationForVestedStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation for vested stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r654"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "cdio_ConsultingAndContractorExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ConsultingAndContractorExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and contractor expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares, Value",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares, shares",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "cdio_ConversionPriceDeterminedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ConversionPriceDeterminedPercentage",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price determined percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ConvertibleInstrumentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ConvertibleInstrumentsPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r298",
      "r314",
      "r480",
      "r488",
      "r500",
      "r651",
      "r653"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_CraigHallumCapitalGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "CraigHallumCapitalGroupLLCMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Craig Hallum Capital Group LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible debt",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares converted",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r156",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r285",
      "r286",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r459"
     ]
    },
    "cdio_DebtDiscountRelatedToDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DebtDiscountRelatedToDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount related to derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r459",
      "r460",
      "r669",
      "r670",
      "r688"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r307",
      "r831"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "cdio_DebtInstrumentOriginalIssueDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DebtInstrumentOriginalIssueDiscount",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument original issue discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "Deposits Assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows",
      "http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "verboseLabel": "Amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance of derivative liabilities - beginning of year",
        "periodEndLabel": "Balance of derivative liabilities - end of year",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r435",
      "r436",
      "r447",
      "r450",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r594",
      "r596",
      "r597",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r653",
      "r824",
      "r825",
      "r826",
      "r883"
     ]
    },
    "cdio_DerivativeLiabilitiesConverted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DerivativeLiabilitiesConverted",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_DerivativeLiabilitiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DerivativeLiabilitiesIssued",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liability",
        "label": "Derivatives and Fair Value [Text Block]",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84"
     ]
    },
    "cdio_DisclosureDerivativeLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DisclosureDerivativeLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_DisclosureFinanceAgreementPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DisclosureFinanceAgreementPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Agreement Payable"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_DisclosureMergerAgreementAndReverseRecapitalizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DisclosureMergerAgreementAndReverseRecapitalizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement And Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_DisclosurePatentCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "DisclosurePatentCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r722",
      "r723"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "cdio_EarlyPaymentDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "EarlyPaymentDiscount",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Early payment discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and fully diluted income (loss) per common share:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r184",
      "r185",
      "r186",
      "r190",
      "r410",
      "r414",
      "r432",
      "r433",
      "r496",
      "r516",
      "r657"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r174",
      "r182",
      "r184",
      "r185",
      "r186",
      "r190",
      "r410",
      "r414",
      "r432",
      "r433",
      "r496",
      "r516",
      "r657"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r187",
      "r188",
      "r189"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r680"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Statutory U.S. federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r380",
      "r401",
      "r680"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r680",
      "r746",
      "r813"
     ]
    },
    "cdio_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of derivative liability",
        "label": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax ownership percentage",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r813",
      "r814"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r813",
      "r814"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r680"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to amortization."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r813",
      "r815"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r746",
      "r813",
      "r815"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal income tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r680",
      "r746",
      "r813"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r680"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://cdio.ai/role/StockholdersEquityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r126",
      "r143",
      "r144",
      "r145",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r175",
      "r177",
      "r192",
      "r235",
      "r238",
      "r264",
      "r326",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r465",
      "r477",
      "r515",
      "r538",
      "r539",
      "r540",
      "r559",
      "r619"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value hierarchy level",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r446",
      "r447",
      "r449",
      "r483",
      "r484",
      "r485",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r683",
      "r684"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r328",
      "r333",
      "r436",
      "r447",
      "r483",
      "r673",
      "r674",
      "r675",
      "r683"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r328",
      "r333",
      "r436",
      "r437",
      "r447",
      "r484",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r683"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r436",
      "r437",
      "r438",
      "r439",
      "r447",
      "r485",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r683",
      "r684"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r446",
      "r447",
      "r449",
      "r483",
      "r484",
      "r485",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r683",
      "r684"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurements",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r445",
      "r448"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionQuantitativeDisclosuresTextBlock",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of option liability",
        "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r827",
      "r829",
      "r830"
     ]
    },
    "cdio_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FederalMember",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_FilingFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FilingFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filing fees expense"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_FinanceAgreementPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FinanceAgreementPayable",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance agreement payable",
        "verboseLabel": "Finance agreement payable"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_FinanceAgreementPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FinanceAgreementPayableTextBlock",
     "presentation": [
      "http://cdio.ai/role/FinanceAgreementPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance Agreement Payable",
        "label": "FinanceAgreementPayableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "cdio_FinancingAgreementEnteredIntoForPrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FinancingAgreementEnteredIntoForPrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows",
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing agreement entered into for prepaid insurance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "verboseLabel": "Estimated useful lives",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IntangibleAssetsDetails",
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated amortization",
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r239",
      "r257",
      "r668"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r259",
      "r260",
      "r494",
      "r495",
      "r647"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Know-how license",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r257",
      "r495",
      "r668"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r257",
      "r259",
      "r260",
      "r262",
      "r494",
      "r647",
      "r668"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r259",
      "r260",
      "r647"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://cdio.ai/role/IntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r771"
     ]
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patent costs, net",
        "label": "Finite-Lived Patents, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r771"
     ]
    },
    "cdio_FractionalSharesAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FractionalSharesAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional shares adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_FractionalSharesAdjustmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "FractionalSharesAdjustmentShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional shares adjustment, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on extinguishment of debt",
        "negatedLabel": "Gain on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r32"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r604"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r497",
      "r498",
      "r666"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r497",
      "r498"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_IA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "IA",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOWA"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "IL",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ImpactOfReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ImpactOfReverseStockSplitMember",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of Reverse Stock Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r89",
      "r94",
      "r498",
      "r512",
      "r659",
      "r662",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r380",
      "r381",
      "r388",
      "r396",
      "r680",
      "r818"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r380",
      "r381",
      "r388",
      "r396",
      "r680",
      "r818"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r376",
      "r380",
      "r385",
      "r386",
      "r387",
      "r389",
      "r394",
      "r402",
      "r404",
      "r405",
      "r406",
      "r556",
      "r680"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest or penalties",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r107",
      "r176",
      "r177",
      "r191",
      "r202",
      "r222",
      "r379",
      "r380",
      "r403",
      "r517",
      "r680"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r377",
      "r378",
      "r389",
      "r390",
      "r393",
      "r398",
      "r553"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r153",
      "r395",
      "r396"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits",
        "label": "Increase (Decrease) in Deposit Assets",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r744"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cdio_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Current",
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r261",
      "r263",
      "r646",
      "r647"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r494",
      "r655",
      "r764"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest expense, net",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r194",
      "r198",
      "r204",
      "r222",
      "r458",
      "r662",
      "r663"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r602",
      "r637",
      "r638",
      "r662",
      "r705",
      "r706",
      "r742",
      "r889"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r151",
      "r152"
     ]
    },
    "cdio_InvestorRelationsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "InvestorRelationsExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor relations expense"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r730"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r730"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of cash paid and related right-of-use operating lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "cdio_LeaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "LeaseOneMember",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease one [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_LeaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "LeaseTwoMember",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r474"
     ]
    },
    "cdio_LegacyCardioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "LegacyCardioMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Cardio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_LegacyCardioStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "LegacyCardioStockholdersMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Cardio Stockholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments due",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 (remaining period)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://cdio.ai/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r45",
      "r46",
      "r47",
      "r49",
      "r50",
      "r51",
      "r52",
      "r158",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r418",
      "r421",
      "r422",
      "r451",
      "r577",
      "r658",
      "r708",
      "r782",
      "r839",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r88",
      "r507",
      "r690",
      "r745",
      "r761",
      "r828"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r131",
      "r158",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r418",
      "r421",
      "r422",
      "r451",
      "r690",
      "r782",
      "r839",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability \u2013 long term",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r49",
      "r50",
      "r51",
      "r52",
      "r158",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r418",
      "r421",
      "r422",
      "r451",
      "r782",
      "r839",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r87",
      "r850"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office and computer equipment",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "cdio_ManasFormerOfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ManasFormerOfficersAndDirectorsMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mana\u0092s former officers and directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r335",
      "r372",
      "r439",
      "r489",
      "r536",
      "r537",
      "r548",
      "r569",
      "r570",
      "r625",
      "r626",
      "r627",
      "r628",
      "r636",
      "r644",
      "r645",
      "r665",
      "r671",
      "r678",
      "r684",
      "r685",
      "r686",
      "r687",
      "r692",
      "r784",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "cdio_MergerAgreementAndReverseRecapitalizationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "MergerAgreementAndReverseRecapitalizationTextBlock",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement and Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r335",
      "r372",
      "r439",
      "r489",
      "r536",
      "r537",
      "r548",
      "r569",
      "r570",
      "r625",
      "r626",
      "r627",
      "r628",
      "r636",
      "r644",
      "r645",
      "r665",
      "r671",
      "r678",
      "r684",
      "r685",
      "r686",
      "r692",
      "r784",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "cdio_N2022PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "N2022PlanMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Loss attributable to common shareholders",
        "terseLabel": "Total Segment Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r67",
      "r90",
      "r129",
      "r140",
      "r141",
      "r145",
      "r158",
      "r165",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r183",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r410",
      "r414",
      "r433",
      "r451",
      "r514",
      "r601",
      "r617",
      "r618",
      "r706",
      "r782"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed payable",
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "cdio_NorthlandSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NorthlandSecuritiesMember",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Northland Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_NotePayableConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NotePayableConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable converted to common stock",
        "label": "NotePayableConvertedToCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_NotesPayableConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NotesPayableConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable converted to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_NotesPayableConvertedToCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NotesPayableConvertedToCommonStockShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable converted to common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_NumberOfSharesTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "NumberOfSharesTransferred",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares transferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses",
        "verboseLabel": "Segment Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r659",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rental expense for operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails1",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - current",
        "verboseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r470"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/OperatingLeasesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets, net",
        "verboseLabel": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r689"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "cdio_OptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "OptionsVestedAndExercisable",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vested and exercisable",
        "label": "OptionsVestedAndExercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r82",
      "r549",
      "r550"
     ]
    },
    "cdio_OriginalIssueDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "OriginalIssueDiscount",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "cdio_OtherSegmentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "OtherSegmentItems",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other segment items"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PatentAndTrademarkCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PatentAndTrademarkCostsPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patent Costs",
        "label": "PatentAndTrademarkCostsPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PatentAndTrademarkCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PatentAndTrademarkCostsTextBlock",
     "presentation": [
      "http://cdio.ai/role/PatentCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patent Costs",
        "label": "PatentAndTrademarkCostsTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r773"
     ]
    },
    "cdio_PaymentsForRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PaymentsForRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for right of use asset",
        "label": "PaymentsForRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PaymentsOfPlacementAgentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PaymentsOfPlacementAgentFee",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of placement agent fee",
        "label": "PaymentsOfPlacementAgentFee"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PaymentsToAcquireFinanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PaymentsToAcquireFinanceReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of finance agreement",
        "label": "PaymentsToAcquireFinanceReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Patent costs incurred",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "cdio_PayrollAndRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PayrollAndRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PlacementAgentAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PlacementAgentAgreementDescription",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PlacementAgentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PlacementAgentAgreementMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PlacementAgentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PlacementAgentFee",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent fees"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_PlacementAgentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PlacementAgentFees",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent fee"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_Plan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "Plan2022Member",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "cdio_PostmergerLiabilitiesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PostmergerLiabilitiesBalance",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-merger liabilities balance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r312"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r578"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r312"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r578",
      "r599",
      "r887",
      "r888"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r504",
      "r690"
     ]
    },
    "cdio_PremisesAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PremisesAllowance",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premises allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r136",
      "r592",
      "r849"
     ]
    },
    "cdio_PrincipalAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "PrincipalAmountReceived",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recent Accounting Pronouncements",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes payable, net of original issue discount of $500,000",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock and warrants, net of issuance costs",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r554"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r493",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r649",
      "r672",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r780",
      "r781",
      "r785",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "cdio_ProductTestSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ProductTestSalesMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Test Sales [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "auth_ref": [
      "r226",
      "r493",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r649",
      "r672",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r780",
      "r781",
      "r785",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and professional expense",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r706",
      "r885",
      "r886"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r140",
      "r141",
      "r149",
      "r158",
      "r165",
      "r172",
      "r176",
      "r177",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r410",
      "r414",
      "r416",
      "r419",
      "r420",
      "r433",
      "r451",
      "r498",
      "r513",
      "r558",
      "r601",
      "r617",
      "r618",
      "r681",
      "r682",
      "r707",
      "r741",
      "r782"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r102",
      "r105",
      "r106"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/PropertyAndEquipmentDetails",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r474",
      "r499",
      "r511",
      "r690"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOther",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r102",
      "r105",
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cdio.ai/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r327",
      "r335",
      "r364",
      "r365",
      "r366",
      "r372",
      "r439",
      "r486",
      "r487",
      "r489",
      "r536",
      "r537",
      "r548",
      "r569",
      "r570",
      "r625",
      "r626",
      "r627",
      "r628",
      "r636",
      "r644",
      "r645",
      "r665",
      "r671",
      "r678",
      "r684",
      "r685",
      "r686",
      "r687",
      "r692",
      "r699",
      "r778",
      "r784",
      "r825",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r327",
      "r335",
      "r364",
      "r365",
      "r366",
      "r372",
      "r439",
      "r486",
      "r487",
      "r489",
      "r536",
      "r537",
      "r548",
      "r569",
      "r570",
      "r625",
      "r626",
      "r627",
      "r628",
      "r636",
      "r644",
      "r645",
      "r665",
      "r671",
      "r678",
      "r684",
      "r685",
      "r686",
      "r687",
      "r692",
      "r699",
      "r778",
      "r784",
      "r825",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_RecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RecapitalizationCosts",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recapitalization cost",
        "documentation": "Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount receivable",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r760"
     ]
    },
    "cdio_ReclassificationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ReclassificationPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_RedemptionPricePerShre": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RedemptionPricePerShre",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per shre"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ReductionOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ReductionOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ReimbursementReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ReimbursementReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r334",
      "r478",
      "r479",
      "r502",
      "r508",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r598",
      "r600",
      "r624"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r334",
      "r478",
      "r479",
      "r502",
      "r508",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r598",
      "r600",
      "r624",
      "r838"
     ]
    },
    "cdio_RentAndFacilityExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RentAndFacilityExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent and facility expense"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable segments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r160",
      "r161",
      "r298",
      "r314",
      "r480",
      "r488",
      "r500",
      "r652",
      "r653"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r647",
      "r662",
      "r848"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r190",
      "r236",
      "r237",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r430",
      "r431",
      "r432",
      "r433",
      "r461",
      "r463",
      "r476",
      "r477",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r551",
      "r757"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "auth_ref": [
      "r127",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r190",
      "r236",
      "r237",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r430",
      "r431",
      "r432",
      "r433",
      "r461",
      "r463",
      "r476",
      "r477",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r551",
      "r757"
     ]
    },
    "cdio_RestrictedStockAwardsVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RestrictedStockAwardsVested",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards vested"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_RestrictedStockAwardsVestedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RestrictedStockAwardsVestedShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards vested, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r77",
      "r506",
      "r542",
      "r547",
      "r555",
      "r579",
      "r690"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r175",
      "r177",
      "r235",
      "r238",
      "r264",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r423",
      "r425",
      "r426",
      "r428",
      "r431",
      "r462",
      "r465",
      "r538",
      "r540",
      "r559",
      "r887"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r648",
      "r656"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r146",
      "r158",
      "r191",
      "r195",
      "r196",
      "r217",
      "r222",
      "r226",
      "r227",
      "r228",
      "r234",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r451",
      "r498",
      "r662",
      "r782"
     ]
    },
    "cdio_ReverseRecapitalizationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ReverseRecapitalizationShares",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse recapitalization shares"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_RightOfUseAssetAddedToOperatingLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RightOfUseAssetAddedToOperatingLease",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset added for operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r689"
     ]
    },
    "cdio_RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use lease assets obtained in the exchange for lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleLeasebackTransactionMonthlyRentalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionMonthlyRentalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly rent payment",
        "documentation": "The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares received",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesCommissionsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesCommissionsAndFees",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales commissions",
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r177",
      "r190",
      "r408",
      "r410",
      "r411",
      "r413",
      "r414",
      "r430",
      "r431",
      "r432",
      "r461",
      "r463",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r551",
      "r729",
      "r732",
      "r733",
      "r734",
      "r750",
      "r757",
      "r762",
      "r763",
      "r821",
      "r835",
      "r836"
     ]
    },
    "cdio_ScheduleOWarrantsExercisableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOWarrantsExercisableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti dilutive earning per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "cdio_ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease ROU assets and operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred income tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective income tax rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r680",
      "r813"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://cdio.ai/role/PatentCostsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r257",
      "r259",
      "r260",
      "r262",
      "r494",
      "r647",
      "r668"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r770"
     ]
    },
    "cdio_ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of loss per share and weighted average shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r474"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfSubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsequentEventsTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of subsequent events",
        "documentation": "Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "cdio_ScheduleOfWarrantsAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ScheduleOfWarrantsAdjustmentsTableTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Warrants adjustment",
        "label": "ScheduleOfWarrantsAdjustmentsTableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r228",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r262",
      "r275",
      "r278",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r661",
      "r662",
      "r663",
      "r667",
      "r694",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r225",
      "r227",
      "r660",
      "r661",
      "r664"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing",
        "verboseLabel": "Sales and marketing expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expenses",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "cdio_SevenAccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "SevenAccreditedInvestorsMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "7 accredited investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "verboseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants granted",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired or cancelled or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired or cancelled or forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/StockholdersEquityDetails1",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "verboseLabel": "Number of shares granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning",
        "periodEndLabel": "Options outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "cdio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning",
        "periodEndLabel": "Options outstanding, ending",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning",
        "periodEndLabel": "Weighted average exercise price outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price vested and exercisable",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4",
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Options expired or cancelled or forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price, granted",
        "label": "Weighted average exercise price granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r342",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "cdio_ShareOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "ShareOutstanding",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "ShareOutstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cdio.ai/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock option vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest outstanding principal balance accrues percentage",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest outstanding principal balance remains uncured percentage",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r155"
     ]
    },
    "cdio_SoftwareAndWebComputingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "SoftwareAndWebComputingExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and web computing expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r128",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r228",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r262",
      "r265",
      "r275",
      "r278",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r661",
      "r662",
      "r663",
      "r667",
      "r694",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://cdio.ai/role/StockholdersEquityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r54",
      "r57",
      "r58",
      "r126",
      "r143",
      "r144",
      "r145",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r175",
      "r177",
      "r192",
      "r235",
      "r238",
      "r264",
      "r326",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r465",
      "r477",
      "r515",
      "r538",
      "r539",
      "r540",
      "r559",
      "r619"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://cdio.ai/role/DerivativeLiabilityDetails",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r192",
      "r465",
      "r493",
      "r552",
      "r561",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r700"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://cdio.ai/role/DerivativeLiabilityDetails",
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails2",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3",
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4",
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r192",
      "r229",
      "r465",
      "r493",
      "r552",
      "r561",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r700"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of aggregate shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r53",
      "r54",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Number of common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r77",
      "r554",
      "r619",
      "r639"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for services, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r77",
      "r559",
      "r619",
      "r639",
      "r707"
     ]
    },
    "cdio_StockOption1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "StockOption1Member",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option #1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "cdio_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails",
      "http://cdio.ai/role/StockholdersEquityDetails1",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_StockOptionsValued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "StockOptionsValued",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options valued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock redeemed shares",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption amount",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cdio_StockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "StockWarrantsMember",
     "presentation": [
      "http://cdio.ai/role/EarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r69",
      "r580",
      "r599",
      "r620",
      "r621",
      "r690",
      "r708",
      "r745",
      "r761",
      "r828",
      "r887"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedBalanceSheets",
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r41",
      "r126",
      "r127",
      "r144",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r175",
      "r235",
      "r238",
      "r264",
      "r326",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r452",
      "r453",
      "r457",
      "r463",
      "r477",
      "r539",
      "r540",
      "r557",
      "r580",
      "r599",
      "r620",
      "r621",
      "r640",
      "r707",
      "r745",
      "r761",
      "r828",
      "r887"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r157",
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r429",
      "r622",
      "r623",
      "r641"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingInterestRate",
     "presentation": [
      "http://cdio.ai/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing rate",
        "documentation": "Stated interest rate of the subordinated debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cdio.ai/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TaxProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TaxProvision",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax provision"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination fee"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TheBenchmarkCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TheBenchmarkCompanyLLCMember",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Benchmark Company L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TheBenchmarkCompanyLLCRightOfFirstRefusalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TheBenchmarkCompanyLLCRightOfFirstRefusalMember",
     "presentation": [
      "http://cdio.ai/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Benchmark Company LLC Right Of First Refusal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r837"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TransferAgentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TransferAgentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer agent expense"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_TwoInvestmentBankersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "TwoInvestmentBankersMember",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two investment bankers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cdio.ai/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative",
      "http://cdio.ai/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://cdio.ai/role/FinanceAgreementPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized balance",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cdio.ai/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates in the Preparation of Financial Statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r100",
      "r101",
      "r103",
      "r104"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetails",
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r701",
      "r702",
      "r703",
      "r704"
     ]
    },
    "cdio_WarrantsCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WarrantsCancelled",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WarrantsConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WarrantsConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants converted to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WarrantsConvertedToCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WarrantsConvertedToCommonStockShares",
     "presentation": [
      "http://cdio.ai/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants converted to common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://cdio.ai/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WeightedAverageCommonSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WeightedAverageCommonSharesOutstandingBasic",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common shares outstanding, basic",
        "label": "WeightedAverageCommonSharesOutstandingBasic"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WeightedAverageCommonSharesOutstandingFullyDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WeightedAverageCommonSharesOutstandingFullyDiluted",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common shares outstanding, fully diluted",
        "label": "WeightedAverageCommonSharesOutstandingFullyDiluted"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WeightedAverageExercisePriceCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WeightedAverageExercisePriceCancelled",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "cdio_WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable",
     "presentation": [
      "http://cdio.ai/role/OrganizationAndBasisOfPresentationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price outstanding, Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, fully diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cdio.ai/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cdio.ai/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "cdio_YorkvilleConvertibleDebentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cdio.ai/20250630",
     "localname": "YorkvilleConvertibleDebentureMember",
     "presentation": [
      "http://cdio.ai/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville Convertible Debenture [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481295/840-40-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-31"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001079973-25-001464-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001079973-25-001464-xbrl.zip
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MX9@SY)(*>N(P#SEFAM[RX@)IXE=G06:&E!22O@Y(241JX1P=P^;+E?MX!AE
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M0Z6;*N7B:R7R)^0@-G+I!M/)<DE,:-*^8]T2BDW/S8.@2JR#8@\V<KCIF=5
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MJF*=F!:KSQ*+KE14%*MO0V,RTV)U],R;MYIH@S^CJR$5K5?>];/8@OSGWD4
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M7.4 8%#?EG:<UQ2+7H"YT9\%T(G+GG0\F4 S-ES><_UK@(,\6-IZ;L$;,;;
MM"X;E5K]XD0.'V3&TC;T%@<+/EV^'!T_W(E;S<!\M%7*<\U+X8*:MK3UO")%
M+HW;E]D#B>&+0)*"GNL;0@RJW-(N<P.57-D;13Q7<Q4KJ&!+N\SE0#M_#K*W
M?>'X#UE)S]4-0@:U;FGWN9[>ID9S]K1?<_;48,ZVM/M<@LH#_?G8&S_$T13!
MMPL5%7JB?P@Y1,4'6S=HLWM?HV1"Z"Q#=<%_D),@+>JY^F',H.)M7:U=A%&*
MPQQ@_OP%W]ZMGQ@'.-#4\IT.$_@@,U;/4W_'<?S/A'Q+;C%B),%AOM%0G6<
M53SG1(\=),3J">MO)%XD*:)9L"Y59M#9*MH+ F280<5;/4PM@M)7*Y@8KM"]
M!U6-7M"@@ ZR8?60=92DF*) I/(]0RDJ\*K8D-?H!1L*Z" ;5H.6L\&ZSJX-
MD[!1L!>ZKR(&56XU5OEVAN)XF>]'I?*-@KU0>14QJ'*KT<CG,TRG?#+\F9)O
MZ6-Q,5BE>FF%7E  (P>IL!IU?/Z\3E>0WY!4\E IW0\2Y+ A!CY:OH:[?B3E
M5J3/1A3@ "[O.0L:X" /EK;.X_01T[*%ED$3PJC"1G2U/.?$"#[(C-6M<SE]
MA'*!+I7S7/L 8%#?5G?&UXN'. HN8H*4^X!2L5YH>QLOJ&RKN^$3E'REBWD:
MO%Q3$F LCH[8:EP:;,>,&N@%0>:2@-39O=J;/](K7G7-7NIEI0<PE.X,1;U>
M$*45 .3'<KHKMK[\A\.3EQL\P50$>MSAY_2$?^BKVM#25O><K7IR@*39BH7.
M<^UR YV1),$Q?$HM*^DY%2!D4.NE'?D_WFY)P[_T=?DWR9\V&JWS> (OES L
M7K5E)(["K+N@6+RDSDT5O#Y$2C=>5C@>O!ZLSES$TPKCJ[/SJ]OS,_'3[?AR
M=#:\X_\X&5X.KT[/![>_G)_?W0Z^^S5!^?'-WTJ2VI3F&HD%Y1&G4;".\-P4
M[?VNH@V^V_B*15'7IV#CR7B.Z6;X\*:8'\S$O+WC__?E_(J+.+X8C*_/;X9W
M(U[ !I=2N4ZSB \^O56?5I<+^K$J*"3>Z2_#JY_/;P>C*_Z'\>D_?QE?GIW?
MW/X5S0G[^^#\?WX=W?UK0_"=I\@)8@_93+1@KZ<(S8O'EN*4+7^SGC"+7]RO
MA*E,/J4ILR@L*[O[Q+X3:NB%D6W$WKPOHE#EYIP/2 !-]QV^+;(30?E@$GM4
MDH@Q!SPVLBVMO%JK]!F]-Z)F :!*)7-'J=.;<+0%$WP6HR@/%&_79-(^1U)+
MU\1$ (B7=A)'N"+&RW=+VB;/PA,F3?@K;6_!!TV*LI6B]Y9W(49C@^@Q>S>[
MK=\DOT91.$I.T3Q*Q0/E:D*4U:R_-M. ';T (%7.N+K!*1<(A^>()L)GIR-)
M7OY>-F-[QHX".;@..:,%WA3)++?MLO>R8U +=-0PK:60O9O)3'S#2Y$JWE3O
M29 B!L="0PZ$,T H]N.[3^_?9<H5ORDOU,,D_!V)UX]3ED6:AA>$GB+V*-&U
MJ&I0TU_5UQ$ M*ZL,Y'WE.9\Y/5[STI)#(B;5LX?VUDP1DD0+\2POA:'<%R_
M:4JCAT4JMM%WY(HD8N_ U<A13+/@2LQDAY7@C-VD?7^[0/MB@J<#[0[?K%.J
M5RA1;KN8OTR :"&%MG(PV7C,Y3/$V8**+I(%J/V&X@6^PM^ROR@];@;5_>6I
MMA00?TW/*/7K6:-%K,\K5]WEJFGH,*#ZY:IY2I(G3%,<WI7! :I75_);]0;8
M(=4W#15NI'IEWS>IVF<:#,9!X]=[ #:N8Y2G)!E.^7\N,*C[:D&_-0W@;=VO
M!>CUAAM7- JRHV1AJ']#-&2_\5]B6=RUJ**HX;>F=<!!E;>\45?@4,XJVGJ]
M5;_)?-+R'OV*I)A=HQ>QZ:BUN.HK^DV#(7Z0AZ;[\<8\*,>$:?6^<V(R0EK>
M!HLS )RP96*'8J0*,.,YE'RQ,)[5]?SFP@P^2$+3K3- PD5V05<<@.4]8!C^
M>\%2X*UR40.NX+?:-;A!?;>\U85A**<A7;6^ZMYDVFEYQ[O^^!VYC-!#%',5
M<4Q\'S[#X2CY@ND4T]^C]/$+2A# 1[U&_&:G@2P@5ZW<IFWBV+NF9!*EET1Z
MJ;PHM"[C+R%RJ. )7TD,>V'K\N!@Q!XO8O(-B'G^5",4>'C[R^#B<OR[PTCG
MI3 &0>O?[RJ9E:#U,9VB)/I/9G4,D_ $L8C+><TG7_[EC=QMA72?/W]^]^X'
M+L]9Q$2,[()B_H]R,P.4A(.LH0&9##:;ZD""?!H:3BG.O1E)>(.Y(<OP#0[R
MJ)T"ETR0S]N"Y*T-5LUEPA0-#JHM=B#/[6(F'A0<3VZC:9*]95>^LGV=Y8[&
MVZ-)"'/T;EN8HBE!0ZFQP;JUP;JY#B3AD]6<[RA>."7B &Y>MA[+N(^V<2\K
M9LHO5>T XXAWS60:\?T/7]>J=VLR?,?;^-:5!LM:7:B/SQU)>DJ8'-7[BM:R
M\H.B0A=S17Y_)9E>8L3D7?!#96)8UADL*W4 +,\YAU>#MMC1R@!^W 98U"V-
M^%7M#I N(];$"GZ-:;'1%L:N#.RG;;#+ZH/O1 -_&_ F!GD;@Z*1+B8DW:V>
M#.OWE<FG5.VO?_GA^.C[OP^6U;M9LH7[0@S*LE=#!K6R>I7J#K+*G?:!,TRC
M)R2R7RVM:JE"*TO3NMZ@5+&3.3$@,WR'GJ5C_+BRS.3E!T6%3KB=S:)L)\+X
M6B(N<?)!@!-@'3RNK">E^MF2LM5")XOX \-_+$1T_A-.I!/X<65965<:+&LY
MLR\4=L9Q9>4QMS.X35O\U(TY:R9<=O](*EIE_:HC6MYL-X+);"E8C,HJ)[>H
MNH6\;5K!<"OK7,7 ZA;IEF$# ZTL<MOF3;<X8>L!AEQ9['0V1+<B5(T)&'IE
M!81-BFY!2U9L$/7[RO(H6[>['GFK!1S&65DER\MXQYU@:W6$0>K7R&Z1&CL7
MSL25E)A=B? 50;5,F,JZ6<O9,/BN^,9@]1%'M]U/21RC!Y)C&(IXG2E>&F=9
M%*W\SUGVO]SA7TW2(;O4U^97'(65!H\X7,1X/&E!&MTM_0Z^Y<U-_RZZW';T
M:V=<>9]GX(ZW/9Z41%'G%P"*N\LKT!USQ$1PD&5GMW8KDB.YL-I[O'4;<I/'
M0,T+V4TDDS.V/P>]/F=#Z+ +=),? 8A"V#(X009%86E91ZD/F@XK8B".=_/K
M,IG[,.";SSRAM7K%!"OL_YJIT55[MY,[857\R/NC+GF,054W*Z-.^WJNI!KP
M:37LDC:?5[R6J;6ZRMU](Z/D">?192+A,*:PL2)JP!5<99,Q'RO$6 QPH7.V
MTHF IT*L\(*KH"2MPG,#5[K_P0U;%OP'.JDA<IU-G-68SB.84TGA/>82DM8[
M2U3(R_O=F%XCFA;_*'6\(HS!@-^:#>TQ]TTTT;8M"RR;YXC&+QR $$D<)(@C
M:&#!E!7=1]*4LH+FC+,IEW"1MB*3)'-MJ=0^<@:)"='5\LV_:R+L+^%K*$WS
M14IR8#2IJNPC0T8R0W2U\OI'XR0N-S@4_J-P3$]1'&]F,@&O4I43H.@;V$?&
M&V@ XM]9$I\S_)".$I;2[+D-(<4LNSEY3:, <_B!N(<P54R\A@WL,?]U- #Q
MW_+-R"J(VT<*3=3RPOM(F$9:B)Q67ACM9'+.TDSM,#=G]?>1Z?H*@,AO.5$1
M$ JER26BJ+./[)D)#3H66G:\ED)&68$*2K<C*[JO!(&R^N>1W>Y$&_?#9$F^
M)<7WD4:MO""5)2>-I;O29K<4BG!/623I3M<4BG;;#!YE-"WU7?ZO=;_E_Q Y
MU-()H;,\6I[04_HR3TD6V5_AL]2%>56SFBV.Q.:20.&9:BF\";0T5O;FL#.2
M3K6Z>10&>8$BFAE1)R^K'W^)N% T>'RYY,M"K([R,*UO/^BC#DNDD4S>G8RL
MT'[!2$R2V3I3%4$7(E"S&3=1'C5) ABNHRB? D!<,.US8(B]WN#IRU$KN*-D
MODA9)O)[72RLHI*CD,IF Q.@4RZ5=[/V^JY<?N^S?!"?KH2YPHKG#8R;N/]D
MF=>&)E8CN2!F6_8G5&]&<CAYZG+ K:"HT1="3,1H>V35T?\JDV<="E:5>L_"
MIB2@O=*R8RU[ WF4K ;B#0X(WXC_1V3*JS[\O.UK,ZO=)VKJB 2:$'Y[9E;A
M5&773"7U0@/7S.#HX)PY.&<.SIF#<^;@G#DX9P[.F8-S9K^=,T=-G#-'>^F<
M.?+8.2/#>]R$NF.W3TUWQ5U9+' F]HJ]G;RB'_:+O;)8$'L?W+-W\K)*(G8:
M(\:,K5Y9M9X:N[ &/+I.OL);<DT5738<)S<X6% 1NY<E2O\U(0\,TR<A?M8E
MA;,D"7BMS$NR+;&QM=3=IYW;THH^ /2;KGGPTNS>P\[7$_/>GP[JZ4Y@[;S/
M<[!'*%Y?/6 ;RE ;*34;<KUCZ'P>@LX-C;7CW5HJ/><QZ1"EXO='LJ[NX>F)
M7@B#PUT?STN.9><EE=S/3<Y+CAUE0EVFU>8T9\EA5YFU52<G1663NJZSEH(8
MC7.1ZEIP?[92@P[I.*VK+>]/6D Q3EY$ECWUAM.HL@=9SPRYJKR^9JH9C]QV
ML*C\HSIKWJBRF\U@'38,>:QJQ*=-7==$^KRQZI1L3S=(XPFW?? *KVX;)"WN
M:+-39X01,RF\FU<O%I1KD1NM7+Z+Z%G\I-VJPG5<Y;%KSI1&%I"OED,@+]&#
M?HB(DM6"K@Z@&NA<(8!_1TW96SCBG9;1;$[)4WY$HQL:BDKWMG?N.X\-G3#@
M8N.?E?@KPY-%?!E-%/L]@\JNGE9NO*\SE:FGSACE2S75QQP;.&5*S]38>A%-
M<66Z\@X6]"3:ZGJT9=!*0BI/86G0=ZW\[;?=8,5_D#P767G<K5.= UA5^OX@
M>1P+ MUY/U\_ VR"O/)B5OE98'_>D+H0BL&7'$"XS8^![]2LMFOOJ0*EL?]4
MWX8W'M0ZE((^5%.=>>]%50AR\O(%_9M0D_"=.HUXX%4U9H\T%],_/P",?HW]
M"LVT+KK:#3D*PFG EC'?*HWYY(MU1;K//EKK'<-3OVUN<6D='AO%7 6E-!R)
M1"V)=W/T)9ZB^ *K@D961>Z/7,6E-S>@ML ;^"2\F2Z'0;"8+6+>A<+AC-"T
M2-S6:,8$VNHCHTVE]&[HP8*8>!9-:N\7O=MR@;:/L^<GPW\O\A>,+@@U&[)@
ME3Y2IQ$&M$>L^X.++ O)-#N-4/GH*B^3KZH.\KH=N^CD2&7Y%3Y44E^"4$46
M!7M@9<&-'RK)(&"PQS;!*CV(E8A,&+1K+^)MRA=!PWA+65E7J= +)#HOX%8Y
M;SQ]L-HK.<MEDGKON_L9DRE%\\<HX.,@I='#8OMUQ2I9JCKN/'-R_1-CY-Y9
MDW*P.B>+NI8;-YJ!VDUX\M=%UCY5/CN_6J73ZF.LIQP"FA)E[-1&&5<WOXT&
M %&!AE3:SKUNAH,W4_+TEJ5SF@\0\5,I1Q7_U_UH*%&Q^,MHZ"I$IHY>2T@A
M97YT&W=VR@<N14&Z0/$=IC/UJ@W7\'O-UDGJD;M !E6W"*CJN%FMM0K7\^/O
M2MTN13ZOTJW1:'6%SF",$ZP.;]XH9#U5J'G')TK,D$X_M1TV+CY]]TUM]FP6
MNO^^-SK=Q SI]'MG*_4MBG$&] $%7TOO^WSA4C[&+S?BF<&X>-)7Y=.IT\S]
MD:,Q8>XNJ2].VR=]P&@9)@GO>#F$ @ P9"0E/5:\$G';S@_H/6**9Q'#;!C'
MY)OJ$>+M<I[K%<#KG8%Z@P,<9:DVV!5.3Q>4RGMW45Y:W&,J]+ -3JS:Z.<W
M.)H]+"C+X*[A +T=*.VQHK6H0>^#PZ-Y,2ZS)><FFCZFX\FO+#\%59[(0Y4\
M)L<4/.C4<'8)>., ;Y7W!^8'J. _-TK@X+; F06[>. 0>'=*<7A"*"7?./(1
MWXU2S-(;_EN%U:JKZC]7AB* &P\_1M/O6$P!.!P^\=].\0T6.EK^4>RRCDR'
MF;XE_SEM)A%$L;.'QC?%.'^>XX0I!J.T>-_(VH -,5)Z_=M2 %*QV@ZG%&="
M\=V5L(9,@E J-U"+M@:KQ@9%:]8NXITC*@8 NR2,76-:>C-:$5E5N7:Z;&7P
MG6CG;P/>TB!O:I"UU<G[O'6B^Y(T"J-X(?1X*Y(29GGGSI^#>,&U=,$[+$<[
M7Z19Q-MXLA2'BY'!K_1;23!@:U]P?<%O1TF,+P&V\QUOPH?:[F+@9<(V^?$^
M:&E'84]>Y VHST\[_:@'%QI;[4'$GNK:=EUVU#M-+LCI:[HY$;;!GTF/\?N>
M9'>\^WS,[%_?L'I>?9N2X.OOPAI778,4124E'=V$-!Y<1(O>TKE1]O7Q/'M&
M4Z_DC8*N$I\U5G(5/3C5>;;$&0_ZX4RD4NK,U,J;MY\$W8[-WZ)R#$[4;>7S
M$CU?))'#E(D43^F+PM%0R1!5KOU7-"?L[X.\$><>AO7UU7'ZF#E2YA0_BJ7W
M"8^2@,RP<(V8>!)JM^1H9C##J?$'U&O%G]U^0[JW1W@#'7J_9U^Y>_.1*60B
MB0CN4>^Z-=6<[9L;<03<&%-IQ*-][19,W:8&*.YF!VNF:V(B@'\;SS:(\7F+
MV1IYGB;1*;95NB0Z&\4<;1W58X*H\7HWHV4I?\:3 NB8YF$RBY2E* FYT0QS
MH:MY?^0HQWE+)HB9? ;[!P\(/7_FJWK$\#6- KSZ(RO^RA2!#XV:VTOJS83V
M;H!G.]X'Q(U?H0RN"90SP,%/<?ZDQKI($1 ]_(9H6#AA2CT>"A+9NJQPK#!E
M[8/I>U]TIC+0R'/:DT_TFCC9UL0527)EY$MWZ3W$Y9@.-5VVHZ_N1=_L5#>@
MI=JR<UTG"--*LD+.1LDUIA$)MX:;JJ]EGF^;&'K;\QQI"NJ'SH+Y.QAZ/PM[
MQO)46'RSM]W1DF:@[M?TGH+#:1#N9;:&=M_[G!,]03WPDS_G9+($@A\K[Y'H
M#\I$)L%^S>F5KM+BW'WI^CAM'9[7O-,;Q][N_ EO#N+:ZTQ@P&U+?'A_;I=#
M?M$]AKQ5S(-XUK8((BHY_?1X-9)Z+5D2BH?@3 (7N_F:HR!7*;,U3=T=M.O3
MB6+_>Y'/YYFN>IK]P-B&(9N.+B1V.;C549[>GITTL:&JOO>KA?IDN_5/.=O>
M=F=X=J,B[TYP6Y03<&IF1YA6^J(*P*&'[J0X/V?+RDEE]ELV7*2/A$;_P>&O
M"4=9FO_%8L$VQ+L1VBJIHE!.5Z?/U@'N:;_W1;'[<VY=B)_Y85=.VNZF[<WO
M[&DO;5D_;9]/.]RV2J7LR(!H#\2?L)NVK;S].=LN%'!!Z 1'Z4*L/DEX_CR/
M:-:"A3E4^^D_87]M1V5M'X&[GVDEHCJ:;FLB^1/VX4XT:'"F[EF7UFHADU&<
M'77M[ZI\ZD_8*9NI".IUSK(T[BKG;YB)89:M'3C@/]X1\:N2^&[<8+OA.O3G
M+O0)=7YG^2L[MY[<]/V=8!VZ?@?JA'J^_3RA8 "?*D7HQR-E(-]??C@^^KX:
MR>?\Q=K% XO""-$7\=C'>))AKG06:<YH93UG2; +5&.::_H+3A]).$J>Q-2,
M2UAY?ZX47A;3!>.U^A5_XO&,ND(U\7;K&O<^W$ZJ*4V*#+B*NS"\+KB#N@>@
M*9].!]<(16S(>%)Z\4@;'650UU%2#2T#U3>?S+3@52Q<I]SY'*?6/K^>)N 8
M78]UR3=615P%IYF/'0(#]VYBY#;Z$TKQ=8R"K%/J:)"7=_5:86-2%&* 'JI6
MCO"7[S:'.,KIX3^L6>'_N+_$4Q2?)WSW\0*8';Q4I=!>&AHR03L-L-"SDT,!
MEQU>9+.$9<- H3$"(.QVP6];HUXNU[6U;OE%WRD*7DX1788^%VX+S6NTJDH=
ML*">[Z%>2VHA!E??=I=?1M/2TLO_M>[P_!_W=\*O-)Z,DC!ZBL(%BH%IGI<%
MBN[E9 ^+:R?,J2YKOT?IXPV.<T_H8S2_(YJ93":@KA'+RX>6 P579OKH?&/I
M(8U>KEG=4>UL<3->T!PEIM]AU #K7)<YZ@&%?T$)$B=",TS'DTD4\!5VF(1G
M$<4!;T)M5!C5O?_02UK,98.8^M R4R=$'.%-S*B1%[X_^MA+,E32@$;@1ZM6
MX#;$TT<4T1E*0)9X)76=^X^V'Y+<G2Q#H2#./GYRYS@KKIFJCX8V2^VEW2Z5
M%)SC7-.E.S#P(Q6"5)ER??M[;M-,Y5X:RTUIL6H*BT_SWQXKU_G-0O>VEW=U
MYR5*G. BT++=="6^*[ZO5.16J?OCS[ZJ4HH4G"X^.UM1,ZM!!*#1]*5TCL-.
M7LI_4:^W==K8Y]6XOBX]NMM2AJA;/&1EW:S9#50.<^;OJKX;.3ZO[AT0:#?A
M#W["R3 (* XC#B.?)G3[?G4E5^?ZBJ% :F&'=/]]RS;#,.9[W$6(3]$\2E'\
M,R6+^>7EJ5+URCKW1XZ>S313O0%VT,]RW/2H'M#]*471]!<4QXM9'?7KJCE[
MOM*, 3/X( GONQT =3K^TC7JR(!NU.'+F$%?QV=W23_VZZT_&\',S=X"='99
M]O 6H*?V\>$M0$/R/ U%YBAG),GF$ETL;*7HO:,EK,ZC@'+0$ ^?G:42:O0F
MX]$[_PF0( :MM'?.U"^2J8XGI3NB:LL!*+[/%H-20QXE."CG$1DFX@4.M/Y-
MV<^A&VJU&W)C7:AY(;N)Y)^]X8I>GVV4#KN [1.]_'K*<)K]AV+U'9WBX RN
MX\RKU'2@D5J"P2ZGEKT=8OE@9GS(BCIS+;5  RP/[&MRY@?IV]LIW5LMAL^G
M^)N1QON'+P[/I[@WBOK?BWPVK_;K^9063L192B.1$BR;F7_E#+&;VU]U]K:R
MVOV1[2AX&S/$]G&Y5@&@2=$X5KZ%HY55"GD=PY6B]\>^IA9KCU5 :'"-:'SW
MLH-GCXX=A4,Z?/CH6!59>=QV:&4)P)$I.47!^_=[/'94(H,+WE'+<13#].X1
M?T'T*TY'C"U0$F#U,3Y4_OZC(S>\+:HTDD.,?7SG=M426'%XMJ!1,LT3-^:/
MI%SA;]F?E)$!)O7O/SDZ &N6WJZ&3!"E/B3%.N6S><319)W]!@<X>N*=&].2
M/T=!;*UV>D9P ]E B]/+D<O%>L)4;.K&D\Q^;CB"*^WTC.@&LH$VCRNBS_!#
M.DKXEF@A5J4+%.#AC"S6V_ JI5"-?I&GE@*T?EJ^\Y.EJ"_>K&;9K##!E&+9
M8RW9G1JH?$]T;R #I'EG5SA+D2M%%&:._ 8S3/ET?D'HQ4)DJ5[:9$:1.V9-
M]836W<0#[=:6-X%-TY%O=MCA$XIB<=+!I5D_\P?M)[O\9D\ZAR4]0+W(6:AL
M:31<(SJF601C^!N*%YC;"9E 1C,%5+DG]-<5".+162#3:8P8&T^*^+DQO1&/
M#FR\-;#Z(RO^RHX4S#9IKF=<-Q?1NX/A:TH"C$-VP36S7+;&DU)OAIG65NT7
MJX;B0 Q^;G<UWPS+N<"RN;0:OL/+]43I"NR@K\!.&-@99@&-YH!_1Q$R5:K8
M6Q)@84!6G#X^P,3XC)AP0XC(*]Z'5+X:>86>D&4B!$B2PRMS"A]2_GMN[-[R
M_1-?-IOZV2KM](S2!K*!3+M[I%HN168"[TZTO)F]X%DE&DBS0W?1VN^;"53N
MIJI]@;)>OX@TD05DSEG^EPKJW"%<G[F->CUG3B(+R%S_GO!=/RIXAM(N7H;<
M_$"_^D*K0H.=IJE?!]BT+/T*>8\%-BB;A7K""@0<U*R_P?2:AS]_SF4L7OG\
MF1*FLH?:_UA/.D37"@ [5LNNG')X8&;K@:<IE8(]84H%'@P(\/<6 ]2A+E!$
M,]&&?'J:Y:+>1.SK!<5XE*28FX#I33?KK.FG>])A[*H#[(+N7%=M"KY\.?TW
M(M*#QU'Z8K$3RC_^)^Z&*H6 '=&=>ZY=T;M]AE[[S3]UMZOH >QMOKD(<^_)
M.'W4WOI1UNT9^X;R@"PZ\P"V:Y#;VOGTK'=T(#O8DYQY)#,1'O12/@!2_B;N
MY6_%4&GZ4\M?ZV&OZD0#8-\J^4S_\79+.1SNU^7?)'_::!0_IS@)UUOG#5V*
M_><;%+W-])>[>-/H(<97),6,RR%"ZLYPBJ*870D/4QH]K1,YB)=V?GKU^?/G
M=Q^/!Z\'9Q$+8L(6%/-_E-H:9(T-BM8&WQ7M#58-_NV5HS%$:'J'Z4P$?%<Z
M@&P4R,L[F@&"1QPNL@Y<QK61:D,B@[)6JZ,1Q?&KQCD=E=1LCTT#3<AC8I;H
M>*_%X4^O4KJ0*,%!9]0GB &*NTL48\+!]I2JD-BG^T[;./79-X *CI+;*O6L
MX<3GC"KMT.)S7I,6J+.:'NY?A'Y]BN(8EU9_#H>+R(T"Y=5M@YK67T<U'!.D
MOA3^N55/%HROLHP-@S\6$<L5JER P I]6H(T4GMT%U.&5/Q(L7;>,ZCJ9F'2
M:5_/E50#/BU27=+F\\+5,K5[M(@YRJ)E/GIJ+F>=O!_MU=5U#ZP.W0Y8"1YB
MI^5ALXX/S Y2SG#*P7/<(JE%P%&A*701QZ"FWRS4$<*[[6WY:O9ZF&^),TH"
MBA$SO,"N;<9O.AM+Y)W5:"3"&6Z%VV4S^\/MAD2@]>''$I<?AW+821#-46RZ
MSFU5ZP5W>@E >Z3E6Y#+C^:+[3*)$[#* :7]5KD..*3IEA-T;%(^IM$T2E"<
M42\.G0#+3E0UJ.D_ Z9"0&PXO'U1$G%M")U@),(V+J)G\4:J6?1GK8;\IG0'
MF2"&G:7 4 OQ&_^O<+^U0;*LK3W@&10+HMK9W0T!?VTA%6:3Z*/+B2E?'Q37
MX4Q;Z 6MM82!R&QZ7Z)[,@WOIM9K9S^(K8H$;NI+XEJ*X3G#-'K*HFHN^;R2
M15$7\3:RL)WWVV$[Z^J#5?U5Q(ZK.)WE Y\5YA0/!E\ZC\]9(M%%Y&R5\R<&
M!U0[]%*Q!Q$WC*8E<OB_UL3P?]S?B' ]X&"3_[WT9W?'F')M$AE(.\Y$$YV"
MYR)+P(Z>8)3JB\BA63H^;%&=7AX!FJO<YO,Y&JU_X2J;+68JO6\4Z4#S:DL&
MZ*Q$ 0^<':Q.#U_0LU:SY2+6PWSTFJW  V>*_;H6>18]12&W.QU<BBQ_VMFN
MP=@ LJ*!ML]QW=U!48DM=FF*_69WW^Q'+^M.=.\.IO<[V4 ?.EOG&O#NP'S_
MLPO\F?J=0@?>'>?O6SJ!/U<_VQ;=4@1"JU+D&?B!'K/34PWJK_G;5[H6VB!Z
MPM*IP2@)R S?H6?,%*<%'[9/"_)J@ZQ>Z91@C;Y+A$<RB!^-( Z.;(%47IK^
M9 ;6]3WI\\F$+Z/\^ROQQ#)Z@P.2!'Q51872=$<S-9MQLPR;@-0<Z-1HPINS
MGD84;RVIM57G_9WLE2#%BT+IB_I.'%3>V5E2?4J(D4#>^0JJ0'77J^ :;B[#
M:52MX\7?*W#M4>/E:5>;]%F]YG:!Q>NSL?)"VT:9>S=FNK:O$P5>[R:JGS&9
M4C1_C )N^*4T>ECHKUJKZO1V:=$KPB.WH!RL;AY3UW*SS!BHW80G?Y>;]JGR
M>=EIE4X+X1@,!V^FY.DM2^<T9U/\5 H8X/^Z'PUE80+\+Z.A];"+.J. 5)!V
M&X%AILQ+2)F7KA*JU%;FI:=!%V.^7/*%+IE>$L9.$:4O$T*%[T^QF,-U[G]P
M0T<;>W^-5-Z%+IC(?(;#19"Y;7?S]:S;Z3/##21MV_@&-C(<RC4E3U'97-W:
MQY2+])($J1#>F<DKR<Z?T2Q*,I&N<8+B-,+BM<7E^;\XETU4%\YK-M1+2G<0
MU>#PVEK&V-DL2H6)*K"><NN5KP&82V]V /)]-6OLJKT!2L+!1HO^G(C<8'$7
M*$BS[..GA*5<>/X[3,6M&^U!B%EMUUEE-U!F"&/Q+KO RXR3S!HTXLT92!U2
MP0RTQEKS_O!CKS("FM.R8X) KQ(X'A($'A($>NJXZG."P+M'?,(MDL<9HE]%
M4!!*7BXO3V^BZ6,ZGEQ$E*4W>+)@FK.5FJTX.GUIE#>P@6BV]HI29 UX*I#+
MNE:_6"D) HX?J_?%3D76!$SGB*8O5VBFN*TK+]E':P,4QLX67W<C%<\7-'A$
M# ^GO(>)>7T;+;A6B<MUYM7M7PY6JITTD<&2C>$)9U[:&!WP:M7 N"(T?8Q1
M$M[B@,\APA.D7*+ \DYN*=<>*L14DFZ/TW8QW_EZ^E X[VXP8B2Y(%3R-[TQ
M;]C0_4<WAL<./I(F$K9];@19A5FJWNRS%QBZ_;!9J$\$ .@MF=RE5*LG4:BZ
M7R(IV3<U0R(8V'&6//;B]3O\QX+/RN=/PLUNXJ;_8=M-OVYDD+?BCVO^E,2\
M6Y$<0^F:CCB?N")) /SYCO_$4'YX66%8EA&YS:^X=O6W((WQB4![W_+FX*"+
M+@<>,+3-E??G$.+%I?&D)(KZ% (H[H%7H'7FB(G@WAU45"5'<F'!+4_14NV&
MW!QBJ'DANXGDWX&&*WJ]=$1TWP6L^B7$>\ELM:M7NB1D11T=830=5$0OC7>3
MZS4E <8AN^!*$ EJ41)D*\]J5P*/-VU55T]763"OS&1OVQO10HI9#BW/0WR6
M[53S-^OS_,17^%OV)V6R7)/Z>\Q[#05X-]1+C]=O/BN?RS-*2HI0=($:K>QS
M1ZBK!G\<.F,Z14GTGSPM21*>(!:Q\>2:8^<Z*,*RP8P>G[<].^76L@C,K+T!
MF0S*+1XR@A\R@N]+1G#,EF 5><&W"WF<'5PNC^L<X6M4ZF/G2C$'^<(!#4IU
M[-NI?S,U>[EY;D:%1SG%;P/,MYKB 37\%)$%BU]N\)R(MT14R;!UM6SOHI7]
MG=2";>G$<32;<TM-A&&)-UQP9M7=SN-([;'0U'(32J'1NREN4/$M:W[(.(J(
M*3JX*+95RDG"=Q/-RG""\WQWI^;Y1D1_9IZ7NS]R%)-JEDX1P-NV:T6OU2PU
MHX%6\W+]T6H9KW<^BV$89NI"\36*^*[Z%,VC5/5:+5#!8SI,@/?0>2!+MOGI
MW8[> Y&&\^ _./@/#OZ#@__@X#\X^ \._H.#_^#@/SCX#P[^ XM6Y15.\QPT
M(G47;%1N%+O_WO/M5Q6M)0_#[UC<<L;AD \F-,7%QCSS=(P7*>\T21@E4[$M
M"H#>7:,%?VEH(HBEV=T,UL4BCE_.HGB1KK?1C8@J-[0/?%7D,7!F6,[MAVC"
M@;)K3)<OLT@'6U%>6MQ?IK2H0=O5%S[@407(YOWH,< -L?+!7Y??L<SE=[2K
MR^_XX/([N/P.+K^#R^_@\CNX_ XNOX/+[^#R.[C\#BZ_=H-;QOESH_KHEJ*@
MJYL=M:-;RG@M>?1*7_\]NSB8&NAU6;(WBMT ;##I^K99?2_;K![ONEE]?]BL
M'C:KA\WJ8;-ZV*P>-JN'S>IALWK8K!XVJX?-:ANI9(I#2Y$5>R9>-LI-_/7M
M_9.7=9%K]))-D>)!N6('6#J1SB_L0YNR]C_$>YS/F[JN!&Y[N[W[=J,]0;="
M'\Z?N;W*!P:4K'3)AQT 'O<W%XJP8^];[(<_9XZ749+GGNFNNVU^9_][E4Q>
M<'GSMO.P6E)V-)&U!V(/NEW;R@ W<WY97!>$3G"4+FCV+.4I2I( Q['(C01.
M7&V8([K/>MRA[(D/=:$/O9W62G([GMMJ(O&X/SK5"-1%/[8[RQ40?^/[7XXF
M"0LDP(&$J**HX3&71L@AG?_0:43]!ODET[X^-;LW[#F#;0D($?W9WP/;#[(#
MV_>['MA^.!S8'@YL96O>X<#V<&![.+ ]'-@>#FP/![:' ]O#@>WAP+9N&&R,
M&+?DBSC1,<U?\U[O4<"@6%T]S[=HAOB].QV5XM[<8"[_R(J_KI.\21Z\:]*<
MQ]3N+I:EM:.Q _F*)+G?X/R/192^C!+QHJ7X:W8^ 68UZ.Q['G<&"W*W??#8
MM+> OMV5&&S9_2'G[H[]IST$?>]1;6O"TD'B<CX\1<59%.2]W2[G.5\ WK;/
MUAHXT;6:-JGKN_;-93 X2K+VF/)LANC+>'(;39-H$@6\_PR#0#QW+QZ3(G$4
M1)BIKBA]J#ZMG#4I7-RE1@?K5@?+9@_7E Y>[_YXO9L0=+)@7$+&;G.%,/7+
MOYIJGGK(S<#;\9G7X2B'!SIUEV)M%K/L.Z^E6Z(";LF;WC$!7GK5VR+)ZDNX
MN2M9C.<E3*6#$2KNZ$5<>><F9GB].+Z[IB1<!.F8WF+ZQ"U$^*147M+3Q0#$
MV[;[8!>EBT#$ AQ3'>HIBML_0U6JM:)]6$37!ZIM<>#E4M "3U97@0+%'69I
M]D*X<@V0%W9QUJ3OY,0(-C@BG-VF&#*&N5P/+*4H2&&K:+/<_9'MH]2Z&SD9
M7O].G!![5!P@\;\Z4[1"?P1 Z=V.J_  L1L<X.A)6 ]76-7%9<7])T !VXX-
M5(.1:XKG* K/GX5S'_/9=)P^8IJ+>KJ@M+3&5?DQJ.P_6\9"M'TTT=)*H66I
M9WS4T+RSJT$YQBN2!#E,T]6Z6J,OZS:$W. <P_:$1OA.-GVYCL4Y1A**$^VY
MD%.YTJAJ.1XR&LUO3V8Z.2#"/KDB;,P!(W$H=(D1PWEHTN17/A,+Z6'&E-7Z
M1)F!(!!GW[OB;)2D*)E&W+(Q7(. "GWB22D"Q%#36VH[,W2&YX1%?,'-L,+$
M;);K$Q\RY! -GUW1<"$4AR^C)Q$<DPHG],]4^4054*%/Q"A% +>DSK;\NA'2
MOY%A,B(:!ZGOK&\14I_(GRTOBBQ+^&\;;R(%=>UL=[^R+8K=K8%;$:SB/QL:
MZ" ]+<<67J,7+EW,K>\;''/HX2EA8+YM>6%GNC93(3'##RJ\Y;##&YSM=2Y0
M$,51^E) !X^Q987[HW 5?E#A+G?C$\S$B1J*+[!JTM\NV0]&E.!!.IKNM<'L
M_@E;Q *R2*]#D@PMH>IQH*[4#^V;R@$2T70##=V1Y%"HB/-5JWZ[6'^4+4<.
MJK?E'"T7?,9+IF)\J?5;*=<?!0/000TWW=@"&K[CY+()IL,I7V742I85[8^>
M8?3@"5W+<1>W9))^0U0<./V.'\3MFD5) $#IZDK]4;^)'" 1+5]./"&(;MQN
M4E, %>^/\M42@&IO^9;?*'G"C!?.M@WY-3'UFBDOWA^UJR4 U=[RYC0[W"X"
M8J';+EE>MNUR_5$T !W4L+-3Y!O,,$?RR&?!,_R$8Y*=U,'C8.5T4E3SWTMC
M !^DRMD^]A;'<;[%^(+H5ZQ>J5<1ZE =_TG280<9<G:,?(;G% ?1,FG?<$9H
M6B3=4YY^097\YT@+'B3)Y;DQIGP5U(Z=K8+^DR$%#!+@[%CX"J>C)" S?*D\
MA=PHYK_R)7!!U7N<3O1*7-Y/HZ?UE9K2)>N/NZ857;7^MY(&=I(RHY?AX,V4
M/+W%09B+>_TT/W_&P4)\ZI03."4TPFR<Q"^=?W<8_GO!TNRN5_??&R5A]!2%
M"Q1W^[$LF\8=KYA]I6>9T%?@><<7,6E7:(:UUST[^9JK:^"K!W_!BS6KV:Y2
MU,6<VR'5E>OB@&[:NP\"^=Y*SS K[SO)"NXI*9"XH.NY.TZ.3#DY^G-Q<J3C
MI&T?]3"]>\3Y!G#$V$(<_*AS4,+E]Y@AK9;4ESB[LT+E=LL=12+G8UD/:_NE
M "/^\\"UPG_S_P%02P,$%     @ RH,P6WS(^'!C9@  KN4% !4   !C9&EO
M+3(P,C4P-C,P7VQA8BYX;6SMO7MSY#:6)_K_C;C? >O>Z+4CI'95N<<S=D_O
M1I8>GMQ1*362RKY].S8Z*!*9XI@BLT&F2NI/?P'P33S))($CS^V)*4OB.8>_
M0_SP.@ ._O5_O3PEZ!F3/,[2/W_U_@_OOD(X#;,H3G=__NKSW>GJ[FR]_@KE
M19!&09*E^,]?I=E7_^M__M__%Z+_^]?_=GJ*+F.<1#^B\RP\7:?;[$_H.GC"
M/Z*?<(I)4&3D3^CG(#FPOV27<8().LN>]@DN,'U0OOA']/T?/@3H]-3"[,\X
MC3+R^7;=F'TLBGW^X[???OGRY0]I]AQ\R<BO^1_"[,G.X%T1%(>\L?;NY5WU
MOU+]7Y,X_?5']L]#D&-$/U>:__B2QW_^BKVW>NV7[_Z0D=VW']Z]>__M__/I
MZBY\Q$_!:9RRSQ;BKVHM9D6F]_Z''W[XEC^M107)EP>2U._X[ML:3F.9/HTU
M\ATD>?QCSN%=96%0\%(WO@8I)=AOI[78*?O3Z?L/I]^]_\-+'GU5?WS^!4F6
MX%N\1=S-'XO7/652'C,B?%7][9'@K1Q,0LBW3/_;%.^" D?L13^P%[W_GKWH
M=]6?KX('G'R%F"3EA]*O'WJV*J5O78.]P23.HHMT&NJAMB?XM.Z0X@@'NOK.
M7;C/BB"9!+ZKZ1SV-9[VQ5L]]U^:-O-XVI?N:"X"NQ AC_Z\\N^:L#]>T9]Z
M$/%+03LP'-4@F0E-"\S?P#N&RG9C/0M[=A/6FF=$])WUC-QFCL,_[++G;R,<
M4]L?_LA^.&4_<+?I+W^[2(NX>%U%$<%YCO/JAWMJ?_42Y[5I[M>?O[)1^'8(
MFJFN2(T\(*'!_4KBVS"CG=>^.$W*#UVJ;TGV9(>C^E"9C?3?DH?F#>6GI2 4
MKO3$J)'L0$(\JF2[_EA_V KB4T)5V# -IZ>?[[[ZGZ42:K1.ZA\14T1_9:K_
MYU^_;=_E@%(?#WF<4@AG65H$8?$)/SU@(G%8(>>*0%J8-6^D0B#HHD,V9$DM
MBRIA]-=2?%YF;(/\@8,_Y*>[(-B7],!)D==_:7E2_>%O;"".GW!:7/S]0(G,
M9@ETOI$6N:3UL=1QP9]1\!F7K!2\\VH,2J$EXJ*HE5VB\9E",8KH*4OOBBS\
M5=H4:>1<4DD)LTL?00@,953(AC0IY1 7A-,,T4XS9O/B(+D)XFB=G@7[F [W
MM7PQZ+CDCA7\+H^T"F X98-RR*]6!S&ETSA%E1H<MMWB(J#]<701D#1.=[F6
M9BIAE_S2 ^X22RX)AE%:>$,JU<*HEH;#(#:XWVQ7A%"\O*/6#)<4LB[YHX7;
MI8]4$ Q[=.C$?BZAVAD)BO@9HXX."M*H]_NF>,0$%8\!;:EZ2O.,G\(HSAB!
M_NG=]]^]XR1B?_G;)TQVF*QV!',4TB9()^B"/F:@C#MJ*>_$,4(;LJ:418TP
MG!:GGD*N0CK.SWD7JVESE-(N6QT#Y&Z[HQ#U3B [?,KI?D=\V=;D_DNV3I]Q
M7C#2?@S27S&1CVJ,TL[:%3/DIG%1BWHGB!V^(4&H HH;#?10JL!I;"Z#F/"E
MV8^OS8__%F-"/^[CZQ5^IHQ0MSVVRBZ;HG$.=5LF.TWO/)P$=TA+IE$NR:-&
MAP^7KE<_0XDF-5ZMT_VAR+E+WVDG<%H-+R140Y<R3Q2'1S<E1C7'3E"I=(*X
M&OH.8/O7<>O]:)*]AT*R]^-(]OX-D.S]1)*]!TBRCZ]7<? 0)RS2GP2Y;NG%
MH..I2U7#5_2DH@(\LFE0#NG6""(N":6K/,<D?N:AC,LX#=(P#I)UFA?DP :=
M>0TZQOKXYV@K+DDXT<4N+4>: $/4:;B'U&VMH,8,ZMBA[69K"6#;V>D2/HSN
MH#] Z: _C.N@/P"CHAFC?0?] 0[);DBVQZ1XO:'0BU4:L17V/9_BORKV9XW2
M=$FZ$:YTR6>A!H:$]EB%[CM+=Z=7M F,T#W]>_R08+3*<UQ Z<@WVVT<XL8A
M;3NGD'5)-BW<+KVD@F (I4,WI% IBQIA.(W8Y8&D<7$@F%:)R_B%_:0?[^D4
MG/:31N"];E(I#89/1HA")UDK\!A<K3(;M11+"5?!@[ZE44HY6SI00VR6#$01
M[SS0XQ(ZI> !87C-R14.<OR8)='Z:4^R9[Y(JF]/M!HN&Q0+Z-T612/NG4KV
M& 5:U1JHJP*'7W02&A>8#\;6:5&-QOA@+/_X^BGXSXP80V1C+#CMT,:[UNOA
M[-7!\',\9J$/Y!:JT7EKHQR?Y^CA%7$SL )O-T%A;!8',DXG@S)XO6E?5P ,
MF62HAG2I9."T9S_A;$>"_6,<GL=Y0>*'@V'GCD[!)4G,P+N,44N#H8\1XI!+
MK0+J:BR[D>>,OB[89>J!]T# V9A;"JP9;O>>>B]R)21ADV@ILTQS41_4RXL]
M*9L*]E/;1+#?_K9>#; W?W51L@,(K#BK/WDOPSZ.8<&M-[^LO+?M?"S-3O21
M("P.07*/R9.F95>+.Y\%:4 +4R")K'=R6 *43GY01QXQA64;=/[.38HUH92!
MA+LPBA1:&T+I/?9>YFI,\F+.4KQXJ(R]Z/Z+IK<>2K@M6P%:OVR;QX#*=HA)
M7K;%EX7Z[$EG%],BCN+DP!;1[W!X('RM_.(E3 X1CBYIF; SN8>")_[9;.O#
M3#>8W#T&!']\E1O0]"2+OM'IN<GE/UWOU.5RK_->A=SY*)SX["B@5F/9;I6?
M7_XE8,>X%($6M9BS1E@#LFF))3+>N60 -B1 >9;\2R6Z=*?+W[;9,_J:"GX@
MY;;<I1#[Q=X3 53J,ESR0L]*23B=\=WA(:>M44!>[X($;[8<IBZ7B5K>:1X3
M$^Q>#A.5L'<*V2(4R$2E4+:MLU+ B.*O;S;:"'[GN4NJ"+"ZU&@>@J'"$)$0
MR;G9+!M^4^?)NL*[(*FR?LESK0D2KG)C*:#56;$&C[T7MAJ3.'^C4JC*FK9P
MX&47A*]G :&_\':%K7IKC\6:-!Q.WFV@=R;S.G'OY+#'*"-+^(I*+=156WC
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M ?F5I2T+TM>KJ[/;>/=8;+:7,<F+6[P]Y+IZ.MJ$NPO0ISG7WHH^3M\[DXX
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M"B""V>!4T*RG>E+N24$9094!Q"SXW.U<_><J3O%[I?]262_[G65PI1N>NX*
MF*1&I]_R?%+_@)@.VJ102/-AA*L?_)/F@RUI/H FS8<II+G_D@$AS7<C7/W.
M/VF^LR7-=Z!)\]TDTM""]]K6G-$?-^0^^R+;G*V4]$(9$:J4,*T8/+H(V$QD
M80IL/,-4?-*$#ZPVY(9DSW$:JH?,*G$OA%& EK)F( N/.G* )OXT ^):SVM;
M4P[*C96D%O/3RO1!RIN84@8>2?K C(U+*>V3$C=97@3)_QOOM1-QN; 7>D@!
M2TG2DX1'%1D\$V%*'425?$RL*[JR!0WI4;+!<V>KS3)8S1)S]R$($L@023.X
MDG+MR/DY,3;D61$<*%J$_F-GA2P!U91QYQF,(A8!"27,ZS65\5&1KS*V1^HQ
M2]4;!$015R6M E>7]O YB!)7@!J6.A=#7,Y3-/ZEP&DN;[X[SYSU[$,X34=>
M/P!1ND,T0C==/W=<FK^0N*!O/LN>G@YIM<HCVS>HD'-5REJ8=8E+A4"4O@[9
MD F5+.H+.Z;%79;$85S$Z>X3G7R2.)!Y)1-R10@UP)H-H@0(*BAA"4D$&T%4
M2SHFP0W!C(28%@0_!(C3")/-=BOM[77"KDAA!ER30RT)@B1&>)+\QZ=A1P.5
M*HCK^*4-NXH9DU'DD:AXHI 2O()(@CQ$.JE &DE5*OKD5G7IQ.O[#P_W<2%-
M2R>*..N3%.":'FGP' 0W%*"$JQS8,Y8D^_V'KQ^^J2__<!UWO,[N21#1+O'N
M]>DA2Q39IZ12KDB@@5CS0"("@@IJ7.(M,*@21:6LC^Q4/; 2=P;/71% "JLN
M^MY#$(4N0R14_EY9>VKR+U["1W9/LN) @ES,==,O SEL_KLR("B@ 29F-B]%
M42WKXT!"VV7MS(. G;=!P,XP"-A!' 3L; <!.V^#@/JU98H0VBYM'I)X%RB2
M$VJE79-" WG(#XDH**JH\2G;C$8%M3JN,UKR%&?K=)N1)_[^2_J#Q$N%G+.<
MECJ835)+F1 (CNB0"6DMRZ1S'6'$I%WSXA#%!8Y*,)=Q&J1A'"1->D191-RL
MXHPMEN ;XACD87#(#J1 IU*MSF78*+:I+EV'TLL-&+_@)/GW-/N2WN$@SU(<
ME;$4V4J17M[MCAD#[/ZF&84P"#K9(%1LG6%*I[\R+52K59$P+TSZ.4L.:1$0
M?I:<J!/P"W)NF:. V6?,0 @04^3(% QIA%$I[>> =ID]HAEDL09/F@)&+^[X
MN+86].#4ME06$&>T %5GN*N<'^W8N-3R=,2RP"0(B_@9GP=%4&%3^JL2=WVH
M4@=Z>)I2)@N(0EJ RO.3C0Y+%1/4G/*6,H:<T:'6+M/L$A](N4\<(T 4<\<T
M(H#H(<.ER2!#4"WKA0MW3T&2U-<F*GT:2+GE@A1BGPL]$4!<D.%2<(&+HEK6
M"Q<NGC#9T>[M)Y)]*1ZK_*Q*WQ32;KFAA=SGB%04$%=T^!2<J550J5.GU/5#
MGI<VH7B995'MJ434,6V48 ><$>0@$48%3F!+@D,6;[G."G2?H<\Y1L4C1GP[
M:T3_WLD$7]KQ==-(&+(#$>6H/(T"(J.03MCYK2-*P,+=(X(D""(9X:GO(6DT
M4*WBF#4;RF'2G<=Q$.PN/>5I![.**P;9@J]Y9)('P29+D$-.<;7^Y)HK\GL1
M?68SZB:W5P_Q>D*.1\82@(.!<4<"!$>4L%3#XNY= 7YRYQT>DCB\3+) '67I
MR3C.F"?"&R3+:P4 ,4!$I4J1QP41E_12_A^#]%=RV!?AZPW)0HS9+JN\::U,
M\3=+;;><&>52GTU6JH!X-@:O@H&M"=2Q<=+IL7P&\]BF<9;-+0M_O7L,Z ?<
M'(J<]: 4F#H*KE5RO+Q@X<!@D4&C 8AZ%C!5"PY<$W'5$U0JHXZVI_E9WF8!
MQ-''UUN\Q82=.[C'+\5'^J)?-3,,"UW7LS=K=X:3.:,B"!*.1:N:ZN6H:P ]
ML#UBE0GT5V8$<2NN[R\_R](B"-F-,7F6ICA1;#F6B[G+6:$&V::N$&5 $$@#
M3$QDP451(SO_EN-MD#]PX(?\=!<$^Y(6."GR^B\M/ZH__*W93[39-IN,;K(R
MU+5Z8-G:P^'(;9RJ"QY-<89Q:XR>=[Y- "ML8:U5V>;G=D]9K8W^6NO/VU)-
MX>4JSW&1&Q@X%'+)-3G +JOZ$F#X(X4E[#^\N[NXOP/"@FKN8$4&0=8])Q1P
M16H,!($Q1(Y.==E/P'6\$^8LR!\57I6/7-*A"Z9;^NSO8 J[ V98MK__W?OO
MW_U)_)>I>"_I:G4EO\4ACI^#AP1?XT(>:K)3<=I06(#OM1<:>3!,L@!IR[#:
M%"*-+>^$NR%X'\31Q<L>ISE>I1%?E.FUE8H/8Z7IDGXC7.FRT$(-#!GML=IR
MLK*(<&DR1T$:H8POS(6P.D$;3GIDGY%G_AA59$607-D.C53'2YD1F)RXIJ4S
M8C M$W?/%#5HD32B+)@6R0!03)"8[DX+3)Z@,.B&9'M,BM<;"K.@#>K%WP_Q
MG@43:"^O;(1U*FY[/#/X?E>GE@?#* N0]IU;:8IW:KBV<X)2/.^2W13B;2BR
M@"TB7N$@Q[?Q[K'8;#_33IW5"\6G,>BXI)X5_"[WM I@R&>#TI9]7)O%) \Y
MKIH[&-2[C-.XP%?Q,X[6:4%=B>E,I&K(E=PS*;DDGYT#7?;I-<#0SPJF+?]:
M"Z#8=X[W+#*?#T<.BD^B%G?).!/H+M=4LF!89@!HRZ_:C'=&\4FP?4NF%G?:
M@1I ]_I.A2P81AD 6H_7@H)-+L,LA])8E9YHYSX^)H_JJ2+$P((VH@!D'G@5
M!P]Q$A<QSNF<@V_ >LR2").<S3^*5T-DP5[=)5G&.M6EDZTNF#9H)& A,K%>
M?5Q?K>_7%W=H=7V.[NXW9__^;YNK\XO;N_^!+O[C\_K^+Y!8:K=\K%/PQ$2+
MA62U-$2VC5M23EI%[W2J%Z1N@E>V&$6K#?T+.>!(],ZP.F9EP<=:Y C79$N3
M%NI@*#D>\^B%RWUIFL?3@M)XLW+DG<W]V$WM]*N>P"8E?S$UE0/JH-I0 PPS
MK6#:DI';:)K15W1:+TH=2\ PBC/&JG]Z]_UW[SBSV%_^5NXHQ*L=P7R7856]
M!J[J15VPR 8LXXY.SCMC+,#9\J2R@H+:3-UZ>6^HK'M7WYVH75_IN4LT3D*M
MN[_^$C>D@5K'!>O%;H..)Q[9+7MK%;PW4F-0JA? P?-KC-< ^&3-(]C\L>[E
MAN.@W__N7SZ\?_\GE%"&(<8P2*PR?P%O##+P!FQ?INW$(#4NHX.I4,*GXP*F
M;R!$.CHHVE7X'WP'S<P72DS<LKS%M*TL8[P_!\EA.!G32CK>DJR".MB"/!0#
MPQDU-LF-=*4DRLOSZ__]#^_H_][3>1=!STSQ3R@X%(\9B?]!A4[1^W?O3MZ5
M_X]R?M;]3ZC^"<4LB7=4;D=N#\"C(&<[:O[W(<7HNW<GB$W7N<PY#C'+%X2^
M>\__^L<31*WL,<^\FO@G;2<G@(ZQHIC3HST*D+UC/@,9,$15 !-/+/,4"Y84
M_4Y"T?<G__S'=R<?OO^!$^_]R3]1ROWQ^W_YC1)W%47\&&V0W 1QM$[/@GU<
M"#<.&Z6=QO[UD'MQ?KDH&%+K\5G'[QLKB!WV.(U3%):&O-/K%A=!G.+H(B I
MRZZS"L/#TR%A&2?.\9;=L:SX,C:*+DEG[TB7?V8M,%2TACIB5:DV@*+2@G<Z
MBB/D=1HF!]:"W["<3UFZ*@H2/QP*%DF^S]B\/4L+^O$HBAU/]HYS^WG--.-^
MYT#'?!#]?&F*95C3\UE]DL_L<XA3,M/>FXE;=F#MEIJR2PH6/2W1&D-*?. *
MDHC]V>I-0#:$IX>)^)3@!A.>4\UJJJM6]A=!,#FD#BJH-,$,+T;!-88>FOD<
M,$:6*?U6S133ZF.(2OX8J') S;RA!E#&*6 :F5;-^MNH 4C&\2OQQK"M5O#-
MM#YP$\M*:= ,ZT&T95<94P+)+'7666LMWQQ3Y)VU5 '--G/F617ELH6RSAX9
M/!\YI+/2]!1B'S.8LU #PT-[K/K8/)PQG)#0V3B TVIXXIO-T$TC#I%?EH.V
M/J_@C=@$C[3#-:6T5UZI!VH*4;A\T@[19%PZ@3) &W$G@)V*5TH9QF6@;P,8
M =*.89#&8RPO_!-N\BX;MG,II5V2RP"YRRN%*!A*Z?$-V51*HS9)-J!TV+?X
M&:<'Y>[0]K';A=P^J/YR;?D,#!<&@(:%7SWV7M#- ; J<Z4I!;I&WLN!/!5L
MZ5F\H3 8LI@0"O?SU?)PSGC>8;Y2^A-.*;2$'7&-GN(T9FZP_5*58ZK564ME
MI^OKHQSJK9];:8(AWRBXMEM(*J,G:%>:+0\F]PR#XRYU_5- ?L6=BJC_9%(%
M#QS5 )?P4B(-C8MJB,(^^""I5KV?:@7O=+K%.:;?[Y%Z<4Z[^23CR2TK/RY>
MJFTGJ_#OAYBP='+\"KL\/\N4^Y..LNAVB':TZ_U1W61S8"A]O _BV+&TR&D?
MM3:]$W]:YP^JUY_0W;^5?GY:!__3&^B_S_&>X# .^#8^ZMX3V]'W#_ZKXEMH
M-1RGKS1!'V2P5(F#X9D9HW#[4T?$.YF$N9CMG,WS#-AJY@MKUZ,*GGR;8P9O
MTMLX4,;RKK+<R):NI!>^B%"EC&G%@')& "@F=,ASQ#Y"S9PL!< 8EH_U.DNS
MOAOUO3&&X)NELO-LN=8.";ESC9I@NK51<(6 ';^W)RXC_E_7[=<W"R7&.GND
M[\;K]#*("=_=L=F>8Q(_\V%;D^1KX.<H36=IL\:YTF31LE/SSJWQ6(4E2:Y,
MF86V5+W<E<..LT:-A381B??&KSY&4]:<IB57KJ8II-VN3FHA]U<GI:+>26:'
M;\3=!=Q*U9B!X90^QB!(^>"0)H8P$''#F1]*SJ1XQ[8!Z@9=<GBC*5/U>]XY
M\U,0ISD;'N)\DUZ\L%IPB//'\I+K<_R@&G]9Z#F-5=FZT8M6F93 M%>V2(6(
M%=5#64K9UE4I.\4'_T%2_3ARTN 3THA__$@?V/S2!JLB0+',('^F36&L)EW2
M@CS+4NK6@7JV::;%'_$V([B4NP]><$ZK&PDR$L5I0%[7!7[*1YVG7_2-[C>G
M+?KIQ UNB[P.3+.^O(_20- #-XKV)'N.<_H61'^MZVK!7@*DFE*'J[;F(T[Q
M5IEE12GMOGHH(8O4%D2!T5*%3SR;!99&U[@P1J,',BXI(X77)4I/ -;80 9M
MR PJ@Q+ZV#L/ZFQ ]<DN0VQ9+>Z2'2;07:*H9,$T*0: 0^9\#/(XY.OLVT.2
MO*(H3@XL U,]H&2L^@;MV?WOU3D$9O1'<$3C?EA^DDK6)\5Z<'7\XH)@R=5%
MIVJ3!/*<H >F!HY"YR7U+5UOI'W2: !91Z1*%"R5^OA&D*EJL;S3Z1?,+GC&
MT>J93BEV^/K TGANML(Q+UU+-=*&2^I-<J]+R%$&P-!T"NHA>6L;*"B-] C<
M2ZT I6E4>%W54=NSI*.M ."SR44+1JM,0.>T ?<QK.Z-+;VSNSG\>"^YN4LE
MY#;+I@Q@/UMF5P(,LZ2PQ%L$FK.G7,S_P=,&T56<8A[J,_G7$?1"# &HE!R-
M%#R"#*%I2,)$$9>%P!3+7*:^LY?:Y2OUG*&4#N;C+*)%30I=!,PZ,^E'O(M3
M-JN@PZB$W?9W B1CD.V(R?.8R&K4XW=<8TL9RT&,A#'E^&6I39)M_H]5&OT2
M$!*D195AYC(C9T'^./#(7LW=]DA[)]J]D68=[YW42*"Z1"T\HOJE4J[O &&K
M-B'5]\>MLEI,=+M6AL2SOD-CV%9JOAG.]>!.9IY-Z^9T4 +L]H /(/NR>7US
M-6A2M%*<R.J1D$+&69NC@M<T+4,!2(S1 70V\IEGCE4V?N<'PEC.O>:G%*[Q
M%_Y$/4&WTG4^$[-U1VC33(K>.[ I:&WW</?Z->>#J/$C)S##I9%CI+<P,)HX
M&IHP #J"/?70[2Q+GS$I<'2?=5R0>6C2<,8>.^@->_3B,-ACA5%8UJB'SF&M
MA8JL6=M@BEZXHVY_[/2 \$C1%MDHO05.:=LE,[,6;IUNDB L<X3NZ#^76,XG
MF90S]J@A-EP116 P0XE+V,9;"Z* 2:(M7FJN=4OG?20.B^H.B-67@$3YS_2/
MPBXGL[@S"EB ;KB@D85!"C- V[%P:ZF.\W!;Z)D;<T\@=8=DH02!3(JNR*@!
MGEC:3DA/HX4[H.NLP/E-\,KB5/9#9!LM9X2R=Z%AE%D%!J6L<0J;,YDBVI>:
MSL?-9MCJILI>%Q#!% V7K>);(9NV&;.DW/*KN>S8%C] >)F1JOEE+][L^:%"
M14S#I.0R9&3G0#=JI-> 02];F",BD8T]'DPJ^\NJ#\WVL^3Y4K#LDAW?H?:#
MI+K?*/K/0UZP"83,<YVT,UZ9(3>$4HO"8)(1GRV%6D/-E5.-*>?,47>)9AT
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M9NF*4L>1+EXP">/<OAKH%=V3W,81D<(Z+6 $M8!J$?3+$6[U%V^%?Z)#\'*
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M#@ T6FS(4.JA\BVHUC]![$7\\ U[U0FZI][".473>-#Y'%>F$S(&)3]50^>
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M:G6XK#1B'I+T][][__V[/XG_7K,(?6T,)=0:@)NZ1'<U\S:5L%]*JF9?<DG
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MZHR .G)T>.(W"K/$P I:C,0>L=W0RASS6'*[,\\_J;N>I"\!<'.S')^P'>1
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M-,*$K[N6OK$N/>]]SUOV;3K^5M]@4 2W^"F(4_JXOM[D$"3WF#Q]4'+?/S1
M0SUH7T17=YHZT5:;NF:<#*B/.!Y3=6G@H X>Q "]T6[A,B-;'!<'PI><+E[V
M,2FS8*_3,E2S1(=@?"DTNCOQ=<E.H(.BG .U./@)3([DC5+X)QX=JC^G\MKA
M!5[S&Z*ISKLEB5F^M^4@^PM]M\\<+^L\/^#H_$!8TC0.JDK;P<[#2IEEU()$
M%'NP0KGS/*2E+BJ5FU)K\I4P"]X"L@_%.LT+<N W '"<M&]/PW@?)+*"TRH
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MCK@J1 %]>1-"R3G[YC HJC340=?NGZ[H3_3/]9_H/VQ/%OW+_P=02P,$%
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M[5UAZ,J([#*E6PND5';9TLWN4BJ[;$&M3$MM.=9HR"ZX%_N>%&RL .CM^5+
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M/DL"Y?2O(80B@^W=&F@!!9]2B/(_0I*W*E1:FX-/NIS 0B&Q(PB<F"%P D<
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M+LH[N2J]2PB@^L?VA0%2X^#PM"T04-Q05(+0TAI<C,(-!*3R8M5>V=0;YAN
M./"H! !5>R@$V'ZQ7N8#@S!-%X16=V Y,X)]5<:'G@H*"+9S#)4?9TFN5&M0
MKL@[[:"J=\,-;I,1YRI;]A"%_F64>,K]_DXSJ*K=\'E;)$31]*D7?Z79*O6?
M10EH0L3)#]N,08#/!>P BHX;WK"15G#B%,4#5^)%I/R5*S;-4B9F3,Z?,EJA
MI(.BY(:C#-$!TCZ*;>_?D>#T^9;,"!6)&??D*3WE'_JJWE8!R*%08;O6QAHY
M>#YX7JZ6[[Y9$L<DDI\TM[>$XH#M<JOD;%'YWUXWI.&]?UW_M?6/.[V9/!#
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M<:6LY7RE2>I%>4M<J*Z3V#=;\MLHT I*][4;DZL!?4C=T&1%:/I\$XFG'>-
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MZ 47^5X>N+9]*-:VF,Q%9!UU=?OHA3$3*S5AT_CB2:@D"]FB.-HX)P^*A0U
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M_+<+5,E:1+_)\XE47YE77M]9-\5.;N^"A%1B]%VZI"24#A<-&78B>Q>,0)I
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M;0A[$G..LWROJ8<HKW8$HP67&43'QD H1T:9N-039^)23\)7?Z,U"4 *KBB
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M:>)__4/$EU6/#HBFK2VQ4Z*@IEAU'!4B6_+5\R].5T(I !W7&F(GYW16<:O
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M9&)6%>^&;7WW-]'=L+0#7SX?Z&VJX\5UFZ?ZJ*NO]J[Z=V^R0[GG;B][ <E
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MT]EE2%EZ2V89TX35C7O!=@T[/;C745>VG,%6;CK 9(B)M>S$'C%QH,;JF7A
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M,E8TTK-\U>;<@11;J3P!$WED<Q>?=@ OV-^M5#=G2].4M[_41*0JEL8H9?G
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M203CW!X9A%.'X+F;,$"=)!Y$!:1M&V2OPZH&Z!2D2+@^JZCX>X2\&=%[=)5
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MO71] ^AP(/-O0.@W[JY/_H6( &?;87P>[V_*/<HN/#F[O&0OY98=RWH[!0S
MUNMVDGN#1FCCY/;B1IF@#9!%MZ CG[W60WDIYW%6,=EEG<X$;)N[VXM/7[=%
M$RB7JFM]5RY%Q_:^V'%,#.OR[#-($;#U[[:$4Y5+&^-%/ON!_:(CU)'!0E]=
M0&O=MG^5U#]>=O3KV>V9]<?U5^L$^-'Y!6B\7Z[ADRWS@6W0M3A7H,0:916N
M")S+V7^LNVO#W[5=D>#SW>S XZ1.1<]-?:V4]LK[M/'+Z[:1]:Y9<]55 R*=
MJGYC8F(@@ GBG41COP-[*0C[ 3?R:V)2,V6<M_ IRFA.)]#J(N4$-S@S WZO
MH-*['P0!74Z$X^(BIIG2X2>5^Z?1RI.D>2[=QJK_!!!^?'LFXWU.RD6G5/X8
MZZY]!!V/^@@1Q/516!S#&"0M6Q\*/%9 W(N0,(YL [[,<V5=E16TBUR".8:^
M3@N@CQG+M(.55[ G#$^3N:>,3R3[L4NX49H5 @5\U[5ED00:+8[6D1"1P4Z9
M0*.11!J5OU3HUORR!&74+':G0@?&^Y"=@5*TETVJ,Q"7JKUP@M9 8[!/HN((
M,:(&H6SH0^5K0]DT298?V'Z!:FYTSK@P9Z!>LF<U7!PP_>CX[:#O9YE8QO4J
M%O @FM(E7C3PYH& F?:+LLR.EA+T!<.R1!)2GP=B.J&+!3LM,!G?&VJ$W-7P
MK57RR/- @1\@'E,PB".\=/(HO_J$#D;",7H_*ULJ\O8AWA\2#)P3%4,"$3\0
M:3/!\_GIFX; *$$4"5FX1?4GVH++H)>"++O.P/-E3!59@H=0* .@HHC(6>%*
M% T"5H65J<7N63>P$NH +K=D[!%X6U"@'EA$CN;LQZF[-XA4(1*.U(L$E[]A
M(BWSO*")P'>,M82PAZ%B'09"?C'!*E:8:BGF4]"7:/KF35X44?@RRV!60>=/
M+>?8S\LYUG+Z*R[GB%13R,PT]Z3\:4+"^P8CQ^K+>3=>^X5XG:0",.Y>T@9)
M%VLB@JP]"1A>=N*10$R[9?Z#I8*87XU,8?J9;950_G<**0Q7X;55K6YJ<H1H
M%T78>T=W_*"G,Q\K3E;#06,HCD-_(;(4-VQ,J8<,3"#QLWH&D,FX1D>Z\CQ@
M?# HM6#,FJ7J/?+DN8S2!$'.CH *$X8L:F@PY" :06;0J)\%FM<(X"S#ZB6@
ML[C,WR4*3[(1:A/2&X#/FK^E3?A=HX<""5WW69A2PUH[ZI(!$(H"(?U;B8'!
M,)G&JU._;@7WR8:E=X-FUTR6X"BD&%B72_@.$LD(<?5<25J.%+E+O<LK81CS
M6*R%&2U6?SAJJL)C!-EECU401Z9"!Z-'8KK=&H2%F4QQ:]:%D4D[FSUKF?9L
M84'V[*SS)#J5FYCNJ5&8T#(C2\6>J67&YE.U@KI#3B=;^DXVJK6#I3!)0&HV
M.:G!DX+C'O.R  %@13S)8 W%* E<VZDI2E%6@Z2O*#$;@)O6IX$O3)I]LA6P
MU*+J?(?\E(5S)OJ#NGN%%*N$VRT9(N\($K6<W9YU04(C9/<#\0 )(PU*.J+W
MQ0_8@VW<%S>#ORT;<FS:HE-@(]*)*-'5YQZ) 1;D5/8*$N-$8KG/BW.2X?J9
M\N9IGL?"9/ U<N<\&8!M!I2U/:F8;0.S2/G<QR,<#QQYJNNF"86Q0QR,]("$
MAX#MDOM+LG39>-9X1'HT"+9<NL>(S8PW.]6=3D<_"0:A1EPT%.?1IJHF2B,U
M5DV4:BE%Y S)+N99)SXV5/X>Z^D*A&J= M]Z0+QWY?OCWN&RP6=J=(2X=QT7
M\4+:@><%#PIT2^7%HKK9E"4#>\!T,_8'4S@SUR%7C[CF06IQ6)%FH#EGOHSF
MFWD>&!$'+C9A \=W2&[,TZ:A</0)T99 5=!=] "J@#?<#1[\U![N6=/;Y*SD
M+BZ_P]!. ER")GY&];3<AI$BZD)V$77=0$19P<I>Q/A7#3X-.9+(A+30*23:
MPE2,)T-]*2HD/+C4-E]TWQF =L1P12XS"HF=)L!V,YL9-&W9J (7T1>T$OW[
M D.U&4Y^5J@5\*T"Y_-2F@3V]@0# C&['[ [J.>*>Z'@C^#^M&38AA5V3U#_
M!2<@[;<SL-%HE(#2'#MI#0L&^A%=4>60-=ZJL?<URI6Q(ICJ/9Z?*YRQ'X*^
MY.OS*)KPA:FMQ,TM9&RBA/1.]\6=0[=X_)@EU)N%P&NHJ49%BN?U^J/'PBAM
M^.^!+T'WM <(-]QHWR$U3GWZ]S:P1]23N4XRW7\#;4&)"6=J*X41;<6$=U.,
M>9H)^<B^*$_\X\'>.K5P@9EX!+&O0C%&')!Z5>#,!Y+LT'0,_'%:V 8U2K5S
MGFI.F($@PP6%L:PH(0N4=B#F+.HDA<Q*TZ 4T)' /N)[F!4$YV-<][%?JF<Y
MB*1N/OF9U%<%1%!3O:N3"]L<2BLF85#,1E2[S612ZJH\_R84YKD)HWI[4M:B
MN[J?)IB*.(DZ;,DPHO"=I5-H0/.0<59ZYI9#K>AVO-9JH+I8&?[%E=#N"AK,
MN3,$F@[R0--:3G_EN&&)(FK"PTA]TD2)V8:@TN^">"HP:5)R0NS:R2XQO?8B
M_VWY($@YFBV[P9%2(W66!VI!8DWHN*-M3A4>5RDA(YH2?H6O*5I>T EDMRP!
MUE#,KV=NZSC WF$F(<N$9*96TJF.Y[9G-0(/'4048@A COLNWG9JTT9PU:!V
M"1E&FK!B:WS%9!N&U/(E(^?'[,. .Q ,XA&M0YZL[)!R6),=4HK([&M'%3+K
MC6<:7_A[V3:(>S8480]CW1@*M#>0247EN$:O%,+@PY&C;&.I8F@]8,[S9AOG
M37)OYCW8LZ[9MS\SF<#K021+G-^L+9,>/,R)'DH+.AVD0>LXY+B3U.U1%9"=
M,Y#Z.$,%-#-&_L<)%A@3VN6.D2 WS5D64],?)1[<%9<PIVWIN>5J.3I4>AS>
M#?)<>QDIS@ ?X#/8\@FTGJ$1-$BFLFRYNKC^QBMI8;P$SCV*+R6Y]PC,5&$V
MF*DE\_G5)=TLE>Q^MB;Z5R<Y+Q2X-W#G!SMT=KT@^*X[HNDTA<A(%+#)*(-+
MU0LPUTJ&%]E;29UB/!M](A3'$1VEG^L\PB)F>7>U]&$/AM*5]PJL^R<O3KLS
MD#^1+=*66K]A,4NQUM-:^B2/!495DGD2_TIL;NSNUI*Q4S"AVIYN,$J-DSH=
M$<4Z-2"B5I'3]DVZ1.P(+H)RBK1LGZQ7&?@<";)K<=+JLLD5PC2PA:9RMHS/
M.PA3TZ8^9H].RO6[E-'L#4V[B4RL8I9]E>ST7N&S\+%W !KFQJC:^X2K W(#
M0PN3\LG[D+*XC-\ &<*;""4>$P5=E(RZHY^C6@+(;G#%A&H2ZBH65,-1U2UB
M)(VU2'-ZY)PX\?D!+ W=B<F&Q6/=+[IF1B(#DI9&/\8[Y?H#_7E!?S[PG-&'
ME7D[]CF=Y.BG+&7')H(9-J,?H3HQ^B'2S.BLU'Z//1L08=G>V!?8%1>/<NSS
MX,^,*;.C9O132G55,QEIJQARGBB'\%WD;&Y[^-C)L1)&RETSHBQHC<K.Q^D$
M@OT//6'+3 ';2,!RHP)^.?(65(I'/$X48!PE=Q5K-E]HME1KV:@4P;?#]R_%
M^=</$5F-GUE#-5;PPT-7IH,53\,=+H_@#GNB/1J6S !I_]D:BY"D4=L?*Q_#
MUR3XS8?_?&I5EO1,*5YH<OJ?'ZDGF[K!<V_GB^WAT_9-74W)GI2.(+<QN^(!
MN]",UT?\#)_G6SUEJ[E_!JN"D_1)Y> TO?*KK[6;E4^N_.V_)QJJBT()S=X
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MA+1$(\:.^LA"8)<)1!DG,[3JL+4NHC7;#AKD+G UX*NJWPPZ$ :^^]= %7S
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M",L]3CREE5*E7"2> K<6^,+N$/7N:-CK S7::)P@OR*^85-'4C:+E-K1](+
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MLC?,Z&K->D98:CR(A5D= DM,S6F\TM$HGK2I\:J!\R #,\9[,W%UDMK(F N
M4JL2UBUHELJ28H:JFKSBMT89?#*5F.%O]E9"T"NJZ3M#_H\^C<\,VXL[,8BV
M1#K+K JX.*K[H5JM!"F6S/^#^[&(99JZ<6#$/A>6);(8GF=<>6._U6(X 0=B
M_PG8.7#!"?I& MW\-NCUP0($LD,&HEEY S\:].EW'*TH5ZPW!J;#;]>?&@73
M,RH;99,AQ4D/&"-$VY(R<R0>A_@A5+]2"@.H,KE0H#W(&2,&2*ENJ6D@'BF
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M#4VZP$,T3L()WRO\85B (%L8<57;@E3DGHU?;^"U-X47/.BB^"SK=(S!\E7
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MGS:GF=_YI38V5D.?P]>19=4(X 12A\Q&D@.:N!GAXQ#HX_-VB2=#>[PNZM!
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MAU^U5/&A?N0!PUA_^%B'L;YX&L9ZJY[44UWN/<6<O[M^_FN$G/B97QIQQOB
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M2+B9,[?$/[#ONE[Q G%!88$) \TM91AA_ 9-$C*0E9:D3?]9+0!0H7QPUQR
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M-CV.^^DL4[6J&+=0)1$>WNY!FX9G=7WN;1!=;@1\3AS=LG^;#?9-UD!!#C>
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M5H8ES_V09W<+>=73=:5*5Y['B5EM+0W6I.8!O<5WH@I+.<98Z8\HEYN^=HO
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M.MIL D*V2TY;.VDI/8I^_H]IC&3&NUFV3^\6,*D O,97-34?-,W[W]2EE/E
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M/%;)T34S0?U$\8T"Q$5]ZB2"5PI'DF\>X$/;>BN.9B'#%<*  &#2+:@=W+Q
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MP<'NB+83Q2T=:'G\AQ'SD)N1+]B)'!W@3=N!2P!K7>H$*Z(850S$L^.[\7[
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MI9G,[\2;Z*(AH#N"LB[<'_<KF64"0)G;<1U"]5C975-U!+]O"\F]W".WI*6
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M[0EB"C2Z,P(S#4>:#FAPH-A.,K3X9-_PM(4:%BI5(F69C)A?R,CCC?<3=Q3
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M?K6^'3LRJA,,&)758?@T!(_*KC@6X^<8KL/K[!/I+\;7:<@:\Y!<8DB13'2
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MA=L0J,&YP,@)M5,X42/K["[BOXKR_BW 'U\HL2^%B.^P(@06+1=*!<);C"_
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MS:\R4-=,70S2S%8R$S9H^RPW?.&3D>FV]4!\?15<%^7'PQ"LJNPCLUG5R*K
MSXF<C3'/CLM48CS<N$C)#K)PA2ZB()7,[WCVYBQ4P%OFE",H*1HQ?YOF&C3G
M6B1K<E)0H[O/>$CG9AZ#@W:)+@8*.!\65^JC$*ZZ_P^NO8"O7KSDT$RT3%=8
M9[6L"_1&IR%\B:\LI^72/&\"/DY"3PUK;.5DW0J_:-&;R94>UW4\_4A_P$A'
M7PBW).EUE24'_=,0H=/213:5J]<A;8*?934'5AS/M\UX*TYK(HNAEQ(-]"J#
MN:8(U297AO"<"_V%TL2XS/%*98XH#!F&#$/S8_,E3E;!:U<2/R %HRQRW&J#
MLIFG<RGR(81\) ]G4XI]CZR<KA8,CU\%,579M!?&7..1B^)6I@=7\6(I /C-
M!-U%@5S44N%BEH_!WBBWS1T@K(/PDC.-XD1>%'KZ;9*N"[P"1;%Q, +7+]35
M\_9>R75T95WV9O@BL3)K,S09=?[?C0Z, E9^]+YY-D-Y0 J?DE8?$?SA !G+
M _NEKV$UY%Q82G%VC#F>R&E[<_W+Q%Q1FQ7@EZ-ZBN$MO]/?I=X+10L?(><)
M!9\$^S42,U/T4F"^\P)C)DGH_TP*!@JFD43[.[(6C7<V<XMNE3BZ\T -UJ[S
MJ%%&:]91HU.7+<ZBZ\Q"WLQ%NNT1B6RS2[E:SME<.:.W8*XF>*KCZ3;'GQI[
M'/7.4@%H&-,7HR^\D<XEH8EB_+=8UF02V[L4S3&*RIBS7HCV9U- 1+6!>LC6
MFIPF.)ZP.G@EQ=1TKU^D+N;7\=KNJ%&Q+%HO88.Q"F=XU'/TJ3)T'\ ->E#D
M\W6@"_#^#ZU-WC>BQP3C!)YCDM@(4+N.PB;!-U@BZ*3+EL*K4]CXK%A>QN4B
MGJ8K/K1& !R]C;^V\]ILV7/C]HMT4JY06#"&OE62_X'2A,$]9_H;S"JZ2C)'
M+ +=_[;)C@?D\Z02E5M1PKZ38IW'$[3[P08_D+5,^9!4A%,DN_+JV8=*NW<"
M*CP"&>S6FH@SC:D ;NDT5/"IB>U3=Q*[U(?ALQ0-O)1)?16@YC)C@Y7K1*?K
MZ9R]9B58XBL R;24"[@_"A=@,%S"UQR/WX(],C2OK]S0!'!]&]E*81?ECDKF
M$B5GK%M!4U+LDJ\_H1IBQ6+%$C,;G)0HBPDSZ,PE1NU.>)DM87]S5#@V0F%&
MSJ.FWRAB#>(+&/?/?93<2=[B,3XW/*K(;0&N 6/33)%.D:Q=N5CL5:?5Z=+0
MBNDB6C,Z$/_JTZ_^-9!J08QT\^W@)]]@)@L3Y<6( U/[6K^5:#)51YK]B8B%
ML\">0^9<6Y# V M5S <?Y,A<CHWJ07<\BSBAF5^4S"'&1?P4-""K.UN8?EB%
MTP@Y:>'/BLF$<)@(JTT7R46\G&5T[V<$Z8QRQ-9<RMVX>"+,JZ@7@/XCLWDP
MYXBWSK8YICG5\ AA,EX.NG6PCJK:\/2D-8DUV!.8#[$G'U, A!7Y($S]6Y3&
M'/^TI3&GCZ4Q]\:8(S<1AZTD0-"M^UE+<TFA7B2" ( W'.>YX!\%)RD=]XZM
M=@WV6@1#'[Q8KA'W3M-KCAQ"=G*\G-LC./!MP(%'P]N! _>/N\&!9_$BFZ]_
ME4Y'S-0VH,7@T2?#>P$Q>Z:10@M/JF::E[%H!PDU,0&2>X$Y^*MT2X[B/A#U
M?J!5?<Y>M5DU]JLHE(G>+1@TTRI,KYBME"#0X 2R0^XJ@B0%>X</ON61]R!A
M?4OQ)UOE5YSS8O8 L(#00,0R _1"WWT(W[TZ@]5,M ";M\2W["1+\9.MVW,;
M\VF:X%:XIB4B8R(LIH;H&J%+)RXOY!#SV0$'GQP3W/T1:@WC%T?-A--Y')_K
M^W^^#9D7/I>!^-<>Q86Z*7^<R]D'>X@+1=$M_,G6['Q*>#NK4M=A[IH_'H,(
ME7/$$K5$RX>"6RB1Z<SPJK)R .%3JPKAG?!8()HDA0R2+Z9%VKU5?H?L)2Y>
MKIBAV=2U9/>J?8&8,IB+^!'JE)Q04#@.L8:O8\.61R:^4Q1'FPMHWJ?HGX3/
M; 1HY_M&M72]%H #4DCGY,F8ZO!O60AUW_5P;_/PGW'.X5T&)1CY,2-R0"F$
MQ>GEH+$8K&B>EG%V<? /4,FKQ6%(!PCK+24CW?A),RC%<&=12.E]=.@X<F51
M@_!3OQ6.TVF!^]H(@Z/B<UY0N)Y?:V-R]O><=Z-HV/:A:O8'K*S5DJI0<G@Z
M_/6"&$9FX9/^<0"*:X[FA 6H:";=/# X4[2*:OD%9CS.#X;A+)LS]D5S.\*]
M%_"G\$UQ& Z'PX/!\='Q8+S/V<(DG<YC,CV4E"=0V*3G3^GQ&KO7$O@]IRKQ
MI62VND=G4>W.'$XW6AXI(-V\@(%=P W+=AJ-CH^B<>_D*ZV:F>BQE,[3J@5F
MU4Y&Q\>X:NT5"S>MV$B?Y"R9LQ3;5XV-E9I;6&A:F-YVRO?/5TOE">-*R]:+
M08!7D[^D]IO3UJ68G:8;PXAWZXBY1\.<,0>G+0JX)Q-CJB#=L B+M+[$6S_!
M1R02DX&-DZD+63W;:%JE:I#@J+=ZIL'N]RN0V%%_C*;M8C6_H G:C3ZWW=!G
MT_HP:';&QC@-T]3JS2368+]!0\05&!R._Z8K<4$VO$6X1*^=?N*\OW'(R3$H
M-./OOY#4&S,(X.:@ ETPCK>ID2.VC&S"^3O&A6EZ "ZCSL9U\%"2 U='9I4'
MFFW\.7^H5 /!)?DABAFCA[JT;4U@3E+NW';0K?\>1)2<<1[.5A>8D=+3Y5]"
MA#C7CWKC470RZ@=;KA[<\U!;P_BC\R7L[$&<H(F"Y?\Q=G]LEC:/(-;(J19O
MR8#H:AE%QR>#Z.2X'P5Y2G:Y.6^$P\H)>_?D4#^Y)Q1/AL>G46]T0EF1QM%Y
M*'@!8H>"1E[-.<N#Q_*?JX2+@5W[-+#-))CHW75SU5IQ6)A@#+@7S\[@8I[,
MLPJK$V+J1)L34W$8PS(D6FI%*CO36 C5EX1765UB^XNV$IAZC9?_UU1H8](W
MFZ9NV1#'2&$"*VRRH7@( A[;<*#-P7D&(HT#1Q8YWP@;^7DS!MPS6S22'::'
MD7PC29%@04JAS!C83%I50C9%!&^8&X"%>/KJY=D!JDM2D\$EZ&TA[_R$X!MV
M,-QTJ;75/'.L!3-W,ZYVR;+GFX$OTH0P#5Z -QV%S\K5!8_G:5$MJ(:%M/X'
M:>7D#0JHHL!66,##C4%$8 ]:)8)$I6O23_[0?&@%^"(5-(1_F%'9=T58&T5_
MCV#4U/@BTPJ(45$ND2EBK2[$*E>@!6?^2\QSDZ,4K\"$*+7ZSAO(WKC?V_M(
M%AC6JF#-3@Q*2"]2JL!X]_ILWS9YPKBP=$=Z&<1*\[9%@"] 3.7]+BZT%(<1
M-'347B/A',-0?EGRG8AM/8OB2DOQL,,8W1(2"FQS"R[AXSG]"(:1SIODIV06
M\@OX"?^SBHF6D".&WGH<DM0P>@?MTA()0"38534V<0+3RA%) T]Y<*3FH2\X
MW-&GO6UB!F@%#%]FN--=&YABTZ'@!CFH&2VP9VH[H+IZZ<!M#/00#7,0EAA/
M$6LAIB0A4=WP%@S_&[!'WD?8;AJJ,.R66NRM&,%+A3&TRX&%28WA+C"6M64+
MG'9@\R%)WR9YSF9<7JPM=XLB81.K* /S;VP%1(-:"<>OXS6LRRL5VXR+49P6
MB2IU*I:<3>$Z3'? KE'9'#>5C4W@E5*3R.)I:BM@.553X4?<NWQH=T@ OW&7
M%%;YED*Q8;$"? UM(M5A7MD3C#?=OXOR(_M,H:D1?&6U_W/,^_":O\-JE7AA
M+H W_SX_>/KJ^3OCG>Z@!?,Y91PG/VL9QZCW6,9Q;V4<;[5H62 3QEC!.1,K
M)L&K-9M2XW19AU<QD5"1OB&]XI@5M:"X3[%XD?&[U<Q;Q-@,;>D.;>N@?Y-\
MH Y<?!&!I=%5L-E #*1'A)B#.BS;YOU_!QM--<^+9_\;[K7?GAH;&(PW<X7@
M M"D4;@"/(85N !E5L%;]983$Y&*3Q:-*R$OJ/HE+8F1CE/B"[PT7?X,=6Z\
M-ARZ'A%G0,FT4B%BR@/K$HS)O++/:N]#^[81^T*6YP*+D'.Y# @Y UZ:?D0C
ML8[7&GOQ140?'A1+V NQR/37&+FCL.!RF<:&E@)&1E:5\)2E<5YU/!BC>-SO
MQQ66%-O@>>_B?=#IT1J E;<FP?= G-4/#AZ!#R"#M?M</PWF2W$M<!(!<0*@
MP6+89?X"W\BGE[D%\$I^1\"7#QXN ^GF %GT!-&CD<GOGA&,)VX O3C3O-?"
MLV\GK/^9_1?%H$#=.;BZ@LSC8_$$+6"?7SG)M5.2S?][V,]RG7]C$G<VL6Y7
MY+>QKJ]A66S/SFL2_$9RT1-7AIR$M;5Q_"]+TOXZ95KK"54/*->UVJ#]%@K'
MS6\TB7Z8+W[Z?WXY^N6V)O MAK@9[6W#"/^-DDV#>MY"FMJP4AW+<(NQW7FE
M;E&<T=S^K[:0-PSV/5?C_FB2-/BNDH2J\#M+S.,>P"VT(Z>V"W2_O)CL#7JC
M:# \B0;C\?[& NZCH[]UE%698^G/7.^3KI_<H@:\_3-_8[ \ZY?_>K+IK:.;
M?D]9UE_^:SB*3DY[MQ][UR!<-WS7YM\_CGI'XZ\W_R^1PS^9_*&K[&]#%>"F
MNKU->]*Q #=_L>N!/]!@ONW);VW_#?J2Q_?6<"PK;^4/N' _U&"^XKG9N'7M
M$9R;!BN.P,..;;G2;]1=GZTK;Z6I3@;1:'1TIY_>X9W?<6+CDVC<'WWAQ.Y9
M#;0'\UY0"J2LT!1,_+#K/CB-^H/6U?< Y&DTCN"P?$=Y^GR%]'?A<*"R^ 1Q
M;3@9?Y6:*K0?=MU/HO[1:30:GSP\D3J*3H='T=$7:]][5E*=ON;9 NLV.,=\
MXW0ZG[!E%^[@?=YME[[HP:H83J/C84LZ;_)0OU":'MH*=FC6K[&"WT/=;MB<
M#T5MN\*PV^MVBO>!;?7>233J]:+CH^.OM=W[/]D"'H.:/HW&@Y9E^X4+^)TM
MW0W;]);2WWMR6/8))7;1"HH]\"WO'T?CXY:1\'A@;KEZ47\XBH;'+9_D.QZ8
MKW>W# ['[I;AE^#'A\>X96_2.MR;%U5U]RVGQ]Y]T^EG85*L)O/T\R*M7_I8
M>\\,3X;@-@QOVG59P&]R<!["*AX?12?#&R^;.Z]BL[EZMXHM-N LF:(3[ K"
M@^?57&PJN8@(*/")D5A&LL6Z#:XX>V)V8=OCM#1P*'BD L6"_4K@8R(X+0&D
M(PU)[/%_!>[7LSQT@P5GW<&"72SFZN*T,#FV72;0V(3YA6UG2/1)?;BPZSDA
M%\X-^E:5Y82</TVI@^0P>*]0DS<+F<HLY_E\:>7<UZU$]:'(D0WXO[8!_P<E
M4YIP,A1MV-?03G/HK@<WR Z6]CV1U$-+W4GD_C.5'7QV.AQ0E6" M;'8%&.^
M0%33#&?5T'I=DR&R"VQ2$6!6_2FHPR2M",&^QCZA^*$@U-^BW^'TI^UWZ#_V
M.]Q;OP/=S4[BZYF;^'I0BG53?D]MK0XM&&RZC3GUUM:GG+FZK3[%(GZK3OO]
MHZ@W/N:J:_,7>%T NH_ %13ANG:_0-C,IBFD7.6FNXYKQ4F=%CE!!0O,FNFA
MMZRA D?=G%'CR4'SR0_&KMABBML*D =U'&Z1J?3D.+C!QC#9P]:I0+=(TF^?
M:6GTH\%P$)WT!X<!KP\>D9;)D56.Y[7!]B"T"AP=3)#;*\UD]["/IN6ST;GA
MGS$J$Y()52O0#4H227VY_[.*2R2Z0B066)3]",\8]B1)RZ=[7+F+ZBTS=A!5
MLXSAH1PF/T/YH$Z-.[4M%\?&T .G,*/VS7%ZZXN#+XB:DESQ[8;3OL<L*R[!
M@;J/0<B7O([S"V:?JJCAATXAW$^]GL!9U\1^A! L]+<A3TNZHD&)S-<=DZ0'
M4%]T^PWX6'B,KH+WAI_)PWVK5! (-:#I&(PK/ZAS)#E:FFOG=7/#.9),S7Y+
MQFP28O_.I^G&X72<(^RZR^04$"(I,@[I2:13<P(77R\4]"+S%=E@OMUZ1Z,O
M&\?PYG$<P0D=1[W^T+F9+F+":H#OH1>^RJI+Y3!)TDG-@SL=1L-Q+U(V.?C!
M+,Z$!#"@;Y;9%=L-"O'%V$WC:-0[B@:#GD6M[9CXR4Z=VVW-?N?9I_!U@;0T
MTA/E$]E+M]_H:W?[W6/+:J,55+LX$3)G0=!PQ*MENU #6X.AO:&Z6%7VZ8 X
M?$Q+J#!VWW-+Z&.;XH-N4X0S24/J/)<[TO&TV_O_W1O;QH_-A=]]#[YW@^?G
MMP3?W#[4ZA_L+$+HV(L;&V]NT^SSQ<_];GV7&X3]SLV87[^(Z@L[&&_[^-MV
M.)Y$H_ZV!L>O6__\$R_T8!@=G[;*R[_R2C_VE^Y29^)C?^F/,I@?HP;4T7CM
M_SUGG#<EE?V2)K '5AD\C(;]X^CH^*M5TO^,O3OC:'0TBH:]KU:>_@-UWSYV
M\FRK#?[JQ^=G:TSXZD?GAVI,>&S?T7T^C7J]QT/RN=T[_:AWW/^!3L@WN5>\
M1I&?N6T'+Q58UZ/'MITO646X6<;]:'Q\NL-M._>9]X=WX:%[!6?N@54T^'U)
M_-H<:<+P'UZ'4I5]"BGW64E-G9\HYG8//9VM @<C<1W/"]O/&[7J3 =1?XB/
M/_(K3;&>S313X1AL+5UMX(H92=PM9MM2..E%Z=OJ_9H-(%/F8''0 \(T[JC5
MX\H[K6JU'**[4T#0>HF(J2.@6WH"QKV?MB=@\-@3\.U[ NZO6>^[=>HE6*F,
MO(Q4;\@A?U0HI=^2%VQ5JK::QR]Y;-3N.X]%A7H[?8@ [:3B_M4/L?;?T;R"
M\CZ=KY3UD8@7B#8Z?(WT#EC"?XZ453'2/E5R&S'[>GA6UZ@8WM&8F)(AK82%
M#VE0<0X>U:FP0995<!DC2VB:,H$!TO0@XV.6KZ@8B&@RBWQ2P"(CV5H5\B0F
MZ_!? UV"AZ2M3:3W.[<-W/<INLN\\20%-YHG8VT?,#&N+H.'@S=?8/",CJ*C
MX8!I5K5OP![3CKZ!;8T"_,PQ/+,_'&L'C3,FZ0%H3>2H'PU/>_ #7A:XX:3X
M37XQ=IL&B#I]&:_+8CXWK:!F"#)*_A(<4"0UG8M=--ZIBLI[%#7+>J'KRAQW
MO+:VEOT4-FH,PHB:=WO'&%?%CZ/!Z5'$?:V!W]?J?G$P'D0G1T-\K!#N<IWO
M#.P)*IJU(^B/Q]')&"1YGE[(U$$7SU*B+(4/9JF(X;C?!R=A%%'9I5"JPK<#
MXN.-IS4<&//=X> H.NX=1^V^$_YS?Q2=X%+-,N9-T]^-!C _^!P>F%<S&#!Q
MB]N_PQ"PNP>,S5E]C5<##O<ZG9#PKW!(@7=T^B>]"%\6TGWAGS%:_E,\)DHK
M2%1M3"M9^4?P.!KW>C;9-BW*)?:J\0&_3..D<6+!Z3D][=$&=;9-T'K"=^[0
M87&3O+'/U]5-$8!:&PZ'W<T4HY-H#(K"LRP>SW2GLK_MF8;KY>0XZ@UZX9YE
M$+RUDM^/@MOI@I.H/^A%G2WN[O=.X4HZZ=]*$_3@@ \&H@F"S9I@-!I%H^-A
M4Q.$G9H U-7@>+,F "4U'I^T-<'Q470Z/HZ"39H IMZ'$[1%$_CKVQ\>1Z.3
MDVV:X!3'L5D3!-39<(P@;7?0!*/3Z/CD)-RJ"4ZC\<GQ;17!=F]AM$T1H#NR
ML:NJCX/X<?3 +0K?;Q>6VU"^.6J7;V[X9I],WS]3NEFPH7E5;MM^HI[#]DZ1
M(%S)< ;_.@S_45PCDSF:H:$\K-$SNEFQF),;^"?792F=K4K0;I?*_^<T5.MO
MX,C&RPQ%C*0*O*]523+H?!=)Z4C=1(ZZ</Z^B)'%/IY7$8;Q*!Q$S*0K7IJI
M\*,[OR"Z>T/39:S8%/1% F[R?*9&J>L12E-?S,S:4WVNNW@U.ME7:=#@[Z/N
M(5P$:]&DGZ2E:!/!:UPYG(%TZL7C/7_^U- .BA^:&J)C[W&!_.)-7"7Q_X1/
M9:$9.^8P_)-0>6"!8NOTQGF^TKUHP+ P5>T"H4A*VOT(M0*\DO<#R;4O8 ;.
MPY(,B96+4CUQ4N!@Y&?3U'SFM$T9?1RU?DE:-K*LS3Z/KUV83CLM,@(-&F^%
MHP.CC,BA:3=(@>-_"@>NBSZUS6?_6OK@7GSV[]!7^0,T56XW50/'"Z>N2DJ@
M=S554FYX_Y8>^,9>QHV_#QHQ@1N[&<%'0 -J2U?E\/CX"\<QNL4X8&&.AJ.M
M QD?[59O,O4XOLI NR2HDX@)5O3F^[2"ZV2:?DT>SGOR/>R$DK2:EME$6]]M
MQVIL[LFZ"-B:J)&/'-5U1H997%V"V5!<&]R4ZA*T\0&M$9+7'L#N+R@PHR2\
M]).FJLZ0T'Y593F8\0Y5IGOW71<EDM,&:AH@)RY\@=IRJ[1$!E^X:*;PW"KC
MNY&;;-%0EHO4&@HPK4566PY0]0GPGBO@(K_@]]-]2!*/YL/<+!@&K&!>-'1G
M"69EL7")/NW[1$@BO:2STJ[B%%<7K"+\,ER\]O=@BF5HY&-M"-H9^-=E"2N2
M+9'%E!^)][D=F(U*@T\TQ17B0>'"8ZJ0/!OX!2Y__3!<Z%OD"/L_;8YP^)@C
MO$^>]'_&8"F#*S$XLDA (0V?$E@"5$6(C<'919F2 F1WX&D99Q<'_X"3OEH<
MAN]6)1[6.G1_$IJ?T',7\1H4WWP.2J46S8%J(P(5#&8*DP[#IT]!U8$[<TZ1
MG?JR+%87_MNB (P;B<^@?7PH;^OZ/64F%G&2@K^S=8220 .]%:Z6 CL47\!?
M+\@-13OA. 33>HZN%A&O!S$,/ 4O"[XCP:\"'5WA:L;DQ)S,+^;TQL@87#DO
MTDG)2XY1A;T72"#^IC@,A\/AP>#XZ'@PWN>8"[S*>$:2G^N:1]"<QX;1GT:C
MXZ-HW#L1UOA8'<4OG,.8YQ"8.9R,CH_'^P]"4Y^13)VM+E9@#F*X6[-=J'&3
M$ SJ\2@Z&?5%@(,N 43"^!"S\268F_S1^1+,E8,X05IG3+'&8)_*KG0))B>/
M.<=K;TG8XY5$F$;1\<D@.CEF8YI&(>!P',L@HX NVF6<)=Y10AL;'(;1B47U
M)$N#8I/5X;VL\G>-5W$4ZJV5Z6#@:,+IO"!_&ZV8*SQ)2[AS'1U885X<;#AP
MS,&:21,3YH31$27[9(V/D9JG6/V86=@_B8X'Q^'>^*@?'9\.\?E%J2>Z0UKV
M03[0Y-S#4,*@]]L?^%_T[_YO^Q$/)HVGER'^05T>% !XUUZV#U*8LI!V*DG4
M-WL9?PWCH <$4^-]!;3.])+!#,L2M0_($\>GP9=*RVE6(99(-M4<S.&H%^X]
MZ1\>GWASZSH)^YC^Y-%%0;6:_"4Q*#X@M-A[^--?WLDFO---T 5@)['U9SDY
M7(KA&93P=+-3=CN"SNWH'K*]LEHKN6UONQ\F:XHN">*+KW+6QG0)FZ,,KP*-
MO2KAEDHKGK'9%+/R$@"4;W%$X.Z;$: 41;[BN2BQJ-!5/_B$I^)M"110KT?_
M/V2S"VX/A*K$!]ASX^0;]OJ]OX4PFB=]_MV^$XTUTS9Q+%1B*SR-^%[TU=L.
M0UL",$@@?I@)T>)+VH%F6,MEH>^A\">(8D7V9PTV@;,CW6]JB8$LC_V0I _-
MS=6R8'DT)T=VKO74X$^5#+I&-ES2\!\O"G!:SP_Z\!BPK0BXN7US"XXAAE[A
M)Q9_RD9\X!YZ!S?&P7/SFS-X0R)V!0("5?R&99E>9<6JPA@\W/[)IJ'10:/L
M'OQ?A!WE+^".!:2'SCA4^YYBHF8F_=[!?W=@9O%-T05?>9F![L-I\VA('SIS
M?4UIOX%;^84O_Q<C/L[70?O]_S+OEP*/[L*7QHOA 6PN\%"MS4 24<@B@H=0
MUH3;)0%-LS**2-F]G(<WI%0ZDB_?,>K[ Z::R BZC)-(LA><[J CD[8M;OPV
M 9D6^46!&@0C.)3/B/'0.CD"#JE0,&558^Q%@QT; B44N >->DV?:QR)5(\[
M*(F?$"X7O2)G?2>"R?FPQ$"6LF#K7U$#5VE*&F>VHH04S7#"H5,<%4:GDG@-
M#O$!_)]F(*BI-_T<C_R>TW8P$ZKV1DUZL8XPWZ;9LBJMP2-QD[?X"PJRXLK9
M=!8GQOF'YNN4VF%?%+<F1ZT$)X+.-RVI[,R+9V<AZ&LQ7!6+'B]*%A!>V#E>
M2OBS69:#'4##%T!8_)'9Z(!,<B>Q>)&AG5>FZ-E+R0%=N971]""YN#3A58&)
M+@U'XKOHZU'(9AG)5B7N'-S=\WG*.37\))Z3<4([C?L?3(L5N!GP31*XQ+PL
MR>8K+OY$*5E@'PM]BS>(1)0L5S1<8VS56F%&B))*,2U@2](VBA2:P0')38D)
M5UMD)U>8;L#9A]?A6[FS(ZTZ362 E*K#Z2<:Z(1]F,57L/,@G0\B0Z4>(X>,
M5\LI\H=<Z*FD.PX#RFK(H4Q<@@\)YE<4&"F13\PYC:N/O)OQ$E<TY7/-9]D-
MCFXV1O\#]M6Q!V$+J'</=0)GCTLU0G G"-;5>P1(%(P<OCA@4XVJ%<5:\=U<
MT'MUS"J! "E3\_6\R \DV>R((#:+6(D%TT3RNYS7)7LQ>"5.S/L5C'=\-!SO
M)?OB"YR3,_-2%^%=68#U%L]=CX!J0OECK-[(<*LP,JVVJ_ZQTN6E830W(Q"4
M=*=</$\SNK=A'>3^QX,SS^ !9-J1>FUJ&!-)#^-5?5F44H92N6>%'48XE[@F
MAV ;K9W%"^PCG67DN$$=?TSS+AU9XRKP]&#B*E=X$L$P%T-)\>/C,EZDE!;'
M^E68!/Q>_N:O=J"K;?(PQL."%WU:._:?ZI6.<P J<>;M0YC9G> \!JI^LK[I
MWLZ+$(MHLAD($L@'W*+X]&I%!5W63YJL4!G";M!5?\7W$%ZFM ]A?!5G<X&^
MI(6O:,M_I_(EV-%GFK3G!81+'F8WFZ>?,I/@-R?9\8"T:2RPJ0VZK!]$'.PM
M+)#-C8D"ZC(+2,*"),4:&+PA%N@;SJATS4N-:4N%& YH-D2TFG6VT*HW ;5>
M,9BM).&F:8;GE$RM*9C9Q0(UJ-S L _:5-%5R&N-@M:[8-8"FEM1^0Y?R-5J
M25Z!EY)S)[&IG'"&A\>>^,!IM)"[,$Y$',5($%8'L#E>YAS(F645ZBIR?IA\
MBNTF(:"B\!0="V,B8==?VIW3TTQH$N08$4;';D,6T%LGWTR XPDV#OLQQDQ&
M+&&6!P6!W6Q_/HBS<(OLW>"GS=Z-'K-W]Y:]^R.?8^T!J $JTQ5>&5OS )/!
MJS*6HH>@,^,?60LF*;#E2X\MZ)8EJ$(QYSCDACX$7 "1<9;5'V;+)&TXN29W
MYX9>,3OA.,Z<UE=+U35/I4S"!CQ?%<5'(4V[AKO:+5ALCJ?#/V^&_NHTD$NH
M,L4>]HIS0:_M[0;*>4:V7O/QZ MW3]>6+H3;YQ<%$FI"\4/A*:YAF-5EMM0K
M0AZC/H+Q#9V-QMXG= W3)'(</^1#J=68<KW7<(Z7EKVG*MSDZ_GZ0-A1',<!
M4[=TVQ!H0H4>7@KV%I[N"F>&^9%LGEZD:#SF)L1<<&P3C"<VY/TYW+">:(Q/
M,$R&'OF\B',3Z<W*A.=GKG*M;>%76DN9PJ<78IS@)#0::>]!,#=S#K&6$H_#
MZB]8'Q,8<&,T =F2O/@96'Y9Z4H]BJ=C*E)U^KPJ5(HP8\<140V!.+5H#^)V
M_'-+S(CT%)]8/J9:T(HN%C%7F;"MV(7B:'KQ,74%\ =<SD2Y-[M[DSC_N$$"
MZ $Q>H$9UNE[038N4@HT;N<6*;E&GQ%EEE&JV)*S7CF'710:'O+(N%U.&9H;
M%K3V%E6[D\68P^J&_8$4-I)5:"K":06:)6W=<49XZ[K(-67B/C+LC$#ZJCWH
M4J6WTG7.]-F3 ]>OJ-7C"M$KB"OM6_'BK[1,4UC,:K:B;LB$ G)5\2".!^L[
M/ >K7&_LC9?5]66:@R]583 @:FR3R#=EL"2J)LT-S-& =X:5@FN]*\"-7Z!S
M?6Z7F&()_  ,--6B<*E%*6,#RXE;LVM7<9P#W!3PLNF0\56"KU77+DXP=E2G
MKB/ESH%<^$B#GJ GD<BDJDU T>;]/F!<!(,#<.J-U 3;I:9$'TJ]NPH<Q<:L
M2#\_")'ZX.81)2@M%H.-GSC1N< DFTDO\I4:AY=PKW/-]6A,@@#6T+6;RW>^
MTN\?CGO^ERBW+%G?C9GE/9O<#VQRWTG_-R.8G.6>9Q_3>799%(EF-Z4"P8V6
MFB7@6E6=I+%M2CLV/Z@0V)2V2!3'TR76$*'@L=1S$E3BWLAJRP(EF?=F444D
MO4)5+0T?(.-<8,,_H<RTR1X^&1X>G_8"_#'X]YS>[',ERIC,I%N]$\=*3@%,
M1?.(VG>V24C<P*U9M8!'AJ385)LK9= \ZA@S+?@;+)=SVM]K$%ZZ0$ST338(
M3?[<Y$.,_.G)7>6TPU14[&^CD55?"5RL8OPTE:L#!]=ZJ#@ML#3IVBMZR$I_
M49:99%DIN\WR@N6%J^EEY#TZ0/.18[.8&JLOYZ2)N3^2;$L1&1QBNS;!S?7;
M:?V=$DNTO&*?)]F,#&M:W$E:7^OZR^X'FW=?HV92--#:<?W[AAP5?RW2&PHO
M[$7\D9ML*;&73:T9G*3P9#8QJ"6)\V=LW<4V-Z4*6I<&Y< F2S>OB]O21P]8
M5<Z/=74#/R"XZ7$DM>V*CZX<IU:!&+^8#7U#9+ERBNK)LJ& IYLT3I%5BXU+
M"C%/G.Z$Z\;&V"U9P"F2[A.U-)=%+5+@S;E[JF@S.E5$G.3DN)P-2,,C_N+D
MP,,(2S_%=8FEU,)OVZ=".Y"+)\?1Z1&6O?80B,=KB#J.3@;8NWR,WG%'34F+
MP'1XBM1KA[?$ /K00;:%+.A5X*/,W2H0J_W3_J><[K>>COV#Z8VJJ>]10K/?
M [[GD9SKIR#GZFPDW#G&H%W<_^].#/5(SO7]]V!7R+F^ 0-5&WP7P6GI4J5J
M832&.F[4VW,F;84V_D+ZHSO3&T6GQ_UH?-0"P;_;..Y*&_5C+<%H-(Q&X][7
M6X+O00'0(:9=)MX-:-Q;-^:S!>$VVW RC/K#P9U^>8=7?K]Y#>!\]?HMX;I'
MB?H*D/F.<)GJLLFZTU7X83<"Y.MT&!WW6VP&#T#&HN,1]@ZVM/AG2MD]P,O?
MRN5MX*3<AZ]YZX%AK"#X0S2M.[[,(7*[W=/.G,,C<_SFL##W%T_99C3="?[>
MV"HM*!ISA=\)BZ;+I,/X8[+"LL];88<B[-5LE4^U\LY@Y0N\H,+U:V>N+673
M. Z6X]) [/* 3"RJ7S%'4")H,W7Q$-+>&*;9CWS0.1-(0CQ BR;+ =@##J6Z
M&'HM(-QQ='1"@+7Q=(IIC$I"JZ@!&E\.G@P&O>CX:,!]PRDU_UJH?@LM(I%G
MQK-KO1&NH=/AL??*9;RFL [%RJ?3<I4V'NSQ"P1S^H>%R.(<TE%T='3T(.*0
M-TOGS8=F=(-T6LJ(+Y9.P8_$AT5!2SJ/3J,3Q)7TX9&WR&<C3 H_.^K=3D#A
M9>,C.'6]X(L$M'_:1UOT"R0T) D-FA+:BWHGO=V6T+M14PQ_VL+5\6/AZKU1
M4Y"9H:;82^/TNF;5P\'S>WJ3AW\GFXJ][H8UQ1[KY]M2FT9U&Y-*FZ*XY9PS
MH(I*0!<7-O> Z\NUD 8"M0V5JUT,#T+=TJ:_<SSO%\;S?L!2?E.HP9708(M,
M"7F6N/\=WH-XS[>6^,VC"[:>PXVC$T&'08Z0?>8$(<PW0%)@R0^5&G&A!A=:
M6(J()P-X<.]X&#!(L8$7U(KZ6%& MLUBNS;I1+/V9]$;@&D)"PJV^AUF0?43
M!I_"F=))CQ+N[I1<T*JX8W:[=.H)7//M;';PNS1LGU]B]X!SQIV2X_M#V;P?
MI*0_L?L\H>(@JD..\S5BM1QH\WI%:^&5W<<DT=XIN@.0A?N_.]@H3L+RM+!@
MG6\M6&>X>Q"L9^V]C)SF(14) Z2P :94BL.HN(I_8QLRL*MB2E L<P_ UM;)
M..5AV<QK-9>& >L1FR*J8#J/LX6\."ZQ;(J;2&6 E>FG]- /"3Z0E)=3HKSB
MKA.N1Z0R+U.JI45OW"""?52MF05;9A9)J2GUC0O PJI&&.*=TI";[)%W5(?Y
M7AD@+K,E@Q8PL1MU?_Q>8' C3N"YMC7*4Q/S%+';#\11^C4\Z!T.&![XU=-[
M",BJ1WVK(374UC>WPP1^ J]I]%\7TM0L#<EBG%?(98=RBN!>R#HP7XO'(46S
MV$T%EQEA$VJUOH-3'(6O0**G:]TW[\#$#B36V86:^F?)558A9<$YXQZ[\(:$
MYR"P=A;XBG]KOF6A[A(:U]FRS.9:(=V/-LM."%)A4/,ZOM  C(@MQBE2%YB%
M0/N,WSF@T"WV9C26P5DU@@!!7(8YH=G8AY+;,R>T BSYO$ <3FUUGPIR-34_
M5%-LS8D=#,@YQ?,"*F(F "X$3=BP0V$\JQ$IW6X[\3BD4I7JPD?,8L2M0KU3
M+3-L&TV)6HT[XBN7L0$197!L"2P@-E_MMD8R3;2*NNEL7U."+8IMX&\Y[0_W
MPPN@E]3<<I<D-<<CR@TN8:=PVFI?!&F,P_JZ8.Q%>)@IK9<0,A<DZV."<P?E
M3]M[\!*JYS(BCW37*EF\M@P^$*'*N>*P1\AQ8)];;;!Q-?;IU 5XW6,SYMIB
MSX$F(#P#'HF_9N A="S%;Q:#,N;58R^HI/:)V:IBV!8T#.*J$W<C_42<FE=I
M&VL0-F P.A!OR)9/YXF*-O?\SK9/UU-4W4,TRB0P7*4P6,)F83-!&ZUPH<3]
MVJ"3B"X$A&#%VP6B@!AQ[ R#OH73' L]Y]9!4UMQ)5@G?)RIQ)WY1^K"M.3Y
M@DOU_RLAS+DJLN\;EKD?SZ9C(Y Q;%G0U2B80:HE'.[6S0(SP7;L2EBSO%-@
MB[]Q,W,K%%E-_+;4+,E;#G>/A0;>\JYT&J^JM)O-IF-J_!I4]@A51\*\HEO%
MM,88@%3J/LUJ70U\2=<##8M;3#0^=#BD5Y2;=-;T3NH%A(MKOJ;)Q]0,7.0;
MUF>2(H_1(999S=,NY:=GQ5E(!"Z(RTIA2K!M!M0&?#3/A$AAE6=3<41('71/
M1S0NC1QD"7^BB&8ZFX";9*2EE:"(9%+43JYZ4* 6.E]3.6UZ/(G$0!;1:_ L
MHJZ0!D>&3J4PSW5!\#"(@V3Z#.XJH]2WL_;N ,8]0JU.K*3JB.BFZ@9NGNEA
MXYJLX&_YQ5Q/ V&((CB7J,/#\$U1XTM-'YK"QY /&;GJGC0J+CI1Y"T6M"6-
M"1"_E5QB46!G8YPTY[8294CB>$VT6#*K#5=V-\;6M@6.B8NK"K I#$&K4"S!
M6ZZPUY9'#HK,31,[5S^NC/ [24P.S[/#F8'N*/K4?!,(+!E-+Q+2%[YSN2&/
MCR*%]3$"-U??4CJ^C?]NJ,C"..$V3NN3(PAU1_/Q;B&3WG-:=?33IE6/'M.J
M]Y96Q;S>[["\EP@QIOJ2_=_W:JV^(&OU/5NK#RD!]<&Y(M3714O$>,?PX40O
M17);7L=YC KM[;0NL/$/ YGHVY.UTZ7BVQZW\\P(]:]UUSE(\3I>AWU&UQY$
M(;TPS2] $I+0VZS VRP3K- _JU>!UQJJW]?_.UXL?SM#Y8Q!E</P#VQ*5_>\
M@9GB#[+AOE9PA::6@U$"M0$/DJ'LW-@.3!$G<1B^S>%BNI(N]9%.4)\*]XZ5
M0^\!%DP<V4+ZX7/[HE<40O-\+//MP'[/AFN:A#/VV?;;D3,0T\M^0;WCR6W\
MS#E>_F#=_ 5V2'V _Q58+$ "FL$8=/M;X:0H/AZ4*Q"B4K%0.K[5Y:@BJ[T"
MZC%F*O,%,S"\A5<)"#]*02\M($M#G(>'X>_:GTUX )U3=M<)(8DO%.8=W!$P
MU(IK>$ 2+V+\7!P-UR@+TB9AT+^+\N,5&!7X%0MY]2R=P#=Q:A\:YB;Z'CPB
M ^-I1V3'C5 B:8DF"L< .O:G:TT;,2\N@5!M ?.3EFTUP"A3< ?3:[<#8:*I
MGZ4+%#0YAOC/=\9>?ET4->F2%RFL&Z[.0[HZD 4+\UEZ 6!](4@12%0VFQG_
MTF*A!?/X&H5U@4AG-142+IB'E9:N08Q!Q\EUZ)J!*[B-':C_\PY2AY%P"[BZ
M$3X-NG]H;@O+@6"]%QSG<^7L?6J(?LR=<_[\J?D]T2:LM2%^$!:+K$:]:9P#
ME[: 7B:X&KH$O^L5]-2Y>QDK=1'[7JY=+L33@CNN XXW6\!=E5&ZPD2MID59
M2K@"?$N\ E?(PY01&$5L;@2""5Z"4:"<% Q1T[5\B(VDM!^<Y*L+WP/ES3 /
M-U0HYP?AR'MHX&WF/U<P[L&QRIB02@V,>>#@OAA!5&4N5RRMCGXF7[)QBHSX
M;FRXZBHND:$CX&201S",N "SF:VPO<9T*%-3\/+;Q21SR%PJ-"I]B+6S,JKR
MO<K@'/+^"O4(+\O(8[,(+#BT929Q[+ C-</>NCQCO$P,PFT_Y=6$OVT[KZ$Y
MKS;>A' 9S7.(E<-5.D?0=0ZW%P9,)D\OBCJ3;HAPH>IPEJ8F,6- Q36@$$K"
MN86E[2F;P%,>_LUTE5T4)7.L@,K*4AM)HT7MEE\F]UYP/L_;#+/: FFD\'%T
M6-:!'E[\C1<O(-@MBTYF#Q)Q8YM#1W$JHQN*TF"[^Y/R'VVNVXJ*NTO)M.''
MC0NI3(VAP%@IG#?CX<U6)44^[' HF./R(;CG?^L"*K<??#V;DC\)\E,=AF?F
M "5"J0>*P!C<L**&3*:#S.9?$4$6PH-6%.$54U14B905N$IFPO&I .66%Y D
M^)*2*QJ*S 3O"$9!\E@C*B(;)0PJ0RSGF/P!H5VA:0^#PXQ0Q9#<B%A4%4(E
M(1!]DU2S6@AU]5MX*94605<H*?Q&H:3=-Z?>$$ 4RJB;[KNQ:( P O/IX?W5
M,=R;F?72(1LE?!T_:-U,YS6"V"@KL<\_:GT,IDWN=-J;2EXH7$1T!8S=^!SB
MJN'++!T@EDNVZ/\B$NT\)M,N$1L%!]J]\;BGQL@R7S&FEG<QV3@&*D99G\ X
M0!-A<8SI^D%H-:1,^"2%'.&3_IBXU%ITIW;UX#?,A]672]5%&7,-,3L7Y!$M
M$VVSLRMO2E!=LPF9GYLA>U)W%+#@4'6<*]3N$N&F\YHKI+P%) UC_Y.SW (C
MB@Z9#>USXH7=-O>R28J4LP6*2*=.+2BURGDT/V-AH<PVI%'LQ)T<X3LEX?-C
M_E0V:TW)3O*.AP'#Y<7>%.@U99AE27M7BHC,M$9\XV-0A&]$D(^2DY"N.67<
M)T1.],VYJZR0&C)\RH30/E,IG$Y6<)^ EDE6]5KJ\$SJAXC\&(K9@<T.* 4C
M\*F6MPM,I)2$0UATZEIT34)FP[0F14%:P&[[1!V7Q#@NE&*<%=-5)65]+G?\
M;DO W?(@XY\V#W+\F >YMSR(C1B0NXPPV0A"^C(7Y. '9E3=QNJQH8#N:FRL
MAW:8'@J\ZHES$)0A-]E:Y&GW9L]\'PNIXZ@*+M.U)G3]$O<<X["L]P/U=SC0
MX&Y6(9OU()0B7HNW Y3X(\_0-X+[$8$#7A;72!@NW$(O\/MLA#PW%6ZO8)5R
MU^+X3G7/&V=T;W7/=QK5_=5A?VB8OS$"S<Z3:XQ9FD+%8"[;V'!L\(19D0BW
MB<3>'R_?O]CWK*:,NM]K4VU,_SPPK%;I]#*'1;E8>^%D(UI!2[1LQLVOE37A
MD"UBZ6L+"@U06 #K#A%,&7FNBMFOX5Y_/^S_C2K5J80%O8Q?N23VX@)]CSIE
M3O-$<!7"/3*QRYA#,-[?J"D$WK<O8-7<:\$_0VQZ, #@<RHU!3/U@!&B)0,D
MY'V$:9!1VX@DX0I#;>DM&Z?C*+UN*LG#O<%^./@;HUX3X1WVU!'T-Q?E[ UA
MMF/Z @(VE,4ZGL-3J*Z+7#N*X]!2ICB7K.8$6R64C4Z_2T6CPT)MM\R\DI0P
M+;Z?%NZ*R3=U.O6Z#*.CX2DR=)]&_>,>(V@'VVC#S[LY*.$G**,*SE F="T8
M.?=6,+2%CEN$ZC!HGBXL*P17#5S@N4"L$[;$((+]($->T9[QR[3" R*S;'K.
MT9"[%@D\./3V1:=A1]@ZQE_KTJ+_1<WVW9VZ+9N@>?V NZ1P.VE]V/,M".YE
MRF@;FF_7I0,/O*WX3/6]>M\.,+N(KB@UJ5"61\AC RY0;#PU0FAYJH&0ZGPL
MX2BSM ;;)F)F37HF6B^H%XD<U*4IO]VU E9057.F ",DJ\K699O"#I.E(13]
MSM':T*E=C-7_S][;-L=M)$NCW_$K$!OV$U)<D"8IZFV]ST;0E&QSUUKQ6O)N
MG$\WP!F0A(4!9H$9T7-^_>W,JNIN8# D)4NT3#+B'"]%S@"-1G=UO61ENJBU
MZB6=!UD)9C[<'4TI0>?\DDG1D#C<(R;''YEV/]']^2]/>U;#TKQN'_EH'"=1
MY&5&,.;U-R5K.K1#G*IEUY."":PH(Z_?Y]:T!([74T*#,J8%?]4+DRA;+IE0
M*4<R ;-BJLDC&71/#E6:+U1Q-+1#C*RRIAU.A]KKZ.C)U ]0QOHV@?V9PFJQ
M!"'6"# &)*#>LP2_4L(;.=X#!GUD!)."? M /.=M2W'F6"NF4L0P$"OM<KZ8
MK'3,.03GWS>56V?P]Z._SXN%]"J4W>8RQ2<F%+]9RR>=N4@J8=M?E_J-_$)8
MF<=-A0*:B(R^B<3V_K&<GFGC,ZKMG?38!:ZXDT_]&#?$#3?L6V!ZANLR%'%\
M;==-"Q!,X'12]?;AZ?_#P<&Q[2GG[;KKR'.P$">"'_K]7A%@_,;RU7!WO^L3
MVSMQI5)C5E@H"5O?.<-G[XEO[5?_#J5?F*53 2*9EHNHR(BXB?)2&7\44_ZJ
M@Y0)OTDB*K-"0!6DH*.")=D5N+0*3W7%ST57Q7P-7L38W&][W#>M J;-/QZZ
MC\]+]'5PV6-([D2LH?OQKFXN:I%XE3O36Y8?-8.@?26JZ.O3Z;XHB)<.4JU&
MU*V"Q9^4[60Y \!_HII]2215)4<C&YR(7<R[4@R6ZH^$UY&?H +,*\+0X8]P
MW8OH/:Q-FK9\BZ*)&]T4\O7.VN;HNDA$<X&/I;E?/WTFY3&80I6(Z9:SN9<(
M1$NG"E=Q]-O#]Z19%WMHR,6(T@O3P]JE%6XA,^>U8/JW:T.Q]$^>*HGTI54V
M,DJGG^>&*C&,JAKK) ]F>*YF6!:LGS\?8!PL(0Y(J--B47C=G'5\T3:*]41S
M0=)\'KM :TB1:X\#9N!40&'6X9RWB_3HB-?:^_;([=CTJ?[CE7]T?Z<7SCXL
M!:+%-NHZKU;8&X1RZ\9/#GL*<#^';?7:TQ#J'?QI-W*.]4\K#69-2F;6= NK
MG1Y(4+L.<OAG8F!+MK *!&5$6"6H7HEC$8!J+P\%=88LQYY1A:1^U*/335&O
MIBO\-D\XV'*&X47U3_RSS5=Y94M@!'J0;=#/ZY,T:*5(RDBS]9?&^V/K0GYU
MD26J>B;R1U.%3?T6C)IS($\7*(^*?X@!V,HS0=OA$>6MH(!ZV$Y.L$=D[<KZ
MO-"^LF6M$=!V<G0Z-$76$:SFJ"\G2^L8;HQ6MZQ_#MIEO!YM% K(N:D0((!R
M"EKA7NU-P(CT7:E9=^G+[NWQN&?JO"UD=B]G;_HS6LO+I""N3G5>691[<F>+
M<L_NBW*?JR@WNF;+Z?_]B^4?PPJ]WG(^^?MWO[PY^M?+-V^$,^DS<(L/QGPC
MCL_?RK__''2T&0VQIL:C-3@-XDMF>B@G^MN+PGYCGUOZ<UL/8OM^<&#P1^^3
MJ)_[HLS/:G=HE9,N_;&IIM(T3LQ2-#HUT'K)_KF'437M^-_=H^>SM5NSSFBU
M60%56"4P, )M'MB-55@_HT4'C7-YNA(Z.=%RQ%OZA*1@&^YW@PF#^!4:#.XO
M:ZW^*)LD= BQ]R5?L+>S2]+QPZ;-*X*N,JF#H0NM*#KG-B!75Z8/Y%\/TQ?-
M&<9Z?/Y" NR?@2=?I _<_SYTOW7A(/Z=I:]>X#/;Z9&0E0C) FZE^,2$MX8W
M5LL=T94G9(==!.FJ*"9O:I)3<=]>%%5^ >_K$ .?XZH!V.^N^_S/Z(%L>K?1
M["TB$#:4H)NY^;HSB%2Z%?B_19*C>ZOTO+"@"[ P_U<8+'=<BZ([+_\^=[%/
ME1/539YN#;L;T)B3?F!KUK0GH%$;<.FXE](0OW!>(-JR[QO^\O#'%YY.*@$W
MP3NWM.2CQK@B!BD_*1C#N157D1:):$\8N8-V ?\5P<.1.RXJM\'H.]@M#H[L
M#EO3EA*O^-B9+)0?BKIP^V'KY1S?PH]H<'3'HOO._K.];XDUS].)U0Z@Q]I1
M=M;-\AE5:]U@5NAX1!('N$J$#&7=$2-J37AEZ_S^TBW5M"V[=YQGR^*,3W#G
M:6N$*0]84V*Z67$\]1UWF 2TXL!+C^K),E[C("V0 2*F9(9F'=0/F!&3,&OJ
M)E:Y&A;.>5IX^%PX-I*/7 @^>P-N/D ML4(M3F#%#XE^R93'%^<3N9<@(0_*
M 8C8$J'(R4/X=M[,Y3!T 4I1%:V![?-IXY,&QZVJX^I8_$U>^9M(JR<E9/O@
M5&]2;*T90K^36IMSCQ:XPL3-+E_!'(@>2 *7M?:*VCQ[ C LDO.B<GNR6A2^
M'_+70IH I(L"_"@KOFJX(1>-7U[D*!%A7V[TQ#9XA[7!I-WF5W4"M/>C/V7<
MM<GJ]3L@I$-6^B#0OZJ[-IHGGXN6'WHF,2V\#>A,7<'>JS,]:AXWS"WO3SS%
MI$+"A8E0;5,OE=VF:9,9:/[F%<5@WQ6FR1TQC^T^1&VOE%0$P LRA#('9PW
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M9TTPR,1[%/8W,5_.<S!PCW\\>N]Z/*;AP.:$GI<*$P):)Q79EJ,ZBJMX<QY
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M/&X:E/L/FW/XDR__NQ1W\<'QX<N'M^+P<\\KGLSA2_H$NSN,H#G;4MS)JXE
ML*6C-_%^E,VVGV'HPPD*QVM6AWBG!XW+8M)^[5M8GOPJC*M*[>H+>7'T-:#<
M3E!*6W:B,&N-SZMT&#]G,?\*:1F%JZTB:PQ)97(?9KJ[D\'%M^,"_]MU:>$>
M1MPODL2QNH+J&JZ<,,UE35Y$WN:!9X84*;R$)Y4]92>R?!PL5?=2(#>$P%6D
MZ[[,R =#:!^AN?8J!.T1E]-ZASL;Y-%-3VI$0]B-]KLCGP'=VQJQB$J@LV'N
MP8OF#//^JBBZ<Q?EG+N]E_Z??#;_-OUGC4%F8)&>%"O]I7[<O2;GP-OGFHMJ
M@9S$/\OVG?[R^+RLRA/W(C+W9O&_V^D#%_3MHDK]FQM+S?T=Q\N78N#B.B/[
M_;7.*-M*B*4WI#.T*H[N=[?)W(P#N.Q"FJ??N,MO84Q;.[M[CQXR'#U5R:Y<
MDF>]]U*QFW%+%_A?TZV=[1WNA&@PL!GZ_D/Z\)J7B7*,>HE+.1S,= VEVIE:
MT%3X@)P@-LZ0*=W?_UI@;J*>^6B/_[QHW"\4!C@K<N.EP,A$K]=M1_\=_,PO
M $4W<^_N+TH?K7'CY4E339!BR$Q8(A>#SX*='!V?BI<L,-1HF#;$^_:"+]JX
MV<+^XZP;ELLOM739R!8X:B[R],>FF[L3M9+C5#SGSCEA0YMUF<T;L8T'Y[-\
MFJ7?%^UY[AY8?OD3Y(S<Q^K*?^Y566$9_% TK=NCEQC1$=LL9O21,Z/__@#K
M&5<#XKSC1A:7[?0?S9)&.E)=DJQ;>J#082HF[>[]M=AYM//\T?YV^N+U$=_Z
M[NZ3W6_^ 65;9U>WY:]KYA4C81]G57ESY5Y9+D0/@AU?MN*]>2.F"6[53\(K
M)8L>D-[P3Z@([AY+RCOTL>6X4 >.W$&CAHB<-<_VOL[2I\^_EKL\?>)^<)[:
MO%!"__MNIB_;W/SAOM2-6YOBC[(VA W^00;GFO9EX"620I>@QTEQ&7E5KX!X
MGB/5GS[;^;KG2;$13)T19R76_D;O1%?N=F0MO*V(C(4W 9OB\P_YP#62POMW
M-BG\Y#XIO#DIO&F5W=ZSJ*>CMSOO2VA]@M-I7:)K_8[#!Y+]==411DA]+F*]
M2C7B2=J4Z-_4!DA'@NH_%31-J[$G><#ZYBJH2W'K.P-I=Y!KY,PTB5F7[H -
MG9G7?%L?\F:^^)=A4&DA0ZX@L!*('#MC<O3)O9!RELD.R.Q\,[_>IY[79Y]Y
M7ENKO1 !^;&S^U.4>!]R5LI<BM,/Q9Q>DC>+\K^7)7Q32?BJUH=NBTQ5TG(H
M6PE5=[A ?S^<$V'D/C41]L?/N3]NX'7M/A&ROX][6[\$\9)XN:N-ZL1KW)+E
MKEG^]#W(P\0.516F5.!K70ZP0!<P4Q'M4=3RZ5^G?(L:Z4LH+AA""[G["IQE
M@1(]L+O,VW*&"P99M"PMML^V,_5<8X&6I4 I*/3PKI!&$O-O^0S:,\0F3HJS
M2&>N&T_!+M=*5J)IJ2!)/^ ZEY&N#PIES>:LP"QLIV_*64D]O0Q?4;D8H%7'
MB@HBT5FCD518HJ+YEXDO_>N9:FS-"=6_BE;4.X3'A;#K=\#J+*O"@#/8"S)N
MD<R)#Q>&SL+F5+)):N7US5OWB8GP0<SF;F7%%1YLH;F+K.[>_CED_<N*2./V
MCHD*\C\$AEV$.9 VH!Z05B^Y26C5+%+!^J'/FG%?G(S6D"2Q>FFB8\UKU&K]
M>JV^YTM^SLKR")I*T;*O,9TOAV#9Q.,\WUJ<>FCQH(2<6AB_9N;^)0V+SAJK
MOP?^O=U8U?M&RKOC,^W,SZ0T:@.4TD^<7[,!DVS=@W*HP[J-MB V_O2VE (;
M\#9UADJ9P:.X 7J.ZB]7H[<O*ZD(__,@:22IHFE#_HF1+%'R!53<DB^AXI9<
M5G%3?G/H#1;.] D!E?.NF%9A>N79YM0+;54_16LGMW_S;ITF>/M_2#DK&:UD
M/7T2DD?/K))U5&O7:]GAM5Y2P\.?QK$F%L'%2)-DB#1!V4^S9,2%HP1HM;\K
M)E?Z/V-B#1T.7R 3\66G&P.W4?8]-PAC:R6B1K+R? <\S.+$O;L@6T(;<79>
MDX&$#X +\ECTW<@1^-H(+1>F8\GB MU&^UX"U:QP)_=*="\(,>V&I\K81HPU
M/\:TS@DD6>=OSF>#H%VZN_V4OJ%XKGO;^_HO4%LE]B8+Z1[7$@?C]5&$$<T6
M:*%F I>)2K6CKP=FJI;''C%6";5%B;VMO?1GNER4)O(S\H@/_K%$(\'_N 73
M-8T:FN_=N-XWE7,87^3.:F\V4R.&+KD2'7 (M60;%7NGH8NV*>?\S5C..9P#
MH2M?-VSRX=@ #"NV5%A10\GLY1RKX:O]O6S'&1 >" "RYY!5ZK"X3$PIR:=H
MF7/?0V=Y2AO%8%,$W>!_M^_+]]HK;DWPPUT]Q(]=]>JSN-J0_*=TD=;,J@@B
MZ.A>TT%5^3+"C\WI*5V$EZV;V WO[*JRP:YVPR.0:3L]<P9<!&F^Z121=U>Y
M:6;45% JO- 6=XN,\,#YW"W]X[9!5 ?ZHN=9^N3Y\^WD?+&8=W_]YIMI4VXW
M[=DW[LT^>O1\YYMY^WQG?\=]Q+W5(4E/SY#@10]9!/"VW7">[S@'>]79(>J)
M!$33*V5K07.:6)*!D:O$E^&<BYCD[8X23\4TN/3TZ:K[YL'&&U9!J)G_7L.;
M=S>-!W0/J/^4@/K'=[9V\O2^=O+%]-#_CFYM3T:T(0WQ=!Q=OW\Y4U&/I^C9
M(\]3I#F$/[]IP"'&"%8=M.@XZY\6SO2R9<VYFT(6*I3Q1:=A$]K>=L6+;DOF
MOV(/&G#G(@J,AYV@L;"B2+::KG3JW+'E3&7K<6ES8A/O$??)AZTTI*>:'5M+
M4A&)DZR.HCZ#>YR).K7"8!\5GCH*:E\4 /)TWKED+UA![R8A05)QIB>DY&9#
MX-"IH).SEU-/B*^=_3PD&R&_[U' FX],SA_A(#:-HRY(*<%; *=](:-. N_^
M :DAM>%P49 O7X2T>6!;MVR?KI]9)16E#&_^A @'833-T\/CM^GQ3P?N.],B
M5-4\HN$5HNB\2B),0YI?Y.VTF&[4CAI<<V?_T?-?;L7!OJ:],#X!VJU?)R?.
MR3DM%VGM%CNEQ#9H_0A^/R2^+];NXW<M6"2T33+F0&HL8H\UQR43D.AN"4P!
MS!_^^,(YW<+>2/>TQ_,[Q.A22ATQSO^B?N3;S_O]IV&4@7);.))C+J?$)]Z%
M%S2N[5(6UNH>HC%FW<:F(-TL%R[2*'S[P=AH=#^^+Z#=_K[,Q[KHDQOOHD_7
MNNB5T;\C-V?44A]:WC=FK 8*;V$I7+9X)N2@Y2VBA=C3OTV\Q53]8)P.(?I6
MS>X!;;JO[(C<%6EM14E'>L2=.>Q*NOM8C[&4;C0,U?T^TI>8Z KI!JI8RSGZ
MFP*)]F5;,-+Z#>L Q+=K'=LC9-%*>/91;=K;O3/3!$U"%S=W\4FO =F?HDP%
M#4].OA;X/+H5NX+">-LWW+-WD_>*[G)9C//DSL8XS^YCG)MK&B[_/D9U\*%%
M.QHK=NB]Z'7HC=;R;MF6WC!_PU)<*J6XY(9+<9*A'Q&+'29@_T@\=O*E='\D
M7TCW1_(9NS\VE?KJT2Z0Y _I G%/V^L!2=9[0.B)C)7FUHIGVE.R\_6&;I+K
M5R23?D52(U"K2&Y"LOL >[0*^6PG@K!?4H6<-;R" %,25N H?.#N@9J?<^)8
MS[(5=M449Q"\;"?@UW]Y^$,F:D?#$B<Q,(^??;VIX)A<57 ,\I!8$Y^IY)AL
M*CFBS,G;\,L?57?<3K^+_5<A&1C,DDUDPHG<=!P,JI/[475R=_M15)U,!]5)
MQ#;1J[JB^)@EUWG[UZA3?=<V*]K'%SFX "XM%\(.^N>.*?$2C5+D.,PKNEJF
M]T9,'*/?2RP!SX^SJCG!&3HL$_9+A(^VW/\+F,&^HC=E#1-D7KVF$BPK%W57
MY(0JXQVG<.P( [9A= (%L[Q@[S7Q2#M\>^"1@EH_3#8$==D&9 M&"5)"%\T-
MBDZ"Y5LKG44.P/")/0P]JFPEUZ]HI?V*%M:0A']7%#K[Q_@KY_:XO_^CR>LZ
M7UM7_:+H9H1.KS :5N%:F3,Z?9$9%([WC?F'N,()H,):W5"([['V]C-WZ#YZ
MM)UN*F_BMMWN_LZ375F5'UGB3*Y7XAP9ZFU(3'[2C/^C[<^=\K]V=GGLE%A/
M+^_O_+)>2D@_HI20?/)20OJ[2@G)IRLE! G?V[#>QQ+Q8VOE"\G$,^P#M(\_
MN#.>U()Q:/L)$^SI50EV3:4GGRJ5_KL(:9-/DTJ_%B$M!$#RV4R1+:.$M,F'
M$-+>0'8^Z67GTT^4G;\>2EQS^%H8EU1^<MU4?LCDIQ^0R=^XAX>I_.2#4_D?
MR;AZ12H_^>!4?KHAE7][D$D^^>6<YRF7'UJ8JJ(UASF?-G/S[=3-3ZY!+'NR
MNJ<(^Z2MQ#TBBD_=3_Q1;!>:L5"I68@[NX D: RXC5T[TW%>SM7^Y6+BW33'
M=6^W/9NN*]WK^_9S]Z9>]^D^ZZQ%1M0S+/?/#7(KGS%9B:/!&4KL12^+?4>F
MR:LZ.Y^CK!J&/&X.V'GH9DB:#\G +O)5.CN<,Z!OPI*TE7@W)FYT5_8V(_U:
M<<TV.-;>'5/WI>>B?'NE1[)'^^R^Y!_N;LU['CL8/L!DWVX5NX+HYA4_WH4,
MY61S?_ZG5J2^VTCKIW<6A?#\'H5P8R@$=:PQ0UU1="$]G3;4^W"!,Q2QI80S
M0<=^02CK&8M+<@O+CGV H,.]WWWK_6X78N<$,<A9$ZG>(M,4]??H.<-TP["I
M;"X]3703A [C;KA'T7,;LX[1@6AV.9I/]QL5E3W)%R"/N!MS!#=Q'E:&L:?
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M".=KK-LAP9:L7%0$S#*BO><.V+"U/1:DP4**,:IZ"'HZ&<B=8Y</2(=_J2F
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MBZG)S>(LP,*D*7&>-]0;=W>V5FYN@B6!-I]?C?E@%C:@BQX G@B>O1]?N-%
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MH#S!^C@NOWP(?9-^A!L!O*24,.Z4:ICOX8I$%CN#:>8G+C@0%SQ=1MU;Z/V
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MS%>4Z\X/8G4J3Q!7(%R&16W<1PN_L@US[/=\=- J/:WT)^'R/TD NMIH<=P
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MN"ZRQ9E4@8K3/*D%[1&7K25#QSZ!CJ>\4/= 3YH+AM@]:&/%,[?3%]PLFD/
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M:D>Y:^<=D[%"^\7MV+!6?7V;_'7,LCGCO&->NZ^QOBK""L"3-Z^SE&[!J-N
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M,Z1-[]-_'Y#,D+.'G[/TY7&?!'W,FOT!6;G15Q_M?]37KI**SS:M</M?:O/
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M D>@ZZ4C-W<E6T7Z?_+I_ <2./<\N)0/.B%F#6[$K0U"TE&GA_54]YW-5_J
M*Y@EBSFGX[M\$$I>8MX ;<4OQU(V3'?YNDH M?C9HP?I7[YU=$YCSLLSUT [
MTW+W9VB,GE2UN^V/M?Z@Y]E)Y]FZ59(KZ!X-W5LG*.RQ%H5+);Y%/WN9IR]0
MF4_V768%ERZ^0K>\-8(RFR*=_'J+-,NX;)/IHJ$+:JS?C0YI9-2F9M263= L
M'U^#& TD1>.!KK5""^M@<K/JZS<\$D^K$O9*LB_;O5Z]69V)TK_&$$Y7#&$2
MXC6FL$3M[XKU>L.BB*??;5'$[J8HXFL61:S@=*7?2IA[;V=G7W**&%J/I^6B
M':Y>SA6JA:7-SU#J1NK[YZJ9DR$PD7U %1HM9C% KU\6)'I8Z5M"MQM@=OV%
MN&R>^R!$RVDA+G#V&2-!SW =@^Z]+\AKFT7OE#_QLL@_=Y\^W;/PS"@:P:O%
M$,5L.F')T+FW![]-7+Z*>Y[<RY_E9$(U8\A8.((T?OGN=OI<>>K*F732A2$I
M";C(34J?YC O_?=QL%V!F6I-5R_4W)9P?'"M!\,(4W/W_W[TZZ%8'Y;>E '2
M>.0?S[9/N1A8?N)6QVI06BR5AO3X*0\RB=_7D][3G.2Q?.W)0YD;&3<(\XVN
MSD3ZLE,Z,R>6=G1Y2E<%H,&KA)\O_:Q/'DD@T&^F])ZZ0)?["/WCJ>STB%S>
M+3HB>=G)2?X9ZT7+59JY/Y3XHB*_6%:&Q&E.!F'>6E;/X;FXH[HRB<Q]*3U=
M#!![(H>#%L-]8^7\*0R/3L=G)5!P0+;T65#EBGEGR=6?))D(\M%N,-C,WO'P
M#!1:)3H7LC[>8G(M@3Y(Y[)7GOCO(-O9V4G!ML-V#!E ]%AT+V-84CZ5!1_?
MBSXNT@FVGH7V1TI!RH2#LY/.T^;@?5LB V)/VP]?_8;69G[.#0"':UY^U<?E
MZ4%.9T#F:*5QU'?/CQ!Y*#DZX1Z8[(8/I)6LVG*T[N6[:UY^BHH<P X-"TD4
MKOG*VP(K<DC.7+W4+[UQ7TJ0K-0=/>0D -3BE 9P9$M(4\C(FJ O0,^E)U-Z
MI<(;9>0X-BA^B;[9?0=Y2>0X+"6\LI2C?3@85;)5A_!VA\DAX@_+9HH9^DU]
M6Y C4O]9G*B?ZGS<<G>T4XE2F*Y\OM[YF_EX;^2@]UOXL;RRJ9^X0FT6\#MB
M*,<XE&R5:"F[JZ.Z/!=,(SJKW*<L[58(3LJ^<?L1(^;@FT4]E2[)(]\A>=-:
M/!K/-@\![I@;$X</-.TUQ6]("0FR&-V6 &UR&&[B9W'4\N&!CUI&EZK?4-<;
MH6X^\.$J(9.UKFO%L8F2CUP;@JZR$1^YMRR(QRYD%?!;NI1O^NKP]# 3;QBQ
MDF.7RF>+S?+V%H#I^<SS65%#JT:E";O[$JUP*Q6;C(8])=>B:.LZASFVVFG'
MQ9.,;,50"8;?$TW<]<>>@%!:N$BSN-]$(ML8!MMU&HT>12![6@"8HX#(50!B
MD5Z@EW^6'IYP79RF/H.H"YJ_<%(+=F';D',9<<<Q.6=5\'D)O27AX@38"<Y+
MY[PP'W7LED0LA2]41G61UXS<E:-#JO3QA['N_QG$;>8D _$ ]\1_D,J9F;"6
M#?=LRMZ@DP/&?(V(I/TPIBE>%+ZQ+F;'SD6W2PO)=KSQ45W:R[QIY7%:"B:]
M(&233Q:D%+K056N"0.^*&8YKH3 ++M 3/%<PKF@5I@Y)+GCDVT6+1L'PL5NA
MK1%B6R31;/HU>,<)NEZ;0UNQ78:* 1^Q"8+^03!:<1,2)_E!,,;]CJ8KFZ$5
M!,CIW*9[@#%I7PB$Y-L0/.WVX=&^5LY@5"&$4*722\9F5L!ODN .R[F-=JQP
MF(MFD"..QE8*_VU6&;QF#"RG),7K:0I]L/\V"<-59)A@N&0C_V7>TJ\;QW$)
M3./7AV^/-;5PFAZ^.DZ/7K]]\_KMX;OGZ4^O?WO^]M7AJZ/GGU&BU@PTK!OX
MPNNNQ?8<&VGK!<!3BI$695B,5NZ!7 W%'!5L,ZMB#\*PUO#,LVFTEQ<%^RCW
M"#!7-:'4@'%9[@>ZSUY5$D<;%X*'(W=1N788[&!]U582'^<+XWK=N%\\D!MP
M9 81OBL(,Z_CR&RK^7I:O8?S#S=BN7L\_^#Y&SG"N;.](]9T&,T+X<OW99F>
M[.T]^L'1PEY#&P,8]=[W^%_60E^S]W#[@'^_CA)T[;AV.K*-K85] 3O#6?^<
M"';@M;!\(9=,Q)Y)3=*L\35"FCCQP!2K<LGV-><K%0] SL#JJQMA<Y\6!2IL
M./$UX8"35\.-F/5R<JQJ4,8[=&?(#\)I;9H7^JYZWQIMT0K._,HQNH'T=N_@
MS5'Y6D?ETXX$:>Q) 9S<:N:$R LE3@JH[J6D4,*1]_@\>,D."FXDX*45A2F[
MT6/NLQHL#:GAAS0:SP3@9O662L5?TJV=[3U>-3HL;DTV(OI=BR@)&^-H(2(.
M)5D:,!LP(/.9>%CBJ_3JX '9&Z0H44K$8<B L#NMJP%0(-P-X*M K;K^X\3O
MWT[$\;E]J&OSRD]WOMN\\MXFK_S9\\KL[/SJD;-/S0>)JJENGP^/9OFZFA0.
MB'M-L[5VXR7KBO[.<]2W2!7F/&=$F!6X<_&3$$H&FP,*,%MEKK#2HW18UL/%
M%*U]"&T!46N!OIP6)>?591.P<B2,H_E>"N8KAP,V DD FZ.S G%I9$H$<3/7
MXOJ!!L$SQ=O4\7*8G*Q77U$^7LR&42>[;TM<?=UV\CM\PF(2S/1<XE82?L4:
M!M,>Y)-<[6/7))8#+&RXH)&-)\6'4GI^/.8=!L5K.JI02N46F@QR7GT!4$WZ
M#.KM],AJN[J]RT$9)+:^N+K//E,0V7+.M7 EOMXZT#O$9T<Y5R+@PXGVK:H]
M!B=">IO'I!90J6@X<M/%S*5N)=(S[<.LB&E9,OTYAASD!12^"&P?;$0I>O./
M6!T1,E?ADG0ZW+&L$LHOQF,.2L,!D@AXJ6&IJZAWL$H+H;9 72UM/(:;<10>
MH*UXA@PO'!HO@.$U^^X+P4J O3&PU *;#"ISAS-T7B$>QRFYVQ0,$[:NN&OE
MN8\9QX@EMTW/OE[4'^>8)^4*"F!F85"-N\IAXM12.5Y*:2%=A.5H@7R']X\\
M7TAPK/IC]RJ4#><YF-%I6)><[A/M=2%.T[HO!T"47N)3DW@!UKSFL,CD5J.\
MS A35EP%PN%A(&W;Z5L=BW%/A607[LJ6_!+G&*6%'(T(T,T5*IH!V'56Q.U)
M\3R38)Y\-_*9,XW@;XR"29M ;X0,Z?J$B45@NE&9#O1:-.2V2GRO?%1SAD1M
MJ[4;JP)VMF HK]EM3)N@X,ZP.M87L7.9D7:7>):\VZ8P.H U9K5()G \IKNY
M2075@+NT$P-LL:(!7:-^B;M56W^5Z=HMP=1J,-%AC<'_S8*9H^6G]PS26EJ^
MD[&A4+I@6(5ZPM5>D.;]("EPQU8SR*S5A?$G^&@9+UZRHL T0]RJ##;#N@@/
M:M]U0;K)91"YKQK5;6,&1*BGHC!Y).AK&OQ#ND"UD5S^GDACO01=#%FIL18B
M;5VGVQ,-A;V[#F=DT9Y7-=., :Q)9IL*_9B#19)Q-*Q980(R]1.?K>4DOV0H
MHA(E*FC=#LQ\>>^*D/)W'!H3.PQXEEOV:;XT&<9P\W6V>.<>31S:^%H8<@?4
ME$E@M9;JM!B3G"4'VY>CM?$=6AKHUJSCKQPV&![R^O99[6M.F&I1KG%;MESF
M-"B8\:V>AL'76ZZ=^&)R9<LGSOFR$N/;=_- 9 5WR@&<,]8.4Y-HF[4(+3*L
M_ZAJ];#6F".#(LPL;9.'DFJ;?Y^G:D'ZT@?II2F4T2089HA/)E?$G7.;D"M(
MBVH&$@<4JQ4_UG!ZORA9-N6-(".K]<'6Q1SH]K1RQY)/8@=!@%>!@\#1NSU(
MK;[T@5P[7470GW%#MD)4';OU/NW6  IV ?0.<URA;J7YJ)IQ7J[O>5#BFC_<
M3@Z!I#0&5+4 'WBXN,9YE9@8*UA:VPELCG%^078DO) .2AQK[F&UF(SX>P.%
MKQ.([& P'#1 \W7/*O1!E?%(Q,07@T=\#P8>6#]ZKM1:NEQ^X:M"TGS06)2
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MS)FPI&[J6;'D@86=[^R+PY*@3T^VT]\U[(_A<"1*H?)HHYO.^M%J\-[@\>3
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MD)'5X'U+[3=S;I$]J^4LI\^/@K9?B:QA(2Z+"[1.#PI)=<%_"%MWHI?"M_"
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MTCUSKL:) T:R#;B%\#8KJDKQOAG?H&B^O.+ZVAKR]\(X<3T-@='C,?>$S'^
M^1LN;.)P83V:M3BE++E7P-L$N%.LLGK.'DO9=8</:%7)&DE<=_JRF._Q2A0>
M**J"+N-2%;B[*MR"T,#.9542,?@K0^UBA@RCS',3&3F?*L(0RT2?1MQTPW,0
MSC#$%[B#"O(I',$I)C<M<CCA&)HG<TQDVH)8%GHE%<.M ZM;KBB!+AN5(\>+
M)I#ZX48+ K:X0^+<[=]&K*J54_7\GPN0(857S%TZR^\\^^QQF9_-*C(CAPV=
MFXGR'IW,AMO8S;U45B*A7] C(-EO)B3;]V,09_L8_]' D3-F/#)&"G7Y7^:S
M7"4+AS7BMA&B[\YG0U(:\!+T$5SVWGVW6@R#?>HN;\8V0$TJ9\:\!;K 3FF-
M$J.7D& $+?-B#C6SN_,D>W*P$X#2(^1"Z\@H-!*'( U7#\O&AQ2@K^;&J2%A
M"R8S:MJZ9+X?B4XL9DP'6A<]'TGD(YX5H)#)&-E/8VQ"CH7<2<"JH+#E>:6:
MQ#]G"X9  \^033:))NOIR+VIPPO-TJWCH9N*Z09&:G7]DI/B(\-S%S^P-@;P
MFG"Z@NC!Z))(.092Z_CK6:LFL5:U5_  \C.Z@<[@3*R,?^UX \' Q>*&F&F@
M38DXNI]-<#3]_&BY'W)5FGM?/.$ 24ZE0L3_X=/LX.F^_%O%!))&XIZ?>7(G
M?_GKM]!,8]\:)V+I7@A/?3FEBQ9L[R!QM?-=%S T<$<_WMDQ>0P9] YV_I,?
MP%8%K<)B5J0/=X)1(XX0?F*59R41'T""E^<"+^E.0S<R2->FK)2,D3\Z+Y6.
MS$)RMGI[#_&*A_MDC3-_-V84S(/^>.!^2!@(4]>B.Y,LW7WTV$V_\\DUN']/
M'L9?(-TP+ICD1,([;E'<8D\*)N5UP/^.DT6_L+IT=T'3OEY9Z\O":<#=;&=W
M+PIO-XEQ"_:0MT<"'070UU8'A6)OP7,6)!?2O4(\$Q-/6:D_[3[:/MB1?]]$
M4.63P>PAJK0>IP7=*[+3?8NRE^T_O46+\FC[T4>O27<%=&%>D9'"O]W=[UF7
M SIZMV95GFSO?O2J=*;__]E[UZZVD6Q_^+T^A5;.]/,G9PG:5R[)3-8B0+KI
M)H$!,IDY;WK)M@SJV))'DB'N3__L6Y5*LF0;8Q/;\:QS9@+84M6N7?N^?UN(
M4C!<PR!*HSDO429L=Q:)+?NL'90<OS5AH[DMX4;%^.@.>?;THT>V B^*'#W2
M=ZQG?6TRBZ4#6S9VF0K6'>T26Y-\S=<\,4LC2/,@IZC#X\LQI^L'0W)"W83
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M_H:EBHIB.\8(2'.TH\/9O &L%@=M<-B,KKI\&#-N<9PY?U5.H.;R/. +X%M
M[0[MS<+)OC%65:3A:X=//%M3JTH^=*4N,P!)6C]J#_OH3W"1"5)222N3%5@)
MNK0 G@"/7J6/QV#MN*_Y$E$]B<2L^["D,.@,VPF=96";?WSPPYZ>2R)CY(O*
MAGD<-]M^:LQVS[M#7RQ2$[K#:)1A-AQ7O].2%74C=]C94T0^*R=RY'61'X0J
M."$Z<;])42:>@)P/>5) !9Y"1/JBY7F!KE+)#E!2=$_9O^2B"16T(2\62'8
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ME<GEWR(E-JUYBDO*F&FDD4P7JF%-5Y(M$428GHXW\.@YQ05KW**BR[RX#DS
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M&7,#EM/\20$'M7MN'*>MN'H;#Z'@S(,#3A;F6_-L$(Y#XP?97;?O]T:&X4(
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MU!!7JFO3'NTA&J#TG7J(7\1:?E\D2LD"XPD^7$F8YM79%+LY.[&C84_L(RD
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M&SONZYV:CM'?Z.MB';<3QFK'B'ZSLI\;XG2*UZ<_[-W)1"*0#_3XC0"O.#?
MP<:P97(W2"26""E3;KG=1(!DM40RKRP)2XF#9:/=>290XK=0LM(A!:&:N23W
MG3!5\ V%,H:E<2%38N2?WB=0GABD"_L>(^"&""D;>).7NT%75V&C&GA%A=',
M A CFJ,S[*6X$#=G)T\!(\+1R&HBEI/J)D["I-S9'48!@TH22J^38A@5GB[M
M9C[8HF+67"".44J;M" F'3$B1"DEA*#N"ATF6D!6$!;]@4/LK2C\"DX@CF#S
M(A[!@MBA?L\7J.#<1[X#M\];@76,:)Z._:O7>T#<;Q>6X ;Q[D(+L/*H'86
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M)<%P&L.C&Q>"(>II;6.A!$)<DW4P*!]AY. 7X%>EN)G$R ;66CFO%2TG'^@
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M)(_IOX!S8I&C@HJ4&P>H%H^J$,(@XZ+ H8$Z$T?,U6YCQL>DW&9ZT!/\Z>/
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M*,,^WK;\0JVI"]6#SC)K-9>09N,V@L_/R=3P5 ]AD13*1M%5">8,_94[A@W
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M*77\MFFWC[]H1V% 9YYJ\U-U/8%JCU719H+H ]*8[[!*WZ'*+;R @=O3R(H
M[/!>Z=!?&[W)#VQU*:A#+1KR.\.68WIGQ%+#RD!O%*S(D8]./@*U>:H+4L3E
MAJ3,$@1_I97AS#"RY*SEKJ1Y;] _W*DKDXGRLXJZ=O6H7B?.DCLCD?GT>F&[
M8,_O^XF=B:"FH(DTK!XEA\6R4%T/BL#_"<*3)";+6&(P>%37Q_*+KOL ]T_9
M8L@3PT1LL(P4(JR'XGOEC(NT]6K1(C/A!M$NL&XA]4MN#!&[GA8"RU+5."]N
MMVQ4'# %/V:9"D4UJ"+XM2=S* @F27>L*Y^KV.-SE#/8OO>]KC2$TORT5 GJ
M3[CHR*T79/A,#>;5RH^;-Z]M\^;+R9L?=QZH@_<3(Y9?FT6;*,$-F879='!]
M<18,2N]3N9S6IU!IW_@M%MZ [4IJ2"3?)HDZ4Z3%GO>571Q1DCJ@)8CM9+4&
MP3"5C1HM2-O9'"$6R#64CV!&8=2,B:^])C<VHU])\:-S$A?KF_3J@0:]D0%+
MS]W?7(!J^&M@*5";+'_>*3$/Y#$,_NSIT;0R*!GA\;F';0!DP9K-WIC 9LL(
M<?X-.ZO="[G7."UBY3\<51*>YA084ZGUUT*P.H6VN2]:U9KZ9LGP%3- .?FH
M]FR#*> *A K&69<N9.N=-<@L-O)9:CR5*E7./%J-.9,W4]PGSB2P^BX/U<4(
M\UATDXLDB 5QW:KEO90)K=S.R)C%1_1=XN<@O<YBPTUCO"RAUDGOSB  7'0V
MF#_%LE ,HPA 8^$-:N02&#%WIX3PO@B8+N8-L!O+]32*TH(DI.2G-JC8S= S
MB\F;8=QO^)3P!1YL[ON*,?6MR,3)96C,A"6ID<UJZD4)8])E0!0C\&9!!+B$
M7V>&$.U!2'7NZ NWZ8X(P\E:V<% :Z7M)Z[RRC"0B#X->L<]\DOQCLKWM2C"
MBHVX)[<XY50SPFA) %/"47[0[;'Q@!\J"&BN%0.SJU$@3$[3J-4QZ9 U5,.?
MM<^+@2"'_.."] X[%RC_<*BP.-!PJMS9EVHM++.@264AHW*A(WNG!ASF/DQN
MK,.\G=8%C<<"'2&$_TY4+>-4*O+X[U -9;*92DXS.^NDEP&]EUN*)!0+QJ9E
MTJAF0$A^1].>&880(R56D2[GA$"2PC]VO ?"CB1_2C61X!M!&J[5U9"79(SO
M7"*3/L"UYZ"EW]C# 6P8(3^YG)D^ZG?^\>JJYP:7W5,#9AX=-DK@75T<?[(N
M/]BGYS>WU^?O/]^>7W[BFR;YO=78BZ+LDA:F3K*RU_0#+NFGE$^:#T=EP@!(
M!F@<WD:,W26DNF[ O<(/F.+,WA'@@QB[G#HX)@D>(@FG-)882^^("O8E,N-!
M<O*^KMDH>H?1-<*#G6C\!^ZX$P;TOZH]@7Y >,X[_CW<*IP#HE+2I')BJD-D
MTY8&N\$F\45*>B4%M(EIS@H!VJ)U:.EV".X"Q O)2G+ G0Y8$T69"GH0O3O&
MT7LFU"\WC?J\ /K?M"(C-7LY+"A8C'OV%V75$\(NP?=8QKHEZV%TI%)UED2\
M"\\O@^,ZCB7U17<:NA%UN'4]U5CX#:/)'LWSP-:N1'D5,NY>A)[BIDEO6::R
M$HY_@5><88Z@@,:H_ISQXW8L8@G)^"!IM=M7@I#4#A\8RI& ;Y7S5=R&)7DU
M:9_F,;$2EW;4< >&F.4$N=OFB#(V76HU98@&_"!#K1&*/G=5&_HM5L8G,EP*
MQ8E1YV]>A^'=N$D<Z\Y=O\>N$*V#_XAF>EZ!XL/H2P]N-!+$'_RH3I]T\FJ7
MOR%P; QA&WAWX ]3.HJ_OF<?EYT3"C&^4(%GEBAG<8?Z7G(?=F(>&1G+DYA8
M;UZ:E^<M6#R.?*QU^-4#6P)+36 !<)B["P4?VE]C\"%S,=4G[V.12 S4%HRY
MYE84?O7(93,O'F.OF[_PS3O,7]KM>' Q(N7$Q1HR/(J+2QP76+^\9=0?A%%;
M/7)54%-,9$(R*(RJ)=*#IKZ)%13',.'06LC56*JV@/2FK0:YB'CFM[NQ$=6$
M9XMB4U,VS=)>1:@M]V^Y?Q%BVK 8J!A %;+JJL,7X;C-:5E^!M1WM?KC9F+K
MVTSLBT%];RWQ'TK$*Z,YYMJ8K%63L3S$4#&"+]D/=V64N(RQW-HB6T9=)*,2
M6IU4(>:'KS+0%-64Z*(_2C+J/'LZKD4]9,N?6_Y<J" M"LZ9,8PMPVT9;I$,
M%WM)TM.#KN+[,$HX4JUGSLN@>TYWR=#1GONX9<0M(RZ2$3'_:<9J53-)QCR4
MIA :A)8JZ<+TG0J?N<;T1F/4AI%O=+F9P!]@_9#*A:18O5M&WS+Z(AE=,39R
MKFHVQ#J7C" .!WP+=#_)O=?AXAOCCF#'D"<=/_Q,+/&3;VHSUZPHV_+REI<7
MZDYE(! $RIADJ\H$2^89422VO+?EO86Z\JJ*@WG-L% S[;FITXYU@-\AT_!R
MA39++XTKM+1T*74N73D&%,^=H-=#.(IJHV$TAF8;01DB7"%C.';DIEVMZCO9
MZJ_-*)-ZG[5T"3PR[<HN(KU%I$?LX#ON6N7[P"9SG-K,(;4U*Q1RL+3)P]NS
M<V_$IZG1=X@;Y,>Q,D*X*IY:JU0!7>&"=K#VF!'>\U'@=F(DL%73@*ZV2.??
M.>DK]%]?4WRNSRO@GITT/D)#AW$*!_6FN]C?E.!,:O .>%3?$$0 6U;DTF9X
MQU&%EUAPJC >8(GM4:9(F<L9Z1VQX(6TAW$")YTI/TFIQJ/N^R![,*!HD:_R
MX?S3]3'S?ZW1J+Q58^,SKS>S],8"7*H)&PXHDPK_HM&"F7?8Z3N86<\_[N)K
M=JM+*GY^N9MQ3HT.@;24:;]/ >QE"BBS&#)AE,Y^YEIQ7T"<2D499=CP6V&A
MT<VOSWFEZNI9Z80(!&/PDZ$VU%4C#)[W, KD>M-E3(,NDXM.-:^$PXBY12\0
M+XO4@L18+#C"8M]AWV,HGB>)[;&W\OIHI@'WR>&'L: QE=HX^8)[X'BLN!]9
M_"V]*.D7C#S:/)A.$6&#R"O]\0,6#]V(1\$3>J'+("94Z#QIT=3;.!XY4-3'
MS:M]9[8R"\$,#@D'"K!#H!<,3K$F<8I=S"DT8SWR>*YQ6C9A=&\85&>FDNX]
M+H_F R+D%&J<R,K@R2]/1? 8-579-^FBG/SD5<@7Z=0R+[6FO)25#IV%:;;E
M7F/OH%S7@IP+;A6P"O%5EUJMZ/W&(;Q>?]G738MFD(&PYI@:"EBW<1UPD'Z&
MFHDP/D8*3P\B5H.HM? T'HJTS+[#*!TF?:@>I]0V25XX($+^D?XZT]).#\XR
MM"\M!I2SS<J9.A'=@!"R)RV' $$>*987&[7;$[]!VY29&2@+7+& AC@LJ[ (
MB;A?WRV&-BE8,)97:S&=#<:DZ$RHE!%0QJS",]=GL3!EB:!P:*1#0J^'PI"Y
M =\R.BB]%NK+A;2W\[1O">NP26EESIPN4:H*4H&X[A>H5)[+Q'$KRSGC\IHL
M5A5Y1C"B0/K,_+3&?8(FDHK_#EXA:3BWI*?'?+,) 2]Z'GN%C,[<'%Q.J<YD
MVQYL)OJ1L.RY ]&PZ2VQ\XD7Z'-%))I #36N';@-<?^DY4(J.[)6C++B%=_U
MA22629*, "OW/LI\QCV]_DQ_)38TX9&5T]LJIK>@+C-[UG:JU=<EIZ#NU?A8
M G4)M4[.M-GSTZS<TY"JPB_& U4[M$)M10@D!CKRB=],T8.5P810@"!)1%Q'
M;2:VJU7'KM;H+=6#XB7HAFK^!SHK_*]JI;7;Y'\2&?F?>5BG/;NLV2>V@0>P
MAQG' W<0?E'!+_FQ1:C69G_=F-TR!NM>^NFU%UAJ(A^I7;D>KMD(E>DP&Q*D
M:($PX/N(-(I,112K>TFZA+=3W%N(?R'VQAE^820>17H9'?.:.M3_AB&?C#CE
MIXB4Y!\D.D'WFH^7C  ED?5$2]EC.C!.;39KA61D379ZF_1$9J=8IL9,RTL>
M/;  CGMHC'8\W2GV2Q2"HWUQ<<+PI!I*A;$.\+3Z 6/W&?J=C1*&C\M,!K'4
M5<Q,""'J,[)=$*IGPE?'EV=H>= \X,B&2X.J>/%(Y<12Y=J/6ZK<V)8J+[M4
M>9IU6*S8K1D5^[BQIA2TH5$/:AR28G$AN+14H4BH'VQ3@6>+X5!$6E A\0V)
M=]^6VLSD[+5D7#%![DF"VS*4/H:#P$,*8FT &#HE1JTAY](1>6SX2 3":H92
M$# G-_H35:IA>%%%5'EN(]>"W'<9FE1M(@4=%BB<%HKV[&[^.X2;0W4J734]
M1 S3L96S0:3YQ-(1\ZS"U\\4564P:H:A.! =2S!9H@0;PF6?\V<_ 3>(^,3*
MV[3L/#%<@\[*I%-TTQKBB<%;A%\BL%J_/^R!#>"%PQBG+^@PL/1\"Y851A4>
MB#>M7"QCPCN ;\;" 1CZCOPVI46!:&&'PBD=KTM-XO#>:TT ^Z,S-IR9AD<@
MPRB46W/'N1M3&E8OD*79@(4Q[R9/?6W\9,_-,L\ME:*F*Y3=6!J!9_Q8"7")
MOY<V,) -JF+QQ61NA9F4G)6%C3#Q!9AI4K (.%RDZL!7H?YLD#.]D'( I7$+
MDB':F4*G6IV/@K53L7HLT1B,"M^6"!Q >N!YB $3<KPU&DLV9759>GNRRN_U
MAD@2-MC;;D#IQY#\H8B(P:$A./5R[E>0%E8&TJ(L9O3H971#'I^]\#79Z'E.
M%9#:4,5E=!6L/#L@+R&<"[HPBSVQ%SF=2SP(T;4J1O0<$C@3ST<$6A><M1YE
MBCN"VT/? N'%I4\*X\? Y28<0A7)V)32A6,9538 "F.%;;7FV+5*K>D@)]^[
M';OJ'.S7G6KMJ(2BEC&69KG.[1HV^HI#]><P3OSNB%"QKD6KL]9DKKO6P5?D
ML:7,72]9T/(W/7:6-3Y,_YTJ)T+(NN^P@A=I[+XR1+LNGP*Y!9;DG9L8-4)G
M)Z5:F,P^A3XDB=-QI*T=B92KMZB!H0BH*Q8PQM0QE)L.(.F-9'"486NF;M+8
M.'30@'K@.8TY4<.J8O^;#1]+[D%GJL%&"+^9]-BD4=DI!()*]Y:!+\3Y'Z\E
MZ(A9#5ZSY3-L;YIP2'TP2K-W<V(Y!YY$M0>BXNE7G6&DLCX\.5.6C9"F-%O%
MD=PL3TCPU9H>/:M@AG'&W&4CW6\#,0G'@W#G<M#6Z7@O\^6"FZMM-VTGPJX0
M#PJ(ISQBBQ^N\BF9;$>UCKNM-G<ZKPOM<6/OU9IZ]XX@-7+%!EN^L W.W,+_
M15[JC2/XB$^>":WAM:6IIM>^CG"-X[=6E#]?F =O\HVQ4L4XUXW!Q(]*=SV/
MF:TR9G;2:VEZ<NF@L,C02C3X0&I#TILXX6)+(HZ6A<O8I658PD@4!7+-#AZC
M^@C-;SVU!&OTV">R[ZB2!C_^XXU*G7,<ZM.+SY<TN=&<G3IMBF/U)UV1$6("
MQ^ 271:(R\A6B"%&G6%VTKVH'CC[]:J!MU1HUDZ8B3G36,,9*^._TTQ,"B ]
M<$'KH^=][8U$5',KLDR.[ W34$&&KH8XZ=)8$Y <0<>-Z%F&5.%/,-XA)705
MQG^ X^GZ9.,4AKY8/VPL5- -!9]D)HPAQ7/5\S0^LA>'.KU(4><@$+YWLX$U
M&2.*],VB_0<=15<)/@G:9=>F9"LV_G)=$@>;V)5V6UCGN>3"^Q=TJ29X%P5^
MUN>8!M7IDP#"W]RC!CNA"5$4VXN(A]&TROYED[T431"QMK/#3;/E0:GVMOS
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MT\WEQ?GI\>W9J?W^^.+XT\F9??/KV=ESH;NF+;4RMM"J).I.ST[./KX_N\;
ME%K#(HRI&=D5R?2M\^V/>N7TCVJU^L=?Y^?GK='HT]'!/O#RL ^/'=$GWJ1!
M9'O7!D*>GGVZ 2I.("F&.R0*_+JHOG/*CDHK.G.W97)-@$()+FKP,[+@DA9_
M]#!:@]_J=;*GBAC$V9M9@HH,JT1V^\>K6DK=QE'E#PPZ5FOUZJLB,1#A:R<]
M_FEO.\"WU9_QMNFU%F5T+6Q['"/VM*K*V9]W6'AVQ>UY)K%F5)E3WU2\%RZ?
M6?A.-H$N]670Q>!7?0LJAW]XPWCWSG4'N[O'<>PE\7$+\;;:R1_^^S_^^L]_
MSC^>??##VL7AJV=+CZF%&I.ROL<W-Z2!C!*<IPBJF0_UB8^:?Q'KOOQ"=MH?
M8R=!KDJYJE(%OOKJ-W[]MW?;"]OM*7SUM#ZHF7B/U92"U')IF1,52(%Z*%)U
M,ZN161^X0HLI/.UCX[2QA!(.MW;^1]\]^>NW;[_]\5?W2^O#^;_#_N]?.G,<
M\I>)S27[^S\5J$PE)G']\)F]HR9C.L7W^=TJZVC\*1.[ULN_5L1B?RM[:V/:
M]^6D_NY_>Q.$P0<"MP.'-@#O[A^OA.9O<%^O*/ .W[S& LOC^+*+:G6W6MM%
MNX8@:."[%?A/ X0$@[K]XY7_+7D3#/N=, %IZ_?=WBM;_A&3Q3L,?'[@YYO3
M5^\.G,/:@=,X//C[S]GUC,GAIY&GF \W^F3JA2=3G_=DJD[ML.XTT5Y8VLD4
MWOPS4\YS$#^^]MJ>_X >U2<O$>F:DPBUJ^O3X*K7O6G6OH_8'Q<1%+=06[ C
MO8<IZG$B+\[-^\_GO$F'\019T9R;(P^=_6IM*CLNBD(;<PS%@F%_WF-H.$?[
ME46?0J$D.#(DP57D#5R_@\#O0>P=!YU+S'1F[,"\B7#8NK_[\&NWW[];G(GP
M!"F0\:>*K0?9%.&/PZY,D.=VH0E9NHR"ESX+(F=N_G[6@V?B_QDXX0G2Z'#>
M:W#4:#C[A].UX],#,D\2']N#GWKPQ?+O:'[#J'%PX%2/IINLBSCZ62.!3\3T
M6%EG<*46,U4KY?5/]1844,(*"!71K[\=_O'7Y\$OS7^=G\35#R^IB+"\'P>6
M/TF1K*S-,Y]T;U;GO>2'SL%1Q3DXW)J;<\K7YMPA@9ISL-\$U;I,&W,K2E="
ME-;'1.FG,&CGH[KO081>#0_]=N?Q/]$\,=WY1>A%".H[\6A*T#:4.^<I?\BX
M<=@[DHRN>BX<<=!!L((!)K7!AT7]>9ZJS7/W])? _]=C_]!?E8".\MIX#SS?
M4VW L0,O65,9/^E4GJ!M#^85^?L'->=PO_K#Z]HGGT.QZIW;IVT>5)W#@^D^
M[2*".Z>&5!# F>#N F?/7R.I+KN?P<=#H9L3"\U___E_T9?.M]\[C>\2ULG*
M EHKUGP/8T]TQ#H+@HD',;LDV*_,'5RLUYSZ#*[UIDN"IQ]$H2C8G]L!:AXT
MG5IMX0<Q->/SP<<6O0O_P>N<!XD;W/FMGB>VX9@L\&_\KZ/K7WKGWZ:5D+RP
MB9 N?0.$PN0C>8)4F#L7V73J]85KI1_A'(J%0F-NU[RZC(,HE E-0R:<>M3!
M'N==Q)PTJ(;=QK]/NO?O1\MT$HLOO%KBFK)6&86?<+GGSB=6P?9O+CS8L]E'
M4'ROY_:_EG,$4T,^E+^9KN5__=>_>EVO\K5Z7O_>6GZ6G*Z;8+B]'<:S:?T?
M*H57=N)/D#-SY^T.*E6G<GBT3=BNYFD7BK2#N1W)9K7I-"K3TS??.T>;A_E?
MV=#N2BVF4+54Q[()?_B2CR4]<G_V_I_U6C,\J7[W@++BMMH>Z0S.U,Y9ZB//
M>*H(H:_9G7 (-W.^NM;G/O8)Z<?9]</!W'G':L79!Z%1GZ'$L/ (EJDD?M@S
M+M8*<P<2&DYCO^;4]YLO=,1;S; 2FL$,)ESX+D&:^5Y\''1,[$L&3L_DG>\>
M?CMJ_O;II'7X=2DJH[PK;::FS;P/PO[MQ?GQ^_.+\]OSLQO[^-.I?7-[>?([
M-H:?7=_\/_OLGY_/;_^S@B>W4HO97MR5N+A'Q1>WN/'ONG'3^O/RU^3S6>M[
M-_[UTK6N(*E7:C&%YUXIZ &Z<D?8[ !"&WX3#;W..$.D'0!?&K__\5?_/W]^
M_/WPOP^]P7?-%&?;@ :\#<:<Y(WH^O\EAR['K+O%-:/,<#BSV_"'\Y=M'CC[
M:U1'LH('4FAP'\Y?S-FH.[7JRZ2,JJ45)6KOHV(Y<3)Z^.]?=_M_W5PUOW=@
M(!M+IL5K93(BT.UJ]:VJZ5[33,?DLWF"F)@_CUD_<&H'VYS3'"=1+!_F[NFL
MU>K.46UZ4'X1\F'_#Z\]C.$64Y4)H@0?WT4>02J)M,S)A?O3HV'BWK<>.]55
M[2"4C=BNVHFR+[9YB'^\:G?\\$W)43]!S,R=5JU7]IV#_<8VX[1Z)UTLQN8N
MG*T?-!QXP,IGF[9M+,MN<"AT2E5;(&H5U"Z/O=,__OKS/Q]JQP?_'-Y]F2=<
ML5#MDN\5+ A?_,C219E+S_%IC^;.9._7J\[^T=,S%ELMLN1S+M0A1_/'+AI5
MI]I8_8J%K0Y9A@[9+]8A)?V0QX=_=OY[].W7B^H\>:E%]$-N(]R+*U8I/&\N
M@AP,*H-*:C/\WUG_VT?W;!1$R\E'+M8Y+0M?]4(<H %<M%4ZA4IGGOKKHR?4
M7\? +5Y1=42MZ1S.$(S96AHO?^C%QL830A-EA[Z_7W<J1R]SZ-NL^DKHGEJQ
M[M'5DJAJ4.7$_OT??QV^_SKHG]\_GIWW5DCE*(]UZZE.DRM/4"'/@,2J- ^<
M9FT;ZER=(RY2&#@<>^XC;N(U;DQ/KJ^:HLC P-,ZNF[?[XW>3!N 49K$R^#$
M+_7YT[7'DG<W01U]AS>_R):W![I1!SH577Y*"?!O_7\>GOSV[6[PSZ/O556X
M./K<C(].I_7P^/3M1=CDB[ ]T T[T!G UKRN%T4>=SG0(+]\5/'3:?#'7R>=
MVK>SW\[^[__N%YB))&+X-#S]C;U;A)U0JQ18AHNDF=X_K2U&(CCVW]+Y=$BQ
MH\I)*<6NW/^?O3]M3EOI%@;0SY=?H3?U[+I)7=D;,9/LDRH,."%QC&-L9_A"
M"=2 8B$12=B&7W_7ZM8($A)"8)SHG'IV,$@]K%YSKT'OZK3MFD2!=T7TWD34
M27]H-Q/KSR3I%6?*)J[5>=F>:B;J''8,)MZF>&S25K))B]M-&E5..<:TL<U'
M(5_S&A"=RW._"7%%AS/VN*I BT?(QUO5*5K 0<;-VA<6!=)_7&B_X\2Y.=%T
M0#_)<72OGGHE]-39,AK.$'%1S*#O>>9>1[7R=I/&0+&@2;<XU-5IXZ.8$#<.
MV7_.23 OUB*#,2YN6&KP(L%&QU"BD'"BS=C(#F8=[\*Y#9NU8QCSK7%.IB^M
MXUL[8K+NW#1,445!L.6,FOOF^K2-^'N,C^)A>PR7LL%[C#^C?X];(RS;Y184
M%??:*"V*\D!FBU7&#<Q+:Y4;P!A(\X6X?K5#@3%XE;NQSUC\:#N.%<B_+*IC
MS5#<?7*B@84V6V1(I@.B8\->[#%>HL_AEGFJYL$ ,^S1_4"4S*!-W?[QC71B
MD.&)_'0RD250\]]RP!L+\M- 5T 9+.,J00LJO%L]ZLP(_FN0H'*<2+"?Z+<=
M#=_].OZ:VG2JJ1OM8&]E-O9X$B.8O1G# BXDF&Y=C0J?;G,3Q>@)XVLGA5(:
MAF_2)05+^LH16;WYX)..:?+Z3SB&O5O;8KHHA-K:TMTPX18(M4]U=]L5!N)7
M<3=]MYB"C5LJ\]B"+5^L4P5P%0NJF[!@HRT8B %Q#,&U::*MP,"YMC !0W:V
MQ4'NTZ.R"2!;+'$W?THASY=+>;Z4#PIQBX-J\<P1*EK739+,'-FK)EHJUX]#
MI<Q.,S6[(E*2^R^R).<>RV6QRV&U-6IU.C/C:A+":__'5)\05>:$\X@H1^0(
M?!4X2:'")([ EX'>2Y5:+#[Q::X2&)3RAS)]9LV1X6<6P" 5T3 8+&83U>S?
M%J\GTH<[\^>W<K[3S(^_YNO=Z_9=]S9_U^ZT+Z]N%/A?6VE_O;L^OVZ>-;_>
M/IW=W%^>=\XO.]>W=[>WBX9V]ZT\D;Y=SV"<^\]?&_TM6#@%^Q9L.W%!\$(^
M*-GM#[$?4RXKE-X^&S Z@EI4Z-JPTRI8L=Q0G,FFJ&3,+FUFAXUN\G5>J!2.
M ZFS0]V#!/-:(2Z!70%M==0FHZS-@NQ:&58?:J6GPL?A<0B$D%UL(1>2=RFH
M\L5"A2\$)JL<IW@(SKFX)J8HJT1JB[H*'-UH#(?SZ5Q!?T^+C.2A[.F 0 -T
M?A<T,JX5;\Q6]8AR,/8ODERXT!5+##@AIQP8^W](EA85\_]L+&^;A:7.$E]O
MYB?1M!#?;U;<(H'%@-W^WZN3]7I4?+4L\+7 +D=QT6Z_1_TFP_\,_P-%:VF+
M[)X0_!=*?+%2XXN!W;>/$?^S3*&_2;\^IO#K[$#_L .-C*=?SQ3JJ$-ECNSO
M2M.1239,4Y<'<Q/KSMUHF-(/\^J:HL C':S83PS32;-&U=Y)LYZI1>6C\7A)
MC/$1J?AI0IPF;+L1"/XLI. ,I$RU.6K59K-FDPZUQ-?^2XF+5-?Y<KG*5VNU
MH]5Y-N) 1AT9=43;!HE[)A7X>KG&"X'%'8Z6.C*S(-,B,[,@.]!]F05G6W04
M<Q1^JNA_N[LBWT;R]*DI'8NB;W47W(>J[ZG/1(,>=E;]4U]K0O7&WP-QGRCY
MOVV4F_!E'5B_B2**+?3ZQ,TE-G;TC(]MSZC KA'SRR"'@Z8V[$ ?&]?Y$@@F
M6-5/''FUJ3WJ-O1RT//?(++_I<;3^QS[O_]FWOG8ZU&S345]+,.B\^X\L_>[
M#26<UN#A?)I#YD_SB-:"4#DME>G@^+&VQKM8U]!7[WN$8.\Y;0H@6V",HJJ9
M,(^IY<P)03RC]C'>07$CVE1#%A58'7R!?36,T\.O.#5(^8?*_??_3DZX<YDH
MTEON2AP#3^B!.D+4(:*74.5.3BS^)\D/<;T*;"[G=Q8403$1MJ,H%LU0\L._
M 6^']M_K;+^.$'F4)7."&\W_@T/I8=JPW176]_SYB7>3]O;><3>+&8S?T('M
M#-]QE\",& @N-=QUT?O2O_9;^,MJG3Z;RO[[%V 4 "V=B/<G P(<"2:841A;
M$#*U62+P[ 2..,OW;AU!0M' ST*"YO%NBSH]5C !D.^_P?MFX[K5Z7*M3N/#
M9;=WTVGV.&S.V[G\T..YSF43J&OP?A73DT[GQ*.)?2%?>.7P<2_W58@)XYU8
M@(;WZ(G 0KN7O>Y%I]6X:6,38?CG2_ORIL=US[GN5?NZ<=.!!W)LM6Q4_+3]
MVO-K*Q>L%?QH-ZY[7/NR!0MHM9OM+V?M:PR73G<6SVCQT- V XOY2E\0BOWE
MQ=VOK^WKL^J@,P0DG4]AH@5]!.C-YIK<"0< ;;4O>["96*#E7M^JXER2@0V_
M>;7"\@K ;AHZL&6>^TB4!X+F(S [435.+(YG<2FP&Q5Q9@#IV9]6Z"&.ERPD
MR77;$LBP L23_WM5<&%8JE?ZJ/GGA;S0[SL9@$M%GCQ^KE[7GNY'KX(F#:R)
MG'P199RZZ"S"BKZ<W8]:E<ZD:8Z&"1<1UP^Y&<*K4G#=2,!Q%(FK14O"V"5R
MO8"**?FV6TG0#A$!]KN_/Q=PQ3T#+K*2YC5Y(.J<&/16N_/5Z"^7PE"\^/QT
M5LD7]N;LBJ< 6CRO4@&69ZTS&%Q;#";\$XP R<>+W21XNW%+_R0H,&V?IM_P
M/->U*?74Y(43K'L3XK-)WDFOQ-?J\3JSI@#;37PA0X0XB%!T$"'8%Y&\IGR5
MSP<Z(O:."%F7BJ/H4M$,:N?=?IH1U2"&KT3SXVVGE?]Y]52X2%*_-$TIL[Y-
M9^4<L99^A/ _JL4$(H,W%;A': Q$0Y6^B/H]\: %53RF36S=K#1:FD%^B4HM
MW09IR? @K$-63U2LB[&IO96D#"XE"92^C-Q:WH2?;Q)5I)RX2[Q0*_"E4B5%
M$90V</_:,X_0.LK)KPS+-;XL1/>Q20NX@<RNZ+.I#"+JPPE I@5ZF*+-T)ED
MP:;]9(6,-8:_Y[).I(YZI6M#8AA-S3!=;OCX]?<W:=;\17Z6CTQ AC%&>]N4
M-TKNQC-*V0$A$K'/Q.FZA3HO%-)4X#/N>2B<B&*OB:U[H53F0:P^+WOUIF)_
M("KHYPH KB%-955&JP+KKZPIE!?74^6F5V\]_!:/6:&T]D/9INC;T9K]\?>2
M2\2A)V&3E<2-U6J\4*GSI7)0\D'&*8_AZ".X825QQ_<*7R]6^,H!38Q ?NBM
MS]DB,QT6+-($! #2%',1EO1/EQ=^^Z@T-;E[/?Y1>F9U,GY5"N].DD-W'_TE
MTZ6=_<P8B[8VX$XBEIHX8T6H\]5BFOPT9D;+KMPLPZX4L2N*:R=W"]535F$3
M8%=V17$47NG"IBN*OGQ#LSY09$X-ZT+\V^)'=_#U\^?*,HE?^C">F( VVUKH
M+4;&Y5+E<FM8E$AR)@X K_&@#O+52C43GG\A6D6)S,2NP"IPJWJL_O"9U/SS
MI68[2&IVU*$V)1>:X<A-E)=H<CZ>?>DO9]I#OMZ97M?+^ZN F)3:<='<"$C(
M%I.:^E<XV2(JFP4<;2)AMGM1OQJF-/&U:II2;1W";[(SCWWF$9*FNGLA.Q Y
MI0)/^P/L_\PSP7(4@L7;7K=K3HA^J:F:'R,M_<<7/G;9%<W;_.>'X:?ZT<D6
MN@U.IFOG7MO&UYLC/)&C6DP@>I3Z9#@WX!A/3IH341V3CGHNRCKM:] =M> (
M'NA=@)V)N\ JS%0%^3C_V5]>U.6!]FG>_-8XY@M MC/ &&X$>V.M+;#_A.1L
MSZG)L/@;!%;<7H75@(:5V?5;6G;H4)*UM_&(+I&^D-CA4>9!;/"%0IH9!SM>
MP=FUO9C <C0J/S.ZOSB;7'6^??C^E1R9S IC3/:V+&'V]]*"K2N'G',2&ZF:
M/""'SU<.%^V8'7>\XXYB=\F3:N"X#Q=H$NG]L6%B1UL!B[OL2S*]+J%LKOZA
M>GMM-B;&Z-<Q*UT.;[,4]+\!VR,\ 2M'FX2KU1('U@@UOE+:KTC/O#WQSCB"
ME=42%^VM\-5BF<\+08TZ]NG@<3E9RQM'*LJJ@>XN8G35]A-R]KEL3# ,%[7<
M@>E7WQ;=QV\_Q,O'PE XQ@BJV-&FL&L.T(+X-LS,S4'B6/WL+B^FS5HKI6>S
M9K>TSW]+&\E$$G'8Y+E0]2)?+*<I1I_WSM8>(# ^]&A=F4>UF$ Y6(_M=D<A
MR"YW40HZE[NU\>=?MXMR^??3\::G!05%;?;-9\PQY;O%C:B5R,#8(J EK%]6
ME2]7TXS?C\DB,RP['BR+$L!;..?"L(P7BB6^6$TSFW([1,MNN(]"U)9]SC,[
MQ +QL D'+ZMS.-&N$X1T1HMNLN=NQ"=B@$ZIBT!<LBKJBXY)ID9(BRH4T2B:
M44171^7^LO'Q>Z/YN?ME>709Y%;\%2LPRLUT[4$VD*SA3ULVF[CWS%_S=H\8
MDT3\UG>/\L%.E46^5#Z($RC#G0/B3H10K6_A&P['G6J%KQ7W>_V5R<]CDI_G
M:_(3,-72[<Z(2D:R22^?J,PK+Y<E_6.I^//JN8M7QC1+KU(7?G^]M1#7%5LO
M9J[8/_1DG]?)G@F.HQ <)8_@N"3F>K8*E1A7E]*/I^)9BS25HY<85N<@V RG
MP#[20VIKX&TYR7IGGJ3,9*U.[M[FBZ<Z^_ ED:&T17CC 0VEV,VR4G169LBU
M-7)%65*[.\'W84EMBUR9G#P*.5GUR,FVJ*MPA,85T7L34?<GW7QX_#KY_7GV
ML:/NKPUF4AH_$PUY2$NHC>:*LN D69EC+RS[J@_EY1MN1G0@M^D42-+ [;T]
MPC,ZJL7LX2I_9T%BJS]KIYF)K%U-*YLIU'W9#:M,@=):?QC0 F@F 6<P91-7
M''I,/. *# ""3Q$-@TTXFZAF_[9X/9$^W)D_OY7SG69^_#5?[UZW[[JW^;MV
MIWUY=:/ _]I*^^O=]?EU\^SFKGU^>WTKG-\HUS>==OT#_._K]=VGL[NV L]^
M&7\^OYO_^'YW+WZ_5GXV[QOKNVQMV&6+<9!=]NEC1<^QWPA%)/!@$VB[!6P5
MXVH=G<OS$+WCBDYC1 55A1Q%HI65MES9:5$(4(G"6FNF[%S(U/%#\+9V+-ZV
MVEGLI?&V\YB\+>$^_QS>MMG8*N0KS\;;HE96VY:W58+"GHZ$M^VB:H;;%L>K
M6A_58C)3_"5!_%F\SM\(;A9,:A$6B@UVO?+ X+2Y:9A@?V/!07KW(KQCLG#=
M*/^#=)DM+L$.9*S9Q]1@IW0YGPZ(WATQ$=!U#RF>$1?_T(](\ZE'@\.2NFM0
M214@SZXB;=9$ML*4)+:7$#=8C*HNCL823X_:\F 3K3]NHF/P^@L5OE8O\-5\
M4 CP<RM=:4<B9)QXS;3<GA-O,L5>)"<N[<B)TP+('\^)(RQ%(6[E].?BQ%'K
MCWN;'KQ^H<!7:F5>* 9=I1\3)[:-@G]-$7C3^UPN]]]L^ZFGHCZ687SAM(2,
M+L_EW5EF[W<;,\\)0L4>%S_6UK9EMS?O$<*)0Z!* .0"S0)5,V$*4\N9$Z16
ME8:$B4C"(UD5U:$L*K P^ *S9XW3W1<KG I!^\_]]_].3KASF2C26^X*4/8=
MO/A[3M0A@7>$&G=R8DDO27Z(&]C&YG1^IPFJ_]%C!( HBH4.]$H>_P;L&MI_
M>_9W8LA+6$0=86HW/\[G_\&A]##;DL%[Y?GS$^\F[>V]XVX6,QB_H8L#>?B.
MNP1"9B"XU'#7)>]+_]IOX2^K6&JCZ'__ HP"H*43\?Z$)7B\!5I &%L0,K59
M(O#L!(XXR_=N'4%"T6!':CG-EV4U/LG\-WC?;%RW.EVNU6E\N.SV;CK-'O>Q
M>]'J7'[H\3E? *1"3'CIQ +56^XD?UJ@E6TNFZ<.^QJ\WY6,V('1L,<5',^'
M;L-1 \2^D"^^<KCIIN7G*4H  +J7O>Y%I]6X:;=RO1OXYTO[\J;'=<^YYL?&
MY8=VC^M<<KV;;O,S J9]W:/NANH[KOWUMG/S@^W9VGX:6\\';+VR>>L16_S1
M;ESWN/9EJ]WB6NUF^\M9^YHK"CR'E@C7N&SAAV**&WF++/"_ <4'GR2(1X&V
M0E?,G_<%H=1??G_X-).JW9OV0Q'H<SZ%61;T$6 U-@/G3CCO47*QCO+_:QTB
M]_I6%>>2#,+AS:OM=VTQZZ&F*.+,  YD?UIA"W$<<,'.-8M1UQ /Z-^/5 O"
MEQ0I&#7"3:Z-@P4;5; AQ(S_>U4(DA^'7E:Z^W%"D\[.^FX'<1NOVK_GLKEH
M@EJAJ:@G-)YDPWVL28V GJD-[[\05$3[R\&EH'S[+EP7&Z6DL-KHYST.4-6W
M!E4#"!Y57E&Y$F6IHS;%F6R*B@VV7Z6?<D<>WE[)XA\,MMK68+LFIBBK1+(O
M\FQXG4\'7[Z>?Y@)T^H?#*]&?]E8/'T=_;@3!Q/I&#8:]R(EO*B,+[4C52Z:
M;(:(\Z@X4(^3;)-@+XR'<I2)[F%'^X:/*Q'3/&"76W+(+D_DM9:4?R]HAL/Y
M=*Z( 5=[?RU,]K:!OX_?%?;-[YB;\$6C[IX@TYAJ<W6M*&0&&9"13%G.0+,.
MFA89R4,YPYH T- B='OA-$&9/<5RX"4:\5@\H.%-8"RB&\SHZ<N]_G)R4?IU
MT[J2/E?VTRO<<L&4RO]@WHXBJD-TW;3(D%I2MB.LL HFVW/S3_ IKCX5XY+8
MN:BL^:"R=A4)0 D"9%S3<:-WXNM%7KKZ?4?F3Q/G:O.,C&45C4L +P4/;]UJ
MKCK#:_\$WTIOO*^+N)%K&-T1@I_=P]EK[Z\MW7]#5XC;^3OXAJ[.EX427RU%
MY[IN<[[I(<Y:S/I.![!&=FF<@)"XH40]ND;=WPOUC5ZRE1-(WN,ASQ?J15Z(
MT?KN19Q$1&Q^PJ,(]KRM\*'="Y25^7I=X,NEZ!*A&T&VEK+SL@EB!<R)^SR4
M>!"C?#4?W=(D-J;O*4G5TKZ$U2([,1^+&'*[H+S0%^-Z4G>:,MM7MJ]L7SOO
M*ZR-G-WA\INHZR(8#4U-109&I!O-H_/UY?YLEI_E]V*2A6>!^+N'V$M$0<'6
MR)F:$WGIO3#8*=7&-<QJ<<'#+(G]V6EGPO=IY^+K]$M'=$-0(Z&Q9KC%EM*T
M_6*<+<>+IXQK111WB]D7\GD>AHF4[<^4J)48U.D"N9"\O\??#MDMS+%"X@ZC
MQ5H=;(!H6^RY8!VO#&*A4(TJ@_AG(LL*&B3VBQ3K:3"SS#K)M,)L7]F^CGU?
M@=9)P56_KQ1Q2'7GQAC^<TY V3X&B\19%B?BNK@1(7N67HY(/0Y9&E,9*!:.
M5!D(\153;6 =Y_:G+A;CWF"%>XZ+0CFAPO#F6+"D]!=AR<KY;V&4[>O\,UTQ
MD]'9OK)]'?N^ G7%AJLK7A/#U.4AIG^CV=YX%'7)N(,OB7042J.[/N:FY42Z
M0NZ!+G%_+NP-<-FW__J2G'U<"G??R*#N^*\W@V%'WW7D7M/UJ99V*]92S!?Y
M<JEZM"Z_1'!.^6I@BZKS*WK17PW6;6R0Q+[*0JG(U^O'B[]Q[8_ZD=H?^\24
M%4:V1033*@Z4,G_UT>A(V;ZR?67[.K -TG)U[4NL-G0E+K#"Q5%&U-18-PM:
M%&G&UGFPL)K*-G#:MVE2+SPLKW[>/@W.9+?R>#RP[&BCQ-U[RJ9*W#CQL!@;
MOE(H\()PO $*NT \95C'K7P7$),?'0#^%\!W"^NEE#BLJ<Q7@)G68H3<'[G]
M4JJ\//LE+91908;$W@*&#/5R(3-DCD+1RO:5[2O;UX$-F;JKH*,J351#1!9X
MKNF6"QWY<G>&WSUW' ZS8[RKI+WLV26"=;&@L97N6<B]S,B<LO#R=(9(G-R?
MEEF.>]&SKM'S^6*9+U2/]SHB+L84_UJ,6<&%Y-9=2KB0*9F9<,_VE>WKV/<5
MJ&2>N4IF0_H%G]!_>Z-=R.) 5D >$Z-A&/,I 8'\A>ACHG^3S<D7416/(HC'
M73)ZA15WT9S(5LW)*C>EZ^8>8>$<KCS30(/TB1?HM=H.8?>HCB;V<U5+/+S^
MXG716H8[ 8IIXE) J6!%II5FVD"VKVQ?Q[ZO0*W4VS3N2M=&LGFA&<_EY/35
MY S60^TFZ:NP"!ABXW%%U1R->WK;C+-9;0T$0MQEO*#MQ]5U*I&>V@QB*Q"+
MS#K]6R 641+1971;FBIQBB)6=D]MK?'%:H6O%4N1FFG, UTKC_CWGN7*86WA
MTS[P865F1:;.9?O*]G7L^PHLAM^F <PE)X"Y%*\8_L/Y96NA?FGVU%JJIL>&
MRO?%5#QC;K#W>9SB]JN 226R>_[E(C_6;RM77\I;%+>/[<S;KJ+]EI'#U;@E
MCH.CM MYOES*\Z7\"XO2WK(Z])9 K22NR5?('Z^K?!^ W.(*HI+X"D*H\L5"
MA2\<;ZW#="K))S*:MLC%#='#A1)?K( R7CO*DD I G8%<HDO/PI\O5SCA4*T
MX9+=?V0*8K:O;%\O>U^!]Q^"+_3;UJ8:JF37QNT8QIQ(YYK>%(U)7[XJ;M#N
MEX7.K:;I@T>Q57C6:)VF)VN3@\5QCW;Q=)ENA\:,#V%#*1L_E:V@::6Z DRW
M.8*]V4_Z^'?QZ_"++-V-'/LI-B!WS(V-#:U )V?)<7*6MC2[XJI=(697F2\*
M=;Y6?HDUZ&. /&5@;W$QL**IE8\WBOZ0 -["3*LF#U8O8#LJOE)_\?FQU?++
MBQ9+#6E6T"&Q*\1"AWII5ZL],Y,R]33;5[:O8]]76)C8AM+TR_:G[O='32W>
M_Y:S^O0O0#.HY8]4,TBA\G@JZF-MBY:;8?[H\DNO3U_[@[L81.B+M=V#N'8^
M_TQAS 1UMJ]L7\>^KT"%L1FO/OWR:BA)3W=/\YI4?=:**@<M4E_8MDC]7OS=
ME<GY8E"1KK6;R3$7J4_L;ZWOUEVU5N2KB6()GMN%MFV)[,0 KOU5G573 ^LV
M=DABOV6U_"=T5:V]P*ZJ.R/*"@HD;E-0K605ZH]&2\KVE>TKV]>!K9#&-H4=
MEU]_=Q8R^?XH?7M>+W96W3&INE _5H]EZK7Z4M$NZ\DC4OBR4.:%2NVE*YCU
MTE^+,2NXD-B82PL7,DTSD_#9OK)]'?N^POS=075TEN/ZM"[^>+H;3WYEQ72B
MCC KIK.OTC#U2#]:!K$5B$666OQ;(+9; 99P0R5.7FA]B^S&\/HLM2)?BA%"
MGQ73V?8L?8=5S&_13/7 AY79%IE.E^TKV]>Q[RNPF$X]03&==G\Y_R9JYLW=
M<EE+MYA.& <NG%*C(KS43BF*AULC;"LZZ6N<I,T'"HEQIFX<CK"Y5D]P$:-T
M:O44%HO6S[;Q>U1U8F_:=-K00CU;;CW%6C[;A844\W$KI 3'W93*?!U[JQ>C
M@Q<"\2>Y#KXG]/M?++UMUY.,5T)DVZ-,W/ZI5,Z.;__'%_^NIYA/?-=3+/#%
M?)T7*M$]0O^J$TVG6E("J[B8W[UJ::' 5\L"7RMN;VF%'FJD87S<YYGF<:Z<
M5^*[M3I?+E?Y:BWZ;BT1Z=GJYK\F]B-^GZ/_]]_,J[R"WIJ?F?^B6^%&GA*#
MNR2/W+4V%56>?<%S/:++HW?<5-3',DR3I_\/NN-IWEV"K$H$!RO5:J<5%PGB
M_#<7_U'.Y]U3B&D"&L!70X#,6Z[N1;\X_W4<?[/WP6")#1+ KH$#^4$:(YZ6
M$9WS^Q@:+)7*:8D-CQ]K:Y@TA+,$IO2^1P@G#H>@^(KJ I57%=M;8X<H<T*0
M/*@G"K1D*3>255!K95'9?$9Y/"'#5JR-T_2.(/ZNHA>8/GK8(^)0N?_^W\D)
M=RX317K+78EC8%<]\GM.P"I *[+.G9Q8C%.2'^(Z ]E<SN^4!O^C9 _[5A2+
M?5 6A'];^V4B9,V4K2/H'F7)G.!&\__@4'K833\#Z\KSYR?>3=K;>\?=+&8P
M?D,7!_+P'7<)+)B!X%+#79>]+_UKOX6_K'(UFZ7]]R_ * !:.A'O3P8$N#),
M,*,PMB!D:K-$X-D)''&6[]TZ@H2B00B_CH=Y;*_4+;&"'OE0VAB\;S:N6YUN
MKM5I?+CL]FXZS1[WL7O1ZEQ^Z/%<Y[)Y&H/"'=+9G6$EV43T^@;60RC&Q;X
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MJDMB,N"D:@80'?H*Y-&"GB,26$YPTD7\G7)KA6I_6:S^:E?GUS>S<?W5>R^
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M@^=7]9]?.06]H"340\B%'J#?SU *.@0*7/Q")U-15D$;R,W 9#]A-KZ/Q]L
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M,,K=+#V5VFYN')T\0E<]32B7$6PL>F,$ZZ)19"Q\UPH \^R::Z'-&K"H'#,
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ME[]J@U?O$6HY"C;. [<U?CA(2WF.<./O)&F.G;,ZBI2D.7'2,UU[H$4.*)=
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MM&Q$H*4S[_,Q$&<)J4B2ZF&U@,3\P _X9V$)L0#_>EM6X!EU3]Q@BU[:+C?
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M["]O+AZ,K[\_W)S)]W\6]R_TEW<C(5^=W0YKBQ+HEBXD. J*%\3V?6EVC+"
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M-,?/!]1 *5).P7]5+Q;Y,@9?AKE:?+J\C\5@PC8&CZ!-J\L8@BS1;&=,9B;
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M@;$_T1#Q-FGLHGV'W4/!=L"V^H,'^?KXXH@.>,(6/<.IYQ+TY>XL,LMI7W<
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M'.HWMB(?3Z>F9:/9P30'(L<LN>?=X/0Z>NUU.J)7&!"+<V:I!4X49=MSY!G
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MDM-6"?'G2!SNY078TM:J(N*5L_9O&Y#K5A&02QB>MOQQWSH]:?[3:QYJ+R)
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ME8L0G8F0J$?XR1%X1>=N8:QNKC\'I;O;2FHS_DR1.OO5A6\ZXL%L1P-H@_S
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MUTXU[XC\2]>J1^9(MNR%3-J0XD9DQ]@QI@8%)(A>%&.D-*%G6=AZ];-AD!J
M@;<@#\-"!A;VXN^X!/3F\"PK%G@4^S)!N&ZC?5E%P?QSL"\+=%+0T*X4Z:"^
MWK@(M:ZTZJE.CJ?+$NUJJV6)/H9=N2(Z5F97%D63,O9E?7.5W1$FLVWVY78W
MK%J?/U31L$I3M$X\:I*?*2H]L:')\$=ZZ8;F;]>M:GVRJ,J6:.PVT[/_MMW@
M_#VZ5:V/+)5UJTH8S+5"INBC&IXOOEM5+E*$D:&Q?K<J5&_SXHII/;Y[_67G
MY._ZS]FU>F[55^[QG=.'?>6&VKP/>.7-OZO?:@*@,Z<UJ.%I#:$KF33=K_6K
M?_?,R;CPN+67,<>A7>$<AT9_>6BU#K]_O_KG9M)XG>/P.L?A9<]QV#J6&'#O
M;=P=:W:,\O(6%>J('>>F&7+^W<EWZ'%RF;7I_AE(@)+>ES>R 5K>')F%XQD1
M_: >\Z0,)\;(FQIGXV3-1M0X>NQP5XA05["/O2E\69B]^>.DNB&#=.T-])?7
MM_/KYH_&Q!KCK"5O!K?X0-[UIWQ@NL.I[7I@K._(9"VPS4'TN?^/][%\>V L
M='/JRNJ[J,:BYF,5$Z1#N#5][H((X'^+\.4B,R.#>9"1@7&=/0VDSX5^^??Y
M^>RS%FA6(].=3_6'/V7 $4R'9[!$Q9SY,3E"1H:))<[-@ZWCC_[OC18=@9?Q
MS\=]NNCXS?AHS;RQI)'9@W_*G?S++SSJ5#A=F8&WA3:1*)CGI<_B!V9213TC
M0BZDY<V\))B>YVL#F[J>V)I$CF_%O1?=21(4^=1!L@LV>E#FIB;=)3$X-PN#
MWPFX_F!'69CL*)^88T-^2S2W=QN&]>:G$A?3L9C(:S;_2)E1S".=.2.*M61X
ME=B"^D?F;-@5UBLUUKW**+3 $D$/1/>5>5E9;__EO]_&9Z"BS*\NM5@\6K@E
M11X8P+H1R5?PZW @:G\DC\?=:+@[!K]$3YM6TM/67"^TK;2;7:7930I<K8WY
MY:8L;R%9_2>!HBHI;XIC1&1$;]C)7"6=M4;VU<_AI]K-<IP^&3GJ7W]I])<%
M[4JHLKVV_[N^VTV:6/=*E%5M-@T'\^K3!C'/ +FQGC^^XAJ'70H8@EWVPB&6
M"\18 1T9)I4>FZ[Y#$%;G2'<7#N+B_T]XV"1P1#6&Y6N^;ZA G149%QZM]$M
M-B[]T>_FS?ON;KV9DKWS".2[C@;^;6)B+L/J=!O=6J+%D*.1L]S#U4%5V&XK
M9:NM<OQ'TLO#:90;F;8530S=+.P>11L(0VTC$[RZ375#<VLKI(U-B-B71X)N
M*6S*5.8W09]Y"OQSHMOJ0+TAHJYO:A+;DU!U65JM^F6)*+3BT]6J0U4Z)-=Q
M0M97Q8R*K+'JY4/"C6M*L].@CJ@J5JUBG\\)?/7=6NL5<BM)J[SBF*>W*7U[
MOQ('X*?YWN%Y<]H^_&!NRMY?2<86LON;S:VU^SN[;;5RN_]9&ON;L.L?BZ4$
M]D$E57+I)OJF:S>K88Y/;8*O79;07,T3'\3'ZIH&&F#2Q)+?3=H&I-%[0M.Y
M:KHI:SJ_8--X?6+K5F :=^N/2&M9I%.43@O;K\_#5*W"B4^*T+'"U9&'NH4)
MN/0?_JS)%^Y;+,4@<XCZB,+,0WW6$@K' W7"/.V/S,J8X[)V_>&B\_GP\\F>
M'M,N<B_V<5R,;S>KF.2"?#/LL[5>N !L0J65V ]QPX[%E*S"%T/-:I7J3@(V
M;9O.H\A;1NX;5IM*7LF&B+^*L$*ENM-K6&$['2_1_6J[S5R%+"?$T*@.2\AN
MRO-P\I@\LKW!U*B4C6_ZI=P!KS2[H'_7UL@83[G7S8?GG_S*_O/8MZ7MMJM&
M^>VXJ.=RB$*AF/H6AV(JL;26/S]]K;MM[7BF;RH4LVY3M/103&N;0S&J5GDH
M9B6">3Y.G2):!.LTAZ7BS&(@!=>_ET*QF23.PP">K+BJNLY"V=>7;<)5*'0W
MZ[.) ;"*/D:M]:)'@E*X,:MLBY2/1],2 Q*L9'H0[S!)R(,Z_$C;M"L;/Q(0
M*]]1\R@AJ1=-Q^O=0B5$OWX4B]H7VT+SY2EY$R]<PR-32M5B?88D28JI@$&/
MN$ZOVU_>M(:.U^[,1O]VM[1'G/@G:\03/5.UC7G::E2I/S &BZ!YC=AM1X!F
MR%1+>:*_;%Y^&NU?N[V[EK$RO %FNQUD936Y1AIU8,<L657E__XOL%W4OR+M
M0SM:K;\\]_8;M_KLWV_WS3?OP5H@*C@JKK3;%C AQ)A([Z\UV\J'-YG9@*PF
M$F-E>TAO[D7;W:_>8<J2/^O.<")W:'9RJ!V^1-I3D$;$"UO69; >/<=<F+#?
MN0</ =.7]1O'()) ?HN7IM7^N@Q^=<Y_U>._(K]1_WI')V?]TY./C^7S4T4^
M68QV%6P&:EHH$,F"8S"?X&06B(61-'B0_[&=G[?F%*ZZ-[HU71Q*\&%J#_0I
M/'[NO][_E?\J#VU4UJ]=;/9/MC["_FRN,9T2"6RZKF?@)\&[A@**C8P!; PC
MB1)_G8B!!_[7_KM-"^!V@\WPX77POAOLI@R"WQJ:<S#\]1G8B OLK.3-\;6Q
MQJ=[$5(\MER@<P0/$+G1(X^S;-)ZK8,MNJV6KWJ<1]Z3)^W37I HA^L[-?A/
M).[1+AKW"'IOMV*]M]7=U%ZA\@SN!#?N(YLW<(>.2=M2T=URV.]*5^2RD^Z'
M-MH6KY:@.&F^3P;(#>W9S$8B)VVTQV&\ 40AS[O>X =H-7AQM[ICVIY+  5\
MP "XPT(# _XNH=+DCDU4\EQ M05"")"?=??.)!?:*]PBG"VV9;#4<3L+X!>P
MDF-[-Q2_ ?JXX@/I3LX&%2@2O,[ 401#>(%"^L+9%FL'/@;90I[D,P:0##!"
M2%]/W^DBA*G*B@^/#& -,],*1FP-=-=TDWH^"]WI]_VEB()WX"]R#FH?G!=(
M7<1F08W>CVY"V,#<?SBS 7V!EY? ]%*M.C(Z)"<TQO4;)#/$PZ$L4_L.&Y1_
M_=8#5O?5G@*)2KYIP5L&D7.Y[P2$122FG?J%WH$ 0-L!3+PUX.8<G<211OH#
MPM&T1PI@)N"C/IT^L/F&\GAJ8] X>@5)G9K%1%OZ?O)Z@0PCUW!L#1T#<-*_
M]S;-B8]AP%'B)O)X6JD]I-68P7_:J8BP?G>(VFXS=:B=(N'\'. T+FDTNX!+
M051 J0PB<>81_W$@A-G-SW6'<)0\D5((.@=&P1OB/TS!ETJNBK]CI:M:WQ:L
M[6I));R5#<@%3/ US>>I,Q(5BOHS7.Q$%E*F]&1YS&5ADF(4P]]VJDIT3%[M
M:SW]N=6T6HE8VQ?\3"",,=* 2\6=._[6A7W[V^:1G]%X_[3]LWWW][Q;D>X5
M.4DQ9.<ND0)[#M-%IVBJVDXS76UK[J82!M?:%#(VC"KBYH(/!!O%K[@1: P^
M#*AR=\&>>;2[-8_OO][>')TZ7U*OUC](IO:1<I!-7VU1A3SK:AN[Z3-7_:M%
M54'2XW>I!G<9QO$SQP3^HT\)KJ.+@=@R9,C0(]SKPOYR</KO)UOKC@7Y-5C(
MP09EF^V0F84CML?,:RYPQDU?>5'--&/^4;-62VE6P1339,CX9MG9\8%OALE\
MM@TW%,3TI8#C@QV/)H>L#X<.FW.EIPX?V@M%"@1L"%3Y/;!LX U'YKTQBHT2
MV@!&B8I0<.("1W4+V"^!/[[46;/,F=7QJY3"FV'YQ-$K-!GFSO:F(S!;F4X)
M>D04"YJ%L> K_(ENP2U%!)H5X@*$AIY3R* MAA!)Q]X,3I32K#,'U:8C!1D6
M"@AP>,LLG0-CK'M3XD\!71/L(C)-C:H6"%" )(/HVJKYQI3I*\&Q!'H$1ON
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MZGL%G'/CGE=%,L9CG(U^:[ %(YNFPO/(=$ Y3.8$* HCXD*A(Q.3UJ- L <
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M=+U=A&!ZA5*D?!Z^CX[=4%[(&J_N+W\:AS<]8_;S]" SSY_A.\%F,;\_C+Y
MAG+/,;';]R-DXL=2/(-L^49_^??WKU^_].8G)_-FD6SYH!6 @(L$3</D$%$T
M$HTJ(6,S8_KYFD^OD B;9:F14M+.:D:DO^/6FU46S:T\K6S'+QYHX2SM9PVU
M$J.J5\Z07@?4Z3/7JCK?RP5<?<. 6QMAMY^M;SKUCTGC5BLA63%E:.&EK^Q=
M[U[N^CI@1)Z^)@/G35XMHL;U%D<4O#[00S_NFZ?]T=Q,3NKM-<:S\6?//OHX
M$!Q,1>[NS?NWV?&'"K9>+$@=T<>KRKC3U/0.V1O*^WWWQRM%)%%$=W,4$>VM
MM_S:N/]X].7NKJ.-GPM%Q'KF12BBJFS")Z2(K4HBS)!YHLF(*U@&Z0Z1@#',
MI?'[A/"2 ^U%:(( MF>-3FRX;_]WAIM:WJ5[%_:-\[,^'N@A&BY].Y60=-KV
M5Y)NJV;HN7 A\+>$KMZ;H.DJ1=MSQO1FQ9@>DU;COS\.[?&GCR>CUG/#]#RI
MM6IJX;9@^K98;P6EUQ7ZV\D=$Q<H];R[,FDHI9,FFPL ^L@;TD@8Z;H38-'<
M<^8V_/[/3+LWH8%@%BD6[N:1M^ 6;>8Y*#(]VM#=CX^&^L2_LO%\/GAJ6P&I
M'%)2$H&:JKC4[_]5C6]?YTO3" K3LVXC+PFPBMVNHJ?42Z5X9@T=>1RF_5MJ
M)P<;0NN8EF(;K>/F2)U^M-0M1^L<I:1>E7-);>UV'A&OGYDNLC_!'#7LRR?T
MX2,X$F\!^3L2KI"+6H02*#B/K:#5WCCHU>>WZDL52M/3P60Q-BY/;\U@3D2)
M&\K,4JQN_RN)J:I<8Z]B:J/NHLUA>TQ6.=/>]:EV]LW0&BMB>XHA_1CHGB>^
M*O<>J?7T69/;9E0_GA\8$[1I:N=02+W^'6E7JT#%3$YDW[?=1:K(FKLW7X?M
MP<WP>R>2-Q^_EDWIFNG;7DE2555IV]K-*)YZE52/&MA8#=MC(NO[MW'C\/Q+
M8ZXWGPNVYPBJ1E7N VTW7E?^\LVL1+%TAA.3?D>J+"N##BANVY9+0)8J9+XT
MK$EW;%Y_.;OQR8X\44DL);*+561&8U5OQ;:$4'XO/#VL!D_CXF$V/+JX''Z_
MU09/A*=YW'Y5*SP#3UNO5HF8$YOK:/OJ3\_H8;$,%J"M#JG"2<>E$HVK)-S-
MO+&B]#7N #@PQH;C&"/X4<]UC87K7Y)_1ZG":3GXMOARK_[]RZDGN#$2;KL*
MQ;#$QE>29Y6UIVIL0BU,)+L*+:-7NLKH);XANHH)T\\_KPZ&1NU#_2#)&;ZE
M=)4G?ROKXM7<A-PM1U?;8H/EBV5MMYDJF'VLJ*!6(O&]Y?D&>4P>V1X8_8_&
M.JIX:0KW:.1RCWUXG6EY +NSN>$0.DO/.>W=GSJ:/6FZ7X(8=_P65^,&21M9
M18 VMSHK(X4^-BI!7VFAH"3-HH68D+S^V#ER_Q[_.K?-IZ.%'*'7K"J58RMH
M(=*41DIJ%B)TZ^CM]9?Z<-S[^>^1_F6JKMR&@[2/D&N1)A-JV<XTV]?[HK>0
M0FTE2)<7^(DY!DW"6A"7NFWA+.9@4BC5S0AZZT0[D]_RJ+!IN.](%BUMJV N
ML4^& 2K;9GI2-&,#A(/&$#$=$O.U@VVNW8ZBEMB.HM1;P7K]V)M_O;VX^?>F
M6;X5A:QN=3,*\^'NR-R_.6LOBO2B\-%*2+:FV%6R^X2_B4;W2%!;'JY[M]^^
M=>?GW9_^=I(JM=<J<A;>71/$Q"_U;^?;?N/BPX.VZKM?VQ&\MB-XKNT(?**(
MS&N/<,I38]$;N*1A6-_<>[.M5FW(?.6'0,XLTV.\5H84KPP),.,@"S.8 FS=
MG-BNNZ\[S@,HM-C!T>V;Q_WYO#:O]6?ZP57OPW*@G_27=^ZL5E\>?.M>_5@!
MC:J:%E>FC02%3_S/4RQGXZ>701UPL;':LRB=_\_FJN8SK:D2V)/5XC.L:+9J
M!8VHFF]"U<*-/=^\;RK-3DVIU>,3(S944UY5\X)7=,E ET2;NU74_Y2!+B#'
M-$WI=I/:OV\<71)Y=".31Y/0?"([OM6_SG2],;N8C)Y8JI?BO;]/'E%) HFG
M/V2RSJ+^IPQ:T)2ZEE1&5%V&P[KCZG_#VT[F?(WU;UM5VHVDW-W-W'8BJSO*
M8G7G#JIDBX?SJ6XM>M;H\)=GSK&K>#+[NZAWU-[!XNO@;^TIM-%"4<62K)%#
M@#2@-?CQ7^/]CT.2J?A7@BFW*F#*345M5:F=%(Q_K\L3?W=D*S3H'5"D'1WT
M+G* 1[WE1!:]E\6B/SB@O/?-*Y\?+WQ^3%CSZ;)N?.\OS[[OV8W%#^OFPRJ.
M@B?P-Z4QY"M[H4^30C.O&DTR;I1@E463AC)-_U:MK33KZJL.NUTWGJC#MBMP
M]J#UW@ ]-FF&R\;UV*J4S P6M(5^Y:W:3*+(.DP664)\.+ @EM[\<\^>?ZX=
M-+=7-N4GWH<"),)!7]6W#:MO;6UKU+?76][<+=>WYI9?Y<\V;291_K2S3*:$
MV@#SE$NCD=F?N8'==')@G6BM?PYNG>DSEDVOI6#5,:R< LO2!1U9%EF[:!GE
M(UMD!9GFNU<DVRXD2S8"*_"0;L((+(=DKT)YFS93/M1T:BRB7DPF@O^=W(_.
M?C8-=3[9>A&<50"&&4X5^BVWL/(EEMGR.$4O!8R'SN,8#ZDU'1MYT>M5)UUU
M=XNN.E;#DUG!L]]?6@WGRG$Z%W=WS8HK>,J4RO C\#H6XWXX]4;&^__]_W9V
MY"/3F([^E,_U&[C22SHFV8#]U>ORS@Y#PY%YZY]+J]?[RX.CV\;AYU.U-AD6
M3OZ.5_\4KET1(+?CFDO87A</&RK[ -F4)L]H\GCD]T<[XO'YP?^2KQ[FL'[/
MT0?F\"_Y%/0T"IQ3&^&A=L6G_H<_AE]%$>5__?'C +XT0$X7HW^^W1]\F'^L
M!X!T#/WGSL  )0[>/2<7(]92K0"YM2"U;NV7FE#[%4-6GN#_OX/W^[V+@^,S
M^>"X]^'T[/+J>/]2_GAV<G!\^N%2R9[AO%/;U1 XQZ?[NY'QS=%#D'*!C9X$
MAU2[.']\W[8(">@X>_G(M$"=-_6I3$9Q8/*#6]G^4JOLDO8GC&S-&-",>RN"
MV2)5(+D@11#NR)G-5@ZW#V$382]W!LHGK/-RT%QZWW,E>QR'CQ*9;C_R![=8
ML<1W>2CFXF+)&!E!?P]FV,*8/LC_R6I2F%%!,/1KQ/KQN>X];S&Q'7/QT+LW
MW7Z?M^=EH\L^D]/TYU;3"J;2G&7L.B]RN5JJ.MM6/[2KL#7;*9J0O-/TS=E6
M+"^OO9MDR1(&(<_,Z10/=#<QAQ- I0=Y8)##FT 8[!02HM+8A$7APA1"'"Z9
MX5/!;7=7O^T/AGWCZ'/8^('I+AQSX!&? ;EQ=S%W !]Z3W_)N)/^<2]RKT63
M:S/O54OO9N+?Z]MC^TY_1^XL!ON]C<+^9%M@?Q*!?5$W9";L6X5@#_]KV:;[
M3I$=PYW3;@'3!XD2FW$_-QU#UA?RK>Z8MN?**"1=>>S8,V"SC1IP6;#^;R;X
MC\:N?#4QW (TQVC8P\ZJ('_M\1@,<WGL+; D&2QUHCG1:ET)T0(3A8W! ^QP
MY($N)W!V8GFT_W+3IDH:+ME4PI8,?QNN-_B!,YM@)U-S9BZHX]X#AN+(QRB*
M+7TJ71BWAN7A>T<&R#Z* ?6.)KL3VYNR+>)JNGP#ZB$\A7.?++FZ#H6)/5/F
MHY&/O1@'M^\LPW$GYER&PZ(B 9*^BO9)P396:9K2J:KK6#/>)^(/CM)#OX54
M  0=$-: NYB9%J :O5+$'L>X\:;D8&Z@A\[74H% BX'_I^I.HBIS;!$'E.LB
M!M)-P$_$Z2V!JTJBKBH%UK;@!E$)1;"[)AS !4%H(+K)YD(V 8O!"@'$_8FR
MBZ <CADC,\=<)((YCFO!-SBR/IUFM5JX YZ &$SW98QV):0<;[H@DC%KNWP%
M$\$]-XA6)WMS^"&^Z\:P6)<1,C\OB<KED>=PL #BFC8P"9-)? GT)& JH(K#
M473G01Z9@+ .6G4N;)<^[O=2WI4_)X&,-)]@/0%&<)1;^%"?QLXA-)M09% *
MD"^@DD'V+$7V3#@3#FZ;ZI:%N\<*XX5Q P_CYF?Z3WHD@ J]>-S3KDPZ/,L,
M-L$7H;N> .(:+BKQI@N;!J8R]N!R;GG40=)YV$'6;W33<A=YEXO#YO#4#PR^
M"#D=&' N$F6O*Q&DP1^+B/,HM#0<VLZ(@.#.7$SDWN6^W&[40/<+P"3[8))F
M\"CN482J.<X]?2:M1(\-DB9TU[@T;1].:(%C([U!U#MO=7-*,&INNR9I[(,X
M91DW.OF'<0L_A\TK3/4%O$-+#:"ESVQ +9MP 4 PZ\95$J7BS(93.P8* A3O
M0,M$X;7]MC]$O.*D0@'/$?''( ;ID(P(PD;?,/1FA)/B_ XJ50'UV1L?T(!5
M8L@KQY!72EHY">PZV7ZZ,1S280@5#0S#"I.2*W*(@3$U@2SHD$9Q&\$-)R('
MNW,"$C;^DU()LJJ$G1,MQ"$>(R6F$W2#Z2P@?,\=^]9T<1:8>=P?V8)NNVRT
M?_W\X+5O+B8_0E)_SA^)MZ4ZREV;=1+YL*]9^[._O=Y>)W7M]*$LXMK%P^V=
M< (T>IE1-[@#PG8-*Q(*#6NWZ^PE,2K;55?>BV4GZ-EI[:RHLK(0(1L@*A .
M.FE'$K)KQ"U"0K*1XP,*Z^YKL]^->7.N!/K"]D]3%)7(O0GE^? @1,[X^8Y:
M0XZ"W-ZSB/).QJ8"+_" @3@+X!\4F(2#HCXG/JF/1@ 9.H35\%5!7Q?ABI0P
MQ->5AE,=8#)"A<EGC& :H,^!?P/[H2W8#."7%C<!B"B@]X=;QC>.?6>BZSL3
M=^5KHH<&VPS[JM JP75N+& P!##"]JCEI5LIIX>M 9=*DVN+L%P+/<B5/Q?N
M2B?:,GQHW.L<7-+@@3^$EZ S[Q51E :B@%@8PXF%H6(9(RY!<R_^II""-@DK
MZ/[6 K^="WL6VX9)*=<.(/OEF42)9, 3K+@ U,^#-N#JF%$J >8);:L86J&Q
M2YU<'!;4V?4#M&AW9 X9(5S%(+F@;$;W1B:B-;M38CMS2U?FEBX<^]9$Y<-V
M)%R!O(*(=V"I%K. B>H5-[>CLASW3ED9-0:F4\3Q&>X<=!$+Z4O -4+BJ'=R
M>]YWYTD"+(!3+U"U1[8P)1PAU^^ [>,\^#5I'L<<"^C]FP)JH1J&[_#PD("S
M@BM@HJ,R1EPA1,DSI-C&J*@/B )>;(7.2AP7>M(6WPX\2IA#XC>(6$;O*#"X
MUFY["]0AJ3U#=RN%-DLNB 3Z$*@^;9$'@#<YZ.@ [1& AH=,V$[(RTHT-:HT
MZ=S(0N['; YV&V2'$MLA8@1#4[;!,#3=[27!_&"#2%$^CW8!*P',!AIA@ ^
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M6.%#QYPOQ S/,JY97B)8>G,A'VXWZL,M"=HW[\_1QX1S)9D^G'2K%(%0"J'
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MQ#;R)D0/P Q4I^"F^%6$65%$^<56!B35UN2P@!4PK?F&%CM2G);\PGEB[8G
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M()^X#H*F2%862)[+,D 72-Y=F$+,1Y'Y*-#V\8E[CP ?"31/LIE6XB?B(VP
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M,DE1>7MEF/Q)93_4%4]?[ !\<DK,^^2%?7(,3 &!V3J08U&*!.6Q MA=,R9
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M)VGX_";(3%(HHE:5;D3E,H&!6S6(PO>!Y>*AZ!#"TZIK==)1(0G"5UM[)2[
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MHJ<!SK8>(=+=>4O@W_[0 ([]_=O\JP!TE>C,?S^G%H#SJ(\P]*S8_8FN6,1
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M;!?:(A/N[<%TW$"'I:+)  .H1$_+Y4M7%8--ZT#:@H,:P"J@AYICS8 /!&L
M5@$G0/@VB995!I E7$3^#7&NN28!?-2 @.A@73A&&_X.7?:KZ/8G1!P-$!M
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M'\BYLU A%KG$L'/9@G(&?-L[\"D#2@!T1%&&'28%-7-B@[U9*+P)0]+PZ*7
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MA8E XJPI'&ICQ,27J$O9B&^^IZR(AJ4\&&A>;1X<7%J"K6MN@>I.&6Z>F5G
M ^?E-0RO6C8KX[+$A9OWOJV:;@.4&9L8,?E5X@PIR2QPAIG#L30G67!!(H.S
M6SY(9'T2#\1,971VS0+5+%D@U #MA>3AYBBY/PF%G2/IP$N94MBE^1A$7UU$
M'M,,YA5AL0JQLDR)[V36Z@8#G#JJ'7TL:,I0=VH,['"SVR>.[F[U'6\=TQG3
M&=.YJ'2.6U*TRTT6I<@H&5FBIE+1>!($WVQL2M&0EZ ^XX#43D#&/%^";RN
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M3$Z)6'(Z5ZOOJS(9@[_WNO 8TA&P FRDR*#<IR@UX(F*JK178@1^/;0)U1@
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M]H1/++&%DM@#L?W4?FQ_BDZGP[+UX7HB?;WKP>=4_G$@*K\='?T[]J_TA9"
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M/KI%'=?+%V\5M(:(+DB3X:3O;L+N")H[^$^@_WH<^Z1EQA3,4D;INH&FXH2
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MWO!O>T=3D?L8!:&@A:XC-IOEW&(YYK7Q1FG47^:7W9\7PJ3(%J/=]#A!$<:
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M]'&+>V/B!_[J,_2D.XA?["VW3;1UO.IW2Z54[X\W@Q^+-7LW[4@*NV?""AB
M)^U^3WN9]VY[+6  X@7M5/+XBG15*8!L);Z"' )9 QK&=/V32UX(RR7LRS-'
MOU"?:D >B1+0W$ 50W["#(C:QVB KP0D@@P+:\<$G"1D,,3A,M@%/"LR!53
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MA72..FSLS$3(7AX#0$I@4(GW$-@/2>BIO&I!OE$L<GT?3Z^>?:E$[&0I#0
M_]]W1R%Y>. \2J<X.:0N#O"W;VI1$93A#!BQJ1S)<A3)-9-[/&3=U!3UD&F
MWK8N"PI)?)&4)PE*'Y(8":IQ%.S<8M- E?5L\71'IK8$4\+565_8:V[ [SR5
M;6-J68!1(HH$UR!:G5L#(* WG;HQ:NA*]\O/;9"1/4\ S3;U"0'VL5Z!//.O
MI])*C^+'F^<G\\MCO]ML:MM)0N&#9#W3-%/53 D3G/4'(CIP)GY9*!\5 6)9
M4H]N1N\^A]V-R.I468FXN+3]"S >X?=(JBM0JMM/$<9<7BY=KAR2,(47R:@Y
M?QJK":Q6O42,YHXD)H&"4A\\7R'OD(9@TL"VS"5!M'\Z1H1NK\XJQ(B(=4NI
ME1>>!A!(+VC=L*F1O4DTPXXWK%K_;?0?!_?:76X"3@,%0H,-1 Q(]'C37*QF
MYWU.JZ]:%8"4!,S_'!T1/5E2Q(_$I7 '!/%(>EQ)ZA3>U+$<<71DJ011?DIK
M3@:Y&C)R5I%B71>VPF1"U-$1E^KT/=\[<B_27MXGXGJ]!..W=6$B3S\1MX*R
M G\RU"=B -0,QL9 @PA@*/< _]HCP)_\UJ%-Y/_]%^#+A;GMAC?&FXMZG5O/
M-4&[W";E371)>#B:2$#?@+F7:"?<XO*UD5@BSSKU5">?.^VK;G](=/OML\%P
M=-WOC(@OP_-N?W V(HG^H'.,ZZDNBT[_#"CVR$(15#TOD1 -AM>G(^)Z2'2&
M@^[I8'3:A9]&P_-^MWU]VMTY/+W^H#WH]-OGQ.@: '!Q.K@>Q0'Q+U4_;I:Q
M->]O!NV;;A^L^8,]7QIB=S,*Y"#()&EE86^\J?]26?%F\]QM*#L5SU5KI$R,
M6TW9_S1>R]@R_FQ5Y0F_SH69TF9.>AH?:CB%%A;*OYPZ+GC'5E7Z[F%Y_EB_
MIL\?-DK.Y91<O[R@,RI'>?E0F5)"[)!=:OMZKDN2574>P>FI/.\JPDUF774!
MW)?>I2^BA&D%?2%S5$C/UW"J"F)(J%-?!-#4_1KR0V]OQY\%_Q]#67$5_<MC
MQ-12I^I6CZ_9)2 SE%446,\%1)P'=%N,ETZJ_UR5@56D%/OB)]-]^6T\]!@^
M?RGV[$BMI$<!6U6/@A:3X=8QJC)PDV2;R;6HRV*2*AIIODVV["75R*[JH%"$
M+;_43YX73]S+N3)[VVS).FQ9?B^%%I,A,C2:+?EF<HCHKMBR@J8+I?>!+M*>
MX8_HVKN5+:W74OF;KB ^F:<#];<D%BK 7V%?X7+5M8_SLUS=[D@A'QI:9VI,
M5)E_;MV_5ZF3S<IX>7B3K)%997I9@\V0!;DKI;B'[2Y2=+>H*/ W^<$=1B'G
M 2:JBE/*/A+GP\WEX.JT3BLEU@$OP\K)V'%BCW9DKX!)*O*5V-NA<_OP--G,
M;_1&GN)[9;K+<B=M)':!R I+8K^/XKJ[T&!EMZ(H8ARR!0I/UH%1F!Q;7 3A
MQ:R_ZNB@J%5:&344M8=RIX_"T$Z:+?.(D"_\/'6'#>4+?SYO34V]H^RQ9@W+
M*T_HQ;$W7+);)LG6$*20R,R=#LNW2+;Q5TK,O:6%H@(S=]8NUR(;C>1DP$KE
M92M%GQ,@*J??C,94ZHUX7GZK-F:Z]BA_'[MD[=%21&YR!:JTML@FFYR0>!"<
M.Z*$@E*3RY]!S9+-%*60*Y6:5([>,ZU?YZLUUZV+JSPM&%_/VDS=I>;O8Y@"
MK7(*2='\%7(;'-FJ[^Z(=B"*3)U]"@G4_ GB389D6\DIF95*U%ZJ'D"=4_IE
M^'W>IA_R5$??"S,TLEO07\HI:5L6%1*8N>L24URZ'/2#P-P%&105D;F]-A1/
MD3R].[=-4B7KN%Y,HQ]WTZ?!=Y.OE]B+:0>",:9KTU_*$ZE;1Q61C8W<5:!I
MFJ2XW9D-!S)(*@9>1#8V<GMF@&1,42AJ5\9C0DNLH?&P6C>OJ9NSV5LU(..;
M9_VE/)*E@U<A:9F[-#9'<BGZP!^$Y:X(H:B\S.V#::2J %FIO&SF:$SVHR]T
M6KV?_?6LQ-;9.Q"7Z5N8_:4<DZ^/6B$AFK]">9TBFREJU![$Z.Z)HJA S>VC
M@=T!2LU,*!:OF:(_W+?99/E%'=*3+]4T9MV!6$WN)/>7<D[6=G:%!&GNT!/8
MIZ69W*?E($=W20T%)6@SMR>'3==];U?>S11]^MKW9^QR)O#Z38EM<G=R^Y/4
MT>\O992L;06+B,UF[M@3AFQR929Z':1F*5T0"TG-W!Z=!LG2KWQKWDC7+G')
M_A;NJ><3L?-&KLW+:JSXB5!D53J:2Y#DP%<4]T^85$[7:W'ZZ[G7__&CSYT]
M1/=:_$LY-G7#QT)R.W^("],@FRQ]D-S[00=%179^_Q'=(EGNE8-'FZD[66Z6
M"TZ3)XM?LB:^*3,W;>?+OX]+"K7?+"0\\P>_-!BRGJ+]YD%XO@99%)6E!5JL
MT_SNSD*)111BVHINJ*_-P:QU?WW=JZ9=^"ZNL9+;D/Z]7).]%VH12<KG3V*"
MO;C8P_75'M)$03'*YW8I<4VRF:(?4J5RE$[9Y'4CR(V'I[[Z\[Q)ORE[-*XI
M[-_+(CDZTQ:2F[E#9GB2Y0])2_M($D7%9FZ/#DLV6Z\<=4K%=-S=K-;#T480
M.P-JNK<F9V4=>M,#]WJ%D=,R6S4SEMD?N)!,SAUUPY)<O<J:AQ45Y3X07/$^
MQH4D?FXW%$=R3)7U9_,V/&Y$-CS>/-W.O\N+Y>+K)H\2V*L"U8D-DO,C?H_J
M\58]7XGMF8M(_5:6FK=R:"=?BFSP#$F5FC:>OY'S@?AV2'P%-4 K@_LLDOAH
MODFV6J]2CCRRX?2>M4VT8*"387!U4?0UI0XTKZTG]:"VVDU;#U@CUX]I3E:M
M)M&A/UD1']LNU:WQAIV_S/CY@E9%VK,H5WR''8<1%H$1BD[?-!0UWO0OZX-?
MY\O1Y(R*GB:V1W6+KK1'];8I->I1O3UY5=6CVH7.'7>JKF#\ZD;V0&X)HL%J
M 5Z>NANY\FU 9)W'B].S[J]I]WSF9]"R(8EJ)]L%]NARN1:5^V_ZQ;YUUF[\
M?9VUZ9#.VG2)G;5[X\U-76I1%P/JZY([=-8^=-8^=-:V6*,]WCRS\EJGGG_P
M\YTVUO:K"<^?$2<]"OS/U+9GO7>$9$R%)60F?27YC.O&NRP1)9= CD[7[SSJ
MBCU)&Y^&WQYOZ$5;_'YQHTQZ#U7HE8DW'!@]!$X)FHZN)3Z"LP%0$C#.UV_>
M\8W3\89??FT;9U>-Y5,#MA!VQ:6Y%N38/-8_DUV9#16,'QE[AQHJ$# 5VC+\
M1$) -NE*UR7QN);PXG0.)@;OF!JAX28?,'L%J!$"6)7@I/9"+#38@)J0W,VG
M20(2+AH2'AB)9PG,_Q_O/K7JIZE#(G&?,,K3)PRV27*U+HH//:PD,"_(HAZF
M+!!ZQY%T:.@=(E2TQ@ R^4S(9!UDLON 3!8C<^M<<*.2KM=SY[A1/ E&C<(D
M2>B2L93 =P#*-5E#U?4MTC91=_7\Q$UG)&YVSXC;ZVGT[4?NN)?HJ-(8TNYF
M)&UVSTB;C2/MW.$149&8(91]7.%!>^*H-D=]5FON )P%S)VVB)Q2!K!W48L4
M;*-<@VE.%&WZX#-U6!<]);PYWBC<O31=S-3Y0-HS,Z<UWJAG+?&4'CUQ(EBC
M:RE$![=1^G/LFVL@DF%&M: Z?4^ 5>-:L67GN$V;=N!G;1:4+JUP:DAM>@1F
M29(AP4GR&!B #?)?JM9)-O16-48(GR2C*=:HJ I-":8#E=MT:-$DQ8<5_\1(
M0EJ_%.O89X7 [VMAA'J:AE!CS(@*"37.6*!R&PL\V: R4BF?ADIC[(,*J33.
M"J!R6P&1@<0829FMV9T9#K%^]+(M!BI@,70$ QIQ\)_3QY7\)"CPYC+>;G";
M]*G>'V\ZTWOYI4%=W/+[YB3AQQM&[3_*Z^Y]1YN^^PQ7@J@ ?7"MZ4^R(IQ%
M3N$':;M(Y""!=8UT&7I(@/B=6H_6YO+=7%D3B@R>AG=XL$@!NN8FGF5S3FBZ
M#*84%#"WN=)E4Y:0F=&J$Z*P!A]U0I$,,+Z)^% 43 G^O%R!0X1@2,>$V[ 1
M-0FFH$>+M'"J:YL=0=?70 2A6X:QW,<5 $3-4@I0S&WN^X.KF3 [O[RB'''7
M\:'!3R8M3[)5KME9BF:H\>;A3&[]?CQEOK5B9X^5M:GF]XK?MC&<12HFK_UT
M9$A3*'BA\]R0U%BI6Q6<[!%%'S&4%TZZGAM.50O1#.&JPOK').;"$[PW7@=X
MI"8@R@[JC:XT11$?!$.A;]EC+$1D S"%K)K@_Z#7T20$\/<]X(@98!AU*@.F
MD57 F>8* G),M*=3;049:RXIZ/F;X]%Q^,, &,"P,BP?#X:>K!%S];K]#K%:
M0FLL8!AP/CJ&S_;QZ^T%G-7%*AZ+  UJ/0F$P$).C*<,'3X]6=*Y[24 /ED/
M#<]%6^N5-3(*$M ,;+U. :"R20#I]P##%" V8?=U$VZX*,V$E6+:6 [?#R#H
M:O!7V3!6DHX(!?QI2!Z!"29"([^8<&CX45C@'0=(%"4 #8 !T =^!](,VF3P
MPA3*4#"F_;PYA^2T)0'/VO[O_^%IJOD)T(A-4$CZ(G*,)#_P&[2]P8-8H\ Y
M(6[@BB6@104%* '930<&GA2#Y 73H4;9;G"0GGF(9_"HL%SJV@O8:!-884%J
M=E6 P>355T_1Y,-93Y2G3EL%)(Q51F7&XL*M"Y[/#>;K^IJF^ZVMZ1NR#N\:
M8FM Q,*1@?K36L)'L)_65("0-P*NL>-H#^-"5A0(>NCQH947KY:6:VV&EU*?
MT;[6'UX/K^%*)&WUC'B\1A_'++SZS@\>D0,,'D+5L*]5EV&,@UB#W\, * G)
M "PRMFR+$I]5X4Y"/MJ)I,A *ADPT G*K=42OT(\K@34$!=Q7CR;DUATP+=<
M,J^&3#E=NH/E+;&4 G!8$LF LA+"#>,2Y9D\%53S3SD8T?P[-[%=25-%, RT
M2(BM1#_JMNMR[(OCS67C^_W@Y.[F0KC?LX/0R7AS=W?1[QN-J_/'!WB3ZEW*
M'W7^D71HC1'@F ,8!'*A)CHZ%1E^$TE2 2/8*  <"JT#386R Q]X$.M #RO@
M2&N$)>!Y\*> S;@A9DKPDHCOF\$G%+H%.YB#-8%_L#D 3UES0;V3#!0::0)"
MF6L*V"C#TN#(^@1\#8]AR!J=*=HS6.U26"\LXV2I"%,L'7!CA)DD(3F#U@$.
M=!-D>R+ P5\+S9H'UP4']KB@(OX&1@N^^D/3 *J!(9- 4JA@(.@+,J2EH$/X
M:]K*)*&(L-:,(CF!KH;&@O&G2 7XJ[\Y*""82[3;?OYHBQ!(N 5=R0E,]4F*
MGJ??<+:AQIO?TO?S9OO7B7%?Z JF\&W+;_KIZO'^V^CFQST2$W#[K3,+I)%+
M75/!9TR.U;A-=A X*W^V$GZN8=@Q(+4W+.[ZZM:\!I3/D-@P;X].;)9OCVZ(
M@7:,?CVJM\A:?P&8^4ERSBM;9!!=V9@"4P4<  SB/910=/T3?-]Z%WU#??IP
M3+B^A*8#. %CCRL83L;#V['?)AA6= T+Y#)8DZRLP5E*UU9WX/RMSJ&A)[H>
M@V+/]3X42U!B:RIL>HX(&0>>D_B26S:$NSMHVJ!?MN]:<><S("&0R)#5%:3B
M[3T&:3U9@[/8 >7O)Y(JS63S QI\"P8$7I!%E!CL61(X-5KG)Q++?L**LI#
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M[:T)F+6IMJ: LXKCPVY,\<Y4X2KD,O <^V?Q')N=YW(;2TV2XB(3N\)9CL_
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M]&WHDXS@S'#'98#9[B4?M#YKIZ"/N,Z3/!>=X&A)@_<,23<XDJ,:0(;(,%=
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M@2;9!D6R]>@] \A&MAH6T8@LH4Z'&X4\Y[!&G09;@^+%H3HM4.\O-%%2L S
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MT>_5]V]+K$=PM<$P,P$/%)RHEN+X9Q/X9SMO$GY20Y;9W<!P-3T Z%%WHR@
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MS?%LH$L:_$SNI0V"D<);()9'P+.2T^F''I\@7'"IF.6;)NW*@VWTUL^)"7@
MM+HCF]0%R:2026$AVMS] MST#'?DTU)C1*B(1N#2"O?$\&#+>LRR/85QF-L/
M9$3J7%J'=W7?Y26F YG=,QN>QE=@9D!$TM)H&A2$S+5]HB6?)*Z+'CA2L6%A
M,,!VW#([!P;V%#9PDJ0!A2CA/4UGIN$*V@3(7;$P@&=,<[K^B(0Z*&)<O([N
M/HJ!9/QT^$ W^V4\9C#Y+%*-(%(?C4""N1K)(#RCZ1G M?"5:<!JT5X _[TK
M;!O!C<G+D0*/(#>L'KY">B^Z&MRHH0[DBT+(]>%QN2@7LX25&**I2EKB-$ #
MON, Z!(AXKP_,@VR K(JC-Y%'=CG\!J*%)#5#&4U?C)-^U&\%J/1%)FBA32*
M^ +0HR*8+ P2JMQQ<0PA/-2FJ@U,7VEY0N*Z\)MU;RINX$@28(<H:51F8+7C
MI$$>($X'*^3W-J5 1*0M"31$.DSN^L.A+J)5L0646*A#2I'5V$0@(,<CRD+*
M(B1'#16'KE:5HC&1+. )BT=0-5L(H  30)-51)9*#W!BX\$300["2JE8-! C
MFA<Q U[X/<+LV%U0]<C/,!RP9X>#4#<L$%[W2A!S@[B>EE<2[HQ4>1Q(_X&'
MK A:PX)!@>6!'<!"-D#2(E9I9)TA6AW E*;W0$" ]#8 ^5TB%I0#^#(X2#
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M&8D\ZN5&!7U! 884-Y--6D#QNKX9:<:D*%<$#Q5JPO6[R;6CU!-#P*6N5!+
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M83FC<5 ASFAFX8Q(4@]54 6)U,_&$>CF/A,+I.[K)F;>JRY#XNL4_\V"^O9
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M]OF)N./L <O.=M0[']":DRIDO\P^HWSW]!^8$%86+"J%^JA V?6+H*RQ",[
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M6Y6K8Y#B"I;8B3RQR0]3R0#LC!PP:8V1;DK#%Z&0AT1O\T1MHBS$#GZ[J'N
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MHMIGUO19IK^J&R[3EWT%4$L#!!0    ( ,J#,%M%B)?(2%L  #M>   -
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MYY"Q67]K]7 F"PT7RIR7&4D>T6!=1QBQ&&J _I\:G/2GCERN#/$VXWAMG'.
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M-\,<G /E/O9CL+I.H$Q%Q4%?QV^_W.G41=_9W*:J3"4H4].YAQA, B41OB2
M6*H-H9F( !9#PT!TX*+30NL+O0WE][,^\:L54CTO*<\XR3/W!0QWHVJT\"Q,
M[> ?T,B*"%-%^QGK3(3D5&-=M+WAG<,B\.&!Z_J'P(ZFX,F3JVB)I8Q.U/3L
MLG42.FXY--Z/2S/1[</#Z+Q?F8\O'_WJS,@TDE/*T<:V(=>5L!OU<=A7Y#GF
M_T(YE%UZ>,E5^SFZ+B9G7T/5PCSPE7/&'28?FK?9;[:2MD5Q=+$O/6QTHSG-
M>2GYO_9_T'QP,6ARB\=!P;C-H9KL+TS)Q,K@Q5]XU-M5KD\)#M:Y+?HPJ Q+
M=5V2ZDA\SO@9&612/2<D-POC'A%_<1W$IO^! #IXSF]SKN>7\N-P*^DO1PT<
MNRY8*ZPRLC)=T"OO52"HS;^[T&I/J(()OX10HQS@?  )U&6DQ6.:PXE*8/VP
M=\UJ3NVWI9K*^J<1ZHE6"?ZNB;RX/&-&PKJ@J^^DYR=LEEY$YV2;[6W;Y+57
M_JAO)! _II!X>>W%(B-1,.WOPO51FE.PO<P1%,\NI=6 8=I[M]1RZ==>)@G4
M*8N5O+O-%8R]_T#9RZ(UA00*#UBY@E< DIBL&K$?&\[-5YI]B/1<;XB+< 9U
MAO#"+77P*0MR]FZ5UPK^8?J6' F4G'>&D@I#4-C8B1FGFA$?#V]1+M5U2%#C
MZ0'+W! AM&"CY5:F8(3?$Y%;QOS7"6O(^ UMJ$^#<KK 9"G#B]713/ZAD:W8
M^YI>KFBN&D$%!;WY%DM(\?>Q&SI9SL:FVN:"E5I'&F23?L0@8U5%87]:0814
MO(+J%)VY%8<4KFY<IJGV>XT3K\\%41Z^/YL\9@>G;<AP/AH"@LCF#*%3Y9LI
MJ/U<,'O'Y3[W9FK\@')^Z)9@2%5=<5L;B&E3ETCWMFI9 L]2U;;(+H,F@:;U
MP)$UO1D\@4'Z^1U[9F/Y+A6O"!CH*.'=8 TARZRV4N"''M? M1Y_45&&T@N*
M8:+''F+>D2;IHX7Y/)8P[]:Z8P@;>OM*:9?"PLW6&CM!UM Q]X+F3U[N!U J
M>/M#$L@1=9GX&UI542>=G@2^$@#K"'7J/%WVD?:>E?@L(*(EZ*1QZRDFF>G)
MY=#]!WBER4CBGP7(")$MA KCF2C3QRS_FG!I7^.(D77]9;\Z7ZA]4AIU RM&
M05:HAL=$))4W/[.FQ6"TOHHBLFN]/I.C*UM!8X'X&=^$B(&CU9D-8E1OWN6X
M-*PE3P*]G9O\YVH)BC-NF0A!E9!C Q3;  5N5)AU0:X,,(!_O%P%HY4R=^!+
M=1\E 4H"P9A<F6-1K\I)(,'"$WS4X1VW9B$_LJN?1NU6O%T1A=*$,%9A] "A
MRW*=5Q=_L1?K!AORVRW2N:+9B;08= W$]6#&LPO%IRHA@<U2=.AW9;;\):<A
M0UC]4:-)7>:'T3K\NOJ.^OH+XJ'6\@""G3B$0,?.R)O[2E 3PF[.4\Z9?VR'
MQ)FM@O%7\[K35=DQ!^]A+"[K-JBFNNJFNECCFNGJC?2%UW3!WT[$MC*!?<[4
M8H>&<@LPU[K9=NYL2^+OYH=YNJQ=RC(1O:X:1TJ0=X,:WHO'_US@4KOUU8S^
MM]<E):8'^K2Q7OP%8C +^..\LSWRAZEX[O E@VX2B!$/ ZS#=5.,FYV_R:ZZ
M]);.@!45TAZ =_(6-VYQN!=" C9/M98SXG.!</2..J:[VE%Z0OJSGC:_77+8
MBF"*\RGW=]=#"2(]Q:J*P!8?$_JB!Q=N+T-Q+EIAVI-'#R0\ZM-W>+ZG&HEZ
M0@(Y23!M\[$!3$OD:;>+1JPL OP-(C>$<7TB;9]_DT"-WA Z@D3TND@#']2Z
MM;(Y.?2YV1GX5RO7:"1[0A6>C4E'7'KCS[1>N5NMV7C57%%N+/XW,?-_OVK_
MOS<(:11W1&0L(:3*,%T)X&^#UII%[>6\Q"O=R:'!Z'X16S=WN<=9)A3"R&^)
MN,=F-_(MWA_Y1P*0V\2.C9! +IY3D(> ;]E"3(@#NI4FY 9RMA]7F#ET1?-3
MD,_1O4&WK[RHS3)O)AT"'%A%0Y=)H+UKZ+@N*"51]%E%WO+!M2V?+:Z"TI.7
MA<\]-#?=HJ<"YKS+*!DUX-FJR +B) KMB<*S7,.IZYFVUA#6_,SD1/H*@-Z.
M0YTR.T>PR/-;3[@Y7PIQMAL/[SQ7SLM:E[C=4O+'X\F1E=G)=D!]VJYH,+SR
MV.G\&;ZI92OH!)E$ MD>S$HLU>W-HX5U@2.T&C!H%Z#\7DNOOF/1V7\D<=%\
MOHO1Z*%'U'[C<FK:S=;Z38X#:.K*W:,"!>.BLHGWJIL_:(4J(BFSWOY!#083
MZ3 X[I!G9'=Q)LZ?9W091/ASH:)")%<(.J==Y&K1K/M56_#SLY8S'_@W+6GX
M]EK=O9^QB&ZWG?:S4L)MQ<NYK5Z$$HB#9QBBUJP]U'C)K+=<2,7LX5B*][T/
M&:9F(C2QVW_<V"(#8@2?^_5_>/H!5A567XB38-DT4AY;*Q=<)T?NZJ^[UC-L
M^H-N<$3=K@EZAT@WC@N==ADE#D&X:P::6ACO-^;$E09,6(KIW,H'"[:][7-\
MF_!4_B=U^! 5K-@YAY]0BEJ*1U&$6&'RL#- <3E0M<H47SV;2(L7!H)FCC-;
MWGWX\!5AV6C67Y<\R\%\M^2;9$/!&9RS%1)R%R #H8L&!!2DBG@E8*8'9_[;
M5$7WT?CK,U.#FBTYMU<.9>;%9[P=*\\LD0,WK]!EG@Q/[6!M"'DDT%(#M%:U
M9A4>OR#QX'),S5B(<]FP2%Q<J*PVI^V//W<J_1A$1=+XGFLQK%4Q$)<_.3QU
MU=H9%Z19OE.0SYPRZ7I&(#!]2! QA/7?;FSR+"P^9<=SO\6Q!B!6S?;XBXCS
M8.;<AOJ19G:Q.45>PE]AG''73*SB_'-167]".J>]>"!AK3.K'.Z#\Y<8M-9%
M*Y'1!'1Z>%DS"FV\S/B9,65YD>E90>1G!Z8G<<G#_'82=^)U?VZF^PF<(,VI
MP;?WH&$8SZO#4CT#S./I(U;)4^>_2B6>N>AD^H="/^Z*^XW"T+T%\B%YU#4P
M6S) ? Q9*D P_'/MDKYU/G1MFR@W89,,H0.L%:@_2;^YBOV<9=_K>LTN&-'L
M59KLVMGF</)*)D\M(K! C%E+7Y1=_YV<:6FEUKH3GB<19_LRAP\PRR5VM[(T
MF<LD7EV8#4CL?M7C@[42:L?//LKOU6QH-/&"--#;V[P+)=/(2Z>P0?;%BRA;
M"<!"]6:-:ZCQBF-9B!97O<CFH[=4K=GU?#FV,<+0IVE!9D?CN LP<K[CA2\A
MX34>Q3AUV&_C^><!VK[Y8R&O5CB?]O)]%1#T>SD3\/>:;9E>]0J'EG P"-ZJ
MQZWYIUDEW_(E%V^S:;JI+,;"PJ+MZ\U(CM2;-V\MB12!R*$O%[=C-'!OVUSP
M=K$.?ISK8 1NE83)@N@'S-D?*92*6JAF#SY(EL69'0V3ZY(O.9Q4M\'5V#(2
MJ+INMRM] @:)E%:<2&JV^%8OACV3ZK[;%GM^Y6[%HR,6T".'B\0.X@2T>C,,
M8K?XMK&N=S@Z??(TR#0!VZ?2FAE[RCAI?(>&19+R0%XX)PW8]"&SVYNP7@SE
M6@"TY_#JD/)G^V'"R2UDQK*RK+M^28]#ZFQMIBA2>E@KIG0][7:SD(VAZ,YT
MQ2 X&U65@6?KQ-82XCU6 ":<$Z!EA&$(DKW#<)[@IJSND?2^I.*(XO(4B.'1
M,\DG3+_T74\,M,B0*A)N8Z6N;_E>AXEC6M_X=?IP?M\-4]ZGB@Z6VY=#6C#"
M1'H$.8;6@ -;:8EX.)UOMM^D<[1JN9V--T;43M7R+/+AZ91&( GTII4?WMZ,
M8JTILAG#2Y) -.^[ZOM=94^QIO=SW@QO* >J#D+AL?UW:T;+X_M+C#.L]5KW
MH]I_#V*DN0HB?GV5&<UV/3U1 :^2:;C5<N =^]\H!Q35-E=DH?SA7@WT&M/-
MBW=H^F<>6@1RZM,\O^7QP,8<A=8;GEXDTCW K&)S*@D-D)<&UX#P3D7=]8*J
M5KMK.[(A[[XG/K:K7!@&(N*_ G/Y*9F$)D(.Q#YQRK.-C6U!GI"-YUU:9FAW
MK)JH!OZ<5;9PB<98F!I)CG-PX>1?>"G!=0"\)_-2T9/BR &OK.;^(>,)T[UI
ML&[X<KSCS19E?8>XS75_P\@D%&P7GT%VBN_D8%(I)-2VLEBX+C(]E 0..G)>
M-U[/3I='[CG1;T[U;W+[IYG%]'74MR_'@%.@/T[))7'%?_>=#=/N ,XYP,FB
M/JX3BA&I'8MP\ WF$",^#=N@E244\(/N>/?HLK9=7WU%F"(4PI?R%RO]=Z-6
MFY@B%SEK!DK=K<_')3(G.OI=.UW=^5FT/1[?CT[JK_T3],[N-Q<V,1IR >((
MGT%V3'"==H$O _#NS-"]++E,C[Q7%YJ3+1^WVNNQ=KAGV(EZ@.Y2J]Q>;YC\
MT:Y.GVF3];>IOB7SH!\7R/.I5GT/,]J]!A3H-U8FSZO.#9Q Y$X@@(3PKKIS
M0<W^)Q*(5F^]-]W<;50WB>,[SVVG#J0RLSX53 <V J].W#/_AW8D/O6D &!P
MII"[:(WWFS&>$66/+TZU"^3J#B1%9(:^B?X2YUTL&",0@OK-2,;Z%Q&$-\>A
M!CA]<%20VQ"WM\8KF:ZD&]MW(Y] *#-Q'K/+B9T#8$H#]+#>R.M9*-.\^6#A
MG#/;!P$VI*=7@6#B0/RMSM(K4VMKIQ5E$.9U>=J2:3\N_=SIP7D)Z0SCX5YT
M9/"GT8"087:.45>3B_L$R[\P:O+VM>@GHH]6+!-\D%N%%0&RD<UV1'JV;53=
M9"=O%ZB6R]J T.UZ+@2(X>3Q5PC991+5R# 8]W?T>FO!O>?0;AO4-9VX'YQU
M5=YY;V,+,*)8&X "$]Y=JZH(?%IVE[(8/QY[M.MY8!+_O<QSX[I1&373$:/B
MG\*>:E-?,RFL9[ISJ7.H20O##N >C6 <Z6LIV0C7:W'/1VX'K\&]C+>^7!TM
M4$3)05Y R-1F*1_Q(P)5L]D^9=9A2]-LM=R70T;!R6XB<Z(5T[OSP_/:;R[R
MO1W77BU<V]PM(-M?!DC#79_5PLD3QXA\XX75O[6_5]<[B!9/J16NQSY::ZN/
MH;[:R.RWQW'=$57$@\F:?!_R!*! VZV:%-4 A<OEPI9T7TUU?U)\8N%9=GC^
M*$]YZ2XKMD&8Q2B2>YOS'=A9Y]1BQC#4#3_<'X#LW#5Q"QH\=#/XCK0O\ T8
M%&O(R/ YZCDBTBOAKG<7<C>IKW#'U":+I>@G0>7_:K?QI9TM8@Q6Z_;$R O5
MP[A!&%I97J:0MZ2RGEUN4.H:!8W_G=-3^D/>C[^\-/6?V:^]H=Y-B\)?T\4*
M?4?A0JPOCEI5I268>W#)J/;;]VY";0#7=C*4M8[.X40G?++[-J598/JGAS7L
M.LWF^OU+!CYCITC3Q*OV *W(__0*K4'!L;,R?PJ,JJ_>LD_S:WZ- R[M0L'I
MNM_XR^30YG57%01B*:C9@K0@9.JQ3;9_W;,K .5;A-33'@/<5;-=@P[X].H2
MLJT!60CH+<]>IM/3'6 ?= 1+!3Y,I?:1HZ]?8K+XO(+:)8'0/JL?*Z%QBE3I
M=82<Y],$)'P__HOG[(^,@Q=.6\;B<OE'BWLP+8\9J.M5$NA*.$N])/J7JQ;B
MK*:N>W!F4Q?=;4+D_JN; _E!'NM89W(9M=>+NXTW 5@QV2@7,DV<$$56#OCY
MNFM(KTN((X+@DX]&&.UKZ_N<62Y0B'V@X""<C^ZZOVZZ5;US\=F7,(%(CLG<
MFPPBB2] I>*Q2U]!X5.'*CL; #Q&9!WX9/8MQ:C1>7?T[W##*H+1:QIK94!M
M[7&MT(FV-Z#/%[H&D\(+DLV#PBNUCMC6 KVYVUR.Q<PBS_4*>CS<';Q4'9^H
M!K1OF_12QV<Y-C)%(]!FGA%!?N\E\*)BPD_'?=FIKEO^'2QHK)47'SRZFO/U
M@<PITWNX'6(:L7+IRPPJ5AF<-^!]MB@MR>UGJZ^MJGW?H/AZBDDS/XX#]DN5
MMH4+$87GSA?8ZNA3E.E1P?ZR\OG["JI%*.Q\CX.6#)%  X/[)%!VXA"8 8C]
M>O)H(S70;],K!'L\L[F&(F=<9;P5X;NJ-'*/%7.ND*(>NZW49?GQEVN0^Y1,
M2TVS1/_,U_5$306>=#OH;[6;N3237SAZO[!,W4Q@O:I64O0%5'(7= S6R8X^
M@,IU96D;2Y9RZHA(QE;;UL9"'J(G.]WD+B^[&+_3,BTW&S3*;[T]@&]BRHT5
MW63Z\Y_[;^Y16W@<4W-R'@\JT39Y2"8$JJC<]NEU2[@=H-I3#X_F4T77=1K0
M+ ([/6:Z3M^<OW/N[W/G%JV^G8^Y<9\GI6TC6U['R#"VR?%9O(:B]+II=:H=
MJ]]"G]BLDJ\\6.[H:P//Y!"" N+"%(&J=F\Y1ER6<,K4D_EM;6G5ACVZGLJ<
M^*--T/(BY38-,O<PGVW0/;;#Y*OAGW)V3O%$S5?K"CWL8#7Y,EX3(^;IPM=$
M^U1##9^<#X::6CKW%']3:+ \^:=1D\:(!-PKJ#!QB@3Z\<_WR+.(I80\M,1J
M1:;X,>[KYC-H=T3KJ,33JZSS6<T?U^,1>0RE%QA%MQ>R&$8K52Y;T1T5RH]]
MFW%]^EOG]K=,,H&4;;%4(]3!EQ8\9V,7S:H#/8^5MFJ[O9M&'V)R(BJ^/;+G
M*3-[50&9#7M\;U\=NC"Y:XE[24[$3:W46R00#^S2XADV Z1>O.5/94H"Z;10
MWK,@LR632<!@WK?S=GNYP2PU5A40Q'GAKXX1+^+]1MEP>BU0V:%#9;&-SP%?
MSLS\D@E_U^./DCK)ZZ1EQ=^X1:B!+,TMSH9(Y[K[M <=?S4??QQD$"_]\MF'
M+UGEK04>Y:,'_#Y'#[O,=I3' M(3:B-%1$>>ZIX0:Y4M=6GV:\+Q3,<V*MY,
M+G@F<I0LP]LMJ'>9T$-,X:A+XC<R5NKB=G/T9#7I15XJVDF^/[G]88WS6:2N
MO0=]6*](!'C,<_H VP_0XG2)@^DD4(U9IY[+ IRN-D6\N+B/7P)14).OZCO?
MLOLBA06[!)9DLJEW>"0,7";D*%];A0+BU'C6]%4S "'8_Y?(/^Z!-URY-3Z,
MUVV^D:^8S_7ZCF3=:W>J(IOPC<>'2UF3<>T\,OK?;M;RWS4M?&"M.VPIT38J
MU:-S]TD!1M?S2)7,%</DX.WLO@>SP8:>,ZO87BL= Q!4[Y7OMQGK89%M:Y%F
MQ[/]?4'/!7J5Z1M'GSYZA32SH:&SG5@P(1>^%(NJ@45AAI<8BXL0]+HEW,.4
M 05Q2II_*0?SMMN]D&G];^8,V"RC3)%SP[,((NT_:$&#\(VH9+ "C4"QO&:B
M "@?UL3=1X,CI$5+<1RO"7SC:EH;!0TFSNO\/G7W97.7G](!_N1%HCTA>!9<
M;Z8V^B"1*.7,M9#S)W_0H13J8N85F(1(PC=PO!](J<:>($<J6V\7FET[R;)6
MI<L:SQ95$IRMP9% G6"Y^#8=Z;-;(RFI5F=-J$/(-R0@S+2WASX@TEW#*4R%
M0-%?$@8LJ@Z/ASD"@@.<I0=-GG!>\4D/T[>F95HT\&H+)8&2)E##KD1:24S<
M"KE$P8ET:200PSKF]KN"!-2**6"Y:GG=<G<#^/5[*^,'&WT:NQA?G^31 P6/
MC\A=)B+=/\IS LYD +0/"(78543[>K*[\CD4AH>(;K@E$[?\#C*-%!(F%KV<
M$7_CCNXB!^61X9M1OVPBVX,QQ4[T?J&J5CB^";/LG@ GT]8$+MVU5Q#T4R@@
M0MWI"0@C._D]J9/*0AY.BD&)5Z$,^\,*HMC9P4+)6<W%^'A9"6](ZN+4->P%
M0BYDJ0(!]I6885HE%I?(13 6;@8@NT\%\L^S^J<5/3)R6&XIF8^NO8499@S)
M06R@4^K8#V0?&2#^GD'N/<#I;P<E!TC60("B9LT'D7IZ7^6Y]!-:;D;>.%2.
M.>RZ5_J)5I0PA9<%G)>@X0N7_A Y0^[]V9-VI]>LTN65TZN,UV*0U+P+HBQ6
MT59.2?;6"^63 T<MSREUO,@OB$X^W41))"N+<.@TU&A87FEPUMCB([K%+?MW
M'(#P;&C&##1J&9;AFO?20BS3W+G1-_-B+,<'NR_;!J9V?0+)VC)_LQOPSJ';
M-T/KL<B?PH9]1]J(0([\<E:[0U$B?6Z8 2!4ET"QYY,OMU[T $KF/N@'R&DS
MK#<PC>-PL98$?BP-,P%1)E$KC$@[5F*Q2\JO6LRL>64/9]0\U<>WOQU1:JBE
M^G!__#7+WGK.SBTWGRTL$(C,(:>1[UJ[[*5(PM,65Q)(V\WUN$Q(I%R<\W.A
M,/N>:7$U%J+2O5P\OL+14_8THRI(!E:XU87X#MF%OG)SMP<<EHXX.68)V5<(
M]Y')K5)DI'H-\L(SCBODQU\8FRKC&"=W_UBSJ*A%FA_Q]@W!W SPO.]-U',#
M?F7"[<!>""$(F.%13RP0=PF(D< %(DQBEG>IGAT^[>Q&/H1?R^$'_/^])X&A
M57FK56[$TR!:F:K,ZO,3.R<K.9.W,/_JQC?)M75?*0*R P0#Y.=$S\\)")A2
M #4V#8!\Q;L![DH&^:X381M,=ZG2V8V,GCD\SZY\N/VS<PSLL@1Q(R.2X4YH
M#71W=@41KLH?*YOR9%0P0[OQ58I3\6QQ\M RTQ.C%TUO< ,-!A<GES+PW-V8
MS2ZV1E0"W '*_,E4_@:?V)]R!PAF2]J[(+V 6D6*OP.GA0F,*D;6_'+14A@0
M3LPR0FH4"%5OQ.ULA_!9<=I_*KL']#6RIJP;[/9Y(*<(1H1*R%(JM&IRKP"C
MT[FRF2CA.R]A4O<]2G>,6RN-56)WR2\@+U6QMJ/5_HWBE2F/9@98/"#:P<7^
M1OE& <#=\9W>74IK=.^X176.N4,T^%F7H;B!,,T71U0.!!#KW9/$G"YY]H(C
MN:@[F%BWB;R58]4[3>_5%O4S!G1CF,\G[MISG'V/'P FC\,YA:[[C#$-M=K)
M?8V+I*86.0G\*G!FYJHDM57Y6/.2>:0L1Y!RS?5)):)KZ5<"U^?ZA,NP:_!V
M-<@2DA8-Z1XE#L.KQ+)4KV/RC<5R\HKO<7^VI,]8LNB^&.@:U[SJS92FND55
M#V8#7)?!>'9N;%@DA'.;BUBZO);&MK+ J_LD44N0>^.)V-ZJ-TH+=#Y9D(&6
M<4GEC^XV?<\QX.%?>JP5DQGP*:HP.IV=4BT@IA>F\;HU='B[SHNZA?]#:2]$
MAVAS '\)!T0W=V4Q.RC>ZJ^K$+I9>;E)=R[KAQ]*\%WSLR6#;-1*:WH-.]V!
M['NBY%1F 'S")*X*AS6KXU0"XIZCA^)DLM^U_O@BVV8[9M\TJ]CT-L8D3X2U
M]Z+?Q0^*WQ>X;7?ZCUTTGU2%],V_;#S12DK Y(EWC)) +GF*ON(9 FDY2-]Y
M\<(39!:Z?N,#6OZXI$[.KU;6,S!@B\50\X_NG7A6PZ?VR;UO0-MZ< 5$-0K/
M:K=JUHV(E4!K85E'-^M-/NVQ6];6X!SVCGK:K2U?3K'$S@?10HLV^:^;_5I3
M5HCY52)O,Q%GNA C(1N:P8ZII1;,X_KX;:X@W[8F%9$,R:O$DT!9HS'(#5%]
MP@?(TO?6VV^ "A*H^_Q=Q!%8?GH>2'CD8'I\F/L^#ZPWWA_0B^TFY\6/Q'XN
M]\U.Q/MB2:[WJ1,6^G7%LV7?;G.XFY<?W#RS3[XK)Z(][*VB6L+'V_CG*3I@
MQE=P6L5@Z >?G!8M-?1>_XYA(7Y($3RVW5A+EP085R6E(+:@&7"T-H(A1.T/
MW)%&V6PUD45OA1Y^9;ZOV-G42'>3!')4LTI_E&F<<:]/:#.)MD-RYM(#X16#
M&01V!FC!0<CQKE;#?=OWO?Y.^XRTGP0D\H7#LT+SXV[O<*^EZGV.'UL';T1_
M=J!]W315:RDO"]Y^ ,EN##WG(SJMM%ZC2+&1*@L5IC%]93HZO]&D=V;^G!A5
M![JGFO5'U&E]$"[')=R% FY'[<WZJC:@^\U#I):_I27/N#I#JMPO+7C5*5DX
M1_-X/#%3V;&S H3);F(-7"-G15KKC!45+6@"BX2T(NR+K[ )*%V(/L)J'A(E
M@&7=AA>)2$R;]HR^-UCWA.HB)"5XUN6;]:\)(XVBCHK^_ME.WSQVZ'FT=?"(
MD9WU3!1'!V]71[;*[*#0WV!RG6S9*]7,]*(U!E7=(1C[/OJNJ</"!T-S-F_D
M0?'@B:KW^2G Y,]-<R%^"JMEC&05'C\*,5XB2K4Y?91?]3Y;D("]5RVN>'\)
MDQ TYBZ20$O)"FSA+.'M6K[E]#W7\.R$S'+-@G(M+S>/$Y/HN7>-QD>6,VH-
M1U:O(NW2J.6W,C%B[%@?LB-\"C&IXY.85-8+SB?SY^KFL84_]R4_/+["?W-3
MM8&W.U25^JV(HF27G6M/A$.=TC@^<: *P8O&]#QM6_O(53]M#&3+!!3.X*S
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M4UI^>@:\K=P;_9-EU1YH(T5]$[EQ?AFE!*J ,06[::U_KR40+K Q$=H ]N$
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M%%$5#==LHH7GE&E-DF&OKWITZ,_ N]?\19T")8AHBTK)4KQG4X+'D%H3U'[
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M@NS,,2O (^L7-,I$IV/MS<6VD\5U1R.T1C)8E68Q-YQD21*%8Q,-DZ%XEMN
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MVX(M%/OM)'(%A'\3=H#2RN!]9PCE'1D38?D9I'[CY$"><;7'Z\]?+W[]S>U
M-FI!Q3,!02V.:?/52=YABHOM8+]TGZ_#!4/7A_VJW\]^V7)6..?=*SJKC J#
M\CT@=[8R@2.H0Q3S5M4)"3?+^6L#>0_2I[2"#Y<>7U+ZJ;&A*XFB\JUYA>$"
M7W176S5827UVKN[6/K13QD78B?!%CZA-,X&V1O_.<]Q6YJ3NE:!KK][?5E<E
M*?3:65]_Y%#NV$G5#M$:TN&C*2;I#HUP90S6U=2?FJ3;FDB/@0B.R#*:/"6"
MA":654[#(OL6ZWZ_)FJ9E@0XWWC17D70'57FT3:\P TX)A&04=C[C2[MDT<J
MWEURD&M1+#R*#E&4O'6X:^=>&/_ZS)13$/X"TA45YRC &LP8'7E2VBOAUD9'
MX_UI3]0XT)L4F6,&RF%)&6O<K96W/]/?A=PA.UN0HV-T3KN?<_-/WTZB)Q4N
MV%W^07*+X2'(N42%-DEJRYVA$F0Z>F)TN'L9H@'Y%6**!]W61\MRT,-?Y^8M
MJL(CSI2X/',985,&F,!1Q)"D2@81%4-3)]B;'6B1.-A1M:USK.:<>:G7]>;2
M+I'1B/CY4BNR42SF] 0##^6Y+)1F=S-R._KDCY&;W<WC(OL#/_Z:JH'ZXRH8
M\K2CE#BBAZE=OTVK)#^Y,%KQ]8.D(G>Q[,:^W(."SF.Y\A4)37NX!'03-$:'
MBZS6(@$S'?((N3%Q= !B-#1JF9SF=O,7OP:$>'\&&/_ GC& =&<",3IGR0\^
MA*CG+LC=+UB2+^PB.%Q;6]FK6"JM^!%>,__!<6M+.(9VQXO@=1BVO+/4-[R(
M\_#SS4V[JG ER6H$8T%Y1]6BF9()0\KR1I=)!<7:W0,JJ*3I SC&SPO#EYI!
M/[Y>W$'GHT-X)3^3OB$/N/M;P9H5,N@HO\#CK5TO1^YQ+UT#$W0AT.I5.?+=
MSN8C-.M!FD0!$V@I?W&VW^WSF-#@^XH'3352(C(0U9XK+:0$=&R(/]5[<FGD
M55E2T4*5G6#C[W?2Y2G;V^OQ><F= ]X+B%=/S"-@8I6PJ"=8D,)\;VKSI]7R
MU^WGKZSZ:<=*2JWWL'UM276LGX(\W9D0H)"+ [(.A(=<'!$L2W63A 85''^*
MR.0$YK#P;OB-P<DF*+BB^]JT224Y\5-57>1L\6JF[D>'7/W11R(R RHN[=C/
MZ-:B!FAATJ%1\+[E=.4N[:S&POI#=^ZKGYVI$I>D-BZ7TG-U0.,ASJ2L3.6$
MF[Y>0@LV<46N>R_C7IK@LQ]I%(E#2@.1L30I\O)T6AQ\"BLX[)K%2=HL%8.+
M_DP-6-/NSPTA=V!;(!)TUWV=8;->SR8KO6)]N9:[%'R31-UDB0<5Q&<EY\9U
M:X97]+C#'7G)/!/FD! N2B-9S=)M0E$@( IO/D"6 JJN__B@&A; ';MGNIU-
M 1$A,9+<I!Z:W.BOS22A #^<F%QM3.?PV\N/B_8*EXW:DX;G+8:@]ZE>41-\
M5 UW5=A]UXGE$^KW$EK5ORZFI@,S""5&=]8A$KY9G7:+$'R 5!A;X7!!DVIF
M;O869ZXB>$WZ:+/5I$[E)J@9*>@8,$WPB@S10T1Z;4GH'/UM9#!9/2>U!&_5
MND7"3[_N0'$V3Z'Y43P4M1:?$WK%M]U\3%3&5^O"#KN;'[RF0<4/2(KWR6NI
M9"^.F#USO/DJ_I#7OM1W'\).0VY?/U"UY&=4XY1)TAQHW7=!]IQ0[-7X!R_J
M/G1=%#RF$>NYM94WP>Z4"9G7!;]/MCWW-3][7^SI/^FC+@+"!)J=D#/+V-^\
M'DP@N\^()@1B7*MG$(0F][@%FO9>,PX6,@%IET[(ME <$]!UIXN@?R(I)U"T
M9)0X\I>=(IVM>-/5MX@M6C-L-78#%0N!: F3(E=7:28?8[S*V,X-VQO>?TON
MX51'Z]]Y"[J(?L4$'ICIX-M9&@2A0LFPCY0ARV=5T]]R_:P?P0T+Q S=V);*
MC-4-1K9"$AR/4&KSNX()"=9R9+;VH7*)\E'(=N^Z7&W*U/OY[Q?1&9BS[ED@
MBC ZH)4H]-;#2[CM>,[LYL*UYD"1AT9R'Z;77%#N1)5&>^):"P2@>!&S*J<K
MR>)J_/8ZGPF['J_DVZSJ/I: H+)BT;,WG70Z[%_?_QJ3;#K?A?_>M(-.+/-;
MBX7P-=PA^_GVB'<12L$MP??Z<RJKK)239G8C3ZI3&XL/3!)!'5S@2"P8H^ N
MJ6+_MM+#<.3G6JNWW>GRX$")%U4^K;1:FNLGB/=NOYH!S2W%0<N9XW&035?=
MV4D!C%+(?4KJ^ULTW=06'<'>@J?:6K?L<\>$ ];U^1"_X7SXZ:1$+3U28XD*
M2MAM@A]7@>3MRH&+?M.]5U-O2[(HO7O=W_B;H;=!&/7\C0^[T3HO<YV=Q)\&
MV[38R:P>FD:!*<[3VN_*&H/1$&Y;_<#W[GOC.4]GYU[&&WY%/BVA]$R#VE!1
MB*,D/W0,[;XL&9PXG?@;OBRAV"-ZLJY#U."IRNQP8J"V;/B.E.'';SGF,NI[
MUI"X!K=<"K^YF1$,8Z;SS?Y9N/0+[]JO-R'/CR%4R!T1U.L4- &3.DT-CNNV
MZDAW?%O0&?P>GMX>8?=]^[F(3+*LU&&V8T]U7EE-[X1C3BZ@N&ABQ934SDE2
MJGY@F=O:QU^W[2-C+PQ(G8X8<%N;"-.9K,?$=H#J:Y$G)DZ/V*3KKU_.S<G_
M/+CJ%\<%+]8,]X;[_WALL&/>&#BY*I\[ 4>QASCSO"WZGC>6H&IB\ /6(1@(
M&L$\)$7'-/A,,8%G, X,)""X_1:>=N^MZ-#0)^B="O:SR0J(;<U>T-C'R-QC
MD=;BW(URD#;,R?X0L>RQ9=%9.B:CT*YL=TTAP_WTYH[.T!2&@RR3@!!@]*I"
M#M-N$0W):='HQ7[88M"[MDN:&8%2TEJ/>7?".P5MMC]51+1A!3$@BJFUPX3P
MX%9AROI0XHF:E),_O#^M=2FSC5*@V^44A^D$!+=H9QO"8'7T83FC+S+;-'?Q
MT+$#:$L'+[,X:P<%TP]20S//OF_?10;TQ2>TCL:N0T9:FR<@0U@7E+#8LBE<
M+\].>S;AF^'GRI+/XAU?6W^O SL'&H0)64G$'D%$/XIG:]R\'2_4[T@1DJLM
MP?'8'J:]92R'3F]E@\NU(-,.PL0#:7M1X?X2])?^BNX/DLH['K545Q_P"#=U
MP58B0FG*_8SCKJAR)A!/\R8P 3$4SZ^%H*&M[JQ4[B\5-F?*%:;E^%$9R0Y>
M;4DCSC?)-@D5,&[]LB5'S@$D 1)A.^CEJRE46Y?F=N-(#+![TR=S)QM<B1S\
M"GJ=.I)[I_9MGJ$U8VDO"-^JA.B#"$I38'EVMK>-,2=A@NTY(_"@5\GA*G*W
M0-\U.WZU)@9LHS]A1 ."'4G8:(^2!I.R+F*HLX\R?O5(DF?@R($@3F#*SWR4
MBR#YM@2VN"-Y-N'!I]<KU1QW'\2J:XN$.[3CV[T.C@08?F];+K4?=[5Y?+)!
M[4GTCX3QGP).OG,-:MNG^TI4% _1#$SKN8+[9.(4+S_7XJ1YKB5W!W(%Q$Y/
MK<5@E-PD>5*X8#S#E,*K1^QV'>^I]BC=)?":ZW<#H4S LZWM4B'@%%+3TV@J
M]M!B?6M3D SJ6(O-TNE#R 6\[[Q-=BPB31I]/L0$#G:W9V5Y*E.;J]5KD_5&
M-[Q[]*Q"KM)S_%;-.^K,PU'M.Y+B556][P<K(4<"'-LF,FK'O&<Y]D>*=.WU
M?X)XF)RH_J8W7QT4:6(\R@OIP*B1UCIAXI2XJ8EJ0?QS>9I:T6)=G9T!,>%N
M7V[*>GO4Y1>M\15CSNRX+PWLY&*B/#9!RX, .[PLBDK*CVOU^+#@ W\"?9!F
M6CKC#'>6:S^G,Z5^R42$^#XR+]E\1_L\3(3&12DGRO5(+)"7F "OU\FZE'XW
M%11G0*X9_!:MW;+=0TS,?K]S1'^-$M6<LMRN\:!X.D&I;6^\H)1[!3L\P5O5
M9V>OGIVP_6;FQ6&O8Y+!H@#]T'/]BHP;9%R),NK,U#W?8S:MDX*(<P'K:^W;
M5DM[596DUA;A],MJ=M8Y!;9B-2.K4;<=IK.M.C1M!I@ .\WD0T &(>UYD?O>
M!(K(M7CB1*B-V55][VK,).&AGP!;?A'-BH1[1>0VOU(W2'PZ;UI!O;]Q]4F[
M!VCGS1[U)CAZ4C*$@VRW'JQX."!QP+HNTE^[X5Y)N!$9"$K*#YDF#32G0SK-
MH['\*FC1)7.70L> _/F&VLE9V<K*B[:9J"G-H!MIUE63(A@5UPD-DE'TI![)
MZZER1HT4&7@VR@3</6,B$\^'V:G(92;K2C(!?ZHQ376 =C=+N(;LF5DW['5V
M]!"/1;VL-AL-_HGLDJ!LSK&0LC3R.Y<[*H/G:-E))X'Y FWXM"*(HMBZ5TWC
MGV_7>#>>4/(:[PUS3YEL<-)T.%MRL]5O/V]8L!76%1FU9Y2$O<<$N /F82C+
MU_8#%<6@*.D:'?.,];#?V/:M?">=%K)1&X2' FU9)9KYW*P:\#V9<'ORMNJO
M;]CQ3KS41IG]-7HN0W+9SC&_R US+,*BHO^FY&]CP:07)=ZIR8ZAY+4F1UE*
M,@E/8* (QK[+W]]XKGHJ"%L_^E3A&C9]ASIY3CS8VB6RP8QHC)&!,X%#B!.N
M=GS?RUR_3"S6E24!L9HU32>,9VXCP:5"[(OUFI3*@W>S#DP>CODBE1B?=P_R
M=6B$9/ZKI\TFZP2%/[]T)6/R2GWM@#XR5"I$<<&;8M/P801@!VZ$+?VUPW]?
MQ$9!,@&.<":06L8$:@RJ&1$&$)(M9%=CC?K,'KF@;,6^!/L7E8+^^<]EGGD'
M)RX$.G('0-H@PUC;&DI<\#0Z6E(!R1&0=#WAQ*!SP'X</L=0H$[R&<]T^LZZ
MTF;>_?$.[\WE&Z">+##]507U8@,L=+K4'2D:D-J>AG4:1/\6,$R^Q-:BBVUB
M4Y]N=%I@ E\DJQ_7'0@G]L0((TZ1(-&_<7/?#=(%;=X<_W')G_VLP/0ZNC O
M"6'XZ#PE*9];:%9*VQ"<#P2J13,XC++=L7SHUS<"P?$9/H9%X1Y4[%DVBK7*
MSDJ[BQ])K17&W5&M=<05_\A!?OW8I'3R5YC(IOJ)QJX3IW7(,JFI9NG<A$?F
MWWPZ2X$0.,'\F:0*'J-)NX]O.$F,Z]D_UA4(=Y>TMY"O'$28[ [R[KS<\R_[
M"/M5Z9L@TY)*<6E76L1<(-%7ZN+@-H]*E@.U6ODT.P)  Q(L%TR^Y%\NR/OT
M\;YXGS&47<8W)N#*!))P83HPR.>YX@]+.DJ-.!HRM-B42-?1U#;+XF"[EQ">
M0!39U3TJ(EDY&6)(1T7';X(/MM]!WW;5.4E*Z^CW^^['@>=]=N>8UH5/XN@K
MVY>>,0$AG9>3IU>!*L3[,"T9$WJF8HA>'J5@DB@36Q9R1S'F87M\C87 N<N%
M9_J.$>RUYM&"[4N3G['/:0YY"^G@&(SLDATJVE?NEZ+R*++\X]>0 @X^YZ0W
MP'G8C3>"&3J_.IW-?ZG/S./[P]37^ .L(4(4&ZM>K[=IWQ@_34WB70[GA.^/
M)=VCOT#/4>"$<<[ICAT8*27 ;F$L -EVKJ7X9&9(^%$)$>=$^&+2V:S23I%.
MNYO17 D_S'?*NX$ 9,OD,!.PZ T)A28V>!%KM5R(/5_H3[]-?^-M=>-Y?.G8
MM+=6*JX.FP#C\$4E./+'&0W>S^I8Q]VO']BR-QS5?O6-/BS !,Y/-!X[;1%^
M=3U:Y&+G%6 W;6W[+KFZ#;(R+D<T:AMN,".(R4JE>)SJ'W)2^_U,D/_3T@6V
M8X_@M6184WV"*7$R*L0_!XY^K_H*3L_P+BQQ:M<NI&TT4VNVT8ZVJK\U?Z7-
MH\WSM7/'3'HLXI]D@P7ZF("+G+;B5'6LCCBWG4LY3J;FS<0%[KZ2'V).6QUR
M2@[T]"T)C64]? ,OL9/4$UO1?49"-'C8Z9938[7NOMW8X'COV!W<,]6)T6NZ
MJWJ1U[2-@,26,"T>\^' -67M?:/69#_&YX^_EI>)FL7+O6*K_.$)'QIYC9SD
MQH74SSVCSQY='AA=+]:QG!:95J>Y\B;_-#2>3ZQ@6\>]HIX*F&X>"$@;;8$)
MH7VU96X/WALTJQLQ[+_T\S'5-G8A>B6<,*H8^8BB?VW0ZV[F,B]<;:^]U:L.
M4V,X]G-F6Z9:#Z;W;/=+X,K%&2MK[IJN\<0+0<0PG2!R]<HLL='>@7P6 Z%$
MZ[PB3 KX%+G9],HW&<I5QI\LKY:JOCH$1PVK-\B HM (,4H!\B!\1"A+N: A
M2S!=<S0DC;Z4W,7Q'#2!27*-8__:67 QC]<#8&^:]KS8#H0,$\'#0M..).M7
M7M $KUERU+L2I&<SD>L9G\S(N<=:N>L?G;+.6^A33\%'JA,4:%9$\YCJG;VT
M_'S5UT';KL<Y:T\>WO_X&3\J:,^ERZ$M4:E3 .7"6>BV&],Q-Q>FX].'O<\$
MCKACY$D_\Z=[)+X31\&</SR5ZY]4V\Y<$)1[FWD8]7)37+1L\DMUS*9;I3Q[
M*Y1/41D*+-G(^^DDB1_T/#XQFF>;WZ'K3,'W8XR7![>WLW4;._$";%.(<Q1V
MXG,M [\/%$6B!"X"_N&6 BHPW_U(7,8#SIS+R<4N\.3,K*V)$'Z*B3/)J$G#
M/U)Y>+:N*CS]EF<!H%Q^_KLX#Z"RH&,\(;(E(,*PBEC3A8C!$#U!2<_MB:"6
MJ$%T@WK!!/P0T4'-\NFY[8V.S@OVF*"$X8MH1THH"=4Y<11_%EN).:9?2@G"
ML7ON7;+-NV+C.<:=FRCW:V34ZXQZA_I1\2RW[8_.(NI20W6]H.]UT2NPH*J@
MI$C?-<G)7[3S@^B$+7P43O !6X9/&SK^V8,E.3SF)$WB"R6"E+71].@[/?F.
M]'E[O;-R:;'*'1.8-^@KKCO^S5L2;IS\DR#\2)C6:V)2TQR9"40U:+H44IYN
M7,8W:']QT+2)^/CUH_"\>5U38D?-*8I%<<C9I#8L?\--]&T*M7/^2C"78"R;
M^"-#'VK-$1XN_BYT?D-9K?JB1>6G^\UW#?U#?FGU@MXRNB?!TI3[)&?=OGFK
M[6W#AKH>F(:UPO#.4782VM)@!(S+L1V7/BOV]+'19C%7IL_U?7T& H"%@: Q
MN)4)4,Z":>_^'C(_S02>-C&!+CQR[ 1+?>B]?P.Q9&WL6?0Q$T^99K3T(1>X
M8;E^?V+[^ZV80(K2=!*5RX"UWU=!) R&61@(A)U^'PM<[:/TJYP$%$(7'\M6
M7&=?8!6=_A\FV4.;<VFQ@%[6)D*@XCJ;@<#U?9(O,]P&__KW[^GF,2B8"4Q]
M@J[[3>X<K&("O:ZY#"YV)B#CP 0>Q7G1#\0ZA9K^FQ[BYV7^^3S DM6>)?!1
MC?/'-RFO"?8FQL)6\9"E]7G%] NTH- E8%>Q$U*E6EU &3Y!2@I;"[&9*A;K
M.KLE<0NVDV(F\CV&G_*4Q[R_4;-CLN(F*KJ"I5=TD@GC5NW^$V<2\K_TEPP:
M7=1E>_"HS5F2$86Y3U:+9 +E(1Y>T^9/(4?N]!,\KNS!2[D<+;;E[/.LYC_W
M_(AL.O9$O6S#M+(7Z=8=3"B,J80(301(M7GDF4N+2J)BTA=-!5UB#5=?F$N^
M3V?_M09UA5(N8R3@DO+DUY%^7H=:G2_H"48V66<14,\N_[IF(LV90Z)NIYCS
M!<Q];\'(D*+04P[.%A7!JRI^)R(5G"W29OBCV3,EX;-K$O#TRJR(L@"H#9D#
M'[>IR!XP:B9;IADA_<@D:OV^=^L%_JY-M!L]W[.TP83<2E!)C%/V3T^W7U*S
ME[^VLVYW6(X/^FRZ]+JH#:0J$25Z>]F$P/W8*_K)7M+VPRR%9XHI*:"#]TY?
M"_G4=IB(>5E>F[B'DXMQD(FZP9,B<[SYJ+5DFTV;AE',YF46 A\M]7;[>Q+%
M3$I.Q<2KUV^09R](^L_$[HT2Y$O;T2T]H/:  LTWOAE.2WH<QL\#CNT(L/6I
MUA;JKI2[JWY87O_D]M)I[[';'9SO\O.0&J_5@A=,X/O%.6NOKZ*[&U/8%G.N
M@)U6T8+/Z%^F'Y;XEW:.SZ;,Z?75-(%8WF)!VFF&' BPL8Z[T5\1X8$4>F(Z
M__77U\Y+WI9-FP*MAQ-M*G5RJGI>)0ZI'/O;(=%_E/X3V>F)58=.Q2+7#4.\
MF< =5^SF 71?W0M.V7C"M4/SI38I!&NS_$\!=#<VS_>^,BF_M!LYI)6*SYL-
M>P\&676-K_>">K!\3, 9$HWDU0IU(=87JY=X]E_:2:OB%\G&]M"V])IUMO !
M:]L^))FV!)#I@(K940]^TWB#.SIOCS^%WX"TBB7JHBV;OL)>TMUL0%I.P9RN
M8(T^#'N F %)?C)"O@'J'J(>6C-A]R-_9+;'YHG,R<:EUZVPX<XFU$$5>()5
MZXAS6=&%0%-_?R4S:0MDC[+,>ZI-T=2]Q&=6JKE^T"3W;*W'3&#;D'+_ ^5'
M0%HHNQ]^1&<$=]=:R(MEL+:=^%158'>P@'>D96Z8)D+P]&B'NL!;3GO:=C;X
M&/T-WK^U_@>+"AS7F( ^&F;;'BB\TLX$I-<W&"T[R#V)H+W-(J<394/M&K&R
M+.H3^ _3_[^4^:1HW]&O!/MC:MZTXCEH K1")H8&F<;R+Z3?PPDQ@7M5%14#
MI??,\&JO7TMS^$JT.6ULH@MF/;WC=Q;W;%A264B%M4/B0O1MC^"*2?UKG7MG
MA8SW$,7.][(\7ZDOB]QM_3&FOIT'"J0J4_!M(RV4PM8LN:$5FED1Y?&6!\S^
MB]GS1U>B[DL-'9(BH=UKT@U$GOLD%C043O%4OG>?$!M$?FHXZ3.U:8IWVZ0.
MWL@RL?WM!MN_U1V4E]C\\JFQ==>(1I$ V_S$:7I."-L4]JC;A""NP>+.G;))
M,G=FTD81$X /Z&R-<\T]X!;-+1COF$9V59?!-U*),L\(%)/IT5%8+(;M=3M#
M J=B6C^L=3,_0KNMZF?>V;.YR;-;W_9L^G2.4>+R'"@RS9-@A 0E4=@AV'S:
MIK&.<SO(=K]22AO_*9WKX$8@E->#F*!F60'_;CH:7'SP.Z@^ZKKE!8V93>+'
M .?.+ BY*',A: Y5H@QZB'7.5#?_.(<Y&,7E(;5MT-\@D;MD)7%JIU,QW['+
MZ[&H\T-/'8\5'H035,JQB QKWH,TP1)8NV$5Z'ZWSPLI#FX[(W[ME6]/'"78
MEA_U_=VTD5X<OKF).M*@#HG!?H+!!J!5@TS@J]88Q\M@9^W0XH+]7U(>@[41
MKTA"*%)<JQKVLVKN=,:'HPU^YS-N,2;Y^)\HM V+W>NY>IAM,9T*(Z25JS:2
M\"TC[Z;3ZNH&Y.?>]JC['#EK/IWNY(TL%W,FC*_1(W\S@4V-+>RYTA LR=R,
MDN-'<#"A0=&N3_;\MRLGVK(&7U/IRT,-<ODA%A&W(VEZ9:[509X#<_IN#RWU
M-Z%V8=KJ8H^Z-7*>AR=%-DL8F.ER"%C\I^E&& WZS^A/^M]]X]^<P*N,8-61
M_TQCZ"LOY*[HO3K@/9H:%EH\C1R!MFI,/M<Y'?!L$OL<AS<KKV[L2S5Z1ZR$
M^TJMZE5EW:/^0I?0;#\J2Y@'.WRDIU^Z]YD)W,X5?\D$O/HQ9Z+V<)=ZA&-T
ME%_?R>QRC]T7.I[KO989W,^.@SI?W)P=:' /T98L]2;4^BE>:+7$2TP$1ACF
MOY[7_%2:##,V>671K+7:$N1<&@A>^=%;':$X79'1SM<JN'@=<Z;*UI,__$5.
M@-R:X]>^J$YIYX+3[-.*(B$'*#T$I)B;!C(BQ.!.<8![Z*7?2V+C=R0*^D-F
M3QAHOSERK3<87T2!;4,IP844&_V!2K/C*O7=9\9SXJQJQP7B1<HEFG@[YCRU
MSSNNG<2^[=*L 8JHA2!M6>=G96.9U4^T%]AGWXEM'^NO0#ZUPT>4H)T'MN)*
M'2J#0^U&?0[FWU)KNI+5!(!+/2C.4UY)(7?(4I?(+NUF+B:-YN#A[_#"Q3WI
M:T72*06=69?&9LHN+L(,E$]^3A&)^OJ5#CVCE9I),K\Z30D]S3[C3W^%.#Y*
MN;1#N!\=5]%&<?8)\;3SK_8I,G#O:2S5HV;SC_G ;%R##,JBWP^[I<5:_ORY
MO_IY\+.;G$H4SB^XCZ/^C VW;VE+W%<S761.E8"EZ&\07M'^S[88N'H6.R_C
M<.?0]9CSCB94Q<P0S08F\*EQDA'MB!V\ 4SLKID7K!8<K=H28),7Z#GW)-LD
MO?B\ _A]1H-%PXWAR-XEV8R>?+&D?'9QD !ON]$<U:IZX H1J[=II0:Y$GH\
M\O\B:!=AF=A_?FX$GV\L@%93+HH\FSVS>O$.$\"A7R%D]7,H ]LQ@UK:9)FV
M'80HB5[V3GQ$OL0_JG]B\1>"_"-SWS?D,SI\T4L4GL80(OU$EXP;WGO:,OQ;
M0D#\TTT9=HFN]I!B9Y(]$;8*(6@J"@84MN-$?99XZ6BSWL3T+ZTNAZ@9<=SM
M,1V/W+*UP=L&. 7/3:S0(JYN?/(Y3:K _0%>?PAM6Y%R24#8LC-MI(TVWAYZ
M2#I.]+=SY)Y-+..'CB+.#\FSG"5.EHB,0A'!7),2JK.^-2'U@;K7+0T<VQ(K
M5U(0&YR!5EW0B>V<\'-O.7__-+)8,Q.V4'H&WDBN=UN.I=$&,5(A5RD]9(O?
M%1")88JY;;]?7 :W9@LXK.2S[/'?2G2:]Q8:22[X3 Z&#6HI9KL1!YKA"EEX
MQ#&RU.F4BZ=@N\Z\6N)9B%?'0KGF"]A^&BHUY91).=1Z-3R2FX;#1E([1=6:
MF8!@E[^7<QD%?8TL@)#HKX1;Q6F;C$U=!3E%I&@;^([ VEBLRX$Y'>#<.LF[
M50\1<&7(E->D:7ZWMQ(;OMV6,7*^Y_1PARO[TLF:!/PC3Z78QY]:Q4D:C)MD
MN9 [E!YH"W4M 5==%X(0K6IPB6YF7#_EH7[_X+T-Y'S._BKMXA4HSW(:XS1I
M^^W'D4Q[=]4N'\G?!VUTFT(-7=E_8A^H<I%^D_A[MO_";\,7N=/-R_V8.Y3C
M9+0^"1GE)Z_SN]6Q)D7;;L&K>B#=MJ?[5^P6C)OFV4MS*-4OL%T<F1'F<X&/
M+_8(Z,>O=^8#0=>"GWST%WXT*M?0?^;C],E$D/:90;.Z<_#YI-&/1&+/=A#^
M5%66?>!@0=>Q%QVM*(N;?B)5W:1-H5,-LFKUVH/+JONGQB^#J9M;0R4QQ'4(
M=<6&> -Q#'?8W=Y^,,)91BW1?#[=&E\9M5CFSLZ8R&,"HALZ#4G]3&#P3,-'
M]WST#&(4Z6Z'[)F![)"1':E4ZP$&THD)8.,8*I14>FT)LM?G.A-H*H)V)*UV
M.S,BTJ,9'"8,Y=! +KHA:ZEG^=2ZU?8RU?H[ Y'#!##MD!$<;&,+3-^6(PM3
M@V^Q!,]OUFWAELB$X_BMI#WNI>B_]4('R]/,>#_$!%#+OZ$/F4!ER?1C[D$I
M;1UOFSLUL7/GR!I?XR\<O::';NWR&[^?ZT,O+WIZY$7'NE[$+G[):,4T.#B8
M"J4@3.NC:M\4>Z9<NA734Z0R9%CW\7?2NY\UCP,-3EI;S=5N\CP"Y6M^+I =
MJUFSY"FH<YSO+/1]4V%A8-SRMR/L_[?T'QUOBTK(;?R[TC.Z\R$^A#QR4J1?
M*(];0H-H9/&H\L<+7VV=SNW9A"] RXW:%0\OI&G<1'6*44I6IM?O6 _D/AC1
M69K)&MH4CCN[MB7!;E'9OX8M]Y-UNE]5)U=SF;)KFSBMLOX.U88=$6Y"'!N4
M;[@#BK R?2J2AMMCT#VFZQ[KN-S.RF-)P2K:(8HBDI2BR#OFCCF-:J_KJ ]2
M]%QSB3'XV5L#0/0<<Q])\R8+C6VL5P^$WX:PG) O -TN*4;UC_7P+88_ETC(
M2]?^6E.=I;CF*4&UR5&^\HWM:%,VN)L))#+D2,*Q#?YND#;DP0F*4>>VC?"C
M^H5>XVKAOA7H_119@3N8AP\:O0PHI64!X&;$85)G!Q+LZ*XCC*N(LG_GD/Q;
M4O;+D\Z+%LGK'G.8LL$&N;REO817].T,C\! 9U2YF=:=D;.)C\Q<S5RX!Q$W
MVTR4 [F_Z(JX++BR;Z1,-M?EXUM1HNY9H%X_",6Z#O2\9,L#9()YCIOZ> 1O
MSL?[+CI%R;&6J"AJCQA$':4=S.(I'^1)??_+87Q)-&&\(HW<+/W9P_A+$]_4
MGLVO[YQG]00%CHEP)9Y?O)HX(L+&VRX>G'AMB/U4&!2:2HSX$XS'%9$<D6 X
M+^VJ"40_^JJ]\"$EY=I;#3\>KG]+\<D:V@&U=N^#':)ID^82O*M7-1#ON!OJ
M@[QLFQX&NZCTFKCL+S_;PZGU\9S$2[XSNMDSSDF,2EM)(^KY2*_HZD)7&:KC
M6C75;SE'EP% .=>APQ%)T?ZH;>&_%E'\7FP:.]@"IH&80*U[IN\,0=^@<XUW
M(T-FJ4'(KCKXY W&W2]%)"7<-^@DJZ?/(6G%.\+T/A.:,G@+SEC(I<#GK%<8
M;PM)1@-;$@8"-T4Y3B'<[;S(U_=U,PK,=[@118A6Y+JGHZ0V:?(G5NX!$["2
MH49A;V#O8'?5%,&A8KMX!!<E>E[<BS%O3C/JU>[LS]->4GBLOFJ9M;7ZW8<L
M\J?9MX(GN0Q.&1P5 "HL$<KWKN_K,Y/I#W-E&[0P  3^-5FRDYC /X5QH/\0
MY"D #?[+(MRC#\N<_.?"=F/>V\ CDS/"<XN=T[#CM =>G"SI]730#QVG(]&
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MJ##EKEG(E8#N_3E%HE23.F^1P&%WR2Z)GO)E6GI$K*BMN\;,$W=)7-?-I\V
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MI:9H,!2NW\($UM4"D(R6\\@%OZQW1K@*+=;H2OE',X$5*19%Z?EBE';,39G
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MP<'COUM>]^'51:MVMP3*BM7 ZZVL\RG+H;X)K $)713X[%-/;ZSJH6&R&M#
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M0.9 O#U+[))W;8J>V12(/#NI?/Q'G42ROL81!FFEZD+H\P24.Z3U0^LK(N/
MI>/2@UZ=#29^\@E95?\"\Q3%1!';I#!CR@;#Q\I8H3;)H!G3$D*\MC"R1VE'
MA8A)@59P,=%JBNK2+<-(E*HF@SVD;%:R"!\.S-Z&F\4]5O6#%NUM;+1Q54N4
M=+MT,BN&<U$-.&<J341JH%)6&J+:0!$?4MVB(,"A!K@N?IW\G;D"RI(W#JX2
M+S59/'*M&#L!6HAV53QA5'H\H:;7BC*Z><J3T_)R6>F K<T=-; !^>W!80("
MLF(C==N<K?AY^NC'7 C'-FXR.9XTZ.T6_**>)[_U1RMZM";HZ]TF8".O.Y$
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M%M:HGJG*.Z8.JG^63[9/?D ZP^(V#:;D0<M3U$"152P@H?P_>OIHDV"Z+85
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MX&2R&ABSU>"SECL[2"S &ZH5]WO?+%I3"\9JR:=.$B^.1*(M[4M1W,P8Y6S
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M5;Z7\;Y.T-=U5JII)4V'X@2Z%HJ-F=^+23ZH_N/AIE$#)>'6M3REQ<2.8VI
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M?D/SGO"E1<![O9C,NX7<E2;8W[TXEFE]3@T86T=U9UY2]%CE+^BB!N5,PKO
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M5G6WG57L&U3U-8J>>TUWZ8_QB,F XX;*/'E8A)SBIS-D>HMP9!"#->D#[[4
MZ][N]TT9#4^NJ"S>T#@AL'D[4I[?U!!Q8/>R>UKJ$-3PO8\O<GW3%"LJIVD(
ML;2G^)!4(/2K&^(?*?$]$MV1F"6T74S+- 5Q,>AH!L6TZ;I+DAUI?<AUXB@7
M-F_Y*XV5>*SA35JNJV>,0K"]F,"D=9SZM ^QP57YO9:MI0&2=5KNG*KMFOY.
MR:CZCJ<&\LJ1I+;S?^(,B0&4MN0&\M(F[=!"IA%@#U32":P#Q@+0RN5:+COD
M.;'QO^OZWZ_+D^@B(X%1=@F=L"3OR&-:]KH5!^5IM8+GI#'RTZU0 0+5U7^[
M)W'[8+-XV:#5=J'!K; (Y>%?>*BQJBLGR)?(PP$)#L#*L'["CZ!CD @C,#Q"
M##!AQ*SPFIO0*T".M&Z8_E"B]E8@_;"OO!"29W#HJ/J&"73I9-H;O+>L#,0-
M01,[\0[('FNS:;^R<Z%&OF[&=Y[ QW%L[.76<A?T;@V$_Z'?(3P,<AZ=*ECM
MY7D_RGQ%VDEQPP^_.JB3B\OC.@#]0.XEZ0HLC6ZM,">EL69ZW+4CM$DRIS;"
M@D=9PMTT=;\B2!;1O@.]74R>FQD5S]8*E@)8.-J^TZK<N,UC<;9870$^AZL?
MZEA8<@FYQXN>//)#V,W1ON&]E.JX8Y<%=A ;-'>?L*0XR>F(>2F.('. *D.+
M^I4XT./B9FE_:&^T]-T?G277KQ4]H!,%-8O%M5+2S]> +\9=GV,R;M6W35.F
M>OU^[DN/>; K8U@]5P,;.H-_VNCEOT'+<"BAIUU7)MPVB'1DZYUXD^SP[9KJ
M0 WDQGN=54 P\L[*%"""S;A*5^('B,,*UFQ+=I14+@P8_KWWX:3]'.HX(@:[
MXY&C)5#+] SW(X1*B/G/K^2W%XOKZ-UAMM4_86(.H8K9WC0D0WF(HQI0?J!H
M\1*?T\#VVL<+J7"U7>^'O#1R;BN,[[R]>>?:.H?M/S'''Z_;!N,:"*]YO-Y\
M_>/J%QI(T=D79$,B(FJV.TEQC&!W+!"]_MC/@I@'34-:(OS&<^+:?]E)"<-"
M+"EG>27(&FH[C%Z?Z\/W'0]93DP'?LMM9X (KN^XDX<T1:OD?BX9I/4NZ/EY
M\?5^*\U-GCSYJ,<B5;Y]SE2>7F.P2@N=E\'[_XNK^+!,-9 0 QVE:7775-3X
M3$04AJ-5:17SV;K4B&WTF*/HX/O;O':;3-O$7)Q]'"@J6<$$%9)B[X2+K!YQ
M1&XJ?<_ ^%Q-,? JMT"@!$"?$I1YK#B0/SWPB._^[I&C5A7<J/1D%2O1$O^'
MDFE!LT/.MG*T[GGGC2]"8^5']K3.YO-80+1PME-Y&*P3(A/*0CKQV9[J=N)A
M[^1WJQ^GBV+3G0<4VY(V]8?."F"MIU8=CNL0K#/\@IK8XTG<^RE4/=#W6+J]
MLY:TGG"3:;L^XU== ?QB50]V#V426DEN>&3:X&N0N%.ZH2UW\H3X8LS%H"O7
M'DPI!!.YX0R VX\2Z,=9@6=$T^1"?]#MK+J[ZD6-8DM7=LR/^/P/5-H#3Z]W
M'/_N9>U PQ'"M^]FQ&.XB#D<\<[0#!"K0OM^K7K"_/+5V6;JX6S3"[^6D8?1
MT]I$5,JI][?I= H/B(UYZD<LUW.;3+7'?6@MQUL$YR&S%:64<]P"-FMM,/^K
M<--3W5N[3JG?TSKK7<.M>ZMK7/"&J(C>@2*>02LI>^.R=UP"'O0LR":58TS2
M^;$SY):N/*0=JU8;)DS:OU2Y\"\3D@#ZDW[H$DVQ5@/9J6#54&;6*7TDK)12
MV]\J'YUP:^J!]\L"DWO]J#+7H][FY,!NK@8"^^/8C+ -MW'9L ;R5Z0["_S-
M%;T+/0YN1?_='\_CV :I_FND<3>?C9N=K*)GI3:QGL6<4F5%\:K4O'8^<IKS
MWFX4L47+:X^7:R OU/_K3#'Y_^J+@1/*W=+V.[4'HH9:W;T;]Y_,_G2%CJ>"
MF#.]M(N,?:O<V_.55N55)"S<RY"Z#.7<+Z[UXG^;P;XZ<972D)!._%8L,CE=
M(,\]ZXV4^?C7+A>ED_+PHR?!<<HXCAZ=HP=L!J^$1U1FRVCT&I9K>/B"+F[G
M&\&^@C8M*;O DS]@YDO5F1('T>^]Y?@:Y$K\+51 WPHZW:1]+Z:[J$K\&NBC
M^-"0M_?AG<##;H)5B 0"J4(#N9 ICGL[#$2V*!BA-Q:9<F%?CI8HI_6(:U&B
M1_;H=:OSNA 543'A,N2JE(A)IQ**0KYHI(K03AVSV,%+FD%2[\4W>%;],E%^
MZ!F(=NFF/.NL]6=N17E5TVQ:XUHKM/JQCD]&3&>T]--G.-UF<<42DDOGS'SK
M%K=ZD^C]/V-6\FH=O%HR#/>Z;2@NG<DDY'DVRS&6[/V(5R3STE^97Z6\JGG3
M.82*M6"D]R*W67=0$9$J$N/@5E?)4;!!)&<?K94B4A<V65W#KL7CO!\B);+'
M;PL$@I8,\Y&!;-Q!M=>,Y;"78$[%IK[ O)MR"I)TN?98T]S<@?K>#/FI!NR!
M/[Q[QV:=369V^\03>_@*@$\A@;YJ+:=[TJP5]J!MO :27+B\)+<:\8\_/U6;
ML&YJ(&-7)!J(6O\K#43TWP7_CQ7\RV**]G_UT*\TD/GO0$ #6?4+(/5$>8#/
M!PNZIGL(%Q]'!)/5%RX#.-42I!7\E[19HO,:9E/1R-Q<.9#LL _6U\D\ >(H
M;I*GOI)NK@GCJ=(-]+[&W%+>&1[E>(GD59X<RZBLG+5/+6^->,>6Y[;2%25I
M\YS7L*0X@R[U6M",.\K.VNQ@&!SMNO=,Z&5+2^(CN-=BL8.S!/<*:4 XSI2.
MY/#UZ=(#G<]C/[ZDK81:U1P='4Z3*]OEV77GH-_&9'$).]&;2LOR$ UIX'W9
M,(C3)N>0&!970:!6S?!&5,5RM4N:NDE%&Q-4'IB.QTF.L,T$\5$']@A>+R$3
MAZNE00G#-#PL"C-&6QD3WBD41-52]Q!8->%:Z.(5]8@1?6BM-!%^IX'<;@BZ
M"0CWS#D)Q%A[CG@K5D[70  5M<Z]KC-NY82_70J;$S+HQC)J:K69Z&P-Y2Q[
MKZ34DFOKLF?60$81X9,T=%^O:,3/M19A(&OZ>:90R9CB* X+Y"P'Z4[^IQ/&
M&<I0)@O<&2/RLWP=]YUT71ZF2 GO72A^0Z4]QXYT%="/,]L*72PKG/PQ?TPF
M+**P;\A61$L1=)-RGS3P-VY$-16/\GX1[>/;N[3$/9?9(=_-;8NGI5=3#<80
MRY16^9,F^W^ +^\JL?OE0K?5X(.>TU($8Z<\0T5F]-YPTFGLM&MF0PW=MD<$
M2>4W_!ZQ4N2&GJKE[/V<1I@)_LCKZUH*0DO=U\!M3E2B1P=\0PTP5P"+G"=5
M'*1/UVB2UXYH;@DCW8K5@#YR/I2\.K V?<3/Y75;I%4;;>X'CDE>5BR0KAO)
MF'&F#V.%S<9NOBF#]$3E]Y%"E1>P8F+_7CD2V$&VE5%,N9M2*OMQQ-EW;8P9
M0O>RN6XS:F(4D+@?W9 -2X1ORZ[W@A\@'TM!576CQ)':M'>AKKL*&27/F\U;
M=!(P68*!-#&KHLM_#/XOL&R0T[/@CCHAD94%9T5B3$DQ5]9&?NA_)XTIWS+%
MX%5-(]A^J^Y'26(;EN)2@O+]09OZKB-I(UW;;HWT>+7Q_'QR&_1+6F;F@,H>
MRD]#I#M+7D^?AYK$;9.P:2,%>]QCKNBK:@ZT[KE]+)HW1R@J!D_I/.XX3U9:
M <LUD/=#GSX9:79( V%[_#/((#_B_WY^VO*$ ^++0);$Y6?A>T+4<GR<_IFC
MO26$?G,%(%Z%T7+^FS*V96NU$"OSK]M7CS946N@TH1.]3X/%SL=W5G02GJ,\
M[EX4HU+[XT(!]A:=05)3\+5N::K\]D)5UZBK^-G+NJJ04\7%8GW&M+T@$Y'H
M>5,(&%L1=DM),JN74O[3P50]),<6:\]OFQ)YW^H]1X/M\0DC8Y>>^VSIT4#Z
MJ2X@SX1>JNYBK;,EZT[TP@VE!Y@)1?X =N(%L6B3V QU+?V=)?'M2"NK)2-Z
MX4.Q$@4NF),V$"RK)35@(!%=;Q.LM^95S1F^;_:EI-7<'"\QPSM4*O9TBHJ1
MQ(H"R<89*;!:J,@<%>,T-M1M+0Z<S59,5C-](9*9.XB-6+AIW-L<&V8YG=Y-
M0.7C21X=N;6WW&59[RH.3+-K4A1E3G)H)&AOHR4U1$L)ZY67]A^UQOG!5P9:
M@4BS1?KUA-:(K*5Q9DCI-U@1[FK;>4D/W-!9R',X['?DM32XYFS9>9^0\<BP
M*EGY4<70)?=^SS1FA&6^!I) '026-A,0&DC\<018= -NW7&MV!%V&]CLA,-*
M=_IV$%R%P$;\K9$F/L<33]EKO4'(-X\)C_NH@003LVM[B/R('@K+"*2>E\+8
M/+A5H$^'E3)\\.V%+HO[M0S=P*Z@F/NFX%45AF?MM$_RA0)=Q2FU@D-;2XY<
MEE]!EU7,$63$&>L94;C ?H)?TPLW$DQTAD:&PM>33\<6PGRGW;*]T@INGG"V
M%@N(QIF>K#LE!NE.EE*]1OYRB</=:8)#U.6NU[G*@]VY7<;R(U&X54]J>%DP
M47\=:Z:J5'!X#@Z=T$"6+[#6$8YQ:H.(0YA&6H\5=B&ZCMY#N41+]\%>2$F+
M;XDZIGKO['F!-NT;395D'W]9GM5Z1I+ZK'?5T%2;<5N1+328.#?ER$3;,0/5
M"P'X,^[@ED'WN+GSDE'E5S769=&H=N:+]-Y-Z)B!O@!$HS:L1QL$X/%KK 3H
M"N8WR"&JT03?HE>)_*D ;2[V\@D/JLB9.)?%$VL@/83G]-%^QM4('CK2^S?G
M8L(.>L=\VU8K9/WNO/&'>6VI6>>YB90\%SYUP_2B#VKD32GI'UFO"#)I^<^[
M</K_,;>#:AN\5K:9R>_8MF[9UUAS0/6Q1DTJY_<N[0X P-]0JA[O-DB,X)]G
MH12+&LC*HUK::@)F:R"76:K]OIS!+>>@-.@_-N6TUZ-U@O?/JYVJN^</V*L'
M\44JPF3Q=\-$UDZI#></P=\?6""_AC*&! IS&E3UX-DZ?VUWR%/B9P+>.33^
MH; G;[B$BKV"M6,_J#W)LBRVCO.BN'NSH2LJ22OZP7J9XK4]W[AFY8^].Q2P
MOJ#%*B6I0SU)%%Q?;)#5@LZ#* 3WHBSB'E0G^%LV%9\E5_B<.9D4QU-48N=)
M&7+6O@K"/"_R%=RP&S'XA&DN021?<[<6O/9%Q/M.UF^%IO>9(C&<ERK%WB^Y
M[5I".I/\&/Z@7(IX;85Z?09?WZ)X;02>UNF#EY,#[.\C>-Q9K8#+C%L(#-%
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M3ZL".1O(;G=199*F-/OBJU5>NXDK:]VC'('6772#3%:?,4L#63-4#\Q;!K-
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M_@7G'G,EWE3D<F,OP;!T[%_MPEC[FY3*-Q:QUQ(;U,5!Z2W'!">"F@QN:)7
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M=8&C,<A2^061)5OZ.^R3;&E%D_B@#")CW2:YJ&@TJ:4-SV.Z4FJ^_XRGJ)B
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M.$@;'9V U4)DNPL?B=7/&+4E(82<:G.L0W[',F]Z5@@_\V,-PCESC/?)):.
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M**M$]FOX^=KW*^S\](NI96#3:O. A<4=P'=&9LC@K>^\WZ%+[.-H]'M0G<Z
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MR>\F8I!Y\GIHA(?@^-EFK>^LGI'>CD[K@AF%CUT2R@K*0022ETZ&%Y#OY7,
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MX&M2@:)#6J;+]CKG#C[A97V\W" <&6-#N:U<O>3O\J6^1[W-_JK$\&.Z &$
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M']#?JZDP'K38#1+ ]D//*46SQ9,6'DKKU$%@R?MN!B,OFT_=FMOF*DT'4R3
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MA]Z]R&5@*_Y!&PI.CA^\-W.XGEWN&)$GH))7 ,/BK$@ +^;1ODU#C;F=51(
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M!TQU.?HP2G&)US7<E^89KU"18)>2DF[ME"G\D9VF)GW2*7[\XP9_\<8!O;R
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M-)KWXG@@O3[!JDUJK4 R/.,B$_T6*\_O^<NP!/383X%<;/7>"Z"FT2WS,%E
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M2Y<V8L@S&L6I<0$+U[<'=VF)#".5\A2CTS;NU+$7JZX6PY'!*/Y^D& SD W
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M*&*A*@T+?_5 \$U/UMO6M=CZ8H@0>^0QP!B;E1W\B5QY)R;GRX]?CN'?&Q(
M,X-VM7)%JNK:G58U#;8T._J;$403?^>V>5;2@P#,-D&/))VMNT@W)+,-E<^V
MMYUTXU$Y4US2)E*R*J9ZO__CF<3PV EJ9(LDG!C'E*ZT AG6[]ZSF8(XR 3Q
MU%6"D*$98_;)<NK%@/8:?:4]_9@JV FH_N@Q ,V%0@XA]MU%?HW;U0W*_KH[
MD&A@;SOG^LER[K::I$#DZ4[!8F=3'.HEU$(KEPPO6\T8:1!LUP^119RO<U<S
M[]]/9R6FV>>?_Z+'ENN\)0MR>06$9YT@^.!.4N5(=50[BHMDB2)Z=LB?60TD
M64%.AM-5-Z4V:'M^D9!^!PM0F.YRTG!6FJ&T@*H.VCU/4;X)\6-S5V+<J1],
M&CN76N26/J7<?5:'Q8]'4:&_KW[GZS8\H[FDAK",1=@.>^P7@X4(ZG?*A\^$
M#!=TE]H9"A9]\\T[U&'/+(_G4+Q-V&T#LE*$78'8\ W6G(\XV6*#-.5:A7:?
M MMB48.'D[O(Q^XS5@4:8XD5A9P9$_I?0ZZZ^[6 O^CFOO0UNT<R)0P45W>D
M/:VS\9!7,KQ9EIDT._F$6V-/R+K/$7H69TJ2#%;!1Q(@.(8V26RW8;J^EMS0
M<^G>"<_%,+Y%HMBT4S2G\, Y]6NK]HWCJV\"35['#BE F"\4 )UG7KSD;9E>
M:\F?6>-6J> 3KZRM>YWR(.#SZ<YGMV;@S_P/"BR"Y\S#5@: V%M;8+U1V&-P
MU$;VC&T_WC>,JK\VBVL=AXX!)?H+T 6N 30U\&*2#GE\0$?XE-\>&J?N6U5#
M"SM/MAY61JDCZVX+#Y0QH"V0O^WRO_ZPR\-6+^:JCYKVA;@L=8)F!DB7CP%#
MCP/&_ZB%1_ZM%CY&_%T+!^\8/(%M8&#_4@L_]_]=+7SA&& .US:S$M!'";[Z
MC7P?J;#[A>X\7^[G.,"+AVG_=0?"$KJ $+(_VY;\,4!TODV>R*9/&FLZ N^'
M_9U_BO]9=GL+6H12<7X _L]F5M!9T[P_+*T;J;^" ?^1?I8L5U(:XXJT# D,
MQP#Q;EP[!8FF7I"AYGJ@'P[QNOD_65SG^T%);$<'IL<  XTG"((\R9O48Y6K
MEM$D.8H6G?JGQAVC%BK&<__+SHK=ZU*,6KO!4GY_'9VQJ(UZ-D_X.O03UIAB
M"E_4)X?+HO8D-C8N' .LP!=)',> E!7"X#'@?J\GF4GMJ <V.EZ=">.&$R2I
MF"Z>FGH,H ?_)L%44E/XF]T@O2?^?=:W**RYFJO[J!"T /XZ@OCG:3!@+.@O
M3Q<:5K%-"B(T4MJI"\3HP+IYF\2$E,;;'P.28#RP"2?PFL,&S^PQ(-2J\"VL
MR7CY4/2G/X2B:Q[L? S(O?G^>6Z.H"2D5ROW=]'QWP?2_#?$YG<W4\(_$QO0
MYC0%U36//Y=^&'M _8RCW02KL) ^% ZW"".>-K'/[]Z.G_+;)&.S+7#]Q?DS
MZVEJKM&&$-?:[\$[4J>17@U-T/9[QL:].S&[YV2I-T"#0^4Q8#A%4VR?!%'I
MF-^1=X/M;\A3PB _X9-Q^%TL:DMWD7@,8'9I/C?Z/*A85K7Z8AW*/_:R3(P0
M_?#X9:NA9C%>+*7P]UUT0/T!QC_T2/F8/ZYN( WN784?!!P9[[Q> 58<D))E
MQ2F- U2)DK$_Z*!+I"[6'I$AU ;R&'#$A[#G&GW[9R+E[^XS[C\Z3\Z_"958
M>57?O4CQ(HPOY97CU*V:"7U!1*-NM*"E)XLM >>^!75GP06_((1P0>BC]9$&
M.BD_.7@$0E>$QS<L.J[?K8Y<>A!Y]P<QT/O'T1@[-C**+0IXPY['U(3AD;0K
MS#'!_8N=EY"E\D*R(0-*J52UR&]H(00"M:@=)9TAWJ0,PGB0:L/KKPENBS<K
MQJLRO3OG4H)RA5]'(9_)>.[IE0Q$U<ZS[1VB'C.&B&F%:5#7XRFG*CF[CKBS
MD^ES)SQL0L!-!]Y;B9"](TWF:['V>KK#54N0O1O(QY'G\;F,Y3?> J\R1P@T
M !B,!IH(7@N]&ZQJ4\1V?M;9ZO<A)F]XU* LKPK7R\-.W3MB&L0()M=T E6/
M :WJGU[X2V.>--"Z ]L+2:XP\9?CKM897Z-;+]$? ]*T[KO7+9XO!_-J>V/[
M=_&V(U?Z))]3R:T+H\;S8\"$@BN.?JQC?JK(/!FN-2]F.+[<K[#[$ 666:P-
MXZJI352*Y-H9XNWBE."=C@< SMT/M)1+78 QKJI5KMLZA6=/N+'5*8WFOK]S
MLV.?KJ4GKYC8;\D,IR'$;J-OO<:EXS.2%NL'K1SJJFO<SY!T^=\YEBM'G>B&
MX0+>=:?N>N [ Y:T #A$O/YFMR?G@3*0XPJ8!@R9$I^J913Z.89VK(F\M_,H
M6>G,*UC$QCZ; Q86";6 .2M7?W95:UI.8:A.N5V9Z!?:L,S7*C7C8UOKE;?V
M#,+NYCTU)6A&J]#N)^:ZHE<ZRA7-0K/WR2H5?W(W'*V'*J'T WE#%*'ZA% O
M5!</F$T8YU'L"F+V#%!JCY8Q]YV,?G!N!%;^V':@)2E!B'=(X\$"^6Z;9986
M%EE< -Y(9S?D+BYLV[$WO#K1]^+!ZU"V\(AS]S/(/&-(<71?H%UHD<N1(RG=
MJT11H-=@R750X%FVQW)8#>_I%_&C3?JZ0S[%O9Y;S-+2&XV7'X</1*H*T0L7
M^LPPWHR//SIW9S]QPPO^YO-B2T;Z9CCQQM2JV:H98_.%GC=#0D"EJMKFEW9<
MTT,BS-&9OTX;K$*&M9A[$01Q_"SA$3:NH_A"9_>+*[,>\P:C/Q_"JO8"%O7+
M534\="VC%T.7'Q4H'52GM\-I7<>&)Z;][:[5A 7G05RJ"%R/)YY]>L7VMLQ?
ML_B9Z6G7E WNJ:H&Q^SU--R52_-7))QC%4<M;WWT_G$WU<^IM%Y%*5O5X71
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M:)(+0F1G-\"L)$G,A@$T2.PR1&T\%GRSL?(:.UQJAOW"2?50C62#+7 NA9$
M0V]'V=[(<(Z\DFER]E; <@,D2*+F?)H>RT"2F?Y%*D-S(+]J9O'/[A@/I)1B
MI[518P@YUMG.I;')9$/O#YO!@2$^8.NYKWX@%9!+ INA:0RJ*J^V@'35D_V>
M?MF4]:3_#[<D-PUU;XTS)8IJT@_>&'S3"8SW0[B1J=K+"4R'BJ<>)C5,\[0Q
M;)S^2?>^#)),2IAC)M;7N(J*/=1QNZD,3ULUO=<.!.=;@2?F;0DU<XMM#8^Q
M_F7:%QN2[;;YXVA>#"4N^>YU6C<3#-&LEFQ,W7X?K1WR(QP-JQ34/(FTKS^:
MNPP\/!$*=]/ZLE<Q(0>-P&R'SI_6D"5"H5S#5%+$YHK_8DUP6[<6W9UYDS'Z
MPP;^KL)>E;GN/7'!ZC7!L\U6I34I(4,^%NGXV05X5L 2MVMG#=7!'L0YNMNJ
MO\N7Y+QK&S6UP4?#Q\ <2SY)Y;'.25%"8H0HR&*I<6N&R4&\^^-(%Y_"![-/
MD\[0B[/^N+S 'ERL8DA.HW"L.F@(*0\W UWX83$="6KKMVU$KCRK\3/(%K"\
MF;)+TR@V4C0EUNF]8!I.)>'/P7R4(?C9?4$(&A$!-:1#=<K>L>O@1\4"39NJ
M1+;]S]A&=GP\=VE?1M^-;!X3<R<#MS$_R; P5HC)3#IK3U+YX:&A[0WU4?5<
MJOV.>'ZO_E6MKYPQT-NAD[UMJTL9U])"DI:JQ*=]B1K4Y7K+\O_0&5SW1WOY
M/W4&8Y.BLD106-AF)L8DR-A_V&QH;]8,_^-;XRMC3H^U^F<J+ 48E+B6,F4*
M2,4/5[93:U/B"1[/W^WU!KW=/Y5RJX*H?ACJN_/LF?*W&:M-GDWBYTG_E 7M
M(27U&\W#\IVSI;-5X=)7Y(P:5$0CS?07P<)4*JQS#'@,IB5I$O0_S4'E"(_3
MCI:.9N[<,_QDTZ>1=Y(S9UG;0X46\;'0[+TB4Y$;9??PW-]:DO,[030P-U-@
M2-\CVV/ 2Y%@-9KBMPD+396[%8]8SGI^5\;>"H;L@=O 9WWFXT-HR9E(1XRK
M[-*XDKV9JYSM$/#B9<O5S^C+7CM%XY&PUJL@1P0;Z3KU1%BH.0%R8:T&<C?O
M \PT8_Z^HZ^7T#(8[TW:V/",;:;_$<)/R%S(CR0IYFEGN_BJM<M6)U1@KH8;
ME;7 6MXE+=[*-?+NJ.8JK3T&U-K\'E-2A\)1OZ6Q_L@76!'X(\7B@C[#4>X1
M4W*S5Q;)EPIB9A+_TRU Y8]:'>B(QK"O!]@42CL5LI40P?]ATL^X QMA7IY<
MG44?3,&0'U %ZPV\*9_MO /!V*YV6$ELL)KO2;ZQ^_5K3%/?[H093=(^$& E
M6+7'8%/P21)L)*6!J/[@\[7=Z!VK60<Q[%9Z'%*U:-4V5GWM*#=G3(59P-TI
MUEQBX=*28,XN6%*>Q)&"#SE)N38U3CE-%<?\L7?#/-]-+WNOGJ8EB9.S0UO)
M9<_9GNBX=]<?*HYSX<%M)B#;H69^@L= 1\CYJ,[ 3>7H](S1NA/J]>H-"S3A
M8%58.U6".F/;*6(-@R<9&&SA62'5>P/M P!7$!/IS"=_X^NQ!L^#149EW;/3
MKF\6--$\&OM<A;[P"]4VVXZ8/8(K_YNC^,[XWQ@5Z-\95>!A-^[WR]:H=((A
M)A5&=PQ(A+V3VLN_:Y6KAA0+^LTK_NO&+'\^:/XO[:A4>/(P)5A?V;LK9/OJ
M,4 3=K2/U8]N%H?@:YI!XQA<?@>S)Y>K@PRJXLO+Z33L]Z>=_H\2/,0@,,G[
M$_0[]M;>54OC\%.J3X+-;('!V_@^U5OZ-ZUZP9Q(/RDPH6O L&'T"I'(QD?0
M&POJ'%ERD>/&8+Y6M+.+]^@EZNE="WG6<5 @VWS>.'=^O;C8M'B]4+ZSKBKS
M0NVH6*URZRA35/?15ROXS'./5(=^G4JMTL_-P17DW&KFM;U2V\76S_)1&<W-
MS0(5., HMW'*TP/Z,4FAX5Z!!P$M\9=>U:K'TJD7R3+CT\:J9;UO0.9I<Y,B
M?,!G'0BW!&U\WF2AY=!I&(FE("\.REI?)>!&8^0O<^S-JX;/F8$Z@PX\6#@^
M#$7(QFP9M8'8UHX\,EV]@FAF2[/7:[9H^W@AI1I=I4S-0[U1S[1I7YPJ#M$B
M4%6^>.?1>!0)N/"59./UT;5\W;;=WFWC?KE8UH-87F^!P^3+'2NLY0 FOIVV
M1$MNS0^9]*FW=*'UGTDZ8\T2E&$M)N1PJ9 GS0Q!#L3N6B'H9NSDI?&:0K'3
M38(T1)V)GHWFFSEMR%6-&\<GC&L)NCE(#9+4T63E7QOM#3+\H[.4RH+,QR<"
M+AJDS;%'E+WE%9/)Q-"FVB]4WPTWN3 B$\RE"^U>9)NFT1 HV$CKRW5M*,V/
M6*RAS-;!+>VU<,O)I_)]*BH<7_552&8[L8J<*]>=:QG+CZ.&^SX[[69<[L_,
MA8A1I/P",5.[V,VS^)2XBW--V$)34^.-Z4F.)6[+Y_USI^T ^&?,BJO/GDK&
M75P$J_C/X]NJL7XQ4%,66\T$2@0ZZ&M)M4WNF"6KX6P-#\185""@E[].ML&@
MYWQ->/Q[&!?T(<ZFFOSY;$<&KR<#X:ZI<Z4[T-Y%7I UV;!:S.!-5S]C2I]<
ME_(B ^W@YA*W\ZC1X9.[&QV_M"X3,F_C(JNS_4&MHAT9SE$>[D_VX]:J4ZOK
MK%+/3-AUX"Z][>:,$_5,UGC_POH]W+&&U^RIE?A5T7,'9.^AW&*/\]O_M2;I
M]$^B@8VH? SH[DY ;:K*[W)M"SM1;Q4F+'BRD>R7< S85%$*P@1W'(V7OCT&
M(%$;G[7 $52)9V4\!CMZ=M_J< P6HZ>A603[[[RRZ28A.)#28?9J.>C7ON:%
M0X/=I-_#74ZG_'VXRU8 VR;J&""61(WY9;O4(.=43!E%5>GF;S9B8P^Z_3)D
MYZ,Y&#%5B5VC'4$YKUXQ?[5 5BVFM:ZXM/;Y_>3QG^KYI^Y0S?@:5H&-@9 3
MI'LUA%UL5+N#>O6PW/-HI6)OE8FR:.?XR,?W>1\]6[XUUC)SZ:EB+&X^!L6#
M-,3.X]\V-M2-?)]G?;[%WZJTI3KH.YG;UU&><.TL2:&AHX+M\.?F?.L]J=.W
MNK^D#A2^63(;_R[$2EC$:&II@@UKJK1D<0Z%BTW>1D.RU<RH"FVZW*K<MST2
MB=?+]3*O,<5OO0%XORX';JD4STZOV=JGAXXB';TPS B6>5<>M8;<TH0EY;85
MV)1&Y<^V0>1-OMM:YT(V+SERK_6X<&M%Y57>W^OSCXH"N;&Q' /:&,FH1:NX
M5K\O$)YF8..7@ 1,=Y"[M$S,N>@7#5_L6U+O1O(!PJ0'-.[@&/=0W"3?AJ:Z
MT6I-H:[%=KW^_F[S(%&./HZECG6:V]^UA<F;#Y/SYJ^5[V>\3WR;B\B"&A)O
MNAW1'<3)H;&7[0G&;7/"<=='JV%;$8EH:$>-I[( 3"**R</\JBL[J5Z@,O0#
M!C7-T=WN<'%<U%ZH:Z4]0ZBD02O[J4^5R<UOCPV6D@7."_ ]TO=A. CM!Y[R
M?1:DZLNLN!8HW:IA0M2;)=S%9*6@@^]J#_,8C53751G("8]GIYMQ?$W\T7LA
MMLNW[?LGOX"(D0>QIV=YVN;C&KH[MCSM==# S0$VUXR(L8P&Y%&L^LP RS3
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ME@#&2Y"GY1O/[XH0FQ3FCX;7:14VY#OF=^36P7_8!"%W_N5/-_0?O=A+'<<
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M,B8\$4\?J(L1T754%X0F\XI_G0[]*NA)Q1>7V;L6Z6V!>?D+ YM4L.Q"EVJ
MB@1OFCX?JC(S]I!SAU;O0)<2OKU)ML]W4?=[?#=?C-L9=0>L03B)3QG7L"\F
ML*S/G3)A;F]6AA0'B]^I':,;Z?&FO3Q0X7_#L%KHZD6)KYN&\2?H*6IP(:@U
M[G3Z(A7)PS7D(9C@0$$9B$IQ@1M\$H\?VQ+5YX^A-4M/G5+U+6L!W*R4T]67
MGI )G%9FE7H?>WA+/F9JOO,8D !C^/6\5.X16GJ6@VB3/+@_*?,X\:= ILN'
MO$0Q$9AP5<SRKXF?UV\IQQYEG6 BY3\=F-,DKSO^BGZ"@EJ%A@S-[VB2Q*AT
M=@_6!YEW)&+^O4)J#5J$HO!C_GP'Q+C]*$KJV57>@6\!OUP7L_8FFM>.,H*?
M-<X<=%TZ+.([!HS)#Q^-]/VC2+J4BD)<^OO$'^A_F?CC3%&,^VW3HWZ-3Q>"
M[0H=$M2Z,*L=NR5GJO*N1JX$?_SPT4^\MEEZ53'8B_T80/<[85N12WP'HXJ+
MSTV2?%]&=Z@D 4QT%M^B*B;&%U2I>7&W+>I:G4%'Q<!*SL;Y)R=\Y7KTYM^I
M=FGW# AN;S$BW&PUQ]L&\\%]#VN;589+/6Y<?G+V^N!W6]%UWB(<I<\_459=
MJ&>S'O-*>='!!->-<4)@*=.&)MR+;6FU/!57+Q,09FE#HE7.3[PZ!1K35F0'
MK_4,Z"S6@+A)-KA'73!&Y-V%8*EO_=L=#DS(9C6'Q@*CFK1-Q^K9NJZH[XX7
M4@TLOHI]0/F6:C?I/]J8DNY&JN*:@[T7Z,NI>*E;.7(ET^0.XHK7,[$;C5^2
M_?-C+IY<T4N;Q??4I@JG,L0N+I _:KBBUZK&<)Z1>^H0$+N+549_Y)4/MUQG
M+]16\["Z/QO@("_)W(AIF; 27'NFKLRM]9H*X./]U%\4J &#9?M?'))G) 2V
M=V9=W96KLG/=MUFJKJR(';V8%E3+O3[=KCS(>9^\UQM:E\B \>OPY(9:PR(:
MKKL<:;X?0[&+_T#JYYD4V<MPS-I.SGR+3=9EES])9Q-)$MQ@2@4IL-Y->?!H
M,V&/!]-\<XAT6PD5 V?L_^"JG/!D3@VG6=I7,=^KX:<G+?##/OS<_3H6D?[1
MZ9V]4GD&Z ,<5W_J HR-P-#6H-FT$NV^/SU*F1Z3$Q( 58"[7J9-[!B(*2I,
M*=2*OCI+U^"N3I=4T/JU[\I5<:Y=:<J(&J4<O4TKJ&CP ZI9O%%S]'+<+T1B
M5$CV\IR=9 ='Z[E"OLL&V_5OML"OC=E->^W4K+K(WCKD)!0:XC8F6;1AB/XY
M#C;-.'F_S.9FF&!NCA3@O/DQ@/UVT$C=%5;K(XZ,OG ':9SI8EDQ]AC0X7!A
M6$9#V>?P.8)5KI'S=G^;38Z*EFG:;>D'@-ZTKFL,3)!8SX04?Q3Z9TH!I(;"
M@SL+Y%K+@)KY@VWKK3G[I#8#N%X+J9C,=!U:+;P_&6KT_JT-_+;DUQRG5D0&
MFIQ-LB>7>A7WH-WY0?23A"X8P[T^<J[T.EWGCU Y#L53)HW1WSP&GCZE<UH'
M5L'B]E'1-?RWTAI.)^3 >7O0[TIFEQK':J[;9Z"W!M+*VX6OM=8*EJOU[/Z:
M*KQ^"_UH_;IW;.3OH@74>N*2PH"IJ=MC>$!S:CR%A^QW?FN7;/I&BQ'6LTMR
MH08#QUI*A&#P8]3ZQM)\&'@'>@S@!VWRN5-O4_T_AI'B*STQPW_<D&([SU +
MO;^M#+^EMA)5<ULE!OW' O[?S0.IE*,1*^!ZSC$@%"9J3&'XZ0R*=(!G:\C_
M)]= 1$@O"K>-V2:R])*E9Q\245BI?46V@T(H2@PZP K[6I14<@S8*TQ\D_PM
MNU"0K-@'W2^@]-JFDM-CGU\DO"NS\U?L:$B=)5-"Z2(^5^:.Y!DNV(5%C-YK
M/*'=SXCX7)ZA'+O[<,97JU"3[2P.M#F;#U'P+[&%I#=<.1K+SG$K-V'Q^EIC
MMO:935CDZOD4LJ ?_4:6@J$7\>JD/<3*[[)_TFVB3)9<#>ZEK\DY85UOIBW_
MWHB>6 ?>\&][@I!I@Y:2)COKX3W_(9/K1W.=@F'9,]_*(SVOV<6/>O?6&U9V
M;<*<"F3V$]08-6R*[OD#3<9 Z//EV.SI%I%$@LE*]SO\82E_?Y^(GD$[3?+U
M4%L\O!*?Z?YY-= 3WT2\^!K3HV&=_%!SR$1L]]M]J+"0-5$;\((-D*R8LN8W
MA<_,$0Z:)AK?:'$_4"R!"M'0[O<4>9;.J,1^&AHW3MT[?)+0,TK7H640O'#*
MUV/^J^H,CV!EUHF?!>UW^S0TB5JF^:0[%;C(\D7F;0[#W.I>UU?W;*9;-4*>
MMMIXB-#\XKJ-UDFD5SNH7=P.K0VYB'/X5.;OUY4!#RNKSN2M:GI$U)KC:Y[V
MY N.S[/0,O]VX6D%XMI,,7MN4+ *AB=2R<1E%6^+SPPNNE#?$&0<E!- &]#J
M>^= SW C,;):1HDL;U8%*3;1&_HY>J[+.=;G^1PCK^RZ@M'NIF@<%MYJ#VQU
MD!NL=A<Q?+*UE\3:B0Z2O<0^J _AC%W5.=,H+.%@*LKW$RF^.!".M"\BN8]J
M:+M_VLC?G++_4!OE-'S%!&15\VXP-W6R;Y#5#://%++^ZO67A^TGUZ=-W+K-
M:Y(Q8SM3ZU/*CP/.O[DL"6ZJV^/=L-82)\#12:<(6MN=MI&()\^E[XG.Z8@T
M_')B DC/7WSO9FBT1;,<Z+>Y7^9VH$!(W.T\ZW_7=OQC50/N5GKNI-T]'=E-
M7URG3-K.@$ 57=K5P=CD4_'L)SFZBW ,+9J*X,%F<=<=B,J7[L4>T;2?!FUI
MU9(0UKHS7FE70TW[4M(TOS! (!A5S_WIQBM?'@]]*J]MBK+>Q2C<?.Q*8W%]
M>N3S9P4G^_P0F@O6S$>WBA^43C/',=?)?Q3WS'07:4A6>,^U%K]+V3_M7?=K
M0)PJCYVI&OSE@-E8E2?W["J_4^GS]*GJB.J(D@29U=AXG*E(VLNK"7X% \*O
MOY1?].0.Z<<WRWC&8(TQ=D03^>X,9WSP5I@.,W, ,J*6YTR]_3*R&IP:PR>6
M6"V[O26 W@ +Z:#?7>GS*K6S-3T-BGY8&^^*6S?3_YF+.!K4PN3J9Y2_;76D
MZX*,E[9(>(=IB^:!!@Z/!B7[?)@KNY40H585A.Z[HTCUQ5GG-F6U)>S,AJ]:
M,))#H#;&@CEG@$]Y\VM10N6/U*F6UU-0Y4&219X))@9J6BSW.3VC8W?MJ=PP
M7EU&JI-1JKB1SGHIGC1Q(;IGRT)/S2PTUF3^F9[*'+CMWS,2.O\_F$"[!OIS
M FT>A%\WL?&!4F2V(_TGQZ>-CM5U"8\-Z;W#2ENY?L*HYR ERTK_W39D3XVJ
M!U-C%*>_^:?O5E34#I>>KZH.4P_R?R.B<^+)C7M/N?0!7C^LSOIAX88HW$J,
MABETNT 7X8)S20^T;V,(+1WY:B=*^P%S/>=Y"^*:=^SW$:59T*TTB6WYK5(A
M/?,;6??COW=$ #@4D]F$1ML#/)(>*+8CE8@7K?U%6X\LT]%4;;=AF=$55S3G
MEN'4Y%]N;\HV16-S_YV];Q]??!%I7F$BG@E32Z7QJFM'7'.A!3,;4VF%I1.0
M="V1$1^! C1KX5R?QWUG'_.IZ/*7Y@8M4^5ZJL(IJX&UL0]JAZHS/T@^&E<2
M5&9\K&91.G*G1ZRH_@RW+S.?&$W:??J PK,=OJ_LIK0^>=-G>EU-B*C^CHO2
M=\1H,;(8?CTT[+_,R%NT4J#^=OYT"/\D2;4:1\M]X UF=;Z''!<C7I=4,/26
M?XM[ 3C47C4%Y7HURY'?/]&P0A#F;Z=T\.#3YJ233(CN;[S:OJ;8&/")Z3O*
MJ$B]E+JE^G4I8\\1Q]*#D34U;1B>ZS6E7FZ7?1NY!^S]_?<T'JAX7L^T2K^6
M'W*2XQ3/IE(CZ_5^2)V\>YG[0R?#_%C=Q]?K9QAI0Q/?2)K?E O(0A UUS)0
MD2'"+@DE8!VV>*7JL5_B-Y*"2SZYC^3 Y*5T"WI@V^]]B\Q"!B[;$'X>6 ^2
MP,&?7?G3\GR"R"+, C;V97[2H%1O$3Z1Q.L%]JH,'W)5.(*EVRD:V.U8'W<=
MDR&E8M:[M[\89.TP&Z;=!;Q2B&^>>S?U5(WB,R1,]^P:/?Q*6CK7Y.Z'@<W7
MGG*-LIM""B/N,N=Q(OY%75/J D[)S)V9WQV3_<QV.K1])CK<!^8.+9N<T0/M
MTYY1@4X(9W=OS?7Y]?' 2LVOM[\-?[5_Q4Y_K9]&]>JZMWW9X)K!G6!%PW[3
M@GN'5/H$KT#C:*?($;4)/O;2;?QSB-.-RJ&LI8T%S<9O\YTX&M)W/J!9'O'R
M/=3N4;(R)Z><;\+1EP:X+FKJ?1O;[5 @%,U-7B':.-:,<.M"W\TR:^B[DJ?W
M&&CJ ,&<G*?#.;D$UPI[?)BS6#&PR;1AZNO'@ 0C'P%CTS,;EG.BL:/NZ#1I
M=<(-T>\T;PX'0:_/N"Q]2PRNV8,S:C&CVN79_5.L86?N050"CZ:J29[.=%5:
M4(53R*_)PAK5"D6LX:++/1=BE-8S+=]_I.D\MU/]]MZ3:W2+PL]72K5BI?XW
M4B+_LMD-,@5O^R_.GXW@#=3E8P"TF'+QZ1+U3)\H7$?Q,!18G3($W#&GL,,F
M7'[G0VZ YA$??A<.#Z5@IT";5T![8B67P-TA<")$=9<:&OZ1$#'\1T*DGBU$
M783O3>4)Q6ZO\0(,TH,MC/]7'.YL1];%'UHBZ[9*2=%*5WV,R9RN8RD=VX+(
MVY=E$ )JTA<:G!G"&/<'JLW86:],R:WT9W&34]#8D.J/#MJ+LMJ;2-72FN)<
M.YBS;92IDG@L1CV&UBZ?)?VR5/W4W?"4V%HT?#*X2AK!: OV'[<>(XFCFW3W
M@T'7ZFMK;O!,Y[KD)#^^(]H5:>F8]/ZJGMA69S!-5: 9ERUTZ!>/QG8WD/D8
M@%; 185IF+B7SJXVP",]<I_O/(R]T1#F:)'%8$4K\8 _H6=7CO%<RKVR1J*2
M:\- N_3 J4Z$&[L!1<238WK=P?S6_0:B:Z.N?^QFFO B1#3I[<DL+X<)\T#+
MD.)2UREI;3QQ P*LNIHHZJ76\=CS5UD(#I^3*U;R=N#,T#' L=$8TH.00UH5
MVL\,E+F&"-=-NKI["MA/O@?$1BMGORBZ6\.F'E,69TL059K+7A2TTL.9X".*
M",GK8[]LN,?F,+R4 <#+CD&CM\G*@!4_X87">]YKZ1ES\+P9.SO[^6G;@:?3
M#Q,#4H5T5K,)A8@RUYZ"O/>>I; JHVT[Q<N'':?1ET%JT%WFRBX-5:*,:_/_
MH.V]XYKJFG;A*"@J DKO46E*5:HH$%%I<F.0*B!$*=($! 0"!*(BO8. U$AO
M B*AET@7$9&68"@AH4E/J %"^(+W<S_OT[YSWO,[[_D#\MN!M5?9LV;-M6?F
M&LZA)J43J' OCN;!ZN@[9G7UKR<O#Z[J_B#,*82;GA/E?W/^G-%+CV[E,B)N
MVQ@<BD4%R;!U[F ^DC6$/PVYQ*0[GW)6OG3^7>&+*![;7:-4C]/B]V67P;5W
M"$RREK<)WU7O#50\YDF;$ 7+7O#=Q0A'?'*[*,''D_ODLLA5,DM,X6"*PMVV
M95+_J<#OBI-\Q+772&?$^47>:L2;:ATWY.BJ"][@20+V(2?:(#[Z5ZD<0FZ-
MW^.^. M38!]HE#<EU&658E^R2.4D-JVYXU=.0I]$/\M?GXE1]!V ]30AXSL>
MQ]=ZWU\^ZR^=2'LRHTG(_7T7#1OK!'G6#Z\>>M%7 #:G%\S%<P5.JI9DS(]$
M+*]#6"@,@Q10 >4:,LBX.0UXS*K?QV%0V&:%2:JLLY(54')RI,%S_=570@$Y
MB!BRTV$E'=EIQ4VB(9K7L+MHNGN-C;55M0T1BS^4H0.YJ=K,,:O&W4+^Q[G/
MQQJ+(T\(%'M>K9^U8B:?SX$*=0B>1PVN5AC@VOVDYB)/E/5*AKRH2SMMEV9Z
M@75VJJ>;OEZ(+F*+^^0P(,&]"VRX1MXJOM4I]4<S_K\;![?XOZ-8GOMO4BS_
M^<(%M2E<41;QFEE3"[-GV@/Y'2,7>!V.R0/ML9IBZ'XGHDU\A\?2HQ(0U#CH
MKNGOC#>[ *5[GP8''SC:GWB?U%OW6N'6\JW><S>R&-3:ZH&1H#//J)(+:7I)
MZ(H2!SG'&QF\S?FK<23A@?YSSPMEM2Y-,X^[E/\RT0JC@/.@(+T4(XR7A2I0
M+W1M G+_HR;"U)H!;R7NYCG:_',6 ZGJ23?XH9#:%$!HC#V_P*ARNDSN)W+#
M7/=CC^O2=D"Z)V_<8NFEY&=7Z2/Z!U%VEF+M?C[!4\2=2)C>^W&R:]<:>,BM
M3+0V"5^399>48Y? :6H\6I(__!' O\JCABB":1"SXO&E+H'['5B-K"#/H)/Y
M[@'\WH-!0\^BGL/I=$LH.L3DEPW.BX%B@Y)L!N*25G/4R^A?65E6#]WZJTT5
M[@?S>V<3TV3.!/9;72##\0]=I2?U@/JU-2Z:GI(84\,/,>MZ5[ILD\W,?GXZ
M.:=Z@QG>!JQRR5EH>$$5(S&$59<NN;&HA3HZ^WO2:>7E$4L>[4KQ.]=3]55Z
M&*< QQ06_2IBFY1RE]#F4CMAR$955_))Y,>L;>&Z#'NJ69>%YW'-ZZ4V'=A[
MCABEZ&*L5&93GXM"?P;G]3S3T2_WG^>I<;D5[11D[#YC8"*PO-HSJ<*O,?S\
MN=A0'EH,U6&5 EI\3)"IL9!)FJF[I/U3P/:/DV<1BL< YYCD-,ET[QVV6[B,
M&D>D79&0<[H$&[ADR=-AF=D0J&VR!QL]>WWBK'Z$VJVK)[S-?6(HRD7DB*5V
MM!\UW;/<'-[=E<HTKN?)U7A7V>H@L'H@Y_5UZHN,&21CEJ[S_LU?BCY4@1;D
M<+7SS3+&CI3 2S5IRKDW9^K-# @GF:-44LP>/G[RN0O#X=:*.D8!3949MNUL
M<_E%)3IP-B3E%Z?9V<6[E0ME0>08-\Z1BB"WF#T\P,4G.J6QRK/CTK!LDL24
M8&X>#JI[?^#%&KL3E67PR7 YI\O)'7" AO2J:].<F5#S<=&PD(L"LDM1L!(=
MM50\\-C2I!*9QQ<O$Q&&Z?]PQ]?>.^<AVMW^2KRUCNT;WT"/#E//#@Z?EZ:J
MX,J5//&;0YXN3(U9UW*IWP?,'CGQ1N_$JEB6.N]@[SETF]4UO&8L>J(#&W;X
M=O6]UL1.N&$CZ*K*D"0-);BP*-7REC>6+OEU91<O[)6A2U\\CK!(J0+](B5%
M*$1=X O'9H=;ZRRK%EW>S*=C]^RM*^\7!E6MA1JJHP:9Y@I<9)KT)R7C([LL
M7?NZL8I1!?3^W9KT<>Z-!2I@;;(]25>#E$DM+C!SWG.+<(/=49CMW!A?,"1[
M?9A<RJ !D?MG7#X?X$Y 7BH&5U1^.1F=.YB6;KK!&->E]FB:1[D;U%LM^SMV
M->2:OLY.^L+#_\LX"['_MW$6S8< P<E_C;.X]I^9J_7HY%>39D4#]-&44$^(
M*'6P1; 9Q+-Y8&->T]A$?-LBH,AIH(%7ANFP*R$<GJ;J-:FG71&4.V6FB*^1
M37[TI.63F&@LOL1@UL8<R()UR.(B@F.;KMA-XYB76F0_59%]3GR2SL;/#Z\2
M[)O?7M)S=OWT2=G@'/]5RSII69\'GXC@<!5E(OH.H53/4RM&Y@VV[&U*Q%=I
MR=[O*V[/Q)Z>CPQ^F8-'K,$Y YWV;Y'!NH)7:>#[K;G8]M H#8GS??)=ITL]
M#L?]T4W*)X4&R\/YR9[Z1&JCC6!AKM-Y>243CYD/1>/Q7:?4WO!'X+!8+$??
M#$SX1>H6XA2TK5T;>8,A<DN5[8\8,,.O299AI/;:,RGI^#5![C6AR!5#[EGH
M]I7O[54)LR%;N/9< O X3+V.N%+06&+F)'8'Z2+-PJ#[?O3;C\7SR(0[KHLB
M/MH[#'&:Q<%T*OP!IGA@4(L ,;!EKZ\!@G.:-+3H]B]9E)OL97^F;JN9-/:4
M<&PZ@X8K_8]]F9F96;]AF&11=L[3%\A',2?K?%CPJ^U<N?F9RH^X]V.+3X;9
MJM<Y;Z%OVW](H&^TY5Q;HX&.2E(HS$DG[@0]ZV@YW(ALYDS O:%!2;?-3#93
MS+/5Z4&LJC!9:C/2<;XV-7,>B?32L7K"%C:!OM9TJ21%_-9^I?]@8D22);;G
M1'^LFCA4R0RSUG)Q'&K8GI;SRS2+F9CQW-S\H:X#AO/'XHTW*2;NFK>3XEUP
M3*?:9=Y%W)KHKX0Q(UI]/* 1&Y];S@[#KA3J"!]WCLP\[L++N&"LW6&R<0GT
MY>H'JD&%.$=&J<LV<\'K:_J+GF4/I! (07DDJ3QS.O8<.5?SAXJ.)\E*M^\V
MS^8#_%+XBUY_S3OLO&71K<"G^T;/Q:?6GKZK:M._9J"V0@SZD,4_F.HJ4QXW
MIFD2<)\S9%$#>W5(Z)+L%TW&*\87YB_PCEF]K99%R-YK?9X3-]W,P\%ES?T/
M3-H2?R\%_.,?0BB8]I7@Y2340<A<!0Q<AS G@OY3]$0SZ)^C)VS&*J;-LHY\
MK?ZTW5QA!M]D,W?Y5_JQ"ED@_S]F==. 2]^_,8;E-$5N/S["+OE':=VH33FK
MVG&,ZY,"Q5IR:N=;^)>64+)^3Y?1^@WW^#C5I5EP#/!T=S3,A?2)NM9FX"Q)
M!6C+^Q=+ICW=?VA1P_C,.TZ4:1:1,M_SARF:<3"YSAH[(EA/@D11V7&.?AR_
M?JA<]'=3JR2&&E8.=R$*&YI7=E^#I)4C7EI-56FS*WWO1-256ETEJQX"3IM2
MI/8S35M3;I3AR;YY%@ML.H7:@^E?WK>X)'\S2DH5ODK,>&VJL*UNUR]?HLYO
MDO6C%,$%TR:RA&WM0\*/PYD735=*H(:MZ$Z3KYI<LIV^+UQSN2&I<3>2Z=[2
ML[7F3D/:E]P8'E'<0K5_E&^ZL2RF,83,O%85_!;I?Z N(V/P<% $*QJ?:^$P
M$R'7//R^5;)Z.\BKW+.+RC! O>00F^M< W_VR=$F\Y9W=&ZR(A-_V-+K\@]T
MQUD>&*]X__!1N;EMG*)50P+%K@P25&\^&K:K&9%6N<80ZB8OX7Q*I:(J[V.K
M#Z]*Y)7:F[/&HV:W8^L3-S-\&7MZ>LJ%/N/.J("(AX '+</RHVYBPVO6$:?7
MMB1HX$7P<OBUSKE[WVX?7QU3[YJSB='S_N*9F+&'-DB:Z+%]:^AQ0GHQ/<S\
MRK$^*2Y 3L3M6SE34NSC48/SER)?=B_]*2X^!C1Q<00=B8M9EACM"T_#OWUA
MRK#_9:^BC[\N:3_U$! ">1M[X]^JX*R#_[52SAT:R@WXOT"Y5?\KE'LA)^+R
M[U!09^#& N0*=:3!"Q<!L]YCI[)%+ YNM ^-.>Z5D@U<7,I79^TAGR0C]QM5
MGO#UO<VA3$L>3]MKB'#\.6[_6>WRH R!.!^D@"-KPM3+R,MDD&XE38?[=U"9
MZX==MAB+C-9>N=:L5F9H<ZM\DCU^IB?E0;U_LZ$V+\.*_$Z:4L@6DZ?A,$7K
M1-_R#<R;N4MHX*7K,\U(-,<?.F<=2L-X:CF97QWSVV>.P&"E.Q^19=K0O.7U
M))LV\[Z=5ZM(QE]-6L7M!%7%[M8=]X-DB5BD9HOW>P\9 VOCW@)R%V66R^49
MF;'5+R5,AJ([Y>+-9+UQCPS.<[K!@:PY6^8)Q129]Y3U7'>T'N)E7[[S5:NO
M,Z!4EC)6F7$6GJ4EB KVG&0@*D9.Z=[<#^#L*S.A;NO=7IC)G$OPG:%[$;/.
M^LV[Y'+/E/BKS^PWLM2_0666$]EK!$5(G @;_":$N;W@80DT GQ:#U^:6LAR
M6=%C[$OX/%);R%,VNG1N>9$I0)73VY/*OB>A?+,QH2WB<O$1>>(QJW_/Q+7:
M__>@W/(F(*D%LN^L<G;_H'.OG7;8AV^R0UX<Z!TE7H$,P>4F_M-\:X$<]#0)
M@K/,&];^O:AFU1$[C'31KL04D()@Z6;9VPP]!-R^MS=U9%S\R0\3^0_\,#=,
M&S/@@BS[;P\!FT%=7VE0^2@ER)P$QIK/6]5\(I8N^+'OU20W% 68+';KZ!FL
MMUUD6TYCM#_+Z)NN7Z=E:VK-'MT94,SMLJ1>P2F3E(7]0;91)_N4.@B>#J[&
MG87B_AA^@>!<XFH(F$O,,8,<9$UN[!2M6#>.)(T0[VK#BI6N8)6,6F2(_5$V
M1'A0=6-L*+89T:&L<N7@G?R!V*VJX1=7++Y-<$1MSXXM6\0F]UT8XW]<M\'G
M"AXW,HDIC#==5[M WL*OA0E>0ZO8%P*/+S+"MO<LT6]?"+ .0BLZ+O$\E85\
M^YQ7^8<TZ_5:(1<-6R:46"$:)A3@N:]9^%KJ&0OEXJ14?34Y'"9X-9(>'1$'
M=B5E:67*.JY[*+NI;(PMZ;AW^?GL &?0@BE3F7SW2)IEA)LNBJ>V#@RN9S>A
MZ&3_B)<6N@UOD(7NR(_H'9_O@S.J@,J@%M-Z22'!>-5 W&WJT/#JE@9),]+U
M9):HF?#&BL+UGU%S.JFFO4Q"S^)K?:VO2BQ=_O0^J%OLU<+89GY8D=5539TO
M,[R!&G9*WW4Y(UX3H.]-?"T-% "5GJ]BAK<NO%3_HA*4,3S9)IR3=N56ZY&B
M>F!TY&ND Q85">_W;1;C_O:)H!F8Y3.J+?#B]=#_P/8"2_\/"=16:!>*.7SJ
MB" YR\24PG,4<" >,'"_X"A1B]3_^%\CRJ/_T:5I\ \E%QWAGRG?YHF]0YOV
MP=1>'&GEGSR9Q(J?_E35IK\J+^;!G\.;K0J>4+=D4F;9YNKL_YXGW4G"A:\T
ML>&EG#M,LR>'="K3MK5_O'QX*?FS6/;N<[7J#4R')9R@UKA_@[SSD/2''[NY
M:"&>+W+?;B!JR<M>0I/'6J3.+?[=FE542])F2U6!^H?11Z,3;;6*/E>;Y&X?
M KSOVHE_#0@34XE8SU3:MB,>Q$26.&"L+I T:W,ACK*_%/<"\XNK6@M_MC!J
MG<G)%IN])1S7&'RKY&M>T+Q&IVN SCSO?.<2*M00=G^8IA46/CG[688&YW!Q
MR?5&#GF)Q7$^BGNOU?S1,''\VI0<P:TSVJ^[#<[:I#JMRGB7Q#3WRC\;#/QI
M[N#B>K$1%6PMRS0V0K"3//5,H/3S@E6IS/(L/EI7%^TB8S\B S$+NO>:.F>1
M/7]/?@?GZ@$X5K43\9+;>ZN9L/8RD(O4C LO5U#WGR.'.>9LMGOH S_VS=\2
MZI;88$E'(^=#K<L]S;DZ6,($;Y*R*D"A+O*G8"*YSBO9$Q80GN"MKW>-7>UU
MN&8,&L/O7EC%>K35(YBI@TH[.+Y--\:>(@?>R>@/.-P"B8F3K\!9JR9"ATOI
M?L[-$ G&DT8\)L*VTV*H.C)#;N^TCE>OBUN'N2W7C3<W.N="GQ2]0^[W(EM9
MM=]-JE].C[NJ-=KX"A#11]Q9;L17,#F9,XV$5!,4:HC47.GLG(5/3F?06)]W
MD+YP+OL^MM,"[A>]]6^9_/&@#]"P[ &OPD5?(OONLR],2@USZHZYL&@->^G@
M>7!70QQG+KA^YWD]==9>V$32;RTZE]Q+''M(RH4&#O?B#^SU(U35?*TC1N7U
MO]ADCB8]SE09B"5<GVM&M2(88#>GP*$^:@RU,=,/B$C"G%"AD\%NR86,*M4Z
M84_NR6GZ33%AS,4\:J\:9_5#FY$M""LYYY1\>ME)-,9LY&S/B> .9_ZX8N/;
MN$L 8>O!^(Q*^=S+$@5<6@BR_78T"11I3Y(.XLS'K]RFD,V7($,* >+?%_D<
MLI2,1E7P^YN"SYY]ZG!O';]A\ O%H^*(KWAY"&!T50"S0RU5],I^+4#MAZ5<
M5PL:U.E=ZVJ"7I3/J-G&/R\!@]^9%D+MM[T'-E5MP,.N3>H$2X]5S/VZ <*-
MFO>?3GY\>_FJ;,EE\3-"(==AT]*C "/DP3NDJF)O6V\A-*63D\N*ORI=MPI5
M.\R %6S3U%3T4$K9Z&@Q\H<R*TKS&WO>^;C:R(FLB*Z]T;_< ^SD<Y'E7LNG
MF57;GX>PFM=.<TI]2W_)X'!A:L_SD6#9_EUR%3Y7W7^Z#*33-.3E=@9'3M'3
M8^@S>Y+P_;IP EIO^JR *YW$ZU.7V_DC-@6<IX;]N):W*F#*Q-+Q1UJB*3YV
MA=*%[G/LK&NC(>#5\BGVQ#C 3)S> R)B&9.]L#W01]"=@'36RCJXO#] 6#3+
MC8V:WRMRO1AL;/1*2$/0,E)G_5((HR'TS*\9%3.25I<@_V UCIER>Q"F6GH(
M<(;*F6 D\4/F1K6>3O&GE_/'=1YK?#U_:?VS3O>];#@)U:W88!H6^F:SGT6]
MD*S5UN 39OMZ=][7E5774<3?X;LF+IFU5,B>AX?C%Q:\/((?NVEIK0I^2.(*
M*QA&.L)4!;Y7%OE^>CBJ&RO+Z!'6Z&%\VN?LLHW>-W<+;QIJA\EQ5(2[#+BB
M0>=^Q?WB>MD?O^WP!&KHMF-A&YVX9)1/7\-8WIW\"\*FXOL!]@SC)C_M6 (U
MAK$XEIN1O>@CO803PK'71S8^WKRQ(FVZ&ER>N.U"[BNAZ/-&\:[FYY17N+@P
M=:+#W>R];. %7Z;G(ARD =8E'J\U=A\6=_LMNE#I?REBM\H+'?W+'NJ>?)TE
MD"#AHI&CFVY,KVDK$<J:+6ERU^Y)XVL_HZQCY&LV4Y8>\V8I5AC*@]*>IPT>
M5M"0%;%D1F/K-N'+X1F5/4_'Y_DK%63?6K75_VIRY5YV3/Q- >WXY5IM@6=B
MS-N??P*UR/]#?W+Y7_YDU_\1?_([T$S< GQKTNW@+-IM)9PT9'*0J<;@1%48
M:%*$Z?FXR%_E\Y:\&"SL4F#FO?'Q^?757O-_=2P7T,=(- +M8LK@<_:<#V@]
M[@'Q6AF!WU%LU< HW$F8U+2+Q9V4]K20*N?M</F%JK>[86?KYVU>"GA^1W/@
M#P$UM9V7)14FV-J\)^7=3CFA>;WZ(Z1F8WR%N$SC!&I,!I_M#Z@T[N0^_]HR
MLI7WTKUQ[O/WR7K@_0/GU $*7<$OP6L8BAY#!K:F)GG!1_Z[F?%%@Z+XV"GU
M^IB;R6+5SPL=K;""]7C$.93CRFW@:3)+IZ @)Z_2&YA.+I,U^/P2VE3)1%_[
M2TQR8C7J'&N9Z"YD%B*YP^'<!4*>;'Q/T1O8#"^79Z)KKU7<9L4N[C4I&9@Y
MRX+C+ZG[<Z_;_%P_@>M-9:M4P#P*[+LAS,OJ@%4*HQCCRQ2 ^B"[006PM!S'
M^(KD1]]G/,=#XIL^E0BPXQ]:9Y8%]@7RH5V6GX&J*>HV>*B4Y/(,L;D@YWZ*
MBN)[2>V!ABKQE^<4NRSQF@>C9;[OS1T(37K[.DY6@N1ZEYSN /R!J49Z!^<>
M?5K 6R4#R['46]\2QM^L<]H]%1Y#O).6VV"S,&?IGK PJ?NAHO;L&0JOD-Z9
MTB(P(DGI6G\?,F#N**T%P*]$(X-45W,YBGWVKY']UHR:DQ10;&8+&TL,'0\6
MO!O"+'0MM;^+)D"[!G=]Z2HU[6_9PL03KE 9R'J>+OOJY'F"27%A>T'ZOH0+
M$!S"V/7N6V6"?:,7]CROAL5#4L^80[WR=?I\1H>7_>17Y>1!W'8.V2YGP3P_
M$Q6\)J]GM;@Z:.0I2?T#?::SOE6HWS+#]BG8O'4P4 6*TB=K^$Y'F[LQD,V[
M5DF2+RJ0/9[2W)8ZC->,'_4*B1?'7&X5:<14D OQ,9D$!!\4W&DXZ<1IC@H]
MT>'=_T2M(XN'4G&#Q]1Q,NIQ6'R78E#:O S</I9I$LJ@26QN1N?GM[Y?A&"Q
M)KF.SSD7O_^Z69OVIMCPVZ=R]-G\1Z]9N-_B[=PM!2%YU"'J%0Q,+$\D&9'W
MR'G'2DF0*6M1>_4"TDMQO7?[%5O)US?TCW)MX@+=='D1*Z>GF_G:TMYRI=F%
M;L]%$X+>+]V8R(P>F8C.1_W\MN3MDO/M:]D[PN+M5+K$*)I.E]EV)7:EP$\,
M09;\@CO\E@5%-F0JON6O$8*G9.-K 3>T?4J"]6]/'3/= KWRLZURJC5W;23(
M,#OQ9I4K%+N]B+[3ZPYZ>TG\07Q\KGCI?JT)7SU T&DW>U0Z]N: BO6D++F4
M"+%*-!Y2D&_\X=5CUSR0'V>N$U+=RE=/;W.V;(?[JLI<$4S^(!>F->W&&WNV
MLQ@*,:L;1CIG&NH-(QO]6^W=)/^(_/AEVN6;5A^][GF>,_?5GEA%VNTK0.\/
MLK#<37 R%)!<O.0[V\",C6LY!,2V>L6'LGX\\9$]Y#2R'!OT&5=E$CRE"FF_
M\89W+5Q!&09RP+JFI26_%]:63.50^VITP?36>>;IC3F%\9FG,0[>-*4>3Y$F
MYY:8463))PA@P8/8#O,D7,B:UU.TC2QCT>-8/9V,J19,4LB=*EO^Y[(=&#>\
M6W2+8DWBYX;8B&5YR+(;/[8)^XP7DB8VE+]_I2&&QS+FIX_FA\:0_G=GZ2QC
MWZ#LX2Q0I7O$9 3']_QB+-E<(M)27%73_<;8F"[@Y6?-SU8*MTI*.C*8"W*(
M*<LX/(YA49&UH+A\T=M<KPG=()I: @G(P6B%#V<_//8HKC*1-Y4QZ0Z2WVCC
M]OX)C$T(V9VTU(5MIR@.J^C9X'^]  G^2H28BV;*%^W!*K&,F9_NC7/_I(-]
M9LIC;@9?12 URZ:=P9QDZT. _H^MR "M5K^:*L<2!T7,\VZ&Q-FN@=.BQ^QO
M2Y\+MWY&Q^<*>(RIE?DL<[HF:&KBC(.,M#SNS,*&HZ([V..ACIM(Q4];,_")
MGN@PAJ#$#!/%Z'W97[Q_8%]@_&@+/U"XD.(G\LDI+:*7=V'G6D[/,R/-W-Z#
M;RYUE-UH=>OC+X??<VDY$^UJ82)$4S'JK1J(;^3Y_3>+.LI[\VF_5![\1? U
M"/\E6DSF:DNFGB2&).'W=1O'EO043]2$3#^(T[FIV739&V!/Q_CC^8E'OS.<
M$0=^/4<9SF&'@/,*$__'I&!S_^,%LOXB!;NXUFW[_YZ!Y+]=W/8W\Q?Q-_.7
M-GQ3N*)406<2W>9+>%5N%\Z3S([/NRY\66WF&.0*[-_*]3Q.FD8WCT]@FT"M
M?W*$E9)E?Y>\E9M%C$9NYY(P*V+ J.ZHII,P8?E(9,2D?D*)MEDZ3&K.P_)X
M5'S7J;6TA4. *YAE86]^F52J$^#DFH;1'[(-;_\DZX:JC1[EF%=[%(/25-@\
M=5M+H1-F1M;+IE@3?_Q0N;L7-AA5_)RT@-DPYQ%49$Y/4S0PNFK2Y5>2-3)=
M+R;1S.) .@2$H\[!//&6-MTWQ%[-#[PH WZFLM6@R\K*)2?QA1>E00.M9X]?
MT>:XXZ'>+R A"H_($HV<EL)%@6H8*!?=88I@=GB;2CQ;$K!)_-/:F4?QL5<+
M)ZX+R%G1'NPI%3EQ9XAC;5UCBL6 H?JP6%UC@EFYRWD!(SDYVQ:11)GA>>4"
M#2*D#3UY<< +6N9JW3#X(BC[=JGOY0AG2<#%+-4Q>SH&P<?7>X08TH:R4DVU
M0J&ZTSL=OB\V1Q0$!.?VVC;::],:>\5"5C>7 @0)-VU4W'T'G]A'5U9=F%EA
MR.:H=B/Q$8)Q(8&<54[F]+R(F#4C'L/[<=V%YC7O=D2\D?7)ZL*V&9^VGF ;
M*\Y2^[+.$H=-3Q]?W/'V>*B;;V$&6>+BXMSSRNBMGJK6"J@4_5&BN X / >4
MH%C5CK<3.L@V^:.]THCW4)/-+VV,/Q\WQ A7)I]J*AZI93#Q$HYYSL3_XQDS
M Y7+K<,TI+^-V)==&UE&\:,R-8\(5WLZRT-^E@76,IYZ;MRF<J'(>]9"3$"N
M&H=E([ M94G&WAY<W8K'6ZK+!^7]A#HMXKT<<[6CV].+QNQ:UN27#>.RU3U#
M.59H9@83'GC6<4\@LZSL6Z[62![F<5-C4YI%:L5,C/9,?5U\N&RC9$7"9$X.
M26QY"R_##BV?MZS3,QE9PRHK\ F C.N15</"T48:(AWGZ\P$;K_O:;W(SO_R
MA#1TW$?E9J>:$,D[]1# I!%0!AF%(MKW-#/3P<R+:3ZI@*=#V:D&&O98F];'
M7Z][=&R7=W<@^"D:V1-+5#8D<FB:=!?;$EL(=:27F6TN(YZU\Z(_!!1KNYF]
MG(KTVXSVF;(/AFD4DVNV5R?)%9'/0%5>Z=H5^;K^>=C*M6LGL2+K7;AKMVYJ
M.%A1+A/+"Z?[6<CH &%0.))/![FB1OZR&W+E)&;:FR]Z].D,P[. :;WOC.\M
M!7GR G]DJ9!D(H-7$W,6N2:!$ Z!8YN1<.:)&LGDM>7!23[2_L>!&EMQ-<L(
M+7WGQ2^OSGC&W/=@@1 KQ"$_-]JDIMW(.@:J!J>#:89][?:C&_EM"V7^7[BD
MG#[YVO4;N+_V "M7&+Z<E<MLW^_F)V%BF.P?=%*$/YE?SGFOKL&.?L8K?1ST
MX+<;UJ#J;-0P4\\S/][?9$*Z1V1"5_[_R(0. 3.[5+E#P*CTV._WF4=?U_X7
MJU_B_R"KWP[%'_H7JY\VE:9M_9K^8X#^WVC][NZ6\\")2?]$6%PJM'@[XG*A
M[3$-]@>/>2<<Z"YE:C")'C\687XY^P+OA*-IOM1O%N.<WWR'MS3_HZMK\']1
M5$?L;\1_-&BU\E=-'<C_MJ:.$.T;W'_3S>7W=S?7R SH-T92_3M&6ESY!L(Y
MP\,SS+0HD;_@P4PV08\@,8%7H7+XR=PG-@0(VT(#Q^SVB2;36D:^JU+1W3['
M/$[U3$W':'C+)L;=."Z'@$7!;^R.=>[=;YQ"1 K>.&):M9J W1FB0 I_FIOE
M-WQ>8+N;((0=]\T[A7?!1V84CW^.4<9'- YO]>N08KM8F,G0)7.[%E0.D/WA
MZ/@CZ23_P(\N#BO?=M].(1^\:>=2Y:@RDG>+G>1$D8L"^7N*;K5(1>J&&B:?
MLI7B%-!E9Z"+2X=D*39D%33-0\C&Y9..<&3'QU\/:/"58]275^ZXG+=F3!P]
MLV]W9C/@LV 0O1'O6ML:VP1YVAA9.SB/K"&QM-\E+OO-2+98)BU;P\+O)2QU
ME(:<\;O*<*EVIL!<>]N-F>) 5(I\.F(]0#'.=_)P?(#<>8W%/[K#FR'_9E,\
M[WR=>YS6 R.I%JE?6<(CFP^;Y,H=>+L0[OZJ2<L+1;&RRJS#WUF%]6'=9XQ3
M3P.$./LY-OI# MF@"(L!$YS^0),C9S7M #WEQ&M<LCCH&/=0I /=R_+S/>?'
MW$<7/XM_'S.E66.<SJ@ZL@V!CP_XJC?7X:J&4LCR&NNZZ&E^Q0W%).%KH48@
M660C^XHJBWS]A2R\K5]_4* ,5(9PLJS(L46 ))U>#ADMWX]TEGAU4:/'LIV.
M.3V(J?U"G":TT[MGB"(Q WJCQDD.P7&I\4-C._SLP[)405HC\@$/9,KD>RTL
M&,/[\B*D3$8>8,<4OV?GR7H(=?&Y5Y2[?+>A(H+MY7,K)9,C+A=]?/WW37#T
MZ[C27[ZVWZ[9(U];[+ ))!PU8WF4VHX%']"/M$_'EE &>L,A]7]CFMFH^%?/
MFO"_>=_6OJ%PXK2#/.,OPI=<X!KF^R$ &4I) KT!;O,"]UA-!UC^S3;CYR+A
M"JG8[S0CYZ#S$! !W#-7"PLZ, @XH?.@];<Y5GX'%_/E<D[$F7_5-O_X(]%+
M_?BO*8>_Z';Z8+O[]PX!7PX!1 2UG69H_+K=0(1W'7GW?GM^?G=H!,ZV/JJ'
MN,4/]"052R2M_K/KIV?'B6L?%6POA=@:MWRPKO7/50&^'K1O5<2W . ]:Q37
M/Y,0A2O*4U:I"JM'E1!_*T^&Z"3X;]VIJO55@JZS1>%'$XL=QR$@3,%9C[=O
MYII(YTPI;]6R/?;TXKU<?N9 <]S]D";@=E&=\Q4JVWAW04VEI)H2,OGFJ6VW
MI.1!(B7]BV5[Q;/I,NA A)LA]N8^,*J%89@BY49XJ&*1!W_<=]-"-&<G+/[T
M+6MKR?&3W* K\Z^6]"=A'N0 ZSU62VB[5JV+!_?JBXF=>RC'B/M"<6Q=:.56
M%=93_$%6IY7:^EFA8QT^@E?2VU@7S*TJI_LDC'@5WPO)66#'S)L,)GJX11ZD
MDKIT/C.H#$.X6LZ3LZ8)#!UC-LZ$%=/VR9LUR-J::F+WMOW/$=:QY?56=Y%Q
M68664XZ<=R\\O1,EBV[YGFJB&CGML\*&=PO"BM9N1YOJ(3K0YD8-92VA[CXS
M37AU\=.MH]ROCX&@,R83B$Y&?XM# +M>V>0OK$EBCKFYI:Z[R-[N1\G**A"6
M_=5,5/ 9WXE^?E.:WF2E'"/TJ75/AX8\@[$4D3^!^<W'>O.<K^G05:QN]OI#
M+N%GQ+\LB%1].<TMZJKV;*2"%R9("EB+5/$LNY,-=\ >5+0UO%74U* STCTW
M1V#O#9@R<T>]_FQ=FL I$+^8)7Q0JL8#]6E/4VR@2GYL'*RV-%'EO;(R.S'[
MZ)K^Y&-A=NP'[E6>5L.!8*\&K0Y&BXKS3C>\9K>3CA\"'$41A?G-4\D6*<X:
M]5>$H8*/TN^T3'I$-I)+OZ@$9ET@S0=OKL#!9,=BA_6%2=G!:JW*. N1@P/D
M29"B=<2X"_ "\UA-QRGN3B,2O"V6W>DTR>W1T*:/I:,*N !:V%:RGE,]C*Y1
MC!B(D7T-D?;W_AYH!LRP+DS@K&[[LKUVCF).A ?+[Z>OF'8H<IJ@4X+ :5KO
M8+4:=TZY#]??:728=Q.+& SJ3'/-Q@L1I,37<<:#YB,54JME3TTB;(TES]1-
MN]';+T!DG% ,*G;O+2CRI#?NSO:&R!2S9A*[H*"N\M9EUVK1$(UD^8;HZ<2O
MY](];DVR@E.B1Y90IU48//%NK]/R7U6AI2JJY>"P9UNE878-9O:3'4 15GG)
M;P]+SA[O1K_-/N%R^\L,<FU,XM8PW)Z!G/7B)GGK;$ F3-KN.&GUI\IH]K@_
M-\H?E?/>AJ+P*^LDN=]E&L[UT"'><<BBQQ>?#F+]L';![O3SV;M0@>XR*#I^
M7VH7?@HYX6=AT3I="@^%C$)&;T]%&A8%!"T3+#/I\;J?A9>C1I2"EV$6Q-BN
M%NZ1 B)G,X$/0C;=>QHNOG"<1W!R\:2H]OA-&?X8S[%\BRA6;S;M/:W.0-D?
M%(Y"*2JJ!.N UKL0["HC8F1B\[TU*R]8A1E:;M"^'43V+.G)[;2?MN0E!%AK
MO>YD7:'3NZ38I9X57;=RK%Z8]/ 0P .3*X$> O3([E(Q<1M2%1'R*R;K6(_W
M8Y^++UKO3JT\U;\]G^];$:7&[%R+!79]^4 !\:?PKD7)ET%TQ<\I?'._4Q N
M0K_9KJ%&!_>J1%>]L1$I>KBCITM#/*^1".X[>%T4FV-RB]"[(CU9B[@JUD4S
MCE?[^2^M.>I5;,H\(+P@!]Q9F%35\(?IX<T)K<[D2-=V]81EC2MF^7?YPO;S
MBB5I_^A]J2FQ \@$@W"FDOCP>U"3'<,FDFDDXE$ER>]=7UF3; ][I'!LDW:"
MA>13CF.>;R(9Z F(**H N0W7#F*CL'&]DJD>JS@'+:-HV)=_WIX;]'>T?Q6R
MXUEO%WZNLPJP$GZFDOX5+&[UIM "$X2 "]J4X38GFQP".OQ<*L)<SRQ_3,:;
MW'Z4R M<K7J5Q)",==>G*)"#Q&+=5!S/)CL[J:A6/'+XTBM]"%"UB5'<8,D6
MO7UMS 4V3V )RKJ<V"5XDSA7YC8MI:M!,@V'UUQ,5T^_'WO_:FW"';#*1[XP
MX= >[''4)873T5W-N5-901^@SATX#BDO2VG_ZQ5->M+%-M!.6&G1TY"K/%>A
M=M<R/T]M]-D;7%'_>0@PCQ<I[-]2J9IZU[W2^[<@1E;3WY&-?Y"%?0+'$3Q?
MIN!VV)<,]\_:;'7!>?<& M>FK<K_R^^K9D;AD5GKWQ &-_Q9)^8_<W/>\:26
M@'/AXIE[B'S]^B-3^L>/I+5URK=%1QZ_P"B2V\_0 ZTHT+*2T@;'JO9S%%&<
MS"O#[TSE'*[V#P":U@WE)J^:O@@K/SVNZ;OV$B2.I!F08V)NX6Y?5'ON[?^A
MJ1/6,>*5*V+OVJ)-T96<SF V#8YASK^BK/YUQ1S[U2K0?C*;G!L HYU4C*%=
MAX!-65R@HQ9%&L@/_]$;L)OO?@@HW4J.R0O<&+$2ML-MS,%W9781?FNT)IQJ
MU\A3+T@*9(H! M@%%-!N->UH"&HDLE\%O3<TIE98^\Q'US;WT([ E&2QWF5Q
MRQ4[ ?BZS9K IJM8/DQ IG--(/LXY/RB?M;[&],D_C.FY,;ICR45!%4-.OY2
MFS7@_LQ@+(NU;7U][@YJ_0HY,45SX4=1&15(U=YO]Q5PP$$8X&V3I,GU6(*>
M.H1?VI=28P#JQ G<]4:%>[&+)7"+SQ,OZ)/]SR'GHP\TF[1ZQY#/MX!?5<M;
M,!9R:U*;;A7!(+PC]&!9;51AXH\QX2RS!@#-I)W]LO8%%'T;Q4WQ>%E$DGZO
MO&CI2UD45 _#X&*R; *%[4H3-L4GS5<$*FRI4K7[L4T^ RTM9T'<3:ZGN\,K
M4E00J<J%%A0+T@SF?#=#V-;IPKB5A]/'4EM>7IDK)E(OW?P.BG5^HZ+5.S=H
M).Z$W5<:ZDVW^!4P.>@98?SL#/G>&F$^5LI5D*=)HVBLCP=+^M);!X2]"M*'
MM^%)=2XX8B+.E;IM**\52F)UWHFOH@&JJ=/DQ.2NKT9.8O[RPX8FDWN;:ELX
MS3VR!)6+)7H=3BAH45[T>'O4OOO@;"TNS8#ZN>P0 !+:.01\9B6)2?F5R-4>
M-%+M)^\? JX7%2K'@+.IQL04BK0,/\MNJAM*/KM%AHR]S]>1\MV][HJX9TRS
M&I(&LI;OP/E=%N]2='HS;)-X<%0:F).;!#T]!)#))-1!J"C5NGE!;08>#%O;
MOWQOAU<K+#_I6T)/$8./3<*W!Z?%-BIRV%:UR*;IJ9W=7)=;$#.Q'_'*):D:
MI_-1<ICO'O"BZ2/<18.Q7U!_\3.)KFU]@',J]I]=C!ZWN ?=OF-E#/3+LYE#
MR0=(2_RA"M;:E>M'/>7L;A.0HS;J_898S5M$KE#J16AZNY^1(J]5O8^]O> ]
M#1[]D[YK6V5 LL51\9KLM$, =>_>/@7,2'#GF#=7N/0V<PL%B=\M9XRZ"E51
MN;IUI:>N]*:4?/W.4T\-F!AMHP1U35.?.A\"]A>NP/'/:8@RQ/_H0@)Q8$"S
M-OM'X3.X&1]X!3=P=PM4#T_=L>0@(BC2+'Q'E%%PFL4I B36J;@=P4*:0;SY
M%E["C=K=9Z&D4T*I38_A\^/46:K]Q%O3-CBQ#G;T;ZID&E(^:@1S/[HZ!,R]
MA1>3^W=W@91TFIG/M;?QZA" ,-Q/V45X/VC\K\[Z?W<F\T]=B[7]U5DPK3/4
M/ T1L&RH+1U)#)C*Q17=3?F&.03L##Z@S3/V2"'(00X!.!WPGU/[<C0UX-)W
M!FH F$A[XJM]M'WTAH8[GY/'#P'?_M/L:+(B":$<A%+UJ+</ 58?@1NK\%#:
M0-UH*N3*7XOY>_TN'P*"VZ?A>SQKAX"UO'QJ,0$UOPQ:=UL'_FV"%-"W_8H
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M?>AT9ZFW]!8KWSP>/Q/[X3*]9-8 Z= SU1V4SU2\O#*)TZ.=BM6/I<N:^KX
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ML_Y:RH[L3YHI=+(&;/B0*DX[B)R-_DR@HK,R/N'TXR@8KX+]$/!S4685U8-
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MID3^!-<S*_G.!5N/,/M-_7(YY4M[?_B=K)1Z:YY44/22@2OY[EMEGBZP\B&
M-T^M?J?B:::=R9D\@2'316CUE:]O)Y3SO0J^7/F@3&%9EU\$$RBFNR,2!=B
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M"3W2.R34 "DG[/;LO9_W>\]W7><Z/_*#E5G&N,<][CGF8JV9C<,8@CSQO7@
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M,VT81]D^?\C*R4=>IN1QQ1]/1I\H\,AW9$3@L]S%R #- 3C!"9VHCB\E&B[
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M5W?+' /W/6],T NQ'J:\Y4F+F<W@4C@31'X0'BYWTS7=Q*OKR,/:+<S1@6M
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M.$APIS_:0Q#,_':+H^)WM6?.X=0$:)6V!.K9GPGJQ3\RB)\;[U?-<\SUZPV
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M/YU*11T[%78 N?FG%S6_1/UA%]W@G'B'P^UFG?$Q$YM;&I0BG:4SO*'BQ/9
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M9$"F*$%J,2AD"N^.NP_;T*D"==8VZZZP"<YOXKUHWK(@F\F ,/PN&?!6<6D
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M@;(="QF0PMR2\#N"\[UX>] E2BK"C^L<ISQ7RB#+JNMYR(#>M5F<+W; G@S
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M)BRY;#; RZBF96(;:IA+/5056.R2))S.Z+;WC87Y5MG-NY2C703J#5YZS 4
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MH_3\V[Y13ESE4X<J[Y?QD,]68G/?F"CXXJF$>B90.OB0901=WBO"S9Y<HH.
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MUH1T]M\W64V3]]R#)OP*S-U/OCY*C'A@;T(I<AJD8J.FQEY@ZQ.](E( >G_
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M&MN-"B[%O;7[Z9OF<EAKMV"W0>?PK ,A1@X@WJC.(:0L%E)+W'9.OS\2P=D
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M7+6QEC7Q=JV\\K.E[Y59GQ)>$O>E(J/1<LNMW,[.=M8^RN ]SW!F&H=UY+)
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M-K?@OW0-UPCX+\-?]S<DBT%D_U&^$3#@RGF)8CQA_9!;[FM=N1?3Y/P\I"<
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M??TK^3;7X_R(;D,5O6-&]OT"_3 D<A*B.AJ?O^(C:JEGW^LHR'IUV2_!/R)
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MMKW&F#;:V4:Y0# 08GH^*B^3:\*0FJ-%GGP]WX34ZUD]T(>*3$^9AKBKV/6
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MFVRZ4G^VY#>D/Q?SJ $.M;?WOI$'&PPQ3AC":B5_V39\NW&UX'@V$D;,X#]
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M^_H'(G5J/W>N$Z:X&&E6=?W" FZF14PN^M5?#86(],H<0=J*\WX @?:&Q27
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M0"'RB<Q[<[P=7&9V@A70<T%%-2+Q237R HM!N-S<H;)Y;Y&-AAN*21:U_E*
M!E5DC*]O7]O6!*DT)E'0;6;:K.UO19KO&TD97L/PP5NH9V_J'CK;^B;O]&AD
M9@[*^7JV)-=S$WG_</ ?2 <$<I>XIR?;IDX1X\P&>;]C_!N?1>[^TMM^.RM3
MY>XDS%30S3,7%#$\73K1^ZI%-[X+IB"'/S(\C[6Q0H$\G]KQGEKW)/_5EA%T
M'1OV@K51^0T<"!Y?1*?#]A(/F13[(T"/PY?@(31/-W^J47"$3^V% 45&Q(L=
MDR+SB\[7C!! T4O+J=N@O9*)J2T#""N#CJS[C256JC:_C&HU)&O6-3S?@!]4
M>Q7B@\C$LYA!??TL>)FKP,:)JS[W$9CDG-4<D%:< +<:\0O(\8G*M*%8+<;
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M%.&2IW:5PF K4/?]E.^$?4U4(;Q/,_R56?IN'4TB8<PL*$$V&<WS-2:%9$*
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M,>4]5GG8LB3(V$SZ:VNZ]W1*J&SX4H7P^'SP@VW7PJ^3%L8_Q<GVE.F824N
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MQ1^J"G$PF47C62I3SZ$=\>WD=G)P=S..8*QQJ>&X(]P&QQ4YZ@.3/Z)0\,6
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M1J K'A T<V1GA6+RCE5O_06D3K%%5VX3_D-C,#Z)=O%CK'.4ZK7LT[XI I0
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M6$$F$#\HKWTC![09)O46(C*\(R:OB"\CQ-3[9(U^%-2Z%]UJGYMAP(NM-/Q
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M?MV973W&74?CTWM^6;9,C*@Y%9N?7-HONOVZ. 0OMJ/V:>7V#X_:-Q>OC\>
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M6GNW((771?D\.4"L =T[JG@AK%Z;2PC9*-(9\7EWQQ[,M*QM0I$>1U9#DV1
M$;X*MN$NJIN4)09-CON-EF:X\P24X?3;RTMV^?I)Q@PJ66.^1+,=HR)QXN'2
M#? B4.58\ &?T]'6F)2+/M=A#X@;(\TIZ!_QKDP,.<"*E_>)-R<''+)5!;5
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MLBNO_4OMP)I_O"]L>T/SR+,A0L7?W2MO L>X^!COE[*!PD-1>FG0FKO4JI]
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M\3 =F/1JO50<W")CK\,;/Y8HH&L^@6#%*(#BK\/%M5UYMUP%FM(-OAQP\&>
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M?<P=P6&_-&8>&LW#\3:!KM7E=2AZS5_UY$J4+?03!B\KAKT3M< O#F&TYW-
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M;2+QE-R3Q8V0]A3(CY7A):(X:C5(8E)]$WW0*NU%ZR8FW%NQS0!]@QIUR>0
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MOY,D85]*<%XCMQJ'_VS21>:?=+Q3J<.+[,>TF<7<_DI#';IC7X)IFY[4GJ6
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M [6J!S^;9);W8KWJ#]Y4@"_VUN;#M_0G@5T(!2"E$F)YJTH06>C9!IV%B&R
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M)?4R=M=M ;9!N@^S 78*'%<KG')2K$)T=VK*X*7QI23N]\%^RP,?>)%!2-/
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ML3/+@>9$-&RL :XS&4H9'[?1?;"2?^KQ:R!?&M*4;?=GIG"3YM6YV2BC5CV
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M0HI=;_9F71VEW^0T^C'59C5\A=NZ;48:7^0X<LUT[^OTU?=<:5KK!"98L4*
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M[YC,GO:KT&F'[NB)0=QIL0JSKNHZ#)T'QYU__Y:[AA[$89_5L4]ZYV*[>BF
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MUO3G/?[32_GH5].EF<7&^/C:TZUYR\#<^]H(J$0_X> DVK7Q5;9Z8G*LL'M
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M<7X.&#T$S9E=.RG;(T;OF[&^7$E &!;7H6E=*>T/R[Z<>6C^06F<3D64!0C
MJDJM9V&WSJ:HCX/.T"7)0^.!TV^PX(#!U=>$Q.0]$+/"[E=_AC621-8M?X.[
M<--/ _@;@,C"->/"!OE9([E[Q[HI\1/7F0SW@NO2%IUI.])VE%MZ'Y=!GF.%
MDL&;;?5PM$_\W-F,P(\KU.9'2?Q00SQ[7C1EW&G0PVK W2^./!CX8:K@AX0?
M/+X7YYE;8<XQ!2CQ\+-XXS'#WK3Q9IMVO>H9_%*'=9'-IXKQ41H4MJ1S[19M
M5[;,C"5+@8&I(;/"VE7^* &C.VR]A^^I*IU^[0*MJY"AESNT*4IW12IH Y#R
MR!]SD!U^QZ^NX8YHMQ#,^N$XL=D0Z$$2\%5<UE 3].5,](L&1J9,>*;4HDWQ
M+F R[IP+3W9I2F<2;_##ZA])5Q,,>TE74=9DPRER<> 1R^]YL=Z4"@AS^,VC
M#8 Y:XJEFF4OL-\XA)^Y6S?<!Q%PA2/=!T<'JA77_X!OF2GP/4^(+(U)9C6)
M39>1I1\\ZX.D8)Q>A*S@5^;'EL$BO]H]EK0E)66Y<I*GDC"4EB.3?<F0(@U
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M"TZF]-4Q>]6!Z@F)(V>MY?J%29+TSN+^FIK4X4NU#4/V95.,?0G !4E&UP;
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M 9*][JH /\9)JD"#CJ>;6TJ+8<*%AW :1D\/!"3,)5X1EB:@/6(KNY[4?&A
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MW/(%_I6X^?R1.\$'7Q(;'0JN]S\9P4<4IO_X?[[$^S^^K<--?Q3+<TR*!BE
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MV\/<(\%GR6$%P*;*T!#5&?LZ^'H$!#'.A[SP=XJN/ N,?-Z2FOR@) ]J0VN
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M68=LCH[<R-V(H_,=*--=DP>P4R]P-;XP3]+-% L^^_%FR1O9'8FVCP%3" K
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MK_6M(3?,E(SQ=WE61[@V++,R=3,:AS 93:<C>*64_3+JZ8N6&S1S(,=I-?-
MB_Y=-CC[%+3)IQGDS&.,, 4)!O' Y:X,+6J[TW71BC;;A\O[L9LBRU,G&@O:
MHYYG:R(0DZV)Y>#<XI)?0=H!HI+2D+'I[J(660E5F0=2AE:)1D8'&^!()DH4
MGQ!9#2H4./?5%XI1&BK\ TL;6C")O)?S\WO/H\^A)S?='PY]N=1O$3I>FCDS
ML>W+J@9:W,Y(1!6Z]V&4=G3"7^JGJU9/O ZEC0^N [BB[<XI^;6.C=KCWX1U
MG*U?\P?9H<LC4:,:DT':3&*HNVX=H$B7)8G>H]RGC<U[%<N[ V,ZAT+",MR@
M$_5-KH\C/.L-TR#!:50AM%UIYT7XJW$=0"PC[U_JVG^55NY20-Z.E[D+:Q57
MVW&K),)JX#V+F=IIXQ!8QMUO"6\X24;9I@J1W49.96Z4@(K*GV&,A:X#+M;^
M3MB^VG!Y@#,_#":#2JT6LYZ\2VT^D.DB$%ZKTS:Y\ZBV[]J5MLH])*[ZX>*:
M<_QN>X_9R.%%ISV6^?R,RP_VN5Q[6\>B4VK7 3=<,P\\K\XHZ9I,[R(>B^CT
M-?X[[)U9D^D3@MPM#!R^S$!*U9ITS#_ 6^CK84 CSX"ZA=G0<3CYU(@3&;E-
M(/0TOV%]?0-)EA.J-\70_Q-6L-PX1=.3]/&<XR<QQGO.?2'][6E;H0UD<)Y1
M1F2K-!"7M!@>&G%6T$#7CRSYKP/2#M-R(L:3&@4$-QAEZ5]R")8^;9FM6@6S
MT#<DKJ"9E# <BG;QS ]P2'[+;/XG)$XL4.:&B.?-XQO4,2.9F,7Q@9 YIDEK
MP[: W,94%C%3DL)JB&8=<^4-#($4=W++U4.HT5O7;$FL96DM^1##:>XE5U>\
MZAA9ORA9W1Q]>B<PN2B"T3=& ]XIGU &Z#G5&G(,6[F;^V7OC7-7KMA9]MP=
MV%26673P,;;H%(\8<U1^MJM7/I&!&/<9<2XZN BQ6&-;A(-T\F1L7)\L'XE?
MIK[3R28;+QX362SP<'F$D_AH^GE<-!DG^:X@\2^I*3SL&R0NJ]B S.F&EOA8
MJXA*>4D':[A?L(-);MGA?4<R2&]*QO-2*9Q5O ;/K>RXR_NA.AY$_)44PDXP
MQ8QX!J$(M@.:=0"C>)P[!]U^2<^BP4]"<(O.U2X'(V,CK>%!V$G;4S.G00>V
M](L$(N6\X$!'?LEI1G-V#CEF;,;R48=YI'GVB\.4G#AX/?-6^,#)KG7 ]ZN"
M3>$0Q'1,8FQ'"S8;9(ZUS0Q37B=W&DAG--/J'X+SA-YK=81[?.J#%GQ!5^=Y
MHN,"LS,[CN-?A]"/X.)Y3+HY%T6B:X^M PKAMOZB!-3@6KM$<X2_<WBS%.-?
M1HCXT@2F->'-BFM'SEE*_W.#]W\X2N<2C[W?- #\_UY%)Y4"XV7JHR(>2/\Z
MRUW_9_@0#/+7X!1IJ7<=X)?[Q.]@A=>A3=9MI.<USRZV#_Z@H@4LG2K45=<>
MJ?=. G?OM*>+B_E)=LYIC47M&$O5B:X>WJ%A6:<X0@R^'T>!-W?9N7U*G7!3
MZ)VQM9$FUTQRWN>8;.>R$*[V;QO[H73JL/A2GA_"0GB04%C,2TE@BFK#IZEW
MMW%WG:HRB>!DOAH66UT,*_YH@ 4K&M_A=\+='!D[O"''Y//F;_9^HI<%*39F
M7FH[)JB7,D9WN.O(&J'(\>*V?RN.9.1-S9$M/[MD-I1'UCO.'E)@S4,F.OI$
MW7OFUIQ$T_K58T$K7P7LFZ;@O4LO\AHZ%=3K@Q[^CGL3_VC)1<:1\R+Y*E.>
MTSI @DEK=6:XJZ)>O^:)JSL>S3YTMN/9IQ\YTK=<U]VBS\*\&%PV\/J3T2#]
MUZJT$P^H'N4\%^DPSW%<VE@.H[2#,S>*2O87G>8!.[K3X75CS*_J$8ZK/2.(
MREOGF.,$,)7V\K%CO-.8S_+M.I8R!O*VCZ49KTXR9SR#/%;\>RF+]^ZZ<?<J
MN^,X[.K,J_B]@:)U0&V H="O8](ZV(%O%I ?\P4YO(VZL3)E$U]PJ$#UH"T<
M.CG'OK@.>%TWO(\\TM#@[&I_%,D9M6WS>_1!;43V#@^+(61?TXXP]J@2$R<%
M&Y7'"\_1VY:T':BH9 M4L\$#=?K7U_>)LJ\CUP'ODZ(/?=G=WV T3<FMXR8R
MT)1*9)T A$2D3%^P+;'(3B^%(K4K_)U,H.YP4B4QY[W';O)M<VSW\V88/EAI
M41$ V_&!=6"0["-33AE,[13.0V^E<BU775.,R9U2'?W7QA(J'T[II_OACUXY
M=@81<%+K0&?MYGRWI'HK .K(CT'@01O]B\3DL87$^.R?L9:P#)N5BY10OK[&
MS5L_HS:?4?LF)GG]E;M?-3L9X0H"V9;,'R)]<SJ%(BW?88?+C=/;I,>$8@0:
MVIV(]SE'/N_9._(%;'F&[-8Q^DP3O2?N0=.4,3\L;&+C")P<T_4Q[4:5B"^(
MFIB__^=KRLH)Y;&Q%)^4_.N'9>KM"NT#YE5W!#^L,6?K9Z7YGA]B4VORH=L<
M8(D)!W3#?S&FF_BT*P:1B</($<_M'",VD]<!^26;[G2>6G.K4(:E&\$=.2 ;
MFOIP?5!F<QU0[M%3/UJ8*9>=*/0I61[CG\?J8L[@0&AO:"OBC!EZD;DRV)>"
M%DEB9:A6"?1C_+W.DU/$!H0"[1.8LG(,7,^_*+ A\E@#@@\)?*F4WW[2,;!6
MN_/]:J1-AI0,.2P1"Q')C4U.PTF4>L)A:M^0#V')9L*-;,\A2S? 9 \:*N:$
M1HP.CA.B?-P%-Q(?<-BM#?M5D\\ZP(XDA JINI40MN8WE9-1[1\6MSDG=V[S
M$'1_[7)80M6<M':7NQ>OA I@DTY/B8E1!P@;7Q 33YYN@7N,91N5-JN_N_^@
M?J"!)O95TY-N8P!:5R-1=[+3XA<^ZS(%[2%$8^<Z;.YWH&C*Y'-M JJ*(IUY
M ME$?]T?IY1LG@QPZVXD;7T!W^]N\LKKR=A9ZO>90?NEBP3!<EP>5 G!Y(OK
M\86%"[ :55YB\@^)'>>'*^M!WS1<K=T?!DV\?(,QB]',4%.9-RTVTC&IV8K\
M!7NN-( %B?K]^=+82U['WE1XW= K<V#V-6F8 ?N3@-]Z HF"Z&BVZ:LC+,_^
M7+?1_C%F'$9[Y^SAJJ]4X"DL;HI]V=&ICQ_T\$MD=[H'&TF&/VAR(.Z@*BD>
MZX 6_9C4CMS; ]\XDA3L1:EV< NW[G;:UUQ<3FM?Z2RTWM1C@W$73^M(4HI5
M%>K <.O@]W-1K*2L2DG/4P1649M^^/"SY<YRD9T]BJ4]1D&H#9OQK$UE7S&!
MIIN'C#V_.3\G^TC-6U%&H:=!L^1N)FN9B6]GH-^M=$AXBT\2S'>M XRZNC;.
M])E:/$W4OCB"O@NAY,"[_B$DK /*,/2"84*@="6\$RB'_28_ L;[.6F)^)EA
M254)=\@6%TM]IQ^4$F2A:.#'P7MP^.P#^B([]<?-5QVH&\K"\Z3@!HE^F&4O
M7=600QF;YZP0'0Q(;%1 </;;1MPY<''DLX0'>-.-['JW +NXT:?%>J6@8CJ
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M<HR.?V?&\:OO0SR6,&%8WL"O6 GB8L3?APMIU$N_-]!40!HX9K,*[GYC=5?
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MU[WY&8\__EX&I(TBM9%7XS)K8SX#N=N-7,L./L.QV] ?!"N-W%@H7G-/,[*
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M4>6=M& 5KJZJ^*H7)=>K\U%TA:73QV*J016DE:-EQ3E2L6X*)>HZ3PXL.))
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M]Y[=<@J*2DI*.V65]^Y1W"NOJ*3X\R(;-DG.V;QE^Y8MVQ5EI&44_V\?X@\
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M(P^+=%=DF@Y8>3%U;TVDR64=F_C+E:O$ *T(B?Y?O/)7+/PI6S^Q_.+/E(8
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M%<K[KGO($4PI4!<8>B=2\S7/=[SI#BIN.1JXRY'8V7VU(M' G[Y*.*\,OU[
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M_N$QQ.00M^#6NIZ2%*_A/C]N+:ESE;QV*!H403>7;J:ZIX_I+5 I#GT&+.#
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MK3 VIE:>$P/,_<0 TI;+T-TP5(,8D)CQ:K%HT5^X+L )^Z<6HEW&^N9TCK_
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M,';E%.WH&ECX>@G('G K@7,]6\BY)9TR JG"=W;[4,<\VW*M5-LLIRDJR]K
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MT;U"X,A6:#S-&NTMNR$;A^]5)_;7G[9L#<>*>H 4"3U7Z-;QP=+,&",>I'7
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M-D]!\F#9PU<DU,>FQ8C +F/NG N.2E^N^7U -UH[40SZ<VH>*_@3^#[;YV"
MOYQ"O%/F9VGVY/<K'0TNM^"?\[V$S)D,>GEPPHFR:]\/4[^TG??TF(R'E)/
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M3]B@)LAZW7%6<R#94!M52VZQLQ>#_H[Z$[F%-V7-%J4B0V-^D.+MAO>AL/)
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MA5K>2W962]U OX2RA%:G^T1T?+I$/2*1XJ0(X.]YM0?P[7KH,SQ\Z%/D1&^
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M,K-^\#%,XTZ/P]W1(5V(C@/83+[??O!^%BEMG"PSM[$GKK#I@Y]RJ#02X1=
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MJ7C*AN*^$J7O'QY;%DZ3*0C#I.KU.4WL2-'<()Y]_>I55=(P<\*</GB:@([
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MD>+ECW!.HGTFAK36%E@.GNX[5D5>;3 ("^>AEOD;-@ZT\>W.+.#'W5&9%"U
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M6ZF6),&^NM+AP!.5<BO-+.7\T&++MT2475 KR1#,$EC 4A_!X?%F7%@X5F
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M?.[3-O ^>"B9*\$B,:JO(K=J[%4F!W37W4W[D/<+*E57K8N)'9H^M:A;+2*
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M2P$"% ,4    " #*@S!;V8M],UD3  #^[   $0              @ $
M8V1I;RTR,#(U,#8S,"YX<V102P$"% ,4    " #*@S!;LOK +P41  "AWP
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M,#(U,#8S,%]P<F4N>&UL4$L! A0#%     @ RH,P6U&'Q+2CJ00 'PDF  X
M             ( !/! ! &-D:6]?<&]S86TN:'1M4$L! A0#%     @ RH,P
M6S9B^EW= @  G@D   H              ( !"[H% &5X,C-X,2YH=&U02P$"
M% ,4    " #*@S!;18B7R$A;   [7@  #0              @ $0O04 :6UA
M9V5?,# X+FIP9U!+ 0(4 Q0    ( ,J#,%LP>$_X%5,  #E=   -
M      "  8,8!@!I;6%G95\P,#DN:G!G4$L! A0#%     @ RH,P6YDG9Y!B
M>   6ID   T              ( !PVL& &EM86=E7S Q,"YJ<&=02P$"% ,4
M    " #*@S!;1X\[)'5V 0!(D $ #0              @ %0Y 8 :6UA9V5?
M,#$Q+FIP9U!+ 0(4 Q0    ( ,J#,%M6L0;FS,(  /':   -
M  "  ?!:" !I;6%G95\P,3(N:G!G4$L! A0#%     @ RH,P6S IE,;B- $
MKD4!  T              ( !YQT) &EM86=E7S Q,RYJ<&=02P$"% ,4
M" #*@S!;"K^"9M*^  !VU@  #0              @ 'T4@H :6UA9V5?,#$T
:+FIP9U!+!08     #@ . %P#  #Q$0L    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>cdio_posam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdio="http://cdio.ai/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdio-20250630.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012022-10-25_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-25_custom_TwoInvestmentBankersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TwoInvestmentBankersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="AsOf2023-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cdio:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-08-022023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ChicagoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">cdio:ChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdio:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2023-10-25</instant>
        </period>
    </context>
    <context id="AsOf2024-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-10-25</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2025-10-25</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LegacyCardioStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cdio:LegacyCardioStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LegacyCardioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:LegacyCardioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LegacyCardioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:LegacyCardioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ManasFormerOfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:ManasFormerOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Plan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:Plan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-23_custom_Plan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:Plan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:AltitudeCapitalGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:CraigHallumCapitalGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cdio:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2022-05-23</instant>
        </period>
    </context>
    <context id="From2023-06-012023-06-23_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-23_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionsMember51358140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-23_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOption1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_N2022PlanMember_custom_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOption1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockOptionsMember51358187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-11-14_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsMember51358218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-23_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:SevenAccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cdio:AltitudeCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:AtTheMarketIssuanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:AtTheMarketIssuanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-23_custom_N2022PlanMember_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_StockOptionsMember_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StockOptionsMember_custom_N2022PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdio:N2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_StockOptionsMember51358328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdio:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="From2023-03-072023-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:YorkvilleConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cdio:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_stpr_IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_stpr_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TheBenchmarkCompanyLLCRightOfFirstRefusalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TheBenchmarkCompanyLLCRightOfFirstRefusalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdio:NorthlandSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_TheBenchmarkCompanyLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdio:TheBenchmarkCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-02-012025-02-07_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-20_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-20</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:ImpactOfReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_AsRevisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">cdio:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdio:ProductTestSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_ReportableSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001870144</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdio:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-06-30" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-06-30" id="Fact000004">0001870144</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0010">POS AM</dei:DocumentType>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:ChangeInFairValueOfDerivativeLiability
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:WarrantsConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:PlacementAgentFees
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:PlacementAgentFees
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:NotesPayableConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CommonStockAndWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:PlacementAgentFees
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:PlacementAgentFees
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:NoncashInterestExpense
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:ChangeInFairValueOfDerivativeLiabilities
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:PaymentsForRightOfUseAsset
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:DebtDiscountRelatedToDerivativeLiability
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:NotePayableConvertedToCommonStock
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:AdjustmentToLiabilitiesAssumedInAcquisition
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RightOfUseAssetAddedToOperatingLease
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:DerivativeLiabilitiesIssued
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:DerivativeLiabilitiesConverted
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:ChangeInFairValueRecognizedInOperations
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0999"
      unitRef="Ratio"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl1285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl1287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1341"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1346"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1353"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1359"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1370"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1372"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1377"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1379"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:FractionalSharesAdjustment
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:FractionalSharesAdjustment
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1383"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:FractionalSharesAdjustment
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:FractionalSharesAdjustment
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl1385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1410"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1415"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1417"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1422"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1441"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1446"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1448"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1453"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      id="xdx2ixbrl1639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      id="xdx2ixbrl1669"
      unitRef="USD"
      xsi:nil="true"/>
    <cdio:WarrantsCancelled
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl1800"
      unitRef="Shares"
      xsi:nil="true"/>
    <cdio:WeightedAverageExercisePriceCancelled
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl1802"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cdio:WarrantsCancelled
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      id="xdx2ixbrl1804"
      unitRef="Shares"
      xsi:nil="true"/>
    <cdio:WeightedAverageExercisePriceCancelled
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      id="xdx2ixbrl1806"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cdio:WarrantsCancelled
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      id="xdx2ixbrl1808"
      unitRef="Shares"
      xsi:nil="true"/>
    <cdio:WeightedAverageExercisePriceCancelled
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      id="xdx2ixbrl1810"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      id="xdx2ixbrl1859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl2076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl2322"
      unitRef="Shares"
      xsi:nil="true"/>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl2324"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-06-30" id="Fact000011">CARDIO DIAGNOSTICS HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-06-30" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="From2025-01-01to2025-06-30" id="Fact000013">6770</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-06-30" id="Fact000014">87-0925574</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-06-30" id="Fact000015">311 West Superior Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-06-30" id="Fact000016">Suite 444</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-06-30" id="Fact000017">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-06-30" id="Fact000018">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-06-30" id="Fact000019">60654</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-06-30" id="Fact000020">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-06-30" id="Fact000021">226-9991</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000022">Meeshanthini V. Dogan, Ph.D.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000023">311 West Superior Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000024">Suite 444</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000025">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000026">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000027">60654</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000028">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-01-012025-06-30_dei_BusinessContactMember"
      id="Fact000029">226-9991</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-06-30" id="Fact000030">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-06-30" id="Fact000031">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-06-30" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-06-30" id="Fact000033">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="From2025-01-01to2025-06-30" id="Fact000034">This Post-Effective
Amendment No. 1 (this &#x201c;Post-Effective Amendment&#x201d;) to the Registration Statement on Form S-1 (File No. 333-283419) of
Cardio Diagnostics Holdings, Inc. (the &#x201c;Company,&#x201d; &#x201c;Cardio,&#x201d; &#x201c;we,&#x201d; or &#x201c;us&#x201d;), which
was originally declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on December 3, 2024 (the
&#x201c;Original Registration Statement&#x201d;) is being filed to update the Original Registration Statement and the Prospectus
contained therein with information from the registrant&#x2019;s Annual Report on Form 10-K for the year ended&#160;December 31, 2024,
which was filed with the SEC on March 20, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025, which was
filed on August&#160;14, 2025, and to update certain other information in the Original Registration Statement. Unless otherwise
noted, all of the share and price per share information in this Post- Effective Amendment has been adjusted to reflect the 1-for-30
reverse stock split implemented by the Company on May 12, 2025. The audited financial statements included herein have not been
adjusted for the reverse stock split. Certain pre-reverse stock split information included in the Form 10-Q for the period ended
June 30, 2025 has been omitted in this Post-Effective Amendment.

&#160;

This Post-Effective Amendment contains an updated
prospectus (the &#x201c;Prospectus&#x201d;) relating to the offer and sale of the securities registered by the Original Registration Statement.
No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time
of the initial filing of the Original Registration Statement on November 22, 2024.
</dei:AmendmentDescription>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">7827487</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">1283523</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">18612</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">4960</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">944683</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">1477197</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">8790782</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">2765680</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">672861</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">571873</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">432397</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">575227</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">5333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">21333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">12850</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">12850</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">701089</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">515402</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">10615312</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">4462365</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">87661</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">243213</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">237270</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">223929</us-gaap:OperatingLeaseLiabilityCurrent>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">306764</cdio:FinanceAgreementPayable>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">374000</cdio:FinanceAgreementPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">631695</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">841142</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">425829</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">663099</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">1057524</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">1504241</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000108"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000110"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000116"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000124"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000126"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">20540409</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">20540409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">205</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">17326299</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">-22751833</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">-14368380</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">9557788</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">2958124</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">10615312</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">4462365</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">34890</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">17065</us-gaap:Revenues>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">182446</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">158514</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">29125</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">145182</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">8169458</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">6936646</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">19738</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">19182</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">8400767</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">7259524</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">-8365877</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">-7242459</us-gaap:OperatingIncomeLoss>
    <cdio:ChangeInFairValueOfDerivativeLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">5406220</cdio:ChangeInFairValueOfDerivativeLiability>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">1064</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">1068</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">18640</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">6735013</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">193350</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-17576</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-1134375</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-8383453</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-8376834</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-8383453</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-8376834</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="USDPShares">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000206"
      unitRef="USDPShares">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000208"
      unitRef="USDPShares">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">26892705</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">26892705</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">12685133</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">12685133</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000223"
      unitRef="Shares">9514743</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000218"
      unitRef="USD">95</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000219"
      unitRef="USD">10293159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-5991546</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">4301708</us-gaap:StockholdersEquity>
    <cdio:WarrantsConvertedToCommonStockShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">100000</cdio:WarrantsConvertedToCommonStockShares>
    <cdio:WarrantsConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000225"
      unitRef="USD">1</cdio:WarrantsConvertedToCommonStock>
    <cdio:WarrantsConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000226"
      unitRef="USD">389999</cdio:WarrantsConvertedToCommonStock>
    <cdio:WarrantsConvertedToCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">390000</cdio:WarrantsConvertedToCommonStock>
    <cdio:PlacementAgentFees
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000233"
      unitRef="USD">-315000</cdio:PlacementAgentFees>
    <cdio:PlacementAgentFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-315000</cdio:PlacementAgentFees>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">303547</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">3</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">243997</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">244000</cdio:RestrictedStockAwardsVested>
    <cdio:NotesPayableConvertedToCommonStockShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">10622119</cdio:NotesPayableConvertedToCommonStockShares>
    <cdio:NotesPayableConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">106</cdio:NotesPayableConvertedToCommonStock>
    <cdio:NotesPayableConvertedToCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">5604846</cdio:NotesPayableConvertedToCommonStock>
    <cdio:NotesPayableConvertedToCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">5604952</cdio:NotesPayableConvertedToCommonStock>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">1035273</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">1035273</cdio:CompensationForVestedStockOptions>
    <cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">74025</cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana>
    <cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">74025</cdio:AdjustmentToLiabilitiesAssumedInMergerWithMana>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-8376834</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-8376834</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">20540409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">205</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">17326299</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-14368380</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">2958124</us-gaap:StockholdersEquity>
    <cdio:CommonStockAndWarrantsIssuedForCashShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">25319850</cdio:CommonStockAndWarrantsIssuedForCashShares>
    <cdio:CommonStockAndWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">253</cdio:CommonStockAndWarrantsIssuedForCash>
    <cdio:CommonStockAndWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">12546696</cdio:CommonStockAndWarrantsIssuedForCash>
    <cdio:CommonStockAndWarrantsIssuedForCash
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">12546949</cdio:CommonStockAndWarrantsIssuedForCash>
    <cdio:PlacementAgentFees
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-155000</cdio:PlacementAgentFees>
    <cdio:PlacementAgentFees
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">-155000</cdio:PlacementAgentFees>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">83780</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">1</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">75999</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">76000</cdio:RestrictedStockAwardsVested>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">2515168</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">2515168</cdio:CompensationForVestedStockOptions>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">-8383453</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-8383453</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">45944039</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">459</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">32309162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">-22751833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">9557788</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-8383453</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-8376834</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">113777</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">3790</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">162568</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">107830</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">2591168</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">1279273</us-gaap:ShareBasedCompensation>
    <cdio:NoncashInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">6704522</cdio:NoncashInterestExpense>
    <cdio:ChangeInFairValueOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">5406220</cdio:ChangeInFairValueOfDerivativeLiabilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">193350</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">13652</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">4960</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-915969</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-758669</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">7900</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-155552</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">-781500</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">-223929</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000352"
      unitRef="USD">244505</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-4993104</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-5672175</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000360"
      unitRef="USD">214765</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">575663</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cdio:PaymentsForRightOfUseAsset
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000364"
      unitRef="USD">21352</cdio:PaymentsForRightOfUseAsset>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">189425</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">197276</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-404190</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-794291</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">12546949</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <cdio:OriginalIssueDiscount
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">500000</cdio:OriginalIssueDiscount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000379"
      unitRef="USD">4500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">390000</us-gaap:ProceedsFromWarrantExercises>
    <cdio:PaymentsToAcquireFinanceReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000386"
      unitRef="USD">450691</cdio:PaymentsToAcquireFinanceReceivable>
    <cdio:PaymentsToAcquireFinanceReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">942532</cdio:PaymentsToAcquireFinanceReceivable>
    <cdio:PaymentsOfPlacementAgentFee
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">155000</cdio:PaymentsOfPlacementAgentFee>
    <cdio:PaymentsOfPlacementAgentFee
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">315000</cdio:PaymentsOfPlacementAgentFee>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">11941258</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">3632468</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">6543964</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-2833998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">1283523</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">4117521</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">7827487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000402"
      unitRef="USD">1283523</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">18640</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">30491</us-gaap:InterestPaidNet>
    <cdio:DebtDiscountRelatedToDerivativeLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">5000000</cdio:DebtDiscountRelatedToDerivativeLiability>
    <cdio:NotePayableConvertedToCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">5000000</cdio:NotePayableConvertedToCommonStock>
    <cdio:AdjustmentToLiabilitiesAssumedInAcquisition
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">74025</cdio:AdjustmentToLiabilitiesAssumedInAcquisition>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">383455</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">467500</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <cdio:RightOfUseAssetAddedToOperatingLease
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">642523</cdio:RightOfUseAssetAddedToOperatingLease>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000434">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zd6hdXQ8Jgsg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_827_z37jE7uRTpg9"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the &#x201c;Company&#x201d;) and its wholly-owned
subsidiary, Cardio Diagnostics, Inc. (&#x201c;Legacy Cardio&#x201d;). The Company was incorporated as Mana Capital Acquisition Corp. (&#x201c;Mana&#x201d;)
under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability
company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed
to develop and commercialize a patent-pending Artificial Intelligence (&#x201c;AI&#x201d;)-driven DNA biomarker testing technology (&#x201c;Core
Technology&#x201d;) for cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the
leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The
Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated
into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD),
stroke, heart failure and diabetes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Business
&lt;span style="letter-spacing: 0pt"&gt;Combination&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 27, 2022, Mana, Mana Merger Sub, Inc.
(&#x201c;Merger Sub&#x201d;), a wholly-owned direct subsidiary of Mana, Meeshanthini Dogan, the Shareholders&#x2019; Representative, and
Legacy Cardio entered into the Business Combination Agreement (the &#x201c;Merger Agreement&#x201d;). On October 25, 2022, pursuant to
the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana.
Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc.&lt;/p&gt;



</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cdio:MergerAgreementAndReverseRecapitalizationTextBlock contextRef="From2024-01-012024-12-31" id="Fact000436">&lt;p id="xdx_80B_ecustom--MergerAgreementAndReverseRecapitalizationTextBlock_zrZsdLZbQaM3" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Note
2 &#x2013; &lt;span id="xdx_829_zRZ5U0uGlsUb"&gt;Merger Agreement and Reverse Recapitalization&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;As
discussed in Note 1, on October 25, 2022, the Company (formerly known as Mana) and Legacy Cardio entered into the Merger Agreement, which
has been accounted for as a reverse recapitalization in accordance with GAAP. Pursuant to the Merger Agreement, the Company acquired
cash of $&lt;span id="xdx_903_eus-gaap--CashAcquiredFromAcquisition_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Cash Acquired from Acquisition"&gt;4,021&lt;/span&gt; and assumed liabilities of $&lt;span id="xdx_900_eus-gaap--LiabilitiesAssumed1_c20221001__20221025__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_pp0p0" title="Liabilities assumed"&gt;928,500&lt;/span&gt; from Mana. The liabilities assumed &lt;span style="letter-spacing: -0.25pt"&gt;of $&lt;span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionPayablesAssumed1_c20221001__20221025__us-gaap--BusinessAcquisitionAxis__custom--TwoInvestmentBankersMember_pp0p0" title="Liabilities assumed payable"&gt;928,500&lt;/span&gt;
were payable to two investment bankers and due on October 25, 2023. The assumed liabilities decreased to $&lt;span id="xdx_90A_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zSaqstvLsjr6" title="Liabilities assumed"&gt;&lt;span id="xdx_908_eus-gaap--LiabilitiesAssumed1_pp0p0_c20230301__20230322_zV0xJXhRWKhi" title="Liabilities assumed"&gt;854,475&lt;/span&gt;&lt;/span&gt;, net of an early payment
discount of $&lt;span id="xdx_90A_ecustom--EarlyPaymentDiscount_c20230301__20230322_pp0p0" title="Early payment discount"&gt;74,025&lt;/span&gt; issued by one of the two investment bankers on March 22, 2023. On March 27, 2023, the Company accepted the early
payment discount and paid Ladenburg the net balance due and payable of $&lt;span id="xdx_902_eus-gaap--LoansPayable_c20230327_pp0p0" title="Loans payable"&gt;419,475&lt;/span&gt;. On October 24, 2023, the Company paid the remaining
post-merger liabilities balance of $&lt;span id="xdx_901_ecustom--PostmergerLiabilitiesBalance_c20231024_pp0p0" title="Post-merger liabilities balance"&gt;435,000&lt;/span&gt; to Benchmark.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Mana&#x2019;s
common stock had a redemption right in connection with the business combination. Mana&#x2019;s stockholders exercised their right to redeem
&lt;span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20240101__20241231_pdd" title="Stock redeemed shares"&gt;6,465,452&lt;/span&gt; shares of common stock, which constituted approximately &lt;span id="xdx_90E_eus-gaap--DebtInstrumentRedemptionPricePercentage_c20240101__20241231_pdd" title="Redemption percentage"&gt;99.5%&lt;/span&gt; of the shares with redemption rights, for cash at a redemption
price of approximately $&lt;span id="xdx_902_ecustom--RedemptionPricePerShre_c20241231_pdd" title="Redemption price per shre"&gt;10.10&lt;/span&gt; per share, for an aggregate redemption amount of $&lt;span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240101__20241231_pp0p0" title="Redemption amount"&gt;65,310,892&lt;/span&gt;. In accounting for the reverse recapitalization,
the Company&#x2019;s legacy issued and outstanding &lt;span id="xdx_904_ecustom--ReverseRecapitalizationShares_c20240101__20241231_pdd" title="Reverse recapitalization shares"&gt;1,976,749&lt;/span&gt; shares of common stock were reversed and the Mana shares of common stock
totaling &lt;span id="xdx_90E_ecustom--CommonSharesReversed_c20240101__20241231_pdd" title="Common shares reversed"&gt;9,514,743&lt;/span&gt; were recorded, as described in Note 10. Transactions costs incurred in connection with the recapitalization totaled
$&lt;span id="xdx_903_eus-gaap--RecapitalizationCosts_c20240101__20241231_pp0p0" title="Recapitalization cost"&gt;1,535,035&lt;/span&gt; and were recorded as a reduction to additional paid in &lt;span style="letter-spacing: 0pt"&gt;capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;As
additional consideration for the transaction, Cardio will issue to each holder who was entitled to merger consideration at the Closing,
its &lt;i&gt;pro rata &lt;/i&gt;proportion of up to 1,000,000 shares of our authorized but unissued common stock (the &#x201c;Earnout Shares&#x201d;
or &#x201c;Contingently Issuable Common Stock&#x201d;), if on or prior to the fourth anniversary of the Closing Date (the &#x201c;Earnout
Period&#x201d;), the VWAP of the Company&#x2019;s Common Stock equals or exceeds four different price triggers for 30 of any 40 consecutive
trading days, as follows: (i) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $12.50 per share for the
stated period; (ii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $15.00 per share for the stated &lt;span style="letter-spacing: 0pt"&gt;period;
(iii) one-quarter of the Earnout Shares will be issued if the VWAP equals or exceeds $17.50 for the stated period; and (iv) one-quarter
of the Earnout Shares will be issued if the VWAP equals or exceeds $20.00 for the stated period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In
evaluating the accounting treatment for the earnout, we have concluded that the earnout is not a liability under Accounting Standards
Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity, is not subject to the accounting guidance under ASC 718,
Compensation&#x2014;Stock Compensation, and is not subject to derivative accounting under ASC 815, Derivative and Hedging. As such, the
earnout is recognized in equity at fair value upon the closing of the Business Combination. As of the date of filing of this Annual Report
on Form 10-K, the Company&#x2019;s common stock did not trade at equal to or greater than $12.50 for a period of at least 30 trading days
out of 40 consecutive trading days and the Company has not issued any Earnout Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</cdio:MergerAgreementAndReverseRecapitalizationTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2022-10-012022-10-25_custom_MergerAgreementMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">4021</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2022-10-012022-10-25_custom_MergerAgreementMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">928500</us-gaap:LiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="From2022-10-012022-10-25_custom_TwoInvestmentBankersMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">928500</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2023-03-012023-03-22"
      decimals="0"
      id="Fact000444"
      unitRef="USD">854475</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2023-03-012023-03-22"
      decimals="0"
      id="Fact000446"
      unitRef="USD">854475</us-gaap:LiabilitiesAssumed1>
    <cdio:EarlyPaymentDiscount
      contextRef="From2023-03-012023-03-22"
      decimals="0"
      id="Fact000448"
      unitRef="USD">74025</cdio:EarlyPaymentDiscount>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-03-27"
      decimals="0"
      id="Fact000450"
      unitRef="USD">419475</us-gaap:LoansPayable>
    <cdio:PostmergerLiabilitiesBalance
      contextRef="AsOf2023-10-24"
      decimals="0"
      id="Fact000452"
      unitRef="USD">435000</cdio:PostmergerLiabilitiesBalance>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">6465452</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000456"
      unitRef="Ratio">0.995</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <cdio:RedemptionPricePerShre
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000458"
      unitRef="USDPShares">10.10</cdio:RedemptionPricePerShre>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">65310892</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <cdio:ReverseRecapitalizationShares
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000462"
      unitRef="Shares">1976749</cdio:ReverseRecapitalizationShares>
    <cdio:CommonSharesReversed
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000464"
      unitRef="Shares">9514743</cdio:CommonSharesReversed>
    <us-gaap:RecapitalizationCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">1535035</us-gaap:RecapitalizationCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-012024-12-31" id="Fact000468">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_z96x6CklUkj1" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Note
3 &#x2013; &lt;span id="xdx_821_zHEdPJSos6R"&gt;Summary of Significant Accounting &lt;span style="letter-spacing: 0pt"&gt;Policies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zDNg8b34BS05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zr8jCQLjXzu6"&gt;Principles
of &lt;span style="letter-spacing: 0pt"&gt;Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio. All intercompany
accounts and transactions have been &lt;span style="letter-spacing: 0pt"&gt;eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zLNQ2uKwnaZ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zS1mDvUJESNd"&gt;Use
of Estimates in the Preparation of Financial &lt;span style="letter-spacing: 0pt"&gt;Statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 1.25pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could
differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z91QthiMFmrj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zCxlZUH7zj8b"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
Company adopted the provisions of ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields
on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level
1 &#x2013; quoted prices in active markets for identical assets or &lt;span style="letter-spacing: 0pt"&gt;liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level
2 &#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level 3 &#x2013; inputs that
are unobservable (for example cash flow modeling inputs based on &lt;span style="letter-spacing: 0pt"&gt;assumptions)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level
3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for
the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains
and losses for the years ended December 31, 2024 and 2023.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&lt;span id="xdx_8B9_zQfF87metW1a" style="display: none"&gt;Schedule of fair value measurements&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Balance of derivative liabilities &#x2013; beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0479"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0481"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;Issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;9,192,672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Converted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;(3,786,452&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value recognized in operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;(5,406,220&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Balance of derivative liabilities &#x2013; end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zhAz12pT12J7" style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table represents the Company&#x2019;s
derivative instruments that are measured at fair value on a recurring basis as of December 31, 2024 and 2023, for each fair value hierarchy
level:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_zhbf4g3brmh7" style="display: none"&gt;Schedule of fair value hierarchy level&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0501"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Level II&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Level III&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0513"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level II&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level III&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0521"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zmS7sqkIBUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ConvertibleInstrumentsPolicyTextBlock_zTtsCCOGiFb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zY6ocY8PrD24"&gt;Convertible &lt;span style="letter-spacing: 0pt"&gt;Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company evaluates and accounts for conversion options
embedded in convertible instruments in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging &lt;span style="letter-spacing: 0pt"&gt;Activities.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Applicable GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes
in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument
would be considered a derivative &lt;span style="letter-spacing: 0pt"&gt;instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for
convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded
in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term
of the related debt to their stated date of redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z7k6YLTKgNKd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zGtXQv2t4pl4"&gt;Revenue &lt;span style="letter-spacing: 0pt"&gt;Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company offers its products, Epi+Gen CHD and PrecisionCHD, via telemedicine providers, provider organizations such as concierge practices,
longevity clinics, and risk-bearing provider organizations, and employer organizations. The Company is continuing to expand its markets
and payment optionality, and therefore, other organization types not listed below may be added, and from time-to-time, there may be additional
payment options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt; letter-spacing: 0pt"&gt;Telemedicine&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For telemedicine, the telemedicine
provider collects payments from patients upon completion of eligibility screening and test order. Patients then send their samples to
the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation and shares test
reports with the ordering healthcare provider. Revenue is recognized upon invoicing the telemedicine providers. Telemedicine providers
are invoiced at the end of each month for all tests completed since prior invoicing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 7.2pt"&gt;&lt;/td&gt;&lt;td style="width: 13.95pt"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;Provider organizations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For provider organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the provider organization type
and testing volume commitment. Upon ordering a test, a patient&#x2019;s sample is sent to the lab for biomarker assessments. The Company
performs all quality control, analytical assessments and report generation and shares test reports with the ordering healthcare provider.
Revenue is recognized upon invoicing the provider organization. The provider organization is invoiced the agreed upon pricing at the end
of each month for all samples accepted or tests completed since prior invoicing.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Employer organizations&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For employer organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing volume commitment. Patient
samples are sent to the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation
and shares test reports with the ordering healthcare provider. Revenue is recognized upon invoicing the employer organization. The employer
organization is invoiced the agreed upon pricing once a heart disease fair is completed or all testing is completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for revenue
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;, using
the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect
adjustment to the opening balance of accumulated deficit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company determines the measurement of revenue and the timing
of revenue recognition utilizing the following core principles:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Identifying
                                            the contract with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Identifying
                                            the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Determining
                                            the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Allocating
                                            the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBbGafxvms2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zlmVP2BBeDid"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Research and development
costs are expensed as incurred. Research and development costs charged to operations for the years ended December 31, 2024 and 2023 were
$&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_pp0p0" title="Research and development expense"&gt;29,125&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_pp0p0" title="Research and development expense"&gt;145,182&lt;/span&gt;, &lt;span style="letter-spacing: 0pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zTLvsQqGTBik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zVf107pUc8y4"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company expenses advertising costs as incurred. Advertising
costs of $&lt;span id="xdx_905_eus-gaap--AdvertisingExpense_c20240101__20241231_pp0p0" title="Advertising costs"&gt;182,446&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20230101__20231231_pp0p0" title="Advertising costs"&gt;158,514&lt;/span&gt; were charged to operations for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJs1obmk6Fvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_ztokn6a3ZbA7"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Cash and cash equivalents are comprised of
cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241231_z9AChdOqs003" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zfiDJ26ZzsVd" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any
cash equivalents as of December 31, 2024 and 2023. Cash is maintained at a major financial institution. Accounts held at U.S. financial
institutions are insured by the FDIC up to $&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20241231_pp0p0" title="FDIC Insured limit"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions
or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#x2019;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of December 31, 2024 and 2023, was approximately $&lt;span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_zkcfnxA4Tm9f" title="Amount in excess of FDIC insurance"&gt;7.5&lt;/span&gt; million and $&lt;span id="xdx_90C_ecustom--AmountInExcessOfFdicInsurance_iI_pp0p0_c20231231_zoEZpwfaSeCg" title="Amount in excess of FDIC insurance"&gt;933,523&lt;/span&gt;, respectively. The Company has not experienced any losses
on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk with regard
to these deposits is not significant.&lt;/p&gt;



&lt;p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_z0c9VQPN9uAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zjLAHRTGqYll"&gt;Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Accounts receivable is stated
at invoiced amount, net of an allowance for doubtful accounts and bear no interest. An allowance for losses is established through a provision
for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely.
The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based
on evaluation of the collectability of the accounts and prior loss experience.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0"&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyanY13R5eG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zH37bjb3G8H5"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&lt;span id="xdx_8B8_zSC0gG9hqifc" style="display: none"&gt;Schedule of estimated lives&lt;/span&gt;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
  &lt;td style="width: 40%"&gt;Office and computer equipment&lt;/td&gt;
  &lt;td style="width: 50%"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Furniture and fixtures&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives"&gt;7 &lt;/span&gt;years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Lab equipment&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Leasehold improvements&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;

&lt;p id="xdx_8A9_z3ZZlPuyTwi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;	&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;







&lt;p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITHZUwl7a7j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zD5TjXIatc38"&gt;Intangible &lt;span style="letter-spacing: 0pt"&gt;Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Intangible
assets are acquired individually or as part of a group of assets, and are initially recorded at cost. The cost of a group of assets acquired
in a transaction is allocated to the individual assets based on their relative fair values. Intangible assets are carried at cost less
accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line
method over the period of estimated useful life. The estimated useful life of the Company&#x2019;s intangible assets (Know-how license)
is &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zCfcXVkoKSEe" title="Useful life"&gt;5&lt;/span&gt; years. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets
might be impaired.&lt;/p&gt;

&lt;p id="xdx_846_ecustom--PatentAndTrademarkCostsPolicyTextBlock_ze5KSEOQ1fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zw0QsOV54Bfd"&gt;Patent Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company accounts for patents in accordance
with ASC 350-30, &lt;i&gt;General Intangibles Other than Goodwill&lt;/i&gt;. The Company capitalizes patent costs representing legal fees associated
with filing patent applications and amortize them on a straight-line basis. The Company evaluates its patents&#x2019; estimated useful
life and begins amortizing the patents when they are brought to the market or otherwise commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.95pt 0 0"&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhZLkfI2Wpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z7dyBmZQQyqd"&gt;Impairment
of Long-Lived &lt;span style="letter-spacing: 0pt"&gt;Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In accordance with ASC 360-10-35,
the Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value
might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit
of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present.
If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an
impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows
exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the
asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally
measured by the present value of the estimated cash flows.&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zZVaUfZxgLMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zxjoSA4ulfbc"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for leases
under ASC &lt;i&gt;842, &#x201c;Leases&#x201d;. &lt;/i&gt;The Company determines if an arrangement is a lease or contains a lease at inception of the
arrangement. Operating lease liabilities are recognized based on the present value of the remaining lease payments, discounted using the
discount rate for the lease at the commencement date. As the rate implicit in the lease is not readily determinable for the operating
lease, the Company generally uses an incremental borrowing rate based on information available at the commencement date to determine the
present value of future lease payments. Operating lease right-of-use assets (&#x201c;ROU assets&#x201d;) represent the Company&#x2019;s right
to control the use of an identified asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease
payments arising from the lease. ROU assets are generally recognized based on the amount of the initial measurement of the lease liability.
Lease expense is recognized on a straight-line basis over the lease term. The Company elected to keep leases with an initial term of 12
months or less off the balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;ROU assets are reviewed for
impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance
in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. ROU assets are tested for impairment individually
or as part of an asset group if the cash flows related to the ROU assets are not independent from the cash flows of other assets and liabilities.
An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable
cash flows are largely independent of the cash flows of other groups of assets and liabilities.&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJw8YL6Iavr" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zlTdxiM7gO0f"&gt;Stock-Based &lt;span style="letter-spacing: 0pt"&gt;Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for its stock-based
awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires
the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value
on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company
uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing
model requires the input of highly subjective assumptions including the expected stock price volatility of the Company&#x2019;s common
stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption
related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of
the Company&#x2019;s stock options and warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zzzlr7ysTP2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zfHg5iI9wen"&gt;Income
&lt;span style="letter-spacing: 0pt"&gt;Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for income
taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company applies the provisions
of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the
Company&#x2019;s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold
and measurement attribute for the financial statement recognition and measurement of a tax position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5RenvA8vA4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zXRvAiswOSKg"&gt;Recent Accounting &lt;span style="letter-spacing: 0pt"&gt;Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;We have reviewed other recent
accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated
financial statements as a result of future adoption.&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000470">&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zDNg8b34BS05" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zr8jCQLjXzu6"&gt;Principles
of &lt;span style="letter-spacing: 0pt"&gt;Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio. All intercompany
accounts and transactions have been &lt;span style="letter-spacing: 0pt"&gt;eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-012024-12-31" id="Fact000472">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zLNQ2uKwnaZ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zS1mDvUJESNd"&gt;Use
of Estimates in the Preparation of Financial &lt;span style="letter-spacing: 0pt"&gt;Statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 1.25pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could
differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000474">&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z91QthiMFmrj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zCxlZUH7zj8b"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
Company adopted the provisions of ASC Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures, &lt;/i&gt;which defines fair value as used in
numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and
accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these
instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields
on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants
and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level
1 &#x2013; quoted prices in active markets for identical assets or &lt;span style="letter-spacing: 0pt"&gt;liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level
2 &#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Level 3 &#x2013; inputs that
are unobservable (for example cash flow modeling inputs based on &lt;span style="letter-spacing: 0pt"&gt;assumptions)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level
3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for
the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains
and losses for the years ended December 31, 2024 and 2023.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 3.2pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&lt;span id="xdx_8B9_zQfF87metW1a" style="display: none"&gt;Schedule of fair value measurements&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Balance of derivative liabilities &#x2013; beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0479"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0481"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;Issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;9,192,672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Converted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;(3,786,452&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value recognized in operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;(5,406,220&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Balance of derivative liabilities &#x2013; end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zhAz12pT12J7" style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table represents the Company&#x2019;s
derivative instruments that are measured at fair value on a recurring basis as of December 31, 2024 and 2023, for each fair value hierarchy
level:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_zhbf4g3brmh7" style="display: none"&gt;Schedule of fair value hierarchy level&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0501"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Level II&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Level III&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0513"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level II&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level III&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0521"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zmS7sqkIBUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000477">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zGswxGq5zXU2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&lt;span id="xdx_8B9_zQfF87metW1a" style="display: none"&gt;Schedule of fair value measurements&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Balance of derivative liabilities &#x2013; beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5NX6O57Xfg4" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0479"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z93HjveOASpd" style="text-align: right" title="Balance of derivative liabilities - beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0481"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;Issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DerivativeLiabilitiesIssued_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesIssued_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 14%; text-align: right" title="Issued"&gt;9,192,672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Converted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DerivativeLiabilitiesConverted_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Converted"&gt;(3,786,452&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value recognized in operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ChangeInFairValueRecognizedInOperations_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value recognized in operations"&gt;(5,406,220&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Balance of derivative liabilities &#x2013; end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zObA8mtsVOWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhkFHO0Tntg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance of derivative liabilities - end of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <cdio:DerivativeLiabilitiesIssued
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000485"
      unitRef="USD">9192672</cdio:DerivativeLiabilitiesIssued>
    <cdio:DerivativeLiabilitiesConverted
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000489"
      unitRef="USD">-3786452</cdio:DerivativeLiabilitiesConverted>
    <cdio:ChangeInFairValueRecognizedInOperations
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000493"
      unitRef="USD">-5406220</cdio:ChangeInFairValueRecognizedInOperations>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2024-01-012024-12-31" id="Fact000499">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zwakxzgT6fx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B3_zhbf4g3brmh7" style="display: none"&gt;Schedule of fair value hierarchy level&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: left"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0501"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 14%; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Level II&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Level III&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 66%"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0513"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level II&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Level III&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0521"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXFcWsyftxQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <cdio:ConvertibleInstrumentsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000525">&lt;p id="xdx_841_ecustom--ConvertibleInstrumentsPolicyTextBlock_zTtsCCOGiFb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zY6ocY8PrD24"&gt;Convertible &lt;span style="letter-spacing: 0pt"&gt;Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company evaluates and accounts for conversion options
embedded in convertible instruments in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging &lt;span style="letter-spacing: 0pt"&gt;Activities.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Applicable GAAP requires companies
to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according
to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes
in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument
would be considered a derivative &lt;span style="letter-spacing: 0pt"&gt;instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for
convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments)
as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded
in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note
transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term
of the related debt to their stated date of redemption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment
standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current
fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.&lt;/p&gt;

</cdio:ConvertibleInstrumentsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000527">&lt;p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_z7k6YLTKgNKd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zGtXQv2t4pl4"&gt;Revenue &lt;span style="letter-spacing: 0pt"&gt;Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company offers its products, Epi+Gen CHD and PrecisionCHD, via telemedicine providers, provider organizations such as concierge practices,
longevity clinics, and risk-bearing provider organizations, and employer organizations. The Company is continuing to expand its markets
and payment optionality, and therefore, other organization types not listed below may be added, and from time-to-time, there may be additional
payment options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt; letter-spacing: 0pt"&gt;Telemedicine&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For telemedicine, the telemedicine
provider collects payments from patients upon completion of eligibility screening and test order. Patients then send their samples to
the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation and shares test
reports with the ordering healthcare provider. Revenue is recognized upon invoicing the telemedicine providers. Telemedicine providers
are invoiced at the end of each month for all tests completed since prior invoicing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 7.2pt"&gt;&lt;/td&gt;&lt;td style="width: 13.95pt"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;Provider organizations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For provider organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the provider organization type
and testing volume commitment. Upon ordering a test, a patient&#x2019;s sample is sent to the lab for biomarker assessments. The Company
performs all quality control, analytical assessments and report generation and shares test reports with the ordering healthcare provider.
Revenue is recognized upon invoicing the provider organization. The provider organization is invoiced the agreed upon pricing at the end
of each month for all samples accepted or tests completed since prior invoicing.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Employer organizations&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;For employer organizations,
the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing volume commitment. Patient
samples are sent to the lab for biomarker assessments. The Company performs all quality control, analytical assessments and report generation
and shares test reports with the ordering healthcare provider. Revenue is recognized upon invoicing the employer organization. The employer
organization is invoiced the agreed upon pricing once a heart disease fair is completed or all testing is completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for revenue
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;, using
the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect
adjustment to the opening balance of accumulated deficit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company determines the measurement of revenue and the timing
of revenue recognition utilizing the following core principles:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Identifying
                                            the contract with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Identifying
                                            the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Determining
                                            the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Allocating
                                            the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 5%"&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 92%"&gt;&lt;span style="font-size: 10pt"&gt;Recognizing
                                            revenue when (or as) the Company satisfies its performance obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-012024-12-31" id="Fact000531">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zBbGafxvms2e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zlmVP2BBeDid"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Research and development
costs are expensed as incurred. Research and development costs charged to operations for the years ended December 31, 2024 and 2023 were
$&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_pp0p0" title="Research and development expense"&gt;29,125&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_pp0p0" title="Research and development expense"&gt;145,182&lt;/span&gt;, &lt;span style="letter-spacing: 0pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">29125</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">145182</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000537">&lt;p id="xdx_840_eus-gaap--AdvertisingCostsPolicyTextBlock_zTLvsQqGTBik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zVf107pUc8y4"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company expenses advertising costs as incurred. Advertising
costs of $&lt;span id="xdx_905_eus-gaap--AdvertisingExpense_c20240101__20241231_pp0p0" title="Advertising costs"&gt;182,446&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20230101__20231231_pp0p0" title="Advertising costs"&gt;158,514&lt;/span&gt; were charged to operations for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">182446</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">158514</us-gaap:AdvertisingExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000543">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJs1obmk6Fvg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_ztokn6a3ZbA7"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Cash and cash equivalents are comprised of
cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241231_z9AChdOqs003" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20231231_zfiDJ26ZzsVd" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any
cash equivalents as of December 31, 2024 and 2023. Cash is maintained at a major financial institution. Accounts held at U.S. financial
institutions are insured by the FDIC up to $&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20241231_pp0p0" title="FDIC Insured limit"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions
or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#x2019;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of December 31, 2024 and 2023, was approximately $&lt;span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_zkcfnxA4Tm9f" title="Amount in excess of FDIC insurance"&gt;7.5&lt;/span&gt; million and $&lt;span id="xdx_90C_ecustom--AmountInExcessOfFdicInsurance_iI_pp0p0_c20231231_zoEZpwfaSeCg" title="Amount in excess of FDIC insurance"&gt;933,523&lt;/span&gt;, respectively. The Company has not experienced any losses
on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk with regard
to these deposits is not significant.&lt;/p&gt;



</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <cdio:AmountInExcessOfFdicInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000551"
      unitRef="USD">7500000</cdio:AmountInExcessOfFdicInsurance>
    <cdio:AmountInExcessOfFdicInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">933523</cdio:AmountInExcessOfFdicInsurance>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000555">&lt;p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_z0c9VQPN9uAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zjLAHRTGqYll"&gt;Accounts Receivable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Accounts receivable is stated
at invoiced amount, net of an allowance for doubtful accounts and bear no interest. An allowance for losses is established through a provision
for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely.
The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based
on evaluation of the collectability of the accounts and prior loss experience.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0"&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000557">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyanY13R5eG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zH37bjb3G8H5"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Property
and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired
or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss
is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of
the straight line and accelerated methods over the estimated lives of the respective assets as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&lt;span id="xdx_8B8_zSC0gG9hqifc" style="display: none"&gt;Schedule of estimated lives&lt;/span&gt;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
  &lt;td style="width: 40%"&gt;Office and computer equipment&lt;/td&gt;
  &lt;td style="width: 50%"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Furniture and fixtures&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives"&gt;7 &lt;/span&gt;years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Lab equipment&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Leasehold improvements&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;

&lt;p id="xdx_8A9_z3ZZlPuyTwi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;	&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;







</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cdio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000559">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z3ll7pkdf8Ma" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 2)"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&lt;span id="xdx_8B8_zSC0gG9hqifc" style="display: none"&gt;Schedule of estimated lives&lt;/span&gt;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
  &lt;td style="width: 40%"&gt;Office and computer equipment&lt;/td&gt;
  &lt;td style="width: 50%"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg0OdSkBR8B1" title="Estimated useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Furniture and fixtures&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmSnyJRbnXil" title="Estimated useful lives"&gt;7 &lt;/span&gt;years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Lab equipment&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zpewJ9n1uX81" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;Leasehold improvements&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zKobE8VsLhcb" title="Estimated useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;
  &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 34.5pt"&gt;&lt;/p&gt;

</cdio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      id="Fact000561">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000563">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_LabEquipmentMember"
      id="Fact000565">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      id="Fact000567">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-012024-12-31" id="Fact000572">&lt;p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITHZUwl7a7j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zD5TjXIatc38"&gt;Intangible &lt;span style="letter-spacing: 0pt"&gt;Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Intangible
assets are acquired individually or as part of a group of assets, and are initially recorded at cost. The cost of a group of assets acquired
in a transaction is allocated to the individual assets based on their relative fair values. Intangible assets are carried at cost less
accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line
method over the period of estimated useful life. The estimated useful life of the Company&#x2019;s intangible assets (Know-how license)
is &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zCfcXVkoKSEe" title="Useful life"&gt;5&lt;/span&gt; years. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets
might be impaired.&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2024-12-31" id="Fact000574">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cdio:PatentAndTrademarkCostsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000576">&lt;p id="xdx_846_ecustom--PatentAndTrademarkCostsPolicyTextBlock_ze5KSEOQ1fmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zw0QsOV54Bfd"&gt;Patent Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company accounts for patents in accordance
with ASC 350-30, &lt;i&gt;General Intangibles Other than Goodwill&lt;/i&gt;. The Company capitalizes patent costs representing legal fees associated
with filing patent applications and amortize them on a straight-line basis. The Company evaluates its patents&#x2019; estimated useful
life and begins amortizing the patents when they are brought to the market or otherwise commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.95pt 0 0"&gt;&lt;/p&gt;

</cdio:PatentAndTrademarkCostsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000578">&lt;p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhZLkfI2Wpa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z7dyBmZQQyqd"&gt;Impairment
of Long-Lived &lt;span style="letter-spacing: 0pt"&gt;Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In accordance with ASC 360-10-35,
the Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value
might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit
of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present.
If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an
impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows
exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the
asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally
measured by the present value of the estimated cash flows.&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000580">&lt;p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zZVaUfZxgLMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zxjoSA4ulfbc"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for leases
under ASC &lt;i&gt;842, &#x201c;Leases&#x201d;. &lt;/i&gt;The Company determines if an arrangement is a lease or contains a lease at inception of the
arrangement. Operating lease liabilities are recognized based on the present value of the remaining lease payments, discounted using the
discount rate for the lease at the commencement date. As the rate implicit in the lease is not readily determinable for the operating
lease, the Company generally uses an incremental borrowing rate based on information available at the commencement date to determine the
present value of future lease payments. Operating lease right-of-use assets (&#x201c;ROU assets&#x201d;) represent the Company&#x2019;s right
to control the use of an identified asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease
payments arising from the lease. ROU assets are generally recognized based on the amount of the initial measurement of the lease liability.
Lease expense is recognized on a straight-line basis over the lease term. The Company elected to keep leases with an initial term of 12
months or less off the balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;ROU assets are reviewed for
impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance
in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived nonfinancial assets. ROU assets are tested for impairment individually
or as part of an asset group if the cash flows related to the ROU assets are not independent from the cash flows of other assets and liabilities.
An asset group is the unit of accounting for long-lived assets to be held and used, which represents the lowest level for which identifiable
cash flows are largely independent of the cash flows of other groups of assets and liabilities.&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-012024-12-31" id="Fact000582">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zJw8YL6Iavr" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zlTdxiM7gO0f"&gt;Stock-Based &lt;span style="letter-spacing: 0pt"&gt;Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for its stock-based
awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires
the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value
on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company
uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing
model requires the input of highly subjective assumptions including the expected stock price volatility of the Company&#x2019;s common
stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption
related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of
the Company&#x2019;s stock options and warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000584">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zzzlr7ysTP2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zfHg5iI9wen"&gt;Income
&lt;span style="letter-spacing: 0pt"&gt;Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company accounts for income
taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets
and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company applies the provisions
of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the
Company&#x2019;s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold
and measurement attribute for the financial statement recognition and measurement of a tax position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-012024-12-31" id="Fact000587">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5RenvA8vA4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zXRvAiswOSKg"&gt;Recent Accounting &lt;span style="letter-spacing: 0pt"&gt;Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;We have reviewed other recent
accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated
financial statements as a result of future adoption.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000589">&lt;p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zwjm4gdBZQSf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_82F_zXVeIf8VHBU1"&gt;Property and &lt;span style="letter-spacing: 0pt"&gt;Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"&gt;Property and equipment are carried at cost and consist of the following at December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9ucvjRd8hu3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8B9_znhDxlo6b4V7" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zdXSpYKrX3z1" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_z1ilcE0qeHli" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAENzR6H_zrB4cuUYLmce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Office and computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21,032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;17,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAENzR6H_zfe8qFobm03j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAENzR6H_z2p6OR1LHEXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAENzR6H_zS9oqLLg4fEe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzR6H_z5xKrDrjTYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(117,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzR6H_zDbXGo7IzTz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;571,873&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Leasehold improvements of $&lt;span id="xdx_90C_eus-gaap--LeaseholdImprovementsGross_c20241231_pp0p0" title="Leasehold Improvements"&gt;502,155&lt;/span&gt; represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024. Depreciation expense of $&lt;span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231_pp0p0" title="Depreciation expense"&gt;113,777&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_pp0p0" title="Depreciation expense"&gt;3,790&lt;/span&gt;
was charged to operations for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-012024-12-31" id="Fact000591">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9ucvjRd8hu3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8B9_znhDxlo6b4V7" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zdXSpYKrX3z1" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_z1ilcE0qeHli" style="font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAENzR6H_zrB4cuUYLmce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Office and computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21,032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;17,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAENzR6H_zfe8qFobm03j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAENzR6H_z2p6OR1LHEXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0600"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAENzR6H_zS9oqLLg4fEe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzR6H_z5xKrDrjTYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(117,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzR6H_zDbXGo7IzTz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;571,873&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">21032</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">17394</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000596"
      unitRef="USD">96818</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000597"
      unitRef="USD">76099</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000599"
      unitRef="USD">170423</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000602"
      unitRef="USD">502155</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">482170</us-gaap:ConstructionInProgressGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">117567</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">3790</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000608"
      unitRef="USD">672861</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000609"
      unitRef="USD">571873</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">502155</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000613"
      unitRef="USD">113777</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">3790</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000617">&lt;p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zbuxR5JbFRC7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_828_zBzoa4Zewyz9"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
following table provides details associated with the Company&#x2019;s acquired identifiable intangible assets at December 31, 2024 and
2023:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zc7Lz3Rjebf7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8B1_zpyq01DYJWF5" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_z579V0nUMvE3" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zrO7yEGUaRhh" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzDBb_zYnczfGzJWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Know-how license&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzDBb_zwhIMPpnEcFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(74,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(58,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzDBb_zYIW5sL1Yq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 5.6pt 0 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Amortization expense charged to operations was $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_pp0p0" title="Amortization expense"&gt;&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_pp0p0" title="Amortization expense"&gt;16,000&lt;/span&gt;&lt;/span&gt; for the
years ended December 31, 2024 and 2023, &lt;span style="letter-spacing: 0pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000619">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zc7Lz3Rjebf7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8B1_zpyq01DYJWF5" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_z579V0nUMvE3" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zrO7yEGUaRhh" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzDBb_zYnczfGzJWXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Know-how license&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzDBb_zwhIMPpnEcFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(74,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(58,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzDBb_zYIW5sL1Yq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000622"
      unitRef="USD">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">74667</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000625"
      unitRef="USD">58667</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000627"
      unitRef="USD">5333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000628"
      unitRef="USD">21333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">16000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">16000</us-gaap:AmortizationOfIntangibleAssets>
    <cdio:PatentAndTrademarkCostsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000634">&lt;p id="xdx_806_ecustom--PatentAndTrademarkCostsTextBlock_zcrwGc6tWs0b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_824_z5wdhx2Sfmvh"&gt;Patent &lt;span style="letter-spacing: 0pt"&gt;Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2024, in the first family
of patents and patent applications owned solely by UIRF and is exclusively licensed by Cardio, there are seven granted patents (US (2),
EU, China, Australia, India and Hong Kong) and other pending patent applications. The Company has pending patent applications in patent
families two, three, four, five and six. Legal fees associated with the patents totaled $&lt;span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zcFqIPzAR06h" title="Legal fees"&gt;701,089&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zykuNE1meSaa" title="Legal fees"&gt;515,402&lt;/span&gt;, net of accumulated amortization
of $&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zofvdqOAqYt3" title="Accumulated amortization"&gt;6,920&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Accumulated amortization"&gt;3,182&lt;/span&gt; as of December 31, 2024 and 2023, respectively and are presented in the consolidated balance sheets as patent costs.
Patents are amortized over their estimated useful lives of approximately 14 and &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgtwhQEcsZXi" title="Estimated useful lives"&gt;15&lt;/span&gt; years, respectively. Amortization expense charged to
operations was $&lt;span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses"&gt;3,738&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Amortization expenses"&gt;3,182&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

</cdio:PatentAndTrademarkCostsTextBlock>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">701089</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">515402</us-gaap:LegalFees>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">6920</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">3182</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      id="Fact000644">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">3738</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2023-01-012023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">3182</us-gaap:AdjustmentForAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-012024-12-31" id="Fact000650">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zWIUiVNtCZR1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_823_zyECJSRl5J4h"&gt;Operating &lt;span style="letter-spacing: 0pt"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company determines if
a contract is, or contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets, current portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#x2019;s
consolidated balance sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance
lease obligations, net of current portion in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;ROU assets represent the right
to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.
ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.
In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement
date and exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments.
Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.
Leases with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In 2023, the Company entered
into a lease agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and
expiring on November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental
installments from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $&lt;span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p0" title="Monthly rent payment"&gt;8,505&lt;/span&gt; ($&lt;span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p0" title="Annually rent payment"&gt;102,060&lt;/span&gt; annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#x201c;TIA&#x201d;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $&lt;span id="xdx_906_ecustom--PremisesAllowance_c20240101__20241231_pp0p0" title="Premises allowance"&gt;253,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Pursuant to ASC Topic 842
Leases, the Company accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated
to be payable on December 1, 2023. The Company received the TIA from landlord in maximum amount of $&lt;span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p0" title="Amount receivable"&gt;253,000&lt;/span&gt; on January 16, 2024 and recorded
a reimbursement receivable from landlord of $&lt;span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p0" title="Reimbursement receivable"&gt;253,000&lt;/span&gt; as of December 31, 2023, which was included in Prepaid expenses and other current
assets on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the year ended December 31, 2023, the
Company recorded ROU assets of $&lt;span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p0" title="ROU assets"&gt;663,875&lt;/span&gt; and operating lease liabilities of $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p0" title="Operating lease liabilities"&gt;642,523&lt;/span&gt; at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be &lt;span id="xdx_90B_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_pdd" title="Borrowing rate"&gt;4.57%&lt;/span&gt; for the Chicago lease and &lt;span id="xdx_90F_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_pdd" title="Borrowing rate"&gt;4.24%&lt;/span&gt; for the Iowa
City lease, respectively, as the interest rate implicit in our lease is not readily determinable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;As
of December 31, 2024 and 2023, operating lease ROU assets and operating lease liabilities are recorded on the consolidated balance sheets
as &lt;span style="letter-spacing: 0pt"&gt;follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zyoLYq3Im9od" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zADQOQFfRyfi" style="font-size: 8pt"&gt;&lt;b style="display: none"&gt;Schedule of operating lease ROU assets and operating lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zzRQXmMCDVHc" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zNUIrXNUIwwf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;Operating Leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease right-of-use assets, net&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;432,397&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;575,227&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;237,270&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;223,929&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zaTmatbFqhb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;425,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;663,099&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zvpAVaPeTkg7" style="font: 10pt Times New Roman, Times, Serif; margin: 5.35pt 0 12pt 0.1in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;As of December 31, 2024, the weighted-average
remaining lease terms of the two operating leases were &lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zeFB5GFznR4a" title="Operating Lease, Weighted Average Remaining Lease Term"&gt;1.9&lt;/span&gt; years and &lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zfCRvCZNnXb3" title="Operating Lease, Weighted Average Remaining Lease Term"&gt;3.9&lt;/span&gt; years, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIsC8qEhRhJ9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8B5_zH4yu9sV5t5c" style="display: none"&gt;Schedule of future minimum payments due&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 81%; font-size: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20241231_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="2025"&gt;260,611&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="Total minimum lease payments"&gt;706,378&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less: Imputed interest"&gt;43,279&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20241231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Present value of lease liabilities"&gt;663,099&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;At December 31, 2024, the Company had the
following future minimum payments due under the non-cancelable lease:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 81%; font-size: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20241231_zjx6NL5YA5E2" style="width: 14%; font-size: 10pt; text-align: right" title="2025"&gt;260,611&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20241231_zf7NWr1e7xch" style="font-size: 10pt; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20241231_z32BNlNXJWHc" style="font-size: 10pt; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20241231_zhmSPc62i7bk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20241231_zuWuaIY5glDk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total minimum lease payments"&gt;706,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zlrBoJ7IUXGf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Consolidated rental expense for all operating
leases was $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_pp0p0" title="Rental expense for operating leases"&gt;204,717&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLeaseExpense_c20230101__20231231_pp0p0" title="Rental expense for operating leases"&gt;138,266&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The following table summarizes the cash paid
and related right-of-use operating lease recognized for the years ended December 31, 2024 and 2023.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zz2OC2XEo2sa" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zBl1bXJOS7i3" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101_20241231" style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101_20231231" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zoPcBHLVkZSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Cash paid for amounts included in the measurement of
    lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;257,508&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,352&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB_zGppz3XnLuKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Right-of-use lease assets obtained in the exchange for
    lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;223,929&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,950&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_zTO3SBrGpVb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2023-08-022023-11-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">8505</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <cdio:AnnuallyRentPayment
      contextRef="From2023-08-022023-11-30"
      decimals="0"
      id="Fact000654"
      unitRef="USD">102060</cdio:AnnuallyRentPayment>
    <cdio:PremisesAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">253000</cdio:PremisesAllowance>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2024-01-16"
      decimals="0"
      id="Fact000658"
      unitRef="USD">253000</us-gaap:ReceivablesNetCurrent>
    <cdio:ReimbursementReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">253000</cdio:ReimbursementReceivable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">663875</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">642523</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="From2023-01-012023-12-31_custom_ChicagoMember"
      decimals="INF"
      id="Fact000666"
      unitRef="Ratio">0.0457</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="From2023-01-012023-12-31_stpr_IA"
      decimals="INF"
      id="Fact000668"
      unitRef="Ratio">0.0424</us-gaap:SubordinatedBorrowingInterestRate>
    <cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000670">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zyoLYq3Im9od" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zADQOQFfRyfi" style="font-size: 8pt"&gt;&lt;b style="display: none"&gt;Schedule of operating lease ROU assets and operating lease liabilities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zzRQXmMCDVHc" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zNUIrXNUIwwf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;Operating Leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease right-of-use assets, net&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;432,397&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;575,227&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;237,270&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;223,929&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zaTmatbFqhb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;425,829&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;663,099&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">432397</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">575227</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">237270</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">223929</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">425829</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000679"
      unitRef="USD">663099</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2024-12-31_custom_LeaseOneMember"
      id="Fact000681">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2024-12-31_custom_LeaseTwoMember"
      id="Fact000683">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000685">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIsC8qEhRhJ9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8B5_zH4yu9sV5t5c" style="display: none"&gt;Schedule of future minimum payments due&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 81%; font-size: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20241231_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="2025"&gt;260,611&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20241231_pp0p0" style="font-size: 10pt; text-align: right" title="Total minimum lease payments"&gt;706,378&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20241231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Less: Imputed interest"&gt;43,279&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20241231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Present value of lease liabilities"&gt;663,099&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;At December 31, 2024, the Company had the
following future minimum payments due under the non-cancelable lease:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 81%; font-size: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20241231_zjx6NL5YA5E2" style="width: 14%; font-size: 10pt; text-align: right" title="2025"&gt;260,611&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20241231_zf7NWr1e7xch" style="font-size: 10pt; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20241231_z32BNlNXJWHc" style="font-size: 10pt; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20241231_zhmSPc62i7bk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20241231_zuWuaIY5glDk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total minimum lease payments"&gt;706,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000687"
      unitRef="USD">260611</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000689"
      unitRef="USD">250152</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000691"
      unitRef="USD">102060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">93555</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">706378</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000697"
      unitRef="USD">43279</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000699"
      unitRef="USD">663099</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000701"
      unitRef="USD">260611</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000703"
      unitRef="USD">250152</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000705"
      unitRef="USD">102060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">93555</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000709"
      unitRef="USD">706378</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">204717</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">138266</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000716">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zz2OC2XEo2sa" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span id="xdx_8B7_zBl1bXJOS7i3" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101_20241231" style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101_20231231" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 8pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zoPcBHLVkZSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Cash paid for amounts included in the measurement of
    lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;257,508&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,352&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--RightofuseLeaseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_iB_zGppz3XnLuKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Right-of-use lease assets obtained in the exchange for
    lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;223,929&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,950&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">257508</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">21352</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">223929</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">4950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cdio:FinanceAgreementPayableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000730">&lt;p id="xdx_803_ecustom--FinanceAgreementPayableTextBlock_zDvD2ZeOC3K7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_82D_zamaU30TCmC4"&gt;Finance Agreement &lt;span style="letter-spacing: 0pt"&gt;Payable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$&lt;span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p0" title="Financing agreement entered into for prepaid insurance"&gt;467,500&lt;/span&gt;&#160;is payable in 10 monthly installments plus interest at a rate of&#160;&lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pdd" title="Interest rate"&gt;8.95%&lt;/span&gt;&#160;through&#160;&lt;span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_c20231025" title="Maturity date"&gt;August
25, 2024&lt;/span&gt;. Accordingly, Directors and Officers insurance premiums of $&lt;span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p0" title="Prepaid expenses"&gt;550,000&lt;/span&gt;&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $&lt;span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p0" title="Financing agreement entered into for prepaid insurance"&gt;383,455&lt;/span&gt; is payable in 10 monthly installments plus interest at a rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pdd" title="Interest rate"&gt;8.80%&lt;/span&gt; through &lt;span id="xdx_90C_eus-gaap--LongTermDebtMaturityDate_c20241025" title="Maturity date"&gt;August
25, 2025&lt;/span&gt;. Accordingly, Directors and Officers insurance premiums of $&lt;span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p0" title="Prepaid expenses"&gt;451,124&lt;/span&gt; has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Finance agreement payable for above two agreements
was $&lt;span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p0" title="Finance agreement payable"&gt;306,764&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--FinanceAgreementPayable_c20231231_pp0p0" title="Finance agreement payable"&gt;374,000&lt;/span&gt; at December 31, 2024 and 2023, respectively. Unamortized balance of Directors and Officers insurance premiums
was $&lt;span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p0" title="Unamortized balance"&gt;368,315&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--UnamortizedDebtIssuanceExpense_c20231231_pp0p0" title="Unamortized balance"&gt;449,041&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/p&gt;

</cdio:FinanceAgreementPayableTextBlock>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2023-10-012023-10-25"
      decimals="0"
      id="Fact000732"
      unitRef="USD">467500</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-10-012023-10-25"
      decimals="INF"
      id="Fact000734"
      unitRef="Ratio">0.0895</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtMaturityDate contextRef="AsOf2023-10-25" id="Fact000736">2024-08-25</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="AsOf2024-10-25"
      decimals="0"
      id="Fact000738"
      unitRef="USD">550000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2024-10-012024-10-25"
      decimals="0"
      id="Fact000740"
      unitRef="USD">383455</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-10-012024-10-25"
      decimals="INF"
      id="Fact000742"
      unitRef="Ratio">0.0880</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtMaturityDate contextRef="AsOf2024-10-25" id="Fact000744">2025-08-25</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="AsOf2025-10-25"
      decimals="0"
      id="Fact000746"
      unitRef="USD">451124</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">306764</cdio:FinanceAgreementPayable>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">374000</cdio:FinanceAgreementPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">368315</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">449041</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-012024-12-31" id="Fact000756">&lt;p id="xdx_803_eus-gaap--EarningsPerShareTextBlock_z5MscUNUo6L" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_82D_z5qW3UYKl5R7"&gt;Earnings (Loss) Per Common &lt;span style="letter-spacing: 0pt"&gt;Share&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates net income (loss) per common
share in accordance with ASC 260 &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; (&#x201c;ASC 260&#x201d;). Basic and diluted net earnings (loss)
per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common
shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options,
and common stock warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2024
and 2023 as the result would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU8iRieUQ1Ld" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8BF_zY0CDmiHV3Y1" style="display: none"&gt;Schedule of anti dilutive earning per share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Years
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Stock warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares"&gt;8,528,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares"&gt;7,854,620&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares"&gt;3,594,202&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares"&gt;2,584,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares"&gt;12,122,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares"&gt;10,439,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 2.5pt 0 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-012024-12-31" id="Fact000758">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU8iRieUQ1Ld" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8BF_zY0CDmiHV3Y1" style="display: none"&gt;Schedule of anti dilutive earning per share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;Years
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 11pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Stock warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares"&gt;8,528,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="width: 14%; text-align: right" title="Anti-dilutive shares"&gt;7,854,620&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares"&gt;3,594,202&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares"&gt;2,584,599&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares"&gt;12,122,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares"&gt;10,439,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_StockWarrantsMember"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">8528766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_StockWarrantsMember"
      decimals="INF"
      id="Fact000762"
      unitRef="Shares">7854620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000764"
      unitRef="Shares">3594202</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">2584599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000768"
      unitRef="Shares">12122968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000770"
      unitRef="Shares">10439219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000772">&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwtqmKaLZ10b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_828_zw2TVCrEUToc"&gt;Stockholders&#x2019; &lt;span style="letter-spacing: 0pt"&gt;Equity&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock &lt;span style="letter-spacing: 0pt"&gt;Transactions&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Pursuant to the Business Combination Agreement on October
25, 2022, the Company issued the following &lt;span style="letter-spacing: 0pt"&gt;securities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Holders of conversion rights issued as a component of units
in Mana&#x2019;s initial public offering (the &#x201c;Public Rights&#x201d;) were issued an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Number of shares issued"&gt;928,571&lt;/span&gt; shares of the Company&#x2019;s
common &lt;span style="letter-spacing: 0pt"&gt;stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Holders of existing shares
of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the &#x201c;Legacy Cardio Stockholders&#x201d;)
received an aggregate of &lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240101__20241231__dei--LegalEntityAxis__custom--LegacyCardioStockholdersMember_pp0p0" title="Number of shares received"&gt;6,883,306&lt;/span&gt; shares of the Company&#x2019;s Common Stock, calculated based on the &lt;span style="color: #202529"&gt;exchange
ratio of 3.427259 pursuant to the Merger Agreement&lt;/span&gt; (the &#x201c;Exchange Ratio&#x201d;) for each share of Legacy Cardio Common Stock
held or, in the case of the equity rights holder, that number of shares of the Company&#x2019;s Common Stock equal to 1% of the Aggregate
Closing Merger Consideration, as defined in the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Legacy Cardio Stockholders
received, in addition, an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20240101__20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pdd" title="Conversion of aggregate shares"&gt;43,334&lt;/span&gt; shares of the Company&#x2019;s Common Stock (&#x201c;Conversion Shares&#x201d;) upon conversion
of an aggregate of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20241231__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pp0p0" title="Principal amount"&gt;433,334&lt;/span&gt; in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such
amount in order to extend Mana&#x2019;s duration through October 26, 2022 (the &#x201c;Extension Notes&#x201d;), which Conversion Shares
were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Mana public stockholders
(excluding Mana Capital, LLC, the SPAC sponsor (the &#x201c;Sponsor&#x201d;), and Mana&#x2019;s former officers and directors) own 34,548
shares of the Company&#x2019;s Common Stock and the Sponsor, Mana&#x2019;s former officers and directors and certain permitted transferees
own &lt;span id="xdx_90C_ecustom--NumberOfSharesTransferred_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ManasFormerOfficersAndDirectorsMember_pdd" title="Number of shares transferred"&gt;1,625,000&lt;/span&gt; shares of the Company&#x2019;s Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Immediately after giving effect to the Business Combination,
there were 9,514,743 issued and outstanding shares of the Company&#x2019;s Common &lt;span style="letter-spacing: 0pt"&gt;Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On October 25, 2022, in connection
with the approval of the Business Combination, the Company&#x2019;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders
by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries,
to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of
Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations
of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock
Units, Stock Appreciation Rights, Performance Units and Performance Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
2022 Plan, as approved, permits the issuance of up to &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20241231__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Common stock issuance"&gt;3,265,516&lt;/span&gt; shares of Common Stock (the &#x201c;Share Reserve&#x201d;) upon exercise
or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#x201c;Evergreen Date&#x201d;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the
Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January
1, 2023. In January 2024, the Compensation Committee approved an annual increase in the Share Reserve of &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Number of shares authorized"&gt;1,060,458&lt;/span&gt; shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common Stock &lt;span style="letter-spacing: 0pt"&gt;Issued&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Private
Placement&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In connection with a private offering memorandum that the
Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with 7 accredited
investors (the &#x201c;Subscription Agreements&#x201d;), whereby the Company issued a total of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Number of shares issued"&gt;561,793&lt;/span&gt; units (&#x201c;Units&#x201d;), with
each Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Common stock , per value"&gt;0.00001&lt;/span&gt; par value (the &#x201c;Common Stock&#x201d;), and (ii)
one six year Common Stock purchase warrant (the &#x201c;Warrants&#x201d;), having an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRz4dkayTmki" title="Warrant exercise price"&gt;1.78&lt;/span&gt; per share (the &#x201c;Private
Placement&#x201d;). The Private Placement resulted in the issuance to investors of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares issued"&gt;561,793&lt;/span&gt; shares of Common Stock and &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares issued"&gt;561,793&lt;/span&gt; Warrants.
The purchase price of the securities was $1.78 per Unit, resulting in gross proceeds to the Company of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock"&gt;1,000,000&lt;/span&gt;, before deducting placement
agent fees (10% or $&lt;span id="xdx_90E_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p0" title="Placement agent fees"&gt;100,000&lt;/span&gt;) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working
capital and general corporate purposes. The Private Placement closed on February 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with the Private Placement, &lt;span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalGroupLLCMember" title="Placement agent agreement description"&gt;the
Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#x201c;Altitude Capital&#x201d;
or the &#x201c;Placement Agent&#x201d;). The Company&#x2019;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 112,353 shares of Common Stock at $1.78
per share through February 2, 2030 (the &#x201c;Placement Agent Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;At-the-Market Issuance&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In connection with an At-the-Market Issuance Sales Agreement
(the &#x201c;Sales Agreement&#x201d;) that the Company entered into with a placement agent on January 26, 2024, the Company sold &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of shares issued"&gt;24,758,057&lt;/span&gt;
shares of Common Stock at various amounts per share to investors for gross proceeds totaling $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock"&gt;11,546,949&lt;/span&gt; before deducting sales commissions
of $&lt;span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Sales commissions"&gt;288,674&lt;/span&gt; to placement agent, during the year ended December 31, 2024. The Company also paid the placement agent a fee of $&lt;span id="xdx_90B_ecustom--PlacementAgentFee_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CraigHallumCapitalGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Placement agent fees"&gt;55,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Other Common Stock Issuance&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;During the year ended December 31, 2024, the Company issued
&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares"&gt;48,568&lt;/span&gt; shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount"&gt;26,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On March 31, 2024, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares"&gt;35,212&lt;/span&gt; shares of Common
Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted, valued at $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount"&gt;50,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 2, 2023, a shareholder exercised warrants
in exchange for &lt;span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230301__20230302_pdd" title="Conversion of shares, shares"&gt;100,000&lt;/span&gt; shares of Common Stock for proceeds of $&lt;span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230301__20230302_pp0p0" title="Conversion of shares, Value"&gt;390,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the year ended December 31, 2023, the
Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Stock issued for services, shares"&gt;52,375&lt;/span&gt; shares of Common Stock to two consultants for services pursuant to vesting of Restricted Stock Units granted, valued
at $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Stock issued for services, amount"&gt;44,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the year ended December 31, 2023, the
Company issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pdd" title="Stock issued for services, shares"&gt;251,172&lt;/span&gt; shares of Common Stock to the board of directors for services pursuant to vesting of Restricted Stock Units granted,
valued at $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pp0p0" title="Stock issued for services, amount"&gt;200,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0 0.1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with the convertible notes payable
(see Note 11 below) the noteholders converted $&lt;span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231_pdd" title="Conversion of shares, shares"&gt;5,000,000&lt;/span&gt; of principal balance to &lt;span id="xdx_90B_eus-gaap--ConversionOfStockAmountIssued1_c20230101__20231231_pp0p0" title="Conversion of shares, Value"&gt;10,622,119&lt;/span&gt; shares of Common Stock during the year ended
December 31, 2023. The number of shares of Common Stock issued was determined based on the terms of the convertible notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 1, 2019, the Company issued warrants
to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20191001_pdd" title="Common stock issuance"&gt;22,500&lt;/span&gt; shares of Common Stock at the time of issuance.
The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the
warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the
next Qualified Equity Financing, or if the warrant became exercisable in connection with a Change in Control before the next Qualified
Equity Financing, the greater of the quotient obtained by dividing $150,000 by the Pre-financing Capitalization, and the price per share
paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation
of any Change of Control, or 15 years after the issuance of the warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In April 2022, the Company issued fully vested
warrants to investors as part of private placement subscription agreements pursuant to which the Company issued Common Stock. Each shareholder
received warrants to purchase 50% of the Common Stock issued at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Warrant exercise price"&gt;3.90&lt;/span&gt; per share with an expiration date of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220401__20220430" title="Expiration date"&gt;June 30,
2027&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of May 23, 2022, the Company issued fully
vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued Common
Stock. Each shareholder received warrants to purchase 50% of the Common Stock issued at an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220523_pdd" title="Warrant exercise price"&gt;6.21&lt;/span&gt; per share with an expiration
date of five years from the date of issue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;All of the warrants issued by Legacy Cardio
were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the year ended December 31, 2024, in
connection with the Private Placement as described above, the Company issued an aggregate of &lt;span id="xdx_905_ecustom--WarrantsIssued_c20240101__20241231_pdd" title="Warrants issued"&gt;674,146&lt;/span&gt; warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Warrant
activity during the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDCwURogRB1f" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zfAb4vTxNTi1" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted
    Average Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Remaining Contractual
                                                                                                Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1Q52kQUQ9E8" style="width: 12%; font-size: 10pt; text-align: right" title="Warrants outstanding, beginning"&gt;7,954,620&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlPPXLz3nx6j" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;9.63&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfgzk0Lz0MC" title="Weighted average remaining contractual life"&gt;4.46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;3.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,854,620&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9.70&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Uu5x01Apb1" title="Weighted average remaining contractual life"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants granted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants granted"&gt;674,146&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, granted"&gt;1.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;8,528,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUZLGB7r6SId" title="Weighted average remaining contractual life"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z6PpS9k3vC75" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="letter-spacing: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On June 23, 2023, the Company granted &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"&gt;825,000&lt;/span&gt;
stock options to management, which vested immediately on grant date. Each option has an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Warrant exercise price"&gt;1.26&lt;/span&gt; per share with an expiration
date of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20230601__20230623__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"&gt;June 23, 2033&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_908_ecustom--StockOptionsValued_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"&gt;1,035,273&lt;/span&gt; at grant date based on the Black-Scholes Option
Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during
the year ended December 31, 2023, risk free interest rate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;5.41%&lt;/span&gt;, volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"&gt;176%&lt;/span&gt; and an exercise price of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"&gt;1.26&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 23, 2024, the Company authorized
an additional 1,060,458 shares to the Equity Incentive Plan Reserve (the &#x201c;2022 Plan&#x201d;) and granted 1,187,826 options to management
and employees, 1,166,826 of which vested immediately with the remaining 21,000 options subject to 50% vesting on June 30, 2024 and 100%
vesting on December 31, 2024. Each option has an exercise price of $2.11 per share with an expiration date of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember" title="Expiration date"&gt;January 23, 2034&lt;/span&gt;. The immediately
vested 1,166,826 stock options were valued at $&lt;span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p0" title="Stock options valued"&gt;2,461,404&lt;/span&gt; at grant date based on the Black-Scholes Option Pricing model. The following
assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the year ended December 31,
2024, risk free interest rate of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Risk free interest rate"&gt;5.22%&lt;/span&gt;, volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Volatility"&gt;228%&lt;/span&gt; and an exercise price of $2.11. For the remaining 21,000 options, 7,500 options
were vested on June 30, 2024, 5,000 options were vested on December 31, 2024 and 8,500 options were forfeited before vesting with the
leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at vesting date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these vested stock options during the
year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;, volatility of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Volatility"&gt;188%&lt;/span&gt; and an exercise price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOption1Member_pdd" title="Exercise price"&gt;2.11&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On June 30, 2024, the Company granted 30,300
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.55 per share
with an expiration date of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"&gt;June 30, 2034&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_90C_ecustom--StockOptionsValued_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"&gt;16,625&lt;/span&gt; at grant date based on the Black-Scholes
Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options
during the year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;, volatility of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"&gt;188%&lt;/span&gt; and an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"&gt;0.55&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On September 30, 2024, the Company granted
&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"&gt;74,744&lt;/span&gt; stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.22 per
share with an expiration date of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"&gt;September 30, 2034&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_901_ecustom--StockOptionsValued_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"&gt;16,618&lt;/span&gt; at grant date based
on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;3.79%&lt;/span&gt;, volatility of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"&gt;184%&lt;/span&gt; and an exercise price
of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"&gt;0.22&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 14, 2024, the Company granted &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"&gt;15,728&lt;/span&gt;
stock options to two independent directors of the board, which vested immediately on grant date. Each option has an exercise price of
$0.27 per share with an expiration date of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"&gt;November 14, 2034&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"&gt;4,125&lt;/span&gt; at grant date
based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately
vested stock options during the year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;4.44%&lt;/span&gt;, volatility of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"&gt;156%&lt;/span&gt; and an exercise price
of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241114__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"&gt;0.27&lt;/span&gt;. The two independent directors did not stand for re-election at the 2024 Annual Meeting but did receive the options upon vesting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 31, 2024, the Company granted &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Options granted"&gt;13,632&lt;/span&gt;
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $0.92 per share
with an expiration date of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember" title="Expiration date"&gt;December 31, 2034&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_90A_ecustom--StockOptionsValued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock options valued"&gt;12,289&lt;/span&gt; at grant date based on the
Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of these immediately vested
stock options during the year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;4.58%&lt;/span&gt;, volatility of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Volatility"&gt;146%&lt;/span&gt; and an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Exercise price"&gt;0.92&lt;/span&gt;.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Option
activity during the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUvpU5j4hnfl" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zERaSKPPmM23" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted
    Average Exercise&#160;Price&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZWfO100pTS2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning"&gt;1,759,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6doTkcJ0gzf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;3.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zgUrtRCBeDtf" title="Weighted average remaining contractual life"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted"&gt;825,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted"&gt;1.26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,584,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3.06&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJpBEP5l7EGi" title="Weighted average remaining contractual life"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Options granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted"&gt;1,322,231&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted"&gt;1.93&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options expired or cancelled or forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0UGR8MEMLBa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options expired or cancelled or forfeited"&gt;(312,628&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options expired or cancelled or forfeited"&gt;1.93&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,594,202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzkJV3s72Ima" title="Weighted average remaining contractual life"&gt;8.12&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Options vested and exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options vested and exercisable"&gt;3,594,202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price vested and exercisable"&gt;2.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zg6cru78mdZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">928571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-01-012024-12-31_custom_LegacyCardioStockholdersMember"
      decimals="0"
      id="Fact000776"
      unitRef="USD">6883306</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2024-01-012024-12-31_custom_LegacyCardioMember"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">43334</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_LegacyCardioMember"
      decimals="0"
      id="Fact000780"
      unitRef="USD">433334</us-gaap:DebtInstrumentFaceAmount>
    <cdio:NumberOfSharesTransferred
      contextRef="From2024-01-012024-12-31_custom_ManasFormerOfficersAndDirectorsMember"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">1625000</cdio:NumberOfSharesTransferred>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_Plan2022Member"
      decimals="INF"
      id="Fact000784"
      unitRef="Shares">3265516</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized
      contextRef="AsOf2024-01-23_custom_Plan2022Member"
      decimals="INF"
      id="Fact000786"
      unitRef="Shares">1060458</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">561793</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000792"
      unitRef="USDPShares">1.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000794"
      unitRef="Shares">561793</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">561793</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdio:PlacementAgentFee
      contextRef="From2024-01-012024-12-31_custom_SevenAccreditedInvestorsMember"
      decimals="0"
      id="Fact000800"
      unitRef="USD">100000</cdio:PlacementAgentFee>
    <cdio:PlacementAgentAgreementDescription
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalGroupLLCMember"
      id="Fact000802">the
Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#x201c;Altitude Capital&#x201d;
or the &#x201c;Placement Agent&#x201d;). The Company&#x2019;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 112,353 shares of Common Stock at $1.78
per share through February 2, 2030 (the &#x201c;Placement Agent Warrants&#x201d;).</cdio:PlacementAgentAgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000804"
      unitRef="Shares">24758057</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">11546949</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">288674</us-gaap:SalesCommissionsAndFees>
    <cdio:PlacementAgentFee
      contextRef="From2024-01-012024-12-31_custom_CraigHallumCapitalGroupLLCMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000810"
      unitRef="USD">55000</cdio:PlacementAgentFee>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">48568</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000814"
      unitRef="USD">26000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-03-31_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">35212</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_custom_BoardOfDirectorsMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-03-012023-03-02"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">100000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2023-03-012023-03-02"
      decimals="0"
      id="Fact000822"
      unitRef="USD">390000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">52375</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Shares">251172</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">5000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000834"
      unitRef="USD">10622119</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2019-10-01"
      decimals="INF"
      id="Fact000836"
      unitRef="Shares">22500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000838"
      unitRef="USDPShares">3.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2022-04-012022-04-30" id="Fact000840">2027-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-23"
      decimals="INF"
      id="Fact000842"
      unitRef="USDPShares">6.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:WarrantsIssued
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">674146</cdio:WarrantsIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-012024-12-31" id="Fact000846">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDCwURogRB1f" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zfAb4vTxNTi1" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted
    Average Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Remaining Contractual
                                                                                                Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1Q52kQUQ9E8" style="width: 12%; font-size: 10pt; text-align: right" title="Warrants outstanding, beginning"&gt;7,954,620&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlPPXLz3nx6j" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;9.63&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfgzk0Lz0MC" title="Weighted average remaining contractual life"&gt;4.46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;3.90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,854,620&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9.70&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Uu5x01Apb1" title="Weighted average remaining contractual life"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants granted&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants granted"&gt;674,146&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, granted"&gt;1.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;8,528,766&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;9.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUZLGB7r6SId" title="Weighted average remaining contractual life"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000848"
      unitRef="Shares">7954620</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000850"
      unitRef="USDPShares">9.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="Fact000852">P4Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">-100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000856"
      unitRef="USDPShares">3.90</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact000858">P3Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">674146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000862"
      unitRef="USDPShares">1.78</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="Fact000864">P2Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-06-012023-06-23_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">825000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-23_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">1.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2023-06-012023-06-23_custom_StockOptionsMember"
      id="Fact000872">2033-06-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      decimals="0"
      id="Fact000874"
      unitRef="USD">1035273</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      decimals="INF"
      id="Fact000876"
      unitRef="Ratio">0.0541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      decimals="INF"
      id="Fact000878"
      unitRef="Ratio">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      id="Fact000882">2034-01-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">2461404</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Ratio">0.0522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Ratio">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member"
      decimals="INF"
      id="Fact000890"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_N2022PlanMember_custom_StockOption1Member"
      decimals="INF"
      id="Fact000892"
      unitRef="Ratio">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_N2022PlanMember_custom_StockOption1Member"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      id="Fact000896">2034-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="0"
      id="Fact000898"
      unitRef="USD">16625</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact000900"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact000902"
      unitRef="Ratio">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000904"
      unitRef="USDPShares">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000906"
      unitRef="Shares">74744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-09-30_custom_StockOptionsMember"
      id="Fact000908">2034-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-09-30_custom_StockOptionsMember"
      decimals="0"
      id="Fact000910"
      unitRef="USD">16618</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Ratio">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Ratio">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000916"
      unitRef="USDPShares">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-11-14_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">15728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-11-14_custom_StockOptionsMember"
      id="Fact000920">2034-11-14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-11-14_custom_StockOptionsMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">4125</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-11-14_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000924"
      unitRef="Ratio">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-11-14_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Ratio">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-11-14_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000928"
      unitRef="USDPShares">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">13632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      id="Fact000932">2034-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="0"
      id="Fact000934"
      unitRef="USD">12289</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000936"
      unitRef="Ratio">0.0458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000938"
      unitRef="Ratio">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000940"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact000943">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUvpU5j4hnfl" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zERaSKPPmM23" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted
    Average Exercise&#160;Price&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 55%; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zZWfO100pTS2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options outstanding, beginning"&gt;1,759,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6doTkcJ0gzf" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;3.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zgUrtRCBeDtf" title="Weighted average remaining contractual life"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted"&gt;825,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted"&gt;1.26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,584,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3.06&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJpBEP5l7EGi" title="Weighted average remaining contractual life"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Options granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options granted"&gt;1,322,231&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price granted"&gt;1.93&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options expired or cancelled or forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0UGR8MEMLBa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options expired or cancelled or forfeited"&gt;(312,628&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options expired or cancelled or forfeited"&gt;1.93&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,594,202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zzkJV3s72Ima" title="Weighted average remaining contractual life"&gt;8.12&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Options vested and exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options vested and exercisable"&gt;3,594,202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price vested and exercisable"&gt;2.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">1759599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000947"
      unitRef="USDPShares">3.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_StockOptionsMember"
      id="Fact000949">P9Y4M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">825000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">1.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      id="Fact000955">P8Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">1322231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000959"
      unitRef="USDPShares">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000961"
      unitRef="Shares">312628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      id="Fact000965">P8Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">3594202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact000969"
      unitRef="USDPShares">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact000971">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z5SJdCUsAw6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"&gt;&lt;b&gt;Note 11 &#x2013; &lt;span id="xdx_820_zPuC4vamZWx5"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0 0"&gt;&lt;b&gt;&lt;span style="letter-spacing: 0pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On March 8, 2023, the Company
entered into a securities purchase agreement (&#x201c;Securities Purchase Agreement&#x201d;) with YA II PN, Ltd., an investment fund managed
by Yorkville Advisors Global, LP (&#x201c;Yorkville&#x201d;) under which the Company agreed to sell and issue to Yorkville convertible debentures
(&#x201c;Convertible Debentures&#x201d;) in a gross aggregate principal amount of up to $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20230308_pp0n6" title="Principal amount"&gt;11.2&lt;/span&gt; million (&#x201c;Subscription Amount&#x201d;).
The Convertible Debentures were convertible into shares of common stock of the Company and were subject to various contingencies being
satisfied as set forth in the Securities Purchase Agreement. The notes were convertible at any time through the maturity date, which,
in each case, was one year from the date of issuance. The conversion price was determined on the basis of &lt;span id="xdx_90A_ecustom--ConversionPriceDeterminedPercentage_c20230308_pdd" title="Conversion price determined percentage"&gt;92%&lt;/span&gt; of the two lowest VWAP (Volume
Weighted Average Prices) of the Common Stock during the prior seven trading day period, initially with a floor conversion price of $&lt;span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20230307__20230308_pdd" title="Floor conversion price"&gt;0.55&lt;/span&gt;,
but subsequently lowered by mutual agreement of the parties to $&lt;span id="xdx_90B_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20230307__20230308_pdd" title="Decrease floor conversion price"&gt;0.20&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On March 8, 2023, the Company
issued and sold to Yorkville a Convertible Debenture in the principal amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentIssuedPrincipal_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_zdfCN7k7wKp9" title="Principal amount"&gt;5.0&lt;/span&gt; million, for which it received $&lt;span id="xdx_904_ecustom--PrincipalAmountReceived_pn5n6_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ziIxVvgFNrQ" title="Principal amount received"&gt;4.5&lt;/span&gt; million, with
a $&lt;span id="xdx_901_ecustom--DebtInstrumentOriginalIssueDiscount_pp0p0_c20230307__20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_ztoQDNZJo29f" title="Debt Instrument original issue discount"&gt;500,000&lt;/span&gt; original issue discount (&#x201c;OID&#x201d;). Interest on the outstanding principal balance accrued at a rate of &lt;span id="xdx_90B_eus-gaap--ShortTermDebtPercentageBearingFixedInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance accrues percentage"&gt;0%&lt;/span&gt; and would
increase to &lt;span id="xdx_905_eus-gaap--ShortTermDebtPercentageBearingVariableInterestRate_c20230308__us-gaap--ShortTermDebtTypeAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Interest outstanding principal balance remains uncured percentage"&gt;15%&lt;/span&gt; upon an Event of Default for so long as it remained uncured.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company recorded a debt
discount related to identified embedded derivatives relating to the conversion features (see Note 12) based on fair values as of the inception
date of the Note. The calculated debt discount, including the OID, equaled the face of the Note and was amortized over the term of the
note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Yorkville fully converted the initial $&lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_z5n84HJU19c3" title="Conversion of convertible debt"&gt;5,000,000&lt;/span&gt;
Convertible Debenture into an aggregate of &lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--YorkvilleConvertibleDebentureMember_pdd" title="Conversion of shares converted"&gt;10,622,119&lt;/span&gt; shares of Common Stock during the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On January 4, 2024, the Company
and Yorkville terminated the Securities Purchase Agreement dated as of March 8, 2023, as amended, by the mutual consent of the parties,
effective as of January 4, 2024. The First Convertible Debenture was fully converted, and as of January 4, 2024, the obligation of the
Company to issue and sell, and Yorkville&#x2019;s obligation to purchase, the Second Convertible Debenture was terminated. At the time
of termination, there were no outstanding borrowings, advance notices or shares of Common Stock to be issued under the Securities Purchase
Agreement. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the Securities Purchase
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-08"
      decimals="0"
      id="Fact000973"
      unitRef="USD">11200000</us-gaap:DebtInstrumentFaceAmount>
    <cdio:ConversionPriceDeterminedPercentage
      contextRef="AsOf2023-03-08"
      decimals="INF"
      id="Fact000975"
      unitRef="Ratio">0.92</cdio:ConversionPriceDeterminedPercentage>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2023-03-072023-03-08"
      decimals="INF"
      id="Fact000977"
      unitRef="USDPShares">0.55</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2023-03-072023-03-08"
      decimals="INF"
      id="Fact000979"
      unitRef="USDPShares">0.20</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember"
      decimals="-5"
      id="Fact000981"
      unitRef="USD">5000000.0</us-gaap:DebtInstrumentIssuedPrincipal>
    <cdio:PrincipalAmountReceived
      contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember"
      decimals="-5"
      id="Fact000983"
      unitRef="USD">4500000</cdio:PrincipalAmountReceived>
    <cdio:DebtInstrumentOriginalIssueDiscount
      contextRef="From2023-03-072023-03-08_custom_YorkvilleConvertibleDebentureMember"
      decimals="0"
      id="Fact000985"
      unitRef="USD">500000</cdio:DebtInstrumentOriginalIssueDiscount>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember"
      decimals="INF"
      id="Fact000987"
      unitRef="Ratio">0</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2023-03-08_custom_YorkvilleConvertibleDebentureMember"
      decimals="INF"
      id="Fact000989"
      unitRef="Ratio">0.15</us-gaap:ShortTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember"
      decimals="0"
      id="Fact000991"
      unitRef="USD">5000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-01-012023-12-31_custom_YorkvilleConvertibleDebentureMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Shares">10622119</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2024-01-012024-12-31" id="Fact000995">&lt;p id="xdx_80C_eus-gaap--DerivativesAndFairValueTextBlock_zOloJLscBhxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
12 &#x2013; &lt;span id="xdx_829_z28Bg1hUmo3l"&gt;Derivative &lt;span style="letter-spacing: 0pt"&gt;Liability&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company has determined
that the conversion feature embedded in the convertible notes described in Note 11 contain a potential variable conversion amount which
constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding
discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately
to interest expense at inception, which aggregated $4,692,672. The Company used the Binomial Black-Scholes Option Pricing model to value
the conversion features.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 1pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes
option-pricing model with the following assumption inputs:&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zITA2HDXmO6g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_8B8_ziN7h3ix7bzh" style="display: none"&gt;Schedule of option liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Annual dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span title="Annual dividend yield"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zWoG2cQUPHx" title="Annual dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span title="Expected life (years)"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zpUNdjQGHwUj" title="Expected life (years)"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&#160;&lt;span title="Risk-free interest rate"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk-free interest rate"&gt;4.89%&lt;/span&gt;&lt;/span&gt; - &lt;span title="Risk-free interest rate"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Risk-free interest rate"&gt;5.59%&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&#160;&lt;span title="Expected volatility"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility"&gt;164%&lt;/span&gt;&lt;/span&gt; - &lt;span title="Expected volatility"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Expected volatility"&gt;187%&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&lt;span title="Exercise price"&gt;$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"&gt;0.19&lt;/span&gt;&lt;/span&gt; - &lt;span title="Exercise price"&gt;$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"&gt;3.53&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&lt;span title="Stock price"&gt;$&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Stock price"&gt;0.22&lt;/span&gt;&lt;/span&gt; - &lt;span title="Stock price"&gt;$&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Stock price"&gt;5.32&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Based
upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40
to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance
date.&#160;&lt;/p&gt;


</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock contextRef="From2024-01-012024-12-31" id="Fact000997">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zITA2HDXmO6g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_8B8_ziN7h3ix7bzh" style="display: none"&gt;Schedule of option liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Annual dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span title="Annual dividend yield"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zWoG2cQUPHx" title="Annual dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span title="Expected life (years)"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zpUNdjQGHwUj" title="Expected life (years)"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&#160;&lt;span title="Risk-free interest rate"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Risk-free interest rate"&gt;4.89%&lt;/span&gt;&lt;/span&gt; - &lt;span title="Risk-free interest rate"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Risk-free interest rate"&gt;5.59%&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&#160;&lt;span title="Expected volatility"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Expected volatility"&gt;164%&lt;/span&gt;&lt;/span&gt; - &lt;span title="Expected volatility"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Expected volatility"&gt;187%&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&lt;span title="Exercise price"&gt;$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"&gt;0.19&lt;/span&gt;&lt;/span&gt; - &lt;span title="Exercise price"&gt;$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"&gt;3.53&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"&gt;&lt;span title="Stock price"&gt;$&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MinimumMember_pdd" title="Stock price"&gt;0.22&lt;/span&gt;&lt;/span&gt; - &lt;span title="Stock price"&gt;$&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_c20241231__srt--RangeAxis__srt--MaximumMember_pdd" title="Stock price"&gt;5.32&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-012024-12-31" id="Fact001001">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001003"
      unitRef="Ratio">0.0489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001005"
      unitRef="Ratio">0.0559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001007"
      unitRef="Ratio">1.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001009"
      unitRef="Ratio">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001011"
      unitRef="USDPShares">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001013"
      unitRef="USDPShares">3.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001015"
      unitRef="USDPShares">0.22</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001017"
      unitRef="USDPShares">5.32</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001019">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zrddLXAWpkF9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
13 &#x2013; &lt;span id="xdx_82E_z5NG03DBmNMb"&gt;Income &lt;span style="letter-spacing: 0pt"&gt;Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The
reconciliation between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense
(benefit) for the years ended December 31, 2024 and 2023 is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkeEgAemkND" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zKXVVQApLLp5" style="display: none"&gt;Schedule of effective income tax rate reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;Statutory U.S. federal income tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_zA4fmfMuoFHb" title="Statutory U.S. federal income tax rate"&gt;(21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20230101__20231231_zV4xHFQww82f" title="Statutory U.S. federal income tax rate"&gt;(21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;State income taxes, net of federal income tax benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zauRogrk3fba" title="State income taxes, net of federal income tax benefit"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zfKHcofJHLd6" title="State income taxes, net of federal income tax benefit"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Tax effect of expenses that are not deductible for income tax purposes:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20240101__20241231_z3xZ1eWVpzie" title="Amortization of debt discount"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20230101__20231231_zoe6I5d1lHn1" title="Amortization of debt discount"&gt;16.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20240101__20241231_zlNbhtfeSNvi" title="Change in fair value of derivative liability"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20230101__20231231_zrlAUN2OWe24" title="Change in fair value of derivative liability"&gt;(13.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20240101__20241231_zpsgVc7bgcX8" title="Stock based compensation"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20230101__20231231_zXWf4EPQ4pa5" title="Stock based compensation"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20240101__20241231_zQ4nh9fiUQOg" title="Other"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20230101__20231231_zXmcFRScXv2b" title="Other"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231_zzbWtQx1Kqr3" title="Change in Valuation Allowance"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zMkTDce0G3Di" title="Change in Valuation Allowance"&gt;15.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20240101__20241231_zAxNr2oh5sQ1" title="Effective tax rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20230101__20231231_zUH8FsKfqPoi" title="Effective tax rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AB_zacfAkZFaQl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 1pt; text-indent: 0pt; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;At
December 31, the significant components of the deferred tax assets (liabilities) are summarized below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzHApVvRgZg5" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_ziywFiCgO7t" style="display: none"&gt;Schedule of deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zyUAvWW9pP9k" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zq1KrWC4RGy2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzbaL_zwsm03zDW9Tj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Net operating losses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,580,034&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;4,222,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzbaL_zvaVmaa4mRhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,743&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGzbaL_zR381ADtVbK2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,169&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzbaL_maDTANz3eX_zOXBo4tjngGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,607,531&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,224,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_zupMAopM0D5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Deferred Tax Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1073"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz3eX_zLDnL26YDvrl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,607,531&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,224,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz3eX_zZhxdOk5e1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zn4rTrr8Rww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;As
of December 31, 2024, the Company had federal net operating loss carryforwards of approximately $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"&gt;17.2&lt;/span&gt; million which may be carried forward
indefinitely, and state net operating loss carryforwards of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IA_pn5n6" title="Operating loss carryforwards"&gt;12.6&lt;/span&gt; million (Iowa) and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_c20241231__us-gaap--GeographicDistributionAxis__stpr--IL_pn5n6" title="Operating loss carryforwards"&gt;16.6&lt;/span&gt; million (Illinois), respectively
which expire at various dates from 2040 through 2044. These net operating loss carryforwards may be used to offset future taxable income
and thereby reduce the Company&#x2019;s U.S. federal income taxes. The net operating losses may be subject to limitation under Internal
Revenue Code Section 382 should there be a greater than &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_c20240101__20241231_pdd" title="Tax ownership percentage"&gt;50%&lt;/span&gt; change in ownership as determined under the regulations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In assessing the realization of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation
allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets
will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In accordance with ASC 740, a valuation allowance
must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration
of available positive and negative evidence, which includes, among other things, the Company&#x2019;s most recent results of operations
and expected future profitability. Based on the Company&#x2019;s cumulative losses in recent years, a full valuation allowance against
the Company&#x2019;s deferred tax assets as of December 31, 2024 and 2023 respectively has been established as Management believes that
the Company will not more likely than not realize the benefit of those deferred tax assets. Therefore, &lt;span id="xdx_909_ecustom--TaxProvision_iI_do_c20241231_z47qkGu7gRhj" title="Tax provision"&gt;&lt;span id="xdx_90F_ecustom--TaxProvision_iI_do_c20231231_zGC2nCmKuAB8" title="Tax provision"&gt;no&lt;/span&gt;&lt;/span&gt; tax provision has been recorded
for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company complies with
the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits
claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize
the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination
by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant
uncertain tax positions requiring recognition under ASC 740-10.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company is subject
to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or
any states in connection with income taxes. The Company&#x2019;s tax years generally remain open to examination for all federal and state
income tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The
federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute
of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a
period within the statute of limitations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company recognizes
interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. &lt;span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20240101__20241231_zK7I2jDtHR54" title="Interest or penalties"&gt;&lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20230101__20231231_zdIvJaIhp8zl" title="Interest or penalties"&gt;No&lt;/span&gt;&lt;/span&gt; interest or penalties
have been recorded for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On
March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic.
The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning
before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding
taxable years to generate a refund of previously paid income taxes. At present the Company does not expect that the NOL carryback provision
of the CARES Act will result in a material cash benefit to us.&lt;/p&gt;



</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001021">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkeEgAemkND" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zKXVVQApLLp5" style="display: none"&gt;Schedule of effective income tax rate reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;Statutory U.S. federal income tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20240101__20241231_zA4fmfMuoFHb" title="Statutory U.S. federal income tax rate"&gt;(21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20230101__20231231_zV4xHFQww82f" title="Statutory U.S. federal income tax rate"&gt;(21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;State income taxes, net of federal income tax benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20240101__20241231_zauRogrk3fba" title="State income taxes, net of federal income tax benefit"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20230101__20231231_zfKHcofJHLd6" title="State income taxes, net of federal income tax benefit"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Tax effect of expenses that are not deductible for income tax purposes:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Amortization of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20240101__20241231_z3xZ1eWVpzie" title="Amortization of debt discount"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_dp_c20230101__20231231_zoe6I5d1lHn1" title="Amortization of debt discount"&gt;16.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20240101__20241231_zlNbhtfeSNvi" title="Change in fair value of derivative liability"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_dp_c20230101__20231231_zrlAUN2OWe24" title="Change in fair value of derivative liability"&gt;(13.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20240101__20241231_zpsgVc7bgcX8" title="Stock based compensation"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_c20230101__20231231_zXWf4EPQ4pa5" title="Stock based compensation"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20240101__20241231_zQ4nh9fiUQOg" title="Other"&gt;(0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_dp_c20230101__20231231_zXmcFRScXv2b" title="Other"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231_zzbWtQx1Kqr3" title="Change in Valuation Allowance"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20230101__20231231_zMkTDce0G3Di" title="Change in Valuation Allowance"&gt;15.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20240101__20241231_zAxNr2oh5sQ1" title="Effective tax rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20230101__20231231_zUH8FsKfqPoi" title="Effective tax rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001023"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001025"
      unitRef="Ratio">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001027"
      unitRef="Ratio">-0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001029"
      unitRef="Ratio">-0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001031"
      unitRef="Ratio">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001033"
      unitRef="Ratio">0.168</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization>
    <cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001035"
      unitRef="Ratio">0.000</cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability>
    <cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001037"
      unitRef="Ratio">-0.135</cdio:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001039"
      unitRef="Ratio">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001041"
      unitRef="Ratio">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001043"
      unitRef="Ratio">-0.000</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001045"
      unitRef="Ratio">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001047"
      unitRef="Ratio">0.147</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001049"
      unitRef="Ratio">0.156</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001051"
      unitRef="Ratio">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001053"
      unitRef="Ratio">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-012024-12-31" id="Fact001055">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzHApVvRgZg5" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_ziywFiCgO7t" style="display: none"&gt;Schedule of deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zyUAvWW9pP9k" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zq1KrWC4RGy2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzbaL_zwsm03zDW9Tj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Net operating losses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,580,034&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;4,222,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGzbaL_zvaVmaa4mRhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,328&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,743&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_maDTAGzbaL_zR381ADtVbK2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;25,169&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzbaL_maDTANz3eX_zOXBo4tjngGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,607,531&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,224,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_zupMAopM0D5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Deferred Tax Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1073"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz3eX_zLDnL26YDvrl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,607,531&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,224,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz3eX_zZhxdOk5e1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001060"
      unitRef="USD">5580034</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001061"
      unitRef="USD">4222999</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001063"
      unitRef="USD">2328</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001064"
      unitRef="USD">1743</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">25169</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">5607531</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001070"
      unitRef="USD">4224742</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001075"
      unitRef="USD">5607531</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001076"
      unitRef="USD">4224742</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_FederalMember"
      decimals="-5"
      id="Fact001081"
      unitRef="USD">17200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_stpr_IA"
      decimals="-5"
      id="Fact001083"
      unitRef="USD">12600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_stpr_IL"
      decimals="-5"
      id="Fact001085"
      unitRef="USD">16600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001087"
      unitRef="Ratio">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <cdio:TaxProvision
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">0</cdio:TaxProvision>
    <cdio:TaxProvision
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">0</cdio:TaxProvision>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001093"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-012024-12-31" id="Fact001097">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7PufVHyV2u" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;Note
14 &#x2013; &lt;span id="xdx_826_zSkZfOyEPvZ5"&gt;Commitments and &lt;span style="letter-spacing: 0pt"&gt;Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Prior
Relationship of Cardio with Boustead Securities, &lt;span style="letter-spacing: -0.25pt"&gt;LLC&lt;/span&gt;&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;At the commencement of efforts
to pursue what ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services
Agreement (the &#x201c;Placement Agent Agreement&#x201d;), dated April 12, 2021, with Boustead Securities, LLC (&#x201c;Boustead Securities&#x201d;).
This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Under the terminated Placement
Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during
which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent
Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the
Company&#x2019;s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#x201c;right of
first refusal&#x201d;). Cardio has taken the position that due to Boustead Securities&#x2019; failure to perform as contemplated by the
Placement Agent Agreement, these provisions purporting to provide future rights are null and void.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Boustead Securities responded
to the termination of the Placement Agent Agreement by disputing Legacy Cardio&#x2019;s contention that it had not performed under the
Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response,
Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio&#x2019;s behalf. While Boustead Securities&#x2019;
contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such
contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination
of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly
disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential
party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so
at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome
will not have a material adverse impact on its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;The Benchmark Company, LLC Right of First Refusal&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;As noted in Note 1, the Company
completed the business combination on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13,
2022, Mana engaged The Benchmark Company, LLC (&#x201c;Benchmark&#x201d;) as its M&amp;amp;A advisor. Upon closing of the business combination,
Legacy Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment
No. 1 Engagement Letter (the &#x201c;Amendment Engagement&#x201d;). &lt;span id="xdx_904_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCRightOfFirstRefusalMember" title="Business combination reason, description"&gt;Pursuant to the Amendment Engagement, the parties agreed that the Company
would pay Benchmark $230,000 at the closing of the business combination and an additional $435,000 on October 25, 2023. Both of those
payments have been made in full. In addition, the Amendment Engagement provided that Benchmark has been granted a right of first refusal
to act as lead or joint-lead investment banker, lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future
public and private equity and debt offerings through October 25, 2023.&lt;/span&gt; Based on the right of first refusal, Benchmark alleges that it
is owed damages because the Company entered into the Yorkville Convertible Debenture Transaction (see Note 11) without first offering
Benchmark the right to serve as the lead or joint-lead placement agent for the transaction. The Company is evaluating the claim. No legal
proceedings have been instigated.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Demand Letter and Potential Mootness Fee &lt;span style="letter-spacing: 0pt"&gt;Claim&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On
June 25, 2022, a plaintiffs&#x2019; securities law firm sent a demand letter to the Company alleging that the Company&#x2019;s Registration
Statement on Form S-4 filed (the &#x201c;S-4 Registration Statement&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of
Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto,
the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022
and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2022,
the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023,
plaintiffs&#x2019; securities law firm contacted the Company&#x2019;s counsel asking who will be negotiating a mootness fee relating to
the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement,
as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required.
The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement
the S-4 Registration Statement under applicable laws. As of the date of filing of this Annual Report on Form 10-K, no lawsuit has been
filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution
cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Northland Securities, Inc.&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;In January 2024, following
the Company&#x2019;s termination of its agreement with Yorkville and in connection with the Company&#x2019;s recent at the market offering
and/or its February 2024 private placement, a managing director of Northland Securities, Inc. (&#x201c;Northland&#x201d;) contacted the
Company claiming the right to be paid a fee of approximately $&lt;span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p0" title="Termination fee"&gt;150,000&lt;/span&gt; pursuant to the agreement of March 1, 2023 between the Company and
Northland regarding the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland
would not proceed with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville
Securities Purchase Agreement and the subsequent financing transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company cannot preclude
the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could
potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing
on its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Directors and Officers Insurance&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with the Company&#x2019;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Notice of Non-Compliance with Nasdaq
Listing Requirements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;On June 3, 2024,
Cardio Diagnostics Holdings, Inc. (the &#x201c;Company&#x201d;) received a letter (the &#x201c;First Nasdaq Bid Price Letter&#x201d;) from The
Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2),
because the minimum bid price of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;) had closed below the minimum $&lt;span id="xdx_906_ecustom--CommonStockBidPrice_c20240603_pdd" title="Common stock bid price"&gt;1.00&lt;/span&gt; per
share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Minimum Bid Price
Requirement&#x201d;). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, or until December 2, 2024, to regain compliance.&#160;On December 4, 2024 (the &#x201c;Second Nasdaq Bid Price Letter&#x201d;), Nasdaq
notified the Company that Nasdaq&#x2019;s Staff has determined that the Company is eligible for an additional 180 calendar day period,
or until June 2, 2025, to regain compliance (the "Second Compliance Period&#x201d;). The determination is based on the Company&#x2019;s
meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing
on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company&#x2019;s written notice of its intention
to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. If the Company chooses to
implement a reverse stock split, it must complete the split no later than ten business days prior to the end of the Second Compliance
Period in order to timely regain compliance. As of the date of this report the Common Stock has not regained compliance with the Minimum
Bid Price Requirement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;If we fail to
regain compliance with the minimum bid requirement within the cure period (or extended cure period) or if we fail to continue to meet
all applicable continued listing requirements for Nasdaq in the future, Nasdaq could delist our securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;/p&gt;



</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationReasonForBusinessCombination
      contextRef="From2024-01-012024-12-31_custom_TheBenchmarkCompanyLLCRightOfFirstRefusalMember"
      id="Fact001099">Pursuant to the Amendment Engagement, the parties agreed that the Company
would pay Benchmark $230,000 at the closing of the business combination and an additional $435,000 on October 25, 2023. Both of those
payments have been made in full. In addition, the Amendment Engagement provided that Benchmark has been granted a right of first refusal
to act as lead or joint-lead investment banker, lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future
public and private equity and debt offerings through October 25, 2023.</us-gaap:BusinessCombinationReasonForBusinessCombination>
    <cdio:TerminationFee
      contextRef="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">150000</cdio:TerminationFee>
    <cdio:CommonStockBidPrice
      contextRef="AsOf2024-06-03"
      decimals="INF"
      id="Fact001104"
      unitRef="USDPShares">1.00</cdio:CommonStockBidPrice>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-012024-12-31" id="Fact001106">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zY9AM4GHUcW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&#160;&lt;b&gt;Note 15 &#x2013; &lt;span id="xdx_825_z3skOqY1fdz"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;The Company evaluated its December 31, 2024 consolidated financial statements
for subsequent events through the date the consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Sales of the Company&#x2019;s Common Stock may
be made pursuant to the Sales Agreement up to an aggregate of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250201__20250207__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zQpiMK8Ymcvg" title="Proceeds from issuance of common stock"&gt;9,476,508&lt;/span&gt; under the Company&#x2019;s Registration Statement on Form
S-3 filed on February 7, 2025 (File No. 333-284775), declared effective by the SEC on February 14, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued&lt;/span&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;Subsequent to December 31, 2024, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Number of common stock issued"&gt;6,201,377&lt;/span&gt; shares of Common
Stock for gross proceeds totaling $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250320__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Proceeds from issuance of common stock"&gt;3,511,042&lt;/span&gt; under the At-the-Market Issuance Sales Agreement as of the date of this report.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-02-012025-02-07_custom_SalesAgreementMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">9476508</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-20_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001110"
      unitRef="Shares">6201377</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-03-20_custom_SalesAgreementMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">3511042</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:Cash
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001120"
      unitRef="USD">7966500</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001121"
      unitRef="USD">7827487</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001123"
      unitRef="USD">12927</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001124"
      unitRef="USD">18612</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001126"
      unitRef="USD">723921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001127"
      unitRef="USD">944683</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001129"
      unitRef="USD">8703348</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001130"
      unitRef="USD">8790782</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001135"
      unitRef="USD">621903</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001136"
      unitRef="USD">672861</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001138"
      unitRef="USD">347298</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001139"
      unitRef="USD">432397</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001142"
      unitRef="USD">5333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001144"
      unitRef="USD">12850</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">12850</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001147"
      unitRef="USD">711148</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001148"
      unitRef="USD">701089</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001150"
      unitRef="USD">10396547</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">10615312</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001159"
      unitRef="USD">48724</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001160"
      unitRef="USD">87661</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001162"
      unitRef="USD">244182</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001163"
      unitRef="USD">237270</us-gaap:OperatingLeaseLiabilityCurrent>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001165"
      unitRef="USD">76691</cdio:FinanceAgreementPayable>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">306764</cdio:FinanceAgreementPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001168"
      unitRef="USD">369597</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001169"
      unitRef="USD">631695</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001174"
      unitRef="USD">302251</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001175"
      unitRef="USD">425829</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001177"
      unitRef="USD">671848</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001178"
      unitRef="USD">1057524</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001186"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001188"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001192"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001198"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001200"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001207"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact001209"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001213"
      unitRef="Shares">1740269</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001215"
      unitRef="Shares">1740269</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001217"
      unitRef="Shares">1531468</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001219"
      unitRef="Shares">1531468</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001202"
      unitRef="USD">17</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001203"
      unitRef="USD">15</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001221"
      unitRef="USD">35794778</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">32309606</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001224"
      unitRef="USD">-26070096</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">-22751833</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001227"
      unitRef="USD">9724699</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001228"
      unitRef="USD">9557788</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001230"
      unitRef="USD">10396547</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">10615312</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001234"
      unitRef="USD">7475</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001235"
      unitRef="USD">7870</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001236"
      unitRef="USD">8415</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001237"
      unitRef="USD">23798</us-gaap:Revenues>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001244"
      unitRef="USD">1686174</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001245"
      unitRef="USD">1290330</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001246"
      unitRef="USD">3317674</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001247"
      unitRef="USD">5464306</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001249"
      unitRef="USD">1686174</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001250"
      unitRef="USD">1290330</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001251"
      unitRef="USD">3317674</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001252"
      unitRef="USD">5464306</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001254"
      unitRef="USD">-1678699</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001255"
      unitRef="USD">-1282460</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001256"
      unitRef="USD">-3309259</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001257"
      unitRef="USD">-5440508</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001264"
      unitRef="USD">190</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001265"
      unitRef="USD">282</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001266"
      unitRef="USD">377</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001267"
      unitRef="USD">563</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001269"
      unitRef="USD">4690</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001270"
      unitRef="USD">5817</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001271"
      unitRef="USD">9381</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001272"
      unitRef="USD">11634</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001274"
      unitRef="USD">-4500</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001275"
      unitRef="USD">-5535</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001276"
      unitRef="USD">-9004</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001277"
      unitRef="USD">-11071</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001279"
      unitRef="USD">-1683199</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001280"
      unitRef="USD">-1287995</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001281"
      unitRef="USD">-3318263</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001282"
      unitRef="USD">-5451579</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001289"
      unitRef="USD">-1683199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001290"
      unitRef="USD">-1287995</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001291"
      unitRef="USD">-3318263</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001292"
      unitRef="USD">-5451579</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact001299"
      unitRef="USDPShares">-0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact001301"
      unitRef="USDPShares">-0.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001303"
      unitRef="USDPShares">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001305"
      unitRef="USDPShares">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001307"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001309"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">-7.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">-7.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact001315"
      unitRef="Shares">1739045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">1739045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001319"
      unitRef="Shares">753587</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001321"
      unitRef="Shares">753587</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001323"
      unitRef="Shares">1712741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">1712741</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">728081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">728081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <cdio:ShareOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">1531468</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001332"
      unitRef="USD">15</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">32309606</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001334"
      unitRef="USD">-22751833</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001335"
      unitRef="USD">9557788</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cdio:CommonStockIssuedForCashShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001344"
      unitRef="Shares">206713</cdio:CommonStockIssuedForCashShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001339"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001340"
      unitRef="USD">3423782</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001342"
      unitRef="USD">3423784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Shares">502</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001349"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001354"
      unitRef="USD">24612</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001356"
      unitRef="USD">24612</cdio:CompensationForVestedStockOptions>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">-1635064</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact001361"
      unitRef="USD">-1635064</us-gaap:ProfitLoss>
    <cdio:ShareOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">1738683</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">17</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">35764000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001365"
      unitRef="USD">-24386897</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact001366"
      unitRef="USD">11377120</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">1559</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001371"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001373"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">24778</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001380"
      unitRef="USD">24778</cdio:CompensationForVestedStockOptions>
    <cdio:FractionalSharesAdjustmentShares
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">27</cdio:FractionalSharesAdjustmentShares>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001391"
      unitRef="USD">-1683199</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact001392"
      unitRef="USD">-1683199</us-gaap:ProfitLoss>
    <cdio:ShareOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001399"
      unitRef="Shares">1740269</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">17</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001395"
      unitRef="USD">35794778</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">-26070096</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001397"
      unitRef="USD">9724699</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cdio:ShareOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">684680</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">7</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001402"
      unitRef="USD">17326497</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">-14368380</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001404"
      unitRef="USD">2958124</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cdio:CommonStockIssuedForCashShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">34963</cdio:CommonStockIssuedForCashShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">1722857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001411"
      unitRef="USD">1722857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Shares">1323</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001416"
      unitRef="USD">58000</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001418"
      unitRef="USD">58000</cdio:RestrictedStockAwardsVested>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">2461404</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001425"
      unitRef="USD">2461404</cdio:CompensationForVestedStockOptions>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001429"
      unitRef="USD">-4163584</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact001430"
      unitRef="USD">-4163584</us-gaap:ProfitLoss>
    <cdio:ShareOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001437"
      unitRef="Shares">720966</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001432"
      unitRef="USD">7</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">21568758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">-18531964</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact001435"
      unitRef="USD">3036801</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cdio:CommonStockIssuedForCashShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001444"
      unitRef="Shares">55822</cdio:CommonStockIssuedForCashShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001440"
      unitRef="USD">1298698</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001442"
      unitRef="USD">1298699</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cdio:RestrictedStockAwardsVestedShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001451"
      unitRef="Shares">315</cdio:RestrictedStockAwardsVestedShares>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:RestrictedStockAwardsVested
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001449"
      unitRef="USD">6000</cdio:RestrictedStockAwardsVested>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001454"
      unitRef="USD">20731</cdio:CompensationForVestedStockOptions>
    <cdio:CompensationForVestedStockOptions
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001456"
      unitRef="USD">20731</cdio:CompensationForVestedStockOptions>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">-1287995</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact001461"
      unitRef="USD">-1287995</us-gaap:ProfitLoss>
    <cdio:ShareOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001468"
      unitRef="Shares">777103</cdio:ShareOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">8</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">22894187</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">-19819959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001466"
      unitRef="USD">3074236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001474"
      unitRef="USD">-3318263</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001475"
      unitRef="USD">-5451579</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001480"
      unitRef="USD">75441</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001481"
      unitRef="USD">39579</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001483"
      unitRef="USD">139022</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001484"
      unitRef="USD">69877</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001486"
      unitRef="USD">61390</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001487"
      unitRef="USD">2546135</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001492"
      unitRef="USD">-5685</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001493"
      unitRef="USD">2560</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001495"
      unitRef="USD">-220762</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001496"
      unitRef="USD">-656310</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001498"
      unitRef="USD">-38937</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001499"
      unitRef="USD">-191132</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001501"
      unitRef="USD">-116666</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001502"
      unitRef="USD">-110080</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001504"
      unitRef="USD">-2971566</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001505"
      unitRef="USD">-2443450</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001510"
      unitRef="USD">24483</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001511"
      unitRef="USD">187881</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001513"
      unitRef="USD">58649</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001514"
      unitRef="USD">83129</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001516"
      unitRef="USD">-83132</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001517"
      unitRef="USD">-271010</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001522"
      unitRef="USD">3423784</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001523"
      unitRef="USD">3021556</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <cdio:PaymentsToAcquireFinanceReceivable
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001525"
      unitRef="USD">230073</cdio:PaymentsToAcquireFinanceReceivable>
    <cdio:PaymentsToAcquireFinanceReceivable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001526"
      unitRef="USD">280500</cdio:PaymentsToAcquireFinanceReceivable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001528"
      unitRef="USD">3193711</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001529"
      unitRef="USD">2741056</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001531"
      unitRef="USD">139013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001532"
      unitRef="USD">26596</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001534"
      unitRef="USD">7827487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001535"
      unitRef="USD">1283523</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001537"
      unitRef="USD">7966500</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001538"
      unitRef="USD">1310119</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001546"
      unitRef="USD">9381</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001547"
      unitRef="USD">11634</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001552">&lt;p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zK9kI5JM98pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1 - &lt;span id="xdx_828_zr0p1iZr6SJ2"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated financial statements presented
are those of Cardio Diagnostics Holdings, Inc., (the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Cardio Diagnostics, Inc.
(&#x201c;Legacy Cardio&#x201d;). The Company was incorporated as Mana Capital Acquisition Corp. (&#x201c;Mana&#x201d;) under the laws of the
state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics,
LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019. The Company was formed to develop and commercialize
a patent-pending Artificial Intelligence (&#x201c;AI&#x201d;)-driven DNA biomarker testing technology (&#x201c;Core Technology&#x201d;) for
cardiovascular disease invented at the University of Iowa by the Founders, with the goal of becoming one of the leading medical technology
companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the
approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for
major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure and
diabetes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Interim Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following (a)  consolidated balance sheet
as of December 31, 2024, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim
financial statements of the Company as of and for the period ended June 30, 2025 have been prepared in accordance with the instructions
to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for
complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative
of results that may be expected for the year ending December 31, 2025 or any future periods. These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December
31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
on March 20, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Reverse Stock Split&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company held its annual meeting of stockholders
on November 15, 2024, where the Company&#x2019;s stockholders approved a reverse stock split at a ratio within a range of&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250101__20250630_z4fc6rvNoeK8" title="Reverse stock split"&gt;1-for-5
and&#160;1-for-40&lt;/span&gt; and granted the Company&#x2019;s Board of Directors the discretion to determine the timing and ratio of the split within
such range.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 10, 2025, the Company&#x2019;s Board
of Directors determined to effect the reverse stock split of the common stock at a&#160;1-for-30 ratio (the "Reverse Stock Split&#x201d;)
and approved the filing of a Certificate of Amendment (the "Certificate of Amendment&#x201d;) to the Third Amended and Restated Certificate
of Incorporation of the Company to effect the Reverse Stock Split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 12, 2025, the Company filed the Certificate
of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, effective immediately after the close of trading
on Nasdaq on May 12, 2025 (the "Effective Time&#x201d;). At the Effective Time, every 30 shares of issued and outstanding common stock
automatically combined into one issued share of common stock, with no change in par value. No fractional shares were issued as a result
of the Reverse Stock Split. Instead of issuing fractional shares, the Company rounded shares up or down to the nearest whole number as
determined by DTC at the participant level. The Reverse Stock Split did not modify any voting rights or other terms of the common stock.
The Company&#x2019;s common stock began trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market at the open of the
markets on May 13, 2025. The Reverse Stock Split was implemented for the purpose of regaining compliance with the minimum bid price requirement
for continued listing of the Company&#x2019;s common stock on the Nasdaq Capital Market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As a result of the Reverse Stock Split,
the number of shares of common stock outstanding was reduced from&#160;52,160,487&#160;shares to&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20250512_zLEhJFGXBrK" title="Common stock, shares outstanding"&gt;1,738,683&lt;/span&gt;&#160;shares,
exclusive of 27 whole shares issued for rounding up fractional shares (which was issued in May 2025), and the number of authorized
shares of common stock remains&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE9yZ2FuaXphdGlvbiBhbmQgQmFzaXMgb2YgUHJlc2VudGF0aW9uIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pn5n6_c20250630_zUXvz5lEfOXi" title="Common stock, shares authorized"&gt;300&lt;/span&gt;&#160;million
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Unless otherwise indicated, all  issued,
and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted
to reflect the&#160;1-for-30 Reverse Stock Split for all prior periods presented.&#160;Proportionate adjustments for the Reverse Stock
Split were made to the exercise prices and number of shares issuable under the Company&#x2019;s equity incentive plans, and the number
of shares underlying outstanding equity awards, as applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The impacts of the Reverse Stock Split were applied
retroactively for all periods presented in accordance with applicable guidance, less the number of rounded whole shares issued for fractional
shares on May 12, 2025. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following
tables may not foot due to rounding.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table illustrates changes in equity,
as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse Stock Split retroactively adjusted for the
periods presented:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSubsequentEventsTextBlock_zpYZjRGCbUsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BF_zt84fx4y3b03" style="display: none"&gt;Schedule of subsequent events&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--CommonStockShares_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z0P94rZzChEg" title="Common stock - shares"&gt;23,313,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(22,535,967&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;777,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--CommonStockValues_iI_pp0d_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbJTmqYMjgwe" title="Common stock - amount"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;22,893,962&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;22,894,187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;March
    31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlCGB6q1lAo5" title="Common stock - shares"&gt;21,628,974&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zY3KZL3tZji5" title="Common stock - shares"&gt;(20,908,008&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z3wGkOP3IwR6" title="Common stock - shares"&gt;720,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zepu5rMhFSc4" title="Common stock - amount"&gt;216&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z9WxqGHZVmEe" title="Common stock - amount"&gt;(209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_zpisezl81zd6" title="Common stock - amount"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzlGBn0KrMzl" title="Additional paid-in capital"&gt;21,568,549&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zWf6HDeIzXd8" title="Additional paid-in capital"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z4DbKHEBQAm1" title="Additional paid-in capital"&gt;21,568,758&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December
    31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"&gt;45,944,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(44,412,571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;1,531,468&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"&gt;459&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(444&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;32,309,162&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;32,309,606&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December
    31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"&gt;20,540,409&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(19,855,729&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;684,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;17,326,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;17,326,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z6w6NjRtD9K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table illustrates changes in loss per
share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse
Stock Split retroactively adjusted for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_zpY1nXvhMbNf" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BD_z3AbVHx5SOmg" style="display: none"&gt;Schedule of loss per share and weighted average shares outstanding&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six months ended June
    30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders"&gt;(5,451,579&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Loss attributable to common shareholders"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1639"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders"&gt;(5,451,579&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares used to compute basic and
    diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zi6jVSxtJug4" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6xhhlWAEj0d" title="Weighted average common shares outstanding, fully diluted"&gt;21,842,422&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;(21,114,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;728,081&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted"&gt;(0.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted"&gt;(7.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted"&gt;(7.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Three
    months ended June 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 5.4pt"&gt;Loss attributable to common shareholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders"&gt;(1,287,995&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--NetIncomeLoss_pp0d_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z608DvtVr0Z7" title="Loss attributable to common shareholders"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders"&gt;(1,287,995&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Weighted average shares used to compute basic and diluted EPS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;22,607,618&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;(21,854,031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;753,587&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Loss per share - basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted"&gt;(0.06&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted"&gt;(1.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted"&gt;(1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zz5rjvTplPx" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation
of diluted shares outstanding because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOWarrantsExercisableTextBlock_zCu6qmEE8mZ7" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8B9_zja0MIWV8Jai" style="display: none"&gt;Schedule of warrants exercisable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six months ended June
    30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBUuIFKhWLKa" title="Common stock options"&gt;3,796,725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock options"&gt;(3,670,168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock options"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZGhGby5IEQ5" title="Common stock warrants"&gt;8,528,766&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock warrants"&gt;(8,244,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock warrants"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zEieOGR6BSG6" style="font: 9pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;Stock options were adjusted retroactively to
give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_zcFHdmLaMnQh" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_zBHOArNBgO1e" style="display: none"&gt;Schedule of Warrants adjustment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zR616nd98ZTb" title="Options outstanding, beginning"&gt;2,584,599&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3uOjSwFxC44" title="Weighted average exercise price outstanding, beginning"&gt;3.06&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z34kfibtIwt3" title="Options outstanding, beginning"&gt;(2,498,446&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zJ9SSnoR0Jw1" title="Weighted average exercise price outstanding, beginning"&gt;88.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zSPbPGFxKZEi" title="Options outstanding, beginning"&gt;86,153&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zD9reunbj5qa" title="Weighted average exercise price outstanding, beginning"&gt;91.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGG3WxZZQ3B8" title="Options granted"&gt;1,218,126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price granted"&gt;2.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options granted"&gt;(1,177,522&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price granted"&gt;60.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options granted"&gt;40,604&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price granted"&gt;62.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmBHkmjywouk" title="Options cancelled"&gt;(6,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price cancelled"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z7OmQWfrVAIk" title="Options cancelled"&gt;5,800&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price cancelled"&gt;61.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zIuYcGYDcfwl" title="Options cancelled"&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price cancelled"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5AzGUcG24hc" title="Options outstanding, ending"&gt;3,796,725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6Yi8BjVYlTc" title="Weighted average exercise price outstanding, ending"&gt;2.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zYSYNxFVGy3b" title="Options outstanding, ending"&gt;(3,670,168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z8ArIw1NhnG7" title="Weighted average exercise price outstanding, ending"&gt;79.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zWcFEIPqnHTb" title="Options outstanding, ending"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_z6RrXAsbfll8" title="Weighted average exercise price outstanding, ending"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--OptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ywNTqRtCih" title="Options vested and exercisable"&gt;3,789,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zk6bfUxx9En8" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;2.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options vested and exercisable"&gt;(3,662,918&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;79.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options vested and exercisable"&gt;126,307&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zM3n5OyRUNv3" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Warrants were adjusted
retroactively to give effect to the Reverse Stock Split for the six months ended June 30,&#160;2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfWarrantsAdjustmentsTableTextBlock_zDY4zYb0EIta" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_zY1wGgYEBwWj" style="display: none"&gt;Schedule of Warrants adjustment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKWqwhAdgGcj" title="Warrants outstanding, beginning"&gt;7,854,620&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z17giM8MmWsb" title="Weighted average exercise price outstanding, beginning"&gt;9.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ztOJEeRGXhE8" title="Warrants outstanding, beginning"&gt;(7,592,799&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zqDQ5IDT7xq7" title="Weighted average exercise price outstanding, beginning"&gt;281.35&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zEnRBiZbAVni" title="Warrants outstanding, beginning"&gt;261,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zQ7RLz7NP28a" title="Weighted average exercise price outstanding, beginning"&gt;291.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhH8hkXhTj78" title="Warrants granted"&gt;674,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price, granted"&gt;1.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ziFj1lIFLsy6" title="Warrants granted"&gt;(651,675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, granted"&gt;51.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zqFWAjVDb1Ub" title="Warrants granted"&gt;22,471&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, granted"&gt;53.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;Warrants cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFfFZymhHLTc" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zywJi7N2dSv1" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx1gjKa7t7ue" title="Warrants outstanding, ending"&gt;8,528,766&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zT9MFQyIVsw4" title="Weighted average exercise price outstanding, ending"&gt;9.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zZRxYowVaOJ7" title="Warrants outstanding, ending"&gt;(8,244,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zLFD4vn8jDak" title="Weighted average exercise price outstanding, ending"&gt;263.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zpZZgfUzQoed" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zrYGbwhJwujk" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zv1vLxFagL05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-01-01to2025-06-30" id="Fact001554">1-for-5
and&#160;1-for-40</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-05-12"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">1738683</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact001558"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001561">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSubsequentEventsTextBlock_zpYZjRGCbUsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BF_zt84fx4y3b03" style="display: none"&gt;Schedule of subsequent events&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--CommonStockShares_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z0P94rZzChEg" title="Common stock - shares"&gt;23,313,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(22,535,967&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockShares_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;777,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--CommonStockValues_iI_pp0d_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbJTmqYMjgwe" title="Common stock - amount"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--CommonStockValues_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;22,893,962&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;225&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;22,894,187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;March
    31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlCGB6q1lAo5" title="Common stock - shares"&gt;21,628,974&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zY3KZL3tZji5" title="Common stock - shares"&gt;(20,908,008&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockShares_iI_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z3wGkOP3IwR6" title="Common stock - shares"&gt;720,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zepu5rMhFSc4" title="Common stock - amount"&gt;216&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z9WxqGHZVmEe" title="Common stock - amount"&gt;(209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--CommonStockValues_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_zpisezl81zd6" title="Common stock - amount"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzlGBn0KrMzl" title="Additional paid-in capital"&gt;21,568,549&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zWf6HDeIzXd8" title="Additional paid-in capital"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AdditionalPaidInCapital_iI_pp0d_c20240331__srt--RestatementAxis__custom--AsRevisedMember_z4DbKHEBQAm1" title="Additional paid-in capital"&gt;21,568,758&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December
    31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"&gt;45,944,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(44,412,571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--CommonStockShares_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;1,531,468&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"&gt;459&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(444&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--CommonStockValues_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;32,309,162&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AdditionalPaidInCapital_c20241231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;32,309,606&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December
    31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt"&gt;Common stock - shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Common stock - shares"&gt;20,540,409&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock - shares"&gt;(19,855,729&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_902_ecustom--CommonStockShares_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock - shares"&gt;684,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Common stock - amount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Common stock - amount"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Common stock - amount"&gt;(198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--CommonStockValues_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Common stock - amount"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Additional paid-in capital"&gt;17,326,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Additional paid-in capital"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AdditionalPaidInCapital_c20231231__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Additional paid-in capital"&gt;17,326,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSubsequentEventsTextBlock>
    <cdio:CommonStockShares
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">23313070</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">-22535967</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001567"
      unitRef="Shares">777103</cdio:CommonStockShares>
    <cdio:CommonStockValues
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">233</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">-225</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">8</cdio:CommonStockValues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001575"
      unitRef="USD">22893962</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001577"
      unitRef="USD">225</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">22894187</us-gaap:AdditionalPaidInCapital>
    <cdio:CommonStockShares
      contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001581"
      unitRef="Shares">21628974</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001583"
      unitRef="Shares">-20908008</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-03-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001585"
      unitRef="Shares">720966</cdio:CommonStockShares>
    <cdio:CommonStockValues
      contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">216</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001589"
      unitRef="USD">-209</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-03-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001591"
      unitRef="USD">7</cdio:CommonStockValues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">21568549</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001595"
      unitRef="USD">209</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">21568758</us-gaap:AdditionalPaidInCapital>
    <cdio:CommonStockShares
      contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001599"
      unitRef="Shares">45944039</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001601"
      unitRef="Shares">-44412571</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2024-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001603"
      unitRef="Shares">1531468</cdio:CommonStockShares>
    <cdio:CommonStockValues
      contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001605"
      unitRef="USD">459</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001607"
      unitRef="USD">-444</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2024-12-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001609"
      unitRef="USD">15</cdio:CommonStockValues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001611"
      unitRef="USD">32309162</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001613"
      unitRef="USD">444</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001615"
      unitRef="USD">32309606</us-gaap:AdditionalPaidInCapital>
    <cdio:CommonStockShares
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001617"
      unitRef="Shares">20540409</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">-19855729</cdio:CommonStockShares>
    <cdio:CommonStockShares
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001621"
      unitRef="Shares">684680</cdio:CommonStockShares>
    <cdio:CommonStockValues
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001623"
      unitRef="USD">205</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001625"
      unitRef="USD">-198</cdio:CommonStockValues>
    <cdio:CommonStockValues
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001627"
      unitRef="USD">7</cdio:CommonStockValues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001629"
      unitRef="USD">17326299</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="0"
      id="Fact001631"
      unitRef="USD">198</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">17326497</us-gaap:AdditionalPaidInCapital>
    <cdio:ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001635">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock_zpY1nXvhMbNf" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BD_z3AbVHx5SOmg" style="display: none"&gt;Schedule of loss per share and weighted average shares outstanding&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six months ended June
    30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Loss attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders"&gt;(5,451,579&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pp0p" title="Loss attributable to common shareholders"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1639"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders"&gt;(5,451,579&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares used to compute basic and
    diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zi6jVSxtJug4" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6xhhlWAEj0d" title="Weighted average common shares outstanding, fully diluted"&gt;21,842,422&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;(21,114,341&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;728,081&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted"&gt;(0.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted"&gt;(7.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted"&gt;(7.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Three
    months ended June 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 5.4pt"&gt;Loss attributable to common shareholders&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pp0p" title="Loss attributable to common shareholders"&gt;(1,287,995&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--NetIncomeLoss_pp0d_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z608DvtVr0Z7" title="Loss attributable to common shareholders"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pp0p" title="Loss attributable to common shareholders"&gt;(1,287,995&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Weighted average shares used to compute basic and diluted EPS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_907_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;22,607,618&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;(21,854,031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageCommonSharesOutstandingBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, basic"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageCommonSharesOutstandingFullyDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average common shares outstanding, fully diluted"&gt;753,587&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Loss per share - basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Net loss per common share, diluted"&gt;(0.06&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Net loss per common share, diluted"&gt;(1.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Net loss per common share, diluted"&gt;(1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</cdio:ScheduleOfLossPerShareAndWeightedAverageSharesOutstandingTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">-5451579</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="0"
      id="Fact001641"
      unitRef="USD">-5451579</us-gaap:NetIncomeLoss>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001643"
      unitRef="Shares">21842422</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001645"
      unitRef="Shares">21842422</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Shares">-21114341</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001649"
      unitRef="Shares">-21114341</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001651"
      unitRef="Shares">728081</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001653"
      unitRef="Shares">728081</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001655"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001657"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001659"
      unitRef="USDPShares">-7.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001661"
      unitRef="USDPShares">-7.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001663"
      unitRef="USDPShares">-7.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001665"
      unitRef="USDPShares">-7.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001667"
      unitRef="USD">-1287995</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_AsRevisedMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">-1287995</us-gaap:NetIncomeLoss>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001673"
      unitRef="Shares">22607618</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001675"
      unitRef="Shares">22607618</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001677"
      unitRef="Shares">-21854031</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001679"
      unitRef="Shares">-21854031</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <cdio:WeightedAverageCommonSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001681"
      unitRef="Shares">753587</cdio:WeightedAverageCommonSharesOutstandingBasic>
    <cdio:WeightedAverageCommonSharesOutstandingFullyDiluted
      contextRef="From2024-04-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001683"
      unitRef="Shares">753587</cdio:WeightedAverageCommonSharesOutstandingFullyDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001685"
      unitRef="USDPShares">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001687"
      unitRef="USDPShares">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001689"
      unitRef="USDPShares">-1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001691"
      unitRef="USDPShares">-1.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001693"
      unitRef="USDPShares">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001695"
      unitRef="USDPShares">-1.71</us-gaap:EarningsPerShareDiluted>
    <cdio:ScheduleOWarrantsExercisableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001697">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOWarrantsExercisableTextBlock_zCu6qmEE8mZ7" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8B9_zja0MIWV8Jai" style="display: none"&gt;Schedule of warrants exercisable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six months ended June
    30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBUuIFKhWLKa" title="Common stock options"&gt;3,796,725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock options"&gt;(3,670,168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--CommonStockOptions_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock options"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZGhGby5IEQ5" title="Common stock warrants"&gt;8,528,766&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Common stock warrants"&gt;(8,244,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--CommonStockWarrants_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Common stock warrants"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</cdio:ScheduleOWarrantsExercisableTextBlock>
    <cdio:CommonStockOptions
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001699"
      unitRef="Shares">3796725</cdio:CommonStockOptions>
    <cdio:CommonStockOptions
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001701"
      unitRef="Shares">-3670168</cdio:CommonStockOptions>
    <cdio:CommonStockOptions
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001703"
      unitRef="Shares">126557</cdio:CommonStockOptions>
    <cdio:CommonStockWarrants
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001705"
      unitRef="Shares">8528766</cdio:CommonStockWarrants>
    <cdio:CommonStockWarrants
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001707"
      unitRef="Shares">-8244474</cdio:CommonStockWarrants>
    <cdio:CommonStockWarrants
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001709"
      unitRef="Shares">284292</cdio:CommonStockWarrants>
    <cdio:ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001712">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock_zcFHdmLaMnQh" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_zBHOArNBgO1e" style="display: none"&gt;Schedule of Warrants adjustment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zR616nd98ZTb" title="Options outstanding, beginning"&gt;2,584,599&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z3uOjSwFxC44" title="Weighted average exercise price outstanding, beginning"&gt;3.06&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z34kfibtIwt3" title="Options outstanding, beginning"&gt;(2,498,446&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zJ9SSnoR0Jw1" title="Weighted average exercise price outstanding, beginning"&gt;88.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zSPbPGFxKZEi" title="Options outstanding, beginning"&gt;86,153&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zD9reunbj5qa" title="Weighted average exercise price outstanding, beginning"&gt;91.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGG3WxZZQ3B8" title="Options granted"&gt;1,218,126&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price granted"&gt;2.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options granted"&gt;(1,177,522&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price granted"&gt;60.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options granted"&gt;40,604&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price granted"&gt;62.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Options
    cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmBHkmjywouk" title="Options cancelled"&gt;(6,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price cancelled"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z7OmQWfrVAIk" title="Options cancelled"&gt;5,800&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price cancelled"&gt;61.19&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zIuYcGYDcfwl" title="Options cancelled"&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price cancelled"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5AzGUcG24hc" title="Options outstanding, ending"&gt;3,796,725&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z6Yi8BjVYlTc" title="Weighted average exercise price outstanding, ending"&gt;2.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zYSYNxFVGy3b" title="Options outstanding, ending"&gt;(3,670,168&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_z8ArIw1NhnG7" title="Weighted average exercise price outstanding, ending"&gt;79.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zWcFEIPqnHTb" title="Options outstanding, ending"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_z6RrXAsbfll8" title="Weighted average exercise price outstanding, ending"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--OptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ywNTqRtCih" title="Options vested and exercisable"&gt;3,789,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_iI_c20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zk6bfUxx9En8" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;2.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Options vested and exercisable"&gt;(3,662,918&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;79.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--OptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Options vested and exercisable"&gt;126,307&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable_c20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price outstanding, Options vested and exercisable"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</cdio:ScheduleOfGiveEffectToTheReverseStockSplitTableTextBlock>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001714"
      unitRef="Shares">2584599</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001716"
      unitRef="USDPShares">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001718"
      unitRef="Shares">-2498446</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001720"
      unitRef="USDPShares">88.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001722"
      unitRef="Shares">86153</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001724"
      unitRef="USDPShares">91.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001726"
      unitRef="Shares">1218126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001728"
      unitRef="USDPShares">2.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001730"
      unitRef="Shares">-1177522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001732"
      unitRef="USDPShares">60.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001734"
      unitRef="Shares">40604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001736"
      unitRef="USDPShares">62.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Shares">-6000</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001740"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Shares">5800</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">61.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001746"
      unitRef="Shares">-200</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCanncelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">63.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001750"
      unitRef="Shares">3796725</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001752"
      unitRef="USDPShares">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001754"
      unitRef="Shares">-3670168</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001756"
      unitRef="USDPShares">79.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001758"
      unitRef="Shares">126557</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001760"
      unitRef="USDPShares">82.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cdio:OptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Shares">3789225</cdio:OptionsVestedAndExercisable>
    <cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001764"
      unitRef="USDPShares">2.74</cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable>
    <cdio:OptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Shares">-3662918</cdio:OptionsVestedAndExercisable>
    <cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001768"
      unitRef="USDPShares">79.53</cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable>
    <cdio:OptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001770"
      unitRef="Shares">126307</cdio:OptionsVestedAndExercisable>
    <cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001772"
      unitRef="USDPShares">82.27</cdio:WeightedAverageExercisePriceOutstandingOptionsVestedAndExercisable>
    <cdio:ScheduleOfWarrantsAdjustmentsTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001774">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfWarrantsAdjustmentsTableTextBlock_zDY4zYb0EIta" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Basis of Presentation (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_zY1wGgYEBwWj" style="display: none"&gt;Schedule of Warrants adjustment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Previously Reported&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Impact of Reverse Stock
    Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKWqwhAdgGcj" title="Warrants outstanding, beginning"&gt;7,854,620&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z17giM8MmWsb" title="Weighted average exercise price outstanding, beginning"&gt;9.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ztOJEeRGXhE8" title="Warrants outstanding, beginning"&gt;(7,592,799&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zqDQ5IDT7xq7" title="Weighted average exercise price outstanding, beginning"&gt;281.35&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRightOutstandings_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zEnRBiZbAVni" title="Warrants outstanding, beginning"&gt;261,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zQ7RLz7NP28a" title="Weighted average exercise price outstanding, beginning"&gt;291.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhH8hkXhTj78" title="Warrants granted"&gt;674,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_pd" title="Weighted average exercise price, granted"&gt;1.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_ziFj1lIFLsy6" title="Warrants granted"&gt;(651,675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, granted"&gt;51.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zqFWAjVDb1Ub" title="Warrants granted"&gt;22,471&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, granted"&gt;53.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;Warrants cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFfFZymhHLTc" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zywJi7N2dSv1" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_pd" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--WarrantsCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Warrants cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_ecustom--WeightedAverageExercisePriceCancelled_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_pd" title="Weighted average exercise price, cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx1gjKa7t7ue" title="Warrants outstanding, ending"&gt;8,528,766&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zT9MFQyIVsw4" title="Weighted average exercise price outstanding, ending"&gt;9.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zZRxYowVaOJ7" title="Warrants outstanding, ending"&gt;(8,244,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--ImpactOfReverseStockSplitMember_zLFD4vn8jDak" title="Weighted average exercise price outstanding, ending"&gt;263.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightOutstandings_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zpZZgfUzQoed" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__srt--RestatementAxis__custom--AsRevisedMember_zrYGbwhJwujk" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</cdio:ScheduleOfWarrantsAdjustmentsTableTextBlock>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001776"
      unitRef="Shares">7854620</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001778"
      unitRef="USDPShares">9.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001780"
      unitRef="Shares">-7592799</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001782"
      unitRef="USDPShares">281.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001784"
      unitRef="Shares">261821</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001786"
      unitRef="USDPShares">291.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001788"
      unitRef="Shares">674146</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2024-01-012024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001790"
      unitRef="USDPShares">1.78</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001792"
      unitRef="Shares">-651675</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2024-01-012024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001794"
      unitRef="USDPShares">51.62</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001796"
      unitRef="Shares">22471</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentGranted>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2024-01-012024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001798"
      unitRef="USDPShares">53.40</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001812"
      unitRef="Shares">8528766</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="Fact001814"
      unitRef="USDPShares">9.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001816"
      unitRef="Shares">-8244474</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_ImpactOfReverseStockSplitMember"
      decimals="INF"
      id="Fact001818"
      unitRef="USDPShares">263.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdio:ClassOfWarrantOrRightOutstandings
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001820"
      unitRef="Shares">284292</cdio:ClassOfWarrantOrRightOutstandings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_AsRevisedMember"
      decimals="INF"
      id="Fact001822"
      unitRef="USDPShares">272.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001824">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zXnzAM93Vftf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2013; &lt;span id="xdx_82D_zvNMoO0pTkIc"&gt;Summary of Significant Accounting
Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zl60xhPDXMab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zYwROa3I9txl"&gt;Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio.&#160;All intercompany accounts and transactions have been
eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zsYjArLjRd73" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z9vhkwplhIGc"&gt;Use of Estimates in the Preparation of Financial
Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNWmy4gcCel4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zBAIFoxhFVF9"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;), who is our chief executive officer, for making operating decisions and assessing
performance as the source for determining the Company&#x2019;s reportable segments. Management, including the CODM, reviews operating results
solely by monthly revenue and operating results of the Company and, as such, the Company has determined that the Company has one operating
segment (product testing) as defined by ASC Topic 280 &#x201c;Segment Reporting&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;One hundred percent of the Company&#x2019;s revenues
are generated from products tests for major types of cardiovascular disease, and therefore the Company has one operating segment for financial
reporting purposes. The Company&#x2019;s principal products are its Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD assesses the risk for
a coronary heart disease event, including a heart attack, in the next three years. PrecisionCHD aids in diagnosing and managing coronary
heart disease. The tests can be paid for by provider organizations, patients, and/or employers. Customers are generally charged for tests
utilized for the minimum committed test volume and the pricing can vary based on organization type, size and volume.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reportable segment information is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8BB_zGDkB6bUDBQc" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#x200b;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Current Segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%"&gt;&#160;&#160;&#160;&#160;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,966,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,827,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Accounts receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;723,921&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;944,683&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total current segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,703,348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,790,782&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;621,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Right of use assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;347,298&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;432,397&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Intangible assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Patent costs, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"&gt;711,148&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;701,089&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,396,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,615,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reportable segment operating results are presented
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six
    Months Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;961,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,387,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zPhum7r27AA7"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,004&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,318,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,451,579&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right"&gt;(a)&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F18_zwvtHqID77o7" style="text-align: justify"&gt;Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Three Months
    Ended June 30&lt;/b&gt;&lt;/span&gt;,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;360,471&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;451,245&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;89,461&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;209,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,736&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;165,905&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,499&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;158,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,821&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,159&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,804&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;101,723&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;65,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,778&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zcYwFIWWI5Gk"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;136,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,456&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;163,096&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,280&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;57,779&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,794&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,535&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,683,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,287,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt"&gt;Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A1_zCqMEGDYcDLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2mAdQMUlbFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_z8pJAsGR6pv6"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
Research and development costs charged to operations for the six months ended June 30, 2025 and 2024 were $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630_pp0p" title="Research and development expense"&gt;165,296&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_pp0p" title="Research and development expense"&gt;18,120&lt;/span&gt;, respectively,
and for the three months ended June 30, 2025 and 2024 were $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20250401__20250630_pp0p" title="Research and development expense"&gt;163,096&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_pp0p" title="Research and development expense"&gt;7,280&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zl5jecmfnhNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_znG9dE2Sv5dk"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses advertising costs as incurred.
Advertising costs of $&lt;span id="xdx_909_eus-gaap--AdvertisingExpense_c20250101__20250630_pp0p" title="Advertising costs"&gt;50,435&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AdvertisingExpense_c20240101__20240630_pp0p" title="Advertising costs"&gt;92,181&lt;/span&gt; were charged to operations for the six months ended June 30, 2025 and 2024, respectively, and
of $&lt;span id="xdx_90E_eus-gaap--AdvertisingExpense_c20250401__20250630_pp0p" title="Advertising costs"&gt;8,615&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AdvertisingExpense_c20240401__20240630_pp0p" title="Advertising costs"&gt;57,779&lt;/span&gt; for the three months ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCcjix61MV8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_z3nIqiyDjCoc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents are comprised of cash and
highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does &lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zjINRfafLPR1" title="Cash equivalents"&gt;&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20241231_zkGi9ZqE3K91" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents
as of June 30, 2025 and December 31, 2024. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions
are insured by the FDIC up to $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20250630_pp0p" title="FDIC Insured limit"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions or
the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#x2019;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of June 30, 2025 and December 31, 2024 was approximately $&lt;span id="xdx_906_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20250630_zwLs3JyT22I9" title="Amount in excess of FDIC insurance"&gt;7.6&lt;/span&gt; million and $&lt;span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_z9zOPeI3oJ0k" title="Amount in excess of FDIC insurance"&gt;7.5&lt;/span&gt; million, respectively. The Company has not experienced
any losses on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk
with regard to these deposits is not significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ReclassificationPolicyTextBlock_zP6QjNBgUMaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zggMIIs6RLqk"&gt;Reclassification&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period amounts have been reclassified
to conform with the current period presentation. On the condensed consolidated statements of changes in stockholders&#x2019; equity and
cash flows, payment of placement agent fee has been combined with common stock and warrants issued for cash rather than being separated
out, to present net proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZeQL7AYBsje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zZ2vRqjKSUWj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 is intended to improve income tax disclosures primarily
through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income
tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is
effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the
impact that ASU 2023-09 will have on the condensed consolidated financial statements and its plan for adoption, including the adoption
date and transition method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03,
&#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&#x201d;, which requires disaggregated disclosure of income statement expenses for public business entities.
ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying
any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee
compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses
and, in annual reporting periods, an entity&#x2019;s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods
beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance
can be applied prospectively with an option for retrospective application. Early adoption is also permitted. We are currently evaluating
the provisions of this ASU.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have reviewed other recent accounting pronouncements
and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial
statements as a result of future adoption.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001826">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zl60xhPDXMab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zYwROa3I9txl"&gt;Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Legacy Cardio.&#160;All intercompany accounts and transactions have been
eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-06-30" id="Fact001828">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zsYjArLjRd73" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z9vhkwplhIGc"&gt;Use of Estimates in the Preparation of Financial
Statements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001830">&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNWmy4gcCel4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zBAIFoxhFVF9"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the &#x201c;management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker (&#x201c;CODM&#x201d;), who is our chief executive officer, for making operating decisions and assessing
performance as the source for determining the Company&#x2019;s reportable segments. Management, including the CODM, reviews operating results
solely by monthly revenue and operating results of the Company and, as such, the Company has determined that the Company has one operating
segment (product testing) as defined by ASC Topic 280 &#x201c;Segment Reporting&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;One hundred percent of the Company&#x2019;s revenues
are generated from products tests for major types of cardiovascular disease, and therefore the Company has one operating segment for financial
reporting purposes. The Company&#x2019;s principal products are its Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD assesses the risk for
a coronary heart disease event, including a heart attack, in the next three years. PrecisionCHD aids in diagnosing and managing coronary
heart disease. The tests can be paid for by provider organizations, patients, and/or employers. Customers are generally charged for tests
utilized for the minimum committed test volume and the pricing can vary based on organization type, size and volume.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reportable segment information is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8BB_zGDkB6bUDBQc" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#x200b;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Current Segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%"&gt;&#160;&#160;&#160;&#160;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,966,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,827,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Accounts receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;723,921&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;944,683&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total current segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,703,348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,790,782&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;621,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Right of use assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;347,298&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;432,397&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Intangible assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Patent costs, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"&gt;711,148&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;701,089&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,396,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,615,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reportable segment operating results are presented
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six
    Months Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;961,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,387,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zPhum7r27AA7"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,004&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,318,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,451,579&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right"&gt;(a)&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F18_zwvtHqID77o7" style="text-align: justify"&gt;Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Three Months
    Ended June 30&lt;/b&gt;&lt;/span&gt;,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;360,471&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;451,245&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;89,461&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;209,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,736&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;165,905&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,499&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;158,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,821&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,159&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,804&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;101,723&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;65,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,778&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zcYwFIWWI5Gk"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;136,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,456&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;163,096&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,280&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;57,779&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,794&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,535&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,683,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,287,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt"&gt;Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A1_zCqMEGDYcDLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001833">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAQ8NEilR5Uf" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;span id="xdx_8BB_zGDkB6bUDBQc" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zy4j48s4Znqe" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z0Tknj7QWnLf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#x200b;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zXC1aobhjDt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Current Segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Cash_i01I_pp0d_z4njNFgfFIb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%"&gt;&#160;&#160;&#160;&#160;Cash&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,966,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,827,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsReceivableNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Accounts receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18,612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;723,921&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;944,683&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total current segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,703,348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,790,782&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4WVyL2hBi2g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term segment assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;621,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Right of use assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;347,298&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;432,397&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IntangibleAssetsCurrent_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&#160;&#160;&#160;Intangible assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DepositsAssets_i01I_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,850&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedPatentsGross_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Patent costs, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"&gt;711,148&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;701,089&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--Assets_i01I_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total segment assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,396,547&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,615,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accounting policies of the product testing segment
are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the balance
sheet as total consolidated assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reportable segment operating results are presented
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zUB0JjtMXxac" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zgJq9NzuuKRi" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six
    Months Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zTyD3P0firgb" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zGgxWZKopNc1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_pp0p0_c20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_z8VfAn0KSVqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;8,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_pp0p0_c20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zYVP7tu1dZy" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;23,798&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zZE3oGVeCpEg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PayrollAndRelatedCosts_i01_pp0d_zW58VVPlzei3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;961,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,387,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RentAndFacilityExpense_i01_pp0d_znebyEOtimde" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalFees_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ConsultingAndContractorExpense_i01_pp0d_zWZ8WGcPMweb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InsuranceExpense_i01_pp0d_ziubk9s66xz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FilingFeesExpense_i01_pp0d_zaRgAZHOyoX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--TransferAgentExpense_i01_pp0d_z363Ci9Ndmje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zfd70Nm62327" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--BoardCompensationExpense_i01_pp0d_zCXlF8X3Nea1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zjCZbr1Ezo2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--OtherSegmentItems_i01_pp0d_zo7ydqJvhsd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zPhum7r27AA7"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--SellingAndMarketingExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InterestExpense_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,004&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,318,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,451,579&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F00_zC0sS6rlDHX7" style="width: 15pt; text-align: right"&gt;(a)&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F18_zwvtHqID77o7" style="text-align: justify"&gt;Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zJhaflA3BFo8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zkpLq0T2Lkzl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;Three Months
    Ended June 30&lt;/b&gt;&lt;/span&gt;,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Product Test sales&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zmX3DxZskF38" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember__srt--ProductOrServiceAxis__custom--ProductTestSalesMember_zH0Bwmv5xLlf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Revenue&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_pp0p0_c20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zDadvtENnZed" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,475&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pp0p0_c20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentsMember_zyIjn1Bzusxk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"&gt;7,870&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zLOzPNRE02le" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Segment Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PayrollAndRelatedCosts_i01_pp0d_zCVkvbzhUr68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Payroll and related costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;360,471&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;451,245&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RentAndFacilityExpense_i01_pp0d_zlH8Lh9ctrCl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Rent and facility expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;89,461&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0d_zcKs6ceFS88i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Legal and professional expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;209,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,736&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ConsultingAndContractorExpense_i01_pp0d_z9YLuy5D0du3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Consulting and contractor expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;165,905&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;173,499&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--InsuranceExpense_i01_pp0d_zCE2xOQhA2k7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Insurance expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;158,263&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181,821&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FilingFeesExpense_i01_pp0d_zSWgcvNQt808" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Filing fees expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,159&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,804&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TransferAgentExpense_i01_pp0d_zOskuy7T1UGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Transfer agent expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,554&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--SoftwareAndWebComputingExpense_i01_pp0d_zWIaC9FXIyfb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Software and web computing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;101,723&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;65,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BoardCompensationExpense_i01_pp0d_zKfbpHnO2bHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Board compensation expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,778&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestorRelationsExpense_i01_pp0d_zAjG4pfa8rU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Investor relations expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OtherSegmentItems_i01_pp0d_zp4Zaj1wBdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%"&gt;&#160;&#160;&#160;Other segment items &lt;sup id="xdx_F41_zcYwFIWWI5Gk"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;136,742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,456&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_zpm5oibmYiod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Research and development expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;163,096&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,280&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_z1J7Nf9jTTF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Sales and marketing expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211,043&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;57,779&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DepreciationAndAmortization_zai6kvInXL72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Amortization expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,794&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestExpense_zuyOSzadCN1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Interest expense, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,535&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_zvVhQimpmJzc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total Segment Net Income (Loss)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,683,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,287,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span id="xdx_F09_z4hxf8hm2nd2" style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zIP0NYLpSbG1" style="font-size: 10pt"&gt;Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001838"
      unitRef="USD">7966500</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">7827487</us-gaap:Cash>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001841"
      unitRef="USD">12927</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001842"
      unitRef="USD">18612</us-gaap:AccountsReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001844"
      unitRef="USD">723921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">944683</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001847"
      unitRef="USD">8703348</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001848"
      unitRef="USD">8790782</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001853"
      unitRef="USD">621903</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001854"
      unitRef="USD">672861</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001856"
      unitRef="USD">347298</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001857"
      unitRef="USD">432397</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001860"
      unitRef="USD">5333</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:DepositsAssets
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001862"
      unitRef="USD">12850</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001863"
      unitRef="USD">12850</us-gaap:DepositsAssets>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001865"
      unitRef="USD">711148</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001866"
      unitRef="USD">701089</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001868"
      unitRef="USD">10396547</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001869"
      unitRef="USD">10615312</us-gaap:Assets>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember"
      decimals="0"
      id="Fact001871"
      unitRef="USD">8415</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember"
      decimals="0"
      id="Fact001873"
      unitRef="USD">23798</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001875"
      unitRef="USD">8415</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">23798</us-gaap:Revenues>
    <cdio:PayrollAndRelatedCosts
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001882"
      unitRef="USD">961517</cdio:PayrollAndRelatedCosts>
    <cdio:PayrollAndRelatedCosts
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001883"
      unitRef="USD">3387020</cdio:PayrollAndRelatedCosts>
    <cdio:RentAndFacilityExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">155854</cdio:RentAndFacilityExpense>
    <cdio:RentAndFacilityExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001886"
      unitRef="USD">101222</cdio:RentAndFacilityExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001888"
      unitRef="USD">511264</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001889"
      unitRef="USD">444473</us-gaap:ProfessionalFees>
    <cdio:ConsultingAndContractorExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001891"
      unitRef="USD">326707</cdio:ConsultingAndContractorExpense>
    <cdio:ConsultingAndContractorExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001892"
      unitRef="USD">396277</cdio:ConsultingAndContractorExpense>
    <cdio:InsuranceExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001894"
      unitRef="USD">314830</cdio:InsuranceExpense>
    <cdio:InsuranceExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001895"
      unitRef="USD">363558</cdio:InsuranceExpense>
    <cdio:FilingFeesExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001897"
      unitRef="USD">42290</cdio:FilingFeesExpense>
    <cdio:FilingFeesExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001898"
      unitRef="USD">76957</cdio:FilingFeesExpense>
    <cdio:TransferAgentExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001900"
      unitRef="USD">11936</cdio:TransferAgentExpense>
    <cdio:TransferAgentExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001901"
      unitRef="USD">20153</cdio:TransferAgentExpense>
    <cdio:SoftwareAndWebComputingExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001903"
      unitRef="USD">180314</cdio:SoftwareAndWebComputingExpense>
    <cdio:SoftwareAndWebComputingExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001904"
      unitRef="USD">137488</cdio:SoftwareAndWebComputingExpense>
    <cdio:BoardCompensationExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">99390</cdio:BoardCompensationExpense>
    <cdio:BoardCompensationExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001907"
      unitRef="USD">99958</cdio:BoardCompensationExpense>
    <cdio:InvestorRelationsExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001909"
      unitRef="USD">7500</cdio:InvestorRelationsExpense>
    <cdio:InvestorRelationsExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001910"
      unitRef="USD">67524</cdio:InvestorRelationsExpense>
    <cdio:OtherSegmentItems
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001912"
      unitRef="USD">233990</cdio:OtherSegmentItems>
    <cdio:OtherSegmentItems
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001913"
      unitRef="USD">249788</cdio:OtherSegmentItems>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001915"
      unitRef="USD">165296</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001916"
      unitRef="USD">18120</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001918"
      unitRef="USD">252863</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001919"
      unitRef="USD">92181</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001921"
      unitRef="USD">53923</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001922"
      unitRef="USD">9587</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001924"
      unitRef="USD">9004</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001925"
      unitRef="USD">11071</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001927"
      unitRef="USD">-3318263</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001928"
      unitRef="USD">-5451579</us-gaap:NetIncomeLoss>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember"
      decimals="0"
      id="Fact001934"
      unitRef="USD">7475</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember_custom_ProductTestSalesMember"
      decimals="0"
      id="Fact001936"
      unitRef="USD">7870</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">7475</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001940"
      unitRef="USD">7870</us-gaap:Revenues>
    <cdio:PayrollAndRelatedCosts
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001945"
      unitRef="USD">360471</cdio:PayrollAndRelatedCosts>
    <cdio:PayrollAndRelatedCosts
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001946"
      unitRef="USD">451245</cdio:PayrollAndRelatedCosts>
    <cdio:RentAndFacilityExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001948"
      unitRef="USD">89461</cdio:RentAndFacilityExpense>
    <cdio:RentAndFacilityExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001949"
      unitRef="USD">59667</cdio:RentAndFacilityExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001951"
      unitRef="USD">209744</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001952"
      unitRef="USD">94736</us-gaap:ProfessionalFees>
    <cdio:ConsultingAndContractorExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001954"
      unitRef="USD">165905</cdio:ConsultingAndContractorExpense>
    <cdio:ConsultingAndContractorExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001955"
      unitRef="USD">173499</cdio:ConsultingAndContractorExpense>
    <cdio:InsuranceExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001957"
      unitRef="USD">158263</cdio:InsuranceExpense>
    <cdio:InsuranceExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001958"
      unitRef="USD">181821</cdio:InsuranceExpense>
    <cdio:FilingFeesExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001960"
      unitRef="USD">22159</cdio:FilingFeesExpense>
    <cdio:FilingFeesExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001961"
      unitRef="USD">1804</cdio:FilingFeesExpense>
    <cdio:TransferAgentExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001963"
      unitRef="USD">5554</cdio:TransferAgentExpense>
    <cdio:TransferAgentExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001964"
      unitRef="USD">6587</cdio:TransferAgentExpense>
    <cdio:SoftwareAndWebComputingExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001966"
      unitRef="USD">101723</cdio:SoftwareAndWebComputingExpense>
    <cdio:SoftwareAndWebComputingExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001967"
      unitRef="USD">65275</cdio:SoftwareAndWebComputingExpense>
    <cdio:BoardCompensationExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001969"
      unitRef="USD">49778</cdio:BoardCompensationExpense>
    <cdio:BoardCompensationExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001970"
      unitRef="USD">49958</cdio:BoardCompensationExpense>
    <cdio:InvestorRelationsExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001972"
      unitRef="USD">3750</cdio:InvestorRelationsExpense>
    <cdio:InvestorRelationsExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001973"
      unitRef="USD">6429</cdio:InvestorRelationsExpense>
    <cdio:OtherSegmentItems
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001975"
      unitRef="USD">136742</cdio:OtherSegmentItems>
    <cdio:OtherSegmentItems
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001976"
      unitRef="USD">129456</cdio:OtherSegmentItems>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001978"
      unitRef="USD">163096</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001979"
      unitRef="USD">7280</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001981"
      unitRef="USD">211043</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001982"
      unitRef="USD">57779</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001984"
      unitRef="USD">8485</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001985"
      unitRef="USD">4794</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">4500</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001988"
      unitRef="USD">5535</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001990"
      unitRef="USD">-1683199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_ReportableSegmentsMember"
      decimals="0"
      id="Fact001991"
      unitRef="USD">-1287995</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-06-30" id="Fact001996">&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z2mAdQMUlbFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_z8pJAsGR6pv6"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
Research and development costs charged to operations for the six months ended June 30, 2025 and 2024 were $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630_pp0p" title="Research and development expense"&gt;165,296&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630_pp0p" title="Research and development expense"&gt;18,120&lt;/span&gt;, respectively,
and for the three months ended June 30, 2025 and 2024 were $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20250401__20250630_pp0p" title="Research and development expense"&gt;163,096&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_pp0p" title="Research and development expense"&gt;7,280&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001998"
      unitRef="USD">165296</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002000"
      unitRef="USD">18120</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact002002"
      unitRef="USD">163096</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002004"
      unitRef="USD">7280</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002006">&lt;p id="xdx_844_eus-gaap--AdvertisingCostsPolicyTextBlock_zl5jecmfnhNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_znG9dE2Sv5dk"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses advertising costs as incurred.
Advertising costs of $&lt;span id="xdx_909_eus-gaap--AdvertisingExpense_c20250101__20250630_pp0p" title="Advertising costs"&gt;50,435&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AdvertisingExpense_c20240101__20240630_pp0p" title="Advertising costs"&gt;92,181&lt;/span&gt; were charged to operations for the six months ended June 30, 2025 and 2024, respectively, and
of $&lt;span id="xdx_90E_eus-gaap--AdvertisingExpense_c20250401__20250630_pp0p" title="Advertising costs"&gt;8,615&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AdvertisingExpense_c20240401__20240630_pp0p" title="Advertising costs"&gt;57,779&lt;/span&gt; for the three months ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002008"
      unitRef="USD">50435</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002010"
      unitRef="USD">92181</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact002012"
      unitRef="USD">8615</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002014"
      unitRef="USD">57779</us-gaap:AdvertisingExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002016">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCcjix61MV8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_z3nIqiyDjCoc"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents are comprised of cash and
highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does &lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20250630_zjINRfafLPR1" title="Cash equivalents"&gt;&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_do_c20241231_zkGi9ZqE3K91" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt;t have any cash equivalents
as of June 30, 2025 and December 31, 2024. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions
are insured by the FDIC up to $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20250630_pp0p" title="FDIC Insured limit"&gt;250,000&lt;/span&gt;. The Company is exposed to credit risk in the event of default by the financial institutions or
the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured. The Company&#x2019;s
accounts at this major financial institution may, at times, exceed the federally insured limits. The amount in excess of the FDIC insurance
as of June 30, 2025 and December 31, 2024 was approximately $&lt;span id="xdx_906_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20250630_zwLs3JyT22I9" title="Amount in excess of FDIC insurance"&gt;7.6&lt;/span&gt; million and $&lt;span id="xdx_909_ecustom--AmountInExcessOfFdicInsurance_iI_pn3n3_dm_c20241231_z9zOPeI3oJ0k" title="Amount in excess of FDIC insurance"&gt;7.5&lt;/span&gt; million, respectively. The Company has not experienced
any losses on these accounts and management believes, based upon the quality of this major financial institution, that the credit risk
with regard to these deposits is not significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002018"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002020"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002022"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <cdio:AmountInExcessOfFdicInsurance
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact002024"
      unitRef="USD">7600000</cdio:AmountInExcessOfFdicInsurance>
    <cdio:AmountInExcessOfFdicInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002026"
      unitRef="USD">7500000</cdio:AmountInExcessOfFdicInsurance>
    <cdio:ReclassificationPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002028">&lt;p id="xdx_844_ecustom--ReclassificationPolicyTextBlock_zP6QjNBgUMaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zggMIIs6RLqk"&gt;Reclassification&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period amounts have been reclassified
to conform with the current period presentation. On the condensed consolidated statements of changes in stockholders&#x2019; equity and
cash flows, payment of placement agent fee has been combined with common stock and warrants issued for cash rather than being separated
out, to present net proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</cdio:ReclassificationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2025-01-01to2025-06-30" id="Fact002030">&lt;p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZeQL7AYBsje" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zZ2vRqjKSUWj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 is intended to improve income tax disclosures primarily
through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income
tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is
effective for annual reporting periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the
impact that ASU 2023-09 will have on the condensed consolidated financial statements and its plan for adoption, including the adoption
date and transition method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03,
&#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&#x201d;, which requires disaggregated disclosure of income statement expenses for public business entities.
ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying
any relevant income statement expense caption. The prescribed categories include, among other things, purchases of inventory, employee
compensation, depreciation, and intangible asset amortization. Additionally, entities must disclose the total amount of selling expenses
and, in annual reporting periods, an entity&#x2019;s definition of selling expenses. ASU 2024-03 is effective for annual reporting periods
beginning after December 15, 2026, and for interim reporting periods within fiscal years beginning after December 15, 2027. The guidance
can be applied prospectively with an option for retrospective application. Early adoption is also permitted. We are currently evaluating
the provisions of this ASU.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have reviewed other recent accounting pronouncements
and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial
statements as a result of future adoption.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002034">&lt;p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z2Nile72S6Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3 &#x2013; &lt;span id="xdx_825_z8chcBPXzx55"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are carried at cost and consist
of the following at June 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3PtcAmmUii" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_z5QIunZAOLc7" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zLPYcwrjG5a5" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zfasNjvyN0h1" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0d_maPPAENzAGD_zlMCiNM2Btx" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;Office and computer equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21,032&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pp0d_maPPAENzAGD_z81QV8y8prOl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;113,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;96,818&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0d_maPPAENzAGD_zly4O7Rx1KBb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_pp0d_maPPAENzAGD_zxtNEfehQQ5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_msPPAENzAGD_zFVT9ph36CP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(193,008&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(117,567&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0d_mtPPAENzAGD_z7JAVJAVIeR" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;621,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Leasehold improvements of $&lt;span id="xdx_902_eus-gaap--LeaseholdImprovementsGross_c20250630_pp0p" title="Leasehold Improvements"&gt;502,155&lt;/span&gt; represent costs
of the buildout of the leased laboratory in Iowa City, Iowa that was completed in January 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense of $&lt;span id="xdx_907_eus-gaap--Depreciation_c20250101__20250630_pp0p" title="Depreciation expense"&gt;75,441&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_c20240101__20240630_pp0p" title="Depreciation expense"&gt;39,579&lt;/span&gt; was charged
to operations for the six months ended June 30, 2025 and 2024, respectively, and of $&lt;span id="xdx_902_eus-gaap--Depreciation_c20250401__20250630_pp0p" title="Depreciation expense"&gt;37,785&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Depreciation_c20240401__20240630_pp0p" title="Depreciation expense"&gt;35,992&lt;/span&gt; for the three months ended June
30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002036">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3PtcAmmUii" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B1_z5QIunZAOLc7" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zLPYcwrjG5a5" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zfasNjvyN0h1" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0d_maPPAENzAGD_zlMCiNM2Btx" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;Office and computer equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;21,032&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pp0d_maPPAENzAGD_z81QV8y8prOl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;113,069&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;96,818&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0d_maPPAENzAGD_zly4O7Rx1KBb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;170,423&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_pp0d_maPPAENzAGD_zxtNEfehQQ5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;502,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_msPPAENzAGD_zFVT9ph36CP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(193,008&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(117,567&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0d_mtPPAENzAGD_z7JAVJAVIeR" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;621,903&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;672,861&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002038"
      unitRef="USD">29264</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002039"
      unitRef="USD">21032</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002041"
      unitRef="USD">113069</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002042"
      unitRef="USD">96818</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002044"
      unitRef="USD">170423</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002045"
      unitRef="USD">170423</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002047"
      unitRef="USD">502155</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002048"
      unitRef="USD">502155</us-gaap:ConstructionInProgressGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002050"
      unitRef="USD">193008</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002051"
      unitRef="USD">117567</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002053"
      unitRef="USD">621903</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002054"
      unitRef="USD">672861</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002056"
      unitRef="USD">502155</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002058"
      unitRef="USD">75441</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002060"
      unitRef="USD">39579</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact002062"
      unitRef="USD">37785</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002064"
      unitRef="USD">35992</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002066">&lt;p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zY6U7MoBlpad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2013; &lt;span id="xdx_82E_zCBGHDr1yqi5"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides details associated with
the Company&#x2019;s acquired identifiable intangible assets at June 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsomD40dIqVh" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B4_zxMHN2bNC403" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zUmaSQaoeAR2" style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zO7pRLBhVoV1" style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzF5l_zeSLq06VrdX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;Know-how license&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzF5l_zGrk2x9OgeV1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(74,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzF5l_zrlwhrfsnpc8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization expense charged to operations was $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250630_pp0p" title="Amortization expense"&gt;5,333&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240630_pp0p" title="Amortization expense"&gt;8,000&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively, and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20250401__20250630_pp0p" title="Amortization expense"&gt;1,333&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240401__20240630_pp0p" title="Amortization expense"&gt;4,000&lt;/span&gt; for the three months ended June 30, 2025
and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002068">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsomD40dIqVh" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B4_zxMHN2bNC403" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zUmaSQaoeAR2" style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zO7pRLBhVoV1" style="text-align: right"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzF5l_zeSLq06VrdX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;Know-how license&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzF5l_zGrk2x9OgeV1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(80,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(74,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzF5l_zrlwhrfsnpc8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002070"
      unitRef="USD">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002071"
      unitRef="USD">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002073"
      unitRef="USD">80000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002074"
      unitRef="USD">74667</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002077"
      unitRef="USD">5333</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002079"
      unitRef="USD">5333</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002081"
      unitRef="USD">8000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact002083"
      unitRef="USD">1333</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002085"
      unitRef="USD">4000</us-gaap:AmortizationOfIntangibleAssets>
    <cdio:PatentAndTrademarkCostsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002087">&lt;p id="xdx_800_ecustom--PatentAndTrademarkCostsTextBlock_z2ywE5Nusa6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2013; &lt;span id="xdx_82A_zVQTP5XVMP"&gt;Patent Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2025, in the first family of
patents and patent applications owned solely by UIRF which is exclusively licensed by Cardio, there are eight granted patents (US
(2), EU, China, Australia, India, Hong Kong and Japan) and other pending patent applications. The Company has pending patent
applications in patent families two, three, four, five and six. Legal fees associated with the patents totaled $&lt;span id="xdx_90C_eus-gaap--LegalFees_c20250101__20250630_pp0p" title="Legal fees"&gt;711,148&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--LegalFees_c20240101__20240630_pp0p" title="Legal fees"&gt;701,089&lt;/span&gt;, net of accumulated
amortization of $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization"&gt;55,510&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Accumulated amortization"&gt;6,920&lt;/span&gt;
as of June 30, 2025 and December 31, 2024, respectively and are presented in the condensed consolidated balance sheets as patent
costs. Patents are amortized over their estimated useful lives of approximately &lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zolxFMgzKVHc" title="Estimated useful lives"&gt;14&lt;/span&gt;
and &lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1AitjJ5h3L7" title="Estimated useful lives"&gt;15&lt;/span&gt;
years, respectively. Amortization expense charged to operations was $&lt;span id="xdx_909_eus-gaap--AdjustmentForAmortization_c20250101__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"&gt;48,590&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"&gt;1,587&lt;/span&gt;
for the six months ended June 30, 2025 and 2024, respectively, and $&lt;span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20250401__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"&gt;7,152&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--AdjustmentForAmortization_c20240401__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p" title="Amortization expenses"&gt;794&lt;/span&gt;
for the three months ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</cdio:PatentAndTrademarkCostsTextBlock>
    <us-gaap:LegalFees
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002089"
      unitRef="USD">711148</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002091"
      unitRef="USD">701089</us-gaap:LegalFees>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002093"
      unitRef="USD">55510</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002095"
      unitRef="USD">6920</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember"
      id="Fact002097">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      id="Fact002099">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2025-01-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002101"
      unitRef="USD">48590</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002103"
      unitRef="USD">1587</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2025-04-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002105"
      unitRef="USD">7152</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-04-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact002107"
      unitRef="USD">794</us-gaap:AdjustmentForAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002109">&lt;p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_z2Uj1dtFNXEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2013; &lt;span id="xdx_825_zeOBvS5n7AH9"&gt;Operating Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;The Company determines if a contract is, or
contains, a lease at contract inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current
portion of operating lease liabilities and operating lease liabilities, net of current portion in the Company&#x2019;s consolidated balance
sheets. Finance leases are included in property and equipment, current portion of finance lease obligations and finance lease obligations,
net of current portion in the Company&#x2019;s condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;ROU assets represent the right to use an underlying
asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and
lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition,
ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and
exclude lease incentives. The Company used the implicit rate in the lease in determining the present value of lease payments. Lease terms
include options to extend or terminate&#160;the lease when it is reasonably certain that the Company will exercise that option. Leases
with a term of one year or less are generally not included in ROU assets and corresponding operating lease liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;In 2023, the Company entered into a lease
agreement for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and expiring on
November 30, 2026. The monthly rent for August to November 2023 was abated and the Company started to make monthly rental installments
from December 2023 of $12,847. The monthly rental payment increases by approximately 2% every August starting from 2024.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;On July 20, 2023, the Company entered into
another lease agreement for laboratory facilities in Iowa City, Iowa, commencing on August 1, 2023 for a term of five years and four months
and expiring on November 30, 2028. The monthly rent for August to November 2023 was abated and the Company agreed to pay a monthly rent
of $&lt;span id="xdx_907_eus-gaap--SaleLeasebackTransactionMonthlyRentalPayments_c20230802__20231130_pp0p" title="Monthly rent payment"&gt;8,505&lt;/span&gt; ($&lt;span id="xdx_904_ecustom--AnnuallyRentPayment_c20230802__20231130_pp0p" title="Annually rent payment"&gt;102,060&lt;/span&gt; annually) commencing December 1, 2023. In addition, the landlord agreed to provide the Company with a one-time Tenant
Improvement Allowance (&#x201c;TIA&#x201d;) in the amount of up to, but not exceeding $50 per rentable square foot of the premises for a
maximum allowance of $&lt;span id="xdx_902_ecustom--PremisesAllowance_c20250101__20250630_pp0p" title="Premises allowance"&gt;253,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;Pursuant to ASC Topic 842 Leases, the Company
accounted for both leases as operating leases and accounted for the TIA as a lease incentive, which was estimated to be payable on December
1, 2023. The Company received the TIA from landlord in maximum amount of $&lt;span id="xdx_907_eus-gaap--ReceivablesNetCurrent_c20240116_pp0p" title="Amount receivable"&gt;253,000&lt;/span&gt; on January 16, 2024 and recorded a reimbursement receivable
from landlord of $&lt;span id="xdx_903_ecustom--ReimbursementReceivable_c20231231_pp0p" title="Reimbursement receivable"&gt;253,000&lt;/span&gt; as of December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;During the year ended December 31, 2023, the
Company recorded ROU assets of $&lt;span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAsset_c20231231_pp0p" title="ROU assets"&gt;663,875&lt;/span&gt; and operating lease liabilities of $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiability_c20231231_pp0p" title="Operating lease liabilities"&gt;642,523&lt;/span&gt; at the lease commencement date. The discount rate
used to determine the present value is the incremental borrowing rate, estimated to be &lt;span id="xdx_902_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__custom--ChicagoMember_zaeVzAhFJKkb" title="Borrowing rate"&gt;4.57%&lt;/span&gt; for Chicago lease and &lt;span id="xdx_900_eus-gaap--SubordinatedBorrowingInterestRate_c20230101__20231231__us-gaap--GeographicDistributionAxis__stpr--IA_zspWYz9z8Kzf" title="Borrowing rate"&gt;4.24%&lt;/span&gt; for Iowa City
lease, respectively, as the interest rate implicit in our lease is not readily determinable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0pt; text-align: justify"&gt;As of June
30, 2025 and December 31, 2024, operating lease ROU assets and operating lease liabilities are recorded on the condensed consolidated
balance sheets as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zNtVTQFk8b56" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B8_z9dBFAE1NiV7" style="display: none"&gt;Schedule of operating lease ROU assets and operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Operating Leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease right-of-use assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_c20250630_pp0p"&gt;347,298&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20241231_pp0p"&gt;432,397&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_c20250630_pp0p"&gt;244,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_c20241231_pp0p"&gt;237,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20250630_pp0p"&gt;302,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20241231_pp0p"&gt;425,829&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zx2IisfyivP5" style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;As of June 30, 2025, the
weighted-average remaining lease terms of the two operating leases were &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zC4jPIJ7t9Db"&gt;1.42 &lt;/span&gt;years
and &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zWAY2UZMusj"&gt;3.42&lt;/span&gt;
years, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;The following table summarizes maturities
of operating lease liabilities based on lease terms as of December 31:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zh5iJedn1Ybl" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8B0_zFoADQYAUHi9" style="display: none"&gt;Schedule of future minimum payments due&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025 (remaining period)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_c20250630_zsMfhNSLQSG7" title="2025 (remaining period)"&gt;130,958&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_c20250630_zZtYySMFLxlj" title="2026"&gt;250,152&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_c20250630_zgMIsXczn6Wj" title="2027"&gt;102,060&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_c20250630_zSmbhAe3Hxsg" title="2028"&gt;93,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0d_c20250630_zSvUnCBTwA34" title="Total minimum lease payments"&gt;576,725&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0d_c20250630_zSvnyIqZocr2" title="Less: Imputed interest"&gt;30,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0d_c20250630_z4pHZmPwSRT6" title="Present value of lease liabilities"&gt;546,433&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;At June 30, 2025, the Company had the following
future minimum payments due under the non-cancelable lease:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 81%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025 (remaining period)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_zaj12noFBQb1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025 (remaining period)"&gt;130,958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zeObSfRyjXk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20250630_z2dvVzmsSMSh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20250630_z5J4jQGmjp7b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_zKF4aZT1pbmd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total minimum lease payments"&gt;576,725&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zswGVDPHbb81" style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;Consolidated rental expense for all operating
leases was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20250101__20250630_pp0p" title="Rental expense for operating leases"&gt;126,525&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20240630_pp0p" title="Rental expense for operating leases"&gt;91,398&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively, and $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseExpense_c20250401__20250630_pp0p" title="Rental expense for operating leases"&gt;68,939&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240401__20240630_pp0p" title="Rental expense for operating leases"&gt;55,582&lt;/span&gt; for the three months
ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 7.5pt 0 0; text-align: justify"&gt;The following table summarizes the cash paid
and related right-of-use operating lease recognized for the six months ended June 30, 2025 and 2024.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zdGAm3EDPqp2" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BF_zqedldmhoi5e" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250630_z6GuhX4DZPOf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240630_zgOdrKJIYLF8" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six
    Months Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zppCJdUm5oQ7" style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;129,653&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;128,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ReductionOfLeaseLiabilitiesAbstract_i01B_zzKziDeNIiZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reduction of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;116,666&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z24vbAqljPof" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;









</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2023-08-022023-11-30"
      decimals="0"
      id="Fact002112"
      unitRef="USD">8505</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <cdio:AnnuallyRentPayment
      contextRef="From2023-08-022023-11-30"
      decimals="0"
      id="Fact002114"
      unitRef="USD">102060</cdio:AnnuallyRentPayment>
    <cdio:PremisesAllowance
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002116"
      unitRef="USD">253000</cdio:PremisesAllowance>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2024-01-16"
      decimals="0"
      id="Fact002118"
      unitRef="USD">253000</us-gaap:ReceivablesNetCurrent>
    <cdio:ReimbursementReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002120"
      unitRef="USD">253000</cdio:ReimbursementReceivable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002122"
      unitRef="USD">663875</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002124"
      unitRef="USD">642523</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="From2023-01-012023-12-31_custom_ChicagoMember"
      decimals="INF"
      id="Fact002126"
      unitRef="Ratio">0.0457</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="From2023-01-012023-12-31_stpr_IA"
      decimals="INF"
      id="Fact002128"
      unitRef="Ratio">0.0424</us-gaap:SubordinatedBorrowingInterestRate>
    <cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002130">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_zNtVTQFk8b56" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B8_z9dBFAE1NiV7" style="display: none"&gt;Schedule of operating lease ROU assets and operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Operating Leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease right-of-use assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_c20250630_pp0p"&gt;347,298&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20241231_pp0p"&gt;432,397&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Current portion of operating lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_c20250630_pp0p"&gt;244,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_c20241231_pp0p"&gt;237,270&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;&#160;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20250630_pp0p"&gt;302,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20241231_pp0p"&gt;425,829&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</cdio:ScheduleOfBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002131"
      unitRef="USD">347298</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002132"
      unitRef="USD">432397</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002133"
      unitRef="USD">244182</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002134"
      unitRef="USD">237270</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002135"
      unitRef="USD">302251</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002136"
      unitRef="USD">425829</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2025-06-30_custom_LeaseOneMember"
      id="Fact002137">P1Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2025-06-30_custom_LeaseTwoMember"
      id="Fact002138">P3Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002140">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zh5iJedn1Ybl" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span id="xdx_8B0_zFoADQYAUHi9" style="display: none"&gt;Schedule of future minimum payments due&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025 (remaining period)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_c20250630_zsMfhNSLQSG7" title="2025 (remaining period)"&gt;130,958&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_c20250630_zZtYySMFLxlj" title="2026"&gt;250,152&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_c20250630_zgMIsXczn6Wj" title="2027"&gt;102,060&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_c20250630_zSmbhAe3Hxsg" title="2028"&gt;93,555&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0d_c20250630_zSvUnCBTwA34" title="Total minimum lease payments"&gt;576,725&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0d_c20250630_zSvnyIqZocr2" title="Less: Imputed interest"&gt;30,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pp0d_c20250630_z4pHZmPwSRT6" title="Present value of lease liabilities"&gt;546,433&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 9.75pt 0 0; text-align: justify"&gt;At June 30, 2025, the Company had the following
future minimum payments due under the non-cancelable lease:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 81%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025 (remaining period)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_zaj12noFBQb1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025 (remaining period)"&gt;130,958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zeObSfRyjXk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026"&gt;250,152&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20250630_z2dvVzmsSMSh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027"&gt;102,060&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20250630_z5J4jQGmjp7b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028"&gt;93,555&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: bottom; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_zKF4aZT1pbmd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total minimum lease payments"&gt;576,725&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002142"
      unitRef="USD">130958</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002144"
      unitRef="USD">250152</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002146"
      unitRef="USD">102060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002148"
      unitRef="USD">93555</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002150"
      unitRef="USD">576725</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002152"
      unitRef="USD">30292</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002154"
      unitRef="USD">546433</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002156"
      unitRef="USD">130958</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002158"
      unitRef="USD">250152</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002160"
      unitRef="USD">102060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002162"
      unitRef="USD">93555</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002164"
      unitRef="USD">576725</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002166"
      unitRef="USD">126525</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002168"
      unitRef="USD">91398</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact002170"
      unitRef="USD">68939</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002172"
      unitRef="USD">55582</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002174">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zdGAm3EDPqp2" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BF_zqedldmhoi5e" style="display: none"&gt;Schedule of cash paid and related right-of-use operating lease&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250630_z6GuhX4DZPOf" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20240630_zgOdrKJIYLF8" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six
    Months Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_iB_zppCJdUm5oQ7" style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;129,653&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;128,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ReductionOfLeaseLiabilitiesAbstract_i01B_zzKziDeNIiZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Reduction of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;116,666&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002179"
      unitRef="USD">129653</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002180"
      unitRef="USD">128112</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact002185"
      unitRef="USD">116666</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact002186"
      unitRef="USD">110080</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cdio:FinanceAgreementPayableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002191">&lt;p id="xdx_809_ecustom--FinanceAgreementPayableTextBlock_zxKOWPizo3m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7 &#x2013; &lt;span id="xdx_820_zSwJcOPtVmO3"&gt;Finance Agreement Payable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 25, 2023, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2023. The amount financed of&#160;$&lt;span id="xdx_907_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20231001__20231025_pp0p" title="Financing agreement entered into for prepaid insurance"&gt;467,500&lt;/span&gt;&#160;is payable in 10 monthly installments plus interest at a rate of&#160;&lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20231001__20231025_pd" title="Interest rate"&gt;8.95%&lt;/span&gt;&#160;through&#160;&lt;span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20231025_zgPx5S3jAOHg" title="Maturity date"&gt;August
25, 2024&lt;/span&gt;. Accordingly, Directors and Officers insurance premiums of $&lt;span id="xdx_909_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20241025_pp0p" title="Prepaid expenses"&gt;550,000&lt;/span&gt;&#160;was recorded in prepaid expenses and was amortized over
the life of the policy until October 25, 2024. As of October 31, 2024, this finance agreement has been paid in full and insurance premiums
have been fully amortized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 25, 2024, the Company entered into
an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective
October 25, 2024. The amount financed of $&lt;span id="xdx_905_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20241001__20241025_pp0p" title="Financing agreement entered into for prepaid insurance"&gt;383,455&lt;/span&gt; is payable in 10 monthly installments plus interest at a rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20241001__20241025_pd" title="Interest rate"&gt;8.80%&lt;/span&gt; through &lt;span id="xdx_90B_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20241025_zGyVLeKxCET9" title="Maturity date"&gt;August
25, 2025&lt;/span&gt;. Accordingly, Directors and Officers insurance premiums of $&lt;span id="xdx_908_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20251025_pp0p" title="Prepaid expenses"&gt;451,124&lt;/span&gt; has been recorded in prepaid expenses and is being amortized
over the life of the policy until October 25, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Finance agreement payable for this agreement
was $&lt;span id="xdx_90E_ecustom--FinanceAgreementPayable_c20250630_pp0p" title="Finance agreement payable"&gt;76,691&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--FinanceAgreementPayable_c20241231_pp0p" title="Finance agreement payable"&gt;306,764&lt;/span&gt; at June 30, 2025 and December 31, 2024, respectively. Unamortized balance of Directors and Officers insurance
premiums was $&lt;span id="xdx_904_eus-gaap--UnamortizedDebtIssuanceExpense_c20250630_pp0p" title="Unamortized balance"&gt;144,607&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_c20241231_pp0p" title="Unamortized balance"&gt;368,315&lt;/span&gt; as of June 30, 2025 and December 31, 2024, respectively.&lt;/p&gt;

</cdio:FinanceAgreementPayableTextBlock>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2023-10-012023-10-25"
      decimals="0"
      id="Fact002193"
      unitRef="USD">467500</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-10-012023-10-25"
      decimals="INF"
      id="Fact002195"
      unitRef="Ratio">0.0895</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtMaturityDate contextRef="AsOf2023-10-25" id="Fact002197">2024-08-25</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="AsOf2024-10-25"
      decimals="0"
      id="Fact002199"
      unitRef="USD">550000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <cdio:FinancingAgreementEnteredIntoForPrepaidInsurance
      contextRef="From2024-10-012024-10-25"
      decimals="0"
      id="Fact002201"
      unitRef="USD">383455</cdio:FinancingAgreementEnteredIntoForPrepaidInsurance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-10-012024-10-25"
      decimals="INF"
      id="Fact002203"
      unitRef="Ratio">0.0880</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtMaturityDate contextRef="AsOf2024-10-25" id="Fact002205">2025-08-25</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="AsOf2025-10-25"
      decimals="0"
      id="Fact002207"
      unitRef="USD">451124</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002209"
      unitRef="USD">76691</cdio:FinanceAgreementPayable>
    <cdio:FinanceAgreementPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002211"
      unitRef="USD">306764</cdio:FinanceAgreementPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002213"
      unitRef="USD">144607</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002215"
      unitRef="USD">368315</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002217">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zIMc6IP9XQDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 8 - &lt;span id="xdx_823_zApgRt5G9qXg"&gt;Earnings (Loss) Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates net income (loss) per
common share in accordance with ASC 260 &#x201c;&lt;i&gt;Earnings Per Share&lt;/i&gt;&#x201d; (&#x201c;ASC 260&#x201d;). Basic and diluted net
earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted
average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include
outstanding common stock options and common stock warrants presented below
on a post-reverse stock split basis, have not been included in the computation of
diluted net loss per share for the six months ended June 30, 2025 and 2024 as the result would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSAErrEj71d4" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BE_zZlr10vxVjo5" style="display: none"&gt;Schedule of anti dilutive earning per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June
    30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 66%; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Stock warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"&gt;128,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"&gt;126,557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_pd" title="Anti-dilutive shares"&gt;413,152&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_pd" title="Anti-dilutive shares"&gt;410,849&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002219">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSAErrEj71d4" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BE_zZlr10vxVjo5" style="display: none"&gt;Schedule of anti dilutive earning per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;June
    30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 66%; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Stock warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pd" title="Anti-dilutive shares"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"&gt;128,860&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pd" title="Anti-dilutive shares"&gt;126,557&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Total shares excluded from calculation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_pd" title="Anti-dilutive shares"&gt;413,152&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_pd" title="Anti-dilutive shares"&gt;410,849&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_custom_StockWarrantsMember"
      decimals="INF"
      id="Fact002221"
      unitRef="Shares">284292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_StockWarrantsMember"
      decimals="INF"
      id="Fact002223"
      unitRef="Shares">284292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002225"
      unitRef="Shares">128860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002227"
      unitRef="Shares">126557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact002229"
      unitRef="Shares">413152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact002231"
      unitRef="Shares">410849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002233">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zGur66SZ7Dg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 9 &#x2013; &lt;span id="xdx_824_zDlZUxFxRE03"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 25, 2022, in connection with the approval
of the Business Combination, the Company&#x2019;s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan
(the &#x201c;2022 Plan&#x201d;). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing
eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to
increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common
Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the
Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units,
Stock Appreciation Rights, Performance Units and Performance Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan, as approved, permits the issuance
of up to &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630__us-gaap--PlanNameAxis__custom--N2022PlanMember_zkAIl0v4Hta" title="Common stock issuance"&gt;108,851&lt;/span&gt; shares (3,265,516 prior to the Reverse Stock Split) of Common Stock (the &#x201c;Share Reserve&#x201d;) upon exercise or
conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve
will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an &#x201c;Evergreen Date&#x201d;),
in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately
preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation
Committee, which administers the 2022 Plan, in its sole discretion. In January 2024, the Compensation Committee approved an annual increase
in the Share Reserve of &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsBiKgClq0W8" title="Number of shares authorized"&gt;35,349&lt;/span&gt; shares (1,060,458 prior to the Reverse Stock Split). On March 31, 2025, the Compensation Committee approved
an increase in the Share Reserve of &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_iI_c20250331__us-gaap--PlanNameAxis__custom--N2022PlanMember_zl6bp0UFxZh3" title="Number of shares authorized"&gt;95,721&lt;/span&gt; shares (2,871,638 prior to the Reverse Stock Split).&lt;/p&gt;



&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common Stock Issued&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;i&gt;Private Placement&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with a private offering memorandum
that the Company issued through a placement agent on January 23, 2024, the Company completed entering into subscription agreements with
7 accredited investors (the &#x201c;Subscription Agreements&#x201d;), whereby the Company issued a total of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLrkUVlopqxj" title="Number of shares issued"&gt;18,727&lt;/span&gt; units (&#x201c;Units&#x201d;)
(561,793 prior to the Reverse Stock Split), with each Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Common stock , per value"&gt;0.00001&lt;/span&gt; par
value (the &#x201c;Common Stock&#x201d;), and (ii) one six year Common Stock purchase warrant (the &#x201c;Warrants&#x201d;), having an exercise
price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pd" title="Warrant exercise price"&gt;53.40&lt;/span&gt; per share ($1.78 prior to the Reverse Stock Split) (the &#x201c;Private Placement&#x201d;). The Private Placement resulted
in the issuance to investors of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNaO9M2qbZ3g" title="Number of shares issued"&gt;18,727&lt;/span&gt; shares (561,793 prior to the Reverse Stock Split) of Common Stock and &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXc69KzAyn9a" title="Number of shares issued"&gt;18,727&lt;/span&gt; Warrants (561,793
prior to the Reverse Stock Split) during the six months ended June 30, 2024. The purchase price of the securities was $53.40 per Unit
($1.78 prior to the Reverse Stock Split), resulting in gross proceeds to the Company of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Proceeds from issuance of common stock"&gt;1,000,000&lt;/span&gt;, before deducting placement agent fees
(10% or $&lt;span id="xdx_902_ecustom--PlacementAgentFee_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SevenAccreditedInvestorsMember_pp0p" title="Placement agent fees"&gt;100,000&lt;/span&gt;) and other offering expenses. The Company intends to use the net proceeds from the Private Placement for working capital
and general corporate purposes. The Private Placement closed on February 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with the Private Placement, the
&lt;span id="xdx_90A_ecustom--PlacementAgentAgreementDescription_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AltitudeCapitalMember_zIyqMHCp9yH" title="Placement agent agreement description"&gt;Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#x201c;Altitude Capital&#x201d;
or the &#x201c;Placement Agent&#x201d;). The Company&#x2019;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 3,745 shares (112,353 prior to the Reverse
Stock Split) of Common Stock at $53.40 per share ($1.78 prior to the Reverse Stock Split) through February 2, 2030 (the &#x201c;Placement
Agent Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;i&gt;At-the-Market Issuance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with an At-the-Market Issuance
Sales Agreement (the &#x201c;Sales Agreement&#x201d;) that the Company entered into with a placement agent on January 26, 2024, the Company
sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUy9Q6Z7q5Rk" title="Number of shares issued"&gt;206,713&lt;/span&gt; shares (6,201,377 prior to the Reverse Stock Split) of Common Stock at various amounts per share to investors for gross proceeds
totaling $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUgkjQeigyV2" title="Proceeds from issuance of common stock"&gt;3,511,040&lt;/span&gt; before deducting sales commissions of $&lt;span id="xdx_904_eus-gaap--SalesCommissionsAndFees_pp0d_c20250101__20250630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zL8Db4352JNj" title="Sales commissions"&gt;87,256&lt;/span&gt; to the placement agent, during the six months ended June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
connection with the Sales Agreement, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z2iH191Vz27k" title="Number of shares issued"&gt;72,058&lt;/span&gt;
common shares &lt;/span&gt;(2,161,737 prior to the Reverse Stock Split) &lt;span style="background-color: white"&gt;at various amounts per share
to investors for gross proceeds totaling $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zF0NuSAhNK3b" title="Proceeds from issuance of common stock"&gt;2,176,556&lt;/span&gt;,
before deducting sales commissions of $&lt;span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zfdPghkpdd4c" title="Sales commissions"&gt;54,399&lt;/span&gt;
to placement agent, during the six months ended June 30, 2024 (among which&#160;55,822&#160;shares of common stock (1,674,654 prior to the Reverse Stock Split) were sold for gross
proceeds totaling $1,298,699&#160;before deducting sales commissions of $32,452&#160;to placement agent during the three months ended
June 30, 2024). The Company also paid the placement agent a fee of $&lt;span id="xdx_903_ecustom--PlacementAgentFee_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--AtTheMarketIssuanceMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zghdApbIp2a2" title="Placement agent fees"&gt;55,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;i&gt;Other Common Stock Issuance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the three and six months ended June
30, 2025, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"&gt;1,559&lt;/span&gt; shares and &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"&gt;2,061&lt;/span&gt; shares (on a Reverse Stock Split-adjusted basis) of Common Stock to a consultant for
services pursuant to vesting of Restricted Stock Units granted, valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"&gt;6,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"&gt;12,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the three and six months ended June
30, 2024, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"&gt;315&lt;/span&gt; common shares (9,442 prior to the Reverse Stock Split) and &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Stock issued for services, shares"&gt;464&lt;/span&gt; shares (13,919 prior to the Reverse Stock
Split) to 2 consultants for services pursuant to vesting of Restricted Stock Units granted, valued at $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"&gt;6,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p" title="Stock issued for services, amount"&gt;14,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 31, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zSDyvkZpqSQ9" title="Stock issued for services, shares"&gt;1,174&lt;/span&gt;
shares (35,212 prior to the Reverse Stock Split) of Common Stock to the board of directors for services pursuant to vesting of Restricted
Stock Units granted, valued at $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0d_c20240101__20240331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zedwpLnUm6H8" title="Stock issued for services, amount"&gt;50,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended June 30, 2025 and 2024,
in connection with the Private Placement as described above, the Company issued an aggregate of &lt;span id="xdx_901_ecustom--WarrantsIssued_c20250101__20250630_pd" title="Warrants issued"&gt;0&lt;/span&gt; and &lt;span id="xdx_903_ecustom--WarrantsIssued_c20240101__20240630_pd" title="Warrants issued"&gt;22,471&lt;/span&gt; warrants (674,146 prior to
the Reverse Stock Split), respectively.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Warrant activity during the six months ended June
30, 2025 and 2024 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlEGX7ePw5aj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zoCoP1sUAfHb" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average
    Exercise Price&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average
    Remaining&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual Life (Years)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAOwo5LhTg8" title="Warrants outstanding, beginning"&gt;261,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4RmJlBL6xab" title="Weighted average exercise price outstanding, beginning"&gt;291.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfGOYs1XZSpj" title="Weighted average remaining contractual life"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6O41bVQa3z3" title="Warrants granted"&gt;22,471&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pJZNJXcx5a" title="Weighted average exercise price, granted"&gt;53.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCtPHsMVVXa" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HzCSIdJjkd" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lbY9PQTUak" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life"&gt;3.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs5JHNeyCwB1" title="Warrants outstanding, beginning"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyLySFuh2kD9" title="Weighted average exercise price outstanding, beginning"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGh30EF5wXjf" style="text-align: center" title="Weighted average remaining contractual life"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;No warrant activity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLG9eYUxUuj" title="Warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2322"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzAo7Rvt5Cr1" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdg2D1KlSxVh" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNyh32gO7w" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life"&gt;2.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zVlmPyeYasC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;span style="text-decoration: underline"&gt;Options&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 23, 2024, the Company authorized
an additional &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares authorized"&gt;35,349&lt;/span&gt; shares (1,060,458 prior to the Reverse Stock Split) to the Equity Incentive Plan Reserve (the &#x201c;2022 Plan&#x201d;)
and granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zu5cmimglaj" title="Number of shares granted"&gt;39,594&lt;/span&gt; options (1,187,826 prior to the Reverse Stock Split) to management and employees, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of shares granted"&gt;38,894&lt;/span&gt; (1,166,826 prior to the Reverse
Stock Split) of which vested immediately with the remaining 700 options (21,000 prior to the Reverse Stock Split) subject to 50% vesting
on June 30, 2024 and 100% vesting on December 31, 2024. Each option has an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Warrant exercise price"&gt;63.30&lt;/span&gt; per share ($2.11 prior to the Reverse
Stock Split) with an expiration date of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_zMFZCl0RHRU6" title="Expiration date"&gt;January 23, 2034&lt;/span&gt;. The immediately vested &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pd" title="Number of stock option vested"&gt;38,894&lt;/span&gt; stock options (1,166,826 prior to the Reverse
Stock Split) were valued at $&lt;span id="xdx_90E_ecustom--StockOptionsValued_c20240101__20240123__us-gaap--PlanNameAxis__custom--N2022PlanMember_pp0p" title="Stock options valued"&gt;2,461,404&lt;/span&gt; at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized
in the Black-Scholes valuation of these immediately vested stock options during the six months ended June 30, 2024, risk free interest
rate of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zQ20NdqxEqo1" title="Risk free interest rate"&gt;5.22%&lt;/span&gt;, volatility of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLfHNJndiWl3" title="Volatility"&gt;228%&lt;/span&gt; and an exercise price of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_z0wqn6cB2tJh" title="Exercise price"&gt;63.30&lt;/span&gt; ($2.11 prior to the Reverse Stock Split). For the remaining 700 options
(21,000 prior to the Reverse Stock Split), 250 options (7,500 prior to the Reverse Stock Split) were vested on June 30, 2024, 167 options
(5,000 prior to the Reverse Stock Split) were vested on December 31, 2024 and 283 options (8,500 prior to the Reverse Stock Split) were
forfeited before vesting with the leaving of the employees before December 31, 2024. The vested stock options were valued at $4,106 at
vesting date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes valuation of
these vested stock options during the year ended December 31, 2024, risk free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zsrsmU3hBnrb" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;, volatility of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zNO39uuRkL7j" title="Volatility"&gt;188%&lt;/span&gt; and an exercise
price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember__us-gaap--PlanNameAxis__custom--N2022PlanMember_zLCZyLHqCDte" title="Exercise price"&gt;63.30&lt;/span&gt; ($2.11 prior to the Reverse Stock Split).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2025, the Company authorized an
additional 95,721 shares (2,871,638 prior to the Reverse Stock Split) to the 2022 Plan and granted &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"&gt;2,524&lt;/span&gt;
stock options (75,756 prior to the Reverse Stock Split) to the board of directors, which vested immediately on grant date. Each
option has an exercise price of $9.90 per share ($0.33 prior to the Reverse Stock Split) with an expiration date of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBoXVlSUKYR3" title="Expiration date"&gt;March
31, 2035&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_90C_ecustom--StockOptionsValued_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued"&gt;24,612&lt;/span&gt;
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the six months ended June 30, 2025, risk free interest rate of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate"&gt;4.3908%&lt;/span&gt;,
volatility of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility"&gt;148%&lt;/span&gt;
and an exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250331__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price"&gt;9.90&lt;/span&gt;
($0.33 prior to the Reverse Stock Split).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 30, 2025, the Company granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"&gt;6,944&lt;/span&gt;
stock options to the board of directors, which vested immediately on grant date. Each option has an exercise price of $3.60 per
share with an expiration date of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlVfbBiRRbQ6" title="Expiration date"&gt;June
30, 2035&lt;/span&gt;. These immediately vested stock options were valued at $&lt;span id="xdx_90E_ecustom--StockOptionsValued_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p" title="Stock options valued"&gt;24,778&lt;/span&gt;
at grant date based on the Black-Scholes Option Pricing model. The following assumptions were utilized in the Black-Scholes
valuation of these immediately vested stock options during the three and six months ended June 30, 2025, risk free interest rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Risk free interest rate"&gt;4.39%&lt;/span&gt;,
volatility of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Volatility"&gt;161%&lt;/span&gt;
and an exercise price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Exercise price"&gt;3.60&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 30, 2024, the Company granted&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z59sAkIXF6Ta" title="Options granted"&gt;1,012&lt;/span&gt;&#160;stock options
(30,300 prior to the Reverse Stock Split) to the board of directors, which vested&#160;immediately on grant date.&#160;Each option has
an exercise price of&#160;$16.50&#160;per share ($0.55 prior to the Reverse Stock Split) with an expiration date of&#160;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z5HCp0vha9cl" title="Expiration date"&gt;June 30, 2034&lt;/span&gt;.
These immediately vested stock options were valued at $&lt;span id="xdx_90F_ecustom--StockOptionsValued_pp0d_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqDHpmpsf856" title="Stock options valued"&gt;16,625&lt;/span&gt;&#160;at grant date based on the Black-Scholes Option Pricing model. The
following assumptions were utilized in the Black-Scholes valuation of these immediately vested stock options during the three and six
months ended June 30, 2024, risk free interest rate of&#160;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLhmXluWXUt4" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;, volatility of&#160;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zJrgvVaAVFEd" title="Volatility"&gt;188%&lt;/span&gt;&#160;and an exercise price of $16.50 ($&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zK2IDTX5v0ok" title="Exercise price"&gt;0.55&lt;/span&gt;
prior to the Reverse Stock Split).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;









&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;Option activity during the six months ended June 30, 2025 and
2024 was as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGs7bIHxLQp5" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;span id="xdx_8BB_zNmBnhfV8Laa" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options
                                            Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"&gt;&lt;b&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOJXjWefUdP" title="Options outstanding, beginning"&gt;86,153&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDg6ZJOPgxC" title="Weighted average exercise price outstanding, beginning"&gt;91.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUJy2BcWHZUh" title="Weighted average remaining contractual life"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"&gt;40,604&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zKMj6jOusIGh" title="Weighted average exercise price, granted"&gt;62.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    expired or cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV6AelXyevyi" title="Options expired or cancelled or forfeited"&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, expired or cancelled or forfeited"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTSo3OHqjMq8" title="Options outstanding, ending"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHjMIUWBPHih" title="Weighted average exercise price outstanding, ending"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTvB6JrirWF6" title="Weighted average remaining contractual life"&gt;8.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z4n1IAOkDHk7" title="Options vested and exercisable"&gt;126,307&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUtjp5Js5eOg" title="Weighted average exercise price vested and exercisable"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding at
    December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcngGi4b9jza" title="Options outstanding, beginning"&gt;119,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zspxLpDaEV05" title="Weighted average exercise price outstanding, beginning"&gt;82.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCUQxp6NVIoi" title="Weighted average remaining contractual life"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9neLI2AIYX3" title="Options granted"&gt;9,468&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDk7Orw9n4h9" title="Weighted average exercise price, granted"&gt;5.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    expired or cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zklXVoomkO6e" title="Options expired or cancelled or forfeited"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOV21jIxGlHe" title="Weighted average exercise price, expired or cancelled or forfeited"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zyNHHYaSm7y4" title="Options outstanding, ending"&gt;128,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqN8Dz80y938" title="Weighted average exercise price outstanding, ending"&gt;76.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zolOFlBzQHxi" title="Weighted average remaining contractual life"&gt;7.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqiYmyE5a4zf" title="Options vested and exercisable"&gt;128,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zx5LSZ3zbR6j" title="Weighted average exercise price vested and exercisable"&gt;76.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_8AE_z0LUweIq7Wsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-06-30_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002235"
      unitRef="Shares">108851</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized
      contextRef="AsOf2024-01-23_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002237"
      unitRef="Shares">35349</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized
      contextRef="AsOf2025-03-31_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002239"
      unitRef="Shares">95721</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002242"
      unitRef="Shares">18727</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002244"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002246"
      unitRef="USDPShares">53.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002248"
      unitRef="Shares">18727</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-06-30_custom_SevenAccreditedInvestorsMember_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002250"
      unitRef="Shares">18727</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember"
      decimals="0"
      id="Fact002252"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdio:PlacementAgentFee
      contextRef="From2025-01-012025-06-30_custom_SevenAccreditedInvestorsMember"
      decimals="0"
      id="Fact002254"
      unitRef="USD">100000</cdio:PlacementAgentFee>
    <cdio:PlacementAgentAgreementDescription
      contextRef="From2025-01-012025-06-30_custom_PlacementAgentAgreementMember_custom_AltitudeCapitalMember"
      id="Fact002256">Company entered into a Placement Agent Agreement with Altitude Capital Group, LLC, as placement agent (&#x201c;Altitude Capital&#x201d;
or the &#x201c;Placement Agent&#x201d;). The Company&#x2019;s Non-Executive Chairman of the Board owns 10% of Altitude Capital. Pursuant
to the Placement Agent Agreement, at closing, Altitude Capital was paid a cash commission equal to 10% of the gross proceeds received
by the Company, plus 20% warrant coverage, providing Altitude Capital with the right to purchase 3,745 shares (112,353 prior to the Reverse
Stock Split) of Common Stock at $53.40 per share ($1.78 prior to the Reverse Stock Split) through February 2, 2030 (the &#x201c;Placement
Agent Warrants&#x201d;).</cdio:PlacementAgentAgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact002258"
      unitRef="Shares">206713</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002260"
      unitRef="USD">3511040</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2025-01-012025-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002262"
      unitRef="USD">87256</us-gaap:SalesCommissionsAndFees>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact002264"
      unitRef="Shares">72058</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002266"
      unitRef="USD">2176556</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002268"
      unitRef="USD">54399</us-gaap:SalesCommissionsAndFees>
    <cdio:PlacementAgentFee
      contextRef="From2024-01-012024-06-30_custom_AtTheMarketIssuanceMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002270"
      unitRef="USD">55000</cdio:PlacementAgentFee>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002272"
      unitRef="Shares">1559</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002274"
      unitRef="Shares">2061</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact002276"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact002278"
      unitRef="USD">12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002280"
      unitRef="Shares">315</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002282"
      unitRef="Shares">464</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact002284"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact002286"
      unitRef="USD">14000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact002288"
      unitRef="Shares">1174</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      id="Fact002290"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cdio:WarrantsIssued
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact002292"
      unitRef="Shares">0</cdio:WarrantsIssued>
    <cdio:WarrantsIssued
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact002294"
      unitRef="Shares">22471</cdio:WarrantsIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002298">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlEGX7ePw5aj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zoCoP1sUAfHb" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Warrants Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average
    Exercise Price&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average
    Remaining&lt;br/&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual Life (Years)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAOwo5LhTg8" title="Warrants outstanding, beginning"&gt;261,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4RmJlBL6xab" title="Weighted average exercise price outstanding, beginning"&gt;291.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfGOYs1XZSpj" title="Weighted average remaining contractual life"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Warrants granted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6O41bVQa3z3" title="Warrants granted"&gt;22,471&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pJZNJXcx5a" title="Weighted average exercise price, granted"&gt;53.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTCtPHsMVVXa" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HzCSIdJjkd" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lbY9PQTUak" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life"&gt;3.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zs5JHNeyCwB1" title="Warrants outstanding, beginning"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyLySFuh2kD9" title="Weighted average exercise price outstanding, beginning"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGh30EF5wXjf" style="text-align: center" title="Weighted average remaining contractual life"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;No warrant activity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLG9eYUxUuj" title="Warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2322"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Warrants outstanding at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzAo7Rvt5Cr1" title="Warrants outstanding, ending"&gt;284,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdg2D1KlSxVh" title="Weighted average exercise price outstanding, ending"&gt;272.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMNyh32gO7w" style="padding-bottom: 2.5pt; text-align: center" title="Weighted average remaining contractual life"&gt;2.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002300"
      unitRef="Shares">261821</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002302"
      unitRef="USDPShares">291.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact002304">P3Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002306"
      unitRef="Shares">22471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002308"
      unitRef="USDPShares">53.40</cdio:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGranted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002310"
      unitRef="Shares">284292</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002312"
      unitRef="USDPShares">272.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      id="Fact002314">P3Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002316"
      unitRef="Shares">284292</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002318"
      unitRef="USDPShares">272.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="Fact002320">P2Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002326"
      unitRef="Shares">284292</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002328"
      unitRef="USDPShares">272.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      id="Fact002330">P2Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized
      contextRef="AsOf2024-01-23_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002332"
      unitRef="Shares">35349</cdio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002334"
      unitRef="Shares">39594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002336"
      unitRef="Shares">38894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-23_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002338"
      unitRef="USDPShares">63.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      id="Fact002340">2034-01-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002342"
      unitRef="Shares">38894</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-01-23_custom_N2022PlanMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">2461404</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002346"
      unitRef="Ratio">0.0522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002348"
      unitRef="Ratio">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002350"
      unitRef="USDPShares">63.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002352"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002354"
      unitRef="Ratio">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_StockOptionsMember_custom_N2022PlanMember"
      decimals="INF"
      id="Fact002356"
      unitRef="USDPShares">63.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002358"
      unitRef="Shares">2524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2025-01-012025-03-31_custom_StockOptionsMember"
      id="Fact002360">2035-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2025-01-012025-03-31_custom_StockOptionsMember"
      decimals="0"
      id="Fact002362"
      unitRef="USD">24612</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002364"
      unitRef="Ratio">0.043908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002366"
      unitRef="Ratio">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-03-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002368"
      unitRef="USDPShares">9.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002370"
      unitRef="Shares">6944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      id="Fact002372">2035-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="0"
      id="Fact002374"
      unitRef="USD">24778</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002376"
      unitRef="Ratio">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002378"
      unitRef="Ratio">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002380"
      unitRef="USDPShares">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002382"
      unitRef="Shares">1012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      id="Fact002384">2034-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <cdio:StockOptionsValued
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="0"
      id="Fact002386"
      unitRef="USD">16625</cdio:StockOptionsValued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002388"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002390"
      unitRef="Ratio">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002392"
      unitRef="USDPShares">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002396">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGs7bIHxLQp5" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;span id="xdx_8BB_zNmBnhfV8Laa" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;Options
                                            Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 115%"&gt;&lt;b&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOJXjWefUdP" title="Options outstanding, beginning"&gt;86,153&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDg6ZJOPgxC" title="Weighted average exercise price outstanding, beginning"&gt;91.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUJy2BcWHZUh" title="Weighted average remaining contractual life"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Options granted"&gt;40,604&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zKMj6jOusIGh" title="Weighted average exercise price, granted"&gt;62.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    expired or cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zV6AelXyevyi" title="Options expired or cancelled or forfeited"&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, expired or cancelled or forfeited"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTSo3OHqjMq8" title="Options outstanding, ending"&gt;126,557&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zHjMIUWBPHih" title="Weighted average exercise price outstanding, ending"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTvB6JrirWF6" title="Weighted average remaining contractual life"&gt;8.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z4n1IAOkDHk7" title="Options vested and exercisable"&gt;126,307&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUtjp5Js5eOg" title="Weighted average exercise price vested and exercisable"&gt;82.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options outstanding at
    December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zcngGi4b9jza" title="Options outstanding, beginning"&gt;119,807&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zspxLpDaEV05" title="Weighted average exercise price outstanding, beginning"&gt;82.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCUQxp6NVIoi" title="Weighted average remaining contractual life"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z9neLI2AIYX3" title="Options granted"&gt;9,468&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zDk7Orw9n4h9" title="Weighted average exercise price, granted"&gt;5.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    expired or cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zklXVoomkO6e" title="Options expired or cancelled or forfeited"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zOV21jIxGlHe" title="Weighted average exercise price, expired or cancelled or forfeited"&gt;63.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zyNHHYaSm7y4" title="Options outstanding, ending"&gt;128,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqN8Dz80y938" title="Weighted average exercise price outstanding, ending"&gt;76.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zolOFlBzQHxi" title="Weighted average remaining contractual life"&gt;7.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    vested and exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqiYmyE5a4zf" title="Options vested and exercisable"&gt;128,860&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zx5LSZ3zbR6j" title="Weighted average exercise price vested and exercisable"&gt;76.66&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002398"
      unitRef="Shares">86153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002400"
      unitRef="USDPShares">91.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionsMember51358140"
      id="Fact002402">P8Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002404"
      unitRef="Shares">40604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002406"
      unitRef="USDPShares">62.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002408"
      unitRef="Shares">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      decimals="INF"
      id="Fact002410"
      unitRef="USDPShares">63.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002412"
      unitRef="Shares">126557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002414"
      unitRef="USDPShares">82.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-06-30_custom_StockOptionsMember51358187"
      id="Fact002416">P8Y7M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002418"
      unitRef="Shares">126307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002420"
      unitRef="USDPShares">82.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002422"
      unitRef="Shares">119807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002424"
      unitRef="USDPShares">82.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_StockOptionsMember51358218"
      id="Fact002426">P8Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002428"
      unitRef="Shares">9468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002430"
      unitRef="USDPShares">5.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002432"
      unitRef="Shares">415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      decimals="INF"
      id="Fact002434"
      unitRef="USDPShares">63.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002436"
      unitRef="Shares">128860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002438"
      unitRef="USDPShares">76.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_custom_StockOptionsMember51358328"
      id="Fact002440">P7Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002442"
      unitRef="Shares">128860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact002444"
      unitRef="USDPShares">76.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002446">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zShBwFWPfXQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 10 &#x2013; &lt;span id="xdx_82B_zsatqx1pURcg"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Prior Relationship of Cardio with Boustead
Securities, LLC&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;At the commencement of efforts to pursue what
ultimately ended in a terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the
&#x201c;Placement Agent Agreement&#x201d;), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities&#x201d;). This
agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying
escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions
of the closing deadline.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Under the terminated Placement Agent Agreement,
Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead
Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with
any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company&#x2019;s
exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the &#x201c;right of first refusal&#x201d;).
Cardio has taken the position that due to Boustead Securities&#x2019; failure to perform as contemplated by the Placement Agent Agreement,
these provisions purporting to provide future rights are null and void.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Boustead Securities responded to the termination
of the Placement Agent Agreement by disputing Legacy Cardio&#x2019;s contention that it had not performed under the Placement Agent Agreement
because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included
a list of funds that they had supposedly contacted on Legacy Cardio&#x2019;s behalf. While Boustead Securities&#x2019; contention appears
to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions,
Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent
Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this
position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly
was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the
tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material
adverse impact on its financial condition.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;The Benchmark Company, LLC Right of First
Refusal&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company completed the business combination
on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark
Company, LLC (&#x201c;Benchmark&#x201d;) as its M&amp;amp;A advisor. Upon closing of the business combination, Legacy Cardio assumed the contractual
engagement entered into by Mana. On November 14, 2022, the Company and Benchmark entered into Amendment No. 1 Engagement Letter (the &#x201c;Amendment
Engagement&#x201d;). &lt;span id="xdx_90C_eus-gaap--BusinessCombinationReasonForBusinessCombination_c20250101__20250630__us-gaap--BusinessAcquisitionAxis__custom--TheBenchmarkCompanyLLCMember_zyDTS55FLA34" title="Business Combination, Reason for Business Combination"&gt;Pursuant to the Amendment Engagement, the parties agreed that the Company would pay Benchmark $230,000 at the closing
of the business combination and an additional $435,000 on October 25, 2023. Both of those payments have been made in full. In addition,
the Amendment Engagement provided that Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker,
lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings
through October 25, 2023.&lt;/span&gt; Based on the right of first refusal, Benchmark alleges that it is owed damages because the Company entered into
the Yorkville Convertible Debenture Transaction without first offering Benchmark the right to serve as the lead or joint-lead placement
agent for the transaction. The Company is evaluating the claim. No legal proceedings have been instigated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Demand Letter and Potential Mootness
Fee Claim&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On June 25, 2022, a plaintiffs&#x2019; securities
law firm sent a demand letter to the Company alleging that the Company&#x2019;s Registration Statement on Form S-4 filed (the &#x201c;S-4
Registration Statement&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on May 31, 2022 omitted material information
with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures
in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration
Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various
comments of the SEC staff and otherwise updated its disclosure. In October 2022, the SEC completed its review and declared the S-4 registration
statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs&#x2019; securities law firm contacted the Company&#x2019;s
counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The
Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that
no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are
without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the
date of filing of this Annual Report on Form 10-K, no lawsuit has been filed against the Company by that firm. The firm has indicated
its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the
final outcome will not have a material adverse impact on its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Northland Securities, Inc.&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In January 2024, following the Company&#x2019;s
termination of its agreement with Yorkville and in connection with the Company&#x2019;s recent at the market offering and/or its February
2024 private placement, a managing director of Northland Securities, Inc. (&#x201c;Northland&#x201d;) contacted the Company claiming the
right to be paid a fee of approximately $&lt;span id="xdx_908_ecustom--TerminationFee_c20240101__20240131__srt--CounterpartyNameAxis__custom--NorthlandSecuritiesMember_pp0p" title="Termination fee"&gt;150,000&lt;/span&gt; pursuant to the agreement of March 1, 2023 between the Company and Northland regarding
the Yorkville financing. Subsequently, the Company has been advised by another representative of Northland that Northland would not proceed
with any such claim. The Company does not believe that it owes Northland any sum based on the termination of the Yorkville Securities
Purchase Agreement and the subsequent financing transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company cannot preclude the possibility
that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require
significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Directors and Officers Insurance&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In connection with the Company&#x2019;s various
contractual obligations arising in the ordinary course of business, the Company is required to maintain insurance coverage for claims
against its directors and officers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;The University of Iowa Research Foundation
Exclusive License Agreement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
has a worldwide exclusive license agreement with the University of Iowa Research Foundation (UIRF) relating to its patent and patent-pending
technology (the &#x201c;Exclusive License Agreement&#x201d;). Under the terms of the Exclusive License Agreement, the Company will have
to pay each of: (1) 1% of either the: (i) aggregate consideration (and trailing consideration, if any) for a liquidation event; or (ii)
pre-money valuation for an initial public offering, (the &#x201c;Equity Rights&#x201d;) (2) 2% of annual net sales, and (3) 15% of non-royalty
fees paid to licensee if it enters into one or more sublicensing agreements. Upon the Closing of the Business Combination, the Company
issued 3,639 (109,170 prior to the Reverse Stock Split) Shares of Common Stock to UIRF in accordance with the Equity Rights under the
Exclusive License Agreement. The Company has had minimal sales of $&lt;span style="background-color: white"&gt;62,221&lt;/span&gt; to date and has paid 2% or &lt;span style="background-color: white"&gt;approximately $1,300&lt;/span&gt; in total royalty fees to UIRF
under the exclusive license.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationReasonForBusinessCombination
      contextRef="From2025-01-012025-06-30_custom_TheBenchmarkCompanyLLCMember"
      id="Fact002449">Pursuant to the Amendment Engagement, the parties agreed that the Company would pay Benchmark $230,000 at the closing
of the business combination and an additional $435,000 on October 25, 2023. Both of those payments have been made in full. In addition,
the Amendment Engagement provided that Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker,
lead or joint-lead book- runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings
through October 25, 2023.</us-gaap:BusinessCombinationReasonForBusinessCombination>
    <cdio:TerminationFee
      contextRef="From2024-01-012024-01-31_custom_NorthlandSecuritiesMember"
      decimals="0"
      id="Fact002451"
      unitRef="USD">150000</cdio:TerminationFee>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact002453">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zqPowa0bV8Od" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 11 &#x2013; &lt;span id="xdx_82A_zenWtyxGfFVj"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated its June 30, 2025 condensed
consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common Stock Issued&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Subsequent to
June 30, 2025, the Company sold &lt;/span&gt;&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250701__20250715_pd" title="Number of common stock sold"&gt;22,860&lt;/span&gt; &lt;span style="background-color: white"&gt;common shares for gross proceeds totaling &lt;/span&gt;$&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250701__20250715_pp0p" title="Proceeds from common shares"&gt;103,912&lt;/span&gt;
&lt;span style="background-color: white"&gt;under the &lt;/span&gt;At-the-Market&#160;Issuance &lt;span style="background-color: white"&gt;Sales Agreement
as of the date of this report.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-012025-07-15"
      decimals="INF"
      id="Fact002455"
      unitRef="Shares">22860</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-012025-07-15"
      decimals="0"
      id="Fact002457"
      unitRef="USD">103912</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001202"
          xlink:label="Fact001202"
          xlink:type="locator"/>
        <link:footnote id="Footnote001232" xlink:label="Footnote001232" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001202"
          xlink:to="Footnote001232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001203"
          xlink:label="Fact001203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001203"
          xlink:to="Footnote001232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001299"
          xlink:label="Fact001299"
          xlink:type="locator"/>
        <link:footnote id="Footnote001330" xlink:label="Footnote001330" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.&#160;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001299"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001301"
          xlink:label="Fact001301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001301"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001303"
          xlink:label="Fact001303"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001303"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001305"
          xlink:label="Fact001305"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001305"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001307"
          xlink:label="Fact001307"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001307"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001309"
          xlink:label="Fact001309"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001309"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001311"
          xlink:label="Fact001311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001311"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001313"
          xlink:label="Fact001313"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001313"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001315"
          xlink:label="Fact001315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001315"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001317"
          xlink:label="Fact001317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001317"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001319"
          xlink:label="Fact001319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001319"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001321"
          xlink:label="Fact001321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001321"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001323"
          xlink:label="Fact001323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001323"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001325"
          xlink:label="Fact001325"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001325"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001327"
          xlink:label="Fact001327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001327"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001329"
          xlink:label="Fact001329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001329"
          xlink:to="Footnote001330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001332"
          xlink:label="Fact001332"
          xlink:type="locator"/>
        <link:footnote id="Footnote001469" xlink:label="Footnote001469" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively restated for thirty-for-one share consolidation on May 12, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001332"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001337"
          xlink:label="Fact001337"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001337"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001339"
          xlink:label="Fact001339"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001339"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001344"
          xlink:label="Fact001344"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001344"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1346"
          xlink:label="xdx2ixbrl1346"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1346"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001351"
          xlink:label="Fact001351"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001351"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1353"
          xlink:label="xdx2ixbrl1353"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1353"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1358"
          xlink:label="xdx2ixbrl1358"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1358"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001363"
          xlink:label="Fact001363"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001363"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001368"
          xlink:label="Fact001368"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001368"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1370"
          xlink:label="xdx2ixbrl1370"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1370"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001375"
          xlink:label="Fact001375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001375"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1377"
          xlink:label="xdx2ixbrl1377"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1377"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1382"
          xlink:label="xdx2ixbrl1382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1382"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001387"
          xlink:label="Fact001387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001387"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1389"
          xlink:label="xdx2ixbrl1389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1389"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001394"
          xlink:label="Fact001394"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001394"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001399"
          xlink:label="Fact001399"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001399"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001401"
          xlink:label="Fact001401"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001401"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001406"
          xlink:label="Fact001406"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001406"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1408"
          xlink:label="xdx2ixbrl1408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1408"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001413"
          xlink:label="Fact001413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001413"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1415"
          xlink:label="xdx2ixbrl1415"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1415"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001420"
          xlink:label="Fact001420"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001420"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1422"
          xlink:label="xdx2ixbrl1422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1422"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1427"
          xlink:label="xdx2ixbrl1427"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1427"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001432"
          xlink:label="Fact001432"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001432"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001437"
          xlink:label="Fact001437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001437"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001439"
          xlink:label="Fact001439"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001439"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001444"
          xlink:label="Fact001444"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001444"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1446"
          xlink:label="xdx2ixbrl1446"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1446"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001451"
          xlink:label="Fact001451"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001451"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1453"
          xlink:label="xdx2ixbrl1453"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1453"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1458"
          xlink:label="xdx2ixbrl1458"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1458"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001463"
          xlink:label="Fact001463"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001463"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001468"
          xlink:label="Fact001468"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001468"
          xlink:to="Footnote001469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001912"
          xlink:label="Fact001912"
          xlink:type="locator"/>
        <link:footnote id="Footnote001929" xlink:label="Footnote001929" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other segment items included in segment net income (loss) include shipping expense, taxes
expense, subscription fees expense, bank fees expense and other overhead expense.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001912"
          xlink:to="Footnote001929"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001913"
          xlink:label="Fact001913"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001913"
          xlink:to="Footnote001929"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001975"
          xlink:label="Fact001975"
          xlink:type="locator"/>
        <link:footnote id="Footnote001992" xlink:label="Footnote001992" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other segment items included in segment net income (loss) include shipping
expense, taxes expense, subscription fees expense, bank fees expense and other overhead expense.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001975"
          xlink:to="Footnote001992"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001976"
          xlink:label="Fact001976"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001976"
          xlink:to="Footnote001992"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
